ASI,SI,ASSTY,CONFSCO,ASSCETY,SRASSI,ASTET,T,Descr,TII,ASSORG,ASSSTR,CEI,ASCATE,ASSTAI,RELATY,CURB,CHI,BFO,VARII
1,1,B,8,,,,12052,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,,,,,,H,Autocuration,CHEMBL615117,BAO_0000019,
2,1,F,0,,,,22226,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,,,,,,U,Autocuration,CHEMBL615118,BAO_0000219,
3,1,B,0,,,,22226,,,,,,,,U,Autocuration,CHEMBL615119,BAO_0000019,
4,1,B,4,,,,104729,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,,Bos taurus,,,,9913.0,H,Autocuration,CHEMBL615120,BAO_0000249,
5,1,F,1,143B,,,80001,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,Homo sapiens,,163.0,,9606.0,N,Intermediate,CHEMBL615121,BAO_0000219,
6,1,F,1,143B,,,80001,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,Homo sapiens,,163.0,,9606.0,N,Intermediate,CHEMBL615122,BAO_0000219,
7,1,F,1,143B,,,80001,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,,Mus musculus,,163.0,,10090.0,N,Intermediate,CHEMBL615123,BAO_0000219,
8,1,F,1,143B,,,80001,In vitro cell cytotoxicity was determined against 143B cell line,,Homo sapiens,,163.0,,9606.0,N,Expert,CHEMBL615124,BAO_0000219,
9,1,F,1,143B,,,80001,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,,Homo sapiens,,163.0,,9606.0,N,Intermediate,CHEMBL615125,BAO_0000219,
10,1,F,1,143B,,,80001,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,Homo sapiens,,163.0,,9606.0,N,Intermediate,CHEMBL615126,BAO_0000219,
11,1,F,1,143B,,,80001,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,Homo sapiens,,163.0,,9606.0,N,Intermediate,CHEMBL615127,BAO_0000219,
12,1,F,1,143B,,,80001,In vitro cell cytotoxicity was determined against 143B-LTK cell line,,Homo sapiens,,163.0,,9606.0,N,Expert,CHEMBL615128,BAO_0000219,
13,1,F,1,,,,50185,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,Staphylococcus aureus,,,,1280.0,N,Intermediate,CHEMBL857900,BAO_0000218,
14,1,F,1,,,,50185,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,Staphylococcus aureus,,,,1280.0,N,Intermediate,CHEMBL615129,BAO_0000218,
15,1,F,1,,,,50185,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,Staphylococcus aureus,,,,1280.0,N,Intermediate,CHEMBL615130,BAO_0000218,
16,1,F,1,,,,50185,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,Staphylococcus aureus,,,,1280.0,N,Intermediate,CHEMBL615131,BAO_0000218,
17,1,A,9,,,,100122,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL884521,BAO_0000357,
18,1,B,8,,,,12054,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,,,,,,H,Autocuration,CHEMBL615132,BAO_0000357,
19,1,B,8,,,,12054,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,,,,,,H,Autocuration,CHEMBL615133,BAO_0000019,
20,1,B,8,,,,12054,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,,,,,,H,Autocuration,CHEMBL615134,BAO_0000357,
21,1,B,8,,,,12054,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,,,,,,H,Autocuration,CHEMBL615135,BAO_0000357,
22,1,B,8,,,,12054,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,,,,,,H,Autocuration,CHEMBL615136,BAO_0000357,
23,1,B,8,,,,12054,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,,,,,,H,Autocuration,CHEMBL615137,BAO_0000357,
24,1,B,8,,,,12054,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,,,,,,H,Autocuration,CHEMBL615138,BAO_0000357,
25,1,B,0,,,,22226,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,,,,,,U,Autocuration,CHEMBL836324,BAO_0000219,
26,1,B,8,,,,12054,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,,Oryctolagus cuniculus,,,,9986.0,H,Autocuration,CHEMBL615139,BAO_0000357,
27,1,B,8,,,,12054,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),,Oryctolagus cuniculus,,,,9986.0,H,Autocuration,CHEMBL615140,BAO_0000357,
28,1,B,8,,,,12426,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,,,,,,H,Autocuration,CHEMBL615141,BAO_0000219,
29,1,B,8,,,,12054,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,,soya bean,,,,3847.0,H,Autocuration,CHEMBL615142,BAO_0000357,
30,1,B,8,,,,12054,Inhibitory activity against soybean 15-lipoxygenase was evaluated,,Glycine max,,,,3847.0,H,Autocuration,CHEMBL615143,BAO_0000357,
31,1,B,8,,,,12054,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,,Glycine max,,,,3847.0,H,Autocuration,CHEMBL615144,BAO_0000357,
32,1,B,8,,,,12054,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,,Glycine max,,,,3847.0,H,Autocuration,CHEMBL872867,BAO_0000357,
33,1,B,8,,,,12054,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,,Glycine max,,,,3847.0,H,Autocuration,CHEMBL615145,BAO_0000357,
34,1,B,8,,,,12054,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,,Glycine max,,,,3847.0,H,Autocuration,CHEMBL615146,BAO_0000357,
35,1,B,8,,,,12054,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,,Glycine max,,,,3847.0,H,Autocuration,CHEMBL615147,BAO_0000357,
36,1,A,0,,,,22226,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL615148,BAO_0000019,
37,1,B,0,,,,22226,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,,Escherichia coli,,,,562.0,U,Autocuration,CHEMBL615149,BAO_0000019,
38,1,B,0,,,,22226,Dissociation constant with dimeric 16S rRNA RNA construct B,,,,,,,U,Autocuration,CHEMBL615150,BAO_0000019,
39,1,B,3,,,,22222,Dissociation constant towards 16S rRNA construct A,,,,,,,M,Intermediate,CHEMBL615151,BAO_0000225,
40,1,B,3,,,,22222,Dissociation constant towards 16S rRNA construct B,,,,,,,M,Intermediate,CHEMBL615152,BAO_0000225,
41,1,B,3,,,,100263,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,,Escherichia coli,,,,562.0,M,Expert,CHEMBL615153,BAO_0000225,
42,1,B,3,,,,100263,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,,Escherichia coli,,,,562.0,M,Expert,CHEMBL615154,BAO_0000225,
43,1,B,8,,,,13053,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,,,,,H,Autocuration,CHEMBL615155,BAO_0000019,
44,1,B,8,,,,13053,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,,,,,H,Autocuration,CHEMBL615156,BAO_0000019,
45,1,B,8,,,,20001,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,Homo sapiens,,,,9606.0,H,Autocuration,CHEMBL615157,BAO_0000019,
46,1,B,8,,,,20001,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,Homo sapiens,,,,9606.0,H,Autocuration,CHEMBL615158,BAO_0000019,
47,1,B,9,,,,12971,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL615159,BAO_0000019,
48,1,B,9,,,,12971,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL615172,BAO_0000019,
49,1,B,9,,,,12971,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL615173,BAO_0000019,
50,1,B,9,,,,12971,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL615174,BAO_0000019,
51,1,B,8,,,,13053,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,,,,,H,Autocuration,CHEMBL884518,BAO_0000019,
52,1,B,8,,,,11512,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,,,,,,H,Autocuration,CHEMBL615175,BAO_0000357,
53,1,B,8,,,,11512,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,,,,,,H,Autocuration,CHEMBL615176,BAO_0000357,
54,1,B,8,,,,11512,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,,,,,,H,Autocuration,CHEMBL615177,BAO_0000357,
55,1,B,5,,,,104740,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL615178,BAO_0000249,
56,1,F,1,1A9,,,80002,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,,Homo sapiens,,506.0,,9606.0,N,Intermediate,CHEMBL615179,BAO_0000219,
57,1,F,7,Oocytes,,,104835,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL615180,BAO_0000219,
58,1,F,7,Oocytes,,,104821,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL615181,BAO_0000219,
59,1,F,7,Oocytes,,,104848,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL615182,BAO_0000219,
60,1,F,1,1A9,,,80002,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,,Homo sapiens,,506.0,,9606.0,N,Expert,CHEMBL615183,BAO_0000219,
61,1,F,1,1A9,,,80002,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,,Homo sapiens,,506.0,,9606.0,N,Intermediate,CHEMBL615184,BAO_0000219,
62,1,F,1,1A9,,,80002,Cytotoxic activity against human ovarian cancer (1A9) cell line,,Homo sapiens,,506.0,,9606.0,N,Intermediate,CHEMBL615185,BAO_0000219,
63,1,F,1,1A9,,,80002,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,,Homo sapiens,,506.0,,9606.0,N,Intermediate,CHEMBL615186,BAO_0000219,
64,1,F,1,1A9,,,80002,Effective dose of compound against replication of 1A9 cell line was evaluated,,Homo sapiens,,506.0,,9606.0,N,Intermediate,CHEMBL615187,BAO_0000219,
65,1,F,1,1A9,,,80002,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,,Homo sapiens,,506.0,,9606.0,N,Expert,CHEMBL885343,BAO_0000219,
66,1,F,1,1A9,,,80002,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),,Homo sapiens,,506.0,,9606.0,N,Intermediate,CHEMBL615188,BAO_0000219,
67,1,F,1,1A9,,,80002,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,,Homo sapiens,,506.0,,9606.0,N,Intermediate,CHEMBL615189,BAO_0000219,
68,1,F,1,1A9,,,80002,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,,Homo sapiens,,506.0,,9606.0,N,Intermediate,CHEMBL615190,BAO_0000219,
69,1,F,1,1A9,,,80002,Inhibitory activity against Taxol resistant 1A9 cell lines,,Homo sapiens,,506.0,,9606.0,N,Intermediate,CHEMBL615191,BAO_0000219,
70,1,F,1,1A9,,,80002,Cytotoxicity against human ovarian cancer (1A9) cell lines.,,Homo sapiens,,506.0,,9606.0,N,Expert,CHEMBL615192,BAO_0000219,
71,1,F,1,1A9,,,80002,Percentage inhibition of human ovarian cancer (1A9) cell lines.,,Homo sapiens,,506.0,,9606.0,N,Expert,CHEMBL827083,BAO_0000219,
72,1,F,1,1A9,,,80002,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,,Homo sapiens,,506.0,,9606.0,N,Expert,CHEMBL615193,BAO_0000219,
73,1,F,1,1A9,,,80002,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,,Homo sapiens,,506.0,,9606.0,N,Intermediate,CHEMBL615194,BAO_0000219,
74,1,F,1,1A9,,,80002,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,,Homo sapiens,,506.0,,9606.0,N,Intermediate,CHEMBL615195,BAO_0000219,
75,1,F,1,1A9,,,80002,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,,Homo sapiens,,506.0,,9606.0,N,Intermediate,CHEMBL615196,BAO_0000219,
76,1,F,1,Jurkat,,,81072,Inhibitory concentration against Jurkat cells,,Homo sapiens,,503.0,,9606.0,N,Intermediate,CHEMBL615197,BAO_0000219,
77,1,F,0,,,,22226,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,,,,,,U,Intermediate,CHEMBL615198,BAO_0000019,
78,1,A,9,,,,100121,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL615199,BAO_0000357,
79,1,B,8,,,,11231,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,,,,,,H,Expert,CHEMBL615200,BAO_0000357,
80,1,B,8,,,,11231,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,,,,,,H,Expert,CHEMBL615201,BAO_0000357,
81,1,B,8,,,,11231,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,,,,,,H,Expert,CHEMBL615202,BAO_0000357,
82,1,B,8,,,,11231,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",,Candida albicans,,,,5476.0,H,Autocuration,CHEMBL615203,BAO_0000251,
83,1,B,8,,,,11231,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",,Candida albicans,,,,5476.0,H,Autocuration,CHEMBL615204,BAO_0000251,
84,1,B,8,,,,11231,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",,Saccharomyces cerevisiae,,,,4932.0,H,Autocuration,CHEMBL615205,BAO_0000251,
85,1,B,8,,,,11231,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",,Saccharomyces cerevisiae,,,,4932.0,H,Autocuration,CHEMBL615206,BAO_0000251,
86,1,B,8,,,,12083,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",2107.0,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL615207,BAO_0000251,
87,1,B,8,,,,11231,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",,Rattus norvegicus,,,,10116.0,H,Autocuration,CHEMBL827084,BAO_0000019,
88,1,B,8,,,,11231,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",,Rattus norvegicus,,,,10116.0,H,Autocuration,CHEMBL615208,BAO_0000019,
89,1,B,8,,,,11231,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",,Rattus norvegicus,,,,10116.0,H,Autocuration,CHEMBL615209,BAO_0000019,
90,1,B,9,,,,12083,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",2107.0,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL615210,BAO_0000251,
91,1,B,9,,,,12083,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",2107.0,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL615211,BAO_0000251,
92,1,B,9,,,,12083,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",2107.0,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL615212,BAO_0000251,
93,1,B,8,,,,11377,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,,,,,,H,Expert,CHEMBL615213,BAO_0000357,
94,1,B,8,,,,11377,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,,,,,,H,Expert,CHEMBL615273,BAO_0000357,
95,1,F,1,HepG2,,,81020,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,Homo sapiens,,726.0,,9606.0,N,Expert,CHEMBL615274,BAO_0000219,
96,1,F,1,HepG2,,,81020,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,,Homo sapiens,,726.0,,9606.0,N,Intermediate,CHEMBL615275,BAO_0000219,
97,1,F,1,HepG2,,,81020,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,,Homo sapiens,,726.0,,9606.0,N,Intermediate,CHEMBL615276,BAO_0000219,
98,1,F,1,HepG2,,,81020,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,,Homo sapiens,,726.0,,9606.0,N,Intermediate,CHEMBL615277,BAO_0000219,
99,1,F,1,HepG2,,,81020,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,,Homo sapiens,,726.0,,9606.0,N,Intermediate,CHEMBL615326,BAO_0000219,
100,1,F,1,,,,50606,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,Hepatitis B virus,,,,10407.0,N,Expert,CHEMBL883130,BAO_0000218,
101,1,F,1,HepG2,,,81020,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,,Homo sapiens,,726.0,,9606.0,N,Intermediate,CHEMBL884519,BAO_0000219,
102,1,F,1,HepG2,,,81020,Concentration required to inhibit 50% of 2.2.15 cell line,,Homo sapiens,,726.0,,9606.0,N,Intermediate,CHEMBL615327,BAO_0000219,
103,1,A,1,HepG2,,,81020,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,,Homo sapiens,,726.0,,9606.0,N,Intermediate,CHEMBL615328,BAO_0000219,
104,1,F,1,2.2.15,,,50587,Cytotoxic activity of compound against uninfected 2.2.15 cells.,,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL615329,BAO_0000218,
105,1,F,1,2.2.15,,,50587,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL615330,BAO_0000218,
106,1,F,1,2.2.15,,,50606,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",,Hepatitis B virus,,,,10407.0,N,Expert,CHEMBL615331,BAO_0000218,
107,1,F,1,2.2.15,,,50587,In vitro anti-HBV activity in 2.2.15 cells,,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL615332,BAO_0000218,
108,1,F,1,2.2.15,,,50587,In vitro anti-HBV activity in 2.2.15 cells; Not determined,,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL615333,BAO_0000218,
109,1,F,1,2.2.15,,,50587,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL615334,BAO_0000218,
110,1,F,1,2.2.15,,,50587,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL615335,BAO_0000218,
111,1,F,1,2.2.15,,,50587,Cytotoxicity in 2.2.15 cells,,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL615336,BAO_0000218,
112,1,F,1,2.2.15,,,50587,Cytotoxicity in 2.2.15 cells; Not determined,,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL615337,BAO_0000218,
113,1,F,1,2.2.15,,,50587,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL615338,BAO_0000218,
114,1,F,1,2.2.15,,,50587,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL615339,BAO_0000218,
115,1,F,1,2.2.15,,,50587,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL615340,BAO_0000218,
116,1,F,1,HepG2,,,81020,Antiviral activity against HBV was determined in 2.215 cell line,,Homo sapiens,,726.0,,9606.0,N,Intermediate,CHEMBL615341,BAO_0000219,
117,1,B,0,,,,22226,Inhibition of 20-HETE synthesis in human renal microsomes,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL615342,BAO_0000251,
118,1,B,0,,,,22226,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,,,,,,U,Autocuration,CHEMBL615343,BAO_0000019,
119,1,F,1,2008,,,80612,Inhibitory concentration against 2008 (ovarian) cells,,Homo sapiens,,388.0,,9606.0,N,Intermediate,CHEMBL615344,BAO_0000219,
120,1,F,1,2008,,,80612,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,,Homo sapiens,,388.0,,9606.0,N,Intermediate,CHEMBL615345,BAO_0000219,
121,1,F,1,2008,,,80612,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),,Homo sapiens,,388.0,,9606.0,N,Intermediate,CHEMBL615346,BAO_0000219,
122,1,F,1,2008,,,80612,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,,Homo sapiens,,388.0,,9606.0,N,Intermediate,CHEMBL615347,BAO_0000219,
123,1,F,1,2008,,,80612,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,,Homo sapiens,,388.0,,9606.0,N,Intermediate,CHEMBL615348,BAO_0000219,
124,1,F,1,2008/R,,,80613,In vitro inhibition of 2008/R ovarian cancer cell line,,Homo sapiens,,561.0,,9606.0,N,Intermediate,CHEMBL827085,BAO_0000219,
125,1,F,1,2008/R,,,80613,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,,Homo sapiens,,561.0,,9606.0,N,Intermediate,CHEMBL615349,BAO_0000219,
126,1,F,1,2008/S,,,80614,In vitro inhibition of 2008/S ovarian cancer cell line,,Homo sapiens,,389.0,,9606.0,N,Intermediate,CHEMBL615350,BAO_0000219,
127,1,F,1,2008/S,,,80614,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,,Homo sapiens,,389.0,,9606.0,N,Intermediate,CHEMBL615351,BAO_0000219,
128,1,B,2,,,,100256,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,,Homo sapiens,,,,9606.0,S,Expert,CHEMBL615352,BAO_0000220,
129,1,B,2,,,,100256,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,,Homo sapiens,,,,9606.0,S,Intermediate,CHEMBL615353,BAO_0000220,
130,1,B,2,,,,100256,Inhibition of chymotrypsin-like activity of 20S proteasome,,,,,,,S,Expert,CHEMBL615354,BAO_0000220,
131,1,B,2,,,,100256,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,,,,,,S,Expert,CHEMBL615355,BAO_0000220,
132,1,B,2,,,,100256,Inhibitory activity against 20S proteosome,,,,,,,S,Intermediate,CHEMBL615356,BAO_0000220,
133,1,B,0,,,,22226,Compound was tested for inhibitory activity against tryptase,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL615357,BAO_0000019,
134,1,F,1,HepG2,,,81020,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,,Homo sapiens,,726.0,,9606.0,N,Intermediate,CHEMBL615358,BAO_0000219,
135,1,F,1,HepG2,,,81020,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,,Homo sapiens,,726.0,,9606.0,N,Intermediate,CHEMBL827086,BAO_0000219,
136,1,B,0,,,,22226,Compound was tested for the inhibition of Alpha-glucosidase,,,,,,,U,Autocuration,CHEMBL615359,BAO_0000019,
137,1,B,8,,,,235,Inhibitory concentration against human neutrophil elastase (HNE),,,,,,,H,Autocuration,CHEMBL615360,BAO_0000357,
138,1,F,0,,,,22226,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,948.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL615361,BAO_0000218,
139,1,F,8,,,,19640,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,,,,,,H,Autocuration,CHEMBL615362,BAO_0000019,
140,1,F,8,,,,19640,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,,,,,,H,Expert,CHEMBL615363,BAO_0000019,
141,1,B,8,,,,19640,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,,,,,,H,Autocuration,CHEMBL615364,BAO_0000357,
142,1,F,8,,,,19640,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,,,,,,H,Expert,CHEMBL615365,BAO_0000019,
143,1,F,1,P338,,,80360,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,,Mus musculus,,524.0,,10090.0,N,Intermediate,CHEMBL615366,BAO_0000219,
144,1,F,1,P338,,,80360,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,,Mus musculus,,524.0,,10090.0,N,Intermediate,CHEMBL615367,BAO_0000219,
145,1,F,1,PBL,,,80384,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,,Homo sapiens,,554.0,,9606.0,N,Intermediate,CHEMBL615368,BAO_0000219,
146,1,F,0,,,,22226,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,,Ovis aries,,,,9940.0,U,Autocuration,CHEMBL615369,BAO_0000019,
147,1,F,0,,,,22226,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,,Ovis aries,,,,9940.0,U,Autocuration,CHEMBL615370,BAO_0000019,
148,1,B,8,,,,191,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,,,,,,H,Autocuration,CHEMBL615673,BAO_0000357,
149,1,F,0,,,,22226,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL615674,BAO_0000019,
150,1,F,0,,,,22226,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL615675,BAO_0000019,
151,1,F,0,CCRF-CEM,,,22226,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,,Homo sapiens,,635.0,,9606.0,U,Autocuration,CHEMBL615676,BAO_0000219,
152,1,F,0,CCRF-CEM,,,22226,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,,Homo sapiens,,635.0,,9606.0,U,Autocuration,CHEMBL615677,BAO_0000219,
153,1,F,0,CCRF-CEM,,,22226,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,,Homo sapiens,,635.0,,9606.0,U,Autocuration,CHEMBL615678,BAO_0000219,
154,1,F,0,CCRF-CEM,,,22226,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,,Homo sapiens,,635.0,,9606.0,U,Autocuration,CHEMBL615679,BAO_0000219,
155,1,F,0,,,,22226,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL615680,BAO_0000019,
156,1,F,0,,,,22226,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL615681,BAO_0000019,
157,1,B,6,,,,104290,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,,,,,,H,Autocuration,CHEMBL857972,BAO_0000249,
158,1,F,1,,,,50264,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,,Streptococcus pyogenes,,,,1314.0,N,Intermediate,CHEMBL857899,BAO_0000218,
159,1,F,1,,,,50527,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),,Human herpesvirus 3,,,,10335.0,N,Intermediate,CHEMBL615371,BAO_0000218,
160,1,F,1,HEL,,,50527,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,,vericilla zoster virus,,468.0,,10335.0,N,Expert,CHEMBL615372,BAO_0000218,
161,1,F,1,,,,50527,Antiviral activity against 07/1 strain of VZV; ND: No data,,vericilla zoster virus,,,,10335.0,N,Intermediate,CHEMBL615373,BAO_0000218,
162,1,F,1,,,,50527,Antiviral activity against 07/1 strain of VZV; ND=No data,,vericilla zoster virus,,,,10335.0,N,Intermediate,CHEMBL615374,BAO_0000218,
163,1,F,1,,,,50145,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",,escherichia cloac,,,,561.0,N,Intermediate,CHEMBL615375,BAO_0000218,
164,1,B,0,,,,22226,Ratio of Ki at A2 to Ki at A1 receptors,,,,,,,U,Autocuration,CHEMBL615376,BAO_0000019,
165,1,B,8,,,,11143,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",,Candida albicans,,,,5476.0,H,Expert,CHEMBL615377,BAO_0000249,
166,1,B,8,,,,18077,"Inhibition of 1,3-beta-glucan synthase",,Candida glabrata CBS 138,,,,284593.0,H,Expert,CHEMBL615378,BAO_0000357,
167,1,F,1,1-87 tumor cell line,,,80609,Inhibition of growth of 1-87 human tumor cell line,,Homo sapiens,,832.0,,9606.0,N,Intermediate,CHEMBL615379,BAO_0000219,
168,1,B,9,,,,12166,Inhibition of 1-lipoxygenase (LOX)in RBL cells,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL615380,BAO_0000219,
169,1,B,9,,,,100171,Inhibitory activity against soybean 1-lipoxygenase (SLO),,Glycine max,,,,3847.0,D,Autocuration,CHEMBL615381,BAO_0000357,
170,1,B,9,,,,100171,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,,Glycine max,,,,3847.0,D,Autocuration,CHEMBL615382,BAO_0000357,
171,1,B,9,,,,100171,% inhibition against soybean 1-lipoxygenase (SLO),,Glycine max,,,,3847.0,D,Autocuration,CHEMBL615383,BAO_0000357,
172,1,B,9,,,,100171,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,,Glycine max,,,,3847.0,D,Autocuration,CHEMBL615384,BAO_0000357,
173,1,B,9,,,,100171,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,,Glycine max,,,,3847.0,D,Autocuration,CHEMBL615385,BAO_0000357,
174,1,B,9,,,,100171,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,,Glycine max,,,,3847.0,D,Autocuration,CHEMBL615386,BAO_0000357,
175,1,B,9,,,,100171,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,,Glycine max,,,,3847.0,D,Autocuration,CHEMBL615387,BAO_0000357,
176,1,B,9,,,,100171,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,,Glycine max,,,,3847.0,D,Autocuration,CHEMBL615388,BAO_0000357,
177,1,B,9,,,,100171,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,,Glycine max,,,,3847.0,D,Autocuration,CHEMBL615214,BAO_0000357,
178,1,B,9,,,,100171,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,,Glycine max,,,,3847.0,D,Autocuration,CHEMBL827087,BAO_0000357,
179,1,B,9,,,,100171,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,,Glycine max,,,,3847.0,D,Autocuration,CHEMBL615215,BAO_0000357,
180,1,B,9,,,,100171,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,,Glycine max,,,,3847.0,D,Autocuration,CHEMBL615216,BAO_0000357,
181,1,B,9,,,,100171,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,,Glycine max,,,,3847.0,D,Autocuration,CHEMBL615217,BAO_0000357,
182,1,B,9,,,,100171,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,,Glycine max,,,,3847.0,D,Autocuration,CHEMBL615218,BAO_0000357,
183,1,B,9,,,,100171,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,,Glycine max,,,,3847.0,D,Autocuration,CHEMBL615219,BAO_0000357,
184,1,B,0,,,,22226,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,,Mus musculus,,,,10090.0,U,Autocuration,CHEMBL615220,BAO_0000019,
185,1,F,1,C3H 10T1/2,,,80049,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),,Mus musculus,,294.0,,10090.0,N,Intermediate,CHEMBL615221,BAO_0000219,
186,1,F,0,,,,22226,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,,,,,,U,Intermediate,CHEMBL615222,BAO_0000019,
187,1,B,8,,,,11489,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,,,,,,H,Autocuration,CHEMBL615223,BAO_0000357,
188,1,B,8,,,,11862,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,,,,,,H,Autocuration,CHEMBL615224,BAO_0000357,
189,1,B,8,,,,11862,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,,,,,,H,Autocuration,CHEMBL615225,BAO_0000357,
190,1,B,8,,,,11489,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,,,,,,H,Autocuration,CHEMBL615226,BAO_0000357,
191,1,B,8,,,,11862,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,,,,,,H,Autocuration,CHEMBL615227,BAO_0000357,
192,1,F,9,,,,12347,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,,Bos taurus,,,,9913.0,D,Expert,CHEMBL615228,BAO_0000019,
193,1,B,9,,,,100120,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL615229,BAO_0000357,
194,1,B,9,,,,100120,Inhibition of 11 beta-hydroxylase from rat adrenal gland,2369.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL615230,BAO_0000357,
195,1,B,9,,,,100120,Inhibition of rat adrenal 11-beta-hydroxylase,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL615231,BAO_0000357,
196,1,B,9,,,,100120,Inhibition of rat adrenal 11-beta-hydroxylase,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL884520,BAO_0000357,
197,1,B,9,,,,100120,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL615232,BAO_0000357,
198,1,B,8,,,,10328,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,,,,,,H,Autocuration,CHEMBL615233,BAO_0000019,
199,1,B,8,,,,11490,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,,,,,,H,Autocuration,CHEMBL827088,BAO_0000357,
200,1,B,8,,,,11490,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,,,,,,H,Autocuration,CHEMBL615234,BAO_0000357,
201,1,F,8,,,,11134,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,,,,,,H,Autocuration,CHEMBL615235,BAO_0000019,
202,1,B,8,,,,12052,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,,,,,H,Autocuration,CHEMBL615236,BAO_0000019,
203,1,B,8,,,,11134,Compound was tested in vitro for inhibition of 12-LO human platelet,,,,,,,H,Autocuration,CHEMBL615237,BAO_0000019,
204,1,F,8,,,,11134,Inhibitory concentration against human platelet 12-lipoxygenase,,,,,,,H,Autocuration,CHEMBL615238,BAO_0000019,
205,1,B,8,,,,11134,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,,,,,,H,Autocuration,CHEMBL615239,BAO_0000019,
206,1,F,9,,,,11134,Inhibitory concentration against human platelet 12-lipoxygenase,,Homo sapiens,,,,9606.0,D,Autocuration,CHEMBL615240,BAO_0000019,
207,1,B,8,,,,11835,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,,,,,,H,Expert,CHEMBL615241,BAO_0000019,
208,1,B,8,,,,11601,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,,,,,,H,Expert,CHEMBL615242,BAO_0000357,
209,1,B,8,,,,11134,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,,,,,,H,Autocuration,CHEMBL615243,BAO_0000019,
210,1,B,8,,,,11134,Inhibitory activity against human platelet 12-lipoxygenase,,,,,,,H,Autocuration,CHEMBL615244,BAO_0000019,
211,1,B,8,,,,11134,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,,,,,,H,Autocuration,CHEMBL615245,BAO_0000019,
212,1,B,8,,,,11134,% inhibition against human platelet 12-lipoxygenase (12-HLO),,,,,,,H,Autocuration,CHEMBL615246,BAO_0000019,
213,1,B,8,,,,11134,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,,,,,,H,Autocuration,CHEMBL615247,BAO_0000019,
214,1,B,8,,,,11134,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,,,,,,H,Autocuration,CHEMBL615248,BAO_0000019,
215,1,B,8,,,,11601,Inhibitory activity towards porcine 12-lipoxygenase,,,,,,,H,Autocuration,CHEMBL615249,BAO_0000357,
216,1,B,8,,,,11601,Tested for inhibition against porcine 12-LO,,,,,,,H,Autocuration,CHEMBL615250,BAO_0000357,
217,1,B,8,,,,12052,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,,,,,,H,Autocuration,CHEMBL615251,BAO_0000019,
218,1,B,8,,,,12052,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,,,,,,H,Autocuration,CHEMBL615252,BAO_0000019,
219,1,B,8,,,,12052,In vitro inhibition of rat platelet 12-lipoxygenase,,,,,,,H,Expert,CHEMBL828340,BAO_0000019,
220,1,B,8,,,,12052,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,,,,,H,Autocuration,CHEMBL615253,BAO_0000019,
221,1,B,8,,,,12052,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,,,,,,H,Autocuration,CHEMBL615254,BAO_0000019,
222,1,B,8,,,,12052,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,,,,,,H,Autocuration,CHEMBL615255,BAO_0000019,
223,1,B,8,,,,12052,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,,,,,H,Autocuration,CHEMBL615256,BAO_0000019,
224,1,B,8,,,,12052,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,,,,,,H,Autocuration,CHEMBL615257,BAO_0000019,
225,1,B,8,,,,12052,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,,,,,,H,Autocuration,CHEMBL615258,BAO_0000019,
226,1,F,1,41M,,,80007,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,,Homo sapiens,,621.0,,9606.0,N,Intermediate,CHEMBL615259,BAO_0000219,
227,1,F,1,41M,,,80007,In vitro antitumor activity against 41M cell line.,,Homo sapiens,,621.0,,9606.0,N,Expert,CHEMBL615260,BAO_0000219,
228,1,F,1,41M,,,80007,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,,Homo sapiens,,621.0,,9606.0,N,Intermediate,CHEMBL615261,BAO_0000219,
229,1,F,1,41M,,,80007,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,,Homo sapiens,,621.0,,9606.0,N,Intermediate,CHEMBL615262,BAO_0000219,
230,1,F,1,41M,,,80007,In vitro antitumor activity against 41McisR cell line.,,Homo sapiens,,621.0,,9606.0,N,Expert,CHEMBL615263,BAO_0000219,
231,1,F,1,41M,,,80007,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,,Homo sapiens,,621.0,,9606.0,N,Expert,CHEMBL838393,BAO_0000219,
232,1,F,1,41M,,,80007,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,,Homo sapiens,,621.0,,9606.0,N,Intermediate,CHEMBL615264,BAO_0000219,
233,1,B,9,,,,84,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),,Homo sapiens,,,,9606.0,D,Expert,CHEMBL615265,BAO_0000357,
234,1,B,9,,,,68,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,Homo sapiens,,,,9606.0,D,Expert,CHEMBL615266,BAO_0000357,
235,1,B,8,,,,68,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,,,,,,H,Expert,CHEMBL615267,BAO_0000357,
236,1,B,8,,,,10201,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,,,,,,H,Expert,CHEMBL615268,BAO_0000357,
237,1,B,8,,,,10201,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,,,,,,H,Expert,CHEMBL615269,BAO_0000357,
238,1,B,8,,,,10201,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,,,,,,H,Expert,CHEMBL615270,BAO_0000357,
239,1,B,8,,,,12220,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,,,,,,H,Autocuration,CHEMBL615271,BAO_0000357,
240,1,B,8,,,,11303,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,Escherichia coli,,,,562.0,H,Autocuration,CHEMBL615272,BAO_0000357,
241,1,B,8,,,,11303,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,Escherichia coli,,,,562.0,H,Autocuration,CHEMBL615103,BAO_0000357,
242,1,B,8,,,,11303,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",,Escherichia coli,,,,562.0,H,Autocuration,CHEMBL615104,BAO_0000357,
243,1,B,8,,,,12220,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,,,,,,H,Autocuration,CHEMBL615105,BAO_0000357,
244,1,B,8,,,,12220,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,,,,,,H,Autocuration,CHEMBL872866,BAO_0000357,
245,1,B,8,,,,11303,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL615106,BAO_0000357,
246,1,B,8,,,,11303,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL615107,BAO_0000019,
247,1,B,8,,,,11303,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL615108,BAO_0000357,
248,1,B,8,,,,11303,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL615109,BAO_0000357,
249,1,B,8,,,,11303,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL615110,BAO_0000357,
250,1,B,8,,,,11303,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL840105,BAO_0000019,
251,1,B,8,,,,11303,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL615111,BAO_0000019,
252,1,B,8,,,,11303,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL615112,BAO_0000019,
253,1,B,8,,,,11303,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL615113,BAO_0000019,
254,1,B,8,,,,11303,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL615114,BAO_0000019,
255,1,B,8,,,,11303,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL615115,BAO_0000357,
256,1,B,8,,,,11303,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL615116,BAO_0000019,
257,1,B,8,,,,11303,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,,,,,,H,Autocuration,CHEMBL615698,BAO_0000357,
258,1,B,0,,,,22226,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",,Sus scrofa,,,,9823.0,U,Autocuration,CHEMBL615699,BAO_0000019,
259,1,B,0,,,,22226,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",,Sus scrofa,,,,9823.0,U,Autocuration,CHEMBL615700,BAO_0000019,
260,1,B,8,,,,100249,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,,Saccharomyces cerevisiae,,,,4932.0,H,Expert,CHEMBL615701,BAO_0000357,
261,1,B,0,,,,22226,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL615702,BAO_0000019,
262,1,B,0,,,,22226,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL615703,BAO_0000019,
263,1,B,0,,,,22226,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL615704,BAO_0000019,
264,1,F,6,,,,104698,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,,,,,,H,Autocuration,CHEMBL615705,BAO_0000019,
265,1,F,6,,,,104698,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,,,,,,H,Autocuration,CHEMBL615706,BAO_0000019,
266,1,F,9,,,,20033,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,2116.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL615707,BAO_0000221,
267,1,F,8,,,,10623,Stimulatory activity of intragastric pressure was tested in the rat,,,,,,,H,Expert,CHEMBL615708,BAO_0000019,
268,1,B,8,,,,121,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,,,,,,H,Autocuration,CHEMBL615709,BAO_0000357,
269,1,F,0,,,,22226,Dose to reduce neuronal firing against 5-HT cells in rats (iv),,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL615710,BAO_0000218,
270,1,F,8,,,,12688,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,,,,,,H,Autocuration,CHEMBL615711,BAO_0000019,
271,1,B,9,,,,121,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL615712,BAO_0000357,
272,1,B,9,,,,121,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL836325,BAO_0000357,
273,1,F,8,,,,12198,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,,,,,,H,Autocuration,CHEMBL615713,BAO_0000019,
274,1,B,8,,,,12198,Inhibition constant of high-affinity 5-HT uptake,,,,,,,H,Autocuration,CHEMBL615714,BAO_0000357,
275,1,F,8,,,,12198,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,,,,,,H,Autocuration,CHEMBL615715,BAO_0000019,
276,1,F,8,,,,12198,Maximum rate was determined for high affinity transport of 5-HT,,,,,,,H,Autocuration,CHEMBL615716,BAO_0000019,
277,1,F,4,,,,104714,Compound was tested for agonistic activity against 5-HT uptake,,,,,,,H,Autocuration,CHEMBL615717,BAO_0000019,
278,1,B,8,,,,10577,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,,,,,,H,Expert,CHEMBL881818,BAO_0000019,
279,1,B,8,,,,105,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,,Bos taurus,,,,9913.0,H,Expert,CHEMBL884540,BAO_0000357,
280,1,B,5,,,,104744,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL615718,BAO_0000224,
281,1,B,4,,,,104744,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,,,,,,H,Autocuration,CHEMBL615719,BAO_0000224,
282,1,B,4,,,,104744,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,,,,,,,H,Autocuration,CHEMBL615720,BAO_0000249,
283,1,B,4,,,,104744,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,,,,,,,H,Autocuration,CHEMBL615721,BAO_0000249,
284,1,B,4,,,,104744,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,,,,,H,Autocuration,CHEMBL615722,BAO_0000019,
285,1,F,8,,,,51,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,,,,,,H,Autocuration,CHEMBL615723,BAO_0000019,
286,1,B,8,,,,51,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,10000000.0,,,,,,H,Autocuration,CHEMBL615724,BAO_0000221,
287,1,B,8,,,,51,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,10000000.0,,,,,,H,Autocuration,CHEMBL615725,BAO_0000221,
288,1,B,8,,,,51,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,10000000.0,,,,,,H,Autocuration,CHEMBL615726,BAO_0000221,
289,1,F,8,,,In vivo,10576,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),,,,,,,H,Autocuration,CHEMBL615727,BAO_0000218,
290,1,F,9,,,,105570,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL615728,BAO_0000019,
291,1,B,8,CHO,,,279,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,,449.0,,,H,Autocuration,CHEMBL857971,BAO_0000219,
292,1,B,8,,,,107,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL615729,BAO_0000357,
293,1,F,9,,,,12687,Efficacy against 5-hydroxytryptamine 2A receptor,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL615730,BAO_0000019,
294,1,F,8,,,,12687,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,,,,,,H,Expert,CHEMBL615731,BAO_0000019,
295,1,F,8,,,,12687,Relative potency towards 5-HT2A receptor of rat tail artery,,,,,,,H,Expert,CHEMBL615732,BAO_0000019,
296,1,F,8,,,,12687,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,,,,,,H,Expert,CHEMBL615733,BAO_0000019,
297,1,F,8,,,,12687,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,,,,,,H,Expert,CHEMBL615734,BAO_0000019,
298,1,F,8,,,,12687,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,,,,,,H,Autocuration,CHEMBL615735,BAO_0000019,
299,1,F,8,,,,12687,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,,,,,,H,Expert,CHEMBL615736,BAO_0000019,
300,1,F,9,,,,20033,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,2116.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL615737,BAO_0000221,
301,1,F,9,,,,20033,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),2116.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL615738,BAO_0000221,
302,1,F,9,,,,20033,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,2116.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL615739,BAO_0000221,
303,1,B,8,,,,10623,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,,,,,,H,Autocuration,CHEMBL615278,BAO_0000357,
304,1,F,9,,,,10623,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL615279,BAO_0000019,
305,1,B,8,,,,168,Binding affinity against 5-hydroxytryptamine 4 receptor,,,,,,,H,Expert,CHEMBL615280,BAO_0000357,
306,1,B,0,,,,22226,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,,Gallus gallus,,,,9031.0,U,Autocuration,CHEMBL615281,BAO_0000019,
307,1,F,0,,,,22226,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL615282,BAO_0000019,
308,1,F,0,,,,22226,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL615283,BAO_0000019,
309,1,B,1,HL-60,,,80156,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,,Homo sapiens,,649.0,,9606.0,N,Autocuration,CHEMBL615284,BAO_0000219,
310,1,B,0,,,,22226,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL615285,BAO_0000019,
311,1,B,0,,,,22226,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL615286,BAO_0000019,
312,1,B,7,Oocytes,,,104703,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,,Homo sapiens,,,,9606.0,D,Autocuration,CHEMBL615287,BAO_0000219,
313,1,F,2,,,,100256,Chymotryptic inhibitory activity against 26S proteasome,,,,,,,S,Intermediate,CHEMBL615288,BAO_0000220,
314,1,B,2,,,,100256,Inhibitory activity against 26S proteasome degradation of IkB,,,,,,,S,Intermediate,CHEMBL615289,BAO_0000220,
315,1,F,1,A2780,,,81034,In vitro inhibition of 2780/DOX ovarian cancer cell line,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL615290,BAO_0000219,
316,1,F,1,A2780,,,81034,In vitro inhibition of 2780/S ovarian cancer cell line,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL884522,BAO_0000219,
317,1,F,0,,,,22226,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL615291,BAO_0000019,
318,1,B,3,,,,22222,Association constant for binding to AATT 28-mer AATT hairpin,,,,,,,M,Intermediate,CHEMBL615292,BAO_0000225,
319,1,B,3,,,,22222,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,,,,,,M,Intermediate,CHEMBL615293,BAO_0000225,
320,1,B,3,,,,22222,Reaction Rate Parameter for 28-mer AATT hairpin,,,,,,,M,Intermediate,CHEMBL615294,BAO_0000225,
321,1,B,3,,,,22222,Reaction Rate Parameter for 28-mer AATT hairpin,,,,,,,M,Intermediate,CHEMBL615295,BAO_0000225,
322,1,F,0,,,,22226,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL825021,BAO_0000019,
323,1,F,0,,,,22226,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL615296,BAO_0000019,
324,1,F,0,,,,22226,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL615297,BAO_0000019,
325,1,F,0,,,,22226,Cytotoxicity against cell line 2SC/20 determined by MTT test,,Cricetulus griseus,,,,10029.0,U,Autocuration,CHEMBL615298,BAO_0000019,
326,1,F,0,,,,22226,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,,Cricetulus griseus,,,,10029.0,U,Autocuration,CHEMBL615299,BAO_0000019,
327,1,F,0,,,,22226,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,,Cricetulus griseus,,,,10029.0,U,Autocuration,CHEMBL615300,BAO_0000019,
328,1,B,8,,,,241,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,,,,,,H,Autocuration,CHEMBL615301,BAO_0000357,
329,1,B,9,,,,241,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL615302,BAO_0000357,
330,1,B,0,,,,22226,Selectivity ratio of ID50 in liver and heart,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL615303,BAO_0000019,
331,1,B,8,,,,12132,"Selectivity, ratio of relative ID50 in liver and heart",,,,,,,H,Autocuration,CHEMBL615304,BAO_0000019,
332,1,B,8,,,,12132,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,,,,,,H,Autocuration,CHEMBL615305,BAO_0000019,
333,1,B,8,,,,12132,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,,,,,H,Autocuration,CHEMBL615306,BAO_0000218,
334,1,B,8,,,,12132,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,,,,,H,Autocuration,CHEMBL615307,BAO_0000218,
335,1,B,8,,,In vivo,12132,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,,,,,H,Autocuration,CHEMBL615308,BAO_0000218,
336,1,F,8,,,In vivo,12132,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,,,,,H,Autocuration,CHEMBL615309,BAO_0000218,
337,1,B,0,,,,22226,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,,,,,,U,Autocuration,CHEMBL615310,BAO_0000019,
338,1,B,8,,,,12132,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,,,,,,H,Autocuration,CHEMBL615311,BAO_0000019,
339,1,B,0,,,,22226,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL615312,BAO_0000019,
340,1,B,8,,,,12132,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,,,,,,H,Autocuration,CHEMBL615313,BAO_0000019,
341,1,F,8,,,,12132,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,,,,,,H,Autocuration,CHEMBL615314,BAO_0000019,
342,1,B,8,,,,12132,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,,,,,,H,Autocuration,CHEMBL615315,BAO_0000019,
343,1,B,0,,,,22226,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL615316,BAO_0000218,
344,1,B,8,,,In vivo,12132,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,,,,,,,H,Autocuration,CHEMBL615317,BAO_0000218,
345,1,B,8,,,,12132,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,,,,,H,Autocuration,CHEMBL615318,BAO_0000218,
346,1,B,0,,,,22226,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL615319,BAO_0000218,
347,1,B,8,,,,12132,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,,,,,,H,Autocuration,CHEMBL615320,BAO_0000019,
348,1,F,8,,,,12132,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,,,,,,H,Autocuration,CHEMBL615321,BAO_0000019,
349,1,B,0,,,,22226,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL615322,BAO_0000019,
350,1,B,8,,,,19690,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,Escherichia coli,,,,562.0,H,Autocuration,CHEMBL615323,BAO_0000357,
351,1,B,8,,,,19690,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,Escherichia coli,,,,562.0,H,Autocuration,CHEMBL615407,BAO_0000357,
352,1,B,8,,,,19690,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,Escherichia coli,,,,562.0,H,Autocuration,CHEMBL857267,BAO_0000357,
353,1,B,8,,,,19690,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,Escherichia coli,,,,562.0,H,Autocuration,CHEMBL615408,BAO_0000357,
354,1,B,8,,,,19690,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,,,,,,H,Autocuration,CHEMBL615409,BAO_0000357,
355,1,B,8,,,,19690,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,,,,,,H,Autocuration,CHEMBL615410,BAO_0000357,
356,1,B,8,,,,19690,Inhibition constant against 3-dehydroquinate synthase,,,,,,,H,Autocuration,CHEMBL615411,BAO_0000357,
357,1,B,8,,,,19690,Association rate constant against 3-dehydroquinate synthase,,,,,,,H,Autocuration,CHEMBL615412,BAO_0000357,
358,1,B,8,,,,19690,Rate constant against 3-dehydroquinate synthase,,,,,,,H,Autocuration,CHEMBL615413,BAO_0000357,
359,1,B,0,,,,22226,Inhibitory activity against fuc-TVII,,,,,,,U,Autocuration,CHEMBL615414,BAO_0000019,
360,1,B,9,,,,12236,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,2107.0,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL615415,BAO_0000251,
361,1,B,9,,,,12236,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,2107.0,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL615416,BAO_0000251,
362,1,B,9,,,,12236,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,2107.0,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL615417,BAO_0000251,
363,1,B,9,,,,12236,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,2107.0,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL615418,BAO_0000251,
364,1,B,9,,,,12236,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,2107.0,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL615419,BAO_0000251,
365,1,B,9,,,,12236,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,2107.0,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL615420,BAO_0000251,
366,1,B,9,,,,12236,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,2107.0,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL615421,BAO_0000251,
367,1,B,9,,,,12236,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,2107.0,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL615422,BAO_0000251,
368,1,B,9,,,,12236,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,2107.0,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL615423,BAO_0000251,
369,1,B,9,,,,12236,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,2107.0,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL872868,BAO_0000251,
370,1,B,9,,,,12236,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,2107.0,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL615424,BAO_0000251,
371,1,B,4,,,,104832,Inhibitory activity against 3-phosphoglycerate kinase.,,,,,,,H,Autocuration,CHEMBL825022,BAO_0000224,
372,1,B,4,,,,104832,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,,,,,,H,Autocuration,CHEMBL615425,BAO_0000224,
373,1,B,4,,,,104832,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,,,,,,H,Autocuration,CHEMBL615426,BAO_0000224,
374,1,B,9,,,,10612,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL615427,BAO_0000357,
375,1,F,1,3677 melanoma cell line,,,80616,Cytotoxicity on 3677 melanoma cells,,Homo sapiens,,844.0,,9606.0,N,Intermediate,CHEMBL615428,BAO_0000219,
376,1,F,1,3677 melanoma cell line,,,80616,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,,Homo sapiens,,844.0,,9606.0,N,Intermediate,CHEMBL615429,BAO_0000219,
377,1,F,1,MC-38,,,80617,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,,Mus musculus,,700.0,,10090.0,N,Intermediate,CHEMBL615430,BAO_0000219,
378,1,F,0,,,,22226,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,,Homo sapiens,,,,9606.0,U,Intermediate,CHEMBL615431,BAO_0000019,
379,1,F,0,B16,,,22226,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,,,,798.0,,,U,Autocuration,CHEMBL615432,BAO_0000218,
380,1,F,0,B16,,,22226,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,,,,798.0,,,U,Autocuration,CHEMBL615433,BAO_0000218,
381,1,F,9,,,,12464,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,,Human rhinovirus 14,,,,12131.0,D,Expert,CHEMBL615434,BAO_0000019,
382,1,F,1,,,,50085,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,,Human rhinovirus sp.,,,,169066.0,N,Intermediate,CHEMBL615435,BAO_0000218,
383,1,F,1,,,,50679,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,,human rhinovirus type 14,,,,169066.0,N,Intermediate,CHEMBL615436,BAO_0000218,
384,1,F,1,,,,50679,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,,human rhinovirus type 14,,,,169066.0,N,Intermediate,CHEMBL615437,BAO_0000218,
385,1,F,9,,,,12464,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,Human rhinovirus 14,,,,12131.0,D,Expert,CHEMBL615438,BAO_0000019,
386,1,F,9,,,,12464,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,Human rhinovirus 14,,,,12131.0,D,Expert,CHEMBL615439,BAO_0000019,
387,1,F,9,,,,12464,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,Human rhinovirus 14,,,,12131.0,D,Expert,CHEMBL615440,BAO_0000019,
388,1,F,9,,,,12464,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,,Human rhinovirus 14,,,,12131.0,D,Expert,CHEMBL615441,BAO_0000019,
389,1,F,1,,,,50665,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,,Enterovirus,,,,12059.0,N,Intermediate,CHEMBL615641,BAO_0000218,
390,1,F,1,,,,50665,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,,Enterovirus,,,,12059.0,N,Intermediate,CHEMBL872065,BAO_0000218,
391,1,F,1,,,,50665,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,,Enterovirus,,,,12059.0,N,Intermediate,CHEMBL825023,BAO_0000218,
392,1,F,1,,,,50665,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,,Enterovirus,,,,12059.0,N,Intermediate,CHEMBL615642,BAO_0000218,
393,1,B,8,,,,12464,Inhibition of human rhinovirus 3C protease,,Human rhinovirus B,,,,147712.0,H,Expert,CHEMBL615643,BAO_0000357,
394,1,B,0,,,,22226,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL615644,BAO_0000019,
395,1,F,1,3EM 37,,,80619,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),,Mus musculus,,833.0,,10090.0,N,Intermediate,CHEMBL615645,BAO_0000218,
396,1,F,1,3EM 37,,,80619,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),,Mus musculus,,833.0,,10090.0,N,Intermediate,CHEMBL615646,BAO_0000218,
397,1,F,1,3EM 37,,,80619,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),,Mus musculus,,833.0,,10090.0,N,Intermediate,CHEMBL615647,BAO_0000218,
398,1,F,1,3EM 37,,,80619,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),,Mus musculus,,833.0,,10090.0,N,Intermediate,CHEMBL615648,BAO_0000218,
399,1,F,1,3EM 37,,,80619,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,,Mus musculus,,833.0,,10090.0,N,Intermediate,CHEMBL615649,BAO_0000218,
400,1,F,1,3EM 37,,,80619,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,,Mus musculus,,833.0,,10090.0,N,Intermediate,CHEMBL615650,BAO_0000218,
401,1,F,1,3LL cell line,,,80620,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,Mus musculus,,847.0,,10090.0,N,Intermediate,CHEMBL615651,BAO_0000218,
402,1,F,1,3LL cell line,,,80620,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,Mus musculus,,847.0,,10090.0,N,Intermediate,CHEMBL615652,BAO_0000218,
403,1,F,1,3LL cell line,,,80620,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,,Mus musculus,,847.0,,10090.0,N,Expert,CHEMBL615653,BAO_0000218,
404,1,F,1,3LL cell line,,,80620,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,,Mus musculus,,847.0,,10090.0,N,Intermediate,CHEMBL615654,BAO_0000219,
405,1,F,1,3LL cell line,,,80620,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,,Mus musculus,,847.0,,10090.0,N,Intermediate,CHEMBL615655,BAO_0000219,
406,1,F,1,3LL cell line,,,80620,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,,Mus musculus,,847.0,,10090.0,N,Intermediate,CHEMBL825024,BAO_0000219,
407,1,F,1,3LL cell line,,,80620,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,,Mus musculus,,847.0,,10090.0,N,Intermediate,CHEMBL615656,BAO_0000219,
408,1,F,1,3LL cell line,,,80620,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,,Mus musculus,,847.0,,10090.0,N,Intermediate,CHEMBL615657,BAO_0000219,
409,1,F,1,3LL cell line,,,80620,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,,Mus musculus,,847.0,,10090.0,N,Intermediate,CHEMBL615658,BAO_0000219,
410,1,F,1,3LL cell line,,,80620,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,,Mus musculus,,847.0,,10090.0,N,Intermediate,CHEMBL615659,BAO_0000219,
411,1,F,1,3LL cell line,,,80620,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,,Mus musculus,,847.0,,10090.0,N,Intermediate,CHEMBL615660,BAO_0000219,
412,1,F,1,3LL cell line,,,80620,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,Mus musculus,,847.0,,10090.0,N,Intermediate,CHEMBL615661,BAO_0000219,
413,1,F,1,3LL cell line,,,80620,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,,Mus musculus,,847.0,,10090.0,N,Intermediate,CHEMBL615662,BAO_0000219,
414,1,F,1,3LL cell line,,,80620,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,,Mus musculus,,847.0,,10090.0,N,Intermediate,CHEMBL615663,BAO_0000219,
415,1,F,1,3LL cell line,,,80620,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,,Mus musculus,,847.0,,10090.0,N,Intermediate,CHEMBL615664,BAO_0000219,
416,1,F,1,3LL cell line,,,80620,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,,Mus musculus,,847.0,,10090.0,N,Intermediate,CHEMBL615665,BAO_0000219,
417,1,F,1,3LL cell line,,,80620,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,Mus musculus,,847.0,,10090.0,N,Intermediate,CHEMBL615666,BAO_0000219,
418,1,F,1,3LL cell line,,,80620,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,,Mus musculus,,847.0,,10090.0,N,Intermediate,CHEMBL615667,BAO_0000219,
419,1,F,1,3LL cell line,,,80620,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,,Mus musculus,,847.0,,10090.0,N,Intermediate,CHEMBL615668,BAO_0000219,
420,1,F,1,3LL cell line,,,80620,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,,Mus musculus,,847.0,,10090.0,N,Intermediate,CHEMBL615669,BAO_0000219,
421,1,F,1,3LL cell line,,,80620,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,,Mus musculus,,847.0,,10090.0,N,Intermediate,CHEMBL615670,BAO_0000219,
422,1,F,1,3LL cell line,,,80620,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,,Mus musculus,,847.0,,10090.0,N,Intermediate,CHEMBL836739,BAO_0000219,
423,1,F,1,3LL cell line,,,80620,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,,Mus musculus,,847.0,,10090.0,N,Intermediate,CHEMBL615671,BAO_0000219,
424,1,F,1,3LL cell line,,,80620,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,,Mus musculus,,847.0,,10090.0,N,Intermediate,CHEMBL615672,BAO_0000219,
425,1,F,1,3LL cell line,,,80620,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,,Mus musculus,,847.0,,10090.0,N,Intermediate,CHEMBL615791,BAO_0000219,
426,1,F,1,3LL cell line,,,80620,spermine levels in 3LL cells after the treatment of 1 uM of Compound,,Mus musculus,,847.0,,10090.0,N,Intermediate,CHEMBL615792,BAO_0000219,
427,1,F,1,3LL cell line,,,80620,spermine levels in 3LL cells after the treatment of 10 uM of Compound,,Mus musculus,,847.0,,10090.0,N,Intermediate,CHEMBL615793,BAO_0000219,
428,1,F,1,3LL cell line,,,80620,spermine levels in 3LL cells after the treatment of 250 uM of Compound,,Mus musculus,,847.0,,10090.0,N,Intermediate,CHEMBL615794,BAO_0000219,
429,1,F,1,3LL cell line,,,80620,spermine levels in 3LL cells after the treatment of 50 uM of Compound,,Mus musculus,,847.0,,10090.0,N,Intermediate,CHEMBL615795,BAO_0000219,
430,1,F,1,3LLD122,,,80621,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,,Homo sapiens,,971.0,,9606.0,N,Intermediate,CHEMBL615590,BAO_0000219,
431,1,F,0,,,,22226,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,,,,,,U,Autocuration,CHEMBL615591,BAO_0000218,
432,1,F,0,,,,22226,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,,,,,,U,Autocuration,CHEMBL615592,BAO_0000218,
433,1,F,0,,,,22226,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,,,,,,U,Autocuration,CHEMBL615593,BAO_0000218,
434,1,F,0,,,,22226,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,,,,,,U,Autocuration,CHEMBL615594,BAO_0000218,
435,1,F,1,NIH3T3,,,80951,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,Mus musculus,,723.0,,10090.0,N,Intermediate,CHEMBL615595,BAO_0000219,
436,1,F,1,NIH3T3,,,80951,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,Mus musculus,,723.0,,10090.0,N,Intermediate,CHEMBL615596,BAO_0000219,
437,1,F,8,NIH3T3,,,11169,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,,,,723.0,,,H,Expert,CHEMBL615597,BAO_0000219,
438,1,F,1,NIH3T3,,,80951,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,,Mus musculus,,723.0,,10090.0,N,Intermediate,CHEMBL615598,BAO_0000219,
439,1,F,1,NIH3T3,,,80951,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,,Mus musculus,,723.0,,10090.0,N,Intermediate,CHEMBL615599,BAO_0000219,
440,1,F,1,NIH3T3,,,80951,Effective dose against murine 3T3 fibroblasts cells,,Mus musculus,,723.0,,10090.0,N,Expert,CHEMBL615600,BAO_0000219,
441,1,F,1,NIH3T3,,,80951,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,,Mus musculus,,723.0,,10090.0,N,Expert,CHEMBL615601,BAO_0000219,
442,1,F,1,NIH3T3,,,80951,Cytotoxic effect on 3T3 cells,,Mus musculus,,723.0,,10090.0,N,Expert,CHEMBL615602,BAO_0000219,
443,1,F,1,NIH3T3,,,80951,Cytotoxic effect on 3T3 cells,,Mus musculus,,723.0,,10090.0,N,Expert,CHEMBL615603,BAO_0000219,
444,1,F,1,NIH3T3,,,80951,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,,Mus musculus,,723.0,,10090.0,N,Intermediate,CHEMBL615604,BAO_0000219,
445,1,F,1,NIH3T3,,,80951,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,Mus musculus,,723.0,,10090.0,N,Intermediate,CHEMBL615605,BAO_0000219,
446,1,F,1,NIH3T3,,,80951,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,,Mus musculus,,723.0,,10090.0,N,Intermediate,CHEMBL615606,BAO_0000219,
447,1,F,1,NIH3T3,,,80951,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,,Mus musculus,,723.0,,10090.0,N,Expert,CHEMBL884526,BAO_0000219,
448,1,F,1,NIH3T3,,,80951,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,,Mus musculus,,723.0,,10090.0,N,Expert,CHEMBL615607,BAO_0000219,
449,1,F,1,NIH3T3,,,80951,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,,Mus musculus,,723.0,,10090.0,N,Intermediate,CHEMBL615608,BAO_0000219,
450,1,F,1,NIH3T3,,,80951,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,,Mus musculus,,723.0,,10090.0,N,Expert,CHEMBL615609,BAO_0000219,
451,1,F,1,NIH3T3,,,80951,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,,Mus musculus,,723.0,,10090.0,N,Expert,CHEMBL615682,BAO_0000219,
452,1,F,1,NIH3T3,,,80951,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,,Mus musculus,,723.0,,10090.0,N,Intermediate,CHEMBL615683,BAO_0000219,
453,1,F,1,NIH3T3,,,80951,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,,Mus musculus,,723.0,,10090.0,N,Expert,CHEMBL615684,BAO_0000218,
454,1,F,7,,,,104860,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,,Mus musculus,,,,10090.0,D,Autocuration,CHEMBL615685,BAO_0000219,
455,1,F,1,NIH3T3,,,80951,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,,Mus musculus,,723.0,,10090.0,N,Expert,CHEMBL615686,BAO_0000219,
456,1,F,1,NIH3T3,,,80951,Inhibitory activity against 3T3 cell line,,Mus musculus,,723.0,,10090.0,N,Intermediate,CHEMBL615687,BAO_0000219,
457,1,F,1,NIH3T3,,,80951,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,,Mus musculus,,723.0,,10090.0,N,Intermediate,CHEMBL884523,BAO_0000219,
458,1,F,8,,,,11169,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,,,,,,H,Expert,CHEMBL615688,BAO_0000019,
459,1,F,1,NIH3T3,,,80951,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,,Mus musculus,,723.0,,10090.0,N,Intermediate,CHEMBL615689,BAO_0000219,
460,1,F,1,NIH3T3,,,80951,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,,Mus musculus,,723.0,,10090.0,N,Intermediate,CHEMBL615690,BAO_0000219,
461,1,F,8,,,,11169,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,,,,,,H,Expert,CHEMBL615691,BAO_0000019,
462,1,F,8,,,,11169,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,,,,,,H,Expert,CHEMBL615692,BAO_0000019,
463,1,F,1,NIH3T3,,,80951,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,Mus musculus,,723.0,,10090.0,N,Intermediate,CHEMBL615693,BAO_0000219,
464,1,F,1,NIH3T3,,,80951,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,,Mus musculus,,723.0,,10090.0,N,Expert,CHEMBL615324,BAO_0000219,
465,1,F,9,NIH3T3,,,9,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,,Homo sapiens,,723.0,,9606.0,D,Expert,CHEMBL615325,BAO_0000219,
466,1,F,9,NIH3T3,,,9,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),,Homo sapiens,,723.0,,9606.0,D,Expert,CHEMBL615490,BAO_0000219,
467,1,F,9,NIH3T3,,,188,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,,Homo sapiens,,723.0,,9606.0,D,Expert,CHEMBL615491,BAO_0000219,
468,1,F,9,NIH3T3,,,188,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),,Homo sapiens,,723.0,,9606.0,D,Expert,CHEMBL615492,BAO_0000219,
469,1,F,1,NIH3T3,,,80951,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,,Mus musculus,,723.0,,10090.0,N,Intermediate,CHEMBL615493,BAO_0000219,
470,1,F,1,NIH3T3,,,80951,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,,Mus musculus,,723.0,,10090.0,N,Intermediate,CHEMBL615494,BAO_0000219,
471,1,F,1,NIH3T3,,,80951,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,,Mus musculus,,723.0,,10090.0,N,Intermediate,CHEMBL615495,BAO_0000219,
472,1,F,1,NIH3T3,,,80951,Inhibitory concentration was calculated on 3T3 cells by using growth assay,,Mus musculus,,723.0,,10090.0,N,Intermediate,CHEMBL615496,BAO_0000219,
473,1,F,1,NIH3T3,,,80951,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,,Mus musculus,,723.0,,10090.0,N,Intermediate,CHEMBL615497,BAO_0000219,
474,1,F,1,NIH3T3,,,80951,Inhibition of Swiss 3T3 mouse fibroblast proliferation,,Mus musculus,,723.0,,10090.0,N,Expert,CHEMBL615498,BAO_0000219,
475,1,A,1,NIH3T3,,,80951,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,,Mus musculus,,723.0,,10090.0,N,Intermediate,CHEMBL615499,BAO_0000219,
476,1,F,1,NIH3T3,,,80951,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,,Mus musculus,,723.0,,10090.0,N,Expert,CHEMBL835522,BAO_0000219,
477,1,F,1,NIH3T3,,,80951,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,,Mus musculus,,723.0,,10090.0,N,Intermediate,CHEMBL615500,BAO_0000219,
478,1,F,1,NIH3T3,,,80951,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,Mus musculus,,723.0,,10090.0,N,Intermediate,CHEMBL615501,BAO_0000219,
479,1,F,1,NIH3T3,,,80951,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,Mus musculus,,723.0,,10090.0,N,Intermediate,CHEMBL615502,BAO_0000219,
480,1,F,1,NIH3T3,,,80951,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,Mus musculus,,723.0,,10090.0,N,Intermediate,CHEMBL615503,BAO_0000219,
481,1,F,1,NIH3T3,,,80951,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,Mus musculus,,723.0,,10090.0,N,Intermediate,CHEMBL615504,BAO_0000219,
482,1,F,1,NIH3T3,,,80951,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,Mus musculus,,723.0,,10090.0,N,Intermediate,CHEMBL615505,BAO_0000219,
483,1,F,1,NIH3T3,,,80951,Inhibition of swiss 3T3 mouse fibroblast proliferation,,Mus musculus,,723.0,,10090.0,N,Expert,CHEMBL615506,BAO_0000219,
484,1,F,1,NIH3T3,,,80951,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,,Mus musculus,,723.0,,10090.0,N,Intermediate,CHEMBL615507,BAO_0000219,
485,1,F,1,3T3-L1,,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,,,620.0,,,N,Intermediate,CHEMBL615508,BAO_0000218,
486,1,F,1,3T3-L1,,,80006,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,,Mus musculus,,620.0,,10090.0,N,Intermediate,CHEMBL615509,BAO_0000219,
487,1,F,1,3T3-L1,,,80006,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,,Mus musculus,,620.0,,10090.0,N,Intermediate,CHEMBL615510,BAO_0000219,
488,1,F,1,3T3-L1,,,80006,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,,Mus musculus,,620.0,,10090.0,N,Intermediate,CHEMBL615511,BAO_0000219,
489,1,F,1,3T3-L1,,,80006,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,,Mus musculus,,620.0,,10090.0,N,Intermediate,CHEMBL615512,BAO_0000219,
490,1,F,1,3T3-L1,,,80006,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",,Mus musculus,,620.0,,10090.0,N,Intermediate,CHEMBL615513,BAO_0000218,
491,1,F,1,3T3-L1,,,80006,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",,Mus musculus,,620.0,,10090.0,N,Intermediate,CHEMBL615514,BAO_0000218,
492,1,F,1,3T3-L1,,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,,,,620.0,,,N,Intermediate,CHEMBL615515,BAO_0000219,
493,1,F,1,3T3-L1,,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,,,620.0,,,N,Intermediate,CHEMBL615516,BAO_0000219,
494,1,F,1,3T3-L1,,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,,,620.0,,,N,Intermediate,CHEMBL615517,BAO_0000219,
495,1,F,1,3T3-L1,,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,,,620.0,,,N,Intermediate,CHEMBL615518,BAO_0000219,
496,1,F,1,3T3-L1,,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,,,620.0,,,N,Intermediate,CHEMBL615519,BAO_0000219,
497,1,F,1,3T3-L1,,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,,,,620.0,,,N,Intermediate,CHEMBL615520,BAO_0000218,
498,1,F,1,3T3-L1,,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,,,,620.0,,,N,Intermediate,CHEMBL615521,BAO_0000218,
499,1,F,1,3T3-L1,,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,,,620.0,,,N,Intermediate,CHEMBL615522,BAO_0000218,
500,1,F,1,3T3-L1,,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,,,620.0,,,N,Intermediate,CHEMBL615523,BAO_0000218,
501,1,F,1,3T3-L1,,,80006,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,,,620.0,,,N,Expert,CHEMBL615524,BAO_0000218,
502,1,F,1,3T3-L1,,,80006,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,,,620.0,,,N,Expert,CHEMBL615525,BAO_0000218,
503,1,F,1,3T3-L1,,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,,,620.0,,,N,Intermediate,CHEMBL615526,BAO_0000218,
504,1,F,1,3T3-L1,,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,,,620.0,,,N,Intermediate,CHEMBL615527,BAO_0000218,
505,1,F,1,3T3-L1,,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,,,,620.0,,,N,Intermediate,CHEMBL615528,BAO_0000218,
506,1,F,1,3T3-L1,,,80006,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,,,620.0,,,N,Expert,CHEMBL615529,BAO_0000218,
507,1,F,1,3T3-L1,,,80006,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,,,620.0,,,N,Expert,CHEMBL615530,BAO_0000218,
508,1,F,1,3T3-L1,,,80006,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,,,620.0,,,N,Expert,CHEMBL615531,BAO_0000218,
509,1,F,1,3T3-L1,,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,,,620.0,,,N,Intermediate,CHEMBL615532,BAO_0000219,
510,1,F,1,3T3-L1,,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,,,620.0,,,N,Intermediate,CHEMBL615533,BAO_0000219,
511,1,F,1,3T3-L1,,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,,,620.0,,,N,Intermediate,CHEMBL615534,BAO_0000219,
512,1,F,1,3T3-L1,,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,,,620.0,,,N,Intermediate,CHEMBL615535,BAO_0000218,
513,1,F,1,3T3-L1,,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,,,620.0,,,N,Intermediate,CHEMBL615536,BAO_0000218,
514,1,F,1,3T3-L1,,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,,,620.0,,,N,Intermediate,CHEMBL615537,BAO_0000218,
515,1,F,1,3T3-L1,,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,,,620.0,,,N,Intermediate,CHEMBL615538,BAO_0000218,
516,1,F,1,3T3-L1,,,80006,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,,,620.0,,,N,Intermediate,CHEMBL836166,BAO_0000218,
517,1,F,8,3T3-L1,,,11214,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,,,,620.0,,,H,Expert,CHEMBL615539,BAO_0000219,
518,1,F,1,3T3-L1,,,80006,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,,Mus musculus,,620.0,,10090.0,N,Intermediate,CHEMBL615540,BAO_0000219,
519,1,F,8,3T3-L1,,,11214,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,,,,620.0,,,H,Expert,CHEMBL615541,BAO_0000219,
520,1,F,1,3T3-L1,,,80006,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,,Mus musculus,,620.0,,10090.0,N,Expert,CHEMBL615542,BAO_0000219,
521,1,F,1,3T3-L1,,,80006,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,,Mus musculus,,620.0,,10090.0,N,Intermediate,CHEMBL615543,BAO_0000219,
522,1,F,1,3T3-L1,,,80006,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,,Mus musculus,,620.0,,10090.0,N,Expert,CHEMBL615544,BAO_0000219,
523,1,F,1,3T3-L1,,,80006,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,Mus musculus,,620.0,,10090.0,N,Expert,CHEMBL615545,BAO_0000219,
524,1,F,1,3T3-L1,,,80006,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,Mus musculus,,620.0,,10090.0,N,Expert,CHEMBL615546,BAO_0000219,
525,1,F,1,3T3-L1,,,80006,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,,Mus musculus,,620.0,,10090.0,N,Expert,CHEMBL615547,BAO_0000219,
526,1,F,1,3T3-L1,,,80006,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,,Mus musculus,,620.0,,10090.0,N,Expert,CHEMBL615548,BAO_0000219,
527,1,F,1,3T3-L1,,,80006,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,,Mus musculus,,620.0,,10090.0,N,Expert,CHEMBL615549,BAO_0000219,
528,1,F,1,3T3-L1,,,80006,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,,Mus musculus,,620.0,,10090.0,N,Expert,CHEMBL615550,BAO_0000219,
529,1,F,1,3Y1 cell line,,,80622,Inhibitory activity against rat fibroblast (3Y1) cell line,,Rattus norvegicus,,1118.0,,10116.0,N,Intermediate,CHEMBL615551,BAO_0000219,
530,1,F,1,3Y1 cell line,,,80622,Mean concentration causing inhibition of cell growth in 3Y1 cells.,,Rattus norvegicus,,1118.0,,10116.0,N,Expert,CHEMBL615552,BAO_0000219,
531,1,F,1,3Y1 cell line,,,80622,Cytotoxicity in 3Y1 cells.,,Rattus norvegicus,,1118.0,,10116.0,N,Expert,CHEMBL615553,BAO_0000219,
532,1,F,1,3Y1 cell line,,,80622,Cytostatic effect in 3Y1 cells.,,Rattus norvegicus,,1118.0,,10116.0,N,Expert,CHEMBL615554,BAO_0000219,
533,1,F,1,3Y1 cell line,,,80622,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",,Rattus norvegicus,,1118.0,,10116.0,N,Intermediate,CHEMBL615555,BAO_0000219,
534,1,F,1,3Y1 cell line,,,80622,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,,Rattus norvegicus,,1118.0,,10116.0,N,Expert,CHEMBL615556,BAO_0000219,
535,1,B,0,,,,22226,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,,,,,,U,Autocuration,CHEMBL615557,BAO_0000019,
536,1,B,0,,,,22226,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,,,,,,U,Autocuration,CHEMBL615558,BAO_0000019,
537,1,B,0,,,,22226,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,,,,,,U,Autocuration,CHEMBL872066,BAO_0000019,
538,1,B,9,,,,11607,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,,Sus scrofa,,,,9823.0,D,Expert,CHEMBL615559,BAO_0000019,
539,1,B,8,,,,11607,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,,,,,,H,Autocuration,CHEMBL615560,BAO_0000019,
540,1,B,8,,,,11607,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,,,,,,H,Autocuration,CHEMBL615561,BAO_0000019,
541,1,B,8,,,,11607,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,,,,,,H,Expert,CHEMBL857062,BAO_0000019,
542,1,B,8,,,,11607,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,,,,,,H,Expert,CHEMBL615562,BAO_0000019,
543,1,B,8,,,,11607,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,,,,,,H,Autocuration,CHEMBL615563,BAO_0000019,
544,1,B,8,,,,11607,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,,,,,,H,Autocuration,CHEMBL615564,BAO_0000357,
545,1,B,8,,,,11607,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,,,,,,H,Autocuration,CHEMBL615565,BAO_0000019,
546,1,B,8,,,,11607,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,,,,,,H,Autocuration,CHEMBL615566,BAO_0000019,
547,1,B,9,,,,11607,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,,Sus scrofa,,,,9823.0,D,Expert,CHEMBL615567,BAO_0000019,
548,1,B,8,,,,11607,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,,,,,,H,Autocuration,CHEMBL615568,BAO_0000019,
549,1,B,8,,,,11607,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,,,,,,H,Autocuration,CHEMBL615569,BAO_0000357,
550,1,B,8,,,,11607,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,,,,,,H,Autocuration,CHEMBL615570,BAO_0000019,
551,1,B,8,,,,11607,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,,,,,,H,Autocuration,CHEMBL615571,BAO_0000019,
552,1,B,4,,,,104733,Binding affinity against melatonin (MT1) receptor (pC1),,,,,,,H,Autocuration,CHEMBL615572,BAO_0000224,
553,1,B,0,,,,22226,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,,,,,,U,Autocuration,CHEMBL615573,BAO_0000019,
554,1,B,0,,,,22226,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,,,,,,U,Autocuration,CHEMBL615574,BAO_0000019,
555,1,B,0,,,,22226,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,,,,,,U,Autocuration,CHEMBL615575,BAO_0000019,
556,1,B,8,,,,10619,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,,,,,,H,Autocuration,CHEMBL615576,BAO_0000357,
557,1,B,8,,,,10619,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,,,,,,H,Autocuration,CHEMBL615577,BAO_0000357,
558,1,B,8,,,,51,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,10000000.0,,,,,,H,Autocuration,CHEMBL615578,BAO_0000221,
559,1,B,8,,,,51,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,,,,,,H,Expert,CHEMBL615579,BAO_0000357,
560,1,B,8,,,,51,Binding affinity for 5-hydroxytryptamine 1A receptor,,,,,,,H,Expert,CHEMBL615580,BAO_0000357,
561,1,B,8,,,,51,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,,,,,,H,Expert,CHEMBL615581,BAO_0000019,
562,1,B,8,,,,51,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,10000000.0,,,,,,H,Autocuration,CHEMBL615582,BAO_0000221,
563,1,B,8,,,,51,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,10000000.0,,,,,,H,Autocuration,CHEMBL615583,BAO_0000221,
564,1,B,8,,,,51,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,10000000.0,,,,,,H,Autocuration,CHEMBL615584,BAO_0000221,
565,1,B,8,,,,51,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,10000000.0,,,,,,H,Autocuration,CHEMBL833691,BAO_0000221,
566,1,B,8,,,,51,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,10000000.0,,,,,,H,Autocuration,CHEMBL615585,BAO_0000221,
567,1,B,8,,,,51,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,10000000.0,,,,,,H,Autocuration,CHEMBL615586,BAO_0000221,
568,1,B,8,,,,51,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,10000000.0,,,,,,H,Autocuration,CHEMBL884524,BAO_0000221,
569,1,B,8,,,,51,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,10000000.0,,,,,,H,Autocuration,CHEMBL615587,BAO_0000221,
570,1,B,8,,,,51,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",10000000.0,,,,,,H,Autocuration,CHEMBL615588,BAO_0000221,
571,1,B,9,,,,10576,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL615589,BAO_0000249,
572,1,B,8,,,,51,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,10000000.0,Bos taurus,,,,9913.0,H,Expert,CHEMBL615442,BAO_0000221,
573,1,B,8,,,,51,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,10000000.0,,,,,,H,Autocuration,CHEMBL615443,BAO_0000221,
574,1,B,8,,,,51,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,10000000.0,,,,,,H,Autocuration,CHEMBL615444,BAO_0000221,
575,1,B,8,,,,51,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,10000000.0,,,,,,H,Expert,CHEMBL615445,BAO_0000221,
576,1,B,8,,,,51,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,10000000.0,,,,,,H,Autocuration,CHEMBL615446,BAO_0000221,
577,1,B,8,CHO,,,51,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,,,,449.0,,,H,Autocuration,CHEMBL615447,BAO_0000219,
578,1,B,8,,,,51,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,10000000.0,,,,,,H,Expert,CHEMBL615448,BAO_0000221,
579,1,B,8,,,,51,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,10000000.0,,,,,,H,Expert,CHEMBL615449,BAO_0000221,
580,1,B,8,CHO,,,51,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,,449.0,,,H,Autocuration,CHEMBL615450,BAO_0000219,
581,1,B,8,,,,51,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",10000000.0,,,,,,H,Expert,CHEMBL615451,BAO_0000221,
582,1,B,8,,,,51,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,,,,,,H,Autocuration,CHEMBL615452,BAO_0000357,
583,1,B,8,,,,51,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,10000000.0,,,,,,H,Autocuration,CHEMBL615453,BAO_0000221,
584,1,B,8,,,,51,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,10000000.0,,,,,,H,Autocuration,CHEMBL615454,BAO_0000221,
585,1,B,8,,,,51,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,10000000.0,,,,,,H,Autocuration,CHEMBL615455,BAO_0000221,
586,1,B,8,,,,51,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,10000000.0,,,,,,H,Autocuration,CHEMBL615456,BAO_0000221,
587,1,B,8,,,,51,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,10000000.0,,,,,,H,Autocuration,CHEMBL615457,BAO_0000221,
588,1,B,8,,,,51,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,10000000.0,,,,,,H,Expert,CHEMBL615458,BAO_0000218,
589,1,B,8,,,,51,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,10000000.0,,,,,,H,Expert,CHEMBL615459,BAO_0000221,
590,1,B,9,CHO,,,51,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",,Homo sapiens,,449.0,,9606.0,D,Expert,CHEMBL615460,BAO_0000219,
591,1,F,8,,,,51,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL615461,BAO_0000019,
592,1,F,8,,,,51,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL615462,BAO_0000019,
593,1,F,8,,,,51,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,10000000.0,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL615463,BAO_0000221,
594,1,B,8,,,,51,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,2116.0,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL615464,BAO_0000221,
595,1,B,8,,,,51,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,2116.0,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL615465,BAO_0000221,
596,1,B,8,,,,51,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,2116.0,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL615466,BAO_0000221,
597,1,B,8,,,,51,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,2116.0,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL615467,BAO_0000221,
598,1,B,8,,,,51,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,2116.0,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL615468,BAO_0000221,
599,1,B,8,,,,51,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,2116.0,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL615469,BAO_0000221,
600,1,B,8,,,,51,Binding affinity against 5-hydroxytryptamine 1A receptor,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL615470,BAO_0000357,
601,1,B,8,,,,51,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL615471,BAO_0000357,
602,1,B,8,,,,51,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL615472,BAO_0000357,
603,1,B,8,,,,106,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,10000000.0,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL883242,BAO_0000221,
604,1,F,8,,,,106,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,10000000.0,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL615473,BAO_0000221,
605,1,B,8,CHO,,,11863,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,Cricetulus griseus,,449.0,,10029.0,H,Autocuration,CHEMBL615474,BAO_0000218,
606,1,B,8,,,,51,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL615475,BAO_0000357,
607,1,F,8,HeLa,,,51,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,,,,308.0,,,H,Autocuration,CHEMBL615476,BAO_0000219,
608,1,F,8,HeLa,,,51,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,,,,308.0,,,H,Autocuration,CHEMBL615477,BAO_0000219,
609,1,F,8,,,,51,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL615478,BAO_0000019,
610,1,F,8,CHO,,,51,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,,,449.0,,,H,Autocuration,CHEMBL615160,BAO_0000219,
611,1,F,8,CHO,,,51,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,,,449.0,,,H,Expert,CHEMBL615161,BAO_0000219,
612,1,F,8,CHO,,,51,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,,,,449.0,,,H,Autocuration,CHEMBL615162,BAO_0000219,
613,1,F,8,CHO,,,51,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,,,,449.0,,,H,Autocuration,CHEMBL615163,BAO_0000219,
614,1,B,8,CHO,,,51,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,,449.0,,,H,Expert,CHEMBL615164,BAO_0000219,
615,1,B,8,CHO,,,51,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,,449.0,,,H,Expert,CHEMBL615165,BAO_0000219,
616,1,B,8,CHO,,,51,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,,,,449.0,,,H,Autocuration,CHEMBL615166,BAO_0000219,
617,1,F,8,,,,51,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,,,,,,H,Autocuration,CHEMBL615167,BAO_0000219,
618,1,B,9,HeLa,,,51,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,Homo sapiens,,308.0,,9606.0,D,Expert,CHEMBL615168,BAO_0000219,
619,1,B,9,HeLa,,,51,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,,Homo sapiens,,308.0,,9606.0,D,Expert,CHEMBL615169,BAO_0000219,
620,1,B,9,CHO,,,51,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,,Homo sapiens,,449.0,,9606.0,D,Expert,CHEMBL615170,BAO_0000219,
621,1,B,9,CHO,,,51,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,,Homo sapiens,,449.0,,9606.0,D,Expert,CHEMBL615171,BAO_0000219,
622,1,F,8,,,,51,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL615694,BAO_0000019,
623,1,F,8,,,,51,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL615695,BAO_0000019,
624,1,F,8,,,,51,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,,,,,H,Autocuration,CHEMBL615696,BAO_0000019,
625,1,F,8,CHO,,,51,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,,,449.0,,,H,Autocuration,CHEMBL615697,BAO_0000219,
626,1,F,9,CHO,,,51,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,Homo sapiens,,449.0,,9606.0,D,Expert,CHEMBL859410,BAO_0000219,
627,1,F,8,CHO,,,51,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,,,449.0,,,H,Autocuration,CHEMBL615841,BAO_0000219,
628,1,F,9,CHO,,,51,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,Homo sapiens,,449.0,,9606.0,D,Expert,CHEMBL615842,BAO_0000219,
629,1,F,8,CHO,,,51,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,,,449.0,,,H,Autocuration,CHEMBL835003,BAO_0000219,
630,1,F,8,CHO,,,51,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),,,,449.0,,,H,Autocuration,CHEMBL615843,BAO_0000219,
631,1,F,9,CHO,,,51,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,Homo sapiens,,449.0,,9606.0,D,Expert,CHEMBL615979,BAO_0000219,
632,1,F,8,CHO,,,51,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,,,449.0,,,H,Autocuration,CHEMBL615980,BAO_0000219,
633,1,F,9,CHO,,,51,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,Homo sapiens,,449.0,,9606.0,D,Expert,CHEMBL615981,BAO_0000219,
634,1,F,9,,,,51,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL615982,BAO_0000019,
635,1,F,9,,,,51,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,Homo sapiens,,,,9606.0,D,Expert,CHEMBL615983,BAO_0000019,
636,1,F,9,,,,51,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",,Homo sapiens,,,,9606.0,D,Expert,CHEMBL615984,BAO_0000019,
637,1,F,9,,,,51,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",,Homo sapiens,,,,9606.0,D,Expert,CHEMBL615985,BAO_0000019,
638,1,F,8,CHO,,,51,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,,,449.0,,,H,Autocuration,CHEMBL615986,BAO_0000219,
639,1,F,8,CHO,,,51,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,,,449.0,,,H,Autocuration,CHEMBL615987,BAO_0000219,
640,1,F,8,CHO,,,51,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,,,449.0,,,H,Autocuration,CHEMBL615988,BAO_0000219,
641,1,F,8,CHO,,,51,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,,,449.0,,,H,Expert,CHEMBL615989,BAO_0000219,
642,1,F,8,CHO,,,51,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,,,449.0,,,H,Autocuration,CHEMBL615990,BAO_0000219,
643,1,F,8,CHO,,,51,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,,,,449.0,,,H,Autocuration,CHEMBL615991,BAO_0000219,
644,1,F,8,CHO,,,51,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,,,449.0,,,H,Autocuration,CHEMBL615992,BAO_0000219,
645,1,F,8,CHO,,,51,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,,,,449.0,,,H,Autocuration,CHEMBL615993,BAO_0000219,
646,1,F,8,CHO,,,51,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,,,449.0,,,H,Expert,CHEMBL615994,BAO_0000219,
647,1,F,8,CHO,,,51,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,,,,449.0,,,H,Autocuration,CHEMBL615995,BAO_0000219,
648,1,F,8,CHO,,,51,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,,,449.0,,,H,Autocuration,CHEMBL615996,BAO_0000219,
649,1,F,8,CHO,,,51,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,,,,449.0,,,H,Autocuration,CHEMBL615997,BAO_0000219,
650,1,F,8,,,,51,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,,,,,H,Autocuration,CHEMBL615998,BAO_0000019,
651,1,F,8,,,,51,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,,,,,H,Autocuration,CHEMBL615999,BAO_0000019,
652,1,F,8,,,,51,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,,,,,,H,Autocuration,CHEMBL616000,BAO_0000019,
653,1,F,8,HEK293,,,51,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,,722.0,,,H,Autocuration,CHEMBL616001,BAO_0000219,
654,1,F,9,,,,51,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616002,BAO_0000019,
655,1,F,8,,,,51,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,,,,,,H,Expert,CHEMBL616003,BAO_0000019,
656,1,F,9,,,,51,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616004,BAO_0000019,
657,1,F,9,,,,51,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616005,BAO_0000019,
658,1,F,8,,,,51,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,,,,,H,Autocuration,CHEMBL616006,BAO_0000019,
659,1,F,8,,,,51,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,,,,,,H,Expert,CHEMBL616007,BAO_0000019,
660,1,F,8,,,,51,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,,,,,H,Autocuration,CHEMBL616008,BAO_0000019,
661,1,F,8,,,,51,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,,,,,H,Autocuration,CHEMBL616009,BAO_0000019,
662,1,F,8,,,,51,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,,,,,,H,Expert,CHEMBL616010,BAO_0000019,
663,1,F,9,,,,51,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616011,BAO_0000019,
664,1,F,9,,,,51,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",,Homo sapiens,,,,9606.0,D,Expert,CHEMBL615740,BAO_0000019,
665,1,F,8,,,,51,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,,,,,,H,Autocuration,CHEMBL615741,BAO_0000019,
666,1,F,8,,,,51,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,,,,,,H,Expert,CHEMBL615742,BAO_0000019,
667,1,F,8,,,,51,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,,,,,,H,Autocuration,CHEMBL615743,BAO_0000019,
668,1,F,8,CHO,,,51,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,,,,449.0,,,H,Autocuration,CHEMBL615744,BAO_0000219,
669,1,F,8,CHO,,,51,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,,,,449.0,,,H,Expert,CHEMBL615745,BAO_0000219,
670,1,B,8,,,,51,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,,,,,H,Autocuration,CHEMBL615746,BAO_0000357,
671,1,B,8,,,,51,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,,,,,H,Autocuration,CHEMBL615747,BAO_0000357,
672,1,F,8,,,,51,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,,,,,H,Autocuration,CHEMBL615748,BAO_0000019,
673,1,F,8,,,,51,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,,,,,,H,Autocuration,CHEMBL615749,BAO_0000019,
674,1,F,8,,,,51,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,,,,,,H,Autocuration,CHEMBL615750,BAO_0000019,
675,1,F,9,,,,51,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616259,BAO_0000019,
676,1,F,8,,,,51,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,,,,,H,Autocuration,CHEMBL616260,BAO_0000019,
677,1,F,9,,,,51,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616261,BAO_0000019,
678,1,F,9,,,,51,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616262,BAO_0000019,
679,1,F,9,,,,51,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616263,BAO_0000019,
680,1,F,9,,,,51,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616264,BAO_0000019,
681,1,F,9,,,,51,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616265,BAO_0000019,
682,1,F,9,,,,51,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616266,BAO_0000019,
683,1,F,9,,,,51,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616267,BAO_0000019,
684,1,F,9,,,,51,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616268,BAO_0000019,
685,1,B,9,,,,51,Inhibition of human 5-hydroxytryptamine 1A receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616269,BAO_0000357,
686,1,B,8,CHO,,,51,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,,449.0,,,H,Autocuration,CHEMBL884528,BAO_0000219,
687,1,B,9,HEK293,,,105,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,,,,722.0,,,D,Expert,CHEMBL616270,BAO_0000219,
688,1,B,8,CHO,,,51,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,,,,449.0,,,H,Autocuration,CHEMBL616271,BAO_0000219,
689,1,F,8,CHO,,,51,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,,,449.0,,,H,Autocuration,CHEMBL616272,BAO_0000219,
690,1,B,8,,,,51,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,,,,,,H,Expert,CHEMBL616273,BAO_0000357,
691,1,B,9,,,,51,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616274,BAO_0000357,
692,1,B,8,CHO,,,51,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,,,,449.0,,,H,Autocuration,CHEMBL616275,BAO_0000219,
693,1,B,8,CHO,,,51,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,,449.0,,,H,Autocuration,CHEMBL616276,BAO_0000219,
694,1,F,0,,,In vivo,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL616277,BAO_0000218,
695,1,F,0,,,In vivo,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL616278,BAO_0000218,
696,1,F,0,,,In vivo,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL616279,BAO_0000218,
697,1,F,0,,,In vivo,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL616280,BAO_0000218,
698,1,F,0,,,In vivo,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL616281,BAO_0000218,
699,1,F,0,,,In vivo,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL616282,BAO_0000218,
700,1,F,0,,,In vivo,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL616283,BAO_0000218,
701,1,F,0,,,In vivo,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL616284,BAO_0000218,
702,1,F,0,,,In vivo,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL616285,BAO_0000218,
703,1,F,0,,,In vivo,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL616286,BAO_0000218,
704,1,F,0,,,In vivo,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL616287,BAO_0000218,
705,1,F,0,,,In vivo,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL616288,BAO_0000218,
706,1,F,0,,,In vivo,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL616289,BAO_0000218,
707,1,F,0,,,In vivo,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL615610,BAO_0000218,
708,1,F,0,,,In vivo,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL615611,BAO_0000218,
709,1,F,0,,,In vivo,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL615612,BAO_0000218,
710,1,F,0,,,In vivo,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL615613,BAO_0000218,
711,1,F,0,,,In vivo,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL615614,BAO_0000218,
712,1,F,0,,,In vivo,22226,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL615615,BAO_0000218,
713,1,B,4,,,,105093,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,,,,,,H,Autocuration,CHEMBL615616,BAO_0000019,
714,1,B,8,,,,11923,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,1898.0,,,,,,H,Autocuration,CHEMBL615617,BAO_0000249,
715,1,B,8,,,,10577,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,,,,,,H,Autocuration,CHEMBL615618,BAO_0000019,
716,1,B,8,,,,10577,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,,,,,,H,Autocuration,CHEMBL615619,BAO_0000019,
717,1,B,8,,,,10577,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,,,,,,H,Expert,CHEMBL615620,BAO_0000019,
718,1,B,8,,,,55,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,,,,,,H,Autocuration,CHEMBL615621,BAO_0000357,
719,1,B,8,,,,55,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,,,,,,H,Autocuration,CHEMBL615622,BAO_0000357,
720,1,F,8,,,,12166,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,,,,,,H,Autocuration,CHEMBL615623,BAO_0000019,
721,1,F,8,,,,12166,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,,,,,H,Autocuration,CHEMBL615624,BAO_0000019,
722,1,F,8,,,,12166,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,,,,,H,Autocuration,CHEMBL615625,BAO_0000019,
723,1,F,8,,,,12166,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,,,,,H,Autocuration,CHEMBL767045,BAO_0000019,
724,1,F,8,,,,55,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL615626,BAO_0000019,
725,1,F,8,,,,55,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL615627,BAO_0000019,
726,1,B,8,,,,55,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL615628,BAO_0000019,
727,1,B,8,,,,55,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL615629,BAO_0000357,
728,1,B,9,,,,55,Inhibitory concentration against 5-lipoxygenase from human whole blood,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL615630,BAO_0000357,
729,1,B,8,,,,55,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,,,,,,H,Autocuration,CHEMBL615631,BAO_0000219,
730,1,F,8,,,,17087,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,,,,,,H,Autocuration,CHEMBL615632,BAO_0000218,
731,1,B,8,,,,17087,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,,,,,,H,Autocuration,CHEMBL615633,BAO_0000357,
732,1,F,8,,,,17087,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,,,,,,H,Autocuration,CHEMBL615634,BAO_0000218,
733,1,B,8,,,,55,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,,Sus scrofa,,,,9823.0,H,Expert,CHEMBL615635,BAO_0000019,
734,1,B,8,,,,12166,In vitro inhibition of rat 5-Lipoxygenase,,,,,,,H,Expert,CHEMBL615636,BAO_0000357,
735,1,B,9,,,,12166,Inhibitory activity against 5-Lipoxygenase,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL615637,BAO_0000357,
736,1,B,8,RBL-1,,,12166,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,,,,702.0,,,H,Expert,CHEMBL615638,BAO_0000219,
737,1,B,8,RBL-1,,,12166,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,,,702.0,,,H,Autocuration,CHEMBL615639,BAO_0000219,
738,1,B,8,RBL-1,,,12166,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,,,,702.0,,,H,Autocuration,CHEMBL615640,BAO_0000219,
739,1,B,8,,,,12166,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,,,,,,H,Autocuration,CHEMBL615796,BAO_0000019,
740,1,B,8,,,,12166,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,,,,,,H,Autocuration,CHEMBL615845,BAO_0000219,
741,1,B,8,,,,12166,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,,,,,,H,Autocuration,CHEMBL615846,BAO_0000357,
742,1,B,8,RBL-1,,,12166,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,,,702.0,,,H,Autocuration,CHEMBL615847,BAO_0000219,
743,1,B,8,,,,12166,The compound was tested for inhibition of isolated 5-Lipoxygenase,,,,,,,H,Autocuration,CHEMBL615848,BAO_0000357,
744,1,B,0,,,,22226,Ratio of IC50 against 5-LO and COX,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL615849,BAO_0000019,
745,1,B,8,,,,12166,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,,,,,,H,Autocuration,CHEMBL615850,BAO_0000357,
746,1,B,8,,,,12166,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,,,,,,H,Autocuration,CHEMBL615851,BAO_0000357,
747,1,B,8,,,,12166,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,,,,,,H,Autocuration,CHEMBL615852,BAO_0000219,
748,1,F,8,,,,12166,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,,,,,,H,Autocuration,CHEMBL615853,BAO_0000019,
749,1,B,8,,,,120,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,2367.0,,,,,,H,Autocuration,CHEMBL884527,BAO_0000357,
750,1,B,0,,,,22226,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,,Columba livia,,,,8932.0,U,Autocuration,CHEMBL872871,BAO_0000019,
751,1,B,0,,,,22226,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,,Columba livia,,,,8932.0,U,Autocuration,CHEMBL615854,BAO_0000019,
752,1,B,0,,,,22226,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,,Columba livia,,,,8932.0,U,Autocuration,CHEMBL767046,BAO_0000019,
753,1,B,8,,,,10732,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,,,,,,H,Autocuration,CHEMBL615855,BAO_0000357,
754,1,F,9,,,,12198,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL615856,BAO_0000019,
755,1,F,9,,,,12198,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL615857,BAO_0000019,
756,1,F,9,,,,12198,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL615858,BAO_0000019,
757,1,B,8,,,,10576,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,10000000.0,,,,,,H,Expert,CHEMBL615859,BAO_0000221,
758,1,B,8,,,,51,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,,,,,,H,Autocuration,CHEMBL615860,BAO_0000357,
759,1,B,0,,,,22226,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL615861,BAO_0000019,
760,1,B,0,,,,22226,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL615862,BAO_0000019,
761,1,B,0,,,,22226,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL615863,BAO_0000019,
762,1,B,0,,,,22226,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL615864,BAO_0000019,
763,1,B,4,,,,104744,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,10000000.0,,,,,,H,Autocuration,CHEMBL615865,BAO_0000221,
764,1,B,4,,,,104744,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,10000000.0,,,,,,H,Autocuration,CHEMBL615866,BAO_0000221,
765,1,B,4,,,,104744,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,10000000.0,,,,,,H,Autocuration,CHEMBL615867,BAO_0000221,
766,1,B,4,,,,104744,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,,,,,,,H,Autocuration,CHEMBL615868,BAO_0000249,
767,1,B,5,,,,104744,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL615869,BAO_0000249,
768,1,B,5,,,,104744,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL615870,BAO_0000019,
769,1,B,5,,,,104744,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL615871,BAO_0000019,
770,1,B,4,,,,104744,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,,,,,,H,Autocuration,CHEMBL615872,BAO_0000224,
771,1,B,4,,,,104744,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,10000000.0,,,,,,H,Autocuration,CHEMBL833492,BAO_0000221,
772,1,B,4,,,,104744,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,10000000.0,,,,,,H,Autocuration,CHEMBL615873,BAO_0000221,
773,1,B,4,,,,104744,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,,,,,,H,Autocuration,CHEMBL615479,BAO_0000224,
774,1,B,4,,,,104744,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,,,,,,H,Autocuration,CHEMBL615480,BAO_0000019,
775,1,B,5,,,,104744,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL615481,BAO_0000249,
776,1,B,4,,,,104744,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,,,,,H,Autocuration,CHEMBL872869,BAO_0000019,
777,1,B,4,,,,104744,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,,,,,H,Autocuration,CHEMBL615482,BAO_0000019,
778,1,B,4,,,,104744,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,955.0,,,,,,H,Autocuration,CHEMBL615483,BAO_0000221,
779,1,B,4,,,,104744,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,955.0,,,,,,H,Autocuration,CHEMBL615484,BAO_0000221,
780,1,B,4,,,,104744,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,,,,,,H,Autocuration,CHEMBL615485,BAO_0000019,
781,1,B,5,,,,104744,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL615486,BAO_0000224,
782,1,B,4,,,,104744,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,,,,,,H,Autocuration,CHEMBL615487,BAO_0000224,
783,1,B,4,,,,104744,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,,,,,H,Autocuration,CHEMBL615488,BAO_0000224,
784,1,B,4,,,,104744,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,,,,,H,Autocuration,CHEMBL615489,BAO_0000224,
785,1,B,4,,,,104744,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,,,,,H,Autocuration,CHEMBL615389,BAO_0000224,
786,1,B,4,,,,104744,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,,,,,,H,Autocuration,CHEMBL615390,BAO_0000019,
787,1,B,4,,,,104744,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,,,,,,H,Autocuration,CHEMBL615391,BAO_0000019,
788,1,B,4,,,,104744,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,,,,,,H,Autocuration,CHEMBL615392,BAO_0000224,
789,1,B,0,,,,22226,Affinity for 5-hydroxytryptamine 1 receptor,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL615393,BAO_0000019,
790,1,B,4,,,,104744,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,955.0,,,,,,H,Autocuration,CHEMBL615394,BAO_0000221,
791,1,B,4,,,,104744,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,955.0,,,,,,H,Autocuration,CHEMBL615395,BAO_0000221,
792,1,B,4,,,,104744,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,,,,,,H,Autocuration,CHEMBL615396,BAO_0000224,
793,1,B,4,,,,104744,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,955.0,,,,,,H,Autocuration,CHEMBL615397,BAO_0000221,
794,1,B,4,,,,104744,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,,,,,H,Autocuration,CHEMBL615398,BAO_0000019,
795,1,B,0,,,,22226,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL615399,BAO_0000019,
796,1,B,4,,,,104744,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,,,,,,H,Autocuration,CHEMBL615400,BAO_0000019,
797,1,B,5,,,,104744,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL615401,BAO_0000019,
798,1,B,0,,,,22226,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL615402,BAO_0000019,
799,1,B,4,,,,104744,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,,,,,,H,Autocuration,CHEMBL615403,BAO_0000019,
800,1,B,4,,,,104744,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,955.0,,,,,,H,Autocuration,CHEMBL615404,BAO_0000221,
801,1,B,4,,,,104744,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,,,,,,H,Autocuration,CHEMBL615781,BAO_0000019,
802,1,B,4,,,,104744,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,955.0,,,,,,H,Autocuration,CHEMBL615782,BAO_0000220,
803,1,B,4,,,,104744,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,955.0,,,,,,H,Autocuration,CHEMBL615783,BAO_0000221,
804,1,B,0,,,,22226,Compound was tested for binding affinity against 5-HT1 receptor,,,,,,,U,Autocuration,CHEMBL873481,BAO_0000019,
805,1,B,0,,,,22226,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,,,,,,U,Autocuration,CHEMBL615784,BAO_0000019,
806,1,B,8,,,,10576,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,,,,,,H,Expert,CHEMBL615785,BAO_0000357,
807,1,F,8,,,,10576,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,,,,,,H,Autocuration,CHEMBL615786,BAO_0000249,
808,1,F,8,,,In vivo,10576,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,,,,,,H,Autocuration,CHEMBL615787,BAO_0000218,
809,1,F,8,,,In vivo,10576,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,,,,,,H,Autocuration,CHEMBL615788,BAO_0000218,
810,1,F,8,,,,10576,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL767044,BAO_0000019,
811,1,F,8,,,In vivo,10576,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,,,,,,H,Autocuration,CHEMBL615789,BAO_0000218,
812,1,F,8,,,In vivo,10576,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,,,,,,H,Autocuration,CHEMBL615790,BAO_0000218,
813,1,F,8,,,,10576,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,,,,,,H,Autocuration,CHEMBL615813,BAO_0000019,
814,1,F,8,,,,10576,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,,,,,,H,Autocuration,CHEMBL615814,BAO_0000219,
815,1,F,8,,,,51,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,,,,,,H,Expert,CHEMBL615815,BAO_0000219,
816,1,F,8,,,,10576,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,,,,,,H,Autocuration,CHEMBL615816,BAO_0000219,
817,1,B,8,,,,10576,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,,,,,,H,Expert,CHEMBL615817,BAO_0000249,
818,1,B,8,,,,10576,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,10000000.0,,,,,,H,Autocuration,CHEMBL615818,BAO_0000221,
819,1,B,8,,,,10576,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,10000000.0,,,,,,H,Autocuration,CHEMBL615819,BAO_0000221,
820,1,B,8,,,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,,,,,,,H,Expert,CHEMBL615820,BAO_0000249,
821,1,B,9,,,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,10000000.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL615821,BAO_0000221,
822,1,B,9,,,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,10000000.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL615822,BAO_0000221,
823,1,B,8,,,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,10000000.0,,,,,,H,Expert,CHEMBL615823,BAO_0000221,
824,1,B,9,,,,10576,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,10000000.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL615824,BAO_0000221,
825,1,B,9,,,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,10000000.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL615825,BAO_0000221,
826,1,B,8,,,,10576,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,,,,,,H,Expert,CHEMBL615826,BAO_0000357,
827,1,B,8,,,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,,,,,,H,Expert,CHEMBL615827,BAO_0000249,
828,1,B,8,,,,10576,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,10000000.0,,,,,,H,Expert,CHEMBL615828,BAO_0000249,
829,1,B,8,,,,10576,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10000000.0,,,,,,H,Expert,CHEMBL615829,BAO_0000221,
830,1,B,8,,,,10576,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,10000000.0,,,,,,H,Autocuration,CHEMBL615830,BAO_0000221,
831,1,B,8,,,,10576,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,10000000.0,,,,,,H,Expert,CHEMBL615831,BAO_0000221,
832,1,B,8,,,,10576,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL615832,BAO_0000357,
833,1,B,8,,,,10576,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,,,,,,H,Autocuration,CHEMBL615833,BAO_0000019,
834,1,B,8,,,,10576,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,10000000.0,,,,,,H,Autocuration,CHEMBL615834,BAO_0000221,
835,1,B,8,,,,10576,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,,,,,,H,Intermediate,CHEMBL615835,BAO_0000249,
836,1,B,8,,,,10576,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,10000000.0,,,,,,H,Autocuration,CHEMBL615836,BAO_0000249,
837,1,B,9,,,,10576,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL615837,BAO_0000019,
838,1,B,9,,,,10576,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL615838,BAO_0000019,
839,1,B,8,,,,10576,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,,,,,,H,Expert,CHEMBL615839,BAO_0000249,
840,1,B,8,,,,10576,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,,,,,,H,Autocuration,CHEMBL884525,BAO_0000019,
841,1,B,8,,,,10576,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,,,,,,H,Autocuration,CHEMBL615840,BAO_0000249,
842,1,B,8,,,,10576,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10000000.0,,,,,,H,Expert,CHEMBL615405,BAO_0000221,
843,1,B,8,,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,,,,,H,Expert,CHEMBL615406,BAO_0000019,
844,1,B,8,,,,10576,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,10000000.0,,,,,,H,Expert,CHEMBL615900,BAO_0000221,
845,1,B,8,,,,10576,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,10000000.0,,,,,,H,Expert,CHEMBL615901,BAO_0000221,
846,1,B,8,,,,10576,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,,,,,,H,Expert,CHEMBL615902,BAO_0000357,
847,1,B,8,,,,10576,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,10000000.0,,,,,,H,Autocuration,CHEMBL615903,BAO_0000221,
848,1,B,8,,,,10576,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,,,,,,H,Autocuration,CHEMBL615904,BAO_0000357,
849,1,B,8,,,,10576,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,,,,,,H,Expert,CHEMBL615905,BAO_0000357,
850,1,B,8,,,,10576,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,,,,,,H,Autocuration,CHEMBL615906,BAO_0000019,
851,1,F,8,,,,10576,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,,,,,,H,Autocuration,CHEMBL615907,BAO_0000019,
852,1,B,8,,,,10576,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,,,,,H,Expert,CHEMBL615908,BAO_0000019,
853,1,B,8,,,,10576,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,10000000.0,,,,,,H,Autocuration,CHEMBL615909,BAO_0000221,
854,1,B,8,,,,10576,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,,,,,,H,Autocuration,CHEMBL615910,BAO_0000019,
855,1,B,8,,,,10576,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,,,,,,H,Autocuration,CHEMBL615911,BAO_0000019,
856,1,B,8,,,,10576,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,,,,,,H,Autocuration,CHEMBL615912,BAO_0000019,
857,1,B,8,,,,10576,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,,,,,,H,Expert,CHEMBL615913,BAO_0000019,
858,1,B,8,,,,10576,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,,,,,H,Expert,CHEMBL615914,BAO_0000357,
859,1,B,8,,,,10576,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,10000000.0,,,,,,H,Autocuration,CHEMBL615915,BAO_0000221,
860,1,B,8,,,,10576,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,,,,,,H,Autocuration,CHEMBL615916,BAO_0000357,
861,1,B,8,,,,10576,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,,,,,,H,Expert,CHEMBL615917,BAO_0000357,
862,1,B,8,,,,10576,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,,,,,H,Expert,CHEMBL615918,BAO_0000357,
863,1,B,8,,,,10576,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,10000000.0,,,,,,H,Expert,CHEMBL615919,BAO_0000249,
864,1,B,9,,,,10576,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,10000000.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL615920,BAO_0000221,
865,1,B,8,,,,10576,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL615921,BAO_0000357,
866,1,B,8,,,,10576,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,,,,,,H,Expert,CHEMBL615922,BAO_0000357,
867,1,F,9,,,,10576,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL881290,BAO_0000249,
868,1,B,8,,,,10576,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",10000000.0,,,,,,H,Autocuration,CHEMBL615923,BAO_0000221,
869,1,F,8,,,,10576,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,10000000.0,,,,,,H,Autocuration,CHEMBL615924,BAO_0000221,
870,1,F,8,,,,10576,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,10000000.0,,,,,,H,Autocuration,CHEMBL615925,BAO_0000221,
871,1,B,9,,,,10576,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL615926,BAO_0000357,
872,1,B,9,,,,10576,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL615927,BAO_0000019,
873,1,B,8,,,,10576,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10000000.0,,,,,,H,Autocuration,CHEMBL615928,BAO_0000221,
874,1,B,9,,,,10576,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL615929,BAO_0000357,
875,1,B,8,,,,10576,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,10000000.0,,,,,,H,Autocuration,CHEMBL615930,BAO_0000221,
876,1,B,8,CHO,,,51,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,,449.0,,,H,Autocuration,CHEMBL615931,BAO_0000219,
877,1,F,8,CHO,,,51,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,,,449.0,,,H,Autocuration,CHEMBL615932,BAO_0000219,
878,1,F,8,CHO,,,51,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,,,449.0,,,H,Autocuration,CHEMBL615933,BAO_0000219,
879,1,B,8,,,,51,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL615934,BAO_0000357,
880,1,B,8,,,,51,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,,,,,,H,Autocuration,CHEMBL615935,BAO_0000357,
881,1,F,8,,,,51,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,,,,,H,Autocuration,CHEMBL615936,BAO_0000019,
882,1,B,8,CHO,,,51,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,,,,449.0,,,H,Autocuration,CHEMBL615937,BAO_0000219,
883,1,B,8,,,,51,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL615938,BAO_0000357,
884,1,B,8,,,,51,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,,,,,,H,Autocuration,CHEMBL615797,BAO_0000357,
885,1,B,8,,,,51,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,H,Autocuration,CHEMBL615798,BAO_0000357,
886,1,B,8,,,,51,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,,,,,,H,Autocuration,CHEMBL872870,BAO_0000357,
887,1,B,8,,,,51,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,,,,,,H,Autocuration,CHEMBL615799,BAO_0000357,
888,1,B,8,,,,51,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL615800,BAO_0000357,
889,1,F,8,HEK293,,,51,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,,722.0,,,H,Autocuration,CHEMBL615801,BAO_0000219,
890,1,B,8,,,,51,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,,,,,,H,Autocuration,CHEMBL615802,BAO_0000019,
891,1,B,8,,,,51,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,,,,,,H,Autocuration,CHEMBL615803,BAO_0000357,
892,1,F,8,,,,51,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,,,,,,H,Expert,CHEMBL835002,BAO_0000019,
893,1,F,8,,,,51,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,,,,,,H,Autocuration,CHEMBL615804,BAO_0000019,
894,1,B,8,HeLa,,,51,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,,,,308.0,,,H,Expert,CHEMBL615805,BAO_0000219,
895,1,B,8,CHO,,,51,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,,,,449.0,,,H,Autocuration,CHEMBL615806,BAO_0000219,
896,1,B,9,,,,51,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL615807,BAO_0000357,
897,1,B,8,,,,51,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,,,,,,H,Autocuration,CHEMBL615808,BAO_0000357,
898,1,B,9,,,,51,Binding affinity against 5-hydroxytryptamine 1A receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL615809,BAO_0000357,
899,1,B,8,HeLa,,,51,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,,,,308.0,,,H,Autocuration,CHEMBL615810,BAO_0000219,
900,1,B,8,,,,51,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,H,Autocuration,CHEMBL615811,BAO_0000357,
901,1,B,8,CHO,,,51,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,,,,449.0,,,H,Autocuration,CHEMBL615812,BAO_0000219,
902,1,B,8,CHO,,,51,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,,449.0,,,H,Autocuration,CHEMBL615751,BAO_0000219,
903,1,B,8,,,,51,Binding affinity against human 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL615752,BAO_0000357,
904,1,B,8,CHO,,,51,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,,,,449.0,,,H,Expert,CHEMBL615753,BAO_0000219,
905,1,B,8,CHO,,,51,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,,,,449.0,,,H,Autocuration,CHEMBL615754,BAO_0000219,
906,1,B,8,,,,51,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL615755,BAO_0000357,
907,1,B,9,CHO,,,51,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,Homo sapiens,,449.0,,9606.0,D,Expert,CHEMBL615756,BAO_0000219,
908,1,B,8,,,,51,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,,,,,,H,Autocuration,CHEMBL615757,BAO_0000019,
909,1,B,8,,,,51,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,,,,,,H,Autocuration,CHEMBL615758,BAO_0000357,
910,1,B,8,,,,51,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,,,,,,H,Expert,CHEMBL615759,BAO_0000357,
911,1,B,8,,,,51,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL615760,BAO_0000357,
912,1,B,8,HeLa,,,51,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,,,,308.0,,,H,Expert,CHEMBL615761,BAO_0000219,
913,1,B,8,,,,51,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,,,,,,H,Autocuration,CHEMBL872104,BAO_0000357,
914,1,B,8,,,,51,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,,,,,H,Autocuration,CHEMBL615762,BAO_0000357,
915,1,B,8,,,,51,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,,,,,H,Autocuration,CHEMBL615763,BAO_0000357,
916,1,B,8,,,,51,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,,,,,,H,Autocuration,CHEMBL615764,BAO_0000357,
917,1,B,8,Cell line,,,51,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),,,,1167.0,,,H,Autocuration,CHEMBL615765,BAO_0000219,
918,1,B,8,,,,51,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,,,,,,H,Autocuration,CHEMBL615766,BAO_0000019,
919,1,B,8,,,,51,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,H,Autocuration,CHEMBL615767,BAO_0000357,
920,1,B,8,,,,51,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,H,Expert,CHEMBL615768,BAO_0000357,
921,1,B,8,,,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,H,Autocuration,CHEMBL615769,BAO_0000357,
922,1,B,8,,,,51,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,,,,,,H,Expert,CHEMBL615770,BAO_0000357,
923,1,B,8,,,,51,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,H,Autocuration,CHEMBL615771,BAO_0000357,
924,1,B,8,,,,51,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,,,,,,H,Expert,CHEMBL615772,BAO_0000357,
925,1,B,8,,,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL615773,BAO_0000357,
926,1,B,8,,,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,,,,,,H,Expert,CHEMBL615774,BAO_0000357,
927,1,B,8,,,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,H,Autocuration,CHEMBL615775,BAO_0000357,
928,1,B,8,,,,51,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,,,,,,H,Autocuration,CHEMBL615776,BAO_0000357,
929,1,B,8,,,,51,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,H,Expert,CHEMBL615777,BAO_0000357,
930,1,B,8,,,,51,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,,,,,,H,Autocuration,CHEMBL615778,BAO_0000219,
931,1,B,9,,,,51,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL615779,BAO_0000357,
932,1,B,8,,,,51,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,,,,,H,Autocuration,CHEMBL615780,BAO_0000357,
933,1,B,8,,,,51,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616298,BAO_0000357,
934,1,B,8,,,,51,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616299,BAO_0000357,
935,1,B,8,CHO-K1,,,51,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,,,,485.0,,,H,Autocuration,CHEMBL616300,BAO_0000219,
936,1,F,8,CHO-K1,,,51,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,,,,485.0,,,H,Expert,CHEMBL616301,BAO_0000219,
937,1,B,8,,,,51,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616302,BAO_0000019,
938,1,B,8,,,,51,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,,,,,,H,Autocuration,CHEMBL616117,BAO_0000019,
939,1,B,8,,,,51,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,,,,,,H,Autocuration,CHEMBL616118,BAO_0000019,
940,1,B,8,,,,51,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,,,,,,H,Autocuration,CHEMBL616119,BAO_0000019,
941,1,B,9,HeLa,,,51,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,Homo sapiens,,308.0,,9606.0,D,Expert,CHEMBL616120,BAO_0000219,
942,1,B,8,,,,51,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616121,BAO_0000357,
943,1,B,8,,,,51,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,,,,,,H,Autocuration,CHEMBL616122,BAO_0000357,
944,1,B,8,,,,51,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616123,BAO_0000357,
945,1,B,9,,,,51,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616124,BAO_0000357,
946,1,B,8,,,,51,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,,,,,,H,Expert,CHEMBL616125,BAO_0000357,
947,1,B,8,,,,51,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,,Rattus norvegicus,,,,10116.0,H,Expert,CHEMBL616126,BAO_0000357,
948,1,B,8,CHO,,,51,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,,,,449.0,,,H,Autocuration,CHEMBL616127,BAO_0000219,
949,1,B,8,,,,51,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,,,,,,H,Expert,CHEMBL616128,BAO_0000019,
950,1,B,8,,,,51,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,,,,,,H,Autocuration,CHEMBL616129,BAO_0000357,
951,1,B,8,,,,51,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,,,,,,H,Expert,CHEMBL616130,BAO_0000357,
952,1,B,8,,,,51,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,,,,,,H,Autocuration,CHEMBL616131,BAO_0000357,
953,1,B,8,HeLa,,,51,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,,,,308.0,,,H,Autocuration,CHEMBL616132,BAO_0000219,
954,1,B,9,HeLa,,,51,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,,Homo sapiens,,308.0,,9606.0,D,Expert,CHEMBL616133,BAO_0000219,
955,1,B,8,,,,51,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,H,Autocuration,CHEMBL616134,BAO_0000357,
956,1,B,8,,,,51,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,,,,,,H,Autocuration,CHEMBL616135,BAO_0000357,
957,1,B,9,,,,51,Affinity for 5-hydroxytryptamine 1A receptor subtype,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616136,BAO_0000357,
958,1,B,8,,,,51,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,,,,,,H,Autocuration,CHEMBL616137,BAO_0000019,
959,1,B,8,,,,51,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,,,,,,H,Autocuration,CHEMBL872105,BAO_0000019,
960,1,B,8,,,,51,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,,,,,,H,Autocuration,CHEMBL616138,BAO_0000357,
961,1,B,9,,,,51,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616139,BAO_0000357,
962,1,F,8,,,,51,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,,,,,,H,Autocuration,CHEMBL616140,BAO_0000019,
963,1,B,8,,,,51,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,,,,,,H,Expert,CHEMBL616141,BAO_0000019,
964,1,B,8,,,,51,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,H,Autocuration,CHEMBL616142,BAO_0000357,
965,1,B,8,,,,51,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,,,,,,H,Autocuration,CHEMBL616143,BAO_0000357,
966,1,B,8,HeLa,,,51,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,,,308.0,,,H,Autocuration,CHEMBL616144,BAO_0000219,
967,1,B,8,HeLa,,,51,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,,,,308.0,,,H,Autocuration,CHEMBL616145,BAO_0000219,
968,1,B,8,HeLa,,,51,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,,,308.0,,,H,Autocuration,CHEMBL616012,BAO_0000219,
969,1,B,8,HeLa,,,51,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,,,308.0,,,H,Autocuration,CHEMBL616013,BAO_0000219,
970,1,F,8,,,,51,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,,,,,H,Autocuration,CHEMBL616014,BAO_0000019,
971,1,F,8,,,,51,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,,,,,H,Autocuration,CHEMBL616015,BAO_0000019,
972,1,F,8,,,,51,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,,,,,H,Autocuration,CHEMBL616016,BAO_0000019,
973,1,F,8,,,In vivo,51,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,,,,,,,H,Autocuration,CHEMBL616017,BAO_0000218,
974,1,B,8,,,,51,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,,,,,,H,Autocuration,CHEMBL616018,BAO_0000019,
975,1,F,8,,,,51,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,,,,,,H,Autocuration,CHEMBL616019,BAO_0000019,
976,1,F,8,,,,51,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,,,,,,H,Autocuration,CHEMBL616020,BAO_0000019,
977,1,B,8,,,,51,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL858018,BAO_0000357,
978,1,F,8,HEK293,,,51,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,,722.0,,,H,Autocuration,CHEMBL616021,BAO_0000219,
979,1,F,8,,,,51,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,,,,,,H,Expert,CHEMBL616022,BAO_0000019,
980,1,F,8,,,,51,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,,,,,,H,Autocuration,CHEMBL616023,BAO_0000019,
981,1,F,8,,,,51,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,,,,,,H,Autocuration,CHEMBL616024,BAO_0000019,
982,1,F,8,,,,51,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,,,,,,H,Autocuration,CHEMBL616025,BAO_0000019,
983,1,F,8,CHO,,,51,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,,,449.0,,,H,Autocuration,CHEMBL616026,BAO_0000219,
984,1,F,8,,,,51,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,,,,,,H,Autocuration,CHEMBL616027,BAO_0000019,
985,1,F,9,,,,51,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616028,BAO_0000019,
986,1,F,9,,,,51,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616029,BAO_0000019,
987,1,B,8,CHO,,,51,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,,,,449.0,,,H,Expert,CHEMBL616030,BAO_0000219,
988,1,B,8,,,,51,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,,,,,,H,Expert,CHEMBL616031,BAO_0000019,
989,1,F,9,,,,51,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616032,BAO_0000019,
990,1,F,9,,,,51,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616033,BAO_0000019,
991,1,F,8,,,,51,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,,,,,H,Autocuration,CHEMBL616034,BAO_0000019,
992,1,F,8,,,,51,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,,,,,H,Autocuration,CHEMBL616035,BAO_0000019,
993,1,F,8,,,,51,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616036,BAO_0000019,
994,1,F,8,,,,51,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,,,,,H,Autocuration,CHEMBL616037,BAO_0000019,
995,1,F,8,,,,51,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,,,,,H,Autocuration,CHEMBL616038,BAO_0000019,
996,1,F,8,,,,51,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,,,,,H,Autocuration,CHEMBL616039,BAO_0000019,
997,1,F,8,,,,51,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616040,BAO_0000019,
998,1,F,9,HeLa,,,51,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,Homo sapiens,,308.0,,9606.0,D,Expert,CHEMBL616041,BAO_0000219,
999,1,F,9,HeLa,,,51,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,Homo sapiens,,308.0,,9606.0,D,Expert,CHEMBL616042,BAO_0000219,
1000,1,F,9,HeLa,,,51,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,Homo sapiens,,308.0,,9606.0,D,Expert,CHEMBL616043,BAO_0000219,
1001,1,F,8,,,,51,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,,,,,,H,Autocuration,CHEMBL616044,BAO_0000019,
1002,1,F,8,,,,51,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,,,,,H,Autocuration,CHEMBL616045,BAO_0000019,
1003,1,F,8,HEK293,,,51,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,,722.0,,,H,Autocuration,CHEMBL616046,BAO_0000219,
1004,1,F,8,CHO,,,51,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,,,449.0,,,H,Autocuration,CHEMBL616047,BAO_0000219,
1005,1,F,8,CHO,,,51,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,,,449.0,,,H,Autocuration,CHEMBL616048,BAO_0000219,
1006,1,F,9,CHO,,,51,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),,Homo sapiens,,449.0,,9606.0,D,Expert,CHEMBL616049,BAO_0000219,
1007,1,F,8,CHO,,,51,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,,,449.0,,,H,Autocuration,CHEMBL616050,BAO_0000219,
1008,1,F,8,,,,51,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,,,,,,H,Expert,CHEMBL616051,BAO_0000219,
1009,1,F,8,,,,51,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,,,,,,H,Autocuration,CHEMBL616212,BAO_0000219,
1010,1,F,8,,,,51,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,,,,,H,Autocuration,CHEMBL616213,BAO_0000019,
1011,1,B,8,,,In vitro,51,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,,,,,,,H,Expert,CHEMBL616214,BAO_0000219,
1012,1,B,8,,,In vitro,51,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,,,,,,,H,Expert,CHEMBL616215,BAO_0000219,
1013,1,B,8,,,,51,Binding activity radioligand.,,,,,,,H,Autocuration,CHEMBL616216,BAO_0000357,
1014,1,B,8,,,,51,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,,,,,H,Autocuration,CHEMBL616217,BAO_0000019,
1015,1,B,8,,,,51,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616218,BAO_0000357,
1016,1,B,8,,,,51,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616219,BAO_0000357,
1017,1,B,8,,,,51,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616220,BAO_0000357,
1018,1,B,9,,,,51,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL833493,BAO_0000357,
1019,1,B,8,,,,51,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616221,BAO_0000357,
1020,1,B,9,CHO,,,51,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,Homo sapiens,,449.0,,9606.0,D,Expert,CHEMBL616222,BAO_0000219,
1021,1,F,8,,,,51,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616223,BAO_0000019,
1022,1,F,8,,,,51,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,,,,,,H,Autocuration,CHEMBL616224,BAO_0000019,
1023,1,B,8,,,,51,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,,,,,,H,Expert,CHEMBL616225,BAO_0000019,
1024,1,B,9,HEK293,,,51,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,,Homo sapiens,,722.0,,9606.0,D,Expert,CHEMBL616226,BAO_0000219,
1025,1,B,8,HEK293,,,51,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,,,,722.0,,,H,Autocuration,CHEMBL616227,BAO_0000219,
1026,1,B,8,HEK293,,,51,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,,,,722.0,,,H,Autocuration,CHEMBL616228,BAO_0000219,
1027,1,B,8,HEK293,,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,,,722.0,,,H,Autocuration,CHEMBL616229,BAO_0000219,
1028,1,B,8,HEK293,,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,,,,722.0,,,H,Autocuration,CHEMBL616230,BAO_0000219,
1029,1,B,8,HEK293,,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,,,,722.0,,,H,Autocuration,CHEMBL616231,BAO_0000219,
1030,1,B,8,,,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,,,,,,H,Autocuration,CHEMBL616232,BAO_0000357,
1031,1,B,8,HEK293,,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,,,722.0,,,H,Autocuration,CHEMBL616233,BAO_0000219,
1032,1,B,8,HEK293,,,51,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,,,,722.0,,,H,Autocuration,CHEMBL857973,BAO_0000219,
1033,1,B,8,,,,51,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,,,,,,H,Autocuration,CHEMBL616234,BAO_0000219,
1034,1,B,8,,,,51,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616235,BAO_0000357,
1035,1,B,8,HeLa,,,51,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,,,308.0,,,H,Expert,CHEMBL616236,BAO_0000219,
1036,1,B,8,,,,51,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,,,,,,H,Expert,CHEMBL616237,BAO_0000019,
1037,1,B,8,HEK293,,,51,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,,,,722.0,,,H,Autocuration,CHEMBL616238,BAO_0000219,
1038,1,B,8,HEK293,,,51,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,,,,722.0,,,H,Autocuration,CHEMBL616239,BAO_0000219,
1039,1,B,8,,,,51,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,,,,,,H,Autocuration,CHEMBL616240,BAO_0000219,
1040,1,B,9,HeLa,,,51,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,,Homo sapiens,,308.0,,9606.0,D,Expert,CHEMBL616241,BAO_0000219,
1041,1,B,8,HEK293,,,51,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,,,,722.0,,,H,Autocuration,CHEMBL616242,BAO_0000219,
1042,1,B,8,HEK293,,,51,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",,,,722.0,,,H,Autocuration,CHEMBL616243,BAO_0000219,
1043,1,B,9,,,,51,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,,,,,,D,Expert,CHEMBL616244,BAO_0000357,
1044,1,B,9,,,,51,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,,Homo sapiens,,,,9606.0,D,Autocuration,CHEMBL616245,BAO_0000357,
1045,1,B,8,,,,106,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,,,,,,H,Autocuration,CHEMBL616246,BAO_0000357,
1046,1,B,8,,,,105,Binding affinity against 5-HT1D receptor,,,,,,,H,Autocuration,CHEMBL616247,BAO_0000357,
1047,1,B,8,,,,105,Binding affinity against 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616248,BAO_0000357,
1048,1,B,8,,,,107,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,,,,,H,Autocuration,CHEMBL616249,BAO_0000357,
1049,1,B,8,,,,10576,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,Homo sapiens,,,,9606.0,H,Autocuration,CHEMBL616250,BAO_0000357,
1050,1,B,8,,,,51,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616251,BAO_0000357,
1051,1,F,8,,,In vivo,11863,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,,,,,,,H,Autocuration,CHEMBL616252,BAO_0000218,
1052,1,F,8,,,In vivo,11863,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,,,,,,,H,Autocuration,CHEMBL616253,BAO_0000218,
1053,1,F,8,,,In vivo,11863,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,,,,,,,H,Autocuration,CHEMBL616254,BAO_0000218,
1054,1,F,9,,,,11863,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,,Mus musculus,,,,10090.0,D,Expert,CHEMBL616255,BAO_0000218,
1055,1,F,9,,,,11863,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,,Mus musculus,,,,10090.0,D,Expert,CHEMBL832872,BAO_0000218,
1056,1,F,9,,,,11863,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,,Mus musculus,,,,10090.0,D,Expert,CHEMBL616256,BAO_0000218,
1057,1,F,9,,,,11863,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,,Mus musculus,,,,10090.0,D,Expert,CHEMBL616257,BAO_0000218,
1058,1,F,9,,,,11863,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,,Mus musculus,,,,10090.0,D,Expert,CHEMBL616258,BAO_0000218,
1059,1,F,9,,,,11863,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,,Mus musculus,,,,10090.0,D,Expert,CHEMBL616384,BAO_0000218,
1060,1,B,8,,,,11863,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,10000000.0,,,,,,H,Autocuration,CHEMBL616385,BAO_0000221,
1061,1,B,8,,,,11863,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,,,,,,H,Expert,CHEMBL616386,BAO_0000357,
1062,1,B,9,,,,11863,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,10000000.0,Mus musculus,,,,10090.0,D,Expert,CHEMBL616387,BAO_0000221,
1063,1,B,8,,,,11863,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,10000000.0,,,,,,H,Autocuration,CHEMBL616388,BAO_0000221,
1064,1,B,9,,,,11863,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,10000000.0,Mus musculus,,,,10090.0,D,Expert,CHEMBL616389,BAO_0000221,
1065,1,B,8,,,,11863,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,10000000.0,,,,,,H,Autocuration,CHEMBL616390,BAO_0000221,
1066,1,B,8,,,,11863,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,,,,,,H,Autocuration,CHEMBL616391,BAO_0000357,
1067,1,B,9,,,,11863,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,10000000.0,Mus musculus,,,,10090.0,D,Expert,CHEMBL616392,BAO_0000221,
1068,1,B,8,,,,51,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL616393,BAO_0000357,
1069,1,B,8,,,,51,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL616394,BAO_0000357,
1070,1,B,8,,,,51,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL616395,BAO_0000019,
1071,1,B,8,,,,51,Compound was evaluated for the binding affinity at 5- HT1A receptor,,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL616396,BAO_0000357,
1072,1,B,8,,,,51,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL872907,BAO_0000019,
1073,1,B,8,,,,51,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL616397,BAO_0000019,
1074,1,B,8,,,,51,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL616398,BAO_0000019,
1075,1,B,8,,,,51,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,,Sus scrofa,,,,9823.0,H,Expert,CHEMBL616399,BAO_0000357,
1076,1,B,8,,,,51,Binding activity radioligand.,,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL857065,BAO_0000357,
1077,1,B,8,,,,51,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,Sus scrofa,,,,9823.0,H,Expert,CHEMBL616400,BAO_0000019,
1078,1,B,8,,,,51,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL616401,BAO_0000019,
1079,1,B,8,,,,10624,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,,,,,,H,Expert,CHEMBL616402,BAO_0000019,
1080,1,B,8,,,,51,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,,Sus scrofa,,,,9823.0,H,Expert,CHEMBL616403,BAO_0000019,
1081,1,B,8,,,,51,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,10000000.0,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL616404,BAO_0000221,
1082,1,B,8,,,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL616405,BAO_0000249,
1083,1,B,8,,,,51,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL616406,BAO_0000019,
1084,1,F,8,,,,51,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,,Sus scrofa,,,,9823.0,H,Expert,CHEMBL616407,BAO_0000019,
1085,1,B,8,,,,51,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,,Oryctolagus cuniculus,,,,9986.0,H,Autocuration,CHEMBL616408,BAO_0000019,
1086,1,B,9,,,,10576,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616409,BAO_0000249,
1087,1,B,9,,,,10576,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",10000000.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616410,BAO_0000221,
1088,1,B,8,,,,10576,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,,,,,,H,Autocuration,CHEMBL616411,BAO_0000357,
1089,1,F,9,,,,10576,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616412,BAO_0000249,
1090,1,F,9,,,,10576,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",10000000.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616413,BAO_0000249,
1091,1,B,8,,,,10576,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10000000.0,,,,,,H,Autocuration,CHEMBL616414,BAO_0000221,
1092,1,B,9,,,,10576,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,10000000.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616415,BAO_0000221,
1093,1,B,8,,,,10576,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,,,,,,H,Autocuration,CHEMBL616416,BAO_0000019,
1094,1,B,8,,,,10576,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,,,,,,H,Expert,CHEMBL616417,BAO_0000357,
1095,1,B,8,,,,10576,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,,,,,,H,Autocuration,CHEMBL616418,BAO_0000357,
1096,1,B,8,,,In vitro,10576,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,,,,,,H,Autocuration,CHEMBL616419,BAO_0000219,
1097,1,B,8,,,,10576,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,,,,,,H,Autocuration,CHEMBL616420,BAO_0000357,
1098,1,B,8,,,,10576,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,,,,,,H,Autocuration,CHEMBL616421,BAO_0000249,
1099,1,B,8,,,,10576,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,,,,,,H,Autocuration,CHEMBL616422,BAO_0000249,
1100,1,B,8,,,,10576,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,,,,,,,H,Expert,CHEMBL616423,BAO_0000249,
1101,1,B,9,,,,10576,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616424,BAO_0000357,
1102,1,B,8,,,,10576,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,,,,,,H,Expert,CHEMBL616425,BAO_0000357,
1103,1,B,8,,,,10576,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,,,,,,H,Expert,CHEMBL616426,BAO_0000357,
1104,1,B,8,,,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,10000000.0,,,,,,H,Autocuration,CHEMBL616427,BAO_0000221,
1105,1,B,8,,,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,10000000.0,,,,,,H,Autocuration,CHEMBL616428,BAO_0000221,
1106,1,B,8,,,,10576,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10000000.0,,,,,,H,Autocuration,CHEMBL616290,BAO_0000221,
1107,1,B,9,,,,10576,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616052,BAO_0000357,
1108,1,B,8,,,,10576,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616053,BAO_0000357,
1109,1,B,8,,,,10576,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,,,,,,H,Autocuration,CHEMBL616054,BAO_0000249,
1110,1,B,8,,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616055,BAO_0000357,
1111,1,B,8,,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,,,,,,H,Autocuration,CHEMBL616056,BAO_0000357,
1112,1,B,8,,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,,,,,,H,Expert,CHEMBL616057,BAO_0000019,
1113,1,B,9,,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,955.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616058,BAO_0000221,
1114,1,B,8,,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,955.0,,,,,,H,Autocuration,CHEMBL616059,BAO_0000221,
1115,1,B,8,,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,,,,,,H,Autocuration,CHEMBL616060,BAO_0000249,
1116,1,B,9,,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,10000000.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616061,BAO_0000221,
1117,1,B,8,,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,10000000.0,,,,,,H,Expert,CHEMBL616062,BAO_0000221,
1118,1,B,8,,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,,,,,,H,Autocuration,CHEMBL616063,BAO_0000249,
1119,1,B,8,,,,10576,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",2435.0,,,,,,H,Autocuration,CHEMBL616064,BAO_0000249,
1120,1,B,9,,,,10576,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616065,BAO_0000249,
1121,1,B,9,,,,10576,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616066,BAO_0000249,
1122,1,B,8,,,,10576,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,10000000.0,,,,,,H,Autocuration,CHEMBL616067,BAO_0000221,
1123,1,B,8,,,,10576,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,10000000.0,,,,,,H,Autocuration,CHEMBL616068,BAO_0000221,
1124,1,B,8,,,,10576,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,10000000.0,,,,,,H,Intermediate,CHEMBL616069,BAO_0000221,
1125,1,B,8,,,,10576,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,,,,,H,Expert,CHEMBL616070,BAO_0000249,
1126,1,B,8,,,,10576,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,10000000.0,,,,,,H,Autocuration,CHEMBL616071,BAO_0000221,
1127,1,B,8,,,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,10000000.0,,,,,,H,Expert,CHEMBL616072,BAO_0000221,
1128,1,B,8,,,,10576,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,10000000.0,,,,,,H,Autocuration,CHEMBL616073,BAO_0000221,
1129,1,B,8,,,,10576,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,10000000.0,,,,,,H,Autocuration,CHEMBL616074,BAO_0000221,
1130,1,B,8,,,,10576,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,,,,,,H,Expert,CHEMBL616075,BAO_0000019,
1131,1,B,8,,,,10576,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616076,BAO_0000357,
1132,1,B,9,,,,10576,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616077,BAO_0000019,
1133,1,B,9,,,,10576,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616078,BAO_0000019,
1134,1,B,9,,,,10576,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616079,BAO_0000019,
1135,1,B,9,CHO-K1,,,10576,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,Rattus norvegicus,,485.0,,10116.0,D,Expert,CHEMBL616080,BAO_0000219,
1136,1,B,8,,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616081,BAO_0000357,
1137,1,B,9,,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,10000000.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616082,BAO_0000221,
1138,1,B,8,,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,10000000.0,,,,,,H,Autocuration,CHEMBL616083,BAO_0000221,
1139,1,B,8,,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,,,,,H,Autocuration,CHEMBL616084,BAO_0000019,
1140,1,B,8,,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,,,,,,H,Expert,CHEMBL616085,BAO_0000019,
1141,1,B,8,,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,,,,,,H,Autocuration,CHEMBL616086,BAO_0000019,
1142,1,B,8,,,,10576,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",10000000.0,,,,,,H,Autocuration,CHEMBL616087,BAO_0000221,
1143,1,B,8,,,,10576,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,,,,,,H,Expert,CHEMBL616088,BAO_0000357,
1144,1,B,8,,,,10576,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,,,,,,H,Autocuration,CHEMBL616089,BAO_0000019,
1145,1,B,9,,,,10576,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616090,BAO_0000357,
1146,1,B,8,,,,10576,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,,,,,H,Autocuration,CHEMBL616091,BAO_0000357,
1147,1,B,8,,,,10576,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",2435.0,,,,,,H,Autocuration,CHEMBL616092,BAO_0000249,
1148,1,B,8,,,,10576,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,,,,,,H,Autocuration,CHEMBL616093,BAO_0000357,
1149,1,B,8,,,In vivo,10576,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),,,,,,,H,Autocuration,CHEMBL616094,BAO_0000218,
1150,1,B,8,,,,10576,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,955.0,,,,,,H,Autocuration,CHEMBL616095,BAO_0000221,
1151,1,B,9,,,,10576,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616096,BAO_0000357,
1152,1,B,8,,,,10576,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,,,,,,H,Expert,CHEMBL616097,BAO_0000249,
1153,1,B,9,,,,10576,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616098,BAO_0000249,
1154,1,B,8,,,,10576,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,10000000.0,,,,,,H,Autocuration,CHEMBL616099,BAO_0000221,
1155,1,B,8,,,,10576,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,10000000.0,,,,,,H,Autocuration,CHEMBL616100,BAO_0000221,
1156,1,B,8,,,,10576,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,,,,,,H,Expert,CHEMBL616101,BAO_0000357,
1157,1,B,8,,,,10576,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,,,,,,H,Expert,CHEMBL616102,BAO_0000249,
1158,1,B,8,,,,10576,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616103,BAO_0000357,
1159,1,B,8,,,,10576,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,,,,,,H,Expert,CHEMBL616104,BAO_0000019,
1160,1,B,8,,,,10576,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,,,,,,H,Expert,CHEMBL616105,BAO_0000019,
1161,1,B,9,,,,10576,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616106,BAO_0000019,
1162,1,B,8,,,,10576,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,,,,,,H,Autocuration,CHEMBL616107,BAO_0000019,
1163,1,B,8,,,,10576,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,,,,,,H,Expert,CHEMBL616108,BAO_0000357,
1164,1,B,8,,,,10576,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,10000000.0,,,,,,H,Expert,CHEMBL616109,BAO_0000221,
1165,1,B,8,,,,10576,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,,,,,,H,Autocuration,CHEMBL616110,BAO_0000357,
1166,1,B,8,CHO,,,10576,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,,,,449.0,,,H,Expert,CHEMBL616111,BAO_0000219,
1167,1,B,8,,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,,,,,,H,Expert,CHEMBL616112,BAO_0000019,
1168,1,B,8,,,,10576,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,10000000.0,,,,,,H,Autocuration,CHEMBL616113,BAO_0000221,
1169,1,B,8,,,,10576,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616114,BAO_0000019,
1170,1,B,8,,,,10576,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616115,BAO_0000019,
1171,1,B,8,,,,10576,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616116,BAO_0000357,
1172,1,B,8,,,,10576,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,955.0,,,,,,H,Expert,CHEMBL615844,BAO_0000221,
1173,1,B,8,,,,10576,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,10000000.0,,,,,,H,Expert,CHEMBL615939,BAO_0000221,
1174,1,B,8,,,,10576,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,,,,,,H,Expert,CHEMBL615940,BAO_0000019,
1175,1,B,8,,,,10576,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,10000000.0,,,,,,H,Expert,CHEMBL615941,BAO_0000221,
1176,1,B,8,,,,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,10000000.0,,,,,,H,Autocuration,CHEMBL615942,BAO_0000221,
1177,1,B,8,,,,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,10000000.0,,,,,,H,Autocuration,CHEMBL615943,BAO_0000221,
1178,1,B,8,,,,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,10000000.0,,,,,,H,Autocuration,CHEMBL615944,BAO_0000221,
1179,1,B,8,,,,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,10000000.0,,,,,,H,Autocuration,CHEMBL615945,BAO_0000221,
1180,1,B,8,,,,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,10000000.0,,,,,,H,Autocuration,CHEMBL615946,BAO_0000221,
1181,1,B,8,,,,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,10000000.0,,,,,,H,Autocuration,CHEMBL615947,BAO_0000221,
1182,1,B,8,,,,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,10000000.0,,,,,,H,Autocuration,CHEMBL615948,BAO_0000221,
1183,1,B,8,,,,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,10000000.0,,,,,,H,Autocuration,CHEMBL615949,BAO_0000221,
1184,1,B,8,,,,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,10000000.0,,,,,,H,Autocuration,CHEMBL615950,BAO_0000221,
1185,1,B,8,,,,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,10000000.0,,,,,,H,Autocuration,CHEMBL615951,BAO_0000221,
1186,1,B,8,,,,10576,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,10000000.0,,,,,,H,Autocuration,CHEMBL615952,BAO_0000221,
1187,1,B,8,,,,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,10000000.0,,,,,,H,Autocuration,CHEMBL615953,BAO_0000221,
1188,1,B,8,,,,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,10000000.0,,,,,,H,Autocuration,CHEMBL615954,BAO_0000221,
1189,1,B,9,,,,10576,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,10000000.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL615955,BAO_0000221,
1190,1,B,8,,,,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,10000000.0,,,,,,H,Autocuration,CHEMBL615956,BAO_0000221,
1191,1,B,8,,,,10576,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,10000000.0,,,,,,H,Autocuration,CHEMBL615957,BAO_0000221,
1192,1,B,8,,,,10576,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,,,,,,H,Expert,CHEMBL615958,BAO_0000019,
1193,1,B,8,,,,10576,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,,,,,,H,Expert,CHEMBL615959,BAO_0000019,
1194,1,B,8,,,,10576,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,,,,,,H,Autocuration,CHEMBL615960,BAO_0000019,
1195,1,B,8,,,,10576,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,,,,,,H,Autocuration,CHEMBL615961,BAO_0000019,
1196,1,B,8,,,,10576,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,955.0,,,,,,H,Expert,CHEMBL615962,BAO_0000221,
1197,1,B,8,,,,10576,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,,,,,,H,Expert,CHEMBL615963,BAO_0000019,
1198,1,B,8,,,,10576,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,,,,,,H,Autocuration,CHEMBL615964,BAO_0000019,
1199,1,B,8,,,,10576,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,,,,,,H,Autocuration,CHEMBL615965,BAO_0000019,
1200,1,B,8,CHO,,,10576,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,,,,449.0,,,H,Expert,CHEMBL615966,BAO_0000219,
1201,1,B,8,,,,10576,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,,,,,,H,Expert,CHEMBL615967,BAO_0000249,
1202,1,B,8,,,,10576,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,,,,,,H,Expert,CHEMBL615968,BAO_0000019,
1203,1,B,8,CHO,,,10576,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,,,449.0,,,H,Autocuration,CHEMBL615969,BAO_0000218,
1204,1,B,8,,,,10576,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,,,,,,H,Autocuration,CHEMBL615970,BAO_0000218,
1205,1,B,9,,,,10576,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL615971,BAO_0000357,
1206,1,B,8,,,,10576,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,,,,,H,Expert,CHEMBL615972,BAO_0000249,
1207,1,B,8,,,,10576,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,,,,,,H,Autocuration,CHEMBL615973,BAO_0000249,
1208,1,B,8,,,,10576,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,,,,,,H,Autocuration,CHEMBL615974,BAO_0000249,
1209,1,B,9,CHO,,,51,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,Homo sapiens,,449.0,,9606.0,D,Expert,CHEMBL615975,BAO_0000219,
1210,1,B,8,,,,10576,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,,,,,,H,Expert,CHEMBL615976,BAO_0000249,
1211,1,B,9,,,,10576,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,10000000.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL872106,BAO_0000221,
1212,1,B,8,,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,,,,,H,Autocuration,CHEMBL615977,BAO_0000357,
1213,1,B,8,,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,,,,,,H,Autocuration,CHEMBL615978,BAO_0000357,
1214,1,B,8,,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,,,,,,H,Autocuration,CHEMBL616166,BAO_0000357,
1215,1,B,8,,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,,,,,,H,Autocuration,CHEMBL616167,BAO_0000357,
1216,1,B,8,,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,,,,,,H,Autocuration,CHEMBL616168,BAO_0000357,
1217,1,B,8,,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,,,,,,H,Autocuration,CHEMBL616169,BAO_0000357,
1218,1,B,8,,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,,,,,,H,Autocuration,CHEMBL616170,BAO_0000357,
1219,1,B,8,,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,,,,,,H,Autocuration,CHEMBL616171,BAO_0000357,
1220,1,B,8,,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,,,,,,H,Autocuration,CHEMBL616172,BAO_0000357,
1221,1,B,8,,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,,,,,,H,Autocuration,CHEMBL616173,BAO_0000357,
1222,1,B,8,,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,,,,,,H,Autocuration,CHEMBL616174,BAO_0000357,
1223,1,B,8,,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,,,,,,H,Autocuration,CHEMBL616175,BAO_0000357,
1224,1,B,8,,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,,,,,,H,Autocuration,CHEMBL616176,BAO_0000357,
1225,1,B,8,,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,,,,,,H,Autocuration,CHEMBL616177,BAO_0000357,
1226,1,B,8,,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,,,,,,H,Autocuration,CHEMBL616178,BAO_0000357,
1227,1,B,8,,,,10576,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,,,,,,H,Autocuration,CHEMBL616179,BAO_0000019,
1228,1,B,8,,,,10576,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616180,BAO_0000357,
1229,1,B,8,,,,10576,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,,,,,,H,Autocuration,CHEMBL616181,BAO_0000357,
1230,1,B,8,,,,10576,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,,,,,,H,Autocuration,CHEMBL616182,BAO_0000019,
1231,1,B,8,,,,10576,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,10000000.0,,,,,,H,Autocuration,CHEMBL616183,BAO_0000221,
1232,1,B,8,,,,10576,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,,,,,,H,Expert,CHEMBL615874,BAO_0000019,
1233,1,B,9,CHO-K1,,,10576,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,Rattus norvegicus,,485.0,,10116.0,D,Expert,CHEMBL615875,BAO_0000219,
1234,1,B,8,,,,10576,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,,,,,,H,Autocuration,CHEMBL615876,BAO_0000019,
1235,1,B,8,,,,10576,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,,,,,,H,Autocuration,CHEMBL615877,BAO_0000019,
1236,1,B,8,,,,10576,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,,,,,,H,Autocuration,CHEMBL615878,BAO_0000357,
1237,1,B,8,,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,,,,,,H,Expert,CHEMBL615879,BAO_0000357,
1238,1,B,8,,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,,,,,,H,Expert,CHEMBL615880,BAO_0000357,
1239,1,B,8,,,,10576,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,,,,,,H,Autocuration,CHEMBL615881,BAO_0000019,
1240,1,B,9,,,,10576,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL615882,BAO_0000019,
1241,1,F,8,,,In vivo,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,,,,,,,H,Autocuration,CHEMBL615883,BAO_0000218,
1242,1,F,8,,,In vivo,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),,,,,,,H,Autocuration,CHEMBL615884,BAO_0000218,
1243,1,F,8,,,In vivo,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),,,,,,,H,Autocuration,CHEMBL615885,BAO_0000218,
1244,1,F,8,,,In vivo,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),,,,,,,H,Autocuration,CHEMBL615886,BAO_0000218,
1245,1,F,8,,,In vivo,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),,,,,,,H,Autocuration,CHEMBL615887,BAO_0000218,
1246,1,F,8,,,In vivo,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),,,,,,,H,Autocuration,CHEMBL615888,BAO_0000218,
1247,1,F,8,,,In vivo,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),,,,,,,H,Autocuration,CHEMBL615889,BAO_0000218,
1248,1,F,8,,,In vivo,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),,,,,,,H,Autocuration,CHEMBL615890,BAO_0000218,
1249,1,F,8,,,In vivo,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),,,,,,,H,Autocuration,CHEMBL615891,BAO_0000218,
1250,1,F,8,,,In vivo,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),,,,,,,H,Autocuration,CHEMBL615892,BAO_0000218,
1251,1,F,8,,,In vivo,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),,,,,,,H,Autocuration,CHEMBL615893,BAO_0000218,
1252,1,F,8,,,In vivo,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),,,,,,,H,Autocuration,CHEMBL615894,BAO_0000218,
1253,1,F,8,,,In vivo,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),,,,,,,H,Autocuration,CHEMBL615895,BAO_0000218,
1254,1,F,8,,,In vivo,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),,,,,,,H,Autocuration,CHEMBL615896,BAO_0000218,
1255,1,F,8,,,In vivo,10576,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,,,,,,,H,Autocuration,CHEMBL615897,BAO_0000218,
1256,1,F,9,,,,10576,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL615898,BAO_0000249,
1257,1,B,8,,,,10576,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,,,,,,H,Autocuration,CHEMBL615899,BAO_0000019,
1258,1,B,8,,,,10576,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,,,,,,H,Autocuration,CHEMBL616291,BAO_0000019,
1259,1,B,8,,,,10576,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,,,,,,H,Autocuration,CHEMBL616292,BAO_0000357,
1260,1,F,8,,,,10576,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,,,,,,H,Autocuration,CHEMBL616293,BAO_0000249,
1261,1,B,8,,,,10576,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10000000.0,,,,,,H,Expert,CHEMBL616294,BAO_0000221,
1262,1,B,8,,,,10576,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,10000000.0,,,,,,H,Autocuration,CHEMBL616295,BAO_0000249,
1263,1,B,8,,,,10576,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,955.0,,,,,,H,Autocuration,CHEMBL616296,BAO_0000221,
1264,1,F,8,,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,,,,,,H,Autocuration,CHEMBL616297,BAO_0000019,
1265,1,F,8,,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,,,,,,H,Autocuration,CHEMBL616605,BAO_0000019,
1266,1,F,8,,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,,,,,,H,Autocuration,CHEMBL616606,BAO_0000019,
1267,1,F,8,,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,,,,,,H,Autocuration,CHEMBL616607,BAO_0000019,
1268,1,F,8,,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,,,,,,H,Expert,CHEMBL616608,BAO_0000019,
1269,1,F,8,,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,,,,,,H,Autocuration,CHEMBL616609,BAO_0000019,
1270,1,F,9,,,,10576,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616610,BAO_0000019,
1271,1,F,8,,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,,,,,,H,Autocuration,CHEMBL616611,BAO_0000019,
1272,1,F,8,,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,,,,,,H,Expert,CHEMBL616612,BAO_0000019,
1273,1,F,8,,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,,,,,,H,Autocuration,CHEMBL616613,BAO_0000019,
1274,1,F,8,,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,,,,,,H,Expert,CHEMBL616614,BAO_0000019,
1275,1,F,8,,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,,,,,,H,Autocuration,CHEMBL616615,BAO_0000019,
1276,1,F,8,,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,,,,,,H,Expert,CHEMBL616616,BAO_0000019,
1277,1,F,8,,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,,,,,,H,Autocuration,CHEMBL616617,BAO_0000019,
1278,1,F,8,,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,,,,,,H,Autocuration,CHEMBL616618,BAO_0000019,
1279,1,F,8,,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,,,,,,H,Autocuration,CHEMBL616619,BAO_0000019,
1280,1,F,8,,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,,,,,,H,Expert,CHEMBL616620,BAO_0000019,
1281,1,F,8,,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,,,,,,H,Expert,CHEMBL616621,BAO_0000019,
1282,1,F,8,,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,,,,,,H,Autocuration,CHEMBL616622,BAO_0000019,
1283,1,F,8,,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,,,,,,H,Expert,CHEMBL616146,BAO_0000019,
1284,1,F,8,,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,,,,,,H,Autocuration,CHEMBL832873,BAO_0000019,
1285,1,F,8,,,,10576,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,,,,,,H,Autocuration,CHEMBL616147,BAO_0000019,
1286,1,F,8,,,,10576,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,,,,,,H,Autocuration,CHEMBL872872,BAO_0000019,
1287,1,F,8,,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,,,,,,H,Autocuration,CHEMBL616148,BAO_0000019,
1288,1,B,8,,,,10576,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,10000000.0,,,,,,H,Autocuration,CHEMBL616149,BAO_0000221,
1289,1,B,8,,,,10576,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,10000000.0,,,,,,H,Expert,CHEMBL616150,BAO_0000221,
1290,1,B,9,,,,10576,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616151,BAO_0000249,
1291,1,B,8,,,,10576,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,10000000.0,,,,,,H,Expert,CHEMBL872873,BAO_0000221,
1292,1,B,8,,,,10576,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,10000000.0,,,,,,H,Autocuration,CHEMBL616670,BAO_0000221,
1293,1,B,8,,,,10576,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,10000000.0,,,,,,H,Autocuration,CHEMBL616671,BAO_0000221,
1294,1,F,9,,,,10576,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL884861,BAO_0000249,
1295,1,B,8,,,,10576,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,,,,,,H,Autocuration,CHEMBL616672,BAO_0000357,
1296,1,B,8,,,,10576,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,,,,,,H,Autocuration,CHEMBL616673,BAO_0000019,
1297,1,F,8,,,,10576,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,,,,,,H,Expert,CHEMBL616674,BAO_0000019,
1298,1,B,8,,,,10576,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,,,,,,H,Autocuration,CHEMBL616675,BAO_0000357,
1299,1,B,8,,,,10576,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,10000000.0,,,,,,H,Autocuration,CHEMBL616676,BAO_0000221,
1300,1,B,8,,,,10576,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10000000.0,,,,,,H,Autocuration,CHEMBL616677,BAO_0000221,
1301,1,B,8,,,,10576,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10000000.0,,,,,,H,Autocuration,CHEMBL616678,BAO_0000221,
1302,1,B,9,,,,10576,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616679,BAO_0000357,
1303,1,B,8,,,,10576,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,10000000.0,,,,,,H,Expert,CHEMBL616680,BAO_0000221,
1304,1,B,8,,,,10576,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,10000000.0,,,,,,H,Autocuration,CHEMBL616681,BAO_0000221,
1305,1,B,8,,,,10576,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,10000000.0,,,,,,H,Autocuration,CHEMBL616682,BAO_0000221,
1306,1,B,8,,,,10576,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,10000000.0,,,,,,H,Autocuration,CHEMBL616683,BAO_0000221,
1307,1,B,8,,,,10576,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,10000000.0,,,,,,H,Autocuration,CHEMBL616684,BAO_0000221,
1308,1,B,8,,,,10576,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,10000000.0,,,,,,H,Autocuration,CHEMBL616685,BAO_0000221,
1309,1,B,8,,,,10576,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,955.0,,,,,,H,Autocuration,CHEMBL616686,BAO_0000221,
1310,1,B,8,,,,10576,Affinity for 5-hydroxytryptamine 1A receptor site,,,,,,,H,Autocuration,CHEMBL616687,BAO_0000357,
1311,1,B,8,,,,10576,Affinity for 5-hydroxytryptamine 1A receptor site,,,,,,,H,Autocuration,CHEMBL616688,BAO_0000357,
1312,1,B,8,,,,10576,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,10000000.0,,,,,,H,Autocuration,CHEMBL616689,BAO_0000221,
1313,1,B,8,,,,10576,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,,,,,,H,Autocuration,CHEMBL616690,BAO_0000357,
1314,1,B,8,,,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,,,,,,H,Expert,CHEMBL616691,BAO_0000357,
1315,1,B,9,,,,10576,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,10000000.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616692,BAO_0000221,
1316,1,B,8,,,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,,,,,,H,Expert,CHEMBL616693,BAO_0000249,
1317,1,B,9,,,,10576,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616694,BAO_0000019,
1318,1,B,8,,,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,10000000.0,,,,,,H,Autocuration,CHEMBL616695,BAO_0000221,
1319,1,B,8,,,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,,,,,,H,Autocuration,CHEMBL616696,BAO_0000357,
1320,1,B,8,,,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,,,,,,H,Autocuration,CHEMBL616697,BAO_0000357,
1321,1,B,8,,,,10576,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616698,BAO_0000357,
1322,1,B,9,,,,10576,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616949,BAO_0000019,
1323,1,B,8,,,,10576,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,10000000.0,,,,,,H,Autocuration,CHEMBL616950,BAO_0000221,
1324,1,B,8,,,,10576,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,,,,,,H,Autocuration,CHEMBL832875,BAO_0000357,
1325,1,B,8,,,,10576,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,955.0,,,,,,H,Expert,CHEMBL616951,BAO_0000221,
1326,1,B,8,,,,10576,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,955.0,,,,,,H,Expert,CHEMBL616952,BAO_0000221,
1327,1,B,8,,,,10576,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,,,,,,H,Expert,CHEMBL616953,BAO_0000357,
1328,1,B,8,,,,10576,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,,,,,,H,Autocuration,CHEMBL616954,BAO_0000357,
1329,1,B,8,,,,106,GTPgammaS radioligand binding assay,,,,,,,H,Autocuration,CHEMBL616955,BAO_0000357,
1330,1,B,8,,,,106,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,,,,,,H,Autocuration,CHEMBL616956,BAO_0000357,
1331,1,F,8,,,,106,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,,,,,,H,Autocuration,CHEMBL616957,BAO_0000019,
1332,1,F,8,,,,106,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,,,,,,H,Autocuration,CHEMBL616958,BAO_0000019,
1333,1,B,8,,,,106,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,,,,,,H,Autocuration,CHEMBL616959,BAO_0000357,
1334,1,B,8,,,,106,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,,,,,,H,Autocuration,CHEMBL616960,BAO_0000357,
1335,1,F,8,,,,106,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,,,,,,H,Autocuration,CHEMBL616961,BAO_0000019,
1336,1,B,8,HeLa,,,106,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,,,,308.0,,,H,Expert,CHEMBL616962,BAO_0000219,
1337,1,B,8,HeLa,,,106,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,,,,308.0,,,H,Autocuration,CHEMBL616963,BAO_0000219,
1338,1,B,9,,,,106,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616524,BAO_0000357,
1339,1,B,8,CHO,,,106,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,,,449.0,,,H,Autocuration,CHEMBL616525,BAO_0000219,
1340,1,B,8,,,,106,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,,,,,,H,Autocuration,CHEMBL872908,BAO_0000019,
1341,1,B,8,,,,106,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,,,,,,H,Autocuration,CHEMBL616526,BAO_0000019,
1342,1,B,9,,,,106,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616527,BAO_0000357,
1343,1,B,8,,,,106,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,,,,,,H,Expert,CHEMBL616528,BAO_0000219,
1344,1,B,8,,,,106,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,,,,,H,Autocuration,CHEMBL616529,BAO_0000357,
1345,1,B,8,,,,106,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,,,,,,H,Autocuration,CHEMBL616530,BAO_0000357,
1346,1,B,8,,,,106,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,,,,,,H,Expert,CHEMBL616531,BAO_0000357,
1347,1,B,8,,,,106,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,,,,,,H,Autocuration,CHEMBL616532,BAO_0000357,
1348,1,B,8,,,,106,Binding affinity towards 5-hydroxytryptamine 1B receptor,,,,,,,H,Autocuration,CHEMBL616533,BAO_0000357,
1349,1,B,8,,,,106,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,,,,,,H,Expert,CHEMBL616534,BAO_0000357,
1350,1,B,8,,,,106,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,,,,,,H,Expert,CHEMBL616535,BAO_0000357,
1351,1,B,8,,,,106,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,,,,,,H,Autocuration,CHEMBL616536,BAO_0000357,
1352,1,B,8,,,,106,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,,,,,,H,Autocuration,CHEMBL616537,BAO_0000357,
1353,1,F,8,CHO-K1,,,106,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,,,,485.0,,,H,Expert,CHEMBL616538,BAO_0000219,
1354,1,F,8,,,,106,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,,,,,,H,Expert,CHEMBL616539,BAO_0000019,
1355,1,B,8,,,,106,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,,,,,,H,Expert,CHEMBL616540,BAO_0000019,
1356,1,B,8,,,,106,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,,,,,,H,Autocuration,CHEMBL616429,BAO_0000357,
1357,1,B,8,,,,106,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,,,,,,H,Expert,CHEMBL616430,BAO_0000357,
1358,1,B,9,,,,106,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616431,BAO_0000219,
1359,1,B,9,,,,106,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616432,BAO_0000357,
1360,1,B,9,,,,106,Affinity for 5-hydroxytryptamine 1B receptor subtype,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616433,BAO_0000357,
1361,1,B,9,,,,106,Binding affinity for human 5-hydroxytryptamine 1B receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616434,BAO_0000357,
1362,1,B,8,CHO,,,106,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,,,,449.0,,,H,Autocuration,CHEMBL616435,BAO_0000219,
1363,1,B,8,,,,106,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,,,,,,H,Expert,CHEMBL616436,BAO_0000019,
1364,1,B,8,HeLa,,,106,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,,,308.0,,,H,Autocuration,CHEMBL616437,BAO_0000219,
1365,1,B,8,HeLa,,,106,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,,,,308.0,,,H,Autocuration,CHEMBL616438,BAO_0000219,
1366,1,B,8,HeLa,,,106,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,,,308.0,,,H,Autocuration,CHEMBL616439,BAO_0000219,
1367,1,B,9,,,,106,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616440,BAO_0000357,
1368,1,B,8,CHO-K1,,,106,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,,,,485.0,,,H,Autocuration,CHEMBL616441,BAO_0000219,
1369,1,B,8,,,,106,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,,,,,,H,Expert,CHEMBL616442,BAO_0000357,
1370,1,B,8,,,,106,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,,,,,,H,Autocuration,CHEMBL616443,BAO_0000357,
1371,1,B,8,CHO-K1,,,106,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,,,,485.0,,,H,Expert,CHEMBL616444,BAO_0000219,
1372,1,B,9,,,,106,Binding activity against human 5-hydroxytryptamine 1B receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616445,BAO_0000357,
1373,1,B,9,,,,106,Binding activity against human 5-hydroxytryptamine 1B receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616446,BAO_0000357,
1374,1,B,9,CHO,,,106,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,Homo sapiens,,449.0,,9606.0,D,Expert,CHEMBL616447,BAO_0000219,
1375,1,B,8,,,,106,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,,,,,,H,Autocuration,CHEMBL616448,BAO_0000357,
1376,1,B,8,CHO,,,106,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,,,,449.0,,,H,Autocuration,CHEMBL616449,BAO_0000219,
1377,1,B,8,CHO,,,106,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,,,,449.0,,,H,Autocuration,CHEMBL616450,BAO_0000219,
1378,1,B,8,CHO,,,106,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,,,,449.0,,,H,Autocuration,CHEMBL857974,BAO_0000219,
1379,1,B,8,CHO,,,106,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,,,449.0,,,H,Autocuration,CHEMBL616451,BAO_0000219,
1380,1,B,8,CHO,,,106,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,,,449.0,,,H,Autocuration,CHEMBL616452,BAO_0000219,
1381,1,B,8,CHO,,,106,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,,,,449.0,,,H,Autocuration,CHEMBL616453,BAO_0000219,
1382,1,B,8,CHO,,,106,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,,,,449.0,,,H,Autocuration,CHEMBL616454,BAO_0000219,
1383,1,B,9,,,,106,Binding affinity for human 5-hydroxytryptamine 1B receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616455,BAO_0000357,
1384,1,B,8,CHO,,,106,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,,,449.0,,,H,Autocuration,CHEMBL616456,BAO_0000219,
1385,1,B,8,,,,106,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,,,,,,H,Autocuration,CHEMBL616457,BAO_0000357,
1386,1,B,8,CHO,,,106,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,,,449.0,,,H,Autocuration,CHEMBL616458,BAO_0000219,
1387,1,B,8,CHO,,,106,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",,,,449.0,,,H,Autocuration,CHEMBL616459,BAO_0000219,
1388,1,F,8,,,,106,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,,,,,,H,Expert,CHEMBL616460,BAO_0000019,
1389,1,F,8,,,,106,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,,,,,,H,Expert,CHEMBL616461,BAO_0000019,
1390,1,F,8,CHO,,,106,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",,,,449.0,,,H,Autocuration,CHEMBL616462,BAO_0000219,
1391,1,F,8,CHO,,,106,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",,,,449.0,,,H,Autocuration,CHEMBL616463,BAO_0000219,
1392,1,F,8,,,,105,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,,,,,,H,Autocuration,CHEMBL616464,BAO_0000019,
1393,1,B,8,CHO,,,105,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,,,,449.0,,,H,Autocuration,CHEMBL616465,BAO_0000219,
1394,1,B,8,,,,17105,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,,,,,,H,Autocuration,CHEMBL832874,BAO_0000357,
1395,1,F,8,,,,106,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,,Oryctolagus cuniculus,,,,9986.0,H,Autocuration,CHEMBL616184,BAO_0000019,
1396,1,B,8,,,,106,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,,Oryctolagus cuniculus,,,,9986.0,H,Autocuration,CHEMBL616185,BAO_0000019,
1397,1,B,8,,,,106,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",,Oryctolagus cuniculus,,,,9986.0,H,Intermediate,CHEMBL616186,BAO_0000019,
1398,1,B,8,,,,106,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,,Oryctolagus cuniculus,,,,9986.0,H,Autocuration,CHEMBL616187,BAO_0000019,
1399,1,B,8,,,,10577,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,,,,,,H,Expert,CHEMBL616188,BAO_0000357,
1400,1,B,9,,,,10577,Binding affinity for 5-hydroxytryptamine 1B receptor,,,,,,,D,Intermediate,CHEMBL873475,BAO_0000357,
1401,1,B,9,,,,10577,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,2435.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616189,BAO_0000019,
1402,1,B,8,,,,10577,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,,,,,,H,Expert,CHEMBL616190,BAO_0000357,
1403,1,B,8,,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,,,,,,H,Autocuration,CHEMBL616191,BAO_0000357,
1404,1,B,8,,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,,,,,,H,Autocuration,CHEMBL616192,BAO_0000357,
1405,1,B,8,,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,,,,,,H,Autocuration,CHEMBL616193,BAO_0000357,
1406,1,B,8,,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,,,,,,H,Autocuration,CHEMBL616194,BAO_0000357,
1407,1,B,8,,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,,,,,,H,Autocuration,CHEMBL616195,BAO_0000357,
1408,1,B,8,,,,10576,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,,,,,,H,Autocuration,CHEMBL616196,BAO_0000357,
1409,1,B,8,,,,10576,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,10000000.0,,,,,,H,Autocuration,CHEMBL616197,BAO_0000249,
1410,1,B,8,,,,10576,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,,,,,,H,Intermediate,CHEMBL616198,BAO_0000019,
1411,1,B,8,,,,10576,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,10000000.0,,,,,,H,Autocuration,CHEMBL616199,BAO_0000221,
1412,1,B,8,,,,10576,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,10000000.0,,,,,,H,Expert,CHEMBL616200,BAO_0000221,
1413,1,B,8,,,,10576,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,10000000.0,,,,,,H,Expert,CHEMBL616201,BAO_0000221,
1414,1,B,8,,,,10576,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,10000000.0,,,,,,H,Expert,CHEMBL616202,BAO_0000221,
1415,1,B,8,,,,10576,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,10000000.0,,,,,,H,Expert,CHEMBL616203,BAO_0000221,
1416,1,B,8,,,,10576,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,10000000.0,,,,,,H,Expert,CHEMBL616204,BAO_0000221,
1417,1,B,8,,,,10576,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,10000000.0,,,,,,H,Expert,CHEMBL616205,BAO_0000221,
1418,1,B,8,,,,10576,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,10000000.0,,,,,,H,Expert,CHEMBL616206,BAO_0000221,
1419,1,B,8,,,,10576,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,,,,,,H,Expert,CHEMBL616207,BAO_0000249,
1420,1,B,8,,,,10576,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,,,,,,H,Autocuration,CHEMBL616208,BAO_0000249,
1421,1,B,8,,,,10576,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,,,,,,H,Autocuration,CHEMBL616209,BAO_0000249,
1422,1,B,8,,,,10576,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,,,,,,H,Expert,CHEMBL616210,BAO_0000357,
1423,1,B,8,,,,10576,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,10000000.0,,,,,,H,Expert,CHEMBL616211,BAO_0000221,
1424,1,B,8,,,,10576,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,10000000.0,,,,,,H,Autocuration,CHEMBL616504,BAO_0000221,
1425,1,B,9,,,,10576,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,10000000.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616505,BAO_0000221,
1426,1,F,8,,,,10576,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616506,BAO_0000019,
1427,1,B,8,,,,10576,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10000000.0,,,,,,H,Autocuration,CHEMBL872107,BAO_0000221,
1428,1,B,9,,,,10576,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,10000000.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616507,BAO_0000221,
1429,1,B,8,,,,10576,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,,,,,,H,Autocuration,CHEMBL616303,BAO_0000249,
1430,1,B,8,,,,10576,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,10000000.0,,,,,,H,Autocuration,CHEMBL616304,BAO_0000221,
1431,1,B,8,,,,10576,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,10000000.0,,,,,,H,Expert,CHEMBL616305,BAO_0000221,
1432,1,F,8,,,,10576,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,10000000.0,,,,,,H,Intermediate,CHEMBL616306,BAO_0000221,
1433,1,B,8,,,,10576,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616307,BAO_0000357,
1434,1,B,9,,,,10576,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,10000000.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL881829,BAO_0000221,
1435,1,B,8,,,,10576,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,,,,,,H,Expert,CHEMBL616308,BAO_0000357,
1436,1,B,8,,,,10576,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,,,,,,H,Autocuration,CHEMBL616309,BAO_0000019,
1437,1,B,8,,,,10576,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,,,,,,H,Expert,CHEMBL616310,BAO_0000019,
1438,1,B,8,CHO,,,10576,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,,,,449.0,,,H,Autocuration,CHEMBL616311,BAO_0000219,
1439,1,B,8,,,,10576,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,,,,,,H,Expert,CHEMBL616312,BAO_0000357,
1440,1,B,8,,,,10576,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,,,,,,H,Autocuration,CHEMBL616313,BAO_0000357,
1441,1,B,9,,,,10576,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,10000000.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616314,BAO_0000221,
1442,1,B,8,,,,10576,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,10000000.0,,,,,,H,Autocuration,CHEMBL616315,BAO_0000221,
1443,1,B,8,,,,10576,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,10000000.0,,,,,,H,Autocuration,CHEMBL616567,BAO_0000221,
1444,1,B,8,,,,10576,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,10000000.0,,,,,,H,Autocuration,CHEMBL616568,BAO_0000221,
1445,1,B,8,,,,10576,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,,,,,,H,Intermediate,CHEMBL616569,BAO_0000019,
1446,1,B,8,,,,10576,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,,,,,,H,Expert,CHEMBL616570,BAO_0000357,
1447,1,B,8,,,,10576,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,,,,,,H,Autocuration,CHEMBL616571,BAO_0000357,
1448,1,B,8,,,,10576,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,10000000.0,,,,,,H,Autocuration,CHEMBL616572,BAO_0000221,
1449,1,B,8,,,,10576,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,,,,,,H,Expert,CHEMBL616573,BAO_0000249,
1450,1,B,9,,,,10576,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616574,BAO_0000357,
1451,1,B,8,,,,10576,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,10000000.0,,,,,,H,Expert,CHEMBL616575,BAO_0000221,
1452,1,B,8,,,,10576,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,10000000.0,,,,,,H,Autocuration,CHEMBL872108,BAO_0000221,
1453,1,B,8,,,,10576,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,,,,,,H,Autocuration,CHEMBL616576,BAO_0000357,
1454,1,B,8,,,,10576,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,,,,,,H,Autocuration,CHEMBL616577,BAO_0000249,
1455,1,B,8,,,,10576,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,,,,,,H,Autocuration,CHEMBL616578,BAO_0000249,
1456,1,B,8,,,,10576,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,,,,,,H,Expert,CHEMBL616579,BAO_0000357,
1457,1,B,9,,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616580,BAO_0000019,
1458,1,B,8,,,,10576,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,,,,,,H,Autocuration,CHEMBL616581,BAO_0000019,
1459,1,B,8,,,,10576,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,10000000.0,,,,,,H,Autocuration,CHEMBL616582,BAO_0000221,
1460,1,B,8,,,,10576,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,10000000.0,,,,,,H,Expert,CHEMBL616583,BAO_0000221,
1461,1,B,9,,,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,10000000.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616584,BAO_0000221,
1462,1,B,8,,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,,,,H,Expert,CHEMBL616585,BAO_0000357,
1463,1,B,9,,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,10000000.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616586,BAO_0000221,
1464,1,B,8,,,,10576,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,10000000.0,,,,,,H,Autocuration,CHEMBL616587,BAO_0000221,
1465,1,B,8,,,,10576,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,10000000.0,,,,,,H,Autocuration,CHEMBL616588,BAO_0000221,
1466,1,B,8,,,,10576,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,10000000.0,,,,,,H,Autocuration,CHEMBL616589,BAO_0000221,
1467,1,B,8,,,,10576,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,10000000.0,,,,,,H,Expert,CHEMBL616590,BAO_0000221,
1468,1,B,8,CHO,,,10576,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",,,,449.0,,,H,Expert,CHEMBL616591,BAO_0000219,
1469,1,B,8,,,,10576,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,,,,,H,Expert,CHEMBL616592,BAO_0000357,
1470,1,B,8,,,,10576,The inhibition activity of 5-HT1A at 1 uM,,,,,,,H,Autocuration,CHEMBL616593,BAO_0000357,
1471,1,B,8,CHO-K1,,,10576,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",,,,485.0,,,H,Expert,CHEMBL616594,BAO_0000219,
1472,1,B,8,,,,10576,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,,,,,,H,Expert,CHEMBL616595,BAO_0000249,
1473,1,B,8,,,,10576,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,,,,,,H,Autocuration,CHEMBL616596,BAO_0000357,
1474,1,B,8,,,,10576,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,10000000.0,,,,,,H,Autocuration,CHEMBL616597,BAO_0000221,
1475,1,B,8,,,,10576,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,10000000.0,,,,,,H,Expert,CHEMBL616598,BAO_0000221,
1476,1,F,9,,,,10576,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616599,BAO_0000249,
1477,1,F,9,,,,10576,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",10000000.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616600,BAO_0000249,
1478,1,B,8,,,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,,,,,,H,Autocuration,CHEMBL616601,BAO_0000019,
1479,1,B,8,,,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,,,,,,H,Autocuration,CHEMBL616602,BAO_0000019,
1480,1,B,8,,,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,,,,,,H,Autocuration,CHEMBL616603,BAO_0000019,
1481,1,B,8,,,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,,,,,,H,Autocuration,CHEMBL616604,BAO_0000019,
1482,1,B,8,,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,,,,,,H,Autocuration,CHEMBL616316,BAO_0000249,
1483,1,B,8,,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,,,,,,H,Autocuration,CHEMBL616317,BAO_0000249,
1484,1,B,9,,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616318,BAO_0000019,
1485,1,B,8,,,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,10000000.0,,,,,,H,Autocuration,CHEMBL616319,BAO_0000221,
1486,1,B,8,,,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,10000000.0,,,,,,H,Autocuration,CHEMBL616320,BAO_0000221,
1487,1,B,9,,,,10576,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,10000000.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616321,BAO_0000221,
1488,1,F,8,,,,10576,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,,,,,,H,Autocuration,CHEMBL616322,BAO_0000019,
1489,1,F,8,,,,10576,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,,,,,,H,Autocuration,CHEMBL616323,BAO_0000019,
1490,1,B,8,,,,10576,Ratio of binding affinity to 5-HT 1A and D2 receptor,,,,,,,H,Autocuration,CHEMBL616324,BAO_0000357,
1491,1,B,8,,,,10576,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,10000000.0,,,,,,H,Autocuration,CHEMBL616325,BAO_0000221,
1492,1,B,8,,,,10576,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,10000000.0,,,,,,H,Autocuration,CHEMBL616326,BAO_0000221,
1493,1,B,8,,,,10576,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,10000000.0,,,,,,H,Autocuration,CHEMBL616327,BAO_0000221,
1494,1,B,8,,,,10576,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616328,BAO_0000357,
1495,1,B,8,,,,10576,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,,,,,,H,Autocuration,CHEMBL858110,BAO_0000249,
1496,1,F,8,,,,10576,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,,,,,,H,Autocuration,CHEMBL616329,BAO_0000249,
1497,1,B,8,,,,10576,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,,,,,,H,Autocuration,CHEMBL616330,BAO_0000249,
1498,1,F,8,,,,10576,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,,,,,,H,Autocuration,CHEMBL616331,BAO_0000249,
1499,1,F,8,,,,10576,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,,,,,,H,Autocuration,CHEMBL616332,BAO_0000249,
1500,1,B,8,,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,955.0,,,,,,H,Autocuration,CHEMBL857063,BAO_0000249,
1501,1,B,8,,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,,,,,,H,Autocuration,CHEMBL616333,BAO_0000019,
1502,1,F,8,,,,10576,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,,,,,,H,Expert,CHEMBL616334,BAO_0000019,
1503,1,B,8,,,,10576,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,10000000.0,,,,,,H,Autocuration,CHEMBL616335,BAO_0000221,
1504,1,B,8,,,,10576,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,,,,,,H,Autocuration,CHEMBL616336,BAO_0000019,
1505,1,B,8,,,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,,,,,,H,Expert,CHEMBL616337,BAO_0000249,
1506,1,B,8,,,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,,,,,,H,Autocuration,CHEMBL616338,BAO_0000019,
1507,1,B,8,,,,10576,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,10000000.0,,,,,,H,Autocuration,CHEMBL616339,BAO_0000221,
1508,1,B,8,,,,10576,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,10000000.0,,,,,,H,Autocuration,CHEMBL616340,BAO_0000221,
1509,1,B,8,,,,10576,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,,,,,,H,Autocuration,CHEMBL616341,BAO_0000357,
1510,1,B,9,,,,10576,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616342,BAO_0000357,
1511,1,B,9,,,,10576,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616343,BAO_0000019,
1512,1,B,8,,,,10576,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,,,,,,H,Expert,CHEMBL616344,BAO_0000019,
1513,1,B,8,,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,,,,,H,Expert,CHEMBL616345,BAO_0000357,
1514,1,B,8,,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,,,,,,H,Expert,CHEMBL616346,BAO_0000019,
1515,1,B,8,,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,10000000.0,,,,,,H,Autocuration,CHEMBL616347,BAO_0000221,
1516,1,B,8,,,,10576,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,,,,,,H,Expert,CHEMBL616348,BAO_0000019,
1517,1,B,8,,,,10576,Binding affinity at 5-hydroxytryptamine 1A receptor,,,,,,,H,Expert,CHEMBL616349,BAO_0000357,
1518,1,B,9,,,,10576,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616152,BAO_0000249,
1519,1,B,8,,,,10576,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,,,,,,H,Autocuration,CHEMBL616153,BAO_0000249,
1520,1,B,8,,,,10576,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,,,,,,H,Expert,CHEMBL616154,BAO_0000019,
1521,1,B,8,,,,10576,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,,,,,H,Autocuration,CHEMBL616155,BAO_0000019,
1522,1,B,9,,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,10000000.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616156,BAO_0000221,
1523,1,B,9,,,,10576,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,10000000.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616157,BAO_0000221,
1524,1,B,8,,,,10576,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,10000000.0,,,,,,H,Autocuration,CHEMBL616158,BAO_0000221,
1525,1,B,8,,,,10576,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,,,,,H,Autocuration,CHEMBL616159,BAO_0000357,
1526,1,B,8,,,,10576,pKi value against rat 5-hydroxytryptamine 1A receptor.,,,,,,,H,Expert,CHEMBL616160,BAO_0000357,
1527,1,B,8,,,,10576,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,,,,,,H,Autocuration,CHEMBL616161,BAO_0000019,
1528,1,F,8,,,,10576,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,,,,,,H,Autocuration,CHEMBL616162,BAO_0000019,
1529,1,B,9,,,,12687,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616163,BAO_0000357,
1530,1,B,8,,,,10626,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,,,,,H,Expert,CHEMBL616164,BAO_0000249,
1531,1,B,8,,,,10576,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,955.0,,,,,,H,Autocuration,CHEMBL616165,BAO_0000221,
1532,1,B,8,,,,51,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,,Rattus norvegicus,,,,10116.0,H,Autocuration,CHEMBL616355,BAO_0000019,
1533,1,F,8,,,,10576,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,,,,,,H,Autocuration,CHEMBL616356,BAO_0000019,
1534,1,B,8,,,,10576,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,955.0,,,,,,H,Autocuration,CHEMBL616357,BAO_0000221,
1535,1,B,8,,,,10576,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,,,,,,H,Autocuration,CHEMBL616358,BAO_0000019,
1536,1,B,8,,,,51,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616359,BAO_0000357,
1537,1,B,8,,,,51,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,,,,,,H,Expert,CHEMBL616360,BAO_0000357,
1538,1,B,8,,,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,,,,H,Expert,CHEMBL616361,BAO_0000357,
1539,1,B,8,,,,51,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616362,BAO_0000357,
1540,1,B,8,,,,51,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,,,,,,,H,Autocuration,CHEMBL616363,BAO_0000249,
1541,1,B,8,,,,51,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,,,,,,H,Autocuration,CHEMBL616364,BAO_0000357,
1542,1,B,8,,,,51,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616365,BAO_0000357,
1543,1,B,8,,,,51,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,,,,,,H,Expert,CHEMBL616366,BAO_0000357,
1544,1,B,8,,,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,,,,H,Expert,CHEMBL872906,BAO_0000357,
1545,1,B,8,,,,51,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,,,,,,H,Autocuration,CHEMBL616367,BAO_0000357,
1546,1,B,8,,,,51,Binding affinity against 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616368,BAO_0000357,
1547,1,B,8,,,,51,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,,,,,,H,Autocuration,CHEMBL616369,BAO_0000357,
1548,1,B,9,,,,51,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616370,BAO_0000357,
1549,1,B,9,,,,51,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616371,BAO_0000357,
1550,1,B,8,CHO,,,51,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,,449.0,,,H,Autocuration,CHEMBL616372,BAO_0000219,
1551,1,B,8,,,,51,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,,,,,,H,Expert,CHEMBL616373,BAO_0000219,
1552,1,B,8,,,In vivo,51,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,H,Autocuration,CHEMBL616374,BAO_0000218,
1553,1,B,8,,,,51,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,10000000.0,,,,,,H,Autocuration,CHEMBL616375,BAO_0000221,
1554,1,B,8,,,,51,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,,,,,,H,Autocuration,CHEMBL616376,BAO_0000357,
1555,1,B,8,,,,51,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,,,,,,H,Expert,CHEMBL857064,BAO_0000357,
1556,1,B,8,,,,51,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,,,,,,H,Autocuration,CHEMBL616377,BAO_0000357,
1557,1,B,8,,,,51,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,,,,,,H,Autocuration,CHEMBL616378,BAO_0000357,
1558,1,B,8,,,,51,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616379,BAO_0000357,
1559,1,B,8,,,,11863,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616380,BAO_0000357,
1560,1,B,8,,,,11863,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,,,,,,H,Autocuration,CHEMBL616381,BAO_0000357,
1561,1,B,8,,,,11863,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616382,BAO_0000357,
1562,1,B,8,,,,11863,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,,,,,,H,Autocuration,CHEMBL616383,BAO_0000357,
1563,1,B,9,CHO,,,11863,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,,Mus musculus,,449.0,,10090.0,D,Expert,CHEMBL616350,BAO_0000219,
1564,1,B,8,,,,11863,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616351,BAO_0000357,
1565,1,B,8,,,,11863,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,,,,,,H,Autocuration,CHEMBL616352,BAO_0000357,
1566,1,B,8,,,,11863,Binding affinity against 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616353,BAO_0000357,
1567,1,B,8,,,,11863,Binding affinity against serotonergic 5-HT1a receptor,,,,,,,H,Autocuration,CHEMBL616354,BAO_0000357,
1568,1,B,8,,,,11863,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,,,,,,H,Autocuration,CHEMBL616508,BAO_0000357,
1569,1,B,9,,,,11863,Binding affinity for 5-hydroxytryptamine 1A receptor,,Mus musculus,,,,10090.0,D,Expert,CHEMBL616559,BAO_0000357,
1570,1,B,8,,,,11863,Binding affinity at 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616560,BAO_0000357,
1571,1,B,8,,,,11863,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,,,,,,H,Autocuration,CHEMBL616561,BAO_0000357,
1572,1,B,8,CHO,,,11863,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,,449.0,,,H,Autocuration,CHEMBL616562,BAO_0000219,
1573,1,B,8,CHO,,,11863,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,,449.0,,,H,Autocuration,CHEMBL616563,BAO_0000219,
1574,1,B,8,,,,11863,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616564,BAO_0000357,
1575,1,B,8,,,,11863,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,,,,,,H,Autocuration,CHEMBL616565,BAO_0000357,
1576,1,B,8,,,,11863,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616566,BAO_0000218,
1577,1,B,8,,,,11863,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,,,,,,H,Autocuration,CHEMBL616989,BAO_0000357,
1578,1,B,8,,,,11863,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL857975,BAO_0000357,
1579,1,B,9,,,,11863,Binding affinity against 5-hydroxytryptamine 1A receptor,,Mus musculus,,,,10090.0,D,Expert,CHEMBL616990,BAO_0000357,
1580,1,B,8,,,,11863,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,,,,,,H,Autocuration,CHEMBL616991,BAO_0000357,
1581,1,B,8,,,,11863,Tested against 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616992,BAO_0000357,
1582,1,B,8,,,,11863,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL616993,BAO_0000357,
1583,1,B,8,,,,106,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,,Oryctolagus cuniculus,,,,9986.0,H,Expert,CHEMBL616994,BAO_0000019,
1584,1,B,8,,,,106,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,,Oryctolagus cuniculus,,,,9986.0,H,Autocuration,CHEMBL616995,BAO_0000019,
1585,1,B,9,HEK293,,,105571,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,Gorilla gorilla,,722.0,,9593.0,D,Intermediate,CHEMBL616996,BAO_0000219,
1586,1,F,8,,,In vivo,106,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL616997,BAO_0000218,
1587,1,F,8,,,In vivo,106,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL616998,BAO_0000218,
1588,1,F,8,,,,106,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL616999,BAO_0000019,
1589,1,F,8,,,,106,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL617000,BAO_0000019,
1590,1,F,8,,,,106,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL617001,BAO_0000019,
1591,1,F,8,,,,106,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL858111,BAO_0000019,
1592,1,F,8,,,,106,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,,,,,,H,Autocuration,CHEMBL617002,BAO_0000019,
1593,1,F,8,,,,106,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,,,,,,H,Autocuration,CHEMBL617003,BAO_0000019,
1594,1,F,8,,,,106,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,,,,,,H,Autocuration,CHEMBL617004,BAO_0000019,
1595,1,F,9,,,,106,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL617005,BAO_0000019,
1596,1,F,9,CHO-K1,,,106,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,,Homo sapiens,,485.0,,9606.0,D,Expert,CHEMBL616623,BAO_0000219,
1597,1,F,8,CHO,,,106,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,,,,449.0,,,H,Autocuration,CHEMBL616624,BAO_0000219,
1598,1,B,8,,,,106,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,,,,,,H,Autocuration,CHEMBL883243,BAO_0000357,
1599,1,F,8,,,,106,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,,,,,,H,Autocuration,CHEMBL616625,BAO_0000019,
1600,1,F,8,CHO,,,106,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",,,,449.0,,,H,Expert,CHEMBL616626,BAO_0000219,
1601,1,F,8,CHO,,,106,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,,,,449.0,,,H,Autocuration,CHEMBL616627,BAO_0000219,
1602,1,F,8,CHO,,,106,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,,,,449.0,,,H,Autocuration,CHEMBL616628,BAO_0000219,
1603,1,F,8,CHO,,,106,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,,,,449.0,,,H,Autocuration,CHEMBL616629,BAO_0000219,
1604,1,F,8,CHO,,,106,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,,,,449.0,,,H,Autocuration,CHEMBL616630,BAO_0000219,
1605,1,F,8,,,,106,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,,,,,,H,Expert,CHEMBL616631,BAO_0000019,
1606,1,F,8,,,,106,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,,,,,,H,Autocuration,CHEMBL616632,BAO_0000019,
1607,1,B,9,,,,106,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616633,BAO_0000357,
1608,1,B,8,CHO,,,106,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,,,,449.0,,,H,Expert,CHEMBL616634,BAO_0000219,
1609,1,B,8,,,,106,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,,,,,,H,Autocuration,CHEMBL616635,BAO_0000357,
1610,1,B,9,,,,106,Binding affinity against 5-hydroxytryptamine 1B receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL885358,BAO_0000357,
1611,1,B,9,CHO,,,106,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,Homo sapiens,,449.0,,9606.0,D,Expert,CHEMBL616636,BAO_0000219,
1612,1,B,8,CHO,,,106,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,,,,449.0,,,H,Expert,CHEMBL616637,BAO_0000219,
1613,1,B,8,,,,106,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,,,,,,H,Autocuration,CHEMBL616638,BAO_0000357,
1614,1,B,8,CHO,,,106,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,,,449.0,,,H,Expert,CHEMBL616639,BAO_0000219,
1615,1,B,8,CHO,,,106,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,,,,449.0,,,H,Expert,CHEMBL616640,BAO_0000219,
1616,1,B,8,CHO,,,106,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,,,449.0,,,H,Expert,CHEMBL616641,BAO_0000219,
1617,1,B,8,CHO,,,106,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,,,,449.0,,,H,Expert,CHEMBL616642,BAO_0000219,
1618,1,B,8,CHO,,,106,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,,,449.0,,,H,Expert,CHEMBL616643,BAO_0000219,
1619,1,B,8,,,,106,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,,,,,,H,Autocuration,CHEMBL616644,BAO_0000357,
1620,1,B,8,,,,106,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,,,,,,H,Autocuration,CHEMBL616645,BAO_0000357,
1621,1,F,8,,,,105,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,Oryctolagus cuniculus,,,,9986.0,H,Autocuration,CHEMBL616646,BAO_0000019,
1622,1,F,8,,,,105,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,Oryctolagus cuniculus,,,,9986.0,H,Expert,CHEMBL616647,BAO_0000019,
1623,1,B,8,,,,105,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,,,,,,H,Autocuration,CHEMBL616509,BAO_0000357,
1624,1,B,8,,,,105,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,,,,,,H,Autocuration,CHEMBL616510,BAO_0000357,
1625,1,B,8,,,,105,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,,,,,,H,Autocuration,CHEMBL616511,BAO_0000357,
1626,1,B,8,,,,105,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,,Bos taurus,,,,9913.0,H,Expert,CHEMBL616512,BAO_0000357,
1627,1,B,8,,,,105,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,,Bos taurus,,,,9913.0,H,Autocuration,CHEMBL616513,BAO_0000357,
1628,1,B,8,,,,105,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,2435.0,Bos taurus,,,,9913.0,H,Autocuration,CHEMBL616514,BAO_0000019,
1629,1,B,8,,,,105,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,,Bos taurus,,,,9913.0,H,Expert,CHEMBL616515,BAO_0000357,
1630,1,B,8,,,,105,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,,Bos taurus,,,,9913.0,H,Autocuration,CHEMBL616516,BAO_0000019,
1631,1,B,8,,,,105,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,Bos taurus,,,,9913.0,H,Autocuration,CHEMBL616517,BAO_0000357,
1632,1,B,8,,,,105,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,Bos taurus,,,,9913.0,H,Autocuration,CHEMBL616518,BAO_0000357,
1633,1,B,8,,,,105,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,Bos taurus,,,,9913.0,H,Autocuration,CHEMBL616519,BAO_0000357,
1634,1,B,8,,,,105,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,Bos taurus,,,,9913.0,H,Autocuration,CHEMBL616520,BAO_0000357,
1635,1,B,8,,,,105,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,,Bos taurus,,,,9913.0,H,Autocuration,CHEMBL616521,BAO_0000357,
1636,1,B,8,,,,105,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,,Bos taurus,,,,9913.0,H,Autocuration,CHEMBL616522,BAO_0000357,
1637,1,B,8,,,,105,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,Bos taurus,,,,9913.0,H,Autocuration,CHEMBL884531,BAO_0000357,
1638,1,B,8,,,,105,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,,Bos taurus,,,,9913.0,H,Autocuration,CHEMBL616523,BAO_0000357,
1639,1,B,8,,,,105,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,2435.0,Bos taurus,,,,9913.0,H,Autocuration,CHEMBL616731,BAO_0000019,
1640,1,B,8,,,,105,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,,Bos taurus,,,,9913.0,H,Autocuration,CHEMBL616732,BAO_0000019,
1641,1,B,8,,,,105,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,,Bos taurus,,,,9913.0,H,Autocuration,CHEMBL616733,BAO_0000357,
1642,1,B,8,,,,105,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,Bos taurus,,,,9913.0,H,Autocuration,CHEMBL616734,BAO_0000357,
1643,1,B,8,,,,105,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,,Bos taurus,,,,9913.0,H,Autocuration,CHEMBL616735,BAO_0000249,
1644,1,B,8,,,,105,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,,Bos taurus,,,,9913.0,H,Autocuration,CHEMBL616736,BAO_0000249,
1645,1,F,8,,,,105,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,Bos taurus,,,,9913.0,H,Expert,CHEMBL616737,BAO_0000019,
1646,1,B,8,,,,105,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,,Bos taurus,,,,9913.0,H,Autocuration,CHEMBL616738,BAO_0000019,
1647,1,F,8,,,,105,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,Bos taurus,,,,9913.0,H,Expert,CHEMBL616739,BAO_0000019,
1648,1,F,8,,,,105,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,Bos taurus,,,,9913.0,H,Expert,CHEMBL616740,BAO_0000019,
1649,1,F,8,,,,105,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,Bos taurus,,,,9913.0,H,Expert,CHEMBL616741,BAO_0000019,
1650,1,B,8,HEK293,,,105,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,Gorilla gorilla,,722.0,,9593.0,H,Autocuration,CHEMBL616742,BAO_0000219,
1651,1,B,9,,,,105570,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL616743,BAO_0000019,
1652,1,B,9,,,,105570,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL616744,BAO_0000019,
1653,1,F,9,,,,105570,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL616745,BAO_0000019,
1654,1,F,9,,,,105570,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL616746,BAO_0000019,
1655,1,F,9,,,,105570,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL616747,BAO_0000019,
1656,1,F,9,,,,105570,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL616748,BAO_0000019,
1657,1,F,9,,,,105570,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL616648,BAO_0000019,
1658,1,B,9,,,,105570,Binding affinity against 5-hydroxytryptamine 1D receptor,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL616649,BAO_0000357,
1659,1,B,9,,,,105570,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL616650,BAO_0000357,
1660,1,F,9,,,,105570,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL616651,BAO_0000218,
1661,1,F,9,,,,105570,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL616652,BAO_0000218,
1662,1,F,9,,,,105570,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL616653,BAO_0000218,
1663,1,F,9,,,,105570,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL616654,BAO_0000218,
1664,1,B,9,,,,105570,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL616655,BAO_0000019,
1665,1,B,9,,,,105570,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL616656,BAO_0000357,
1666,1,B,8,,,,105,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL616657,BAO_0000019,
1667,1,B,9,,,,105570,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,2435.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL616658,BAO_0000357,
1668,1,B,9,,,,105570,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL616659,BAO_0000357,
1669,1,B,8,,,,51,Binding affinity against 5-hydroxytryptamine 1D receptor,,,,,,,H,Autocuration,CHEMBL616660,BAO_0000357,
1670,1,B,8,,,,106,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,,,,,,H,Autocuration,CHEMBL616661,BAO_0000357,
1671,1,F,8,,,,105,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,,,,,,H,Expert,CHEMBL616662,BAO_0000019,
1672,1,F,8,,,,105,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,,,,,,H,Autocuration,CHEMBL616663,BAO_0000019,
1673,1,F,8,,,,105,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,,,,,,H,Autocuration,CHEMBL616664,BAO_0000019,
1674,1,F,9,CHO,,,105,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",,Homo sapiens,,449.0,,9606.0,D,Expert,CHEMBL881820,BAO_0000219,
1675,1,F,8,CHO,,,105,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",,,,449.0,,,H,Autocuration,CHEMBL616665,BAO_0000219,
1676,1,B,8,CHO,,,105,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,,,449.0,,,H,Expert,CHEMBL616666,BAO_0000219,
1677,1,B,8,CHO,,,105,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,,,,449.0,,,H,Autocuration,CHEMBL616667,BAO_0000219,
1678,1,F,8,CHO,,,105,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,,,449.0,,,H,Expert,CHEMBL616668,BAO_0000219,
1679,1,F,9,CHO,,,105,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,Homo sapiens,,449.0,,9606.0,D,Expert,CHEMBL616669,BAO_0000219,
1680,1,F,8,CHO,,,105,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",,,,449.0,,,H,Expert,CHEMBL617040,BAO_0000219,
1681,1,F,8,CHO,,,105,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",,,,449.0,,,H,Autocuration,CHEMBL617041,BAO_0000219,
1682,1,F,8,CHO,,,105,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",,,,449.0,,,H,Expert,CHEMBL617042,BAO_0000219,
1683,1,F,8,CHO,,,105,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",,,,449.0,,,H,Expert,CHEMBL617043,BAO_0000219,
1684,1,F,8,,,,105,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,,,,,,H,Autocuration,CHEMBL617044,BAO_0000019,
1685,1,F,8,CHO,,,105,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,,,449.0,,,H,Expert,CHEMBL617045,BAO_0000219,
1686,1,F,9,CHO,,,105,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,Homo sapiens,,449.0,,9606.0,D,Expert,CHEMBL617046,BAO_0000219,
1687,1,F,9,CHO,,,105,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,Homo sapiens,,449.0,,9606.0,D,Expert,CHEMBL617047,BAO_0000219,
1688,1,F,8,,,,105,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,,,,,,H,Expert,CHEMBL617048,BAO_0000019,
1689,1,F,8,,,,105,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,,,,,,H,Autocuration,CHEMBL616897,BAO_0000019,
1690,1,F,9,,,,105,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616898,BAO_0000019,
1691,1,F,9,CHO,,,105,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,,Homo sapiens,,449.0,,9606.0,D,Expert,CHEMBL858201,BAO_0000219,
1692,1,F,8,,,,105,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,,,,,,H,Autocuration,CHEMBL616899,BAO_0000019,
1693,1,B,8,,,In vitro,105,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),,,,,,,H,Autocuration,CHEMBL616900,BAO_0000219,
1694,1,B,8,CHO,,,105,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,,,,449.0,,,H,Expert,CHEMBL616901,BAO_0000219,
1695,1,B,8,,,,105,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,,,,,,H,Autocuration,CHEMBL616902,BAO_0000357,
1696,1,B,9,CHO,,,105,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,Homo sapiens,,449.0,,9606.0,D,Expert,CHEMBL616903,BAO_0000219,
1697,1,B,8,CHO,,,105,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,,,,449.0,,,H,Expert,CHEMBL616904,BAO_0000219,
1698,1,B,8,,,,105,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,,,,,,H,Autocuration,CHEMBL616905,BAO_0000357,
1699,1,B,8,CHO,,,105,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,,,,449.0,,,H,Expert,CHEMBL616906,BAO_0000219,
1700,1,B,8,CHO,,,105,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,,,449.0,,,H,Expert,CHEMBL616907,BAO_0000219,
1701,1,B,8,CHO,,,105,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,,,449.0,,,H,Expert,CHEMBL616908,BAO_0000219,
1702,1,B,9,CHO,,,105,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,Homo sapiens,,449.0,,9606.0,D,Expert,CHEMBL616909,BAO_0000219,
1703,1,B,9,CHO,,,105,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,Homo sapiens,,449.0,,9606.0,D,Expert,CHEMBL616910,BAO_0000219,
1704,1,B,8,CHO,,,105,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,,,449.0,,,H,Expert,CHEMBL616911,BAO_0000219,
1705,1,B,8,CHO,,,105,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,,,449.0,,,H,Expert,CHEMBL616912,BAO_0000219,
1706,1,B,8,,,,105,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,,,,,,H,Autocuration,CHEMBL616913,BAO_0000357,
1707,1,B,9,CHO,,,105,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,,Homo sapiens,,449.0,,9606.0,D,Expert,CHEMBL616914,BAO_0000219,
1708,1,B,8,CHO,,,105,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,,,449.0,,,H,Autocuration,CHEMBL616915,BAO_0000219,
1709,1,B,8,,,,105,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,,,,,,H,Autocuration,CHEMBL616916,BAO_0000019,
1710,1,B,9,,,,105,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616917,BAO_0000357,
1711,1,B,8,,,,105,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,,,,,,H,Autocuration,CHEMBL616918,BAO_0000357,
1712,1,B,8,,,,105,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,,,,,,H,Expert,CHEMBL616919,BAO_0000219,
1713,1,B,8,,,,105,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,,,,,,H,Autocuration,CHEMBL616920,BAO_0000357,
1714,1,B,8,,,,105,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,,,,,,H,Autocuration,CHEMBL872914,BAO_0000357,
1715,1,B,8,,,,105,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,,,,,,H,Autocuration,CHEMBL616921,BAO_0000357,
1716,1,B,8,,,,105,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,,,,,,H,Expert,CHEMBL616922,BAO_0000357,
1717,1,B,8,,,,105,Binding affinity towards 5-hydroxytryptamine 1D receptor,,,,,,,H,Autocuration,CHEMBL616923,BAO_0000357,
1718,1,B,8,,,,105,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,,,,,,H,Expert,CHEMBL616924,BAO_0000357,
1719,1,B,8,,,,105,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,,,,,,H,Expert,CHEMBL875909,BAO_0000357,
1720,1,B,8,,,,105,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,,,,,,H,Autocuration,CHEMBL616925,BAO_0000357,
1721,1,B,8,,,,105,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,,,,,,H,Autocuration,CHEMBL616926,BAO_0000357,
1722,1,B,8,,,,105,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,,,,,,H,Autocuration,CHEMBL616927,BAO_0000357,
1723,1,F,8,CHO-K1,,,105,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,,,,485.0,,,H,Expert,CHEMBL616928,BAO_0000219,
1724,1,B,9,,,In vitro,105,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616929,BAO_0000219,
1725,1,B,9,,,,105,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616930,BAO_0000357,
1726,1,B,8,,,,105,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,,,,,,H,Expert,CHEMBL616931,BAO_0000019,
1727,1,B,8,,,,105,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,,,,,,H,Autocuration,CHEMBL616932,BAO_0000357,
1728,1,B,8,,,,105,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,,,,,,H,Expert,CHEMBL616933,BAO_0000357,
1729,1,B,9,,,,105,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616934,BAO_0000219,
1730,1,B,9,,,,105,Binding affinity for human 5-hydroxytryptamine 1D receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616935,BAO_0000357,
1731,1,B,8,,,,105,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,,,,,,H,Autocuration,CHEMBL616936,BAO_0000357,
1732,1,B,9,,,,105,Affinity for 5-hydroxytryptamine 1D receptor subtype,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616937,BAO_0000357,
1733,1,B,9,,,,105,Binding affinity for human 5-hydroxytryptamine 1D receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616938,BAO_0000357,
1734,1,B,8,,,,105,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,,,,,,H,Autocuration,CHEMBL616939,BAO_0000019,
1735,1,B,8,,,,105,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,,,,,,H,Expert,CHEMBL616940,BAO_0000019,
1736,1,B,9,,,,105,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616941,BAO_0000357,
1737,1,B,8,CHO-K1,,,105,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,,,,485.0,,,H,Autocuration,CHEMBL616942,BAO_0000219,
1738,1,B,8,CHO-K1,,,105,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,,,,485.0,,,H,Autocuration,CHEMBL616943,BAO_0000219,
1739,1,B,4,CHO,,,104802,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,,,,449.0,,,H,Autocuration,CHEMBL616944,BAO_0000219,
1740,1,F,8,,,,105,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,,,,,,H,Autocuration,CHEMBL616945,BAO_0000019,
1741,1,B,8,,,,105,Binding activity radioligand.,,,,,,,H,Autocuration,CHEMBL616946,BAO_0000357,
1742,1,B,8,,,,105,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,,,,,H,Autocuration,CHEMBL616947,BAO_0000019,
1743,1,B,8,CHO-K1,,,105,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,,,,485.0,,,H,Expert,CHEMBL616948,BAO_0000219,
1744,1,B,8,,,,105,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,,,,,,H,Autocuration,CHEMBL616851,BAO_0000357,
1745,1,B,8,,,,105,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,,,,,,H,Autocuration,CHEMBL616852,BAO_0000357,
1746,1,B,8,,,,105,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,,,,,,H,Autocuration,CHEMBL616853,BAO_0000357,
1747,1,B,9,,,,105,Binding activity against human 5-hydroxytryptamine 1D receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616854,BAO_0000357,
1748,1,B,9,CHO,,,105,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,Homo sapiens,,449.0,,9606.0,D,Expert,CHEMBL616855,BAO_0000219,
1749,1,B,8,CHO,,,105,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,,,,449.0,,,H,Autocuration,CHEMBL616856,BAO_0000219,
1750,1,B,8,CHO,,,105,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,,449.0,,,H,Autocuration,CHEMBL616857,BAO_0000219,
1751,1,B,8,,,,105,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,,,,,,H,Autocuration,CHEMBL616858,BAO_0000357,
1752,1,B,8,CHO,,,105,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,,,,449.0,,,H,Autocuration,CHEMBL616859,BAO_0000219,
1753,1,B,8,CHO,,,105,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,,,,449.0,,,H,Autocuration,CHEMBL616860,BAO_0000219,
1754,1,B,8,HEK293,,,105,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,,,722.0,,,H,Autocuration,CHEMBL616861,BAO_0000219,
1755,1,B,8,HEK293,,,105,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,,,722.0,,,H,Autocuration,CHEMBL616541,BAO_0000219,
1756,1,B,8,HEK293,,,105,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,,,,722.0,,,H,Autocuration,CHEMBL616542,BAO_0000219,
1757,1,B,8,CHO,,,105,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,,,,449.0,,,H,Autocuration,CHEMBL616543,BAO_0000219,
1758,1,B,9,,,,105,Binding affinity for human 5-hydroxytryptamine 1D receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616544,BAO_0000357,
1759,1,B,8,CHO,,,105,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,,,,449.0,,,H,Autocuration,CHEMBL616545,BAO_0000219,
1760,1,B,8,,,,105,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,,,,,,H,Autocuration,CHEMBL616546,BAO_0000357,
1761,1,B,8,CHO,,,105,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,,,,449.0,,,H,Autocuration,CHEMBL616547,BAO_0000219,
1762,1,B,8,CHO,,,105,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",,,,449.0,,,H,Autocuration,CHEMBL616548,BAO_0000219,
1763,1,F,8,,,,105,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,,,,,,H,Expert,CHEMBL616549,BAO_0000019,
1764,1,F,8,,,,105,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,,,,,,H,Expert,CHEMBL616550,BAO_0000019,
1765,1,B,8,,,,108,Binding affinity against 5-HT2C receptor,,,,,,,H,Autocuration,CHEMBL857066,BAO_0000357,
1766,1,B,8,,,,108,Binding affinity against 5-hydroxytryptamine 1D receptor,,,,,,,H,Autocuration,CHEMBL616551,BAO_0000357,
1767,1,B,8,,,,10577,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,,,,,,H,Autocuration,CHEMBL616552,BAO_0000357,
1768,1,F,8,,,,10577,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,,,,,,H,Autocuration,CHEMBL832876,BAO_0000019,
1769,1,B,8,,,,10577,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,,,,,,H,Expert,CHEMBL616553,BAO_0000019,
1770,1,B,8,,,,10577,Binding affinity towards 5-HT1B was determined,,,,,,,H,Autocuration,CHEMBL616554,BAO_0000357,
1771,1,B,8,,,,10577,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,,,,,,H,Expert,CHEMBL616555,BAO_0000019,
1772,1,B,8,,,,10577,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,,,,,,H,Expert,CHEMBL616556,BAO_0000019,
1773,1,B,8,,,,10577,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,,,,,,H,Autocuration,CHEMBL616557,BAO_0000019,
1774,1,B,8,,,,10577,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,,,,,H,Expert,CHEMBL616558,BAO_0000019,
1775,1,B,9,,,,10577,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616749,BAO_0000019,
1776,1,B,8,,,,10577,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,,,,,,H,Autocuration,CHEMBL616750,BAO_0000357,
1777,1,B,8,,,,10577,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,,,,,,H,Autocuration,CHEMBL616751,BAO_0000357,
1778,1,B,8,,,,10577,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,,,,,,H,Autocuration,CHEMBL616752,BAO_0000249,
1779,1,B,8,,,,10577,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,2435.0,,,,,,H,Autocuration,CHEMBL616753,BAO_0000019,
1780,1,B,9,,,,10577,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616754,BAO_0000357,
1781,1,B,8,,,,10577,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,,,,,,H,Autocuration,CHEMBL616755,BAO_0000019,
1782,1,B,8,,,,10577,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,2435.0,,,,,,H,Autocuration,CHEMBL616756,BAO_0000019,
1783,1,B,8,,,,10577,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,2435.0,,,,,,H,Autocuration,CHEMBL616757,BAO_0000019,
1784,1,B,8,,,,10577,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,2435.0,,,,,,H,Autocuration,CHEMBL616758,BAO_0000357,
1785,1,B,8,,,,10577,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,,,,,,H,Autocuration,CHEMBL616759,BAO_0000249,
1786,1,B,8,,,,10577,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,,,,,,H,Autocuration,CHEMBL616760,BAO_0000357,
1787,1,B,8,,,,10577,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,2435.0,,,,,,H,Autocuration,CHEMBL616761,BAO_0000019,
1788,1,B,8,,,,10577,Binding affinity against 5-HT1B serotonin receptor in rat striatum,2435.0,,,,,,H,Autocuration,CHEMBL616762,BAO_0000019,
1789,1,B,8,,,,10577,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,,,,,,H,Autocuration,CHEMBL616763,BAO_0000019,
1790,1,B,8,,,,10577,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,,,,,,H,Expert,CHEMBL872909,BAO_0000357,
1791,1,B,8,,,,10577,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,,,,,,H,Autocuration,CHEMBL616764,BAO_0000357,
1792,1,B,9,,,,10577,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616765,BAO_0000357,
1793,1,B,8,,,,10577,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,2435.0,,,,,,H,Autocuration,CHEMBL616766,BAO_0000357,
1794,1,B,8,,,,10577,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,2435.0,,,,,,H,Autocuration,CHEMBL616767,BAO_0000357,
1795,1,B,8,,,,10577,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,,,,,,H,Autocuration,CHEMBL616768,BAO_0000357,
1796,1,B,8,,,,10577,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,,,,,,H,Autocuration,CHEMBL616769,BAO_0000357,
1797,1,B,8,,,,10577,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,,,,,,H,Autocuration,CHEMBL616770,BAO_0000019,
1798,1,B,8,,,,10577,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,,,,,,H,Autocuration,CHEMBL616771,BAO_0000019,
1799,1,B,8,,,,10577,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,2435.0,,,,,,H,Autocuration,CHEMBL616772,BAO_0000019,
1800,1,B,8,,,,10577,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,,,,,,H,Expert,CHEMBL616773,BAO_0000019,
1801,1,B,8,,,,10577,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,,,,,,H,Autocuration,CHEMBL616774,BAO_0000019,
1802,1,B,8,,,,10577,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,,,,,,H,Autocuration,CHEMBL616775,BAO_0000357,
1803,1,B,8,,,,10577,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,,,,,,H,Autocuration,CHEMBL616776,BAO_0000249,
1804,1,B,8,,,,10577,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,,,,,,H,Autocuration,CHEMBL616777,BAO_0000357,
1805,1,B,8,,,,10577,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,,,,,,H,Autocuration,CHEMBL616778,BAO_0000357,
1806,1,B,9,,,,10577,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616779,BAO_0000249,
1807,1,B,9,,,,10577,Binding affinity towards 5-hydroxytryptamine 1B receptor,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616780,BAO_0000357,
1808,1,B,8,,,,10577,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,,,,,,H,Autocuration,CHEMBL616781,BAO_0000019,
1809,1,B,8,,,,10577,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,,,,,,H,Autocuration,CHEMBL616782,BAO_0000357,
1810,1,B,8,,,,10577,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,,,,,,H,Autocuration,CHEMBL616783,BAO_0000357,
1811,1,B,8,,,,10577,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,2435.0,,,,,,H,Expert,CHEMBL616784,BAO_0000019,
1812,1,B,8,,,,10577,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,,,,,,H,Autocuration,CHEMBL616785,BAO_0000357,
1813,1,B,8,,,,10577,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,955.0,,,,,,H,Autocuration,CHEMBL857067,BAO_0000249,
1814,1,B,8,,,,10577,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,,,,,,H,Autocuration,CHEMBL616786,BAO_0000019,
1815,1,B,8,,,,10577,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,955.0,,,,,,H,Autocuration,CHEMBL616787,BAO_0000249,
1816,1,B,8,,,,10577,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,,,,,,H,Autocuration,CHEMBL616788,BAO_0000357,
1817,1,B,8,,,,10577,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,,,,,,H,Autocuration,CHEMBL616789,BAO_0000357,
1818,1,B,9,,,,10577,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616790,BAO_0000019,
1819,1,B,8,,,,10577,Binding affinity at 5-hydroxytryptamine 1B receptor,,,,,,,H,Expert,CHEMBL616791,BAO_0000357,
1820,1,B,8,,,,10577,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,,,,,,H,Autocuration,CHEMBL616792,BAO_0000019,
1821,1,B,9,,,,10577,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616793,BAO_0000249,
1822,1,B,8,,,,10577,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,,,,,,H,Autocuration,CHEMBL616794,BAO_0000357,
1823,1,B,8,,,,10577,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,,,,,H,Autocuration,CHEMBL616795,BAO_0000357,
1824,1,B,4,,,,104686,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,,,,,,H,Autocuration,CHEMBL616796,BAO_0000019,
1825,1,B,8,,,,106,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,,,,,,H,Autocuration,CHEMBL616797,BAO_0000357,
1826,1,B,8,,,,106,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,,,,,,,H,Autocuration,CHEMBL616798,BAO_0000249,
1827,1,B,8,,,,106,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,,,,,,H,Autocuration,CHEMBL616799,BAO_0000357,
1828,1,B,8,,,,106,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,,,,,,H,Autocuration,CHEMBL616800,BAO_0000357,
1829,1,B,8,,,,106,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,,,,,,H,Autocuration,CHEMBL616801,BAO_0000357,
1830,1,B,8,,,,106,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,,,,,,H,Autocuration,CHEMBL616802,BAO_0000357,
1831,1,B,8,,,,106,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,,,,,,H,Autocuration,CHEMBL616803,BAO_0000357,
1832,1,B,8,,,,106,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,,,,,,H,Expert,CHEMBL857068,BAO_0000357,
1833,1,B,8,,,,106,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,,,,,,H,Autocuration,CHEMBL616804,BAO_0000357,
1834,1,B,8,,,,106,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,,,,,,H,Autocuration,CHEMBL616805,BAO_0000357,
1835,1,B,8,,,,106,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,,,,,,H,Autocuration,CHEMBL616806,BAO_0000357,
1836,1,B,8,,,,106,Binding affinity against 5-hydroxytryptamine 1B receptor,,,,,,,H,Autocuration,CHEMBL616807,BAO_0000357,
1837,1,B,8,,,,106,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,,,,,,H,Autocuration,CHEMBL616808,BAO_0000357,
1838,1,B,8,,,,106,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,,,,,H,Autocuration,CHEMBL616809,BAO_0000357,
1839,1,B,8,,,,106,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,,,,,,H,Autocuration,CHEMBL616810,BAO_0000357,
1840,1,B,4,,,,104802,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,,,,,,H,Autocuration,CHEMBL616811,BAO_0000224,
1841,1,B,8,,,,108,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,,Bos taurus,,,,9913.0,H,Autocuration,CHEMBL616812,BAO_0000357,
1842,1,B,8,,,,108,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL616813,BAO_0000357,
1843,1,B,8,,,,108,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL616814,BAO_0000357,
1844,1,B,8,,,,108,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL616815,BAO_0000357,
1845,1,B,8,,,,108,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL616816,BAO_0000357,
1846,1,B,8,,,,108,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL616817,BAO_0000357,
1847,1,B,8,,,,108,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL616818,BAO_0000357,
1848,1,B,8,,,,108,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,,Sus scrofa,,,,9823.0,H,Expert,CHEMBL616819,BAO_0000357,
1849,1,B,8,,,,108,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,,Sus scrofa,,,,9823.0,H,Expert,CHEMBL616820,BAO_0000357,
1850,1,B,8,,,,108,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,,Sus scrofa,,,,9823.0,H,Expert,CHEMBL616821,BAO_0000019,
1851,1,B,8,,,,108,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL616822,BAO_0000357,
1852,1,B,8,,,,108,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,Oryctolagus cuniculus,,,,9986.0,H,Autocuration,CHEMBL616823,BAO_0000019,
1853,1,B,9,,,,12689,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL616824,BAO_0000357,
1854,1,B,9,,,,12689,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL616825,BAO_0000357,
1855,1,B,9,,,,12689,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL616826,BAO_0000357,
1856,1,B,9,,,,12689,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616827,BAO_0000019,
1857,1,B,9,,,,12689,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL616828,BAO_0000357,
1858,1,B,9,,,,12689,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL616829,BAO_0000357,
1859,1,B,9,,,,12689,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL616830,BAO_0000019,
1860,1,B,9,,,,12689,Binding affinity against 5-hydroxytryptamine 1C receptor,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616831,BAO_0000357,
1861,1,B,9,,,,12689,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL616832,BAO_0000019,
1862,1,B,9,,,,12689,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL616833,BAO_0000019,
1863,1,B,9,,,,12689,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL616834,BAO_0000019,
1864,1,B,9,,,,12689,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL829595,BAO_0000019,
1865,1,B,9,,,,12689,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL616835,BAO_0000357,
1866,1,B,9,,,,12689,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL872910,BAO_0000249,
1867,1,B,8,,,,12689,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,,,,,,H,Expert,CHEMBL616836,BAO_0000357,
1868,1,B,9,,,,12689,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL616837,BAO_0000357,
1869,1,B,9,,,,12689,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL616466,BAO_0000019,
1870,1,B,9,HEK293,,,12689,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,,Rattus norvegicus,,722.0,,10116.0,D,Autocuration,CHEMBL616467,BAO_0000219,
1871,1,B,8,,,,108,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,,,,,,H,Autocuration,CHEMBL616468,BAO_0000357,
1872,1,B,8,,,,108,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,,,,,,H,Autocuration,CHEMBL616469,BAO_0000357,
1873,1,B,8,,,,108,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,,,,,,H,Autocuration,CHEMBL616470,BAO_0000357,
1874,1,B,8,,,,12689,Binding affinity against 5-hydroxytryptamine 1C receptor,,,,,,,H,Autocuration,CHEMBL616471,BAO_0000357,
1875,1,B,8,,,,12689,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,,,,,,H,Autocuration,CHEMBL616472,BAO_0000357,
1876,1,B,8,,,,12689,Binding affinity against 5-hydroxytryptamine 1C receptor,,,,,,,H,Autocuration,CHEMBL616473,BAO_0000357,
1877,1,B,8,,,,12689,Binding affinity against serotonergic 5-HT1c receptor,,,,,,,H,Autocuration,CHEMBL616474,BAO_0000357,
1878,1,B,8,,,,12689,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,,,,,,H,Autocuration,CHEMBL616475,BAO_0000357,
1879,1,B,8,,,,12689,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,,,,,,H,Autocuration,CHEMBL616476,BAO_0000357,
1880,1,B,8,,,,105,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,Oryctolagus cuniculus,,,,9986.0,H,Autocuration,CHEMBL616477,BAO_0000019,
1881,1,B,4,,,,104686,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,,,,,,H,Autocuration,CHEMBL616478,BAO_0000224,
1882,1,B,4,,,,104686,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,,,,,,H,Autocuration,CHEMBL616479,BAO_0000224,
1883,1,B,4,,,,104686,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,,,,,,H,Autocuration,CHEMBL616480,BAO_0000019,
1884,1,B,5,,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL616481,BAO_0000019,
1885,1,B,5,,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL616482,BAO_0000249,
1886,1,B,5,,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,955.0,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL884713,BAO_0000221,
1887,1,B,4,,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,,,,,,H,Autocuration,CHEMBL616483,BAO_0000224,
1888,1,B,4,,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,,,,,,H,Autocuration,CHEMBL616484,BAO_0000224,
1889,1,B,4,,,,104686,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,,,,,,H,Autocuration,CHEMBL616485,BAO_0000019,
1890,1,B,4,,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,,,,,H,Autocuration,CHEMBL616486,BAO_0000224,
1891,1,B,4,,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,,,,,,H,Autocuration,CHEMBL616487,BAO_0000224,
1892,1,B,4,,,,104686,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,,,,,,H,Autocuration,CHEMBL616488,BAO_0000224,
1893,1,B,4,,,,104686,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,,,,,H,Autocuration,CHEMBL616489,BAO_0000019,
1894,1,B,4,,,,104686,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,,,,,H,Autocuration,CHEMBL616490,BAO_0000019,
1895,1,B,4,,,,104686,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,,,,,,H,Autocuration,CHEMBL616491,BAO_0000019,
1896,1,B,4,,,,104686,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,,,,,,H,Autocuration,CHEMBL616492,BAO_0000019,
1897,1,B,4,,,,104686,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,,,,,H,Autocuration,CHEMBL616493,BAO_0000019,
1898,1,B,4,,,,104686,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,,,,,,H,Autocuration,CHEMBL616494,BAO_0000019,
1899,1,B,4,,,,104686,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,,,,,,H,Autocuration,CHEMBL616495,BAO_0000019,
1900,1,B,4,,,,104686,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,,,,,,H,Autocuration,CHEMBL616496,BAO_0000019,
1901,1,B,4,,,,104686,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,,,,,H,Autocuration,CHEMBL616497,BAO_0000019,
1902,1,B,4,,,,104686,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,,,,,H,Autocuration,CHEMBL616498,BAO_0000019,
1903,1,B,4,,,,104686,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,,,,,,H,Autocuration,CHEMBL616499,BAO_0000019,
1904,1,B,4,,,,104686,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,,,,,,H,Autocuration,CHEMBL616500,BAO_0000019,
1905,1,B,5,,,,104686,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,955.0,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL616501,BAO_0000221,
1906,1,B,4,,,,104686,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,955.0,,,,,,H,Autocuration,CHEMBL616502,BAO_0000221,
1907,1,B,4,,,,104686,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,,,,,,H,Autocuration,CHEMBL884529,BAO_0000249,
1908,1,B,4,,,,104686,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,,,,,,H,Autocuration,CHEMBL616503,BAO_0000249,
1909,1,B,4,,,,104686,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL616964,BAO_0000224,
1910,1,B,4,,,,104686,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,,,,,,H,Autocuration,CHEMBL616965,BAO_0000249,
1911,1,B,4,,,,104686,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,,,,,,H,Autocuration,CHEMBL616966,BAO_0000224,
1912,1,B,4,,,,104686,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,,,,,,H,Autocuration,CHEMBL616967,BAO_0000224,
1913,1,B,5,,,,104686,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL616968,BAO_0000224,
1914,1,B,4,,,,104686,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,,,,,,H,Autocuration,CHEMBL616969,BAO_0000224,
1915,1,B,4,,,,104686,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,,,,,,H,Autocuration,CHEMBL884530,BAO_0000019,
1916,1,B,4,,,,104686,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL616970,BAO_0000224,
1917,1,B,4,,,,104686,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,,,,,,H,Autocuration,CHEMBL616971,BAO_0000224,
1918,1,B,4,,,,104686,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,,,,,,H,Autocuration,CHEMBL616972,BAO_0000224,
1919,1,B,4,,,,104686,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,,,,,,H,Autocuration,CHEMBL616973,BAO_0000224,
1920,1,B,4,,,,104686,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,,,,,,H,Autocuration,CHEMBL616974,BAO_0000224,
1921,1,B,4,,,,104686,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,,,,,,H,Autocuration,CHEMBL616975,BAO_0000019,
1922,1,B,4,,,,104686,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,,,,,,H,Autocuration,CHEMBL616976,BAO_0000019,
1923,1,B,4,,,,104686,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,,,,,,H,Autocuration,CHEMBL616977,BAO_0000224,
1924,1,B,4,,,,104686,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,,,,,,H,Autocuration,CHEMBL616978,BAO_0000224,
1925,1,B,4,,,,104686,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,,,,,,H,Autocuration,CHEMBL616979,BAO_0000224,
1926,1,B,4,,,,104686,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL616980,BAO_0000224,
1927,1,B,4,,,,104686,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,,,,,,,H,Autocuration,CHEMBL616981,BAO_0000249,
1928,1,B,4,,,,104686,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,,,,,,,H,Autocuration,CHEMBL616982,BAO_0000249,
1929,1,B,4,,,,104686,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,,,,,,H,Autocuration,CHEMBL616983,BAO_0000224,
1930,1,B,4,,,,104686,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,,,,,,H,Autocuration,CHEMBL616984,BAO_0000019,
1931,1,B,5,,,,104686,Inhibitory activity against 5-hydroxytryptamine 2 receptor,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL616985,BAO_0000224,
1932,1,B,4,,,,104686,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,,,,,,H,Autocuration,CHEMBL616986,BAO_0000224,
1933,1,B,4,,,,104686,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,,,,,,H,Autocuration,CHEMBL616987,BAO_0000224,
1934,1,B,4,,,,104686,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,,,,,,H,Autocuration,CHEMBL616988,BAO_0000019,
1935,1,B,4,,,,104686,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,,,,,,H,Autocuration,CHEMBL617243,BAO_0000019,
1936,1,B,4,,,,104686,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,,,,,,H,Autocuration,CHEMBL617244,BAO_0000019,
1937,1,B,5,CHO-K1,,,104686,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,Rattus norvegicus,,485.0,,10116.0,D,Autocuration,CHEMBL617245,BAO_0000219,
1938,1,B,4,,,,104686,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,,,,,,H,Autocuration,CHEMBL617246,BAO_0000249,
1939,1,B,4,,,,104686,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,,,,,,H,Autocuration,CHEMBL617546,BAO_0000224,
1940,1,B,4,,,,104686,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),,,,,,,H,Autocuration,CHEMBL617547,BAO_0000249,
1941,1,B,4,,,In vitro,104686,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,,,,,,H,Autocuration,CHEMBL617548,BAO_0000219,
1942,1,B,4,,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL617549,BAO_0000224,
1943,1,B,4,,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,,,,,,H,Autocuration,CHEMBL617550,BAO_0000224,
1944,1,B,4,,,,104686,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,,,,,,H,Autocuration,CHEMBL617551,BAO_0000224,
1945,1,B,4,,,,104686,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,,,,,,,H,Autocuration,CHEMBL617552,BAO_0000249,
1946,1,B,4,,,,104686,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,,,,,,,H,Autocuration,CHEMBL617553,BAO_0000249,
1947,1,F,4,,,,104686,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,1515.0,,,,,,H,Autocuration,CHEMBL617554,BAO_0000019,
1948,1,B,4,,,,104686,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL617555,BAO_0000019,
1949,1,B,4,,,,104686,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,,,,,,H,Autocuration,CHEMBL617556,BAO_0000224,
1950,1,B,8,,,,10624,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,,,,,,H,Autocuration,CHEMBL617557,BAO_0000357,
1951,1,B,8,,,,10624,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,,,,,,H,Autocuration,CHEMBL617558,BAO_0000357,
1952,1,B,8,,,,17106,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,,,,,,H,Expert,CHEMBL617559,BAO_0000357,
1953,1,B,9,,,,17106,Binding affinity for 5-hydroxytryptamine 1D receptor,,,,,,,D,Expert,CHEMBL617560,BAO_0000357,
1954,1,B,8,,,,17106,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,,,,,H,Autocuration,CHEMBL617561,BAO_0000249,
1955,1,B,8,,,,17106,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,,,,,H,Autocuration,CHEMBL617562,BAO_0000249,
1956,1,B,8,,,,17106,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,2435.0,,,,,,H,Autocuration,CHEMBL617563,BAO_0000357,
1957,1,F,8,,,,17106,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,,,,,,H,Autocuration,CHEMBL617564,BAO_0000019,
1958,1,B,8,,,,17106,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,,,,,,H,Expert,CHEMBL617565,BAO_0000019,
1959,1,B,8,,,,17106,Binding activity radioligand.,,,,,,,H,Autocuration,CHEMBL856076,BAO_0000357,
1960,1,B,8,,,,17106,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,,,,,H,Autocuration,CHEMBL617566,BAO_0000019,
1961,1,B,8,,,,17106,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,,,,,H,Expert,CHEMBL875911,BAO_0000019,
1962,1,B,8,,,,17106,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,,,,,,H,Autocuration,CHEMBL617567,BAO_0000019,
1963,1,B,8,,,,17106,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,,,,,H,Autocuration,CHEMBL617568,BAO_0000249,
1964,1,B,8,,,,17106,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,,,,,,H,Expert,CHEMBL617569,BAO_0000019,
1965,1,B,8,,,,17106,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,,,,,,H,Expert,CHEMBL617570,BAO_0000249,
1966,1,B,8,,,,17106,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,,,,,,H,Autocuration,CHEMBL617571,BAO_0000357,
1967,1,B,8,,,,105,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL617572,BAO_0000357,
1968,1,B,8,,,,105,The compound was tested for intrinsic activity against 5-HT1D receptor,,Oryctolagus cuniculus,,,,9986.0,H,Expert,CHEMBL617573,BAO_0000357,
1969,1,B,8,,,,105,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,Oryctolagus cuniculus,,,,9986.0,H,Autocuration,CHEMBL617574,BAO_0000019,
1970,1,B,8,,,,105,The compound was tested for binding affinity against 5-HT1D receptor,,Oryctolagus cuniculus,,,,9986.0,H,Expert,CHEMBL617575,BAO_0000357,
1971,1,B,8,,,,10578,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,,,,,,H,Autocuration,CHEMBL617576,BAO_0000357,
1972,1,F,8,,,,10578,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,,,,,,H,Autocuration,CHEMBL617577,BAO_0000019,
1973,1,F,8,,,,10578,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,,,,,,H,Autocuration,CHEMBL617578,BAO_0000019,
1974,1,B,8,,,,10578,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,,,,,,H,Autocuration,CHEMBL617579,BAO_0000357,
1975,1,B,8,,,,10578,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,,,,,H,Expert,CHEMBL617580,BAO_0000019,
1976,1,B,8,,,,10578,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,,,,,,H,Autocuration,CHEMBL617581,BAO_0000249,
1977,1,B,8,,,,10578,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,,,,,,H,Autocuration,CHEMBL617582,BAO_0000357,
1978,1,B,8,,,,10578,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,,,,,,H,Expert,CHEMBL617583,BAO_0000019,
1979,1,B,8,,,,105,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,,,,,,H,Autocuration,CHEMBL617584,BAO_0000357,
1980,1,B,8,,,,105,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,,,,,,H,Autocuration,CHEMBL617585,BAO_0000357,
1981,1,B,8,,,,105,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,,,,,,H,Autocuration,CHEMBL875912,BAO_0000357,
1982,1,B,8,,,,105,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,,,,,,H,Autocuration,CHEMBL617586,BAO_0000357,
1983,1,B,8,,,,105,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,,,,,,H,Autocuration,CHEMBL617587,BAO_0000357,
1984,1,B,8,,,,105,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,,,,,,H,Autocuration,CHEMBL617588,BAO_0000357,
1985,1,B,8,,,,105,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,,,,,,H,Autocuration,CHEMBL857980,BAO_0000357,
1986,1,B,8,,,,105,Tested against 5-hydroxytryptamine 1D receptor,,,,,,,H,Autocuration,CHEMBL617589,BAO_0000357,
1987,1,B,8,,,,105,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,,,,,,H,Autocuration,CHEMBL617590,BAO_0000357,
1988,1,B,8,HEK293,,,105,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,,,722.0,,,H,Autocuration,CHEMBL617591,BAO_0000219,
1989,1,B,9,,,,105,Binding affinity against 5-Hydroxytryptamine 1D receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL617592,BAO_0000357,
1990,1,B,8,,,,105,,,,,,,,H,Autocuration,CHEMBL617593,BAO_0000357,
1991,1,B,8,CHO-K1,,,106,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,,,485.0,,,H,Autocuration,CHEMBL617594,BAO_0000219,
1992,1,B,8,CHO-K1,,,105,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,,,485.0,,,H,Autocuration,CHEMBL617595,BAO_0000219,
1993,1,B,8,HEK293,,,105,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,,,,722.0,,,H,Autocuration,CHEMBL617596,BAO_0000219,
1994,1,B,8,HEK293,,,105,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,,,722.0,,,H,Autocuration,CHEMBL617597,BAO_0000219,
1995,1,B,8,,,,105,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,,,,,,H,Autocuration,CHEMBL617598,BAO_0000019,
1996,1,B,8,,,,105,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,,,,,,H,Autocuration,CHEMBL872916,BAO_0000357,
1997,1,B,8,,,,105,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,,,,,,H,Expert,CHEMBL617599,BAO_0000357,
1998,1,B,8,,,,105,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,,,,,,H,Autocuration,CHEMBL617091,BAO_0000357,
1999,1,B,8,CHO-K1,,,105,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",,,,485.0,,,H,Expert,CHEMBL617092,BAO_0000219,
2000,1,B,8,CHO-K1,,,105,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,,,485.0,,,H,Autocuration,CHEMBL617093,BAO_0000219,
2001,1,F,8,,,,105,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,,,,,,H,Autocuration,CHEMBL617094,BAO_0000019,
2002,1,F,8,,,,105,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,,,,,H,Autocuration,CHEMBL617095,BAO_0000019,
2003,1,F,8,,,,105,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,,,,,H,Autocuration,CHEMBL617096,BAO_0000019,
2004,1,F,8,,,,105,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,,,,,H,Autocuration,CHEMBL617097,BAO_0000019,
2005,1,F,8,,,,105,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,,,,,H,Autocuration,CHEMBL617098,BAO_0000019,
2006,1,B,8,,,,105,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,,,,,,H,Autocuration,CHEMBL617301,BAO_0000357,
2007,1,B,8,,,,105,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,,,,,,H,Autocuration,CHEMBL617302,BAO_0000357,
2008,1,B,8,,,,105,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,,,,,,H,Autocuration,CHEMBL617303,BAO_0000357,
2009,1,B,8,,,,105,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,,,,,,H,Expert,CHEMBL617304,BAO_0000357,
2010,1,B,8,CHO,,,105,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",,,,449.0,,,H,Expert,CHEMBL617305,BAO_0000219,
2011,1,B,9,,,,105,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,,Homo sapiens,,,,9606.0,D,Autocuration,CHEMBL617306,BAO_0000219,
2012,1,B,8,,,,17106,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,,,,,,H,Autocuration,CHEMBL617307,BAO_0000357,
2013,1,B,8,,,,105,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,Oryctolagus cuniculus,,,,9986.0,H,Autocuration,CHEMBL617308,BAO_0000019,
2014,1,B,8,,,,105,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,,,,,,H,Autocuration,CHEMBL617309,BAO_0000357,
2015,1,B,8,,,,105,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,,,,,,H,Autocuration,CHEMBL617310,BAO_0000357,
2016,1,B,8,,,,105,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,,,,,,H,Autocuration,CHEMBL617311,BAO_0000357,
2017,1,B,8,,,,105,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,,,,,,H,Autocuration,CHEMBL617312,BAO_0000357,
2018,1,B,8,,,,105,Affinity against 5-hydroxytryptamine 1D receptor alpha,,,,,,,H,Autocuration,CHEMBL617313,BAO_0000357,
2019,1,B,8,,,,105,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,,,,,,H,Expert,CHEMBL617314,BAO_0000357,
2020,1,F,8,,,,106,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,,,,,H,Autocuration,CHEMBL617315,BAO_0000019,
2021,1,B,8,HEK293,,,106,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,,,,722.0,,,H,Autocuration,CHEMBL617316,BAO_0000219,
2022,1,B,8,HEK293,,,106,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,,,722.0,,,H,Autocuration,CHEMBL617317,BAO_0000219,
2023,1,B,8,CHO,,,106,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,,,449.0,,,H,Autocuration,CHEMBL617318,BAO_0000219,
2024,1,B,8,,,,106,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,,,,,,H,Autocuration,CHEMBL617319,BAO_0000019,
2025,1,B,9,,,,106,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,,,,,D,Expert,CHEMBL617320,BAO_0000357,
2026,1,B,9,,,,106,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,,,,,D,Expert,CHEMBL617321,BAO_0000357,
2027,1,B,9,,,,106,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,,,,,D,Expert,CHEMBL617322,BAO_0000357,
2028,1,B,8,,,,106,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,,,,,,H,Autocuration,CHEMBL616862,BAO_0000357,
2029,1,B,8,,,,106,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,,,,,,H,Autocuration,CHEMBL616863,BAO_0000357,
2030,1,B,8,CHO,,,106,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,,,,449.0,,,H,Autocuration,CHEMBL616864,BAO_0000219,
2031,1,B,8,CHO-K1,,,106,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,,,,485.0,,,H,Autocuration,CHEMBL616865,BAO_0000219,
2032,1,B,8,CHO-K1,,,106,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,,,,485.0,,,H,Autocuration,CHEMBL616866,BAO_0000219,
2033,1,F,8,,,,106,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,,,,,H,Autocuration,CHEMBL616867,BAO_0000019,
2034,1,B,8,CHO-K1,,,106,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",,,,485.0,,,H,Expert,CHEMBL616868,BAO_0000219,
2035,1,B,8,,,,105,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,,,,,,H,Expert,CHEMBL616869,BAO_0000357,
2036,1,B,8,CHO,,,106,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,,,449.0,,,H,Expert,CHEMBL616870,BAO_0000219,
2037,1,F,8,CHO-K1,,,105,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,,,,485.0,,,H,Autocuration,CHEMBL616871,BAO_0000219,
2038,1,F,8,CHO-K1,,,105,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,,,,485.0,,,H,Autocuration,CHEMBL616872,BAO_0000219,
2039,1,F,8,CHO-K1,,,105,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,,,,485.0,,,H,Autocuration,CHEMBL616873,BAO_0000219,
2040,1,F,8,CHO-K1,,,105,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,,,,485.0,,,H,Autocuration,CHEMBL616838,BAO_0000219,
2041,1,B,8,,,,105,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,,,,,,H,Autocuration,CHEMBL616839,BAO_0000357,
2042,1,B,8,,,,106,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,,Oryctolagus cuniculus,,,,9986.0,H,Autocuration,CHEMBL616840,BAO_0000019,
2043,1,B,8,,,,105,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,,,,,,H,Autocuration,CHEMBL616841,BAO_0000357,
2044,1,B,8,,,,105,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,,,,,,H,Autocuration,CHEMBL616842,BAO_0000357,
2045,1,B,8,,,,105,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,,,,,,H,Expert,CHEMBL857976,BAO_0000357,
2046,1,B,8,CHO,,,10618,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,,,,449.0,,,H,Autocuration,CHEMBL616843,BAO_0000219,
2047,1,B,9,,,,10618,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616844,BAO_0000357,
2048,1,B,8,,,,10618,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,,,,,,H,Autocuration,CHEMBL616845,BAO_0000357,
2049,1,B,9,,,,10618,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616846,BAO_0000357,
2050,1,B,8,,,,10618,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,,,,,,H,Autocuration,CHEMBL616847,BAO_0000357,
2051,1,B,8,,,,10618,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,,,,,,H,Autocuration,CHEMBL616848,BAO_0000019,
2052,1,B,8,,,,10618,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,,,,,,H,Autocuration,CHEMBL616849,BAO_0000357,
2053,1,B,8,,,,10618,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,,,,,,H,Autocuration,CHEMBL872911,BAO_0000357,
2054,1,B,8,,,,10618,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,,,,,,H,Autocuration,CHEMBL616850,BAO_0000019,
2055,1,B,9,CHO,,,10618,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,,Homo sapiens,,449.0,,9606.0,D,Expert,CHEMBL616699,BAO_0000219,
2056,1,B,8,,,,10618,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,,,,,,H,Autocuration,CHEMBL616700,BAO_0000357,
2057,1,B,8,CHO,,,10618,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,,449.0,,,H,Autocuration,CHEMBL616701,BAO_0000219,
2058,1,B,8,CHO,,,10618,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,,,,449.0,,,H,Autocuration,CHEMBL616702,BAO_0000219,
2059,1,B,8,CHO,,,10618,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,,,,449.0,,,H,Autocuration,CHEMBL616703,BAO_0000219,
2060,1,B,8,,,,10618,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,,,,,,H,Autocuration,CHEMBL616704,BAO_0000357,
2061,1,B,8,CHO,,,10618,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,,,,449.0,,,H,Autocuration,CHEMBL616705,BAO_0000219,
2062,1,B,8,,,,10618,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,,,,,,H,Autocuration,CHEMBL616706,BAO_0000357,
2063,1,B,8,CHO,,,10618,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,,,,449.0,,,H,Autocuration,CHEMBL616707,BAO_0000219,
2064,1,B,8,,,,10618,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,,,,,,H,Autocuration,CHEMBL616708,BAO_0000357,
2065,1,B,8,,,,10618,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,,,,,,H,Autocuration,CHEMBL616709,BAO_0000357,
2066,1,B,8,CHO,,,10618,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,,,,449.0,,,H,Autocuration,CHEMBL616710,BAO_0000219,
2067,1,B,8,CHO,,,10618,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,,,,449.0,,,H,Autocuration,CHEMBL616711,BAO_0000219,
2068,1,B,8,CHO,,,10618,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",,,,449.0,,,H,Autocuration,CHEMBL616712,BAO_0000219,
2069,1,B,8,,,,10618,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,,,,,,H,Autocuration,CHEMBL616713,BAO_0000357,
2070,1,B,8,,,,10618,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,,,,,,H,Autocuration,CHEMBL616714,BAO_0000357,
2071,1,B,8,,,,10618,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,,,,,,H,Autocuration,CHEMBL616715,BAO_0000357,
2072,1,B,8,,,,10618,Binding affinity towards 5-hydroxytryptamine 1E receptor,,,,,,,H,Autocuration,CHEMBL616716,BAO_0000357,
2073,1,F,8,,,,279,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,,,,,,H,Autocuration,CHEMBL616717,BAO_0000019,
2074,1,F,8,,,,279,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,,,,,,H,Expert,CHEMBL616718,BAO_0000019,
2075,1,F,8,,,,279,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,,,,,,H,Autocuration,CHEMBL875905,BAO_0000019,
2076,1,F,8,,,,279,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,,,,,,H,Autocuration,CHEMBL616719,BAO_0000019,
2077,1,F,8,,,,279,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,,,,,,H,Expert,CHEMBL616720,BAO_0000019,
2078,1,B,8,,,,279,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,,,,,,H,Autocuration,CHEMBL616721,BAO_0000357,
2079,1,B,8,CHO,,,279,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,,,,449.0,,,H,Autocuration,CHEMBL616722,BAO_0000219,
2080,1,B,8,,,,279,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,,,,,,H,Autocuration,CHEMBL616723,BAO_0000357,
2081,1,B,8,CHO,,,279,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,,,,449.0,,,H,Autocuration,CHEMBL616724,BAO_0000219,
2082,1,B,8,,,,279,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,,,,,,H,Autocuration,CHEMBL616725,BAO_0000357,
2083,1,B,8,,,,279,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,,,,,,H,Autocuration,CHEMBL616726,BAO_0000357,
2084,1,B,8,,,,279,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,,,,,,H,Autocuration,CHEMBL616727,BAO_0000357,
2085,1,B,8,,,,279,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,,,,,,H,Autocuration,CHEMBL616728,BAO_0000357,
2086,1,B,8,,,,279,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,,,,,,H,Autocuration,CHEMBL616729,BAO_0000357,
2087,1,B,8,,,,279,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,,,,,,H,Expert,CHEMBL616730,BAO_0000019,
2088,1,B,8,,,,279,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,,,,,,H,Autocuration,CHEMBL617125,BAO_0000357,
2089,1,B,8,,,,279,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,,,,,,H,Autocuration,CHEMBL857977,BAO_0000357,
2090,1,B,8,CHO,,,279,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,,449.0,,,H,Autocuration,CHEMBL617126,BAO_0000219,
2091,1,B,8,CHO,,,279,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,,,,449.0,,,H,Autocuration,CHEMBL617127,BAO_0000219,
2092,1,B,8,,,,279,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,,,,,,H,Autocuration,CHEMBL617128,BAO_0000357,
2093,1,B,8,CHO,,,279,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,,,,449.0,,,H,Autocuration,CHEMBL617129,BAO_0000219,
2094,1,B,8,,,,279,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,,,,,,H,Autocuration,CHEMBL617130,BAO_0000357,
2095,1,B,8,CHO,,,279,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,,,,449.0,,,H,Autocuration,CHEMBL617131,BAO_0000219,
2096,1,B,8,CHO,,,279,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,,,449.0,,,H,Autocuration,CHEMBL617132,BAO_0000219,
2097,1,B,8,CHO,,,279,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,,,449.0,,,H,Autocuration,CHEMBL617133,BAO_0000219,
2098,1,B,8,,,,279,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,,,,,,H,Autocuration,CHEMBL617134,BAO_0000357,
2099,1,B,8,,,,279,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,,,,,,H,Autocuration,CHEMBL617135,BAO_0000357,
2100,1,B,8,,,,279,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,,,,,,H,Autocuration,CHEMBL617136,BAO_0000357,
2101,1,B,4,,,,104686,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,,,,,,H,Autocuration,CHEMBL617137,BAO_0000019,
2102,1,B,4,,,,104686,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,,,,,,H,Autocuration,CHEMBL617138,BAO_0000019,
2103,1,B,4,,,,104686,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,,,,,H,Autocuration,CHEMBL617139,BAO_0000019,
2104,1,B,8,,,,12687,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL617140,BAO_0000019,
2105,1,F,4,,,In vivo,104686,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",,,,,,,H,Autocuration,CHEMBL617141,BAO_0000218,
2106,1,F,4,,,,104686,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,,,,,H,Autocuration,CHEMBL858112,BAO_0000019,
2107,1,B,8,,,,17005,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,,,,,,H,Intermediate,CHEMBL617142,BAO_0000019,
2108,1,B,0,,,,22226,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",,Bos taurus,,,,9913.0,U,Autocuration,CHEMBL617143,BAO_0000019,
2109,1,B,0,,,,22226,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,,Bos taurus,,,,9913.0,U,Autocuration,CHEMBL617144,BAO_0000019,
2110,1,B,0,,,,22226,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,,Bos taurus,,,,9913.0,U,Autocuration,CHEMBL617145,BAO_0000019,
2111,1,B,0,,,,22226,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,,,,,,U,Autocuration,CHEMBL617146,BAO_0000019,
2112,1,B,4,,,,104784,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL617147,BAO_0000019,
2113,1,B,4,,,,104784,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL617148,BAO_0000019,
2114,1,B,4,,,,104784,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL617149,BAO_0000019,
2115,1,B,4,,,,104784,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,,,,,,H,Autocuration,CHEMBL617150,BAO_0000224,
2116,1,B,4,,,,104784,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,,,,,H,Autocuration,CHEMBL617151,BAO_0000224,
2117,1,B,4,,,,104784,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL617201,BAO_0000224,
2118,1,B,8,,,,10209,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,,,,,,H,Autocuration,CHEMBL617202,BAO_0000357,
2119,1,B,4,,,In vivo,104826,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,,,,,,H,Autocuration,CHEMBL617203,BAO_0000218,
2120,1,B,4,,,,104826,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,,,,,,H,Autocuration,CHEMBL617204,BAO_0000019,
2121,1,B,4,,,,104826,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,,,,,,H,Autocuration,CHEMBL617205,BAO_0000224,
2122,1,B,5,,,,104826,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,,Mus musculus,,,,10090.0,D,Autocuration,CHEMBL617206,BAO_0000019,
2123,1,B,4,,,In vivo,104826,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,,,,,,H,Autocuration,CHEMBL617207,BAO_0000218,
2124,1,B,5,,,,104826,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,,Mus musculus,,,,10090.0,D,Autocuration,CHEMBL617208,BAO_0000019,
2125,1,B,4,,,,104826,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL617209,BAO_0000224,
2126,1,B,4,,,,104826,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,,,,,,H,Autocuration,CHEMBL617210,BAO_0000224,
2127,1,B,4,,,,104826,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,,,,,,H,Autocuration,CHEMBL617211,BAO_0000224,
2128,1,B,5,,,,104826,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,Mus musculus,,,,10090.0,D,Autocuration,CHEMBL617212,BAO_0000019,
2129,1,B,4,,,,104784,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL617213,BAO_0000224,
2130,1,B,4,,,,104784,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL617214,BAO_0000224,
2131,1,B,0,,,,22226,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,,,,,,U,Autocuration,CHEMBL617215,BAO_0000221,
2132,1,B,0,,,,22226,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,,,,,,U,Autocuration,CHEMBL617216,BAO_0000221,
2133,1,B,8,,,,17005,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL617217,BAO_0000357,
2134,1,B,4,,,,104686,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL617218,BAO_0000019,
2135,1,B,4,,,,104686,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL872913,BAO_0000019,
2136,1,B,4,,,,104826,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,,,,,,H,Autocuration,CHEMBL617219,BAO_0000019,
2137,1,B,4,,,,104686,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL873482,BAO_0000224,
2138,1,B,5,,,,104686,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617220,BAO_0000019,
2139,1,B,4,,,,104686,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,,,,,,H,Autocuration,CHEMBL617221,BAO_0000019,
2140,1,B,4,,,,104686,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,,,,,,H,Autocuration,CHEMBL617222,BAO_0000019,
2141,1,F,4,,,,104686,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,,,,,,H,Autocuration,CHEMBL875906,BAO_0000019,
2142,1,B,4,,,,104686,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,,,,,,H,Autocuration,CHEMBL617223,BAO_0000019,
2143,1,B,4,,,,104686,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL617224,BAO_0000224,
2144,1,B,5,,,,104686,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617225,BAO_0000224,
2145,1,B,4,,,,104686,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,,,,,,H,Autocuration,CHEMBL617226,BAO_0000224,
2146,1,B,4,,,,104686,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,,,,,,H,Autocuration,CHEMBL617227,BAO_0000224,
2147,1,B,4,,,,104686,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,,,,,,H,Autocuration,CHEMBL617228,BAO_0000224,
2148,1,B,4,,,,104686,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,,,,,,H,Autocuration,CHEMBL617229,BAO_0000224,
2149,1,B,4,,,,104686,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,,,,,,H,Autocuration,CHEMBL617230,BAO_0000224,
2150,1,B,4,,,,104686,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,,,,,,H,Autocuration,CHEMBL617231,BAO_0000224,
2151,1,B,4,,,,104686,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,,,,,,H,Autocuration,CHEMBL617232,BAO_0000224,
2152,1,B,4,,,,104686,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL617233,BAO_0000224,
2153,1,B,4,,,,104686,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,,,,,,H,Autocuration,CHEMBL617234,BAO_0000224,
2154,1,F,4,,,,104686,Compound was tested for the inhibition of quipazine induced head twitches in rats,,,,,,,H,Autocuration,CHEMBL617235,BAO_0000019,
2155,1,F,4,,,,104686,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,,,,,,H,Autocuration,CHEMBL617236,BAO_0000019,
2156,1,B,4,,,,104686,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,10000000.0,,,,,,H,Autocuration,CHEMBL617237,BAO_0000221,
2157,1,B,4,,,,104686,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,10000000.0,,,,,,H,Autocuration,CHEMBL617238,BAO_0000221,
2158,1,B,5,,,,104686,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,955.0,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617239,BAO_0000221,
2159,1,B,4,,,,104686,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,,,,,,H,Autocuration,CHEMBL617240,BAO_0000019,
2160,1,B,4,,,,104686,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,,,,,,H,Autocuration,CHEMBL617241,BAO_0000249,
2161,1,B,4,,,,104686,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,,,,,,H,Autocuration,CHEMBL875907,BAO_0000249,
2162,1,B,4,,,,104686,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,,,,,,H,Autocuration,CHEMBL617242,BAO_0000019,
2163,1,F,4,,,,104686,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,,,,,,H,Autocuration,CHEMBL617152,BAO_0000019,
2164,1,B,5,,,,104686,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,955.0,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617153,BAO_0000221,
2165,1,B,5,,,,104686,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617154,BAO_0000249,
2166,1,B,4,,,,104686,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,955.0,,,,,,H,Autocuration,CHEMBL617155,BAO_0000221,
2167,1,F,4,,,,104686,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,,,,,,H,Autocuration,CHEMBL617156,BAO_0000019,
2168,1,F,4,,,,104686,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,,,,,,H,Autocuration,CHEMBL617157,BAO_0000019,
2169,1,F,4,,,,104686,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,,,,,H,Autocuration,CHEMBL617158,BAO_0000019,
2170,1,F,4,,,,104686,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,,,,,,H,Autocuration,CHEMBL617159,BAO_0000019,
2171,1,F,4,,,,104686,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,,,,,,H,Autocuration,CHEMBL617160,BAO_0000019,
2172,1,F,4,,,,104686,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,,,,,H,Autocuration,CHEMBL858113,BAO_0000019,
2173,1,B,4,,,,104686,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,955.0,,,,,,H,Autocuration,CHEMBL617247,BAO_0000220,
2174,1,B,4,,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,,,,,,H,Autocuration,CHEMBL617248,BAO_0000019,
2175,1,B,4,,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,955.0,,,,,,H,Autocuration,CHEMBL617249,BAO_0000249,
2176,1,B,4,,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,,,,,,H,Autocuration,CHEMBL617250,BAO_0000019,
2177,1,B,4,,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,,,,,,H,Autocuration,CHEMBL617251,BAO_0000019,
2178,1,B,5,,,,104686,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617252,BAO_0000019,
2179,1,B,4,,,,104686,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,,,,,,H,Autocuration,CHEMBL617006,BAO_0000019,
2180,1,B,4,,,,104686,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,,,,,,H,Autocuration,CHEMBL617007,BAO_0000019,
2181,1,F,4,,,,104686,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,,,,,,H,Autocuration,CHEMBL617008,BAO_0000019,
2182,1,B,4,,,,104686,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,,,,,,H,Autocuration,CHEMBL617009,BAO_0000019,
2183,1,B,5,,,,104686,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617010,BAO_0000224,
2184,1,B,5,,,,104686,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL857978,BAO_0000019,
2185,1,B,5,,,,104686,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617011,BAO_0000019,
2186,1,B,5,,,,104686,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617012,BAO_0000019,
2187,1,B,4,,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,,,,,,H,Autocuration,CHEMBL617013,BAO_0000224,
2188,1,B,4,,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,,,,,,H,Autocuration,CHEMBL617014,BAO_0000249,
2189,1,B,4,,,,104686,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL617015,BAO_0000019,
2190,1,B,4,,,,104686,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,,,,,,H,Autocuration,CHEMBL617016,BAO_0000019,
2191,1,B,4,,,,104686,pKi value for 5-hydroxytryptamine 2 receptor binding site,,,,,,,H,Autocuration,CHEMBL617017,BAO_0000224,
2192,1,B,4,,,,104686,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,955.0,,,,,,H,Autocuration,CHEMBL617018,BAO_0000221,
2193,1,F,4,,,,104686,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,,,,,,H,Autocuration,CHEMBL617019,BAO_0000019,
2194,1,B,4,,,,105075,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,,,,,H,Autocuration,CHEMBL617020,BAO_0000019,
2195,1,B,4,,,,105075,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,,,,,H,Autocuration,CHEMBL617021,BAO_0000019,
2196,1,B,4,,,,105075,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,,,,,H,Autocuration,CHEMBL617022,BAO_0000019,
2197,1,B,4,,,,105075,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,,,,,H,Autocuration,CHEMBL617023,BAO_0000019,
2198,1,B,4,,,,105075,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,,,,,H,Autocuration,CHEMBL617024,BAO_0000019,
2199,1,B,4,,,,105075,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,,,,,H,Autocuration,CHEMBL617025,BAO_0000019,
2200,1,B,4,,,,105075,Hill coefficient of compound was determined,,,,,,,H,Autocuration,CHEMBL617026,BAO_0000224,
2201,1,B,0,,,,22226,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,,,,,,U,Autocuration,CHEMBL617027,BAO_0000019,
2202,1,B,5,,,,104686,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617028,BAO_0000019,
2203,1,B,8,,,,12687,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,,,,,,H,Expert,CHEMBL617029,BAO_0000019,
2204,1,B,8,,,,12687,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,,,,,,H,Expert,CHEMBL875908,BAO_0000019,
2205,1,B,8,,,,12687,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,,,,,,H,Autocuration,CHEMBL617030,BAO_0000357,
2206,1,B,8,,,,12687,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,,,,,,H,Autocuration,CHEMBL617031,BAO_0000019,
2207,1,B,8,,,,12687,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,,,,,,H,Autocuration,CHEMBL617032,BAO_0000019,
2208,1,B,5,,,,104686,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617033,BAO_0000224,
2209,1,B,4,,,,104686,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,,,,,,H,Autocuration,CHEMBL617034,BAO_0000224,
2210,1,B,4,,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,,,,,,H,Autocuration,CHEMBL617035,BAO_0000224,
2211,1,B,4,,,,104686,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,,,,,H,Autocuration,CHEMBL617036,BAO_0000019,
2212,1,B,4,,,,104784,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL617037,BAO_0000224,
2213,1,B,0,,,,22226,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,,,,,,U,Autocuration,CHEMBL617038,BAO_0000219,
2214,1,B,4,,,,104784,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,,,,,,H,Autocuration,CHEMBL617039,BAO_0000219,
2215,1,B,4,,,,104784,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL617161,BAO_0000224,
2216,1,B,4,,,,104784,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL617162,BAO_0000224,
2217,1,B,4,,,,104784,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL617163,BAO_0000224,
2218,1,B,4,,,,104784,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL617164,BAO_0000224,
2219,1,B,4,,,,104784,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,,,,,,,H,Autocuration,CHEMBL617165,BAO_0000249,
2220,1,B,4,,,,104784,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,,,,,,H,Autocuration,CHEMBL617166,BAO_0000224,
2221,1,B,4,,,,104784,Binding affinity towards 5-HT2 receptor,,,,,,,H,Autocuration,CHEMBL617167,BAO_0000224,
2222,1,B,4,,,,104784,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL872912,BAO_0000224,
2223,1,B,4,,,,104784,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,,,,,,H,Autocuration,CHEMBL617168,BAO_0000224,
2224,1,B,4,,,,104686,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,,,,,,H,Autocuration,CHEMBL617169,BAO_0000224,
2225,1,B,4,,,,104784,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL617170,BAO_0000224,
2226,1,B,4,,,,104784,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,,,,,,H,Autocuration,CHEMBL617171,BAO_0000224,
2227,1,B,4,,,,104784,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,,,,,,H,Autocuration,CHEMBL617172,BAO_0000224,
2228,1,B,4,,,,104784,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL617173,BAO_0000224,
2229,1,B,0,,,,22226,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,,,,,U,Autocuration,CHEMBL617174,BAO_0000019,
2230,1,B,4,,,,104784,5-hydroxytryptamine 2 receptor binding affinity,,,,,,,H,Autocuration,CHEMBL617175,BAO_0000224,
2231,1,B,8,,,,17005,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,,,,,,H,Autocuration,CHEMBL617176,BAO_0000357,
2232,1,B,8,,,,17005,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,,,,,,H,Autocuration,CHEMBL617177,BAO_0000357,
2233,1,B,4,,,,104784,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,,,,,,H,Autocuration,CHEMBL617178,BAO_0000224,
2234,1,B,4,,,,104784,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,,,,,,H,Autocuration,CHEMBL617179,BAO_0000224,
2235,1,B,4,,,,104784,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,,,,,,H,Autocuration,CHEMBL617180,BAO_0000224,
2236,1,B,8,,,,17005,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,,,,,,H,Autocuration,CHEMBL617181,BAO_0000357,
2237,1,B,8,,,,17005,Binding affinity against 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL617182,BAO_0000357,
2238,1,B,8,,,,17005,Binding affinity against 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL617183,BAO_0000357,
2239,1,B,8,,,,17005,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,,,,,,H,Autocuration,CHEMBL617184,BAO_0000357,
2240,1,B,8,,,,17005,Binding affinity against serotonergic 5-HT2 receptor,,,,,,,H,Autocuration,CHEMBL617185,BAO_0000357,
2241,1,B,8,,,,17005,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,,,,,,H,Autocuration,CHEMBL617186,BAO_0000357,
2242,1,B,8,,,,17005,Compound was evaluated for the binding affinity at 5- HT2 receptor,,,,,,,H,Autocuration,CHEMBL617187,BAO_0000357,
2243,1,B,8,,,,17005,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL617188,BAO_0000357,
2244,1,B,8,,,,17005,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL617189,BAO_0000218,
2245,1,B,5,,,,104784,Inhibitory activity against cloned human 5-HT2 receptor,,Homo sapiens,,,,9606.0,D,Autocuration,CHEMBL617190,BAO_0000224,
2246,1,B,5,CHO,,,104784,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",,Homo sapiens,,449.0,,9606.0,D,Autocuration,CHEMBL617191,BAO_0000219,
2247,1,B,5,CHO,,,104784,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",,Homo sapiens,,449.0,,9606.0,D,Autocuration,CHEMBL617192,BAO_0000219,
2248,1,B,5,CHO,,,104784,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",,Homo sapiens,,449.0,,9606.0,D,Autocuration,CHEMBL617193,BAO_0000219,
2249,1,B,5,CHO,,,104784,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",,Homo sapiens,,449.0,,9606.0,D,Autocuration,CHEMBL617194,BAO_0000219,
2250,1,B,4,,,,104784,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL617195,BAO_0000224,
2251,1,B,4,,,,104784,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,,,,,,H,Autocuration,CHEMBL881830,BAO_0000224,
2252,1,B,8,,,,17005,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL617196,BAO_0000357,
2253,1,B,4,,,,104686,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,,,,,,H,Autocuration,CHEMBL617197,BAO_0000224,
2254,1,B,8,,,,17005,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,,,,,,H,Expert,CHEMBL617198,BAO_0000357,
2255,1,B,8,,,,17005,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,,,,,H,Expert,CHEMBL873476,BAO_0000357,
2256,1,B,8,,,,17005,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,,,,,,H,Expert,CHEMBL617199,BAO_0000019,
2257,1,B,8,,,,107,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL617200,BAO_0000357,
2258,1,B,8,,,,51,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,,,,,H,Autocuration,CHEMBL617484,BAO_0000357,
2259,1,B,8,,,,107,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,,,,,H,Autocuration,CHEMBL617485,BAO_0000357,
2260,1,B,8,,,,51,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,,,,,H,Autocuration,CHEMBL617486,BAO_0000357,
2261,1,B,8,,,,107,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,,,,,,H,Autocuration,CHEMBL858022,BAO_0000357,
2262,1,B,8,CHO,,,107,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,,,449.0,,,H,Autocuration,CHEMBL617049,BAO_0000219,
2263,1,F,9,CHO,,,107,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,,Homo sapiens,,449.0,,9606.0,D,Expert,CHEMBL617050,BAO_0000219,
2264,1,F,8,,,,107,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,,,,,,H,Autocuration,CHEMBL617051,BAO_0000219,
2265,1,F,8,,,,107,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,,,,,,H,Autocuration,CHEMBL617052,BAO_0000219,
2266,1,F,8,,,,107,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,,,,,,H,Autocuration,CHEMBL617053,BAO_0000219,
2267,1,B,8,CHO,,,107,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",,,,449.0,,,H,Autocuration,CHEMBL617054,BAO_0000219,
2268,1,B,8,CHO,,,107,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",,,,449.0,,,H,Autocuration,CHEMBL617055,BAO_0000219,
2269,1,B,8,,,,107,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,,,,,,H,Autocuration,CHEMBL882924,BAO_0000357,
2270,1,B,9,,,,107,Inhibition of human 5-hydroxytryptamine 2A receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL617056,BAO_0000357,
2271,1,B,8,CHO,,,107,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,,449.0,,,H,Autocuration,CHEMBL617057,BAO_0000219,
2272,1,B,8,,,,107,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,,,,,,H,Expert,CHEMBL617058,BAO_0000219,
2273,1,B,8,,,,107,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,,,,,,H,Autocuration,CHEMBL617059,BAO_0000357,
2274,1,B,8,CHO,,,107,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,,,,449.0,,,H,Autocuration,CHEMBL617060,BAO_0000219,
2275,1,B,8,CHO,,,107,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,,,,449.0,,,H,Expert,CHEMBL617061,BAO_0000219,
2276,1,B,8,L929,,,107,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,,,,307.0,,,H,Expert,CHEMBL617062,BAO_0000219,
2277,1,B,8,CHO,,,107,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,,449.0,,,H,Expert,CHEMBL617063,BAO_0000219,
2278,1,F,8,,,,107,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,,,,,,H,Autocuration,CHEMBL617064,BAO_0000019,
2279,1,F,8,,,,107,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,,,,,H,Autocuration,CHEMBL617065,BAO_0000019,
2280,1,B,8,CHO,,,107,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,,,449.0,,,H,Autocuration,CHEMBL617066,BAO_0000219,
2281,1,B,8,CHO,,,107,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,,,,449.0,,,H,Autocuration,CHEMBL617067,BAO_0000219,
2282,1,F,8,,,,107,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,,,,,,H,Autocuration,CHEMBL617068,BAO_0000019,
2283,1,F,8,,,,107,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,,,,,,H,Autocuration,CHEMBL617069,BAO_0000019,
2284,1,F,8,,,,107,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,,,,H,Autocuration,CHEMBL617070,BAO_0000019,
2285,1,B,8,,,,107,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,,,,,,H,Autocuration,CHEMBL617071,BAO_0000357,
2286,1,B,8,,,,107,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,,,,H,Autocuration,CHEMBL872915,BAO_0000357,
2287,1,B,8,,,,107,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,,,,,,H,Autocuration,CHEMBL617072,BAO_0000357,
2288,1,B,8,,,,107,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,,,,,,H,Autocuration,CHEMBL617073,BAO_0000357,
2289,1,B,8,,,,107,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,,,,,,H,Autocuration,CHEMBL617074,BAO_0000357,
2290,1,B,8,CHO,,,107,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,,449.0,,,H,Expert,CHEMBL617075,BAO_0000219,
2291,1,B,8,,,,107,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL617076,BAO_0000357,
2292,1,B,9,,,,107,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL617077,BAO_0000019,
2293,1,B,8,,,,107,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,,,,,,H,Expert,CHEMBL617078,BAO_0000357,
2294,1,B,9,,,,107,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL617079,BAO_0000357,
2295,1,B,8,,,,107,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,,,,,,H,Autocuration,CHEMBL617080,BAO_0000357,
2296,1,B,8,CHO,,,107,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,,,,449.0,,,H,Expert,CHEMBL617081,BAO_0000219,
2297,1,B,8,,,,107,Binding affinity towards human 5-HT2A receptor in BEK cells,,,,,,,H,Expert,CHEMBL617082,BAO_0000219,
2298,1,B,8,,,,107,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL617083,BAO_0000357,
2299,1,B,8,,,,107,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,,,,,,H,Autocuration,CHEMBL617084,BAO_0000357,
2300,1,B,9,,,,107,Binding affinity for human 5-hydroxytryptamine 2A receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL617085,BAO_0000357,
2301,1,B,8,,,,107,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,,,,,H,Autocuration,CHEMBL617086,BAO_0000357,
2302,1,B,8,,,,107,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,,,,,,H,Autocuration,CHEMBL617087,BAO_0000219,
2303,1,B,8,,,,107,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL617088,BAO_0000357,
2304,1,B,8,,,,107,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL617089,BAO_0000357,
2305,1,B,8,,,,107,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,,,,,,H,Expert,CHEMBL617090,BAO_0000019,
2306,1,B,8,,,,107,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,,,,,,H,Autocuration,CHEMBL617513,BAO_0000357,
2307,1,B,8,HEK293,,,107,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,,,,722.0,,,H,Autocuration,CHEMBL617514,BAO_0000219,
2308,1,B,8,,,,107,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL617515,BAO_0000019,
2309,1,B,8,,,,107,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,,,,,H,Autocuration,CHEMBL617516,BAO_0000357,
2310,1,B,9,,,,107,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL617517,BAO_0000357,
2311,1,B,9,CHO,,,107,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,,Homo sapiens,,449.0,,9606.0,D,Expert,CHEMBL617518,BAO_0000219,
2312,1,B,8,,,,107,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL617519,BAO_0000357,
2313,1,B,9,,,,107,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL617520,BAO_0000357,
2314,1,B,8,,,,107,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,,,,,,H,Autocuration,CHEMBL617521,BAO_0000357,
2315,1,B,9,,,,107,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL617522,BAO_0000357,
2316,1,B,8,,,,107,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,,,,,,H,Autocuration,CHEMBL617523,BAO_0000357,
2317,1,B,8,,,,107,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,,,,,H,Autocuration,CHEMBL617524,BAO_0000357,
2318,1,B,4,,,,104686,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,,,,,,H,Autocuration,CHEMBL617525,BAO_0000019,
2319,1,B,5,,,,104686,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617526,BAO_0000019,
2320,1,B,4,,,,104686,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,,,,,,H,Autocuration,CHEMBL617527,BAO_0000224,
2321,1,B,4,,,,104686,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,,,,,,H,Autocuration,CHEMBL617528,BAO_0000019,
2322,1,B,4,,,,104686,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,,,,,,H,Autocuration,CHEMBL617529,BAO_0000019,
2323,1,B,4,,,,104686,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,,,,,,H,Autocuration,CHEMBL617530,BAO_0000224,
2324,1,B,4,,,,104686,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,,,,,,H,Autocuration,CHEMBL617531,BAO_0000019,
2325,1,B,4,,,,104686,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,,,,,,H,Autocuration,CHEMBL617532,BAO_0000019,
2326,1,B,4,,,,104686,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,,,,,,H,Autocuration,CHEMBL617533,BAO_0000019,
2327,1,B,4,,,,104686,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,,,,,,H,Autocuration,CHEMBL617534,BAO_0000019,
2328,1,B,4,,,,104686,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,,,,,,H,Autocuration,CHEMBL617535,BAO_0000224,
2329,1,B,4,,,,104686,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,,,,,,H,Autocuration,CHEMBL617536,BAO_0000224,
2330,1,B,4,,,,104686,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL617537,BAO_0000224,
2331,1,B,4,,,,104686,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL617538,BAO_0000224,
2332,1,B,4,,,In vitro,104686,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,,,,,,H,Autocuration,CHEMBL617539,BAO_0000219,
2333,1,B,5,,,,104686,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617540,BAO_0000224,
2334,1,B,5,,,,104686,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617541,BAO_0000224,
2335,1,B,4,,,,104686,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL617542,BAO_0000224,
2336,1,B,4,,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,,,,,,H,Autocuration,CHEMBL617543,BAO_0000224,
2337,1,B,5,CHO-K1,,,104686,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,Rattus norvegicus,,485.0,,10116.0,D,Autocuration,CHEMBL617544,BAO_0000219,
2338,1,B,5,CHO-K1,,,104686,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,Rattus norvegicus,,485.0,,10116.0,D,Autocuration,CHEMBL617545,BAO_0000219,
2339,1,B,5,,,,104686,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617413,BAO_0000019,
2340,1,B,4,,,,104686,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,,,,,,H,Autocuration,CHEMBL617414,BAO_0000019,
2341,1,B,5,,,,104686,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617415,BAO_0000019,
2342,1,B,4,,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL617416,BAO_0000224,
2343,1,B,4,,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,,,,,,H,Autocuration,CHEMBL617417,BAO_0000224,
2344,1,B,4,,,,104686,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,,,,,,H,Autocuration,CHEMBL617418,BAO_0000019,
2345,1,B,4,,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,,,,,,H,Autocuration,CHEMBL617419,BAO_0000019,
2346,1,B,4,,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,,,,,H,Autocuration,CHEMBL617420,BAO_0000224,
2347,1,B,5,,,,104686,Affinity for 5-hydroxytryptamine 2 receptor,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617421,BAO_0000224,
2348,1,B,4,,,,104686,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,,,,,,H,Autocuration,CHEMBL617422,BAO_0000224,
2349,1,B,4,,,,104686,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,,,,,,H,Autocuration,CHEMBL617423,BAO_0000019,
2350,1,B,4,,,,104686,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,,,,,,H,Autocuration,CHEMBL617424,BAO_0000019,
2351,1,B,4,,,,104686,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,,,,,,H,Autocuration,CHEMBL617425,BAO_0000019,
2352,1,B,4,,,,104686,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,,,,,,H,Autocuration,CHEMBL617426,BAO_0000224,
2353,1,B,4,,,In vivo,104686,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),,,,,,,H,Autocuration,CHEMBL617427,BAO_0000218,
2354,1,B,4,,,,104686,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,955.0,,,,,,H,Autocuration,CHEMBL617428,BAO_0000221,
2355,1,B,4,,,,104686,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,,,,,,H,Autocuration,CHEMBL617429,BAO_0000224,
2356,1,B,4,,,,104686,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,,,,,,H,Autocuration,CHEMBL617430,BAO_0000019,
2357,1,B,4,,,,104686,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,,,,,,H,Autocuration,CHEMBL617431,BAO_0000019,
2358,1,B,4,,,,104686,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,1870.0,,,,,,H,Autocuration,CHEMBL617432,BAO_0000019,
2359,1,B,4,,,,104686,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL617433,BAO_0000224,
2360,1,B,4,,,,104686,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL617434,BAO_0000224,
2361,1,B,5,,,,104686,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617435,BAO_0000224,
2362,1,B,4,,,,104686,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,,,,,,H,Autocuration,CHEMBL617436,BAO_0000019,
2363,1,B,5,,,,104686,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,2435.0,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617437,BAO_0000019,
2364,1,B,4,,,,104686,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,,,,,,H,Autocuration,CHEMBL617438,BAO_0000019,
2365,1,B,4,,,,104686,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,,,,,H,Autocuration,CHEMBL617439,BAO_0000019,
2366,1,B,4,,,,104686,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL617440,BAO_0000224,
2367,1,B,4,,,,104686,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL617441,BAO_0000224,
2368,1,B,5,,,,104686,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL872918,BAO_0000019,
2369,1,B,5,,,,104686,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617442,BAO_0000019,
2370,1,B,4,,,,104686,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,,,,,,H,Autocuration,CHEMBL617443,BAO_0000019,
2371,1,B,4,,,,104686,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,,,,,,H,Autocuration,CHEMBL617444,BAO_0000019,
2372,1,B,4,,,,104686,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,,,,,,H,Autocuration,CHEMBL617445,BAO_0000019,
2373,1,B,4,,,,104686,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,,,,,,H,Autocuration,CHEMBL617446,BAO_0000019,
2374,1,B,4,,,,104686,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,,,,,,H,Autocuration,CHEMBL617447,BAO_0000249,
2375,1,B,4,,,,104686,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,,,,,,H,Autocuration,CHEMBL617448,BAO_0000019,
2376,1,B,4,,,,104686,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,,,,,,H,Autocuration,CHEMBL617449,BAO_0000019,
2377,1,B,4,,,,104686,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,,,,,,H,Autocuration,CHEMBL617450,BAO_0000019,
2378,1,B,4,,,,104686,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,,,,,,H,Autocuration,CHEMBL617451,BAO_0000019,
2379,1,B,4,,,,104686,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,,,,,,H,Autocuration,CHEMBL617452,BAO_0000019,
2380,1,B,4,,,,104686,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,,,,,,H,Autocuration,CHEMBL617453,BAO_0000019,
2381,1,B,4,,,,104686,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,,,,,,H,Autocuration,CHEMBL617660,BAO_0000019,
2382,1,B,4,,,,104686,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,,,,,,H,Autocuration,CHEMBL617661,BAO_0000019,
2383,1,B,4,,,,104686,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,,,,,,H,Autocuration,CHEMBL617662,BAO_0000019,
2384,1,B,4,,,,104686,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,,,,,,H,Autocuration,CHEMBL872919,BAO_0000019,
2385,1,B,4,,,,104686,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,,,,,,H,Autocuration,CHEMBL617663,BAO_0000019,
2386,1,B,4,,,,104686,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,,,,,,H,Autocuration,CHEMBL617664,BAO_0000019,
2387,1,B,4,,,,104686,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,,,,,,H,Autocuration,CHEMBL617665,BAO_0000019,
2388,1,B,4,,,,104686,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,,,,,,H,Autocuration,CHEMBL617666,BAO_0000019,
2389,1,B,4,,,,104686,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,,,,,,H,Autocuration,CHEMBL617667,BAO_0000019,
2390,1,B,4,,,,104686,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,,,,,,H,Autocuration,CHEMBL617668,BAO_0000249,
2391,1,B,4,,,,104686,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,,,,,,H,Autocuration,CHEMBL617669,BAO_0000249,
2392,1,B,4,,,,104686,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL617670,BAO_0000224,
2393,1,B,5,,,,104686,Inhibitory constant against 5-hydroxytryptamine 2 receptor,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617671,BAO_0000224,
2394,1,B,4,,,,104686,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL617672,BAO_0000224,
2395,1,B,4,,,,104686,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,,,,,,H,Autocuration,CHEMBL617673,BAO_0000019,
2396,1,B,4,,,,104686,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,,,,,,H,Autocuration,CHEMBL617674,BAO_0000224,
2397,1,B,4,,,,104686,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,,,,,,H,Autocuration,CHEMBL617675,BAO_0000019,
2398,1,B,4,,,,104686,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,,,,,,H,Autocuration,CHEMBL617676,BAO_0000019,
2399,1,B,4,,,,104686,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,,,,,,H,Autocuration,CHEMBL617677,BAO_0000019,
2400,1,B,5,,,,104686,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,,,,,,D,Autocuration,CHEMBL617678,BAO_0000019,
2401,1,B,4,,,,104686,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,,,,,,H,Autocuration,CHEMBL617679,BAO_0000224,
2402,1,B,4,,,,104686,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,,,,,,H,Autocuration,CHEMBL617680,BAO_0000224,
2403,1,B,4,,,,104686,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,,,,,,H,Autocuration,CHEMBL617681,BAO_0000019,
2404,1,B,4,,,,104686,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,955.0,,,,,,H,Autocuration,CHEMBL617682,BAO_0000221,
2405,1,B,4,,,,104686,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,,,,,,H,Autocuration,CHEMBL617683,BAO_0000224,
2406,1,B,4,,,,104686,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,,,,,,H,Autocuration,CHEMBL617684,BAO_0000224,
2407,1,B,5,,,,104686,Binding affinity towards 5-hydroxytryptamine 2 receptor,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617685,BAO_0000224,
2408,1,B,4,,,,104686,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,,,,,,H,Autocuration,CHEMBL617686,BAO_0000019,
2409,1,B,4,,,,104686,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,,,,,,H,Autocuration,CHEMBL617687,BAO_0000224,
2410,1,B,4,,,,104686,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,,,,,H,Autocuration,CHEMBL617688,BAO_0000224,
2411,1,F,4,,,,104686,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,,,,,H,Autocuration,CHEMBL617689,BAO_0000019,
2412,1,F,4,,,,104686,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,,,,,H,Autocuration,CHEMBL617690,BAO_0000019,
2413,1,F,4,,,In vivo,104686,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,,,,,,H,Autocuration,CHEMBL617691,BAO_0000218,
2414,1,F,4,,,In vivo,104686,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,,,,,,H,Autocuration,CHEMBL617692,BAO_0000218,
2415,1,F,4,,,In vivo,104686,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,,,,,,H,Autocuration,CHEMBL617693,BAO_0000218,
2416,1,F,4,,,In vivo,104686,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,,,,,,H,Autocuration,CHEMBL617694,BAO_0000218,
2417,1,B,8,,,,12687,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,955.0,,,,,,H,Expert,CHEMBL857985,BAO_0000221,
2418,1,B,9,,,,12687,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617695,BAO_0000019,
2419,1,B,8,,,,12687,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,,,,,,H,Autocuration,CHEMBL617696,BAO_0000019,
2420,1,B,8,,,,12687,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,,,,,,H,Autocuration,CHEMBL617697,BAO_0000357,
2421,1,B,9,,,,12687,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617257,BAO_0000019,
2422,1,B,9,,,,12687,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617258,BAO_0000357,
2423,1,B,8,,,,12687,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,,,,,,H,Expert,CHEMBL617259,BAO_0000019,
2424,1,B,8,,,,12687,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,,,,,,H,Autocuration,CHEMBL617260,BAO_0000357,
2425,1,B,9,,,,12687,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617261,BAO_0000357,
2426,1,B,8,,,,12687,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,,,,,,H,Autocuration,CHEMBL617262,BAO_0000019,
2427,1,B,8,,,,12687,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,,,,,,H,Expert,CHEMBL617263,BAO_0000019,
2428,1,B,8,,,,12687,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,,,,,,H,Autocuration,CHEMBL617264,BAO_0000019,
2429,1,B,9,,,,12687,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617265,BAO_0000019,
2430,1,B,8,,,,12687,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL617266,BAO_0000249,
2431,1,B,8,,,,12687,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,,,,,,H,Autocuration,CHEMBL617267,BAO_0000019,
2432,1,B,8,,,,12687,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,,,,,,H,Expert,CHEMBL617268,BAO_0000019,
2433,1,B,8,CHO,,,12687,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,,,449.0,,,H,Autocuration,CHEMBL617269,BAO_0000219,
2434,1,B,8,,,,12687,Kinetic inhibition constant evaluated by measuring serotonergic activity,,,,,,,H,Expert,CHEMBL617323,BAO_0000357,
2435,1,B,8,,,,12687,Serotonergic activity of the compound.,,,,,,,H,Autocuration,CHEMBL617324,BAO_0000357,
2436,1,B,8,,,,12687,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,,,,,,H,Autocuration,CHEMBL617325,BAO_0000249,
2437,1,B,9,,,,12687,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617326,BAO_0000019,
2438,1,B,8,,,,12687,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,,,,,,H,Expert,CHEMBL617327,BAO_0000249,
2439,1,F,9,,,,12687,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617328,BAO_0000019,
2440,1,F,9,,,,12687,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617329,BAO_0000019,
2441,1,F,9,,,,12687,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617330,BAO_0000019,
2442,1,B,8,,,,12687,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,,,,H,Autocuration,CHEMBL617331,BAO_0000357,
2443,1,B,8,,,,12687,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,,,,,,H,Autocuration,CHEMBL617332,BAO_0000357,
2444,1,B,8,,,,107,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,,,,,H,Expert,CHEMBL617333,BAO_0000357,
2445,1,B,8,,,,107,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,,,,,,H,Autocuration,CHEMBL617334,BAO_0000357,
2446,1,B,8,,,,107,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,,,,,,H,Autocuration,CHEMBL617335,BAO_0000357,
2447,1,B,8,,,,107,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,,,,,,H,Autocuration,CHEMBL617336,BAO_0000357,
2448,1,B,8,,,,107,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,,,,,,H,Autocuration,CHEMBL617337,BAO_0000357,
2449,1,B,9,,,,107,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL617338,BAO_0000357,
2450,1,B,8,,,,107,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL617339,BAO_0000357,
2451,1,B,8,,,,107,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,,,,,H,Expert,CHEMBL617340,BAO_0000357,
2452,1,B,8,,,,107,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,,,,,,H,Autocuration,CHEMBL617341,BAO_0000357,
2453,1,B,8,,,,107,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,,,,,,H,Expert,CHEMBL617342,BAO_0000357,
2454,1,B,8,,,,107,Affinity for 5-hydroxytryptamine 2A receptor,,,,,,,H,Expert,CHEMBL617343,BAO_0000357,
2455,1,B,8,NIH3T3,,,107,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,,,,723.0,,,H,Expert,CHEMBL617344,BAO_0000219,
2456,1,B,8,,,,107,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,,,,,,H,Expert,CHEMBL617345,BAO_0000357,
2457,1,B,8,,,,107,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,,,,,,H,Expert,CHEMBL617346,BAO_0000357,
2458,1,B,8,,,,107,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL617347,BAO_0000357,
2459,1,B,8,,,,107,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,,,,,,H,Autocuration,CHEMBL617348,BAO_0000357,
2460,1,B,8,,,,107,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,,,,,,H,Autocuration,CHEMBL617349,BAO_0000357,
2461,1,F,8,,,,107,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL617350,BAO_0000019,
2462,1,B,8,,,,107,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,,,,,,H,Expert,CHEMBL872339,BAO_0000357,
2463,1,B,8,,,,107,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,,,,,,H,Autocuration,CHEMBL617351,BAO_0000357,
2464,1,B,8,,,,107,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,,,,,,H,Expert,CHEMBL617352,BAO_0000357,
2465,1,B,8,,,,107,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL617353,BAO_0000357,
2466,1,B,8,,,,107,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL617354,BAO_0000357,
2467,1,B,8,,,,107,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL617355,BAO_0000357,
2468,1,B,8,CHO,,,107,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,,Mus musculus,,449.0,,10090.0,H,Expert,CHEMBL617356,BAO_0000219,
2469,1,B,8,,,,107,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL617357,BAO_0000357,
2470,1,B,8,,,,107,Binding affinity at 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL617358,BAO_0000357,
2471,1,B,8,,,,107,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,,,,,,H,Expert,CHEMBL617359,BAO_0000357,
2472,1,B,8,,,,107,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,,,,,,H,Autocuration,CHEMBL617360,BAO_0000357,
2473,1,B,8,,,,107,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,,,,,,H,Autocuration,CHEMBL875913,BAO_0000357,
2474,1,B,8,,,,107,Affinity against 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL617361,BAO_0000357,
2475,1,B,9,,,,107,Binding affinity against 5-Hydroxytryptamine 2A receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL617362,BAO_0000357,
2476,1,B,8,,,,107,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,,,,,,H,Autocuration,CHEMBL617363,BAO_0000357,
2477,1,B,8,,,,107,Tested against 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL617364,BAO_0000357,
2478,1,B,4,,,,105075,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,,,,,,H,Autocuration,CHEMBL617365,BAO_0000224,
2479,1,B,4,,,,105075,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,,,,,,H,Autocuration,CHEMBL617366,BAO_0000224,
2480,1,B,4,,,,105075,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,,,,,,H,Autocuration,CHEMBL617367,BAO_0000224,
2481,1,B,4,,,,105075,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,,,,,,H,Autocuration,CHEMBL617368,BAO_0000224,
2482,1,B,8,,,,107,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,,,,,,H,Autocuration,CHEMBL617369,BAO_0000357,
2483,1,B,9,HEK293,,,227,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,,Homo sapiens,,722.0,,9606.0,D,Expert,CHEMBL617370,BAO_0000219,
2484,1,F,9,CHO,,,227,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,,Homo sapiens,,449.0,,9606.0,D,Expert,CHEMBL617371,BAO_0000219,
2485,1,B,8,,,,227,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,,,,,,H,Autocuration,CHEMBL617372,BAO_0000357,
2486,1,B,9,,,,227,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL617373,BAO_0000357,
2487,1,F,8,,,,227,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,,,,,,H,Autocuration,CHEMBL617374,BAO_0000019,
2488,1,F,8,,,,227,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,,,,,,H,Autocuration,CHEMBL617375,BAO_0000019,
2489,1,F,8,,,,227,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,,,,,,H,Autocuration,CHEMBL617376,BAO_0000019,
2490,1,F,8,,,,227,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,,,,,,H,Autocuration,CHEMBL617377,BAO_0000019,
2491,1,F,8,,,,227,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,,,,,,H,Autocuration,CHEMBL617378,BAO_0000019,
2492,1,F,8,,,,227,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,,,,,,H,Autocuration,CHEMBL617379,BAO_0000019,
2493,1,B,8,,,,227,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,,,,,,H,Autocuration,CHEMBL617380,BAO_0000357,
2494,1,B,8,,,,227,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,,,,,,H,Autocuration,CHEMBL617381,BAO_0000357,
2495,1,B,8,,,,227,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,,,,,,H,Autocuration,CHEMBL617382,BAO_0000357,
2496,1,B,8,,,,107,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL617383,BAO_0000357,
2497,1,B,8,,,,107,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,,,,,,H,Expert,CHEMBL617384,BAO_0000357,
2498,1,B,8,,,,107,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,,,,,,H,Expert,CHEMBL617385,BAO_0000357,
2499,1,B,8,,,,107,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,,,,,,H,Autocuration,CHEMBL617386,BAO_0000019,
2500,1,B,8,,,,107,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,,,,,,H,Autocuration,CHEMBL617387,BAO_0000019,
2501,1,B,8,NIH3T3,,,107,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,,723.0,,,H,Autocuration,CHEMBL617388,BAO_0000219,
2502,1,F,8,CHO,,,107,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,,,449.0,,,H,Autocuration,CHEMBL617389,BAO_0000219,
2503,1,F,9,CHO,,,107,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,Homo sapiens,,449.0,,9606.0,D,Expert,CHEMBL617390,BAO_0000219,
2504,1,B,4,,,,104817,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,,,,,,H,Autocuration,CHEMBL617391,BAO_0000224,
2505,1,B,8,,,,107,Binding activity radioligand.,,,,,,,H,Autocuration,CHEMBL617392,BAO_0000357,
2506,1,B,8,,,,107,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,,,,,H,Autocuration,CHEMBL617393,BAO_0000019,
2507,1,B,8,L929,,,107,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,,,307.0,,,H,Autocuration,CHEMBL617394,BAO_0000219,
2508,1,B,8,L929,,,107,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,,,307.0,,,H,Expert,CHEMBL617395,BAO_0000219,
2509,1,B,8,L929,,,107,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,,,307.0,,,H,Expert,CHEMBL617396,BAO_0000219,
2510,1,B,8,L929,,,107,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,,,,307.0,,,H,Autocuration,CHEMBL617397,BAO_0000219,
2511,1,B,8,,,,107,Binding affinity against 5-HT2A receptor,,,,,,,H,Autocuration,CHEMBL617398,BAO_0000357,
2512,1,B,8,,,,107,Binding affinity against 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL617399,BAO_0000357,
2513,1,B,8,HEK293,,,107,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,,,722.0,,,H,Autocuration,CHEMBL617400,BAO_0000219,
2514,1,B,8,HEK293,,,107,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,,,722.0,,,H,Autocuration,CHEMBL617401,BAO_0000219,
2515,1,B,9,HEK293,,,107,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,,Homo sapiens,,722.0,,9606.0,D,Expert,CHEMBL617402,BAO_0000219,
2516,1,B,9,HEK293,,,107,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,Homo sapiens,,722.0,,9606.0,D,Expert,CHEMBL617403,BAO_0000219,
2517,1,B,8,,,,107,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,,,,,,H,Expert,CHEMBL617404,BAO_0000357,
2518,1,B,9,HEK293,,,107,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,Homo sapiens,,722.0,,9606.0,D,Expert,CHEMBL857981,BAO_0000219,
2519,1,B,9,HEK293,,,107,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,Homo sapiens,,722.0,,9606.0,D,Expert,CHEMBL617405,BAO_0000219,
2520,1,B,9,HEK293,,,107,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,,Homo sapiens,,722.0,,9606.0,D,Expert,CHEMBL617253,BAO_0000219,
2521,1,B,8,,,,107,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,,,,,,H,Expert,CHEMBL617254,BAO_0000357,
2522,1,B,8,HEK293,,,107,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,,,722.0,,,H,Autocuration,CHEMBL617255,BAO_0000219,
2523,1,B,8,HEK293,,,107,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,,,722.0,,,H,Autocuration,CHEMBL617256,BAO_0000219,
2524,1,B,8,HEK293,,,107,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,,,,722.0,,,H,Autocuration,CHEMBL616874,BAO_0000219,
2525,1,B,9,HEK293,,,107,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,,Homo sapiens,,722.0,,9606.0,D,Expert,CHEMBL616875,BAO_0000219,
2526,1,B,8,HEK293,,,107,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,,,,722.0,,,H,Expert,CHEMBL616876,BAO_0000219,
2527,1,B,8,HEK293,,,107,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",,,,722.0,,,H,Expert,CHEMBL616877,BAO_0000219,
2528,1,B,9,HEK293,,,107,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,,Homo sapiens,,722.0,,9606.0,D,Expert,CHEMBL616878,BAO_0000219,
2529,1,B,8,HEK293,,,107,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,,,,722.0,,,H,Expert,CHEMBL616879,BAO_0000219,
2530,1,B,8,HEK293,,,107,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,,,,722.0,,,H,Expert,CHEMBL616880,BAO_0000219,
2531,1,B,9,HEK293,,,107,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,Homo sapiens,,722.0,,9606.0,D,Expert,CHEMBL616881,BAO_0000219,
2532,1,B,8,NIH3T3,,,107,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,,,723.0,,,H,Autocuration,CHEMBL616882,BAO_0000219,
2533,1,B,8,NIH3T3,,,107,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,,723.0,,,H,Autocuration,CHEMBL616883,BAO_0000219,
2534,1,B,8,NIH3T3,,,107,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,,723.0,,,H,Autocuration,CHEMBL616884,BAO_0000219,
2535,1,B,8,HEK293,,,107,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,,,,722.0,,,H,Autocuration,CHEMBL616885,BAO_0000219,
2536,1,B,8,CHO-K1,,,107,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,,,,485.0,,,H,Autocuration,CHEMBL616886,BAO_0000219,
2537,1,B,8,CHO-K1,,,107,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,,,,485.0,,,H,Expert,CHEMBL616887,BAO_0000219,
2538,1,B,9,,,,107,Binding affinity for human 5-hydroxytryptamine 2A receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL616888,BAO_0000357,
2539,1,B,8,HEK293,,,107,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,,,,722.0,,,H,Autocuration,CHEMBL616889,BAO_0000219,
2540,1,B,8,HEK293,,,107,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,,,,722.0,,,H,Autocuration,CHEMBL616890,BAO_0000219,
2541,1,B,9,CHO,,,107,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,Homo sapiens,,449.0,,9606.0,D,Expert,CHEMBL616891,BAO_0000219,
2542,1,B,8,HEK293,,,107,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,,,,722.0,,,H,Autocuration,CHEMBL616892,BAO_0000219,
2543,1,B,8,HEK293,,,107,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",,,,722.0,,,H,Autocuration,CHEMBL616893,BAO_0000219,
2544,1,F,8,NIH3T3,,,10620,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,,,,723.0,,,H,Autocuration,CHEMBL616894,BAO_0000219,
2545,1,B,8,NIH3T3,,,107,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,,,,723.0,,,H,Expert,CHEMBL616895,BAO_0000219,
2546,1,F,8,,,,10620,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL616896,BAO_0000019,
2547,1,B,8,,,,10621,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL617099,BAO_0000357,
2548,1,B,8,,,,10621,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,,,,,,H,Autocuration,CHEMBL617100,BAO_0000357,
2549,1,B,8,,,,107,Binding affinity against rabbit aorta 5-HT2A receptor,,Oryctolagus cuniculus,,,,9986.0,H,Autocuration,CHEMBL884532,BAO_0000357,
2550,1,B,8,,,,107,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,,Oryctolagus cuniculus,,,,9986.0,H,Expert,CHEMBL617101,BAO_0000357,
2551,1,B,8,,,,107,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,,Oryctolagus cuniculus,,,,9986.0,H,Expert,CHEMBL617102,BAO_0000357,
2552,1,B,8,,,,107,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,Oryctolagus cuniculus,,,,9986.0,H,Autocuration,CHEMBL617103,BAO_0000019,
2553,1,B,8,,,,107,The compound was tested for binding affinity against 5-HT2A receptor,,Oryctolagus cuniculus,,,,9986.0,H,Expert,CHEMBL617104,BAO_0000357,
2554,1,B,8,CHO-K1,,,10576,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,,,,485.0,,,H,Autocuration,CHEMBL857979,BAO_0000219,
2555,1,B,8,,,,12687,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,,,,,,H,Autocuration,CHEMBL857502,BAO_0000019,
2556,1,B,8,,,,12687,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,,,,,,H,Autocuration,CHEMBL617105,BAO_0000019,
2557,1,B,8,,,,12687,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,945.0,,,,,,H,Autocuration,CHEMBL858021,BAO_0000019,
2558,1,B,9,,,,12687,Binding affinity for 5-HT 2A in rat stomach fundus,945.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL875910,BAO_0000019,
2559,1,B,8,,,,12687,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,,,,,,H,Autocuration,CHEMBL617106,BAO_0000019,
2560,1,B,8,NIH3T3,,,12687,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,,,,723.0,,,H,Expert,CHEMBL617107,BAO_0000219,
2561,1,F,8,,,,12687,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL617108,BAO_0000019,
2562,1,F,8,,,,12687,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL617109,BAO_0000019,
2563,1,B,8,,,,12687,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL617110,BAO_0000357,
2564,1,B,8,,,,12687,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,,,,,,H,Autocuration,CHEMBL617111,BAO_0000357,
2565,1,F,9,,,,12687,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617112,BAO_0000019,
2566,1,B,8,,,,12687,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL617113,BAO_0000357,
2567,1,B,8,,,,12687,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL617114,BAO_0000357,
2568,1,B,8,,,,12687,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL617115,BAO_0000357,
2569,1,F,8,,,,12687,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,,,,,H,Autocuration,CHEMBL617116,BAO_0000219,
2570,1,F,8,,,,12687,Efficacy at 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL617117,BAO_0000019,
2571,1,B,8,,,,12687,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,,,,,,H,Autocuration,CHEMBL617118,BAO_0000357,
2572,1,B,9,,,,12687,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617119,BAO_0000357,
2573,1,B,9,,,,12687,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617120,BAO_0000357,
2574,1,F,9,,,,12687,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617121,BAO_0000219,
2575,1,F,8,,,,12687,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,,,,,H,Autocuration,CHEMBL617122,BAO_0000219,
2576,1,B,8,,,,12687,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL617123,BAO_0000019,
2577,1,B,8,,,,12687,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,,,,,,H,Expert,CHEMBL617124,BAO_0000019,
2578,1,B,8,,,,12687,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,,,,,,H,Expert,CHEMBL617600,BAO_0000249,
2579,1,B,8,,,,12687,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,,,,,,H,Expert,CHEMBL617601,BAO_0000357,
2580,1,B,8,,,,12687,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,,,,,,H,Expert,CHEMBL882923,BAO_0000019,
2581,1,B,8,,,,12687,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL617602,BAO_0000357,
2582,1,B,8,,,,12687,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,,,,,,H,Autocuration,CHEMBL617603,BAO_0000019,
2583,1,B,8,,,,12687,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL617604,BAO_0000357,
2584,1,B,8,,,,12687,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,,,,,,H,Expert,CHEMBL617605,BAO_0000019,
2585,1,B,8,,,,12687,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,,,,,,H,Expert,CHEMBL617606,BAO_0000019,
2586,1,B,9,,,,12687,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617607,BAO_0000019,
2587,1,B,8,,,,12687,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,,,,H,Autocuration,CHEMBL617455,BAO_0000249,
2588,1,B,9,,,,12687,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617456,BAO_0000019,
2589,1,B,8,,,,12687,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,,,,,,H,Expert,CHEMBL617457,BAO_0000357,
2590,1,B,9,,,,12687,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617458,BAO_0000357,
2591,1,B,9,,,,12687,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617459,BAO_0000019,
2592,1,B,8,,,,12687,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,,,,,,H,Expert,CHEMBL617460,BAO_0000357,
2593,1,B,8,,,,12687,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,,,,,,H,Expert,CHEMBL617461,BAO_0000357,
2594,1,B,9,,,,12687,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617462,BAO_0000019,
2595,1,B,8,,,,12687,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,,,,,,H,Autocuration,CHEMBL617463,BAO_0000357,
2596,1,B,8,,,,12687,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,,,,,,H,Autocuration,CHEMBL617464,BAO_0000019,
2597,1,B,8,,,,12687,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,,,,,,H,Autocuration,CHEMBL617465,BAO_0000019,
2598,1,B,8,,,,12687,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,,,,,,H,Expert,CHEMBL617466,BAO_0000019,
2599,1,B,8,,,,12687,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,,,,,,H,Autocuration,CHEMBL617467,BAO_0000019,
2600,1,B,8,,,,12687,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,,,,,,H,Expert,CHEMBL617468,BAO_0000019,
2601,1,B,8,,,,12687,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,,,,,,H,Autocuration,CHEMBL617469,BAO_0000019,
2602,1,B,8,,,,12687,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL617470,BAO_0000019,
2603,1,B,8,,,,12687,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,,,,,,H,Autocuration,CHEMBL617471,BAO_0000019,
2604,1,B,8,NIH3T3,,,12687,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,,,,723.0,,,H,Expert,CHEMBL617472,BAO_0000219,
2605,1,B,8,,,,12687,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,,,,,,H,Expert,CHEMBL617473,BAO_0000357,
2606,1,B,9,,,,12687,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617474,BAO_0000019,
2607,1,B,9,,,,12687,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617475,BAO_0000019,
2608,1,B,8,,,,12687,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,955.0,,,,,,H,Autocuration,CHEMBL617476,BAO_0000221,
2609,1,B,8,,,,12687,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,,,,,,H,Expert,CHEMBL617477,BAO_0000357,
2610,1,B,8,NIH3T3,,,12687,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,,,,723.0,,,H,Expert,CHEMBL617478,BAO_0000219,
2611,1,F,8,,,,12687,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,,,,,,H,Autocuration,CHEMBL617479,BAO_0000221,
2612,1,B,8,,,,12687,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,,,,,,H,Autocuration,CHEMBL617480,BAO_0000357,
2613,1,B,8,,,,12687,Binding affinity against 5-hydroxytryptamine 2A receptor,,,,,,,H,Expert,CHEMBL617481,BAO_0000357,
2614,1,B,8,,,,12687,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,,,,,,H,Expert,CHEMBL617482,BAO_0000019,
2615,1,B,8,,,,12687,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,,,,,,H,Autocuration,CHEMBL617483,BAO_0000019,
2616,1,B,8,,,,12687,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,,,,,H,Autocuration,CHEMBL621528,BAO_0000357,
2617,1,B,9,NIH3T3,,,12687,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,,Rattus norvegicus,,723.0,,10116.0,D,Expert,CHEMBL621529,BAO_0000219,
2618,1,B,8,,,,12687,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,,,,,H,Expert,CHEMBL621530,BAO_0000357,
2619,1,B,8,,,,12687,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,,,,H,Expert,CHEMBL621531,BAO_0000357,
2620,1,B,9,,,,12687,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL621532,BAO_0000019,
2621,1,B,8,,,,12687,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,,,,,H,Expert,CHEMBL621533,BAO_0000357,
2622,1,B,8,CHO,,,12687,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,,449.0,,,H,Expert,CHEMBL621534,BAO_0000219,
2623,1,B,8,,,,12687,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,,,,,,H,Autocuration,CHEMBL621535,BAO_0000019,
2624,1,B,8,,,,12687,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,,,,,,H,Autocuration,CHEMBL621536,BAO_0000357,
2625,1,B,8,,,,12687,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL621537,BAO_0000357,
2626,1,B,9,,,,12687,Binding affinity for 5-hydroxytryptamine 2A receptor,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL621538,BAO_0000357,
2627,1,B,8,,,,12687,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,,,,,,H,Autocuration,CHEMBL621539,BAO_0000019,
2628,1,B,8,,,,12687,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,,,,,,H,Autocuration,CHEMBL621540,BAO_0000019,
2629,1,B,8,,,,12687,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,,,,,,H,Autocuration,CHEMBL621541,BAO_0000019,
2630,1,B,8,,,,12687,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,,,,,,H,Autocuration,CHEMBL621542,BAO_0000019,
2631,1,B,8,,,,12687,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,,,,,,H,Expert,CHEMBL621543,BAO_0000357,
2632,1,B,8,,,,12687,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,,,,,,H,Expert,CHEMBL621544,BAO_0000357,
2633,1,B,9,,,,12687,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL621545,BAO_0000357,
2634,1,B,8,,,,12687,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,,,,H,Autocuration,CHEMBL621546,BAO_0000357,
2635,1,B,8,,,,12687,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,,,,,,H,Autocuration,CHEMBL621547,BAO_0000357,
2636,1,B,8,NIH3T3,,,12687,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,,,,723.0,,,H,Expert,CHEMBL618692,BAO_0000219,
2637,1,B,8,,,,12687,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL618693,BAO_0000357,
2638,1,B,8,,,,12687,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,,,,,H,Autocuration,CHEMBL872922,BAO_0000357,
2639,1,B,8,,,,12687,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,,,,,,H,Autocuration,CHEMBL618694,BAO_0000357,
2640,1,B,9,,,,12687,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL618695,BAO_0000357,
2641,1,B,8,,,,12687,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,,,,,,H,Autocuration,CHEMBL618696,BAO_0000357,
2642,1,B,8,,,,12687,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,,,,,,H,Expert,CHEMBL618697,BAO_0000357,
2643,1,B,8,,,,12687,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,,,,,,H,Autocuration,CHEMBL618892,BAO_0000357,
2644,1,B,8,,,,12687,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,,,,,,H,Autocuration,CHEMBL618893,BAO_0000357,
2645,1,B,8,,,,12687,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL618894,BAO_0000357,
2646,1,B,8,NIH3T3,,,12687,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,,,,723.0,,,H,Expert,CHEMBL618895,BAO_0000219,
2647,1,B,9,,,,12687,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL618896,BAO_0000357,
2648,1,B,8,,,,12687,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,5383.0,,,,,,H,Autocuration,CHEMBL618897,BAO_0000019,
2649,1,B,8,,,,12687,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,,,,,,H,Autocuration,CHEMBL618898,BAO_0000357,
2650,1,B,8,,,,12687,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,,,,,,H,Autocuration,CHEMBL618899,BAO_0000357,
2651,1,B,8,,,,12687,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,,,,,,H,Autocuration,CHEMBL618900,BAO_0000357,
2652,1,B,8,,,,12687,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,,,,,,H,Autocuration,CHEMBL618901,BAO_0000019,
2653,1,B,8,,,,12687,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL618902,BAO_0000357,
2654,1,B,9,,,,12687,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,10000000.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL618903,BAO_0000221,
2655,1,B,8,,,,12687,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL618904,BAO_0000357,
2656,1,B,8,,,,12687,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,,,,,,H,Autocuration,CHEMBL618905,BAO_0000357,
2657,1,B,8,,,,12687,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,,,,,,H,Autocuration,CHEMBL618906,BAO_0000357,
2658,1,B,8,NIH3T3,,,12687,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,,,,723.0,,,H,Expert,CHEMBL618907,BAO_0000219,
2659,1,B,8,,,,12687,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,,,,,,H,Autocuration,CHEMBL618908,BAO_0000019,
2660,1,B,8,,,,12687,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL617909,BAO_0000357,
2661,1,B,8,,,,12687,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,,,,,,H,Expert,CHEMBL617910,BAO_0000019,
2662,1,B,8,,,,12687,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,955.0,,,,,,H,Autocuration,CHEMBL617911,BAO_0000221,
2663,1,B,8,,,,12687,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,,,,H,Autocuration,CHEMBL872923,BAO_0000249,
2664,1,B,8,,,,12687,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,,,,H,Autocuration,CHEMBL617912,BAO_0000249,
2665,1,B,9,,,,12687,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617913,BAO_0000019,
2666,1,B,8,,,,12687,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,,,,H,Expert,CHEMBL617914,BAO_0000249,
2667,1,B,8,,,,12687,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,,,,H,Autocuration,CHEMBL617915,BAO_0000249,
2668,1,B,8,,,,12687,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,,,,H,Autocuration,CHEMBL617916,BAO_0000249,
2669,1,B,9,,,,12687,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617917,BAO_0000019,
2670,1,B,8,,,,12687,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,,,,,,H,Expert,CHEMBL617918,BAO_0000019,
2671,1,B,8,,,,12687,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,,,,,,H,Autocuration,CHEMBL617919,BAO_0000019,
2672,1,B,9,,,,12687,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617920,BAO_0000019,
2673,1,B,9,,,,12687,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617921,BAO_0000019,
2674,1,B,5,,,,105102,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617922,BAO_0000224,
2675,1,B,8,,,,12687,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,,,,,H,Autocuration,CHEMBL617923,BAO_0000357,
2676,1,B,8,,,,12687,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,,,,H,Autocuration,CHEMBL617924,BAO_0000357,
2677,1,B,8,,,,12687,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,,,,,,H,Autocuration,CHEMBL617925,BAO_0000357,
2678,1,B,9,,,,12687,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617926,BAO_0000357,
2679,1,B,8,,,,12687,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,,,,,,H,Autocuration,CHEMBL617927,BAO_0000357,
2680,1,B,8,,,,12687,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,,,,,,H,Autocuration,CHEMBL617928,BAO_0000357,
2681,1,B,9,,,,12687,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617929,BAO_0000019,
2682,1,B,8,,,,12687,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,,,,,,H,Expert,CHEMBL617930,BAO_0000019,
2683,1,B,8,,,,12687,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,,,,,,H,Autocuration,CHEMBL617931,BAO_0000019,
2684,1,B,8,,,,12687,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,,,,,,H,Autocuration,CHEMBL617932,BAO_0000019,
2685,1,B,8,CHO,,,12687,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,,,,449.0,,,H,Autocuration,CHEMBL617933,BAO_0000219,
2686,1,B,8,,,,12687,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,,,,,,H,Autocuration,CHEMBL617934,BAO_0000019,
2687,1,B,8,,,,12687,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,,,,,,H,Autocuration,CHEMBL617935,BAO_0000019,
2688,1,B,8,,,,12687,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,,,,,,H,Autocuration,CHEMBL617936,BAO_0000357,
2689,1,B,8,,,,12687,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,,,,,,H,Autocuration,CHEMBL617937,BAO_0000019,
2690,1,B,8,,,,12687,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,,,,,,H,Autocuration,CHEMBL617938,BAO_0000019,
2691,1,B,8,,,,12687,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,,,,,,H,Autocuration,CHEMBL617939,BAO_0000218,
2692,1,B,8,,,,12687,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,,,,,,H,Autocuration,CHEMBL617940,BAO_0000218,
2693,1,B,8,,,,12687,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,,,,,,H,Autocuration,CHEMBL617941,BAO_0000218,
2694,1,B,8,,,,12687,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,,,,,,H,Expert,CHEMBL617942,BAO_0000357,
2695,1,B,8,,,,12687,Ratio of pKi of 5-HT2A to that of D2 receptor,,,,,,,H,Expert,CHEMBL617943,BAO_0000357,
2696,1,B,4,,,,105093,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,,,,,,H,Expert,CHEMBL617944,BAO_0000224,
2697,1,B,4,,,,105093,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,,,,,,H,Expert,CHEMBL617945,BAO_0000224,
2698,1,B,4,,,,105075,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,,,,,,H,Expert,CHEMBL617946,BAO_0000224,
2699,1,B,8,,,,12687,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,,,,,,H,Autocuration,CHEMBL617947,BAO_0000357,
2700,1,B,8,,,,12687,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,,,,,,H,Expert,CHEMBL617948,BAO_0000357,
2701,1,F,8,,,,12687,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,,,,,,H,Autocuration,CHEMBL858116,BAO_0000019,
2702,1,F,8,,,,12687,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,,,,,,H,Autocuration,CHEMBL617949,BAO_0000019,
2703,1,F,8,,,,12687,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,,,,,,H,Autocuration,CHEMBL617950,BAO_0000019,
2704,1,F,8,,,,12687,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,1515.0,,,,,,H,Expert,CHEMBL617951,BAO_0000019,
2705,1,F,8,,,,12687,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,1515.0,,,,,,H,Expert,CHEMBL617952,BAO_0000019,
2706,1,F,8,,,,12687,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,1515.0,,,,,,H,Autocuration,CHEMBL617953,BAO_0000019,
2707,1,B,8,,,,12687,Binding activity radioligand.,,,,,,,H,Autocuration,CHEMBL617954,BAO_0000357,
2708,1,B,8,,,,12687,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,,,,,H,Expert,CHEMBL617955,BAO_0000019,
2709,1,B,8,,,,12687,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,,,,,,H,Autocuration,CHEMBL857071,BAO_0000019,
2710,1,B,8,,,,12687,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,,,,,,H,Expert,CHEMBL617270,BAO_0000019,
2711,1,B,8,N1E-115,,,12687,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,,,,339.0,,,H,Autocuration,CHEMBL617271,BAO_0000219,
2712,1,B,8,N1E-115,,,12687,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,,,,339.0,,,H,Autocuration,CHEMBL617272,BAO_0000219,
2713,1,B,8,,,,12687,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,,,,,,H,Autocuration,CHEMBL617273,BAO_0000019,
2714,1,F,9,,,,12687,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617274,BAO_0000019,
2715,1,B,8,,,,108,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,,,,,,H,Autocuration,CHEMBL617275,BAO_0000357,
2716,1,B,8,,,,108,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,,,,,H,Autocuration,CHEMBL617276,BAO_0000357,
2717,1,B,8,,,,108,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,,,,,,H,Autocuration,CHEMBL617277,BAO_0000357,
2718,1,B,8,,,,108,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,,,,,,H,Expert,CHEMBL617278,BAO_0000019,
2719,1,B,8,,,,108,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,,,,,,H,Expert,CHEMBL617279,BAO_0000019,
2720,1,B,8,,,,108,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,,,,,,H,Expert,CHEMBL617280,BAO_0000019,
2721,1,B,8,,,,108,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,,,,,,H,Autocuration,CHEMBL617281,BAO_0000357,
2722,1,B,8,,,,108,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,,,,,,H,Autocuration,CHEMBL617282,BAO_0000357,
2723,1,B,8,,,,108,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,,,,,,H,Expert,CHEMBL617283,BAO_0000019,
2724,1,B,8,,,,108,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,,,,,,H,Expert,CHEMBL617284,BAO_0000019,
2725,1,B,8,HEK293,,,108,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,,,,722.0,,,H,Autocuration,CHEMBL617285,BAO_0000219,
2726,1,B,8,,,,108,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,,,,,,H,Autocuration,CHEMBL617286,BAO_0000019,
2727,1,B,9,,,,108,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL617287,BAO_0000357,
2728,1,B,8,,,,108,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,,,,,,H,Expert,CHEMBL617288,BAO_0000357,
2729,1,B,8,,,,108,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,,,,,,H,Autocuration,CHEMBL617289,BAO_0000357,
2730,1,B,8,,,,108,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,,,,,H,Autocuration,CHEMBL872917,BAO_0000357,
2731,1,B,8,,,,108,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,,,,,,H,Autocuration,CHEMBL617290,BAO_0000357,
2732,1,B,8,CHO,,,108,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,,,449.0,,,H,Autocuration,CHEMBL617291,BAO_0000219,
2733,1,B,8,CHO,,,108,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,,,,449.0,,,H,Autocuration,CHEMBL617292,BAO_0000219,
2734,1,B,8,NIH3T3,,,108,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,,723.0,,,H,Autocuration,CHEMBL617293,BAO_0000219,
2735,1,F,9,CHO,,,108,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,Homo sapiens,,449.0,,9606.0,D,Expert,CHEMBL617294,BAO_0000219,
2736,1,B,8,,,,108,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,,,,,,H,Expert,CHEMBL617295,BAO_0000019,
2737,1,B,8,,,,108,Binding activity radioligand.,,,,,,,H,Autocuration,CHEMBL617296,BAO_0000357,
2738,1,B,8,,,,108,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,,,,,H,Autocuration,CHEMBL617297,BAO_0000019,
2739,1,B,8,CHO,,,108,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,,,,449.0,,,H,Expert,CHEMBL617298,BAO_0000219,
2740,1,B,8,CHO,,,108,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,,,,449.0,,,H,Expert,CHEMBL617299,BAO_0000219,
2741,1,B,8,CHO,,,108,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,,,,449.0,,,H,Autocuration,CHEMBL617300,BAO_0000219,
2742,1,B,8,,,,108,Binding affinity against 5-HT2C receptor,,,,,,,H,Autocuration,CHEMBL617454,BAO_0000357,
2743,1,B,8,HEK293,,,108,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,,,722.0,,,H,Autocuration,CHEMBL617505,BAO_0000219,
2744,1,B,9,HEK293,,,108,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,,Homo sapiens,,722.0,,9606.0,D,Expert,CHEMBL617506,BAO_0000219,
2745,1,B,9,HEK293,,,108,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,Homo sapiens,,722.0,,9606.0,D,Expert,CHEMBL617507,BAO_0000219,
2746,1,B,8,,,,108,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,,,,,,H,Expert,CHEMBL617508,BAO_0000357,
2747,1,B,9,HEK293,,,108,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,Homo sapiens,,722.0,,9606.0,D,Expert,CHEMBL857982,BAO_0000219,
2748,1,B,9,HEK293,,,108,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,,Homo sapiens,,722.0,,9606.0,D,Expert,CHEMBL617509,BAO_0000219,
2749,1,B,9,HEK293,,,108,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,,Homo sapiens,,722.0,,9606.0,D,Expert,CHEMBL617510,BAO_0000219,
2750,1,B,8,,,,108,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,,,,,,H,Autocuration,CHEMBL617511,BAO_0000357,
2751,1,B,8,HEK293,,,108,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,,,,722.0,,,H,Autocuration,CHEMBL617512,BAO_0000219,
2752,1,B,8,HEK293,,,108,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,,,,722.0,,,H,Autocuration,CHEMBL617749,BAO_0000219,
2753,1,B,8,HEK293,,,108,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,,722.0,,,H,Autocuration,CHEMBL617750,BAO_0000219,
2754,1,B,8,HEK293,,,108,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,,722.0,,,H,Autocuration,CHEMBL617751,BAO_0000219,
2755,1,B,8,HEK293,,,108,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,,,,722.0,,,H,Expert,CHEMBL617752,BAO_0000219,
2756,1,B,8,HEK293,,,108,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",,,,722.0,,,H,Autocuration,CHEMBL617753,BAO_0000219,
2757,1,B,8,HEK293,,,108,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",,,,722.0,,,H,Expert,CHEMBL617754,BAO_0000219,
2758,1,B,9,HEK293,,,108,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,,Homo sapiens,,722.0,,9606.0,D,Expert,CHEMBL617755,BAO_0000219,
2759,1,B,8,HEK293,,,108,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",,,,722.0,,,H,Autocuration,CHEMBL617756,BAO_0000219,
2760,1,B,8,HEK293,,,108,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,,,,722.0,,,H,Expert,CHEMBL617757,BAO_0000219,
2761,1,B,8,HEK293,,,108,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,,,,722.0,,,H,Expert,CHEMBL617758,BAO_0000219,
2762,1,B,8,NIH3T3,,,108,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,,,723.0,,,H,Autocuration,CHEMBL617759,BAO_0000219,
2763,1,B,8,HEK293,,,108,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,,,,722.0,,,H,Autocuration,CHEMBL617760,BAO_0000219,
2764,1,B,8,CHO-K1,,,108,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,,,,485.0,,,H,Expert,CHEMBL617761,BAO_0000219,
2765,1,B,9,,,,108,Binding affinity against 5-hydroxytryptamine 2C receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL617762,BAO_0000357,
2766,1,B,8,,,,108,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,,,,,,H,Autocuration,CHEMBL617763,BAO_0000357,
2767,1,B,8,HEK293,,,108,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,,,,722.0,,,H,Autocuration,CHEMBL857983,BAO_0000219,
2768,1,B,8,HEK293,,,108,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,,,,722.0,,,H,Autocuration,CHEMBL617764,BAO_0000219,
2769,1,B,8,HeLa,,,108,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,,,,308.0,,,H,Autocuration,CHEMBL617765,BAO_0000219,
2770,1,F,8,,,,108,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,,,,,,H,Autocuration,CHEMBL617766,BAO_0000019,
2771,1,F,8,,,,108,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,10000000.0,,,,,,H,Autocuration,CHEMBL617767,BAO_0000221,
2772,1,B,8,HEK293,,,108,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,,,,722.0,,,H,Autocuration,CHEMBL617768,BAO_0000219,
2773,1,B,8,HEK293,,,108,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",,,,722.0,,,H,Autocuration,CHEMBL617769,BAO_0000219,
2774,1,B,8,,,,11864,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,,,,,,H,Autocuration,CHEMBL858023,BAO_0000357,
2775,1,B,8,,,,11864,Binding affinity analysed on 5-HT 2C in rat stomach fundus,945.0,,,,,,H,Autocuration,CHEMBL617770,BAO_0000019,
2776,1,B,8,,,,11864,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,945.0,,,,,,H,Autocuration,CHEMBL617771,BAO_0000019,
2777,1,F,8,A9,,,11864,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,,,,625.0,,,H,Autocuration,CHEMBL617772,BAO_0000219,
2778,1,B,8,NIH3T3,,,11864,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,,,723.0,,,H,Autocuration,CHEMBL617773,BAO_0000219,
2779,1,B,8,NIH3T3,,,11864,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,,,,723.0,,,H,Autocuration,CHEMBL617850,BAO_0000219,
2780,1,B,8,NIH3T3,,,11864,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,,,723.0,,,H,Autocuration,CHEMBL617851,BAO_0000219,
2781,1,F,8,,,,11864,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,,,,,,H,Autocuration,CHEMBL617852,BAO_0000019,
2782,1,B,8,,,,12689,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,945.0,Mus musculus,,,,10090.0,H,Autocuration,CHEMBL858024,BAO_0000019,
2783,1,B,9,,,,12689,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,945.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617853,BAO_0000019,
2784,1,B,8,,,,108,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,,,,,,H,Expert,CHEMBL617854,BAO_0000357,
2785,1,B,8,,,,108,Binding affinity for 5-hydroxytryptamine 2C receptor,,Sus scrofa,,,,9823.0,H,Expert,CHEMBL873477,BAO_0000357,
2786,1,B,8,,,,108,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,,,,,H,Expert,CHEMBL617855,BAO_0000357,
2787,1,B,8,,,,108,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,,,,,,H,Expert,CHEMBL617856,BAO_0000019,
2788,1,B,8,,,,108,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,,,,,,H,Autocuration,CHEMBL617857,BAO_0000019,
2789,1,B,8,,,,108,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,,,,,,H,Autocuration,CHEMBL617858,BAO_0000249,
2790,1,B,8,,,,108,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,,,,,,H,Autocuration,CHEMBL617859,BAO_0000357,
2791,1,B,8,,,,108,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,,,,,,H,Autocuration,CHEMBL617860,BAO_0000357,
2792,1,B,8,,,,108,Binding activity radioligand.,,,,,,,H,Autocuration,CHEMBL617861,BAO_0000357,
2793,1,B,8,,,,108,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,,,,,H,Expert,CHEMBL617862,BAO_0000019,
2794,1,B,8,,,,108,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,,,,,,H,Autocuration,CHEMBL617863,BAO_0000019,
2795,1,B,8,,,,108,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,,,,,,H,Autocuration,CHEMBL617864,BAO_0000249,
2796,1,B,8,,,,108,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,,,,,,H,Autocuration,CHEMBL617649,BAO_0000249,
2797,1,F,8,,,,108,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,Sus scrofa,,,,9823.0,H,Expert,CHEMBL617650,BAO_0000019,
2798,1,F,8,,,,108,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,Sus scrofa,,,,9823.0,H,Expert,CHEMBL617651,BAO_0000019,
2799,1,B,8,,,,108,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL617652,BAO_0000357,
2800,1,B,8,,,,108,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL857072,BAO_0000019,
2801,1,B,8,,,,108,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL617653,BAO_0000357,
2802,1,B,8,,,,12687,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,,,,,H,Autocuration,CHEMBL617654,BAO_0000019,
2803,1,F,8,,,,12689,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,,,,,,H,Autocuration,CHEMBL617655,BAO_0000019,
2804,1,B,8,,,,12689,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,,,,,,H,Expert,CHEMBL617656,BAO_0000357,
2805,1,B,8,,,,12689,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,,,,,,H,Autocuration,CHEMBL617657,BAO_0000357,
2806,1,B,8,,,,12689,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,,,,,,H,Autocuration,CHEMBL617658,BAO_0000357,
2807,1,B,9,,,,12689,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617659,BAO_0000357,
2808,1,B,9,,,,12689,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617838,BAO_0000357,
2809,1,B,9,,,,12689,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617839,BAO_0000249,
2810,1,B,8,,,,12689,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,,,,,,H,Autocuration,CHEMBL617840,BAO_0000357,
2811,1,B,8,,,,12689,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,,,,,,H,Autocuration,CHEMBL617841,BAO_0000019,
2812,1,B,8,,,,12689,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,,,,,,H,Autocuration,CHEMBL875915,BAO_0000019,
2813,1,B,8,,,In vitro,12689,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,,,,,,,H,Expert,CHEMBL617842,BAO_0000219,
2814,1,B,8,NIH3T3,,,12689,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,,,,723.0,,,H,Expert,CHEMBL617843,BAO_0000219,
2815,1,B,8,,,,12689,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,,,,,,H,Expert,CHEMBL617844,BAO_0000357,
2816,1,B,8,,,,12689,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,,,,,,H,Expert,CHEMBL617845,BAO_0000357,
2817,1,B,8,NIH3T3,,,12689,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,,,,723.0,,,H,Expert,CHEMBL617846,BAO_0000219,
2818,1,B,8,,,,12689,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,,,,,,H,Autocuration,CHEMBL617847,BAO_0000357,
2819,1,B,8,,,,12689,Binding affinity against 5-hydroxytryptamine 2C receptor,,,,,,,H,Expert,CHEMBL617848,BAO_0000357,
2820,1,B,8,,,,12689,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,,,,,H,Autocuration,CHEMBL617849,BAO_0000357,
2821,1,B,8,,,,12689,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,,,,,H,Expert,CHEMBL621507,BAO_0000357,
2822,1,B,8,,,,12689,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,,,,,,H,Expert,CHEMBL621508,BAO_0000357,
2823,1,B,8,,,,12689,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,,,,,,H,Autocuration,CHEMBL621509,BAO_0000019,
2824,1,B,8,,,,12689,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,,,,,,H,Autocuration,CHEMBL621510,BAO_0000019,
2825,1,B,8,,,,12689,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,,,,,,H,Autocuration,CHEMBL621511,BAO_0000019,
2826,1,B,8,A9,,,12689,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,,,,625.0,,,H,Expert,CHEMBL621512,BAO_0000219,
2827,1,B,8,,,,12689,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,,,,,H,Autocuration,CHEMBL621513,BAO_0000357,
2828,1,B,8,,,,12689,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,,,,,,H,Expert,CHEMBL621514,BAO_0000357,
2829,1,B,8,,,In vitro,12689,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,,,,,,,H,Expert,CHEMBL621515,BAO_0000219,
2830,1,B,8,,,,12689,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,,,,,,H,Autocuration,CHEMBL621516,BAO_0000219,
2831,1,B,8,,,,12689,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,5383.0,,,,,,H,Autocuration,CHEMBL621517,BAO_0000019,
2832,1,B,8,,,,12689,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,,,,,,H,Autocuration,CHEMBL621518,BAO_0000357,
2833,1,B,8,,,,12689,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,,,,,,H,Autocuration,CHEMBL621519,BAO_0000019,
2834,1,B,8,,,,12689,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,,,,,,H,Autocuration,CHEMBL621520,BAO_0000357,
2835,1,B,8,,,,12689,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,,,,,,H,Autocuration,CHEMBL621521,BAO_0000357,
2836,1,B,8,,,,12689,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,,,,,,H,Autocuration,CHEMBL621522,BAO_0000357,
2837,1,B,8,,,,12689,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,,,,,,H,Expert,CHEMBL621523,BAO_0000219,
2838,1,B,8,,,,12689,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,,,,,,H,Autocuration,CHEMBL621524,BAO_0000357,
2839,1,B,9,,,,12689,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL621525,BAO_0000357,
2840,1,B,8,,,,12689,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,,,,,,H,Autocuration,CHEMBL872921,BAO_0000357,
2841,1,B,8,,,,12689,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,,,,,,H,Autocuration,CHEMBL621526,BAO_0000357,
2842,1,B,8,,,,12689,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,,,,,,H,Expert,CHEMBL621527,BAO_0000219,
2843,1,B,9,,,,12689,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617865,BAO_0000019,
2844,1,B,8,,,,12689,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,,,,,,H,Autocuration,CHEMBL617866,BAO_0000357,
2845,1,B,8,,,,12689,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,,,,,,H,Autocuration,CHEMBL617867,BAO_0000019,
2846,1,B,8,,,,12689,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,,,,,,H,Autocuration,CHEMBL617487,BAO_0000357,
2847,1,B,8,,,,12689,Binding affinity for 5-hydroxytryptamine 2C receptor,,,,,,,H,Expert,CHEMBL617488,BAO_0000357,
2848,1,B,8,,,,12689,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,,,,,,H,Autocuration,CHEMBL617489,BAO_0000357,
2849,1,B,8,,,,12689,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,,,,,,H,Autocuration,CHEMBL617490,BAO_0000019,
2850,1,B,8,,,,12689,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,,,,,,H,Autocuration,CHEMBL617491,BAO_0000019,
2851,1,B,8,,,,12689,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,,,,,,H,Autocuration,CHEMBL617492,BAO_0000019,
2852,1,B,8,,,,12689,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,,,,,,H,Autocuration,CHEMBL617493,BAO_0000019,
2853,1,B,8,,,,12689,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,,,,,,H,Autocuration,CHEMBL617494,BAO_0000357,
2854,1,B,9,,,,12689,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617495,BAO_0000019,
2855,1,B,8,,,,12689,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,,,,,,H,Autocuration,CHEMBL617496,BAO_0000357,
2856,1,B,8,CHO-K1,,,12689,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,,,,485.0,,,H,Autocuration,CHEMBL617497,BAO_0000219,
2857,1,B,8,,,,12689,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,,,,,H,Autocuration,CHEMBL617498,BAO_0000357,
2858,1,B,8,,,,12689,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,,,,,,H,Autocuration,CHEMBL617499,BAO_0000357,
2859,1,F,8,,,,12689,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,,,,,,H,Autocuration,CHEMBL617500,BAO_0000019,
2860,1,B,8,,,,108,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,,,,,,H,Autocuration,CHEMBL617501,BAO_0000357,
2861,1,B,8,,,,108,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,,,,,H,Expert,CHEMBL617502,BAO_0000357,
2862,1,B,8,,,,227,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,,,,,,H,Autocuration,CHEMBL617503,BAO_0000357,
2863,1,B,8,,,,227,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,,,,,,H,Autocuration,CHEMBL617504,BAO_0000357,
2864,1,B,8,,,,227,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,,,,,,H,Autocuration,CHEMBL617406,BAO_0000357,
2865,1,B,9,,,,227,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL617407,BAO_0000019,
2866,1,B,8,,,,227,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,,,,,,H,Autocuration,CHEMBL617408,BAO_0000357,
2867,1,B,8,,,,227,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,,,,,,H,Autocuration,CHEMBL617409,BAO_0000357,
2868,1,B,8,,,,227,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,,,,,,H,Autocuration,CHEMBL617410,BAO_0000357,
2869,1,B,8,,,,227,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,,,,,,H,Autocuration,CHEMBL617411,BAO_0000357,
2870,1,B,8,,,,227,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,,,,,,H,Autocuration,CHEMBL617412,BAO_0000019,
2871,1,B,9,,,,227,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL617774,BAO_0000357,
2872,1,B,9,HEK293,,,227,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,Homo sapiens,,722.0,,9606.0,D,Expert,CHEMBL617775,BAO_0000219,
2873,1,B,9,HEK293,,,227,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,Homo sapiens,,722.0,,9606.0,D,Expert,CHEMBL617776,BAO_0000219,
2874,1,F,9,CHO,,,227,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,Homo sapiens,,449.0,,9606.0,D,Expert,CHEMBL617777,BAO_0000219,
2875,1,F,9,CHO,,,227,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,Homo sapiens,,449.0,,9606.0,D,Expert,CHEMBL617778,BAO_0000219,
2876,1,B,8,HEK293,,,227,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,,,722.0,,,H,Autocuration,CHEMBL617779,BAO_0000219,
2877,1,B,8,HEK293,,,227,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,,,,722.0,,,H,Expert,CHEMBL617780,BAO_0000219,
2878,1,B,8,HEK293,,,227,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",,,,722.0,,,H,Autocuration,CHEMBL617781,BAO_0000219,
2879,1,B,9,HEK293,,,227,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,,Homo sapiens,,722.0,,9606.0,D,Expert,CHEMBL617782,BAO_0000219,
2880,1,B,9,HEK293,,,227,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,,Homo sapiens,,722.0,,9606.0,D,Expert,CHEMBL617783,BAO_0000219,
2881,1,B,8,,,,227,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,,,,,,H,Autocuration,CHEMBL617784,BAO_0000357,
2882,1,B,8,HEK293,,,227,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,,,,722.0,,,H,Autocuration,CHEMBL617785,BAO_0000219,
2883,1,B,8,HEK293,,,227,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,,,,722.0,,,H,Expert,CHEMBL857984,BAO_0000219,
2884,1,B,8,HEK293,,,227,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,,,,722.0,,,H,Expert,CHEMBL617786,BAO_0000219,
2885,1,B,8,HEK293,,,227,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,,,,722.0,,,H,Expert,CHEMBL617787,BAO_0000219,
2886,1,B,9,HEK293,,,227,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,,Homo sapiens,,722.0,,9606.0,D,Expert,CHEMBL617788,BAO_0000219,
2887,1,B,9,HEK293,,,227,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,,Homo sapiens,,722.0,,9606.0,D,Expert,CHEMBL617789,BAO_0000219,
2888,1,B,8,HEK293,,,227,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,,,,722.0,,,H,Autocuration,CHEMBL617790,BAO_0000219,
2889,1,B,8,CHO-K1,,,227,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,,,,485.0,,,H,Expert,CHEMBL617791,BAO_0000219,
2890,1,B,8,,,,227,Binding affinity against 5-hydroxytryptamine 2B receptor,,,,,,,H,Expert,CHEMBL617608,BAO_0000357,
2891,1,B,8,HEK293,,,227,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,,,,722.0,,,H,Autocuration,CHEMBL617609,BAO_0000219,
2892,1,B,8,HEK293,,,227,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,,,,722.0,,,H,Autocuration,CHEMBL617610,BAO_0000219,
2893,1,B,8,HEK293,,,227,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,,,,722.0,,,H,Autocuration,CHEMBL617611,BAO_0000219,
2894,1,B,8,HEK293,,,227,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,,,722.0,,,H,Autocuration,CHEMBL617612,BAO_0000219,
2895,1,B,8,HEK293,,,227,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,,,722.0,,,H,Autocuration,CHEMBL617613,BAO_0000219,
2896,1,B,8,,,,227,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,,Oryctolagus cuniculus,,,,9986.0,H,Autocuration,CHEMBL617614,BAO_0000019,
2897,1,B,8,,,,12688,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,945.0,,,,,,H,Expert,CHEMBL617615,BAO_0000019,
2898,1,B,8,,,,12688,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,945.0,,,,,,H,Expert,CHEMBL858114,BAO_0000357,
2899,1,B,8,,,,12688,Affinity against serotonergic receptor in the isolated rat stomach fundus,945.0,,,,,,H,Autocuration,CHEMBL617616,BAO_0000357,
2900,1,F,9,,,,12688,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,945.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617617,BAO_0000019,
2901,1,F,9,,,,12688,Antagonistic against 5-hydroxytryptamine 2B receptor,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL875914,BAO_0000019,
2902,1,F,8,,,,12688,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,945.0,,,,,,H,Autocuration,CHEMBL617618,BAO_0000019,
2903,1,B,9,,,,12688,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,945.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617619,BAO_0000357,
2904,1,F,8,,,,12688,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,,,,,,H,Autocuration,CHEMBL617620,BAO_0000019,
2905,1,F,8,,,,12688,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,,,,,,H,Autocuration,CHEMBL617621,BAO_0000019,
2906,1,F,8,,,,12688,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,,,,,,H,Autocuration,CHEMBL617622,BAO_0000019,
2907,1,B,9,,,,12688,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,945.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617623,BAO_0000357,
2908,1,B,9,,,,12688,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,945.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617624,BAO_0000357,
2909,1,B,9,,,,12688,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,945.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617625,BAO_0000357,
2910,1,B,9,,,,12688,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,945.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617626,BAO_0000357,
2911,1,F,8,,,,12688,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,945.0,,,,,,H,Autocuration,CHEMBL617627,BAO_0000019,
2912,1,F,8,,,,12688,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,945.0,,,,,,H,Expert,CHEMBL617628,BAO_0000019,
2913,1,F,8,,,,12688,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,945.0,,,,,,H,Autocuration,CHEMBL617629,BAO_0000019,
2914,1,F,8,,,,12688,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,945.0,,,,,,H,Autocuration,CHEMBL858115,BAO_0000019,
2915,1,F,9,,,,12688,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,945.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL617630,BAO_0000019,
2916,1,F,8,,,,12688,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,1515.0,,,,,,H,Autocuration,CHEMBL617631,BAO_0000019,
2917,1,B,8,,,,12688,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,,,,,,H,Autocuration,CHEMBL617632,BAO_0000357,
2918,1,B,8,,,,12688,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,,,,,,H,Expert,CHEMBL617633,BAO_0000357,
2919,1,B,8,,,,12688,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,,,,,,H,Autocuration,CHEMBL617634,BAO_0000357,
2920,1,B,8,,,,12688,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,,,,,,H,Autocuration,CHEMBL617635,BAO_0000357,
2922,1,F,9,,,,12688,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,945.0,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617637,BAO_0000019,
2923,1,B,8,,,,227,Binding affinity against 5-hydroxytryptamine 1A receptor,,,,,,,H,Autocuration,CHEMBL617638,BAO_0000357,
2924,1,B,8,,,,227,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,,,,,,H,Autocuration,CHEMBL617639,BAO_0000357,
2925,1,B,8,,,,227,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,,,,,,H,Autocuration,CHEMBL617640,BAO_0000357,
2926,1,B,8,,,,227,Evaluated for the binding affinity to 5-HT 2B receptor,,,,,,,H,Autocuration,CHEMBL617641,BAO_0000357,
2927,1,B,8,,,,227,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,,,,,,H,Autocuration,CHEMBL617642,BAO_0000357,
2928,1,B,8,,,,227,Binding affinities against 5-hydroxytryptamine 2B receptor,,,,,,,H,Autocuration,CHEMBL617643,BAO_0000357,
2929,1,B,8,,,,227,Binding affinities towards 5-hydroxytryptamine 2B receptor,,,,,,,H,Autocuration,CHEMBL617644,BAO_0000357,
2930,1,B,8,,,,227,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,,,,,,H,Autocuration,CHEMBL617645,BAO_0000357,
2931,1,B,8,,,,108,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,,,,,,H,Expert,CHEMBL617646,BAO_0000357,
2932,1,B,8,,,,108,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,Bos taurus,,,,9913.0,H,Autocuration,CHEMBL617647,BAO_0000357,
2933,1,B,8,,,,108,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,,Bos taurus,,,,9913.0,H,Autocuration,CHEMBL617648,BAO_0000357,
2934,1,B,8,,,,108,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,,Bos taurus,,,,9913.0,H,Autocuration,CHEMBL617875,BAO_0000357,
2935,1,B,8,,,,108,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,,Bos taurus,,,,9913.0,H,Autocuration,CHEMBL617876,BAO_0000357,
2936,1,B,8,,,,108,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,,Bos taurus,,,,9913.0,H,Expert,CHEMBL617877,BAO_0000357,
2937,1,B,8,,,,108,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,Bos taurus,,,,9913.0,H,Expert,CHEMBL617878,BAO_0000357,
2938,1,B,8,,,,108,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,Bos taurus,,,,9913.0,H,Autocuration,CHEMBL617879,BAO_0000357,
2939,1,B,8,,,,108,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL617880,BAO_0000019,
2940,1,B,9,,,,20033,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,2435.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL617881,BAO_0000357,
2941,1,B,8,,,,51,Binding affinity against 5-HT1A receptor,,,,,,,H,Autocuration,CHEMBL857073,BAO_0000357,
2942,1,F,8,CHO,,,108,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,,,,449.0,,,H,Expert,CHEMBL617882,BAO_0000219,
2943,1,F,9,CHO,,,108,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,,Homo sapiens,,449.0,,9606.0,D,Expert,CHEMBL617883,BAO_0000219,
2944,1,F,8,,,,108,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,,,,,,H,Autocuration,CHEMBL617884,BAO_0000219,
2945,1,B,8,CHO,,,108,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,,,,449.0,,,H,Autocuration,CHEMBL617885,BAO_0000219,
2946,1,B,8,CHO,,,108,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",,,,449.0,,,H,Autocuration,CHEMBL617886,BAO_0000219,
2947,1,B,9,,,,108,Inhibition of human 5-hydroxytryptamine 2C receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL617887,BAO_0000357,
2948,1,B,8,,,,108,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,,,,,,H,Autocuration,CHEMBL617888,BAO_0000357,
2949,1,B,8,,,,108,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,,,,,,H,Autocuration,CHEMBL617889,BAO_0000019,
2950,1,B,8,,,,108,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,,,,,,H,Autocuration,CHEMBL617890,BAO_0000357,
2951,1,B,8,,,,108,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,,,,,,H,Autocuration,CHEMBL617891,BAO_0000357,
2952,1,B,8,,,,108,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,,,,,,H,Autocuration,CHEMBL617892,BAO_0000357,
2953,1,B,8,CHO,,,108,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,,,,449.0,,,H,Expert,CHEMBL617893,BAO_0000219,
2954,1,B,8,CHO,,,108,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,,,,449.0,,,H,Expert,CHEMBL617894,BAO_0000219,
2955,1,B,8,CHO,,,108,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,,,449.0,,,H,Expert,CHEMBL617895,BAO_0000219,
2956,1,B,8,CHO,,,108,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,,,,449.0,,,H,Autocuration,CHEMBL617896,BAO_0000219,
2957,1,B,9,,,,108,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL617897,BAO_0000357,
2958,1,F,8,,,,108,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,,,,,,H,Autocuration,CHEMBL617898,BAO_0000019,
2959,1,F,8,,,,108,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,,,,,H,Autocuration,CHEMBL617899,BAO_0000019,
2960,1,B,8,CHO,,,108,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,,Rattus norvegicus,,449.0,,10116.0,H,Expert,CHEMBL617900,BAO_0000219,
2961,1,F,8,,,,108,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,,,,,,H,Autocuration,CHEMBL617901,BAO_0000019,
2962,1,F,8,,,,108,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,,,,,,H,Autocuration,CHEMBL617902,BAO_0000019,
2963,1,F,8,,,,108,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,,,,,H,Autocuration,CHEMBL617903,BAO_0000019,
2964,1,B,8,,,,108,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,,,,,,H,Autocuration,CHEMBL617904,BAO_0000357,
2965,1,B,8,,,,108,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,,,,,,H,Autocuration,CHEMBL617905,BAO_0000357,
2966,1,B,8,,,,108,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,,,,,,H,Autocuration,CHEMBL617906,BAO_0000357,
2967,1,B,8,,,,108,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,,,,,,H,Autocuration,CHEMBL617907,BAO_0000357,
2968,1,B,8,,,,108,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,,,,,,H,Autocuration,CHEMBL617908,BAO_0000357,
2969,1,B,8,CHO,,,108,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,,,449.0,,,H,Expert,CHEMBL620617,BAO_0000219,
2970,1,B,9,,,,108,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL620618,BAO_0000019,
2971,1,B,8,,,,108,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,,,,,,H,Expert,CHEMBL620619,BAO_0000357,
2972,1,B,9,,,,108,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL620620,BAO_0000357,
2973,1,B,8,,,,108,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,,,,,,H,Autocuration,CHEMBL620621,BAO_0000357,
2974,1,B,7,,,,104698,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL872920,BAO_0000249,
2975,1,B,6,,,,104698,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,,,,,,H,Autocuration,CHEMBL620622,BAO_0000223,
2976,1,B,7,,,,104698,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL620623,BAO_0000019,
2977,1,B,6,,,,104698,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,,,,,,H,Autocuration,CHEMBL620624,BAO_0000019,
2978,1,B,6,,,,104698,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,,,,,,H,Autocuration,CHEMBL620625,BAO_0000019,
2979,1,B,6,,,,104698,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,,,,,,H,Autocuration,CHEMBL620626,BAO_0000219,
2980,1,B,6,,,,104698,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,,,,,,H,Autocuration,CHEMBL621307,BAO_0000019,
2981,1,B,6,,,,104698,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,,,,,,H,Autocuration,CHEMBL621308,BAO_0000019,
2982,1,B,6,,,,104698,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,,,,,,H,Autocuration,CHEMBL621309,BAO_0000223,
2983,1,B,6,,,,104698,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,,,,,,H,Autocuration,CHEMBL621310,BAO_0000223,
2984,1,B,6,,,,104698,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,,,,,,H,Autocuration,CHEMBL621311,BAO_0000223,
2985,1,B,6,,,,104698,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,,,,,,H,Autocuration,CHEMBL621502,BAO_0000249,
2986,1,B,6,,,,104698,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,,,,,,H,Autocuration,CHEMBL621503,BAO_0000249,
2987,1,B,6,,,,104698,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,,,,,,,H,Autocuration,CHEMBL621504,BAO_0000249,
2988,1,B,6,,,,104698,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,,,,,,H,Autocuration,CHEMBL621505,BAO_0000223,
2989,1,B,6,,,,104698,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,,,,,,H,Autocuration,CHEMBL621506,BAO_0000019,
2990,1,B,6,,,,104698,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,,,,,,H,Autocuration,CHEMBL619781,BAO_0000223,
2991,1,B,6,,,,104698,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,,,,,,H,Autocuration,CHEMBL619782,BAO_0000223,
2992,1,B,6,,,,104698,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,,,,,,H,Autocuration,CHEMBL619783,BAO_0000019,
2993,1,B,7,,,,104698,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL619784,BAO_0000019,
2994,1,B,6,,,,104698,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,,,,,H,Autocuration,CHEMBL619785,BAO_0000249,
2995,1,B,6,,,,104698,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,,,,,,H,Autocuration,CHEMBL619786,BAO_0000223,
2996,1,B,6,,,,104698,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,,,,,,H,Autocuration,CHEMBL619787,BAO_0000019,
2997,1,B,6,,,,104698,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,,,,,,H,Autocuration,CHEMBL872925,BAO_0000019,
2998,1,B,6,,,,104698,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,,,,,,H,Autocuration,CHEMBL619788,BAO_0000019,
2999,1,B,6,,,,104698,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,,,,,,H,Autocuration,CHEMBL619789,BAO_0000249,
3000,1,B,6,,,,104698,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,,,,,,H,Autocuration,CHEMBL619790,BAO_0000249,
3001,1,B,6,,,,104698,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,,,,,,H,Autocuration,CHEMBL619791,BAO_0000019,
3002,1,B,6,,,,104698,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,,,,,,H,Autocuration,CHEMBL619792,BAO_0000019,
3003,1,B,6,,,,104698,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,,,,,,,H,Autocuration,CHEMBL619793,BAO_0000249,
3004,1,B,7,,,,104698,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL619794,BAO_0000223,
3005,1,B,6,,,,104698,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,955.0,,,,,,H,Autocuration,CHEMBL619795,BAO_0000221,
3006,1,B,6,,,,104698,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,,,,,,H,Autocuration,CHEMBL619796,BAO_0000019,
3007,1,B,6,,,,104698,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,,,,,,H,Autocuration,CHEMBL620448,BAO_0000223,
3008,1,B,6,,,,104698,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,,,,,,H,Autocuration,CHEMBL620449,BAO_0000223,
3009,1,B,6,,,,104698,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,,,,,,H,Autocuration,CHEMBL620450,BAO_0000223,
3010,1,B,6,,,,104698,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,,,,,,H,Autocuration,CHEMBL620451,BAO_0000223,
3011,1,B,6,,,,104698,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,,,,,,H,Autocuration,CHEMBL620631,BAO_0000223,
3012,1,B,6,,,,104698,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,,,,,,H,Autocuration,CHEMBL620632,BAO_0000019,
3013,1,B,6,,,,104698,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,,,,,,H,Autocuration,CHEMBL620633,BAO_0000019,
3014,1,B,6,,,,104698,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,,,,,,H,Autocuration,CHEMBL620634,BAO_0000223,
3015,1,B,6,,,,104698,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,,,,,,H,Autocuration,CHEMBL620635,BAO_0000019,
3016,1,F,6,,,In vivo,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL620636,BAO_0000218,
3017,1,F,6,,,In vivo,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL620637,BAO_0000218,
3018,1,F,6,,,In vivo,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL620638,BAO_0000218,
3019,1,F,6,,,In vivo,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL620639,BAO_0000218,
3020,1,F,6,,,In vivo,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL620640,BAO_0000218,
3021,1,F,6,,,In vivo,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL620641,BAO_0000218,
3022,1,F,6,,,In vivo,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL620642,BAO_0000218,
3023,1,F,6,,,In vivo,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL620643,BAO_0000218,
3024,1,F,6,,,In vivo,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL620644,BAO_0000218,
3025,1,F,6,,,In vivo,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL620645,BAO_0000218,
3026,1,F,6,,,In vivo,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL620646,BAO_0000218,
3027,1,F,6,,,In vivo,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL620647,BAO_0000218,
3028,1,F,6,,,In vivo,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL620648,BAO_0000218,
3029,1,F,6,,,In vivo,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL620649,BAO_0000218,
3030,1,F,6,,,In vivo,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL620650,BAO_0000218,
3031,1,F,6,,,In vivo,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL620651,BAO_0000218,
3032,1,F,6,,,In vivo,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL872875,BAO_0000218,
3033,1,F,6,,,In vivo,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL620652,BAO_0000218,
3034,1,F,6,,,,104698,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,,,,,,H,Autocuration,CHEMBL620653,BAO_0000019,
3035,1,B,6,,,,104698,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,,,,,,H,Autocuration,CHEMBL857076,BAO_0000019,
3036,1,B,7,,,,104698,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL620654,BAO_0000019,
3037,1,B,6,,,,104698,Binding activity radioligand.,,,,,,,H,Autocuration,CHEMBL620655,BAO_0000223,
3038,1,B,6,,,,104698,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,,,,,,,H,Autocuration,CHEMBL620656,BAO_0000249,
3039,1,B,6,,,,104698,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,,,,,,,H,Autocuration,CHEMBL620657,BAO_0000249,
3040,1,B,8,,,,108,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,,,,,,H,Autocuration,CHEMBL620658,BAO_0000357,
3041,1,B,8,,,,108,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,,,,,,H,Autocuration,CHEMBL620659,BAO_0000357,
3042,1,B,8,,,,108,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,,,,,,H,Autocuration,CHEMBL620660,BAO_0000357,
3043,1,B,8,,,,108,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,,,,,,H,Autocuration,CHEMBL620661,BAO_0000357,
3044,1,B,8,,,,108,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,,,,,,H,Autocuration,CHEMBL620662,BAO_0000357,
3045,1,B,8,,,,108,Affinity for 5-hydroxytryptamine 2C receptor,,,,,,,H,Expert,CHEMBL620663,BAO_0000357,
3046,1,B,8,,,,108,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,,,,,H,Autocuration,CHEMBL620664,BAO_0000357,
3047,1,B,8,,,,108,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,,,,,,H,Expert,CHEMBL620665,BAO_0000357,
3048,1,B,8,,,,108,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,,,,,,H,Autocuration,CHEMBL620666,BAO_0000357,
3049,1,B,8,,,,108,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,,,,,,H,Autocuration,CHEMBL620667,BAO_0000357,
3050,1,B,8,,,,108,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,,,,,,H,Expert,CHEMBL620668,BAO_0000357,
3051,1,B,8,,,,108,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,,,,,,H,Autocuration,CHEMBL620669,BAO_0000357,
3052,1,B,8,,,,108,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,,,,,,H,Expert,CHEMBL620670,BAO_0000357,
3053,1,B,8,,,,108,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,,,,,,H,Autocuration,CHEMBL620671,BAO_0000357,
3054,1,B,8,,,,108,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,,,,,,H,Autocuration,CHEMBL620672,BAO_0000357,
3055,1,B,8,,,,108,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,,,,,,H,Autocuration,CHEMBL620673,BAO_0000357,
3056,1,B,8,,,,108,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,,,,,,H,Autocuration,CHEMBL620674,BAO_0000357,
3057,1,B,8,,,,108,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,,,,,,H,Autocuration,CHEMBL620675,BAO_0000357,
3058,1,B,8,,,,108,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,,,,,,H,Autocuration,CHEMBL620676,BAO_0000357,
3059,1,B,8,,,,108,Affinity against 5-hydroxytryptamine 2C receptor,,,,,,,H,Autocuration,CHEMBL621382,BAO_0000357,
3060,1,B,9,,,,108,Binding affinity against 5-hydroxytryptamine 2C receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL621383,BAO_0000357,
3061,1,B,8,,,,108,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,,,,,,H,Autocuration,CHEMBL621384,BAO_0000357,
3062,1,B,8,,,,144,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,,Bos taurus,,,,9913.0,H,Autocuration,CHEMBL621385,BAO_0000357,
3063,1,B,8,,,,144,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,,Bos taurus,,,,9913.0,H,Autocuration,CHEMBL617989,BAO_0000357,
3064,1,F,4,,,,104714,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,,Cavia porcellus,,,,10141.0,H,Expert,CHEMBL617990,BAO_0000019,
3065,1,B,4,,,,104714,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,2116.0,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL875085,BAO_0000221,
3066,1,F,4,,,,104714,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL617991,BAO_0000019,
3067,1,F,4,,,,104714,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL617992,BAO_0000019,
3068,1,B,4,,,,104714,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,2116.0,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL617993,BAO_0000221,
3069,1,B,4,,,,104714,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,2116.0,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL617994,BAO_0000221,
3070,1,F,4,,,,104714,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL617995,BAO_0000019,
3071,1,F,4,,,,104714,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL617996,BAO_0000019,
3072,1,F,4,,,,104714,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL617997,BAO_0000019,
3073,1,F,4,,,,104714,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL617998,BAO_0000019,
3074,1,F,4,,,,104714,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL617999,BAO_0000019,
3075,1,F,4,,,,104714,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL618000,BAO_0000019,
3076,1,F,4,,,,104714,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",2116.0,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL617815,BAO_0000221,
3077,1,F,4,,,,104714,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",2116.0,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL617816,BAO_0000221,
3078,1,F,4,,,,104714,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,2116.0,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL617817,BAO_0000221,
3079,1,B,4,,,,104714,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,2116.0,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL617818,BAO_0000221,
3080,1,B,4,,,,104714,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,2116.0,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL617819,BAO_0000221,
3081,1,B,4,,,,104714,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL617820,BAO_0000223,
3082,1,B,4,,,,104714,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,2116.0,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL617821,BAO_0000221,
3083,1,F,4,,,,104714,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),2116.0,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL617822,BAO_0000221,
3084,1,F,4,,,,104714,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),2116.0,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL617823,BAO_0000221,
3085,1,F,4,,,,104714,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,2116.0,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL617824,BAO_0000221,
3086,1,F,4,,,,104714,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,2116.0,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL617825,BAO_0000221,
3087,1,F,4,,,,104714,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,2116.0,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL617826,BAO_0000221,
3088,1,B,4,,,,104714,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,2116.0,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL617827,BAO_0000221,
3089,1,F,4,,,,104714,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),2116.0,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL617828,BAO_0000221,
3090,1,B,4,,,,104714,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,2116.0,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL617829,BAO_0000221,
3091,1,B,4,,,,104714,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,2116.0,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL617830,BAO_0000221,
3092,1,B,4,,,,104714,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,2116.0,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL617831,BAO_0000221,
3093,1,B,4,,,,104714,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,2116.0,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL617832,BAO_0000221,
3094,1,B,0,,,,22226,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,Cavia porcellus,,,,10141.0,U,Autocuration,CHEMBL617833,BAO_0000019,
3095,1,B,8,,,,51,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,,,,,,H,Autocuration,CHEMBL617834,BAO_0000357,
3096,1,B,5,,,,104714,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL617835,BAO_0000223,
3097,1,B,4,,,,104714,Binding affinity towards 5-HT3 receptor,,,,,,,H,Autocuration,CHEMBL617836,BAO_0000223,
3098,1,B,4,,,,104714,Binding activity radioligand.,,,,,,,H,Autocuration,CHEMBL617837,BAO_0000223,
3099,1,B,4,,,,104714,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,,,,,,H,Autocuration,CHEMBL620392,BAO_0000019,
3100,1,B,4,,,,104714,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,,,,,,H,Autocuration,CHEMBL620393,BAO_0000223,
3101,1,B,4,,,,104714,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,,,,,,H,Autocuration,CHEMBL620394,BAO_0000223,
3102,1,B,4,,,,104714,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,,,,,,H,Autocuration,CHEMBL620395,BAO_0000223,
3103,1,B,0,,,,22226,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,,,,,,U,Autocuration,CHEMBL620396,BAO_0000019,
3104,1,B,4,NG108-15,,,105030,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,,,,433.0,,,H,Expert,CHEMBL620582,BAO_0000219,
3105,1,B,4,,,In vivo,105030,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",,,,,,,H,Autocuration,CHEMBL620583,BAO_0000218,
3106,1,B,4,,,,105030,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,,,,,,H,Autocuration,CHEMBL620584,BAO_0000019,
3107,1,B,4,,,,105030,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,,,,,,H,Autocuration,CHEMBL620585,BAO_0000224,
3108,1,B,4,,,,105030,Compound was evaluated for the binding affinity at 5- HT3 receptor,,,,,,,H,Autocuration,CHEMBL620586,BAO_0000224,
3109,1,B,4,,,,105030,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,,,,,,H,Autocuration,CHEMBL620587,BAO_0000019,
3110,1,B,4,,,,105030,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,,,,,,H,Autocuration,CHEMBL620588,BAO_0000019,
3111,1,F,4,,,,105030,5-hydroxytryptamine 3 receptor agonism in mouse,,,,,,,H,Autocuration,CHEMBL620589,BAO_0000218,
3112,1,B,4,,,,105030,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,,,,,,H,Autocuration,CHEMBL620590,BAO_0000219,
3113,1,B,4,,,,105030,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,,,,,,H,Autocuration,CHEMBL617956,BAO_0000019,
3114,1,B,4,,,,105030,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,,,,,,H,Autocuration,CHEMBL617957,BAO_0000019,
3115,1,B,4,,,,105030,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,,,,,,H,Autocuration,CHEMBL617958,BAO_0000224,
3116,1,B,4,,,,105030,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,,,,,,H,Autocuration,CHEMBL617959,BAO_0000219,
3117,1,B,4,,,,105030,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,,,,,,H,Autocuration,CHEMBL617960,BAO_0000219,
3118,1,B,4,,,,105030,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,,,,,,H,Autocuration,CHEMBL617961,BAO_0000224,
3119,1,B,4,,,In vitro,105030,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,,,,,,,H,Autocuration,CHEMBL617962,BAO_0000219,
3120,1,B,4,N1E-115,,,105030,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,,,,339.0,,,H,Autocuration,CHEMBL617963,BAO_0000219,
3121,1,B,8,,,,11765,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,,,,,,H,Autocuration,CHEMBL617964,BAO_0000019,
3122,1,B,8,,,,11765,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,,,,,,H,Autocuration,CHEMBL617965,BAO_0000219,
3123,1,B,9,,,,10630,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,,Mus musculus,,,,10090.0,D,Autocuration,CHEMBL617966,BAO_0000357,
3124,1,B,8,,,,17106,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,,,,,H,Autocuration,CHEMBL857074,BAO_0000019,
3125,1,B,8,,,,144,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL617967,BAO_0000357,
3126,1,B,8,,,,144,Binding activity radioligand.,,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL617968,BAO_0000357,
3127,1,B,4,,,,104714,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,,Oryctolagus cuniculus,,,,9986.0,H,Autocuration,CHEMBL617969,BAO_0000223,
3128,1,B,4,,,,104714,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,Oryctolagus cuniculus,,,,9986.0,H,Autocuration,CHEMBL617970,BAO_0000223,
3129,1,B,4,,,,104714,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,,Oryctolagus cuniculus,,,,9986.0,H,Autocuration,CHEMBL617971,BAO_0000223,
3130,1,B,4,,,,104714,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,Oryctolagus cuniculus,,,,9986.0,H,Autocuration,CHEMBL617972,BAO_0000019,
3131,1,F,4,,,,104714,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,Oryctolagus cuniculus,,,,9986.0,H,Autocuration,CHEMBL617973,BAO_0000019,
3132,1,F,4,,,,104714,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,Oryctolagus cuniculus,,,,9986.0,H,Autocuration,CHEMBL617974,BAO_0000019,
3133,1,F,4,,,,104714,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),2116.0,Oryctolagus cuniculus,,,,9986.0,H,Autocuration,CHEMBL617975,BAO_0000221,
3134,1,F,4,,,,104714,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,Oryctolagus cuniculus,,,,9986.0,H,Autocuration,CHEMBL617976,BAO_0000019,
3135,1,F,4,,,,104714,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,Oryctolagus cuniculus,,,,9986.0,H,Autocuration,CHEMBL617977,BAO_0000019,
3136,1,F,4,,,,104714,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,Oryctolagus cuniculus,,,,9986.0,H,Autocuration,CHEMBL617978,BAO_0000019,
3137,1,F,4,,,,104714,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,Oryctolagus cuniculus,,,,9986.0,H,Autocuration,CHEMBL617979,BAO_0000019,
3138,1,B,4,CHO,,,104714,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,,Oryctolagus cuniculus,,449.0,,9986.0,H,Autocuration,CHEMBL617980,BAO_0000219,
3139,1,B,7,,,,104698,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617981,BAO_0000019,
3140,1,B,8,,,,12020,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,,,,,,H,Autocuration,CHEMBL617982,BAO_0000019,
3141,1,B,8,,,,12020,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,,,,,,H,Autocuration,CHEMBL617983,BAO_0000357,
3142,1,B,7,,,,104698,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617984,BAO_0000019,
3143,1,B,6,,,,104698,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,,,,,,H,Autocuration,CHEMBL617985,BAO_0000019,
3144,1,F,6,,,In vivo,104698,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",948.0,,,,,,H,Autocuration,CHEMBL617986,BAO_0000218,
3145,1,F,6,,,,104698,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",948.0,,,,,,H,Autocuration,CHEMBL617987,BAO_0000019,
3146,1,F,6,,,,104698,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",948.0,,,,,,H,Autocuration,CHEMBL617988,BAO_0000019,
3147,1,F,6,,,,104698,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",948.0,,,,,,H,Autocuration,CHEMBL617792,BAO_0000019,
3148,1,F,6,,,,104698,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",948.0,,,,,,H,Autocuration,CHEMBL617793,BAO_0000019,
3149,1,F,6,,,,104698,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,,,,,,H,Autocuration,CHEMBL617794,BAO_0000019,
3150,1,F,6,,,,104698,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,,,,,,H,Autocuration,CHEMBL617795,BAO_0000019,
3151,1,F,6,,,,104698,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,,,,,,H,Autocuration,CHEMBL617796,BAO_0000019,
3152,1,F,6,,,,104698,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,,,,,,H,Autocuration,CHEMBL617797,BAO_0000019,
3153,1,F,7,,,In vivo,104698,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617798,BAO_0000218,
3154,1,F,6,,,In vivo,104698,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),,,,,,,H,Autocuration,CHEMBL617799,BAO_0000218,
3155,1,F,7,,,In vivo,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617800,BAO_0000218,
3156,1,F,7,,,,104698,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617801,BAO_0000019,
3157,1,F,7,,,In vivo,104698,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617802,BAO_0000218,
3158,1,F,7,,,,104698,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617803,BAO_0000019,
3159,1,B,6,,,,104698,Binding affinity towards 5-HT3 receptor in rat was evaluated,,,,,,,H,Autocuration,CHEMBL617804,BAO_0000019,
3160,1,B,7,,,,104698,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617805,BAO_0000019,
3161,1,B,6,,,,104698,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,,,,,,H,Autocuration,CHEMBL617806,BAO_0000223,
3162,1,B,6,,,,104698,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,,,,,,H,Autocuration,CHEMBL617807,BAO_0000019,
3163,1,B,6,,,,104698,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,,,,,,H,Autocuration,CHEMBL617808,BAO_0000019,
3164,1,B,6,,,,104698,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,,,,,,H,Autocuration,CHEMBL617809,BAO_0000249,
3165,1,B,6,,,,104698,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,,,,,,H,Autocuration,CHEMBL617810,BAO_0000019,
3166,1,B,6,,,,104698,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,955.0,,,,,,H,Autocuration,CHEMBL617811,BAO_0000249,
3167,1,B,6,,,,104698,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,955.0,,,,,,H,Autocuration,CHEMBL617812,BAO_0000221,
3168,1,B,6,,,,104698,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,,,,,H,Autocuration,CHEMBL617813,BAO_0000249,
3169,1,B,6,,,,104698,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,,,,,H,Autocuration,CHEMBL617814,BAO_0000249,
3170,1,B,6,,,,104698,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,,,,,,H,Autocuration,CHEMBL617698,BAO_0000019,
3171,1,B,7,,,,104698,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617699,BAO_0000019,
3172,1,B,7,,,,104698,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617700,BAO_0000019,
3173,1,B,7,,,,104698,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617701,BAO_0000223,
3174,1,B,6,,,,104698,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,,,,,,H,Autocuration,CHEMBL617702,BAO_0000019,
3175,1,B,6,,,,104698,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",,,,,,,H,Autocuration,CHEMBL617703,BAO_0000249,
3176,1,B,7,,,,104698,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617704,BAO_0000019,
3177,1,B,6,,,,104698,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,,,,,,H,Autocuration,CHEMBL617705,BAO_0000223,
3178,1,B,7,,,,104698,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617706,BAO_0000223,
3179,1,B,6,NG108-15,,,104698,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),,,,433.0,,,H,Autocuration,CHEMBL617707,BAO_0000219,
3180,1,B,6,NG108-15,,,104698,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,,,,433.0,,,H,Autocuration,CHEMBL617708,BAO_0000219,
3181,1,B,6,,,,104698,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,,,,,,H,Autocuration,CHEMBL617709,BAO_0000019,
3182,1,B,6,,,,104698,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,,,,,,H,Autocuration,CHEMBL617710,BAO_0000019,
3183,1,B,6,,,,104698,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,,,,,,H,Autocuration,CHEMBL882925,BAO_0000019,
3184,1,B,6,,,,104698,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,,,,,,H,Autocuration,CHEMBL617711,BAO_0000019,
3185,1,F,6,,,,104698,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,,,,,,H,Autocuration,CHEMBL617712,BAO_0000019,
3186,1,F,7,,,,104698,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617713,BAO_0000019,
3187,1,F,6,,,,104698,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,,,,,,H,Autocuration,CHEMBL617714,BAO_0000019,
3188,1,F,6,,,,104698,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,,,,,,H,Autocuration,CHEMBL617715,BAO_0000218,
3189,1,F,6,,,In vivo,104698,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,,,,,,,H,Autocuration,CHEMBL617716,BAO_0000218,
3190,1,F,6,,,,104698,Inhibition of 5-HT evoked reflex bradycardia in rat.,,,,,,,H,Autocuration,CHEMBL617717,BAO_0000218,
3191,1,F,6,,,In vivo,104698,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL617718,BAO_0000218,
3192,1,F,6,,,In vivo,104698,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL617719,BAO_0000218,
3193,1,F,6,,,In vivo,104698,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),,,,,,,H,Autocuration,CHEMBL617720,BAO_0000218,
3194,1,F,7,,,In vivo,104698,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL617721,BAO_0000218,
3195,1,F,6,,,In vivo,104698,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL617722,BAO_0000218,
3196,1,F,6,,,In vivo,104698,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,,,,,,,H,Autocuration,CHEMBL617723,BAO_0000218,
3197,1,F,6,,,In vivo,104698,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL617724,BAO_0000218,
3198,1,F,6,,,In vivo,104698,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL617725,BAO_0000218,
3199,1,F,6,,,In vivo,104698,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL617726,BAO_0000218,
3200,1,F,6,,,In vivo,104698,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL617727,BAO_0000218,
3201,1,F,6,,,In vivo,104698,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL617728,BAO_0000218,
3202,1,F,6,,,In vivo,104698,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL617729,BAO_0000218,
3203,1,F,6,,,In vivo,104698,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL617730,BAO_0000218,
3204,1,F,6,,,In vivo,104698,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL617731,BAO_0000218,
3205,1,F,6,,,In vivo,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL617732,BAO_0000218,
3206,1,F,6,,,In vivo,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL617733,BAO_0000218,
3207,1,F,6,,,In vivo,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL617734,BAO_0000218,
3208,1,F,6,,,In vivo,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,,,,,,,H,Autocuration,CHEMBL872874,BAO_0000218,
3209,1,F,6,,,In vivo,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,,,,,,,H,Autocuration,CHEMBL617735,BAO_0000218,
3210,1,F,6,,,In vivo,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,,,,,,,H,Autocuration,CHEMBL617736,BAO_0000218,
3211,1,F,6,,,In vivo,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,,,,,,,H,Autocuration,CHEMBL617737,BAO_0000218,
3212,1,F,6,,,In vivo,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,,,,,,,H,Autocuration,CHEMBL617738,BAO_0000218,
3213,1,F,6,,,In vivo,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL617739,BAO_0000218,
3214,1,F,6,,,In vivo,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL617740,BAO_0000218,
3215,1,F,6,,,In vivo,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL617741,BAO_0000218,
3216,1,F,6,,,In vivo,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL617742,BAO_0000218,
3217,1,F,6,,,In vivo,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL617743,BAO_0000218,
3218,1,F,6,,,In vivo,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL617744,BAO_0000218,
3219,1,F,6,,,In vivo,104698,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,,,,,,,H,Autocuration,CHEMBL617745,BAO_0000218,
3220,1,F,6,,,,104698,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,,,,,,H,Autocuration,CHEMBL617746,BAO_0000218,
3221,1,F,6,,,,104698,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,,,,,,H,Autocuration,CHEMBL617747,BAO_0000218,
3222,1,F,6,,,In vivo,104698,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,,,,,,,H,Autocuration,CHEMBL617748,BAO_0000218,
3223,1,F,6,,,In vivo,104698,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,,,,,,,H,Autocuration,CHEMBL618909,BAO_0000218,
3224,1,F,6,,,In vivo,104698,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,,,,,,,H,Autocuration,CHEMBL618910,BAO_0000218,
3225,1,F,6,,,In vivo,104698,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,,,,,,,H,Autocuration,CHEMBL618911,BAO_0000218,
3226,1,F,6,,,In vivo,104698,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,,,,,,,H,Autocuration,CHEMBL618912,BAO_0000218,
3227,1,F,6,,,In vivo,104698,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),,,,,,,H,Autocuration,CHEMBL618913,BAO_0000218,
3228,1,F,6,,,,104698,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,,,,,,H,Autocuration,CHEMBL618914,BAO_0000019,
3229,1,F,6,,,,104698,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,,,,,,H,Autocuration,CHEMBL618915,BAO_0000019,
3230,1,B,7,,,,104698,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL618916,BAO_0000223,
3231,1,F,6,,,,104698,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,,,,,,H,Autocuration,CHEMBL618917,BAO_0000019,
3232,1,B,7,,,,104698,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,10000000.0,,,,,,D,Intermediate,CHEMBL618918,BAO_0000221,
3233,1,B,7,,,,104698,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL618919,BAO_0000019,
3234,1,B,7,,,,104698,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL618920,BAO_0000019,
3235,1,B,6,,,,104698,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,,,,,,H,Autocuration,CHEMBL618921,BAO_0000223,
3236,1,B,6,,,,104698,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,,,,,,H,Autocuration,CHEMBL618922,BAO_0000019,
3237,1,B,6,,,,104698,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,,,,,,H,Autocuration,CHEMBL618923,BAO_0000019,
3238,1,B,6,,,,104698,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,,,,,,H,Autocuration,CHEMBL618924,BAO_0000019,
3239,1,B,6,,,,104698,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,,,,,,H,Autocuration,CHEMBL618925,BAO_0000019,
3240,1,B,6,,,,104698,Binding affinity towards 5-HT3 receptor in rat was evaluated,,,,,,,H,Autocuration,CHEMBL618926,BAO_0000019,
3241,1,F,9,,,,20033,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,2116.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL618927,BAO_0000221,
3242,1,F,9,,,,20033,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,2116.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL618928,BAO_0000221,
3243,1,F,9,,,,20033,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",2116.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL618929,BAO_0000221,
3244,1,F,9,,,,20033,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",2116.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL618930,BAO_0000221,
3245,1,F,9,,,,20033,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",2116.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL618931,BAO_0000221,
3246,1,F,9,,,,20033,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",2116.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619594,BAO_0000221,
3247,1,F,9,,,,20033,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",2116.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619595,BAO_0000221,
3248,1,F,9,,,,20033,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,2116.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619596,BAO_0000221,
3249,1,F,9,,,,20033,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,2116.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619755,BAO_0000221,
3250,1,F,9,,,,20033,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,2116.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619756,BAO_0000221,
3251,1,F,9,,,,20033,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,2116.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619757,BAO_0000221,
3252,1,F,9,,,,20033,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,2116.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619758,BAO_0000221,
3253,1,F,9,,,,20033,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",2116.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619759,BAO_0000221,
3254,1,F,9,,,,20033,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",2116.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619760,BAO_0000221,
3255,1,F,9,,,,20033,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",2116.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619761,BAO_0000221,
3256,1,F,9,,,,20033,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,2116.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619762,BAO_0000221,
3257,1,F,9,,,,20033,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",2116.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619763,BAO_0000221,
3258,1,F,9,,,,20033,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",2116.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL617868,BAO_0000221,
3259,1,B,9,,,,20033,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL617869,BAO_0000357,
3260,1,B,9,,,,20033,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,2435.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL882926,BAO_0000249,
3261,1,B,9,,,,20033,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,2435.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL617870,BAO_0000249,
3262,1,B,9,,,,20033,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,2435.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL617871,BAO_0000357,
3263,1,B,9,,,,20033,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,2435.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL617872,BAO_0000357,
3264,1,B,9,,,,20033,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,2435.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL617873,BAO_0000357,
3265,1,B,9,,,,20033,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,2435.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL617874,BAO_0000357,
3266,1,F,9,,,,20033,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,2116.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619067,BAO_0000221,
3267,1,F,9,,,,20033,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,2116.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619068,BAO_0000221,
3268,1,F,9,,,,20033,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,2116.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619069,BAO_0000221,
3269,1,B,9,,,,20033,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619070,BAO_0000357,
3270,1,B,9,,,,20033,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619071,BAO_0000357,
3271,1,F,9,,,,20033,Agonistic activity against 5-hydroxytryptamine 4 receptor,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619072,BAO_0000019,
3272,1,F,9,,,,20033,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619073,BAO_0000019,
3273,1,F,9,,,,20033,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619074,BAO_0000019,
3274,1,B,9,,,,20033,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619075,BAO_0000357,
3275,1,B,9,,,,20033,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,2435.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619076,BAO_0000357,
3276,1,B,9,,,,20033,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,2435.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619077,BAO_0000357,
3277,1,B,9,,,,20033,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,2435.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619078,BAO_0000249,
3278,1,B,9,,,,20033,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,2435.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619079,BAO_0000249,
3279,1,B,9,,,,20033,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,2116.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619080,BAO_0000221,
3280,1,B,9,,,,20033,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,,Cavia porcellus,,,,10141.0,D,Expert,CHEMBL619081,BAO_0000357,
3281,1,B,9,,,,20033,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619082,BAO_0000357,
3282,1,B,9,,,,20033,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619083,BAO_0000357,
3283,1,B,9,,,,20033,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619084,BAO_0000357,
3284,1,F,9,,,,20033,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,2116.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL859397,BAO_0000221,
3285,1,F,9,,,,20033,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,2116.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619085,BAO_0000221,
3286,1,F,9,,,,20033,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,2116.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619086,BAO_0000221,
3287,1,F,9,,,,20033,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,2116.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619087,BAO_0000221,
3288,1,F,9,,,,20033,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,2116.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619088,BAO_0000221,
3289,1,B,9,,,,20033,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619089,BAO_0000357,
3290,1,B,8,,,,168,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL619090,BAO_0000357,
3291,1,F,9,,,,20033,Antagonistic activity against 5-hydroxytryptamine 4 receptor,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619091,BAO_0000019,
3292,1,B,9,,,,20033,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619092,BAO_0000357,
3293,1,B,9,,,,20033,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619093,BAO_0000019,
3294,1,B,8,HEK293,,,168,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,,Cavia porcellus,,722.0,,10141.0,H,Autocuration,CHEMBL619094,BAO_0000219,
3295,1,B,9,,,,20033,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619095,BAO_0000019,
3296,1,B,9,,,,20033,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL857988,BAO_0000357,
3297,1,B,9,,,,20033,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619096,BAO_0000357,
3298,1,B,9,,,,20033,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,2435.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619097,BAO_0000357,
3299,1,B,9,,,,20033,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,10000000.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619098,BAO_0000221,
3300,1,B,9,,,,20033,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619751,BAO_0000357,
3301,1,B,9,,,,20033,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619752,BAO_0000357,
3302,1,F,9,,,,20033,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,2116.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL875096,BAO_0000221,
3303,1,B,8,,,,108,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,,,,,,H,Autocuration,CHEMBL619004,BAO_0000357,
3304,1,B,8,,,,168,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,,,,,,H,Autocuration,CHEMBL619005,BAO_0000357,
3305,1,B,8,,,,168,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,,,,,,H,Autocuration,CHEMBL619006,BAO_0000019,
3306,1,B,8,HeLa,,,168,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,,,,308.0,,,H,Autocuration,CHEMBL619007,BAO_0000219,
3307,1,B,8,,,,168,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,,,,,,H,Autocuration,CHEMBL619008,BAO_0000357,
3308,1,B,8,,,,168,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,,,,,,H,Autocuration,CHEMBL619009,BAO_0000357,
3309,1,B,8,HeLa,,,168,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",,,,308.0,,,H,Autocuration,CHEMBL619010,BAO_0000219,
3310,1,B,8,,,,10622,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,,,,,,H,Autocuration,CHEMBL619011,BAO_0000357,
3311,1,B,8,,,,10622,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,,,,,,H,Autocuration,CHEMBL619012,BAO_0000357,
3312,1,B,8,,,,10622,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,,,,,,H,Autocuration,CHEMBL619013,BAO_0000219,
3313,1,B,8,,,,10622,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,,,,,,H,Autocuration,CHEMBL619014,BAO_0000357,
3314,1,F,8,,,,11249,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,2081.0,,,,,,H,Autocuration,CHEMBL857503,BAO_0000019,
3315,1,F,8,,,,11249,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,2081.0,,,,,,H,Autocuration,CHEMBL619015,BAO_0000019,
3316,1,B,8,,,,11249,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,,,,,,H,Autocuration,CHEMBL619016,BAO_0000357,
3317,1,B,8,,,,11249,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,10000000.0,,,,,,H,Autocuration,CHEMBL619017,BAO_0000221,
3318,1,B,8,,,,168,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,10000000.0,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL619018,BAO_0000221,
3319,1,B,8,,,,168,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,,Oryctolagus cuniculus,,,,9986.0,H,Autocuration,CHEMBL619019,BAO_0000019,
3320,1,B,9,,,,10623,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL619020,BAO_0000357,
3321,1,F,8,,,,10623,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,,,,,,H,Autocuration,CHEMBL619021,BAO_0000019,
3322,1,B,8,,,,10623,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,,,,,,H,Autocuration,CHEMBL619022,BAO_0000357,
3323,1,B,8,,,,10623,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,,,,,,H,Autocuration,CHEMBL619023,BAO_0000357,
3324,1,F,8,,,,10623,lntrinsic activity relative to 5-HT receptor,,,,,,,H,Autocuration,CHEMBL619024,BAO_0000019,
3325,1,F,8,,,,10623,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,,,,,,H,Autocuration,CHEMBL619025,BAO_0000019,
3326,1,F,8,,,,10623,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,,,,,,H,Expert,CHEMBL619026,BAO_0000019,
3327,1,F,8,,,,10623,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,,,,,,H,Autocuration,CHEMBL619027,BAO_0000019,
3328,1,F,8,,,,10623,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,,,,,,H,Autocuration,CHEMBL619028,BAO_0000019,
3329,1,F,8,,,,10623,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,,,,,,H,Autocuration,CHEMBL619029,BAO_0000019,
3330,1,F,8,,,,10623,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,,,,,,H,Autocuration,CHEMBL619030,BAO_0000019,
3331,1,B,8,,,,10623,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,,,,,,H,Expert,CHEMBL619031,BAO_0000357,
3332,1,F,8,,,,10623,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,,,,,,H,Autocuration,CHEMBL619032,BAO_0000019,
3333,1,B,9,,,,10623,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL619033,BAO_0000357,
3334,1,B,8,,,,10623,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,,,,,,H,Autocuration,CHEMBL619034,BAO_0000357,
3335,1,B,8,,,,10623,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,,,,,,H,Autocuration,CHEMBL619035,BAO_0000357,
3336,1,B,8,,,,10623,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,,,,,,H,Autocuration,CHEMBL619036,BAO_0000357,
3337,1,B,9,,,,10623,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL619037,BAO_0000019,
3338,1,B,8,,,,10623,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,2435.0,,,,,,H,Autocuration,CHEMBL619038,BAO_0000249,
3339,1,B,8,,,,10623,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,,,,,,H,Autocuration,CHEMBL619039,BAO_0000249,
3340,1,B,8,,,,10623,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,,,,,,H,Expert,CHEMBL619040,BAO_0000249,
3341,1,B,9,,,,10623,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,2435.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL619041,BAO_0000019,
3342,1,B,8,,,,10623,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,2435.0,,,,,,H,Autocuration,CHEMBL619042,BAO_0000019,
3343,1,B,8,,,,10623,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,2435.0,,,,,,H,Expert,CHEMBL619043,BAO_0000249,
3344,1,B,8,,,,10623,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,2435.0,,,,,,H,Expert,CHEMBL619044,BAO_0000019,
3345,1,B,8,,,,10623,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,2435.0,,,,,,H,Expert,CHEMBL619045,BAO_0000249,
3346,1,B,8,,,,10623,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,2435.0,,,,,,H,Expert,CHEMBL619046,BAO_0000249,
3347,1,B,8,,,,10623,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,,,,,,H,Expert,CHEMBL619047,BAO_0000249,
3348,1,F,8,,,,10623,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,955.0,,,,,,H,Autocuration,CHEMBL619048,BAO_0000221,
3349,1,F,8,,,,10623,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,,,,,,H,Autocuration,CHEMBL859398,BAO_0000019,
3350,1,F,8,,,,10623,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,,,,,,H,Autocuration,CHEMBL619049,BAO_0000019,
3351,1,F,8,,,,10623,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,,,,,,H,Autocuration,CHEMBL857886,BAO_0000019,
3352,1,F,8,,,,10623,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,,,,,,H,Autocuration,CHEMBL619050,BAO_0000019,
3353,1,F,8,,,,10623,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,,,,,,H,Autocuration,CHEMBL620591,BAO_0000019,
3354,1,B,9,,,,10623,Binding affinity against rat 5-hydroxytryptamine 4 receptor,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL620592,BAO_0000357,
3355,1,B,8,,,,10623,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,2435.0,,,,,,H,Expert,CHEMBL620593,BAO_0000249,
3356,1,F,9,,,,10623,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL620594,BAO_0000019,
3357,1,F,8,,,,10623,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,,,,,,H,Expert,CHEMBL875079,BAO_0000019,
3358,1,F,8,,,,10623,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,,,,,,H,Expert,CHEMBL620595,BAO_0000019,
3359,1,F,9,,,,10623,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL620596,BAO_0000019,
3360,1,F,8,,,,10623,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,,,,,,H,Autocuration,CHEMBL620597,BAO_0000019,
3361,1,F,8,,,,10623,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,,,,,,H,Expert,CHEMBL620598,BAO_0000019,
3362,1,F,8,,,,10623,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,,,,,,H,Expert,CHEMBL620599,BAO_0000218,
3363,1,F,8,,,,10623,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,,,,,,H,Autocuration,CHEMBL620600,BAO_0000019,
3364,1,F,8,,,,168,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,,Rattus norvegicus,,,,10116.0,H,Autocuration,CHEMBL620601,BAO_0000019,
3365,1,F,8,,,,168,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,,,,,,H,Autocuration,CHEMBL620602,BAO_0000019,
3366,1,B,8,,,,168,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,,,,,,H,Autocuration,CHEMBL620603,BAO_0000357,
3367,1,B,8,,,,168,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,,,,,,H,Autocuration,CHEMBL620604,BAO_0000357,
3368,1,B,8,,,,168,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,,,,,,H,Autocuration,CHEMBL620605,BAO_0000357,
3369,1,B,8,,,,168,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,,,,,,H,Autocuration,CHEMBL620606,BAO_0000357,
3370,1,F,8,,,,168,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,,,,,H,Autocuration,CHEMBL620607,BAO_0000019,
3371,1,B,8,,,,168,In vitro binding affinity towards 5-HT4 receptor was determined,,,,,,,H,Autocuration,CHEMBL620608,BAO_0000357,
3372,1,F,8,,,,168,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,,,,,H,Autocuration,CHEMBL620609,BAO_0000019,
3373,1,F,8,,,,168,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,,,,,,H,Autocuration,CHEMBL620610,BAO_0000019,
3374,1,B,8,,,,168,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,,,,,,H,Autocuration,CHEMBL620611,BAO_0000357,
3375,1,B,8,,,,168,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,,,,,,H,Autocuration,CHEMBL620612,BAO_0000357,
3376,1,B,8,,,,168,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,,,,,,H,Autocuration,CHEMBL620613,BAO_0000357,
3377,1,B,8,,,,168,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,,,,,,H,Autocuration,CHEMBL620614,BAO_0000357,
3378,1,B,8,,,,168,Binding affinity against 5-Hydroxytryptamine 4 receptor,,,,,,,H,Expert,CHEMBL620615,BAO_0000357,
3379,1,B,6,,,,104698,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,,,,,,,H,Autocuration,CHEMBL857075,BAO_0000249,
3380,1,B,6,,,,104698,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,,,,,,,H,Autocuration,CHEMBL620616,BAO_0000249,
3381,1,B,6,,,,104698,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,,,,,,,H,Autocuration,CHEMBL619411,BAO_0000249,
3382,1,B,6,,,,104698,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,,,,,,H,Autocuration,CHEMBL619412,BAO_0000019,
3383,1,B,7,,,,104698,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL619413,BAO_0000019,
3384,1,B,6,,,,104698,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,10000000.0,,,,,,H,Autocuration,CHEMBL619414,BAO_0000221,
3385,1,B,6,,,,104698,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,,,,,,H,Autocuration,CHEMBL619415,BAO_0000019,
3386,1,B,6,,,,104698,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,,,,,,H,Autocuration,CHEMBL619416,BAO_0000019,
3387,1,F,6,,,,104698,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,,,,,,H,Autocuration,CHEMBL619417,BAO_0000019,
3388,1,B,7,,,,104698,Binding affinity against rat 5-hydroxytryptamine 3 receptor,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL619418,BAO_0000223,
3389,1,B,7,,,,104698,Binding affinity against 5-Hydroxytryptamine 3 receptor,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL619419,BAO_0000223,
3390,1,B,6,,,,104698,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,,,,,,H,Autocuration,CHEMBL619420,BAO_0000019,
3391,1,B,6,,,,104698,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,,,,,,H,Autocuration,CHEMBL619421,BAO_0000249,
3392,1,B,7,,,,104698,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL619422,BAO_0000019,
3393,1,B,6,,,,104698,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,,,,,,H,Autocuration,CHEMBL619423,BAO_0000019,
3394,1,B,6,,,,104698,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,,,,,,H,Autocuration,CHEMBL875080,BAO_0000019,
3395,1,B,6,,,,104698,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,,,,,,H,Autocuration,CHEMBL619424,BAO_0000019,
3396,1,B,6,,,,104698,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,,,,,,H,Autocuration,CHEMBL619425,BAO_0000249,
3397,1,B,6,,,,104698,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,,,,,,H,Autocuration,CHEMBL619426,BAO_0000223,
3398,1,B,6,,,,104698,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,,,,,,H,Autocuration,CHEMBL619427,BAO_0000223,
3399,1,B,7,,,,104698,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL619645,BAO_0000223,
3400,1,B,9,,,,10576,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,,,,,,D,Expert,CHEMBL619646,BAO_0000249,
3401,1,F,8,,,,12020,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,955.0,,,,,,H,Autocuration,CHEMBL619647,BAO_0000221,
3402,1,F,8,,,,12020,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,,,,,,H,Autocuration,CHEMBL619648,BAO_0000019,
3403,1,F,8,,,,12020,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,,,,,,H,Autocuration,CHEMBL619165,BAO_0000019,
3404,1,F,8,,,In vivo,12020,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,,,,,,,H,Autocuration,CHEMBL620719,BAO_0000218,
3405,1,B,8,,,,12020,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,,,,,,H,Autocuration,CHEMBL872924,BAO_0000019,
3406,1,B,8,,,,12020,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,H,Autocuration,CHEMBL620720,BAO_0000357,
3407,1,B,8,,,,12020,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,,,,,,H,Autocuration,CHEMBL620721,BAO_0000019,
3408,1,B,8,,,,12020,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,,,,,,H,Autocuration,CHEMBL620722,BAO_0000019,
3409,1,B,6,,,,104698,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,,,,,,H,Autocuration,CHEMBL620723,BAO_0000019,
3410,1,B,8,,,,12020,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,,,,,,H,Autocuration,CHEMBL620724,BAO_0000019,
3411,1,B,6,,,,104698,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,,,,,,H,Autocuration,CHEMBL620725,BAO_0000249,
3412,1,F,9,,,,12020,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL620726,BAO_0000019,
3413,1,B,8,,,,144,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,H,Expert,CHEMBL620727,BAO_0000357,
3414,1,B,4,,,,104714,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,,,,,,H,Autocuration,CHEMBL620728,BAO_0000223,
3415,1,B,0,,,,22226,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,,,,,,U,Autocuration,CHEMBL620729,BAO_0000019,
3416,1,F,4,,,,104714,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,,,,,,H,Autocuration,CHEMBL858288,BAO_0000019,
3417,1,B,4,,,,104714,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,H,Autocuration,CHEMBL620730,BAO_0000223,
3418,1,B,4,,,,104714,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,H,Autocuration,CHEMBL620731,BAO_0000223,
3419,1,F,4,,,,104714,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL620732,BAO_0000019,
3420,1,F,4,,,,104714,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL618042,BAO_0000019,
3421,1,F,4,,,,104714,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL618043,BAO_0000019,
3422,1,B,4,,,,104714,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,H,Autocuration,CHEMBL618044,BAO_0000223,
3423,1,F,4,,,,104714,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,,,,,,H,Autocuration,CHEMBL618045,BAO_0000019,
3424,1,B,4,,,,104714,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,,,,,,H,Autocuration,CHEMBL618046,BAO_0000223,
3425,1,F,4,,,,104714,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,,,,,,H,Autocuration,CHEMBL618047,BAO_0000019,
3426,1,F,4,,,,104714,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,,,,,,H,Autocuration,CHEMBL875084,BAO_0000019,
3427,1,F,4,,,,104714,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,,,,,,H,Autocuration,CHEMBL618048,BAO_0000019,
3428,1,B,4,,,,104714,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,,,,,,H,Autocuration,CHEMBL618049,BAO_0000223,
3429,1,F,4,,,,104714,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,,,,,,H,Autocuration,CHEMBL619764,BAO_0000019,
3430,1,F,4,,,,104714,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,,,,,,H,Autocuration,CHEMBL619765,BAO_0000019,
3431,1,F,4,,,,104714,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,,,,,,H,Autocuration,CHEMBL619766,BAO_0000019,
3432,1,B,4,,,,104714,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,,,,,,H,Autocuration,CHEMBL619767,BAO_0000223,
3433,1,B,4,,,,104714,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,,,,,,H,Autocuration,CHEMBL619768,BAO_0000223,
3434,1,F,4,,,,104714,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,,,,,,H,Autocuration,CHEMBL619769,BAO_0000019,
3435,1,B,4,,,,104714,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,,,,,,H,Autocuration,CHEMBL619770,BAO_0000223,
3436,1,B,4,,,,104714,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,H,Autocuration,CHEMBL619771,BAO_0000223,
3437,1,B,4,,,,104714,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,,,,,,H,Autocuration,CHEMBL619772,BAO_0000219,
3438,1,B,4,,,,104714,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,,,,,,H,Autocuration,CHEMBL619773,BAO_0000223,
3439,1,B,4,NG108-15,,,104714,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,,,,433.0,,,H,Autocuration,CHEMBL619774,BAO_0000219,
3440,1,B,4,,,,104714,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,,,,,,H,Autocuration,CHEMBL875083,BAO_0000019,
3441,1,B,4,NG108-15,,,104714,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,,,,433.0,,,H,Autocuration,CHEMBL620718,BAO_0000219,
3442,1,B,4,,,,104714,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,,,,,,H,Autocuration,CHEMBL618127,BAO_0000223,
3443,1,B,4,,,,104714,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,,,,,,H,Autocuration,CHEMBL618128,BAO_0000223,
3444,1,B,4,,,In vitro,104714,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,,,,,,,H,Autocuration,CHEMBL618129,BAO_0000219,
3445,1,B,4,,,,104714,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,,,,,,H,Autocuration,CHEMBL618130,BAO_0000223,
3446,1,F,4,,,,104714,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,,,,,,H,Autocuration,CHEMBL618131,BAO_0000019,
3447,1,F,4,,,,104714,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL618132,BAO_0000019,
3448,1,F,4,,,,104714,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL618133,BAO_0000019,
3449,1,F,4,,,,104714,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL618134,BAO_0000019,
3450,1,F,4,,,,104714,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL618135,BAO_0000019,
3451,1,B,4,,,,104714,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,,,,,,H,Autocuration,CHEMBL618136,BAO_0000223,
3452,1,B,4,,,,104714,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,H,Autocuration,CHEMBL618137,BAO_0000223,
3453,1,B,4,,,,104714,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,,,,,,H,Autocuration,CHEMBL618138,BAO_0000223,
3454,1,B,4,,,,104714,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,,,,,,H,Autocuration,CHEMBL618139,BAO_0000223,
3455,1,B,4,,,,104714,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,,,,,,H,Autocuration,CHEMBL618140,BAO_0000223,
3456,1,B,4,,,,104714,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,,,,,,H,Autocuration,CHEMBL618141,BAO_0000223,
3457,1,B,8,,,,108,Binding affinity for 5-hydroxytryptamine 2C receptor,,,,,,,H,Expert,CHEMBL873478,BAO_0000357,
3458,1,B,6,,,,104698,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,H,Autocuration,CHEMBL618142,BAO_0000223,
3459,1,B,8,,,,144,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,,,,,,H,Autocuration,CHEMBL618143,BAO_0000357,
3460,1,B,8,,,,144,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,H,Autocuration,CHEMBL618144,BAO_0000357,
3461,1,B,8,,,,144,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,,,,,,H,Autocuration,CHEMBL618145,BAO_0000357,
3462,1,B,4,,,,104714,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,,,,,,H,Autocuration,CHEMBL618146,BAO_0000223,
3463,1,B,4,,,,104714,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,,,,,,H,Autocuration,CHEMBL618147,BAO_0000223,
3464,1,B,4,,,,104714,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,,,,,,H,Autocuration,CHEMBL618148,BAO_0000223,
3465,1,B,8,,,,144,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,,,,,,H,Autocuration,CHEMBL618149,BAO_0000019,
3466,1,B,8,,,,144,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,H,Autocuration,CHEMBL872927,BAO_0000357,
3467,1,B,8,,,,144,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,H,Autocuration,CHEMBL618150,BAO_0000357,
3468,1,B,8,,,,144,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,,,,,,H,Autocuration,CHEMBL618151,BAO_0000357,
3469,1,B,8,,,,144,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,,,,,,H,Autocuration,CHEMBL875094,BAO_0000357,
3470,1,B,8,,,,144,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,,,,,,H,Autocuration,CHEMBL618152,BAO_0000019,
3471,1,B,8,,,,144,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,,,,,,H,Autocuration,CHEMBL618153,BAO_0000357,
3472,1,B,8,,,,144,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,,,,,,H,Autocuration,CHEMBL618888,BAO_0000357,
3473,1,F,8,,,,144,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,,,,,,H,Autocuration,CHEMBL618889,BAO_0000019,
3474,1,B,8,,,,144,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,,,,,,H,Autocuration,CHEMBL618890,BAO_0000357,
3475,1,B,8,,,,144,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,,,,,,H,Autocuration,CHEMBL618891,BAO_0000019,
3476,1,B,8,,,,144,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,,,,,,H,Autocuration,CHEMBL619054,BAO_0000019,
3477,1,B,4,,,,104714,Binding affinity against the 5-hydroxytryptamine 3 receptor,,,,,,,H,Autocuration,CHEMBL619055,BAO_0000223,
3478,1,B,8,,,,144,Binding affinity against human 5-hydroxytryptamine 3A receptor,,,,,,,H,Autocuration,CHEMBL619056,BAO_0000357,
3479,1,F,8,,,,144,Percent efficacy against 5-hydroxytryptamine 3A receptor,,,,,,,H,Autocuration,CHEMBL619057,BAO_0000019,
3480,1,B,8,,,,144,Binding affinity against human 5-hydroxytryptamine 3A receptor,,,,,,,H,Autocuration,CHEMBL619058,BAO_0000357,
3481,1,F,9,Oocytes,,,12020,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL619059,BAO_0000219,
3482,1,F,9,Oocytes,,,12020,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL619060,BAO_0000219,
3483,1,F,9,Oocytes,,,12020,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL875095,BAO_0000219,
3484,1,F,9,,,,20033,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,2116.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619061,BAO_0000221,
3485,1,F,9,,,,20033,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,2116.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619062,BAO_0000221,
3486,1,F,9,,,,20033,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619063,BAO_0000019,
3487,1,B,9,,,,20033,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,2116.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619064,BAO_0000221,
3488,1,B,9,,,,20033,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619065,BAO_0000357,
3489,1,B,9,,,,20033,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,2116.0,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL619066,BAO_0000221,
3490,1,B,8,,,,10209,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,2116.0,,,,,,H,Autocuration,CHEMBL619775,BAO_0000221,
3491,1,B,8,,,,10209,Affinity against 5-hydroxytryptamine 7 receptor,,,,,,,H,Autocuration,CHEMBL619776,BAO_0000357,
3492,1,B,4,,,,104841,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL619777,BAO_0000224,
3493,1,B,4,,,,104841,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL619778,BAO_0000224,
3494,1,B,4,,,,104841,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,2116.0,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL619779,BAO_0000221,
3495,1,B,4,,,,104841,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL619780,BAO_0000224,
3496,1,B,4,,,,104841,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL619166,BAO_0000224,
3497,1,F,4,,,,104841,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL619167,BAO_0000019,
3498,1,F,4,,,,104841,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL619168,BAO_0000019,
3499,1,B,9,,,,168,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,2081.0,Homo sapiens,,,,9606.0,D,Expert,CHEMBL619169,BAO_0000219,
3500,1,B,9,,,,168,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,2081.0,Homo sapiens,,,,9606.0,D,Expert,CHEMBL619170,BAO_0000219,
3501,1,F,5,,,,104841,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",,Homo sapiens,,,,9606.0,D,Autocuration,CHEMBL619171,BAO_0000019,
3502,1,F,9,,,,168,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",2081.0,Homo sapiens,,,,9606.0,D,Expert,CHEMBL619172,BAO_0000219,
3503,1,B,0,,,,22226,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,,Mus musculus,,,,10090.0,U,Autocuration,CHEMBL619173,BAO_0000019,
3504,1,B,0,,,,22226,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,,Mus musculus,,,,10090.0,U,Autocuration,CHEMBL619174,BAO_0000019,
3505,1,B,4,,,,104705,5-hydroxytryptamine receptor binding affinity was determined in rats,,,,,,,H,Autocuration,CHEMBL619175,BAO_0000019,
3506,1,B,4,,,,104705,Binding affinity at rat 5-hydroxytryptamine receptor.,,,,,,,H,Autocuration,CHEMBL619176,BAO_0000224,
3507,1,B,4,,,,104705,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,,,,,,H,Autocuration,CHEMBL619177,BAO_0000019,
3508,1,B,4,,,,104705,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,,,,,,H,Autocuration,CHEMBL619178,BAO_0000224,
3509,1,B,4,,,,104705,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,,,,,,H,Autocuration,CHEMBL619179,BAO_0000224,
3510,1,F,4,,,,104705,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,945.0,,,,,,H,Autocuration,CHEMBL619180,BAO_0000019,
3511,1,F,4,,,,104705,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,945.0,,,,,,H,Autocuration,CHEMBL619181,BAO_0000019,
3512,1,F,4,,,,104705,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,,,,,,H,Autocuration,CHEMBL619182,BAO_0000019,
3513,1,B,4,,,,104705,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,,,,,,H,Autocuration,CHEMBL619183,BAO_0000224,
3514,1,B,4,,,,104705,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,,,,,,H,Autocuration,CHEMBL619184,BAO_0000224,
3515,1,B,8,,,,10576,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,10000000.0,,,,,,H,Autocuration,CHEMBL619185,BAO_0000221,
3516,1,B,8,,,,12198,Binding affinity for rat 5-hydroxytryptamine transporter.,,,,,,,H,Expert,CHEMBL619186,BAO_0000357,
3517,1,B,4,,,,104705,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,,,,,,H,Autocuration,CHEMBL619187,BAO_0000019,
3518,1,B,5,,,,104705,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL619188,BAO_0000019,
3519,1,B,5,,,,104705,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL619189,BAO_0000224,
3520,1,F,9,,,,12198,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,955.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL619190,BAO_0000019,
3521,1,F,9,,,,12198,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,2037.0,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL619191,BAO_0000221,
3522,1,B,5,,,,104705,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL619192,BAO_0000019,
3523,1,B,5,,,,104705,Percent binding affinity against 5-hydroxytryptamine receptor,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL619193,BAO_0000224,
3524,1,B,0,,,,22226,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,,,,,,U,Autocuration,CHEMBL619194,BAO_0000019,
3525,1,B,5,,,,104705,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL619195,BAO_0000224,
3526,1,B,5,,,,104705,Affinity against 5-hydroxytryptamine receptor was determined,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL619196,BAO_0000224,
3527,1,B,5,,,,104705,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,945.0,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL619197,BAO_0000019,
3528,1,B,9,,,In vitro,121,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL619198,BAO_0000219,
3529,1,B,9,,,In vitro,121,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL875081,BAO_0000219,
3530,1,B,8,,,,18065,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,,,,,,H,Autocuration,CHEMBL884712,BAO_0000357,
3531,1,B,8,,,,121,Inhibition of 5-hydroxytryptamine reuptake,,,,,,,H,Expert,CHEMBL884710,BAO_0000357,
3532,1,F,8,,,,18065,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,,,,,,H,Autocuration,CHEMBL619199,BAO_0000019,
3533,1,F,8,,,,18065,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,,,,,,H,Autocuration,CHEMBL619200,BAO_0000019,
3534,1,F,8,,,,18065,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,,,,,,H,Autocuration,CHEMBL619201,BAO_0000019,
3535,1,F,8,,,,18065,Tested for 5-hydroxytryptamine receptor uptake,,,,,,,H,Autocuration,CHEMBL619202,BAO_0000019,
3536,1,B,9,CHO,,,51,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,Homo sapiens,,449.0,,9606.0,D,Expert,CHEMBL619203,BAO_0000219,
3537,1,F,9,,,,51,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL619204,BAO_0000019,
3538,1,B,8,,,,10576,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,,Homo sapiens,,,,9606.0,H,Autocuration,CHEMBL619205,BAO_0000249,
3539,1,B,8,,,,10576,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,,,,,,H,Autocuration,CHEMBL619206,BAO_0000357,
3540,1,B,8,,,,10576,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,,,,,,H,Expert,CHEMBL619207,BAO_0000249,
3541,1,F,8,,,,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,2435.0,,,,,,H,Autocuration,CHEMBL619208,BAO_0000019,
3542,1,F,8,,,,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,2435.0,,,,,,H,Autocuration,CHEMBL619209,BAO_0000019,
3543,1,F,8,,,,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,2435.0,,,,,,H,Autocuration,CHEMBL619210,BAO_0000019,
3544,1,F,8,,,,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,2435.0,,,,,,H,Autocuration,CHEMBL619211,BAO_0000019,
3545,1,F,8,,,,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,2435.0,,,,,,H,Autocuration,CHEMBL619212,BAO_0000019,
3546,1,F,8,,,,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,2435.0,,,,,,H,Autocuration,CHEMBL620681,BAO_0000019,
3547,1,F,8,,,,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,2435.0,,,,,,H,Autocuration,CHEMBL620682,BAO_0000019,
3548,1,F,8,,,,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,2435.0,,,,,,H,Autocuration,CHEMBL620683,BAO_0000019,
3549,1,F,8,,,,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,2435.0,,,,,,H,Autocuration,CHEMBL620684,BAO_0000019,
3550,1,F,8,,,,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,2435.0,,,,,,H,Autocuration,CHEMBL620685,BAO_0000019,
3551,1,F,8,,,,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,2435.0,,,,,,H,Autocuration,CHEMBL620686,BAO_0000019,
3552,1,F,8,,,,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,349.0,,,,,,H,Autocuration,CHEMBL620687,BAO_0000019,
3553,1,F,8,,,,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,349.0,,,,,,H,Autocuration,CHEMBL620688,BAO_0000019,
3554,1,F,8,,,,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,349.0,,,,,,H,Autocuration,CHEMBL620689,BAO_0000019,
3555,1,F,8,,,,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,349.0,,,,,,H,Autocuration,CHEMBL620690,BAO_0000019,
3556,1,F,8,,,,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,349.0,,,,,,H,Autocuration,CHEMBL620691,BAO_0000019,
3557,1,F,8,,,,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,349.0,,,,,,H,Autocuration,CHEMBL620692,BAO_0000019,
3558,1,F,8,,,,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,349.0,,,,,,H,Autocuration,CHEMBL620693,BAO_0000019,
3559,1,B,8,,,,168,Binding affinity against 5-hydroxytryptamine 4 receptor,,,,,,,H,Expert,CHEMBL620694,BAO_0000357,
3560,1,F,8,,,,168,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,,,,,H,Autocuration,CHEMBL857986,BAO_0000019,
3561,1,B,8,,,,168,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,,,,,,H,Autocuration,CHEMBL620695,BAO_0000357,
3562,1,B,8,,,,168,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,,,,,,H,Expert,CHEMBL620696,BAO_0000357,
3563,1,B,8,,,,168,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,,,,,,H,Autocuration,CHEMBL620697,BAO_0000357,
3564,1,B,8,,,,168,Binding affinity towards 5-hydroxytryptamine 4 receptor,,,,,,,H,Autocuration,CHEMBL620698,BAO_0000357,
3565,1,B,8,,,,168,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,,,,,,H,Autocuration,CHEMBL620699,BAO_0000357,
3566,1,B,8,,,,168,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,,,,,,H,Autocuration,CHEMBL620700,BAO_0000357,
3567,1,B,8,COS-7,,,168,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,,,,643.0,,,H,Autocuration,CHEMBL620701,BAO_0000219,
3568,1,B,8,COS-7,,,168,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,,,,643.0,,,H,Autocuration,CHEMBL875082,BAO_0000219,
3569,1,B,8,COS-7,,,168,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,,,,643.0,,,H,Autocuration,CHEMBL620702,BAO_0000219,
3570,1,B,8,COS-7,,,168,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,,,,643.0,,,H,Autocuration,CHEMBL620703,BAO_0000219,
3571,1,B,8,C6,,,168,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,,,673.0,,,H,Autocuration,CHEMBL620704,BAO_0000219,
3572,1,B,8,C6,,,168,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,,,673.0,,,H,Expert,CHEMBL620705,BAO_0000219,
3573,1,B,8,C6,,,168,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,,,,673.0,,,H,Expert,CHEMBL620706,BAO_0000219,
3574,1,B,8,C6,,,168,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,,,,673.0,,,H,Expert,CHEMBL620707,BAO_0000219,
3575,1,B,8,,,,10624,Binding affinity towards 5-hydroxytryptamine 5 receptor,,,,,,,H,Expert,CHEMBL620708,BAO_0000357,
3576,1,B,8,,,,105,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,,,,,,H,Autocuration,CHEMBL620709,BAO_0000357,
3577,1,B,9,,,,10624,Binding affinity against 5-hydroxytryptamine 5A receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL620710,BAO_0000357,
3578,1,B,8,CHO,,,10624,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,,,,449.0,,,H,Autocuration,CHEMBL620711,BAO_0000219,
3579,1,B,9,,,,10624,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL620712,BAO_0000357,
3580,1,B,9,,,,10624,Binding affinity towards human 5-hydroxytryptamine 5A receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL620713,BAO_0000357,
3581,1,B,9,,,,10624,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL620714,BAO_0000357,
3582,1,B,9,,,,10624,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL620715,BAO_0000357,
3583,1,B,8,,,,10624,Binding affinity towards 5-HT5A receptor,,,,,,,H,Autocuration,CHEMBL620716,BAO_0000357,
3584,1,B,8,,,,10624,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,,,,,,H,Expert,CHEMBL620717,BAO_0000357,
3585,1,B,8,,,,10624,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,,,,,,H,Autocuration,CHEMBL618072,BAO_0000357,
3586,1,B,8,,,,10624,Binding affinity towards cloned human 5-HT5A receptor was determined,,,,,,,H,Autocuration,CHEMBL857987,BAO_0000357,
3587,1,B,8,HEK293,,,10624,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,,722.0,,,H,Autocuration,CHEMBL618073,BAO_0000219,
3588,1,B,8,HEK293,,,10624,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,,,722.0,,,H,Autocuration,CHEMBL618074,BAO_0000219,
3589,1,B,8,HEK293,,,10624,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),,,,722.0,,,H,Autocuration,CHEMBL618075,BAO_0000219,
3590,1,B,9,,,,10625,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,,Mus musculus,,,,10090.0,D,Expert,CHEMBL618076,BAO_0000357,
3591,1,B,9,,,,10625,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,,Mus musculus,,,,10090.0,D,Expert,CHEMBL618077,BAO_0000357,
3592,1,B,9,,,,10625,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,,Mus musculus,,,,10090.0,D,Expert,CHEMBL618078,BAO_0000357,
3593,1,B,9,,,,10625,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,,Mus musculus,,,,10090.0,D,Expert,CHEMBL881821,BAO_0000357,
3594,1,B,9,,,,10625,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,,Mus musculus,,,,10090.0,D,Expert,CHEMBL618079,BAO_0000357,
3595,1,B,8,,,,10625,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,,,,,,H,Expert,CHEMBL618080,BAO_0000357,
3596,1,B,8,HEK293,,,10576,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,,,722.0,,,H,Autocuration,CHEMBL618081,BAO_0000219,
3597,1,B,8,HEK293,,,10626,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,,,722.0,,,H,Autocuration,CHEMBL618082,BAO_0000219,
3598,1,B,8,,,,10624,Binding affinity towards 5-HT5a receptor,,,,,,,H,Expert,CHEMBL618083,BAO_0000357,
3599,1,B,9,,,,10624,Binding affinity towards 5-hydroxytryptamine 5A receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL618084,BAO_0000357,
3600,1,B,8,,,,10624,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,,,,,,H,Expert,CHEMBL618085,BAO_0000357,
3601,1,B,8,,,,10624,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,,,,,,H,Expert,CHEMBL618086,BAO_0000357,
3602,1,B,8,,,,10624,Binding affinities against 5-hydroxytryptamine 5A receptor,,,,,,,H,Autocuration,CHEMBL875092,BAO_0000357,
3603,1,B,8,,,,10624,Binding affinities towards 5-hydroxytryptamine 5A receptor,,,,,,,H,Autocuration,CHEMBL618087,BAO_0000357,
3604,1,B,8,,,,10624,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,,,,,,H,Autocuration,CHEMBL872926,BAO_0000357,
3605,1,F,4,,,,104714,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL618088,BAO_0000019,
3606,1,B,4,,,,104714,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,,,,,,H,Autocuration,CHEMBL618089,BAO_0000223,
3607,1,B,9,,,,10627,Inhibition of human 5-hydroxytryptamine 6 receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL618090,BAO_0000357,
3608,1,B,9,,,,10627,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL618091,BAO_0000357,
3609,1,B,8,,,,10627,Inhibition against human 5-hydroxytryptamine 6 receptor,,,,,,,H,Autocuration,CHEMBL618092,BAO_0000357,
3610,1,B,9,,,,10627,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL618093,BAO_0000357,
3611,1,B,8,HeLa,,,10627,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,,,,308.0,,,H,Expert,CHEMBL618094,BAO_0000219,
3612,1,B,9,,,,10627,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL618095,BAO_0000357,
3613,1,B,9,,,,10627,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL875093,BAO_0000357,
3614,1,B,9,,,,10627,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL618096,BAO_0000357,
3615,1,B,9,,,,10627,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL618118,BAO_0000357,
3616,1,B,9,,,,10627,Binding affinity against 5-hydroxytryptamine 6 receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL618119,BAO_0000357,
3617,1,B,8,,,,10627,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,,,,H,Expert,CHEMBL618120,BAO_0000357,
3618,1,B,8,,,,10627,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,,,,H,Autocuration,CHEMBL618121,BAO_0000357,
3619,1,B,8,HEK293,,,10627,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",,,,722.0,,,H,Expert,CHEMBL618122,BAO_0000219,
3620,1,B,8,,,,10627,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,,,,,,H,Autocuration,CHEMBL618123,BAO_0000357,
3621,1,B,8,HEK293,,,10627,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,,,,722.0,,,H,Expert,CHEMBL618124,BAO_0000219,
3622,1,B,8,,,,10627,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,,,,H,Autocuration,CHEMBL618125,BAO_0000357,
3623,1,B,9,HEK293,,,10627,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,Homo sapiens,,722.0,,9606.0,D,Expert,CHEMBL618126,BAO_0000219,
3624,1,B,8,,,,10627,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,,,,,,H,Expert,CHEMBL618236,BAO_0000019,
3625,1,B,8,,,,10627,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,,,,,,H,Expert,CHEMBL618237,BAO_0000019,
3626,1,B,8,COS-7,,,10627,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,,,,643.0,,,H,Expert,CHEMBL618238,BAO_0000219,
3627,1,B,9,,,,10627,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL618239,BAO_0000357,
3628,1,B,8,,,,10627,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,,,,,,H,Autocuration,CHEMBL618240,BAO_0000019,
3629,1,B,8,,,,10627,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,,,,,,H,Autocuration,CHEMBL618241,BAO_0000357,
3630,1,B,8,HEK293,,,10627,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,,,722.0,,,H,Autocuration,CHEMBL859399,BAO_0000219,
3631,1,F,8,,,,10627,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,,,,,,H,Autocuration,CHEMBL618242,BAO_0000019,
3632,1,B,8,,,,10627,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,,,,,,H,Autocuration,CHEMBL857991,BAO_0000357,
3633,1,B,8,,,,10627,Binding affinity against human 5-hydroxytryptamine 6 receptor,,,,,,,H,Expert,CHEMBL619951,BAO_0000357,
3634,1,B,9,HeLa,,,10627,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,,Homo sapiens,,308.0,,9606.0,D,Expert,CHEMBL619952,BAO_0000219,
3635,1,B,9,HeLa,,,10627,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,,Homo sapiens,,308.0,,9606.0,D,Expert,CHEMBL619953,BAO_0000219,
3636,1,B,8,HeLa,,,10627,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,,,,308.0,,,H,Autocuration,CHEMBL619954,BAO_0000219,
3637,1,B,8,HeLa,,,10627,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,,,308.0,,,H,Autocuration,CHEMBL619955,BAO_0000219,
3638,1,B,8,HeLa,,,10627,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,,,308.0,,,H,Autocuration,CHEMBL619956,BAO_0000219,
3639,1,B,8,CHO,,,10627,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,,,449.0,,,H,Autocuration,CHEMBL619957,BAO_0000219,
3640,1,B,8,HEK293,,,10627,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,,722.0,,,H,Autocuration,CHEMBL619958,BAO_0000219,
3641,1,B,8,HEK293,,,10627,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,,,,722.0,,,H,Autocuration,CHEMBL620627,BAO_0000219,
3642,1,B,8,HEK293,,,10627,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,,,722.0,,,H,Autocuration,CHEMBL620628,BAO_0000219,
3643,1,B,8,HeLa,,,10627,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,,,,308.0,,,H,Autocuration,CHEMBL620629,BAO_0000219,
3644,1,B,8,,,,10627,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,,,,H,Autocuration,CHEMBL620630,BAO_0000357,
3645,1,B,8,HeLa,,,10627,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,,,,308.0,,,H,Autocuration,CHEMBL620782,BAO_0000219,
3646,1,B,8,,,,10627,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,,,,,,H,Autocuration,CHEMBL620783,BAO_0000357,
3647,1,B,8,,,,10627,Binding affinity against human 5-hydroxytryptamine 6 receptor,,,,,,,H,Expert,CHEMBL620784,BAO_0000357,
3648,1,B,8,HeLa,,,10627,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,,,,308.0,,,H,Expert,CHEMBL620785,BAO_0000219,
3649,1,B,8,,,,10627,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,,,,,,H,Autocuration,CHEMBL857992,BAO_0000357,
3650,1,B,8,,,,10627,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,,,,,,H,Autocuration,CHEMBL620786,BAO_0000219,
3651,1,B,8,HeLa,,,10627,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,,,,308.0,,,H,Autocuration,CHEMBL620787,BAO_0000219,
3652,1,B,8,HeLa,,,10627,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",,,,308.0,,,H,Autocuration,CHEMBL620788,BAO_0000219,
3653,1,B,8,HeLa,,,10627,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",,,,308.0,,,H,Autocuration,CHEMBL620789,BAO_0000219,
3654,1,B,8,HeLa,,,10627,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",,,,308.0,,,H,Autocuration,CHEMBL620790,BAO_0000219,
3655,1,B,8,CHO,,,10628,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,,,,449.0,,,H,Autocuration,CHEMBL620791,BAO_0000219,
3656,1,B,8,,,,10628,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,,,,,,H,Autocuration,CHEMBL620792,BAO_0000019,
3657,1,B,8,,,,10628,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,,,,,,H,Autocuration,CHEMBL620793,BAO_0000357,
3658,1,B,8,,,,10628,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,,,,,,H,Autocuration,CHEMBL620794,BAO_0000357,
3659,1,B,9,HeLa,,,10627,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,,Homo sapiens,,308.0,,9606.0,D,Autocuration,CHEMBL620795,BAO_0000219,
3660,1,B,8,,,,10627,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,,,,H,Expert,CHEMBL620796,BAO_0000357,
3661,1,B,8,,,,10627,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,,,,,,H,Autocuration,CHEMBL620797,BAO_0000357,
3662,1,F,9,,,,10627,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL620798,BAO_0000019,
3663,1,B,8,,,,10627,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,,,,,,H,Autocuration,CHEMBL620799,BAO_0000357,
3664,1,B,8,,,,10627,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,,,,H,Expert,CHEMBL620800,BAO_0000357,
3665,1,B,8,,,,10627,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,,,,,,H,Autocuration,CHEMBL620801,BAO_0000357,
3666,1,B,8,,,,10627,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,,,,,,H,Autocuration,CHEMBL875100,BAO_0000357,
3667,1,B,8,,,,10627,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,,,,,,H,Autocuration,CHEMBL620802,BAO_0000357,
3668,1,F,8,,,,10627,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,,,,,,H,Expert,CHEMBL620803,BAO_0000019,
3669,1,F,8,,,,10627,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,,,,,,H,Expert,CHEMBL620804,BAO_0000019,
3670,1,B,8,,,,10627,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,,,,,,H,Autocuration,CHEMBL620805,BAO_0000357,
3671,1,B,8,,,,10627,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,,,,,,H,Autocuration,CHEMBL620806,BAO_0000357,
3672,1,B,8,,,,10627,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,,,,,,H,Autocuration,CHEMBL620807,BAO_0000357,
3673,1,B,8,,,,10627,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,,,,,,H,Autocuration,CHEMBL620808,BAO_0000357,
3674,1,B,8,,,,10627,Binding affinities against 5-hydroxytryptamine 6 receptor,,,,,,,H,Autocuration,CHEMBL620809,BAO_0000357,
3675,1,B,8,,,,10627,Binding affinities towards 5-hydroxytryptamine 6 receptor,,,,,,,H,Autocuration,CHEMBL620810,BAO_0000357,
3676,1,B,9,,,,10627,Binding affinity towards 5-hydroxytryptamine 6 receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL620811,BAO_0000357,
3677,1,B,8,,,,10627,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,,,,,,H,Autocuration,CHEMBL620812,BAO_0000357,
3678,1,B,8,,,,10627,Affinity against 5-hydroxytryptamine 6 receptor,,,,,,,H,Autocuration,CHEMBL620813,BAO_0000357,
3679,1,B,8,,,,10627,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,,,,,,H,Autocuration,CHEMBL620814,BAO_0000357,
3680,1,B,9,,,,10209,Inhibition of human 5-hydroxytryptamine 7 receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL620815,BAO_0000357,
3681,1,B,8,HEK293,,,10209,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,,,,722.0,,,H,Autocuration,CHEMBL620816,BAO_0000219,
3682,1,B,8,,,,10209,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,,,,,,H,Autocuration,CHEMBL620817,BAO_0000357,
3683,1,B,8,,,,10209,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,,,,,,H,Autocuration,CHEMBL620818,BAO_0000357,
3684,1,B,8,HEK293,,,10209,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,,,,722.0,,,H,Expert,CHEMBL620819,BAO_0000219,
3685,1,B,9,,,,10209,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL620820,BAO_0000357,
3686,1,B,8,CHO,,,10209,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,,,,449.0,,,H,Autocuration,CHEMBL620821,BAO_0000219,
3687,1,B,9,,,,10209,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL620822,BAO_0000357,
3688,1,B,9,,,,10209,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL620823,BAO_0000357,
3689,1,B,9,,,,10209,Binding affinity against 5-hydroxytryptamine 7 receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL620824,BAO_0000357,
3690,1,B,8,CHO,,,10209,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,,,,449.0,,,H,Expert,CHEMBL620825,BAO_0000219,
3691,1,B,8,,,,10209,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,,,,,,H,Autocuration,CHEMBL872930,BAO_0000357,
3692,1,B,8,,,,10209,Binding affinity towards 5-hydroxytryptamine 7 receptor,,,,,,,H,Autocuration,CHEMBL620826,BAO_0000357,
3693,1,B,8,,,,10209,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,,,,,,H,Autocuration,CHEMBL620827,BAO_0000357,
3694,1,B,8,,,,10209,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,,,,,,H,Autocuration,CHEMBL620828,BAO_0000357,
3695,1,B,8,,,,10209,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,,,,,,H,Autocuration,CHEMBL620829,BAO_0000357,
3696,1,B,8,HEK293,,,10209,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,,,,722.0,,,H,Expert,CHEMBL620830,BAO_0000219,
3697,1,B,8,,,,10209,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,,,,,,H,Expert,CHEMBL620831,BAO_0000019,
3698,1,B,8,,,,10209,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,,,,,,H,Expert,CHEMBL620832,BAO_0000019,
3699,1,B,9,,,,10209,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL621548,BAO_0000357,
3700,1,B,8,,,,10209,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,,,,,,H,Autocuration,CHEMBL621549,BAO_0000019,
3701,1,B,8,,,,10209,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,,,,,,H,Autocuration,CHEMBL621550,BAO_0000357,
3702,1,B,8,CHO,,,10209,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,,,,449.0,,,H,Autocuration,CHEMBL621551,BAO_0000219,
3703,1,B,8,,,,10209,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,,,,,,H,Autocuration,CHEMBL621552,BAO_0000019,
3704,1,B,8,,,,10209,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,,,,,,H,Autocuration,CHEMBL857077,BAO_0000357,
3705,1,B,8,,,,10209,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,,,,,,H,Autocuration,CHEMBL618158,BAO_0000357,
3706,1,B,9,COS-7,,,10209,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,Homo sapiens,,643.0,,9606.0,D,Expert,CHEMBL618159,BAO_0000219,
3707,1,B,8,COS-7,,,10209,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,,,643.0,,,H,Autocuration,CHEMBL875101,BAO_0000219,
3708,1,B,9,HEK293,,,10209,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,,Homo sapiens,,722.0,,9606.0,D,Expert,CHEMBL618160,BAO_0000219,
3709,1,B,8,,,,10209,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,,,,,,H,Expert,CHEMBL618161,BAO_0000357,
3710,1,B,8,HEK293,,,10209,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,,,,722.0,,,H,Expert,CHEMBL618162,BAO_0000219,
3711,1,B,8,,,,10209,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,,,,,,H,Expert,CHEMBL618163,BAO_0000357,
3712,1,B,8,,,,10209,Binding affinity against 5-hydroxytryptamine 7 human receptors,,,,,,,H,Autocuration,CHEMBL618164,BAO_0000357,
3713,1,B,8,,,,10209,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,,,,,,H,Expert,CHEMBL618165,BAO_0000219,
3714,1,B,8,HEK293,,,10209,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,,,,722.0,,,H,Autocuration,CHEMBL618166,BAO_0000219,
3715,1,B,8,HEK293,,,10209,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,,,722.0,,,H,Autocuration,CHEMBL857989,BAO_0000219,
3716,1,B,8,HEK293,,,10209,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,,,722.0,,,H,Autocuration,CHEMBL619888,BAO_0000219,
3717,1,B,8,HEK293,,,10209,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,,,722.0,,,H,Autocuration,CHEMBL619889,BAO_0000219,
3718,1,B,8,HEK293,,,10209,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,,,,722.0,,,H,Autocuration,CHEMBL619890,BAO_0000219,
3719,1,B,8,CHO,,,10209,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,,,,449.0,,,H,Autocuration,CHEMBL619891,BAO_0000219,
3720,1,B,8,HEK293,,,10209,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),,,,722.0,,,H,Autocuration,CHEMBL619892,BAO_0000219,
3721,1,B,9,HEK293,,,10209,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,,,,722.0,,,D,Expert,CHEMBL619893,BAO_0000219,
3722,1,B,8,HEK293,,,10209,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),,,,722.0,,,H,Autocuration,CHEMBL619894,BAO_0000219,
3723,1,B,9,HEK293,,,10209,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,,,,722.0,,,D,Intermediate,CHEMBL619895,BAO_0000219,
3724,1,B,9,,,,10209,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,,,,,,D,Intermediate,CHEMBL619896,BAO_0000357,
3725,1,B,8,COS-7,,,10209,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,,,,643.0,,,H,Autocuration,CHEMBL619897,BAO_0000219,
3726,1,B,8,HEK293,,,10209,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,,,,722.0,,,H,Autocuration,CHEMBL619898,BAO_0000219,
3727,1,B,8,HEK293,,,10209,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,,,,722.0,,,H,Expert,CHEMBL619899,BAO_0000219,
3728,1,B,8,HEK293,,,10209,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),,,,722.0,,,H,Autocuration,CHEMBL619900,BAO_0000219,
3729,1,B,9,HEK293,,,10209,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,,Homo sapiens,,722.0,,9606.0,D,Expert,CHEMBL619901,BAO_0000219,
3730,1,B,8,HEK293,,,10209,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,,,,722.0,,,H,Autocuration,CHEMBL620580,BAO_0000219,
3731,1,B,8,HEK293,,,10209,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,,,,722.0,,,H,Autocuration,CHEMBL620581,BAO_0000219,
3732,1,B,8,HEK293,,,10209,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",,,,722.0,,,H,Autocuration,CHEMBL620733,BAO_0000219,
3733,1,B,9,,,,10209,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,,Homo sapiens,,,,9606.0,D,Autocuration,CHEMBL620734,BAO_0000357,
3734,1,B,9,,,,10022,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,Mus musculus,,,,10090.0,D,Expert,CHEMBL620735,BAO_0000357,
3735,1,B,8,,,,10209,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,,Oryctolagus cuniculus,,,,9986.0,H,Autocuration,CHEMBL620736,BAO_0000019,
3736,1,B,8,CHO,,,11923,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,,,,449.0,,,H,Autocuration,CHEMBL620737,BAO_0000219,
3737,1,B,8,CHO,,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,,,,449.0,,,H,Autocuration,CHEMBL620738,BAO_0000219,
3738,1,B,8,CHO,,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,,,,449.0,,,H,Autocuration,CHEMBL620739,BAO_0000219,
3739,1,B,8,CHO,,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,,,,449.0,,,H,Autocuration,CHEMBL620740,BAO_0000219,
3740,1,B,8,CHO,,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,,,,449.0,,,H,Autocuration,CHEMBL620741,BAO_0000219,
3741,1,B,8,CHO,,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,,,,449.0,,,H,Autocuration,CHEMBL620742,BAO_0000219,
3742,1,B,8,CHO,,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,,,,449.0,,,H,Autocuration,CHEMBL620743,BAO_0000219,
3743,1,B,8,CHO,,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,,,,449.0,,,H,Autocuration,CHEMBL620744,BAO_0000219,
3744,1,B,8,CHO,,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,,,,449.0,,,H,Autocuration,CHEMBL620745,BAO_0000219,
3745,1,B,8,CHO,,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,,,,449.0,,,H,Autocuration,CHEMBL620746,BAO_0000219,
3746,1,B,8,CHO,,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,,,,449.0,,,H,Autocuration,CHEMBL620747,BAO_0000219,
3747,1,B,8,CHO,,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,,,,449.0,,,H,Autocuration,CHEMBL620748,BAO_0000219,
3748,1,B,8,CHO,,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,,,,449.0,,,H,Autocuration,CHEMBL620749,BAO_0000219,
3749,1,B,8,,,,11923,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,,,,,,H,Expert,CHEMBL620750,BAO_0000357,
3750,1,B,9,,,,11923,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL620751,BAO_0000357,
3751,1,B,8,,,,11923,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,,,,,,H,Expert,CHEMBL620752,BAO_0000357,
3752,1,B,8,,,,11923,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,,,,,,,H,Autocuration,CHEMBL872929,BAO_0000019,
3753,1,B,9,,,,11923,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL620753,BAO_0000357,
3754,1,B,9,,,,11923,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL620754,BAO_0000357,
3755,1,B,9,CHO,,,11923,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,,Rattus norvegicus,,449.0,,10116.0,D,Expert,CHEMBL620755,BAO_0000219,
3756,1,B,8,,,,11923,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,,,,,,H,Autocuration,CHEMBL620756,BAO_0000357,
3757,1,B,8,,,,11923,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,,,,,,,H,Autocuration,CHEMBL620757,BAO_0000357,
3758,1,B,8,CHO,,,11923,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",,,,449.0,,,H,Autocuration,CHEMBL620758,BAO_0000219,
3759,1,B,8,CHO,,,11923,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",,,,449.0,,,H,Autocuration,CHEMBL620759,BAO_0000219,
3760,1,B,8,CHO,,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,,,,449.0,,,H,Autocuration,CHEMBL620760,BAO_0000219,
3761,1,B,8,CHO,,,11923,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,,,,449.0,,,H,Autocuration,CHEMBL620761,BAO_0000219,
3762,1,F,8,,,,11923,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,2116.0,,,,,,H,Autocuration,CHEMBL620762,BAO_0000221,
3763,1,F,8,,,,11923,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,2116.0,,,,,,H,Autocuration,CHEMBL620763,BAO_0000221,
3764,1,F,8,,,,11923,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,2116.0,,,,,,H,Autocuration,CHEMBL620764,BAO_0000221,
3765,1,B,9,,,,11923,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL857990,BAO_0000249,
3766,1,B,8,,,,11923,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,,,,,,,H,Autocuration,CHEMBL620765,BAO_0000357,
3767,1,B,8,,,,11923,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,,,,,,,H,Expert,CHEMBL620766,BAO_0000357,
3768,1,B,8,,,,11923,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,1898.0,,,,,,H,Expert,CHEMBL620767,BAO_0000019,
3769,1,B,8,,,,11923,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,,,,,,,H,Autocuration,CHEMBL620768,BAO_0000357,
3770,1,B,8,,,,11923,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,1898.0,,,,,,H,Expert,CHEMBL619051,BAO_0000249,
3771,1,B,8,,,,11923,Binding affinity towards 5-hydroxytryptamine 7 receptor,,,,,,,H,Expert,CHEMBL619052,BAO_0000357,
3772,1,F,9,HEK293,,,11923,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,,Rattus norvegicus,,722.0,,10116.0,D,Expert,CHEMBL619053,BAO_0000219,
3773,1,F,9,HEK293,,,11923,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,,Rattus norvegicus,,722.0,,10116.0,D,Expert,CHEMBL619703,BAO_0000219,
3774,1,F,9,HEK293,,,11923,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,,Rattus norvegicus,,722.0,,10116.0,D,Autocuration,CHEMBL619704,BAO_0000219,
3775,1,B,8,,,,10209,Binding affinity towards 5-hydroxytryptamine 7 receptor,,,,,,,H,Expert,CHEMBL619851,BAO_0000357,
3776,1,B,8,,,,10209,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,,,,,,,H,Autocuration,CHEMBL619852,BAO_0000357,
3777,1,B,8,,,,10209,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,,,,,,,H,Autocuration,CHEMBL619853,BAO_0000357,
3778,1,B,9,,,,10209,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL619854,BAO_0000357,
3779,1,B,8,,,,10209,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,,,,,,,H,Expert,CHEMBL619855,BAO_0000357,
3780,1,B,8,,,,10209,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,,,,,,,H,Autocuration,CHEMBL619856,BAO_0000357,
3781,1,B,8,,,,10209,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,,,,,,H,Autocuration,CHEMBL619857,BAO_0000357,
3782,1,F,8,,,,10209,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,,,,,,,H,Expert,CHEMBL619858,BAO_0000019,
3783,1,B,8,,,,10209,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,,,,,,,H,Autocuration,CHEMBL619859,BAO_0000357,
3784,1,B,8,,,,10209,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,,,,,,H,Autocuration,CHEMBL619860,BAO_0000357,
3785,1,B,8,,,,10209,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,,,,,,,H,Autocuration,CHEMBL619861,BAO_0000357,
3786,1,B,8,,,,10209,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,,,,,,,H,Expert,CHEMBL619862,BAO_0000357,
3787,1,B,8,,,,10209,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,,,,,,,H,Autocuration,CHEMBL619863,BAO_0000357,
3788,1,B,8,,,,10209,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,,,,,,,H,Autocuration,CHEMBL619864,BAO_0000357,
3789,1,B,8,,,,10209,Binding affinities against 5-hydroxytryptamine 7 receptor,,,,,,,H,Autocuration,CHEMBL872928,BAO_0000357,
3790,1,B,8,,,,10209,Binding affinities towards 5-hydroxytryptamine 7 receptor,,,,,,,H,Autocuration,CHEMBL619865,BAO_0000357,
3791,1,B,8,,,,10209,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,,,,,,,H,Expert,CHEMBL619866,BAO_0000357,
3792,1,B,8,,,,10209,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,,,,,,,H,Autocuration,CHEMBL619867,BAO_0000357,
3793,1,B,8,,,,10209,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,2116.0,,,,,,H,Autocuration,CHEMBL619868,BAO_0000221,
3794,1,F,8,,,,55,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,,,,,,,H,Autocuration,CHEMBL619869,BAO_0000019,
3795,1,F,9,,,,55,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL619870,BAO_0000019,
3796,1,B,8,,,,55,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,,,,,,,H,Autocuration,CHEMBL619871,BAO_0000357,
3797,1,B,8,,,,55,In vitro inhibition of human recombinant lipoxygenase enzyme,,,,,,,H,Autocuration,CHEMBL619872,BAO_0000357,
3798,1,B,8,,,,55,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,,,,,,,H,Autocuration,CHEMBL619873,BAO_0000357,
3799,1,B,8,,,,55,Inhibition of 5-lipoxygenase in human whole blood.,178.0,,,,,,H,Expert,CHEMBL619874,BAO_0000357,
3800,1,B,8,,,,55,Inhibition of 5-lipoxygenase in human whole blood.,178.0,,,,,,H,Expert,CHEMBL619875,BAO_0000357,
3801,1,B,8,,,,55,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,,,,,,,H,Autocuration,CHEMBL619876,BAO_0000357,
3802,1,B,8,,,,55,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),,,,,,,H,Autocuration,CHEMBL619877,BAO_0000357,
3803,1,F,8,,,,55,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,,,,,,,H,Expert,CHEMBL619878,BAO_0000219,
3804,1,F,8,,,,55,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,178.0,,,,,,H,Autocuration,CHEMBL619879,BAO_0000019,
3805,1,B,8,,,,55,In vitro inhibition of 5-lipoxygenase from human polymorphs,,,,,,,H,Autocuration,CHEMBL619880,BAO_0000357,
3806,1,B,8,,,,55,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),,,,,,,H,Autocuration,CHEMBL619881,BAO_0000357,
3807,1,B,8,,,,55,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,,,,,,,H,Expert,CHEMBL619882,BAO_0000357,
3808,1,B,8,,,,55,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,,,,,,,H,Autocuration,CHEMBL619883,BAO_0000357,
3809,1,B,9,,,,55,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),178.0,Homo sapiens,,,,9606.0,D,Expert,CHEMBL619884,BAO_0000357,
3810,1,B,8,,,,55,In vitro potency against human 5-Lipoxygenase,,,,,,,H,Autocuration,CHEMBL619885,BAO_0000357,
3811,1,F,9,,,,55,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL619886,BAO_0000019,
3812,1,F,8,,,,55,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,178.0,,,,,,H,Autocuration,CHEMBL619887,BAO_0000019,
3813,1,F,8,,,,55,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,,,,,,H,Autocuration,CHEMBL875097,BAO_0000019,
3814,1,B,8,,,,55,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,,,,,,,H,Autocuration,CHEMBL618001,BAO_0000219,
3815,1,B,8,,,,55,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,,,,,,,H,Autocuration,CHEMBL618002,BAO_0000219,
3816,1,B,8,,,,55,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,,,,,,,H,Autocuration,CHEMBL618003,BAO_0000219,
3817,1,B,8,,,,55,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,,,,,,,H,Autocuration,CHEMBL618004,BAO_0000219,
3818,1,B,8,,,,55,Inhibition of human 5-lipoxygenase in human cells,,,,,,,H,Autocuration,CHEMBL618005,BAO_0000219,
3819,1,B,8,,,,55,Inhibition of human neutrophil 5-lipoxygenase,,,,,,,H,Expert,CHEMBL618006,BAO_0000357,
3820,1,B,8,,,,55,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,,,,,,,H,Autocuration,CHEMBL875086,BAO_0000019,
3821,1,B,8,,,,55,Inhibition of 5-lipoxygenase from human whole blood,178.0,,,,,,H,Expert,CHEMBL618007,BAO_0000357,
3822,1,B,8,,,,55,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,,,,,,H,Autocuration,CHEMBL618008,BAO_0000357,
3823,1,B,8,,,,55,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,,,,,,,H,Autocuration,CHEMBL618009,BAO_0000219,
3824,1,B,8,,,,55,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,,,,,,,H,Expert,CHEMBL618010,BAO_0000357,
3825,1,B,8,,,,55,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,,,,,,H,Autocuration,CHEMBL618011,BAO_0000357,
3826,1,B,8,,,,55,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,,,,,,,H,Expert,CHEMBL618012,BAO_0000357,
3827,1,B,8,,,,55,Tested against 5-lipoxygenase,,,,,,,H,Autocuration,CHEMBL882927,BAO_0000357,
3828,1,B,8,,,,55,Tested for activity against 5-Lipoxygenase (5-LO),,,,,,,H,Autocuration,CHEMBL618013,BAO_0000357,
3829,1,B,8,,,,55,Tested for activity against 5-lipoxygenase,,,,,,,H,Autocuration,CHEMBL618014,BAO_0000357,
3830,1,B,8,,,,55,Tested for inhibition of 5-HPETE production by human 5-LO,,,,,,,H,Autocuration,CHEMBL618015,BAO_0000357,
3831,1,F,8,,,,55,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,,,,,,H,Autocuration,CHEMBL618016,BAO_0000019,
3832,1,B,8,,,,55,Inhibition of Human 5-lipoxygenase,,,,,,,H,Expert,CHEMBL618017,BAO_0000357,
3833,1,B,8,,,,55,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,,,,,,,H,Autocuration,CHEMBL618018,BAO_0000019,
3834,1,B,8,,,,55,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],,,,,,,H,Autocuration,CHEMBL875087,BAO_0000219,
3835,1,B,8,,,,55,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],,,,,,,H,Autocuration,CHEMBL618019,BAO_0000219,
3836,1,B,8,,,,55,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,,,,,,,H,Autocuration,CHEMBL618020,BAO_0000019,
3837,1,B,8,,,,55,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,,,,,,,H,Autocuration,CHEMBL618021,BAO_0000019,
3838,1,B,8,,,,55,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),178.0,,,,,,H,Autocuration,CHEMBL618022,BAO_0000357,
3839,1,B,8,,,,55,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,,,,,,,H,Autocuration,CHEMBL618023,BAO_0000357,
3840,1,B,8,,,,55,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,,,,,,H,Autocuration,CHEMBL618024,BAO_0000357,
3841,1,B,8,,,,55,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,,,,,,,H,Expert,CHEMBL873950,BAO_0000019,
3842,1,B,8,,,,55,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,,,,,,H,Autocuration,CHEMBL618025,BAO_0000357,
3843,1,B,8,,,,55,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,,,,,,,H,Autocuration,CHEMBL618026,BAO_0000219,
3844,1,B,8,,,,55,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,,,,,,,H,Autocuration,CHEMBL618027,BAO_0000219,
3845,1,B,8,,,,55,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,,,,,,,H,Autocuration,CHEMBL618028,BAO_0000219,
3846,1,B,8,,,,55,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,,,,,,,H,Autocuration,CHEMBL618029,BAO_0000219,
3847,1,B,8,,,,55,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,,,,,,,H,Expert,CHEMBL618030,BAO_0000357,
3848,1,B,8,,,,55,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,,,,,,,H,Expert,CHEMBL618031,BAO_0000357,
3849,1,B,8,,,,55,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,,,,,,,H,Autocuration,CHEMBL618032,BAO_0000357,
3850,1,B,8,,,,55,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,,,,,,H,Autocuration,CHEMBL618033,BAO_0000357,
3851,1,B,8,,,,55,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,,,,,,,H,Autocuration,CHEMBL618034,BAO_0000357,
3852,1,B,8,,,,55,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,,,,,,H,Autocuration,CHEMBL875088,BAO_0000357,
3853,1,B,8,,,,55,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,,,,,,,H,Autocuration,CHEMBL618035,BAO_0000019,
3854,1,B,8,,,,55,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,,,,,,,H,Autocuration,CHEMBL618036,BAO_0000019,
3855,1,B,8,,,,55,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,,,,,,,H,Expert,CHEMBL618037,BAO_0000357,
3856,1,B,8,,,,55,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,,,,,,H,Expert,CHEMBL618038,BAO_0000357,
3857,1,F,8,,,,55,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,,,,,,H,Autocuration,CHEMBL618761,BAO_0000019,
3858,1,B,8,,,,55,Inhibition of lipoxygenase at the concentration of 0.1 uM,,,,,,,H,Expert,CHEMBL618762,BAO_0000357,
3859,1,B,8,,,,55,Inhibition of lipoxygenase at the concentration of 1 uM,,,,,,,H,Expert,CHEMBL618763,BAO_0000357,
3860,1,B,8,,,,55,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,,,,,,,H,Autocuration,CHEMBL618764,BAO_0000357,
3861,1,B,9,,,,55,Inhibition of 5-Lipoxygenase (5-LOX),,Homo sapiens,,,,9606.0,D,Expert,CHEMBL618765,BAO_0000357,
3862,1,B,8,,,,17087,Inhibition of 5-lipoxygenase in mouse macrophages.,,,,,,,H,Expert,CHEMBL618766,BAO_0000357,
3863,1,B,8,,,,17087,Inhibition of 5-lipoxygenase in mouse macrophages.,,,,,,,H,Expert,CHEMBL618767,BAO_0000357,
3864,1,B,8,,,,17087,Inhibitory activity against lipoxygenase-2 in mice,,,,,,,H,Autocuration,CHEMBL619380,BAO_0000357,
3865,1,B,8,,,,17087,Inhibitory activity against murine lipoxygenase-2.,,,,,,,H,Expert,CHEMBL619381,BAO_0000357,
3866,1,B,9,,,,17087,Inhibition of 5-lipoxygenase from mouse macrophage,,Mus musculus,,,,10090.0,D,Expert,CHEMBL619382,BAO_0000357,
3867,1,B,8,,,,17087,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,,,,,,,H,Autocuration,CHEMBL619383,BAO_0000357,
3868,1,B,8,,,,55,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL619384,BAO_0000019,
3869,1,B,8,,,,55,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,,Sus scrofa,,,,9823.0,H,Autocuration,CHEMBL619385,BAO_0000019,
3870,1,B,8,,,,55,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,,Oryctolagus cuniculus,,,,9986.0,H,Autocuration,CHEMBL882928,BAO_0000019,
3871,1,B,9,,,,12166,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL619386,BAO_0000019,
3872,1,B,8,,,,12166,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",,,,,,,H,Autocuration,CHEMBL619387,BAO_0000019,
3873,1,B,8,,,,12166,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,,,,,,H,Autocuration,CHEMBL619388,BAO_0000019,
3874,1,B,8,,,,12166,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",,,,,,,H,Autocuration,CHEMBL619389,BAO_0000019,
3875,1,B,8,,,,12166,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),,,,,,,H,Expert,CHEMBL619390,BAO_0000019,
3876,1,B,8,,,,12166,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",,,,,,,H,Expert,CHEMBL619391,BAO_0000019,
3877,1,B,8,,,,12166,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,,,,,,,H,Autocuration,CHEMBL619392,BAO_0000019,
3878,1,B,8,,,,12166,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),,,,,,,H,Autocuration,CHEMBL619393,BAO_0000019,
3879,1,B,8,,,,12166,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,,,,,,,H,Autocuration,CHEMBL619394,BAO_0000019,
3880,1,B,8,RBL-1,,,12166,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,,,702.0,,,H,Autocuration,CHEMBL619395,BAO_0000219,
3881,1,B,8,RBL-1,,,12166,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,,,702.0,,,H,Autocuration,CHEMBL619396,BAO_0000219,
3882,1,B,8,,,,12166,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),,,,,,,H,Autocuration,CHEMBL619397,BAO_0000357,
3883,1,B,8,,,,12166,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",,,,,,,H,Autocuration,CHEMBL619398,BAO_0000357,
3884,1,B,8,,,,12166,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",,,,,,,H,Autocuration,CHEMBL619399,BAO_0000357,
3885,1,B,8,,,,12166,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,,,,,,H,Autocuration,CHEMBL619400,BAO_0000357,
3886,1,B,8,,,,12166,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,,,,,,H,Autocuration,CHEMBL619401,BAO_0000019,
3887,1,B,8,,,,12166,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",,,,,,,H,Autocuration,CHEMBL619402,BAO_0000019,
3888,1,B,9,RBL-2H3,,,12166,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,,Rattus norvegicus,,663.0,,10116.0,D,Expert,CHEMBL619403,BAO_0000219,
3889,1,B,8,,,,12166,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,,,,,,H,Autocuration,CHEMBL619404,BAO_0000357,
3890,1,B,8,,,,12166,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,,,,,,,H,Autocuration,CHEMBL619405,BAO_0000357,
3891,1,B,8,RBL-1,,,12166,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,,,,702.0,,,H,Expert,CHEMBL619406,BAO_0000219,
3892,1,B,9,RBL-1,,,12166,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,,Rattus norvegicus,,702.0,,10116.0,D,Expert,CHEMBL619407,BAO_0000219,
3893,1,B,8,,,,12166,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),,,,,,,H,Autocuration,CHEMBL619408,BAO_0000357,
3894,1,B,8,RBL-1,,,12166,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,,,,702.0,,,H,Autocuration,CHEMBL619409,BAO_0000219,
3895,1,B,8,RBL-1,,,12166,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,,,,702.0,,,H,Expert,CHEMBL619410,BAO_0000219,
3896,1,B,8,RBL-1,,,12166,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,,,702.0,,,H,Autocuration,CHEMBL619753,BAO_0000219,
3897,1,B,8,RBL-1,,,12166,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,,,,702.0,,,H,Autocuration,CHEMBL619754,BAO_0000219,
3898,1,B,8,,,,12166,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,,,,,,,H,Expert,CHEMBL619903,BAO_0000357,
3899,1,B,8,,,,12166,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",,,,,,,H,Expert,CHEMBL619904,BAO_0000357,
3900,1,B,8,,,,12166,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,,,,,,,H,Expert,CHEMBL619905,BAO_0000357,
3901,1,B,8,,,,12166,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,,,,,,,H,Autocuration,CHEMBL619906,BAO_0000019,
3902,1,B,8,,,,12166,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,,,,,,,H,Autocuration,CHEMBL619907,BAO_0000019,
3903,1,B,8,,,,12166,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,,,,,,,H,Autocuration,CHEMBL619908,BAO_0000019,
3904,1,B,8,,,,12166,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,,,,,,,H,Autocuration,CHEMBL619909,BAO_0000019,
3905,1,F,8,RBL-1,,,12166,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,,,,702.0,,,H,Expert,CHEMBL619910,BAO_0000219,
3906,1,B,8,RBL-1,,,12166,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,,,,702.0,,,H,Expert,CHEMBL882929,BAO_0000219,
3907,1,B,8,RBL-1,,,12166,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,,,,702.0,,,H,Expert,CHEMBL619911,BAO_0000219,
3908,1,B,8,,,,12166,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,,,,,,,H,Autocuration,CHEMBL619912,BAO_0000019,
3909,1,B,9,,,,12166,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL619913,BAO_0000357,
3910,1,B,8,RBL-1,,,12166,In vitro inhibitory activity against RBL-1 5-LO,,,,702.0,,,H,Expert,CHEMBL619914,BAO_0000219,
3911,1,B,8,RBL-1,,,12166,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),,,,702.0,,,H,Autocuration,CHEMBL619915,BAO_0000219,
3912,1,B,8,RBL-1,,,12166,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),,,,702.0,,,H,Autocuration,CHEMBL619916,BAO_0000219,
3913,1,B,8,,,,12166,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,,,,,,,H,Autocuration,CHEMBL619917,BAO_0000218,
3914,1,B,8,,,,12166,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,,,,,,,H,Autocuration,CHEMBL619918,BAO_0000357,
3915,1,B,8,,,,12166,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,,,,,,,H,Autocuration,CHEMBL619919,BAO_0000218,
3916,1,B,8,RBL-1,,,12166,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,,,,702.0,,,H,Autocuration,CHEMBL883710,BAO_0000219,
3917,1,B,8,,,,12166,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,178.0,,,,,,H,Autocuration,CHEMBL619920,BAO_0000019,
3918,1,B,8,,,,12166,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,,,,,,,H,Expert,CHEMBL619921,BAO_0000357,
3919,1,F,8,,,,12166,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,,,,,,,H,Autocuration,CHEMBL619922,BAO_0000019,
3920,1,F,8,,,,12166,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,,,,,,,H,Autocuration,CHEMBL619923,BAO_0000219,
3921,1,B,8,RBL-1,,,12166,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,,,,702.0,,,H,Expert,CHEMBL619924,BAO_0000219,
3922,1,B,8,,,,12166,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,,,,,,,H,Expert,CHEMBL619925,BAO_0000357,
3923,1,B,8,RBL-1,,,12166,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,,,,702.0,,,H,Expert,CHEMBL619926,BAO_0000219,
3924,1,B,8,RBL-1,,,12166,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,,,,702.0,,,H,Autocuration,CHEMBL619927,BAO_0000219,
3925,1,B,8,RBL-1,,,12166,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,,,,702.0,,,H,Expert,CHEMBL619928,BAO_0000219,
3926,1,B,8,RBL-1,,,12166,In vitro inhibition of RBL-1 5-lipoxygenase,,,,702.0,,,H,Autocuration,CHEMBL619929,BAO_0000219,
3927,1,B,8,RBL-1,,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,,,,702.0,,,H,Autocuration,CHEMBL875089,BAO_0000219,
3928,1,B,8,RBL-1,,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,,,,702.0,,,H,Autocuration,CHEMBL619930,BAO_0000219,
3929,1,B,8,RBL-1,,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,,,,702.0,,,H,Autocuration,CHEMBL619931,BAO_0000219,
3930,1,B,8,RBL-1,,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,,,,702.0,,,H,Autocuration,CHEMBL619932,BAO_0000219,
3931,1,B,8,RBL-1,,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,,,,702.0,,,H,Autocuration,CHEMBL619933,BAO_0000219,
3932,1,B,8,RBL-1,,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,,,,702.0,,,H,Autocuration,CHEMBL619934,BAO_0000219,
3933,1,B,8,RBL-1,,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,,,,702.0,,,H,Autocuration,CHEMBL619935,BAO_0000219,
3934,1,B,8,RBL-1,,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,,,,702.0,,,H,Autocuration,CHEMBL619936,BAO_0000219,
3935,1,B,8,RBL-1,,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,,,,702.0,,,H,Autocuration,CHEMBL619937,BAO_0000219,
3936,1,B,8,RBL-1,,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,,,,702.0,,,H,Autocuration,CHEMBL619938,BAO_0000219,
3937,1,B,8,RBL-1,,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,,,,702.0,,,H,Autocuration,CHEMBL619939,BAO_0000219,
3938,1,B,8,RBL-1,,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,,,,702.0,,,H,Autocuration,CHEMBL619940,BAO_0000219,
3939,1,B,8,RBL-1,,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,,,,702.0,,,H,Autocuration,CHEMBL875090,BAO_0000219,
3940,1,B,8,RBL-1,,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,,,,702.0,,,H,Autocuration,CHEMBL619941,BAO_0000219,
3941,1,B,8,RBL-1,,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,,,,702.0,,,H,Autocuration,CHEMBL619942,BAO_0000219,
3942,1,B,8,RBL-1,,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,,,,702.0,,,H,Autocuration,CHEMBL883711,BAO_0000219,
3943,1,B,8,RBL-1,,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,,,,702.0,,,H,Autocuration,CHEMBL619943,BAO_0000219,
3944,1,B,8,RBL-1,,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,,,,702.0,,,H,Autocuration,CHEMBL619944,BAO_0000219,
3945,1,B,8,RBL-1,,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,,,,702.0,,,H,Autocuration,CHEMBL619945,BAO_0000219,
3946,1,B,8,RBL-1,,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,,,,702.0,,,H,Autocuration,CHEMBL619946,BAO_0000219,
3947,1,B,8,RBL-1,,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,,,,702.0,,,H,Autocuration,CHEMBL619947,BAO_0000219,
3948,1,B,8,RBL-1,,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,,,,702.0,,,H,Autocuration,CHEMBL619948,BAO_0000219,
3949,1,B,8,RBL-1,,,12166,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,,,,702.0,,,H,Autocuration,CHEMBL619949,BAO_0000219,
3950,1,B,8,,,,12166,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,,,,,,,H,Expert,CHEMBL619950,BAO_0000019,
3951,1,B,8,,,,12166,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,,,,,,,H,Autocuration,CHEMBL618050,BAO_0000019,
3952,1,F,8,RBL-2H3,,,12166,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,,,,663.0,,,H,Expert,CHEMBL875091,BAO_0000219,
3953,1,F,8,RBL-2H3,,,12166,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,,,,663.0,,,H,Expert,CHEMBL618051,BAO_0000219,
3954,1,B,9,RBL-1,,,12166,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,,Rattus norvegicus,,702.0,,10116.0,D,Expert,CHEMBL618052,BAO_0000219,
3955,1,B,8,,,,12166,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,,,,,,,H,Autocuration,CHEMBL618053,BAO_0000019,
3956,1,B,8,,,,12166,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),,,,,,,H,Expert,CHEMBL618054,BAO_0000019,
3957,1,B,9,RBL-1,,,12166,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,Rattus norvegicus,,702.0,,10116.0,D,Expert,CHEMBL618055,BAO_0000219,
3958,1,B,8,RBL-1,,,12166,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,,,,702.0,,,H,Expert,CHEMBL618056,BAO_0000219,
3959,1,B,8,,,,12166,In vitro inhibitory activity against 5-lipoxygenase was determined,,,,,,,H,Autocuration,CHEMBL618057,BAO_0000357,
3960,1,B,8,RBL-1,,,12166,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,,,,702.0,,,H,Autocuration,CHEMBL618058,BAO_0000219,
3961,1,B,8,RBL-1,,,12166,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,,,,702.0,,,H,Expert,CHEMBL618059,BAO_0000219,
3962,1,F,9,,,,12166,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL618060,BAO_0000019,
3963,1,B,8,RBL-1,,,12166,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,,,,702.0,,,H,Autocuration,CHEMBL618061,BAO_0000219,
3964,1,B,8,,,,12166,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,,,,,,,H,Autocuration,CHEMBL618062,BAO_0000019,
3965,1,B,8,RBL-1,,,12166,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,,,,702.0,,,H,Expert,CHEMBL618063,BAO_0000219,
3966,1,B,8,,,,12166,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,,,,,,,H,Autocuration,CHEMBL618064,BAO_0000357,
3967,1,B,9,RBL-1,,,12166,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,,Rattus norvegicus,,702.0,,10116.0,D,Expert,CHEMBL618065,BAO_0000219,
3968,1,B,9,RBL-1,,,12166,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,,Rattus norvegicus,,702.0,,10116.0,D,Expert,CHEMBL618066,BAO_0000219,
3969,1,B,8,RBL-1,,,12166,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,,,702.0,,,H,Autocuration,CHEMBL618067,BAO_0000219,
3970,1,B,8,RBL-1,,,12166,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,,,702.0,,,H,Autocuration,CHEMBL618068,BAO_0000219,
3971,1,B,9,RBL-1,,,12166,Inhibition of 5-lipoxygenase in rat RBL-1 cells,,Rattus norvegicus,,702.0,,10116.0,D,Expert,CHEMBL618069,BAO_0000219,
3972,1,B,8,RBL-1,,,12166,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,,,702.0,,,H,Expert,CHEMBL618070,BAO_0000219,
3973,1,F,8,,,,10825,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,349.0,,,,,,H,Autocuration,CHEMBL618071,BAO_0000019,
3974,1,F,8,,,,10825,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,349.0,,,,,,H,Autocuration,CHEMBL619247,BAO_0000019,
3975,1,F,8,,,,10825,Approximate dose levels for a half maximal reduction of 5-HTP levels,,,,,,,H,Autocuration,CHEMBL619248,BAO_0000019,
3976,1,B,8,,,,10576,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,10000000.0,,,,,,H,Autocuration,CHEMBL619249,BAO_0000221,
3977,1,B,8,,,,10576,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,10000000.0,,,,,,H,Autocuration,CHEMBL619250,BAO_0000221,
3978,1,B,8,,,,10577,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,,,,,,H,Autocuration,CHEMBL619251,BAO_0000019,
3979,1,F,8,,,,55,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL619252,BAO_0000019,
3980,1,F,8,,,,55,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,178.0,,,,,,H,Autocuration,CHEMBL619253,BAO_0000019,
3981,1,B,8,,,,12166,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,,,,,,H,Autocuration,CHEMBL619254,BAO_0000219,
3982,1,B,8,,,,17140,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,,,,,,,H,Expert,CHEMBL619255,BAO_0000219,
3983,1,B,8,,,,17140,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,,,,,,,H,Expert,CHEMBL619256,BAO_0000219,
3984,1,B,8,,,,17140,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),,,,,,,H,Autocuration,CHEMBL875418,BAO_0000219,
3985,1,B,8,,,,17140,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,,,,,,H,Expert,CHEMBL619257,BAO_0000219,
3986,1,B,8,,,,17140,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,,,,,,H,Autocuration,CHEMBL619258,BAO_0000219,
3987,1,B,8,,,,17140,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,,,,,,,H,Expert,CHEMBL619259,BAO_0000357,
3988,1,B,8,,,,17140,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,,,,,,,H,Expert,CHEMBL619260,BAO_0000357,
3989,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL619261,BAO_0000218,
3990,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL619263,BAO_0000218,
3991,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL619264,BAO_0000218,
3992,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL619265,BAO_0000218,
3993,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL619266,BAO_0000218,
3994,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL619902,BAO_0000218,
3995,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL620058,BAO_0000218,
3996,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL620059,BAO_0000218,
3997,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL620060,BAO_0000218,
3998,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL620061,BAO_0000218,
3999,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL620062,BAO_0000218,
4000,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL620063,BAO_0000218,
4001,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL620064,BAO_0000218,
4002,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL620065,BAO_0000218,
4003,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL620066,BAO_0000218,
4004,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL620067,BAO_0000218,
4005,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL620068,BAO_0000218,
4006,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL620069,BAO_0000218,
4007,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL620070,BAO_0000218,
4008,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL620071,BAO_0000218,
4009,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL620072,BAO_0000218,
4010,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL620036,BAO_0000218,
4011,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL857702,BAO_0000218,
4012,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL620037,BAO_0000218,
4013,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL620038,BAO_0000218,
4014,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL620039,BAO_0000218,
4015,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL620040,BAO_0000218,
4016,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL620041,BAO_0000218,
4017,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL620042,BAO_0000218,
4018,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL620043,BAO_0000218,
4019,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL620044,BAO_0000218,
4020,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL620045,BAO_0000218,
4021,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL620046,BAO_0000218,
4022,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL620047,BAO_0000218,
4023,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL620048,BAO_0000218,
4024,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL857703,BAO_0000218,
4025,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL620049,BAO_0000218,
4026,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL620050,BAO_0000218,
4027,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL620051,BAO_0000218,
4028,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL619213,BAO_0000218,
4029,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL619214,BAO_0000218,
4030,1,F,8,,,In vivo,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL619804,BAO_0000218,
4031,1,F,8,,,In vivo,55,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL619805,BAO_0000218,
4032,1,F,8,,,In vivo,55,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL619806,BAO_0000218,
4033,1,F,8,,,In vivo,55,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL619807,BAO_0000218,
4034,1,F,8,,,In vivo,55,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",178.0,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL619808,BAO_0000218,
4035,1,B,8,,,,55,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL619809,BAO_0000218,
4036,1,B,8,,,,55,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL619810,BAO_0000218,
4037,1,B,8,,,,55,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL619811,BAO_0000218,
4038,1,B,8,,,,55,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL620769,BAO_0000218,
4039,1,B,8,,,,55,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL620770,BAO_0000218,
4040,1,B,8,,,,55,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL620771,BAO_0000218,
4041,1,B,8,,,,55,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL620772,BAO_0000218,
4042,1,B,8,,,,55,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL620773,BAO_0000218,
4043,1,B,8,,,,55,Ability to inhibit 5-lipoxygenase in guinea pig,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL620774,BAO_0000357,
4044,1,B,8,,,,55,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),,Cavia porcellus,,,,10141.0,H,Expert,CHEMBL620775,BAO_0000357,
4045,1,B,8,,,,55,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL620776,BAO_0000357,
4046,1,B,8,,,,55,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",178.0,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL620777,BAO_0000218,
4047,1,B,8,,,,55,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL620778,BAO_0000357,
4048,1,B,8,,,,55,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL620779,BAO_0000357,
4049,1,B,8,,,,55,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,,Cavia porcellus,,,,10141.0,H,Expert,CHEMBL621500,BAO_0000019,
4050,1,B,8,,,,55,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,Cavia porcellus,,,,10141.0,H,Expert,CHEMBL621501,BAO_0000019,
4051,1,B,8,,,,55,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL618098,BAO_0000019,
4052,1,B,8,,,,55,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL618099,BAO_0000019,
4053,1,B,8,,,,55,Inhibitory activity against 5-lipoxygenase,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL618100,BAO_0000357,
4054,1,B,8,,,,55,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL618101,BAO_0000357,
4055,1,B,8,,,,55,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL618102,BAO_0000357,
4056,1,B,8,,,,55,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL618103,BAO_0000357,
4057,1,B,8,,,,55,Inhibitory activity uM,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL618104,BAO_0000357,
4058,1,B,8,,,,55,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL883712,BAO_0000219,
4059,1,B,8,,,,55,Inhibitory activity against 5-lipoxygenase at 10 uM,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL618105,BAO_0000357,
4060,1,B,8,,,,55,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL618106,BAO_0000357,
4061,1,B,8,,,,55,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL618107,BAO_0000357,
4062,1,B,8,,,,55,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL618108,BAO_0000357,
4063,1,B,8,,,,55,Inhibitory activity uM,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL618109,BAO_0000357,
4064,1,B,8,,,,55,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL618110,BAO_0000357,
4065,1,B,8,,,,55,Inhibitory activity uM,,Cavia porcellus,,,,10141.0,H,Expert,CHEMBL618111,BAO_0000357,
4066,1,F,8,,,,55,Inhibitory activity uM,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL618112,BAO_0000019,
4067,1,B,8,,,,55,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL618113,BAO_0000019,
4068,1,B,8,,,,55,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,Cavia porcellus,,,,10141.0,H,Autocuration,CHEMBL618114,BAO_0000357,
4069,1,F,8,,,,55,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,2116.0,Cavia porcellus,,,,10141.0,H,Expert,CHEMBL620871,BAO_0000221,
4070,1,B,8,,,,55,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,,,,,,H,Autocuration,CHEMBL620872,BAO_0000357,
4071,1,B,8,,,,55,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,,,,,,H,Autocuration,CHEMBL620873,BAO_0000357,
4072,1,B,8,,,,55,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),,,,,,,H,Autocuration,CHEMBL620874,BAO_0000357,
4073,1,B,8,,,,55,In vitro inhibition of human 5-Lipoxygenase.,,,,,,,H,Expert,CHEMBL620875,BAO_0000357,
4074,1,B,0,,,,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL620876,BAO_0000251,
4075,1,B,0,,,,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL620877,BAO_0000251,
4076,1,B,0,,,,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL857854,BAO_0000251,
4077,1,B,0,,,,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL620878,BAO_0000251,
4078,1,B,0,,,,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL620879,BAO_0000251,
4079,1,B,0,,,,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL620880,BAO_0000251,
4080,1,B,0,,,,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL620881,BAO_0000251,
4081,1,B,0,,,,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL620882,BAO_0000251,
4082,1,B,0,,,,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL620883,BAO_0000251,
4083,1,B,0,,,,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL620884,BAO_0000251,
4084,1,B,0,,,,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL620885,BAO_0000251,
4085,1,B,0,,,,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL620886,BAO_0000251,
4086,1,B,0,,,,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL620887,BAO_0000251,
4087,1,B,0,,,,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL618039,BAO_0000251,
4088,1,B,0,,,,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL618040,BAO_0000251,
4089,1,B,0,,,,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL618041,BAO_0000251,
4090,1,B,0,,,,22226,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL618216,BAO_0000251,
4091,1,B,0,,,,22226,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL618217,BAO_0000251,
4092,1,B,0,,,,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL618218,BAO_0000251,
4093,1,B,0,,,,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL618219,BAO_0000251,
4094,1,B,0,,,,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL618220,BAO_0000251,
4095,1,B,0,,,,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL618221,BAO_0000251,
4096,1,B,0,,,,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL618222,BAO_0000251,
4097,1,B,0,,,,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL618223,BAO_0000251,
4098,1,B,0,,,,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL618224,BAO_0000251,
4099,1,B,0,,,,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL618225,BAO_0000251,
4100,1,B,0,,,,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL618226,BAO_0000251,
4101,1,B,0,,,,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL618227,BAO_0000251,
4102,1,B,0,,,,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL618228,BAO_0000251,
4103,1,B,0,,,,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL618229,BAO_0000251,
4104,1,B,0,,,,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL618230,BAO_0000251,
4105,1,B,0,,,,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL618231,BAO_0000251,
4106,1,B,0,,,,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL618232,BAO_0000251,
4107,1,B,0,,,,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL618233,BAO_0000251,
4108,1,B,0,,,,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL618234,BAO_0000251,
4109,1,B,0,,,,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL618235,BAO_0000251,
4110,1,B,0,,,,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL618115,BAO_0000251,
4111,1,B,0,,,,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL618116,BAO_0000251,
4112,1,B,0,,,,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL618117,BAO_0000251,
4113,1,B,0,,,,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL619968,BAO_0000251,
4114,1,B,0,,,,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL619969,BAO_0000251,
4115,1,B,0,,,,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL619970,BAO_0000251,
4116,1,B,0,,,,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL619971,BAO_0000251,
4117,1,B,0,,,,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL619972,BAO_0000251,
4118,1,B,0,,,,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL619973,BAO_0000251,
4119,1,B,0,,,,22226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL619974,BAO_0000251,
4120,1,B,0,,,,22226,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL619975,BAO_0000251,
4121,1,B,0,,,,22226,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL619976,BAO_0000251,
4122,1,B,0,,,,22226,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL619977,BAO_0000251,
4123,1,B,0,,,,22226,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL619978,BAO_0000251,
4124,1,B,0,,,,22226,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL619979,BAO_0000251,
4125,1,B,0,,,,22226,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL619980,BAO_0000251,
4126,1,B,0,,,,22226,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL619981,BAO_0000251,
4127,1,F,1,RPMI-8226,,,80433,In vitro inhibition of 7226/S myeloma cancer cell line,,Homo sapiens,,741.0,,9606.0,N,Intermediate,CHEMBL619982,BAO_0000219,
4128,1,F,1,BEL-7404 tumor cell line,,,80698,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),,Homo sapiens,,993.0,,9606.0,N,Intermediate,CHEMBL619983,BAO_0000219,
4129,1,F,1,786-0,,,80640,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,Homo sapiens,,391.0,,9606.0,N,Intermediate,CHEMBL620031,BAO_0000219,
4130,1,F,1,786-0,,,80640,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,Homo sapiens,,391.0,,9606.0,N,Intermediate,CHEMBL620032,BAO_0000219,
4131,1,F,1,V79,,,81264,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,,Cricetulus griseus,,505.0,,10029.0,N,Expert,CHEMBL620033,BAO_0000219,
4132,1,F,1,V79,,,81264,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,,Cricetulus griseus,,505.0,,10029.0,N,Expert,CHEMBL620034,BAO_0000219,
4133,1,F,1,7800C1 cell line,,,80635,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,,Rattus norvegicus,,1119.0,,10116.0,N,Intermediate,CHEMBL620035,BAO_0000219,
4134,1,F,1,7800C1 cell line,,,80635,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,,Rattus norvegicus,,1119.0,,10116.0,N,Intermediate,CHEMBL618318,BAO_0000219,
4135,1,F,1,7800C1 cell line,,,80635,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,,Rattus norvegicus,,1119.0,,10116.0,N,Intermediate,CHEMBL618319,BAO_0000219,
4136,1,F,1,7800C1 cell line,,,80635,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,,Rattus norvegicus,,1119.0,,10116.0,N,Intermediate,CHEMBL618320,BAO_0000219,
4137,1,F,1,7800C1 cell line,,,80635,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,,Rattus norvegicus,,1119.0,,10116.0,N,Intermediate,CHEMBL618321,BAO_0000219,
4138,1,F,1,7800C1 cell line,,,80635,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,,Rattus norvegicus,,1119.0,,10116.0,N,Intermediate,CHEMBL883118,BAO_0000219,
4139,1,F,1,786-0,,,80640,In vitro antitumor activity against renal 786-0 tumor cell lines,,Homo sapiens,,391.0,,9606.0,N,Intermediate,CHEMBL883795,BAO_0000219,
4140,1,F,1,786-0,,,80640,Cytotoxic activity against 786-0 Renal cancer cell line,,Homo sapiens,,391.0,,9606.0,N,Intermediate,CHEMBL618322,BAO_0000219,
4141,1,F,1,786-0,,,80640,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,,Homo sapiens,,391.0,,9606.0,N,Intermediate,CHEMBL618323,BAO_0000219,
4142,1,F,1,786-0,,,80640,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,,Homo sapiens,,391.0,,9606.0,N,Intermediate,CHEMBL618324,BAO_0000219,
4143,1,F,1,786-0,,,80640,In vitro antitumor activity against human renal 786-0 cell line,,Homo sapiens,,391.0,,9606.0,N,Intermediate,CHEMBL618325,BAO_0000219,
4144,1,F,1,786-0,,,80640,Inhibition of Renal cancer in 786-0 cancer cell lines,,Homo sapiens,,391.0,,9606.0,N,Intermediate,CHEMBL875416,BAO_0000219,
4145,1,F,1,786-0,,,80640,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,,Homo sapiens,,391.0,,9606.0,N,Intermediate,CHEMBL618326,BAO_0000219,
4146,1,F,1,786-0,,,80640,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,,Homo sapiens,,391.0,,9606.0,N,Intermediate,CHEMBL618327,BAO_0000219,
4147,1,F,1,786-0,,,80640,inhibition of the growth of renal cancer(786-0) cell line,,Homo sapiens,,391.0,,9606.0,N,Intermediate,CHEMBL619215,BAO_0000219,
4148,1,F,1,786-0,,,80640,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,Homo sapiens,,391.0,,9606.0,N,Intermediate,CHEMBL619216,BAO_0000219,
4149,1,F,1,786-0,,,80640,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,,Homo sapiens,,391.0,,9606.0,N,Intermediate,CHEMBL619217,BAO_0000219,
4150,1,F,1,786-0,,,80640,The IC50 value was measured on 786-0 cell line in ovarian tumor,,Homo sapiens,,391.0,,9606.0,N,Intermediate,CHEMBL619218,BAO_0000219,
4151,1,F,1,786-0,,,80640,The IC50 value was measured on 786-0 cell line in ovarian tumor t,,Homo sapiens,,391.0,,9606.0,N,Intermediate,CHEMBL619219,BAO_0000219,
4152,1,F,1,786-0,,,80640,The IC50 value was measured on 786-0 cell line in renal tumor type.,,Homo sapiens,,391.0,,9606.0,N,Intermediate,CHEMBL619220,BAO_0000219,
4153,1,F,1,786-0,,,80640,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,,Homo sapiens,,391.0,,9606.0,N,Intermediate,CHEMBL619221,BAO_0000219,
4154,1,F,1,786-0,,,80640,Tested for cytotoxic activity against renal cancer 786-0 cell line,,Homo sapiens,,391.0,,9606.0,N,Intermediate,CHEMBL619222,BAO_0000219,
4155,1,F,1,786-0,,,80640,Compound was tested for growth inhibitory activity against 786-0 cell line,,Homo sapiens,,391.0,,9606.0,N,Intermediate,CHEMBL857454,BAO_0000219,
4156,1,B,8,RBL-1,,,12166,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,,,,702.0,,,H,Autocuration,CHEMBL619223,BAO_0000219,
4157,1,B,8,RBL-1,,,12166,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,,,,702.0,,,H,Autocuration,CHEMBL619224,BAO_0000219,
4158,1,B,8,,,,12166,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,,,,,,H,Autocuration,CHEMBL619225,BAO_0000019,
4159,1,B,8,RBL-1,,,12166,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,,,702.0,,,H,Expert,CHEMBL619226,BAO_0000219,
4160,1,B,8,RBL-1,,,12166,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,,,702.0,,,H,Expert,CHEMBL619227,BAO_0000219,
4161,1,B,8,,,,12166,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,,,,,,,H,Autocuration,CHEMBL619228,BAO_0000357,
4162,1,B,8,,,,12166,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,,,,,,,H,Autocuration,CHEMBL619229,BAO_0000219,
4163,1,B,8,RBL-1,,,12166,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,,,,702.0,,,H,Autocuration,CHEMBL619230,BAO_0000219,
4164,1,B,8,,,,12166,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,,,,,,,H,Autocuration,CHEMBL619231,BAO_0000357,
4165,1,B,8,,,,12166,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",,,,,,,H,Autocuration,CHEMBL619232,BAO_0000357,
4166,1,B,8,,,,12166,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,,,,,,,H,Expert,CHEMBL619233,BAO_0000357,
4167,1,B,8,,,,12166,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,,,,,,,H,Autocuration,CHEMBL619234,BAO_0000357,
4168,1,B,8,,,,12166,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),,,,,,,H,Autocuration,CHEMBL619235,BAO_0000357,
4169,1,B,9,,,,12166,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL619236,BAO_0000019,
4170,1,B,8,RBL-1,,,12166,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,,,,702.0,,,H,Autocuration,CHEMBL619237,BAO_0000219,
4171,1,B,8,,,,12166,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,,,,,,,H,Autocuration,CHEMBL619238,BAO_0000357,
4172,1,B,8,,,,12166,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,,,,,,,H,Expert,CHEMBL619239,BAO_0000357,
4173,1,B,8,,,,12166,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,,,,,,,H,Autocuration,CHEMBL619240,BAO_0000357,
4174,1,B,8,,,,12166,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,,,,,,H,Autocuration,CHEMBL875417,BAO_0000019,
4175,1,B,8,RBL-1,,,12166,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),,,,702.0,,,H,Autocuration,CHEMBL619241,BAO_0000219,
4176,1,F,8,,,,12166,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,,,,,,H,Expert,CHEMBL619242,BAO_0000019,
4177,1,B,8,RBL-1,,,12166,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,,,,702.0,,,H,Autocuration,CHEMBL883796,BAO_0000219,
4178,1,B,8,,,,12166,Tested for its inhibitory activity against 5-lipoxygenase,,,,,,,H,Autocuration,CHEMBL619243,BAO_0000357,
4179,1,B,8,,,,12166,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,,,,,,,H,Autocuration,CHEMBL619244,BAO_0000357,
4180,1,B,8,,,,12166,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",,,,,,,H,Expert,CHEMBL619245,BAO_0000019,
4181,1,B,8,,,,12166,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,,,,,,H,Expert,CHEMBL619246,BAO_0000019,
4182,1,B,8,RBL-1,,,12166,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,,,,702.0,,,H,Expert,CHEMBL619984,BAO_0000219,
4183,1,B,8,RBL-1,,,12166,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,,,,702.0,,,H,Autocuration,CHEMBL619985,BAO_0000219,
4184,1,B,8,RBL-1,,,12166,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,,,702.0,,,H,Autocuration,CHEMBL619986,BAO_0000219,
4185,1,B,8,RBL-1,,,12166,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,,,702.0,,,H,Expert,CHEMBL619987,BAO_0000219,
4186,1,B,8,,,,12166,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,,,,,,,H,Autocuration,CHEMBL619988,BAO_0000218,
4187,1,B,8,RBL-1,,,12166,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,,,,702.0,,,H,Autocuration,CHEMBL619989,BAO_0000219,
4188,1,B,8,RBL-1,,,12166,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,,,702.0,,,H,Autocuration,CHEMBL619990,BAO_0000219,
4189,1,B,8,,,,12166,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,,,,,,H,Autocuration,CHEMBL619991,BAO_0000219,
4190,1,B,8,,,,12166,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),,,,,,,H,Autocuration,CHEMBL619992,BAO_0000219,
4191,1,B,8,,,In vivo,12166,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),,,,,,,H,Autocuration,CHEMBL619993,BAO_0000218,
4192,1,F,8,RBL-2H3,,,12166,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,,,,663.0,,,H,Autocuration,CHEMBL619994,BAO_0000219,
4193,1,F,8,RBL-2H3,,,12166,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,,,,663.0,,,H,Autocuration,CHEMBL619995,BAO_0000219,
4194,1,B,8,,,,12166,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],,,,,,,H,Autocuration,CHEMBL619996,BAO_0000019,
4195,1,B,8,,,,12166,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,,,,,,,H,Autocuration,CHEMBL619997,BAO_0000019,
4196,1,B,8,,,,12166,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,,,,,,,H,Expert,CHEMBL619998,BAO_0000019,
4197,1,B,8,,,,12166,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,,,,,,,H,Expert,CHEMBL619999,BAO_0000019,
4198,1,B,8,,,,12166,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,,,,,,,H,Autocuration,CHEMBL620000,BAO_0000019,
4199,1,B,8,RBL-1,,,12166,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,,,,702.0,,,H,Autocuration,CHEMBL620001,BAO_0000219,
4200,1,B,9,,,,12166,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL620002,BAO_0000357,
4201,1,B,8,RBL-1,,,12166,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,,,,702.0,,,H,Autocuration,CHEMBL620003,BAO_0000219,
4202,1,F,8,RBL-1,,,12166,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,,,,702.0,,,H,Expert,CHEMBL620004,BAO_0000219,
4203,1,B,8,,,,12166,Compound was evaluated for the inhibition of 5-lipoxygenase,,,,,,,H,Autocuration,CHEMBL874063,BAO_0000357,
4204,1,B,8,RBL-1,,,12166,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,,,,702.0,,,H,Autocuration,CHEMBL620005,BAO_0000219,
4205,1,B,8,RBL-1,,,12166,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,,,,702.0,,,H,Autocuration,CHEMBL620006,BAO_0000219,
4206,1,B,8,RBL-1,,,12166,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,,,,702.0,,,H,Autocuration,CHEMBL620007,BAO_0000219,
4207,1,B,8,RBL-1,,,12166,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,,,,702.0,,,H,Autocuration,CHEMBL620008,BAO_0000219,
4208,1,B,9,RBL-1,,,12166,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,,Rattus norvegicus,,702.0,,10116.0,D,Expert,CHEMBL620009,BAO_0000219,
4209,1,B,8,RBL-1,,,12166,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,,,702.0,,,H,Autocuration,CHEMBL620010,BAO_0000219,
4210,1,B,8,RBL-1,,,12166,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,,,,702.0,,,H,Autocuration,CHEMBL620011,BAO_0000219,
4211,1,B,8,RBL-1,,,12166,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,,,,702.0,,,H,Autocuration,CHEMBL620677,BAO_0000219,
4212,1,B,8,RBL-1,,,12166,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,,,,702.0,,,H,Autocuration,CHEMBL620678,BAO_0000219,
4213,1,B,8,RBL-1,,,12166,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,,,,702.0,,,H,Autocuration,CHEMBL620679,BAO_0000219,
4214,1,B,8,RBL-1,,,12166,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,,,,702.0,,,H,Autocuration,CHEMBL620680,BAO_0000219,
4215,1,B,9,,,,12166,Inhibitory activity against 5-lipoxygenase at 10 uM,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL620838,BAO_0000357,
4216,1,B,8,,,,12166,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,,,,,,,H,Autocuration,CHEMBL620839,BAO_0000357,
4217,1,B,8,,,,12166,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,,,,,,,H,Expert,CHEMBL620840,BAO_0000357,
4218,1,B,8,RBL-1,,,12166,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,,,,702.0,,,H,Expert,CHEMBL620841,BAO_0000219,
4219,1,B,8,RBL-1,,,12166,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,,,,702.0,,,H,Autocuration,CHEMBL620842,BAO_0000219,
4220,1,B,8,RBL-1,,,12166,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,,,,702.0,,,H,Autocuration,CHEMBL620843,BAO_0000219,
4221,1,B,8,RBL-1,,,12166,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,,,,702.0,,,H,Autocuration,CHEMBL620844,BAO_0000219,
4222,1,B,8,RBL-1,,,12166,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,,,,702.0,,,H,Autocuration,CHEMBL620845,BAO_0000219,
4223,1,B,8,,,,12166,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,,,,,,,H,Autocuration,CHEMBL620846,BAO_0000019,
4224,1,B,8,,,,12166,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,,,,,,H,Autocuration,CHEMBL873951,BAO_0000357,
4225,1,B,8,,,,12166,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,,,,,,H,Autocuration,CHEMBL620847,BAO_0000357,
4226,1,B,8,RBL-1,,,12166,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,,,702.0,,,H,Autocuration,CHEMBL620848,BAO_0000219,
4227,1,B,8,RBL-1,,,12166,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,,,702.0,,,H,Autocuration,CHEMBL620849,BAO_0000219,
4228,1,B,8,RBL-1,,,12166,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,,,,702.0,,,H,Autocuration,CHEMBL620850,BAO_0000219,
4229,1,B,8,RBL-1,,,12166,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,,,,702.0,,,H,Autocuration,CHEMBL620851,BAO_0000219,
4230,1,B,8,RBL-1,,,12166,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,,,,702.0,,,H,Autocuration,CHEMBL620852,BAO_0000219,
4231,1,B,8,RBL-1,,,12166,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,,,702.0,,,H,Autocuration,CHEMBL875098,BAO_0000219,
4232,1,B,9,RBL-1,,,12166,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,,Rattus norvegicus,,702.0,,10116.0,D,Expert,CHEMBL620853,BAO_0000219,
4233,1,B,8,,,,12166,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,,,,,,,H,Autocuration,CHEMBL620854,BAO_0000019,
4234,1,B,8,RBL-1,,,12166,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,,,702.0,,,H,Autocuration,CHEMBL620855,BAO_0000219,
4235,1,B,8,RBL-1,,,12166,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,,,702.0,,,H,Expert,CHEMBL839884,BAO_0000219,
4236,1,B,8,RBL-1,,,12166,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,,,702.0,,,H,Autocuration,CHEMBL620856,BAO_0000219,
4237,1,B,8,RBL-1,,,12166,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,,,702.0,,,H,Autocuration,CHEMBL620857,BAO_0000219,
4238,1,B,8,,,,12166,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,,,,,,H,Autocuration,CHEMBL620858,BAO_0000019,
4239,1,B,8,,,,12166,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,,,,,,H,Autocuration,CHEMBL620859,BAO_0000019,
4240,1,B,8,,,,12166,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,,,,,,H,Autocuration,CHEMBL620860,BAO_0000019,
4241,1,B,8,,,,12166,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,,,,,,,H,Autocuration,CHEMBL620861,BAO_0000019,
4242,1,B,8,,,,12166,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),,,,,,,H,Expert,CHEMBL620862,BAO_0000357,
4243,1,B,8,,,,12166,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,,,,,,,H,Autocuration,CHEMBL620863,BAO_0000357,
4244,1,B,8,,,,12166,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,,,,,,H,Autocuration,CHEMBL620864,BAO_0000019,
4245,1,B,8,RBL-1,,,12166,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,,,,702.0,,,H,Autocuration,CHEMBL620865,BAO_0000219,
4246,1,B,8,RBL-1,,,12166,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,,,,702.0,,,H,Autocuration,CHEMBL620866,BAO_0000219,
4247,1,B,8,RBL-2H3,,,12166,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,,,,663.0,,,H,Autocuration,CHEMBL620867,BAO_0000219,
4248,1,B,8,RBL-2H3,,,12166,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,,,663.0,,,H,Autocuration,CHEMBL620868,BAO_0000219,
4249,1,F,8,RBL-2H3,,,12166,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,,,663.0,,,H,Autocuration,CHEMBL620869,BAO_0000219,
4250,1,F,8,,,,12166,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,,,,,,,H,Autocuration,CHEMBL873952,BAO_0000019,
4251,1,B,8,,,,12166,The compound was tested for inhibition of isolated 5-lipoxygenase,,,,,,,H,Autocuration,CHEMBL875099,BAO_0000357,
4252,1,F,8,RBL-2H3,,,12166,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,,,,663.0,,,H,Autocuration,CHEMBL620870,BAO_0000219,
4253,1,B,8,,,,12166,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,,,,,,,H,Autocuration,CHEMBL618261,BAO_0000019,
4254,1,B,8,,,,12166,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,,,,,,,H,Autocuration,CHEMBL618262,BAO_0000019,
4255,1,B,8,,,,12166,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,,,,,,,H,Autocuration,CHEMBL619428,BAO_0000019,
4256,1,B,8,,,,12166,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,,,,,,H,Autocuration,CHEMBL619429,BAO_0000019,
4257,1,B,8,,,,12166,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,,,,,,H,Autocuration,CHEMBL619430,BAO_0000019,
4258,1,B,8,RBL-1,,,12166,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,,,,702.0,,,H,Autocuration,CHEMBL620017,BAO_0000219,
4259,1,B,8,RBL-1,,,12166,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,,,,702.0,,,H,Autocuration,CHEMBL620018,BAO_0000219,
4260,1,F,8,RBL-1,,,12166,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,,,,702.0,,,H,Autocuration,CHEMBL620019,BAO_0000219,
4261,1,F,8,RBL-1,,,12166,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,,,,702.0,,,H,Autocuration,CHEMBL620020,BAO_0000219,
4262,1,F,8,RBL-1,,,12166,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,,,,702.0,,,H,Autocuration,CHEMBL620021,BAO_0000219,
4263,1,F,8,RBL-1,,,12166,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,,,,702.0,,,H,Autocuration,CHEMBL620022,BAO_0000219,
4264,1,F,8,RBL-1,,,12166,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,,,,702.0,,,H,Autocuration,CHEMBL620023,BAO_0000219,
4265,1,F,8,RBL-1,,,12166,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,,,,702.0,,,H,Autocuration,CHEMBL620024,BAO_0000219,
4266,1,F,8,RBL-1,,,12166,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,,,,702.0,,,H,Autocuration,CHEMBL620025,BAO_0000219,
4267,1,F,8,RBL-1,,,12166,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,,,,702.0,,,H,Autocuration,CHEMBL620026,BAO_0000219,
4268,1,F,8,RBL-1,,,12166,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,,,,702.0,,,H,Autocuration,CHEMBL620027,BAO_0000219,
4269,1,F,9,,,,12166,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL620028,BAO_0000019,
4270,1,B,8,,,,12166,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,,,,,,,H,Autocuration,CHEMBL620029,BAO_0000357,
4271,1,B,8,,,,12166,Compound was tested for the percent of inhibition against 5-LO at 10 uM,,,,,,,H,Autocuration,CHEMBL620030,BAO_0000357,
4272,1,B,8,RBL-1,,,12166,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,,,,702.0,,,H,Autocuration,CHEMBL875415,BAO_0000219,
4273,1,B,8,RBL-1,,,12166,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,,,702.0,,,H,Autocuration,CHEMBL618256,BAO_0000219,
4274,1,B,8,RBL-1,,,12166,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,,,,702.0,,,H,Autocuration,CHEMBL618257,BAO_0000219,
4275,1,B,8,RBL-1,,,12166,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,,,,702.0,,,H,Autocuration,CHEMBL618258,BAO_0000219,
4276,1,B,8,RBL-1,,,12166,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,,,,702.0,,,H,Autocuration,CHEMBL618259,BAO_0000219,
4277,1,B,8,,,,12166,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,,,,,,H,Autocuration,CHEMBL618260,BAO_0000019,
4278,1,B,8,RBL-1,,,12166,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,,,,702.0,,,H,Autocuration,CHEMBL618215,BAO_0000219,
4279,1,B,8,RBL-1,,,12166,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,,,,702.0,,,H,Autocuration,CHEMBL618390,BAO_0000219,
4280,1,B,8,RBL-1,,,12166,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,,,,702.0,,,H,Autocuration,CHEMBL618391,BAO_0000219,
4281,1,B,8,RBL-1,,,12166,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,,,,702.0,,,H,Autocuration,CHEMBL618392,BAO_0000219,
4282,1,B,8,RBL-1,,,12166,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,,,,702.0,,,H,Autocuration,CHEMBL618393,BAO_0000219,
4283,1,B,8,,,,12166,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,,,,,,,H,Autocuration,CHEMBL618394,BAO_0000219,
4284,1,B,8,RBL-1,,,12166,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,Homo sapiens,,702.0,,9606.0,H,Expert,CHEMBL618395,BAO_0000219,
4285,1,B,9,RBL-1,,,12166,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,Rattus norvegicus,,702.0,,10116.0,D,Expert,CHEMBL618396,BAO_0000219,
4286,1,B,9,RBL-1,,,12166,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),,Rattus norvegicus,,702.0,,10116.0,D,Expert,CHEMBL858253,BAO_0000219,
4287,1,B,9,,,,12166,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL618397,BAO_0000019,
4288,1,B,8,,,,12054,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),,Glycine max,,,,3847.0,H,Autocuration,CHEMBL618398,BAO_0000357,
4289,1,B,0,,,,22226,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",,,,,,,U,Autocuration,CHEMBL618399,BAO_0000019,
4290,1,B,8,,,,55,In vitro inhibition of 5-Lipoxygenase; Inactive.,,,,,,,H,Expert,CHEMBL618400,BAO_0000357,
4291,1,B,8,,,,55,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,,,,,,,H,Autocuration,CHEMBL618401,BAO_0000357,
4292,1,B,8,,,,55,Inhibitory concentration against 5-lipoxygenase; No inhibition,,,,,,,H,Autocuration,CHEMBL618402,BAO_0000357,
4293,1,B,8,RBL-1,,,55,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,,,,702.0,,,H,Autocuration,CHEMBL876400,BAO_0000219,
4294,1,B,8,,,,55,Inhibitory activity against 5-lipoxygenase.,,,,,,,H,Expert,CHEMBL618403,BAO_0000357,
4295,1,B,8,,,,55,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,,,,,,,H,Autocuration,CHEMBL618404,BAO_0000357,
4296,1,B,8,,,,55,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,,,,,,,H,Autocuration,CHEMBL618405,BAO_0000357,
4297,1,B,8,,,,55,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,,,,,,,H,Autocuration,CHEMBL618406,BAO_0000357,
4298,1,F,8,,,,55,Inhibitory concentration against arachidonic acid 5-lipoxygenation,,,,,,,H,Expert,CHEMBL618407,BAO_0000019,
4299,1,B,8,,,,55,Tested for the inhibitory activity against 5-lipoxygenase,,,,,,,H,Autocuration,CHEMBL618408,BAO_0000357,
4300,1,B,8,,,,55,Compound was tested for its inhibitory activity against 5-lipoxygenase,,,,,,,H,Autocuration,CHEMBL618409,BAO_0000357,
4301,1,B,8,,,,55,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,,,,,,,H,Autocuration,CHEMBL618410,BAO_0000357,
4302,1,B,8,,,,55,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,,,,,,,H,Autocuration,CHEMBL618411,BAO_0000357,
4303,1,B,8,,,,55,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,,,,,,,H,Autocuration,CHEMBL618412,BAO_0000357,
4304,1,B,8,RBL-1,,,12166,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,,,,702.0,,,H,Autocuration,CHEMBL618413,BAO_0000219,
4305,1,B,8,,,,12166,,,,,,,,H,Autocuration,CHEMBL618414,BAO_0000357,
4306,1,B,8,,,,10102,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),,,,,,,H,Autocuration,CHEMBL618415,BAO_0000357,
4307,1,B,8,,,,10102,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,,,,,,,H,Autocuration,CHEMBL618416,BAO_0000019,
4308,1,B,8,,,,10102,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,,,,,,,H,Autocuration,CHEMBL876401,BAO_0000357,
4309,1,B,8,,,,10102,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,,,,,,,H,Expert,CHEMBL618417,BAO_0000357,
4310,1,B,8,,,,10102,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,,,,,,,H,Autocuration,CHEMBL618418,BAO_0000357,
4311,1,B,8,,,,10102,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",,,,,,,H,Autocuration,CHEMBL618419,BAO_0000357,
4312,1,B,8,,,,10102,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",,,,,,,H,Autocuration,CHEMBL618420,BAO_0000357,
4313,1,B,8,,,,10102,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,,,,,,,H,Autocuration,CHEMBL618421,BAO_0000357,
4314,1,B,8,,,,11238,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,,,,,,,H,Autocuration,CHEMBL618422,BAO_0000019,
4315,1,B,8,,,,11238,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),,,,,,,H,Autocuration,CHEMBL618423,BAO_0000019,
4316,1,B,8,,,,11238,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),,,,,,,H,Autocuration,CHEMBL618424,BAO_0000019,
4317,1,B,2,,,,100284,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,,,,,,,S,Intermediate,CHEMBL618425,BAO_0000220,
4318,1,F,0,,,,22226,The dark toxicity against 543 human galactophore carcinoma cells,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618426,BAO_0000019,
4319,1,F,1,Panel (56 tumour cell lines),,,80623,Tested in vitro for cytotoxicity against 56 human tumor cell lines,,Homo sapiens,,390.0,,9606.0,N,Expert,CHEMBL618427,BAO_0000219,
4320,1,F,1,5637,,,80008,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,,Homo sapiens,,345.0,,9606.0,N,Expert,CHEMBL618428,BAO_0000219,
4321,1,F,1,5637,,,80008,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,,Homo sapiens,,345.0,,9606.0,N,Intermediate,CHEMBL618429,BAO_0000219,
4322,1,F,1,5637,,,80008,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",,Homo sapiens,,345.0,,9606.0,N,Intermediate,CHEMBL618430,BAO_0000219,
4323,1,F,1,5637,,,80008,Growth inhibition against human 5637 cell lines,,Homo sapiens,,345.0,,9606.0,N,Expert,CHEMBL618431,BAO_0000219,
4324,1,F,1,5637,,,80008,Antitumor activity against human bladder carcinoma 5637 cells.,,Homo sapiens,,345.0,,9606.0,N,Expert,CHEMBL883799,BAO_0000219,
4325,1,F,1,5637,,,80008,Antitumor activity against human bladder carcinoma 5637 cells,,Homo sapiens,,345.0,,9606.0,N,Intermediate,CHEMBL618432,BAO_0000219,
4326,1,F,1,5637,,,80008,Antitumor activity against human bladder carcinoma 5637 cells,,Homo sapiens,,345.0,,9606.0,N,Intermediate,CHEMBL618433,BAO_0000219,
4327,1,B,9,,,,10443,In vitro inhibition of bovine trypsin(Trp).,,Bos taurus,,,,9913.0,D,Expert,CHEMBL618434,BAO_0000357,
4328,1,B,8,CV-1,,,240,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,,Cercopithecidae,,407.0,,9527.0,H,Expert,CHEMBL618435,BAO_0000219,
4329,1,B,8,,,,10577,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,,,,,,,H,Autocuration,CHEMBL876402,BAO_0000357,
4330,1,F,6,,,,104698,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,,,,,,,H,Autocuration,CHEMBL618436,BAO_0000019,
4331,1,F,0,,,In vivo,22226,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,,,,,,,U,Autocuration,CHEMBL618437,BAO_0000218,
4332,1,B,9,,,,20033,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,,Cavia porcellus,,,,10141.0,D,Intermediate,CHEMBL618438,BAO_0000357,
4333,1,A,8,,,,17045,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,Rattus norvegicus,,,,10116.0,H,Expert,CHEMBL883800,BAO_0000251,
4334,1,A,8,,,,17045,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,Rattus norvegicus,,,,10116.0,H,Expert,CHEMBL618439,BAO_0000251,
4335,1,F,0,,,,22226,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,,,,,,U,Intermediate,CHEMBL618440,BAO_0000019,
4336,1,F,0,,,,22226,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,,,,,,U,Intermediate,CHEMBL618441,BAO_0000019,
4337,1,B,8,,,,11938,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,,Trypanosoma brucei,,,,5691.0,H,Expert,CHEMBL618442,BAO_0000019,
4338,1,B,8,,,,11938,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,,Trypanosoma brucei,,,,5691.0,H,Autocuration,CHEMBL618443,BAO_0000019,
4339,1,B,8,,,,11938,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,,Ovis aries,,,,9940.0,H,Expert,CHEMBL619158,BAO_0000019,
4340,1,B,8,,,,11938,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,,Ovis aries,,,,9940.0,H,Autocuration,CHEMBL620974,BAO_0000019,
4341,1,B,8,,,,11938,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,,,,,,,H,Autocuration,CHEMBL620975,BAO_0000357,
4342,1,F,0,,,,22226,Average inhibitory concentration against 60 human cell lines was reported,,Homo sapiens,,,,9606.0,U,Intermediate,CHEMBL620976,BAO_0000019,
4343,1,F,0,,,,22226,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,,Homo sapiens,,,,9606.0,U,Expert,CHEMBL620977,BAO_0000019,
4344,1,F,1,Panel NCI-60 (60 carcinoma cell lines),,,80315,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,,Homo sapiens,,542.0,,9606.0,N,Intermediate,CHEMBL620978,BAO_0000219,
4345,1,F,1,Panel NCI-60 (60 carcinoma cell lines),,,80315,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,,Homo sapiens,,542.0,,9606.0,N,Intermediate,CHEMBL620979,BAO_0000219,
4346,1,F,1,Panel NCI-60 (60 carcinoma cell lines),,,80315,In vitro mean growth inhibitory activity against 60-cell panel,,,,542.0,,,N,Expert,CHEMBL620980,BAO_0000219,
4347,1,F,1,Panel NCI-60 (60 carcinoma cell lines),,,80315,In vitro mean growth lethal concentration against 60-cell panel,,,,542.0,,,N,Expert,CHEMBL620981,BAO_0000219,
4348,1,F,1,Panel NCI-60 (60 carcinoma cell lines),,,80315,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,,,,542.0,,,N,Expert,CHEMBL620982,BAO_0000219,
4349,1,F,1,Panel NCI-60 (60 carcinoma cell lines),,,80315,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,,,,542.0,,,N,Expert,CHEMBL620983,BAO_0000219,
4350,1,F,4,,,,104775,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,,,,,,H,Autocuration,CHEMBL620984,BAO_0000019,
4351,1,F,4,,,,104775,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,,,,,,H,Autocuration,CHEMBL620985,BAO_0000019,
4352,1,B,8,,,,275,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,,,,,,,H,Expert,CHEMBL620986,BAO_0000357,
4353,1,F,1,,,,50425,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,,Plasmodium falciparum,,,,5833.0,N,Expert,CHEMBL620987,BAO_0000218,
4354,1,F,1,,,,50425,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,,Plasmodium falciparum,,,,5833.0,N,Expert,CHEMBL620988,BAO_0000218,
4355,1,F,1,,,,50425,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,,Plasmodium falciparum,,,,5833.0,N,Expert,CHEMBL620989,BAO_0000218,
4356,1,F,1,,,,50425,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,,Plasmodium falciparum,,,,5833.0,N,Expert,CHEMBL620990,BAO_0000218,
4357,1,F,1,,,,50425,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,,Plasmodium falciparum,,,,5833.0,N,Intermediate,CHEMBL620991,BAO_0000218,
4358,1,F,1,6C3HED,,,80628,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,Mus musculus,,850.0,,10090.0,N,Intermediate,CHEMBL620992,BAO_0000218,
4359,1,F,1,6C3HED,,,80628,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,Mus musculus,,850.0,,10090.0,N,Intermediate,CHEMBL620993,BAO_0000218,
4360,1,F,1,6C3HED,,,80628,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,,Mus musculus,,850.0,,10090.0,N,Intermediate,CHEMBL620994,BAO_0000218,
4361,1,F,1,6C3HED,,,80628,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,Mus musculus,,850.0,,10090.0,N,Intermediate,CHEMBL620995,BAO_0000218,
4362,1,F,1,6C3HED,,,80628,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,Mus musculus,,850.0,,10090.0,N,Intermediate,CHEMBL620996,BAO_0000218,
4363,1,F,1,6C3HED,,,80628,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,,Mus musculus,,850.0,,10090.0,N,Intermediate,CHEMBL875581,BAO_0000218,
4364,1,F,0,,,In vivo,22224,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,,Mus musculus,,,,10090.0,U,Autocuration,CHEMBL620997,BAO_0000218,
4365,1,F,0,,,In vivo,22224,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,,Mus musculus,,,,10090.0,U,Autocuration,CHEMBL620998,BAO_0000218,
4366,1,F,0,,,In vivo,22224,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),,Mus musculus,,,,10090.0,U,Autocuration,CHEMBL620999,BAO_0000218,
4367,1,F,0,,,In vivo,22224,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,,Mus musculus,,,,10090.0,U,Autocuration,CHEMBL621000,BAO_0000218,
4368,1,F,0,,,In vivo,22224,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,,Mus musculus,,,,10090.0,U,Autocuration,CHEMBL621001,BAO_0000218,
4369,1,F,0,,,In vivo,22224,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,,Mus musculus,,,,10090.0,U,Autocuration,CHEMBL621002,BAO_0000218,
4370,1,F,0,,,In vivo,22224,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,,Mus musculus,,,,10090.0,U,Autocuration,CHEMBL621003,BAO_0000218,
4371,1,F,0,,,In vivo,22224,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",,Mus musculus,,,,10090.0,U,Autocuration,CHEMBL621004,BAO_0000218,
4372,1,F,0,,,In vivo,22224,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),,Mus musculus,,,,10090.0,U,Autocuration,CHEMBL621005,BAO_0000218,
4373,1,F,0,,,In vivo,22224,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),,Mus musculus,,,,10090.0,U,Autocuration,CHEMBL621006,BAO_0000218,
4374,1,F,0,,,In vivo,22224,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,,Mus musculus,,,,10090.0,U,Autocuration,CHEMBL621007,BAO_0000218,
4375,1,F,0,,,,22224,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,Mus musculus,,,,10090.0,U,Autocuration,CHEMBL621008,BAO_0000218,
4376,1,F,0,,,,22224,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,Mus musculus,,,,10090.0,U,Autocuration,CHEMBL621009,BAO_0000218,
4377,1,F,0,,,,22224,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,Mus musculus,,,,10090.0,U,Autocuration,CHEMBL857705,BAO_0000218,
4378,1,F,0,,,,22224,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,Mus musculus,,,,10090.0,U,Autocuration,CHEMBL619828,BAO_0000218,
4379,1,F,0,,,,22224,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,,Mus musculus,,,,10090.0,U,Autocuration,CHEMBL619829,BAO_0000218,
4380,1,F,0,,,,22224,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,,Mus musculus,,,,10090.0,U,Autocuration,CHEMBL619830,BAO_0000218,
4381,1,F,0,,,,22224,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,,Mus musculus,,,,10090.0,U,Autocuration,CHEMBL619831,BAO_0000218,
4382,1,F,0,,,,22224,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,,Mus musculus,,,,10090.0,U,Autocuration,CHEMBL619832,BAO_0000218,
4383,1,A,0,,,,22224,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,,Mus musculus,,,,10090.0,U,Autocuration,CHEMBL619833,BAO_0000218,
4384,1,A,0,,,,22224,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,,Mus musculus,,,,10090.0,U,Autocuration,CHEMBL619834,BAO_0000218,
4385,1,A,0,,,,22224,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,,Mus musculus,,,,10090.0,U,Autocuration,CHEMBL619835,BAO_0000218,
4386,1,A,0,,,,22224,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,,Mus musculus,,,,10090.0,U,Autocuration,CHEMBL619836,BAO_0000218,
4387,1,F,1,6C3HED,,,80628,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",,Mus musculus,,850.0,,10090.0,N,Intermediate,CHEMBL619837,BAO_0000218,
4388,1,F,0,,,In vivo,22224,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,,,,,,,U,Autocuration,CHEMBL619838,BAO_0000218,
4389,1,A,1,,,,50594,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619839,BAO_0000218,
4390,1,F,1,6C3HED,,In vivo,80628,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,,Mus musculus,,850.0,,10090.0,N,Intermediate,CHEMBL619840,BAO_0000218,
4391,1,F,1,6C3HED,,In vivo,80628,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,,Mus musculus,,850.0,,10090.0,N,Intermediate,CHEMBL619841,BAO_0000218,
4392,1,F,1,6C3HED,,,80628,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),,Mus musculus,,850.0,,10090.0,N,Expert,CHEMBL857704,BAO_0000218,
4393,1,F,1,6C3HED,,,80628,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),,Mus musculus,,850.0,,10090.0,N,Intermediate,CHEMBL619842,BAO_0000218,
4394,1,F,1,6C3HED,,,80628,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),,Mus musculus,,850.0,,10090.0,N,Expert,CHEMBL619843,BAO_0000218,
4395,1,B,0,,,,22226,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",,Staphylococcus aureus,,,,1280.0,U,Autocuration,CHEMBL619844,BAO_0000019,
4396,1,B,0,,,,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL857855,BAO_0000251,
4397,1,B,0,,,,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL619845,BAO_0000251,
4398,1,B,0,,,,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL619846,BAO_0000251,
4399,1,B,0,,,,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL619847,BAO_0000251,
4400,1,B,0,,,,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL619848,BAO_0000251,
4401,1,B,0,,,,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL620893,BAO_0000251,
4402,1,B,0,,,,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL620894,BAO_0000251,
4403,1,B,0,,,,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL620895,BAO_0000251,
4404,1,B,0,,,,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL620896,BAO_0000251,
4405,1,B,0,,,,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL620897,BAO_0000251,
4406,1,B,0,,,,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL620898,BAO_0000251,
4407,1,B,0,,,,22226,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,2107.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL620899,BAO_0000251,
4408,1,A,0,,,In vivo,22224,The apparent total plasma clearance in monkey,1969.0,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620900,BAO_0000218,
4409,1,A,0,,,In vivo,22224,Compound was evaluated for Hepatic clearance in monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620901,BAO_0000218,
4410,1,A,0,,,In vivo,22224,Lower clearance in monkey (i.v.) at 0.5 mpk,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620902,BAO_0000218,
4411,1,A,0,,,In vivo,22224,Plasma clearance in rhesus monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620903,BAO_0000218,
4412,1,A,0,,,In vivo,22224,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620904,BAO_0000218,
4413,1,A,0,,,In vivo,22224,Plasma clearance of compound was determined in monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620905,BAO_0000218,
4414,1,A,0,,,In vivo,22224,Plasma clearance was calculated in rhesus monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620906,BAO_0000218,
4415,1,A,0,,,In vivo,22224,Plasma clearance in rhesus monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL875420,BAO_0000218,
4416,1,A,0,,,In vivo,22224,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620907,BAO_0000218,
4417,1,A,0,,,In vivo,22224,Plasma clearance was evaluated in rhesus,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620908,BAO_0000218,
4418,1,A,0,,,In vivo,22224,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620909,BAO_0000218,
4419,1,A,0,,,In vivo,22224,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620910,BAO_0000218,
4420,1,A,0,,,In vivo,22224,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620911,BAO_0000218,
4421,1,A,0,,,In vivo,22224,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620912,BAO_0000218,
4422,1,A,0,,,In vivo,22224,Cmax 24 hr after 2 mg/kg oral administration in monkeys,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620913,BAO_0000218,
4423,1,A,0,,,In vivo,22224,Cmax in monkey after administration of 1 mg/kg iv,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620914,BAO_0000218,
4424,1,A,0,,,In vivo,22224,Cmax was determine after peroral administration at 10 mpk in Rhesus,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620915,BAO_0000218,
4425,1,A,0,,,In vivo,22224,Cmax in cynomolgus monkey by iv administration,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620916,BAO_0000218,
4426,1,A,0,,,In vivo,22224,Cmax in cynomolgus monkey by po administration,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620917,BAO_0000218,
4427,1,A,0,,,In vivo,22224,Cmax value evaluated in monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620918,BAO_0000218,
4428,1,A,0,,,In vivo,22224,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620919,BAO_0000218,
4429,1,A,0,,,In vivo,22224,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,1969.0,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620920,BAO_0000218,
4430,1,A,0,,,In vivo,22224,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,1969.0,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620921,BAO_0000218,
4431,1,A,0,,,In vivo,22224,Maximal plasma concentration in squirrel monkeys,1969.0,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620922,BAO_0000218,
4432,1,A,0,,,In vivo,22224,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620923,BAO_0000218,
4433,1,A,0,,,In vivo,22224,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,1969.0,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620924,BAO_0000218,
4434,1,A,0,,,In vivo,22224,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620925,BAO_0000218,
4435,1,A,0,,,In vivo,22224,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620926,BAO_0000218,
4436,1,A,0,,,In vivo,22224,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620927,BAO_0000218,
4437,1,A,0,,,In vivo,22224,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620928,BAO_0000218,
4438,1,A,0,,,In vivo,22224,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620929,BAO_0000218,
4439,1,A,0,,,In vivo,22224,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,1969.0,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620930,BAO_0000218,
4440,1,A,0,,,,22224,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620931,BAO_0000218,
4441,1,A,0,,,,22224,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620932,BAO_0000218,
4442,1,A,0,,,In vivo,22224,Absolute bioavailability was evaluated in monkey,,monkey,,,,9443.0,U,Autocuration,CHEMBL620933,BAO_0000218,
4443,1,A,0,,,In vivo,22224,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,,monkey,,,,9443.0,U,Autocuration,CHEMBL620934,BAO_0000218,
4444,1,A,0,,,In vivo,22224,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,,monkey,,,,9443.0,U,Autocuration,CHEMBL620935,BAO_0000218,
4445,1,A,0,,,In vivo,22224,Bioavailability of compound was determined in rhesus monkey,,Macaca mulatta,,,,9544.0,U,Autocuration,CHEMBL620936,BAO_0000218,
4446,1,A,0,,,In vivo,22224,Bioavailability determined after oral administration in marmoset,,marmosets,,,,38020.0,U,Autocuration,CHEMBL620937,BAO_0000218,
4447,1,A,0,,,In vivo,22224,Oral bioavailability in cynomolgus monkey,,Macaca fascicularis,,,,9541.0,U,Autocuration,CHEMBL620938,BAO_0000218,
4448,1,A,0,,,In vivo,22224,Bioavailability in monkey (p.o.) at 2.0 mpk,,monkey,,,,9443.0,U,Autocuration,CHEMBL620939,BAO_0000218,
4449,1,A,0,,,In vivo,22224,Bioavailability was evaluated after oral administration in monkey,,monkey,,,,9443.0,U,Autocuration,CHEMBL620940,BAO_0000218,
4450,1,A,0,,,In vivo,22224,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,Macaca fascicularis,,,,9541.0,U,Autocuration,CHEMBL620941,BAO_0000218,
4451,1,A,0,,,In vivo,22224,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,Macaca mulatta,,,,9544.0,U,Autocuration,CHEMBL620942,BAO_0000218,
4452,1,A,0,,,In vivo,22224,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,Macaca mulatta,,,,9544.0,U,Autocuration,CHEMBL620943,BAO_0000218,
4453,1,A,0,,,In vivo,22224,Bioavailability of the compound was determined in monkey,,monkey,,,,9443.0,U,Autocuration,CHEMBL620944,BAO_0000218,
4454,1,A,0,,,In vivo,22224,Bioavailability in squirrel monkey (dose 5 mg/kg),,Saimiri sciureus,,,,9521.0,U,Autocuration,CHEMBL620945,BAO_0000218,
4455,1,A,0,,,In vivo,22224,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),,monkey,,,,9443.0,U,Autocuration,CHEMBL620946,BAO_0000218,
4456,1,A,0,,,In vivo,22224,Oral bioavailability in monkey,,monkey,,,,9443.0,U,Autocuration,CHEMBL620947,BAO_0000218,
4457,1,A,0,,,In vivo,22224,Compound was tested for bioavailability in squirrel monkey,,Saimiri sciureus,,,,9521.0,U,Autocuration,CHEMBL620948,BAO_0000218,
4458,1,A,0,,,In vivo,22224,Oral bioavailability in Rhesus monkey,,Macaca mulatta,,,,9544.0,U,Autocuration,CHEMBL620949,BAO_0000218,
4459,1,A,0,,,In vivo,22224,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),,Macaca mulatta,,,,9544.0,U,Autocuration,CHEMBL620950,BAO_0000218,
4460,1,A,0,,,In vivo,22224,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,,Macaca fascicularis,,,,9541.0,U,Autocuration,CHEMBL620951,BAO_0000218,
4461,1,A,0,,,In vivo,22224,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,,Macaca fascicularis,,,,9541.0,U,Autocuration,CHEMBL620952,BAO_0000218,
4462,1,A,0,,,In vivo,22224,Oral bioavailability in monkey (dose 5 mg/kg),,monkey,,,,9443.0,U,Autocuration,CHEMBL875421,BAO_0000218,
4463,1,A,0,,,In vivo,22224,Oral bioavailability of compound at 5 mg/kg in monkey,,monkey,,,,9443.0,U,Autocuration,CHEMBL620953,BAO_0000218,
4464,1,A,1,,,In vivo,50588,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL873491,BAO_0000218,
4465,1,A,1,,,In vivo,50588,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL620954,BAO_0000218,
4466,1,A,1,,,,50588,Plasma half life determined,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL620955,BAO_0000218,
4467,1,A,1,,,,50588,Plasma half life in dog,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618097,BAO_0000218,
4468,1,A,1,,,,50588,Plasma half-life in Beagle dogs,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618268,BAO_0000218,
4469,1,A,1,,,In vivo,50588,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618269,BAO_0000218,
4470,1,A,1,,,In vivo,50588,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618270,BAO_0000218,
4471,1,A,1,,,In vivo,50588,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618271,BAO_0000218,
4472,1,A,1,,,In vivo,50588,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL873493,BAO_0000218,
4473,1,A,1,,,,50588,Tested for the half life period in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621031,BAO_0000218,
4474,1,A,1,,,In vivo,50588,Tested for the half life period in dog at dosage of 10 mpk,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621032,BAO_0000218,
4475,1,A,1,,,,50588,The compound was tested for half life in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621033,BAO_0000218,
4476,1,A,1,,,,50588,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621034,BAO_0000218,
4477,1,A,1,,,,50588,The half life was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621035,BAO_0000218,
4478,1,A,1,,,,50588,The plasma half-life in dogs,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621036,BAO_0000218,
4479,1,A,1,,,,50588,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621037,BAO_0000218,
4480,1,A,1,,,,50588,Half life in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619812,BAO_0000218,
4481,1,A,1,,,In vivo,50588,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619813,BAO_0000218,
4482,1,A,1,,,In vivo,50588,tmax upon peroral administration of 10.0 mg/Kg dose in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL873335,BAO_0000218,
4483,1,A,1,,,In vivo,50588,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619814,BAO_0000218,
4484,1,A,1,,,In vivo,50506,Cmax in ferrets after 30 mg/kg oral dose,,Mustela putorius furo,,,,9669.0,N,Expert,CHEMBL619815,BAO_0000218,
4485,1,F,1,,,In vivo,50506,Emesis in ferrets at 30 mg/kg oral dose,,Mustela putorius furo,,,,9669.0,N,Expert,CHEMBL619816,BAO_0000218,
4486,1,A,0,,,In vivo,22224,Bioavailability in cynomolgus monkey,,Macaca fascicularis,,,,9541.0,U,Autocuration,CHEMBL619817,BAO_0000218,
4487,1,A,1,,,In vivo,100710,Volume of distribution in cynomolgus,,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL619818,BAO_0000218,
4488,1,A,0,,,,22224,AUC tested in guinea pig when 3 mg/kg dose was given perorally,1969.0,Cavia porcellus,,,,10141.0,U,Autocuration,CHEMBL619819,BAO_0000218,
4489,1,A,0,,,,22224,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,Cavia porcellus,,,,10141.0,U,Autocuration,CHEMBL619820,BAO_0000218,
4490,1,A,0,,,,22224,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",,Cavia porcellus,,,,10141.0,U,Autocuration,CHEMBL875419,BAO_0000218,
4491,1,A,0,,,In vivo,22224,AUC in guinea pig after 3mg/kg oral dose,1969.0,Cavia porcellus,,,,10141.0,U,Autocuration,CHEMBL619821,BAO_0000218,
4492,1,A,0,,,In vivo,22224,Bioavailability in guinea pig was tested,,Cavia porcellus,,,,10141.0,U,Autocuration,CHEMBL619822,BAO_0000218,
4493,1,A,0,,,In vivo,22224,Tested for oral bioavailability in guinea pig at 5 mg/kg,,Cavia porcellus,,,,10141.0,U,Autocuration,CHEMBL619823,BAO_0000218,
4494,1,A,0,,,In vivo,22224,Tested for the oral bioavailability of the compound,,Cavia porcellus,,,,10141.0,U,Autocuration,CHEMBL619824,BAO_0000218,
4495,1,A,0,,,In vivo,22224,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,,Cavia porcellus,,,,10141.0,U,Autocuration,CHEMBL619825,BAO_0000218,
4496,1,A,0,,,In vivo,22224,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,,Cavia porcellus,,,,10141.0,U,Autocuration,CHEMBL619826,BAO_0000218,
4497,1,A,0,,,In vivo,22224,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,2048.0,Cavia porcellus,,,,10141.0,U,Autocuration,CHEMBL619827,BAO_0000218,
4498,1,A,0,,,In vivo,22224,Cmax in guinea pig after 3mg/kg oral dose,,Cavia porcellus,,,,10141.0,U,Autocuration,CHEMBL618167,BAO_0000218,
4499,1,A,0,,,,22224,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,178.0,Cavia porcellus,,,,10141.0,U,Autocuration,CHEMBL618168,BAO_0000019,
4500,1,A,0,,,,22224,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,955.0,Cavia porcellus,,,,10141.0,U,Autocuration,CHEMBL618169,BAO_0000019,
4501,1,A,0,,,,22224,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,,Cavia porcellus,,,,10141.0,U,Autocuration,CHEMBL618170,BAO_0000019,
4502,1,A,0,,,,22224,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,160.0,Cavia porcellus,,,,10141.0,U,Autocuration,CHEMBL618171,BAO_0000019,
4503,1,A,0,,,,22224,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,2113.0,Cavia porcellus,,,,10141.0,U,Autocuration,CHEMBL618172,BAO_0000019,
4504,1,A,0,,,,22224,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,2107.0,Cavia porcellus,,,,10141.0,U,Autocuration,CHEMBL618173,BAO_0000019,
4505,1,A,0,,,,22224,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,,Cavia porcellus,,,,10141.0,U,Autocuration,CHEMBL618174,BAO_0000019,
4506,1,A,0,,,,22224,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,2106.0,Cavia porcellus,,,,10141.0,U,Autocuration,CHEMBL875408,BAO_0000019,
4507,1,A,0,,,In vivo,22224,Elimination T1/2 in Guinea pig (PO dose),,Cavia porcellus,,,,10141.0,U,Autocuration,CHEMBL839827,BAO_0000218,
4508,1,A,0,,,,22224,Partition coefficient was measured as -log (counts per min ),,Cavia porcellus,,,,10141.0,U,Autocuration,CHEMBL618175,BAO_0000019,
4509,1,A,0,,,In vivo,22224,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,,Cavia porcellus,,,,10141.0,U,Autocuration,CHEMBL618176,BAO_0000218,
4510,1,A,0,,,In vivo,22224,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,,Cavia porcellus,,,,10141.0,U,Autocuration,CHEMBL618177,BAO_0000218,
4511,1,A,0,,,In vivo,22224,Elimination T1/2 in Guinea pig (PO dose),,Cavia porcellus,,,,10141.0,U,Autocuration,CHEMBL618178,BAO_0000218,
4512,1,A,0,,,In vivo,22224,"Tested for the half life period of the compound, intravenously",,Cavia porcellus,,,,10141.0,U,Autocuration,CHEMBL618179,BAO_0000218,
4513,1,A,0,,,,22224,Half-life was measured,,Cavia porcellus,,,,10141.0,U,Autocuration,CHEMBL873489,BAO_0000019,
4514,1,A,0,,,,22224,The time required for onset of inotropy after addition of a single dose of delta F75,,Cavia porcellus,,,,10141.0,U,Autocuration,CHEMBL618180,BAO_0000019,
4515,1,A,0,,,In vivo,22224,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,,Cavia porcellus,,,,10141.0,U,Autocuration,CHEMBL618181,BAO_0000218,
4516,1,A,0,,,In vivo,22224,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,,Cavia porcellus,,,,10141.0,U,Autocuration,CHEMBL618182,BAO_0000218,
4517,1,A,0,,,In vivo,22224,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,Cricetulus griseus,,,,10029.0,U,Autocuration,CHEMBL618183,BAO_0000218,
4518,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618184,BAO_0000218,
4519,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618185,BAO_0000218,
4520,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618186,BAO_0000218,
4521,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618187,BAO_0000218,
4522,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618188,BAO_0000218,
4523,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL875409,BAO_0000218,
4524,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618189,BAO_0000218,
4525,1,A,1,,,In vivo,50594,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618190,BAO_0000218,
4526,1,A,1,,,In vivo,50594,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618191,BAO_0000218,
4527,1,A,1,,,In vivo,50594,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618192,BAO_0000218,
4528,1,A,1,,,In vivo,50594,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,10000001.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618193,BAO_0000218,
4529,1,A,1,,,In vivo,50594,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,10000001.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618194,BAO_0000218,
4530,1,A,1,,,In vivo,50594,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,10000001.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618195,BAO_0000218,
4531,1,A,1,,,In vivo,50594,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618196,BAO_0000218,
4532,1,A,1,,,In vivo,50594,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618197,BAO_0000218,
4533,1,A,1,,,In vivo,50594,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618198,BAO_0000218,
4534,1,A,1,,,In vivo,50594,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618199,BAO_0000218,
4535,1,A,1,,,In vivo,50594,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618200,BAO_0000218,
4536,1,A,1,,,In vivo,50594,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618201,BAO_0000218,
4537,1,A,1,,,In vivo,50594,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,160.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618202,BAO_0000218,
4538,1,A,1,,,In vivo,50594,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,160.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618203,BAO_0000218,
4539,1,A,1,,,In vivo,50594,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,160.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618204,BAO_0000218,
4540,1,A,1,,,In vivo,50594,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618205,BAO_0000218,
4541,1,A,1,,,In vivo,50594,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618206,BAO_0000218,
4542,1,A,1,,,In vivo,50594,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618207,BAO_0000218,
4543,1,A,1,,,In vivo,50594,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618208,BAO_0000218,
4544,1,A,1,,,In vivo,50594,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618932,BAO_0000218,
4545,1,A,1,,,In vivo,50594,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618933,BAO_0000218,
4546,1,A,1,,,In vivo,50594,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,2048.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618934,BAO_0000218,
4547,1,A,1,,,In vivo,50594,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,2048.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618935,BAO_0000218,
4548,1,A,1,,,In vivo,50594,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,2048.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618936,BAO_0000218,
4549,1,A,1,,,In vivo,50594,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,2385.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618937,BAO_0000218,
4550,1,A,1,,,In vivo,50594,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,2385.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618938,BAO_0000218,
4551,1,A,1,,,In vivo,50594,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,2385.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619104,BAO_0000218,
4552,1,A,1,,,In vivo,50594,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619105,BAO_0000218,
4553,1,A,1,,,In vivo,50594,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619106,BAO_0000218,
4554,1,A,1,,,In vivo,50594,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619107,BAO_0000218,
4555,1,A,1,,,In vivo,50594,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,945.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL875410,BAO_0000218,
4556,1,A,1,,,In vivo,50594,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,945.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619108,BAO_0000218,
4557,1,A,1,,,In vivo,50594,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,945.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619109,BAO_0000218,
4558,1,A,1,,,In vivo,50594,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619110,BAO_0000218,
4559,1,F,1,,,In vivo,50594,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619111,BAO_0000218,
4560,1,A,1,,,In vivo,50594,MRT value at a dose of 10 mg/kg intravenous administration in mice.,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619112,BAO_0000218,
4561,1,A,1,,,In vivo,50594,MRT value at a dose of 10 mg/kg peroral administration in mice.,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619113,BAO_0000218,
4562,1,A,1,,,In vivo,50594,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619114,BAO_0000218,
4563,1,F,1,,,In vivo,50594,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619115,BAO_0000218,
4564,1,F,1,A2780,,,81034,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619116,BAO_0000219,
4565,1,F,1,A2780,,,81034,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619117,BAO_0000219,
4566,1,F,1,A2780,,,81034,Compound was evaluated for cytotoxicity against A2780 cell lines.,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619118,BAO_0000219,
4567,1,F,1,A2780,,,81034,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619119,BAO_0000219,
4568,1,F,1,A2780,,,81034,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619120,BAO_0000219,
4569,1,F,1,A2780,,,81034,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619121,BAO_0000219,
4570,1,F,1,A2780,,,81034,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619122,BAO_0000219,
4571,1,F,1,A2780,,,81034,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619123,BAO_0000219,
4572,1,F,1,A2780,,,81034,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619124,BAO_0000219,
4573,1,F,1,A2780,,,81034,Compound was evaluated for cytotoxicity against A2780 cell line,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619125,BAO_0000219,
4574,1,F,1,A2780,,,81034,In vitro inhibitory activity against human tumor cell line A2780,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL875411,BAO_0000219,
4575,1,F,1,A2780,,,81034,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619126,BAO_0000219,
4576,1,F,1,A2780,,,81034,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619127,BAO_0000219,
4577,1,F,1,A2780,,,81034,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619128,BAO_0000219,
4578,1,F,1,A2780,,,81034,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619129,BAO_0000219,
4579,1,F,1,A2780,,,81034,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619130,BAO_0000219,
4580,1,F,1,A2780,,,81034,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619131,BAO_0000219,
4581,1,F,1,A2780,,,81034,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619132,BAO_0000219,
4582,1,F,1,A2780,,,81034,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL619133,BAO_0000218,
4583,1,F,1,A2780,,,81034,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619134,BAO_0000219,
4584,1,F,1,A2780,,,81034,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619135,BAO_0000219,
4585,1,F,1,A2780,,,81034,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619136,BAO_0000219,
4586,1,F,1,A2780,,,81034,Relative resistance factor in A2780 cisplatin-resistant line,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619137,BAO_0000219,
4587,1,F,1,A2780,,,81034,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL883713,BAO_0000219,
4588,1,F,1,A2780,,,81034,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL875412,BAO_0000219,
4589,1,F,1,A2780,,,81034,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL619138,BAO_0000218,
4590,1,F,1,A2780,,,81034,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL619262,BAO_0000218,
4591,1,F,1,A2780,,,81034,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619139,BAO_0000219,
4592,1,F,1,A2780,,,81034,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619140,BAO_0000219,
4593,1,F,1,A2780,,,81034,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619141,BAO_0000219,
4594,1,F,1,A2780,,,81034,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619142,BAO_0000219,
4595,1,F,1,A2780,,,81034,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619143,BAO_0000219,
4596,1,F,1,A2780,,,81034,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619144,BAO_0000219,
4597,1,F,1,A2780,,,81034,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619145,BAO_0000219,
4598,1,F,1,A2780,,,81034,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619146,BAO_0000219,
4599,1,F,1,A2780,,,81034,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619147,BAO_0000219,
4600,1,F,1,A2780,,,81034,Antiproliferative effect of compound on A2780/DX cell line,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619148,BAO_0000219,
4601,1,F,1,A2780,,,81034,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619149,BAO_0000219,
4602,1,F,1,A2780,,,81034,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619150,BAO_0000219,
4603,1,F,1,A2780,,,81034,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619151,BAO_0000219,
4604,1,F,1,A2780,,,81034,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL883794,BAO_0000219,
4605,1,F,1,A2780,,,81034,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619152,BAO_0000219,
4606,1,F,1,A2780,,,81034,In vitro cytotoxicity against A2780ADR cell line,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619153,BAO_0000219,
4607,1,F,1,A2780,,,81034,In vitro cytotoxicity against A2780CIS cell line,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619154,BAO_0000219,
4608,1,F,1,A2780,,,81034,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619155,BAO_0000219,
4609,1,F,1,A2780,,,81034,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619156,BAO_0000219,
4610,1,F,1,A2780,,,81034,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619157,BAO_0000219,
4611,1,F,1,A2780,,,81034,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619797,BAO_0000219,
4612,1,A,0,,,In vivo,22224,Oral bioavailability of compound in rhesus macaques,,Macaca mulatta,,,,9544.0,U,Autocuration,CHEMBL619798,BAO_0000218,
4613,1,A,0,,,In vivo,22224,Oral bioavailability in monkey,,monkey,,,,9443.0,U,Autocuration,CHEMBL619799,BAO_0000218,
4614,1,A,0,,,In vivo,22224,Oral bioavailability evaluated in monkey,,monkey,,,,9443.0,U,Autocuration,CHEMBL619800,BAO_0000218,
4615,1,A,0,,,In vivo,22224,Oral bioavailability in monkey (dose 1 mg/kg p.o.),,monkey,,,,9443.0,U,Autocuration,CHEMBL619801,BAO_0000218,
4616,1,A,0,,,In vivo,22224,Oral bioavailability in Rhesus monkey,,Macaca mulatta,,,,9544.0,U,Autocuration,CHEMBL619802,BAO_0000218,
4617,1,A,0,,,In vivo,22224,Oral bioavailability was calculated in rhesus monkey,,Macaca mulatta,,,,9544.0,U,Autocuration,CHEMBL619803,BAO_0000218,
4618,1,A,0,,,In vivo,22224,Oral bioavailability in cynomolgus monkey,,Macaca fascicularis,,,,9541.0,U,Autocuration,CHEMBL619965,BAO_0000218,
4619,1,A,0,,,In vivo,22224,Oral bioavailability in monkey,,monkey,,,,9443.0,U,Autocuration,CHEMBL619966,BAO_0000218,
4620,1,A,0,,,In vivo,22224,Oral bioavailability in monkey,,monkey,,,,9443.0,U,Autocuration,CHEMBL619967,BAO_0000218,
4621,1,A,0,,,In vivo,22224,Oral bioavailability in monkey (dose 1 mg/kg),,monkey,,,,9443.0,U,Autocuration,CHEMBL620073,BAO_0000218,
4622,1,A,0,,,In vivo,22224,Oral bioavailability in monkey (dose 5 mg/kg),,monkey,,,,9443.0,U,Autocuration,CHEMBL620074,BAO_0000218,
4623,1,A,0,,,In vivo,22224,Oral bioavailability in monkey,,monkey,,,,9443.0,U,Autocuration,CHEMBL620075,BAO_0000218,
4624,1,A,0,,,In vivo,22224,Oral bioavailability in monkey,,monkey,,,,9443.0,U,Autocuration,CHEMBL620076,BAO_0000218,
4625,1,A,0,,,In vivo,22224,Oral bioavailability in rhesus monkey,,Macaca mulatta,,,,9544.0,U,Autocuration,CHEMBL620077,BAO_0000218,
4626,1,A,0,,,In vivo,22224,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,,Macaca mulatta,,,,9544.0,U,Autocuration,CHEMBL620078,BAO_0000218,
4627,1,A,0,,,In vivo,22224,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,,Saimiri sciureus,,,,9521.0,U,Autocuration,CHEMBL620079,BAO_0000218,
4628,1,A,0,,,In vivo,22224,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,monkey,,,,9443.0,U,Autocuration,CHEMBL620080,BAO_0000218,
4629,1,A,0,,,In vivo,22224,Oral bioavailability in Rhesus monkey,,Macaca mulatta,,,,9544.0,U,Autocuration,CHEMBL620081,BAO_0000218,
4630,1,A,0,,,In vivo,22224,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),,Macaca mulatta,,,,9544.0,U,Autocuration,CHEMBL620082,BAO_0000218,
4631,1,A,0,,,In vivo,22224,Oral bioavailability in monkey at 10 mg/kg of the compound,,monkey,,,,9443.0,U,Autocuration,CHEMBL620083,BAO_0000218,
4632,1,A,0,,,In vivo,22224,Bioavailability in Rhesus monkey,,Macaca mulatta,,,,9544.0,U,Autocuration,CHEMBL620084,BAO_0000218,
4633,1,A,0,,,,22224,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620085,BAO_0000218,
4634,1,A,0,,,,22224,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL874595,BAO_0000218,
4635,1,A,0,,,In vivo,22224,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL873352,BAO_0000218,
4636,1,A,0,,,In vivo,22224,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620086,BAO_0000218,
4637,1,A,0,,,In vivo,22224,Mean residence time was determined after intravenous administration in cynomolgus monkeys,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620087,BAO_0000218,
4638,1,A,0,,,In vivo,22224,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620088,BAO_0000218,
4639,1,A,0,,,In vivo,22224,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620089,BAO_0000218,
4640,1,A,0,,,In vivo,22224,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620090,BAO_0000218,
4641,1,A,0,,,In vivo,22224,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620091,BAO_0000218,
4642,1,A,0,,,,22224,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620092,BAO_0000251,
4643,1,A,0,,,,22224,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620093,BAO_0000251,
4644,1,A,0,,,,22224,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620094,BAO_0000251,
4645,1,A,0,,,,22224,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620095,BAO_0000251,
4646,1,A,0,,,In vivo,22224,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620096,BAO_0000218,
4647,1,A,0,,,In vivo,22224,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620097,BAO_0000218,
4648,1,A,0,,,,22224,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620098,BAO_0000019,
4649,1,A,0,,,,22224,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620099,BAO_0000218,
4650,1,A,0,,,,22224,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620100,BAO_0000218,
4651,1,A,0,,,,22224,Elimination Half-life of compound was determined in monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620101,BAO_0000019,
4652,1,A,0,,,,22224,Half life of compound was determined in rhesus monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620102,BAO_0000019,
4653,1,A,0,,,,22224,Half life in monkey plasma,1969.0,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620103,BAO_0000366,
4654,1,A,0,,,,22224,Half life in monkey plasma; Not detected,1969.0,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620104,BAO_0000366,
4655,1,A,0,,,In vivo,22224,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL874596,BAO_0000218,
4656,1,A,0,,,In vivo,22224,Half-life 24 hr after 2 mg/kg iv administration in monkeys,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL873490,BAO_0000218,
4657,1,A,0,,,,22224,Terminal half life of the compound.,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620105,BAO_0000019,
4658,1,A,0,,,In vivo,22224,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620780,BAO_0000218,
4659,1,A,0,,,In vivo,22224,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620781,BAO_0000218,
4660,1,A,0,,,,22224,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620956,BAO_0000218,
4661,1,A,0,,,,22224,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1088.0,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620957,BAO_0000218,
4662,1,A,0,,,,22224,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1088.0,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620958,BAO_0000218,
4663,1,A,0,,,In vivo,22224,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620959,BAO_0000218,
4664,1,A,0,,,In vivo,22224,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620960,BAO_0000218,
4665,1,A,0,,,In vivo,22224,Volume of distribution was evaluated in rhesus,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL620961,BAO_0000218,
4666,1,A,0,,,In vivo,22224,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,Cricetulus griseus,,,,10029.0,U,Autocuration,CHEMBL620962,BAO_0000218,
4667,1,A,0,,,In vivo,22224,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,,Cricetulus griseus,,,,10029.0,U,Autocuration,CHEMBL620963,BAO_0000218,
4668,1,A,0,,,In vivo,22224,Bioavailability in hamster was determined,,Cricetulus griseus,,,,10029.0,U,Autocuration,CHEMBL620964,BAO_0000218,
4669,1,A,0,,,In vivo,22224,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,,Cricetulus griseus,,,,10029.0,U,Autocuration,CHEMBL620965,BAO_0000218,
4670,1,A,0,,,In vivo,22224,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,,Cricetulus griseus,,,,10029.0,U,Autocuration,CHEMBL620966,BAO_0000218,
4671,1,A,0,,,,22224,Half life of compound was determined in hamster blood,178.0,Cricetulus griseus,,,,10029.0,U,Autocuration,CHEMBL620967,BAO_0000221,
4672,1,A,0,,,,22224,Michaelis-Menten constant of the compound.,,Sus scrofa,,,,9823.0,U,Autocuration,CHEMBL620968,BAO_0000019,
4673,1,A,0,,,,22224,Vmax value was measured at 0 uM concentration of silyl ether.,,Sus scrofa,,,,9823.0,U,Autocuration,CHEMBL874597,BAO_0000019,
4674,1,A,0,,,,22224,Vmax value was measured at 10 uM concentration of silyl ether.,,Sus scrofa,,,,9823.0,U,Autocuration,CHEMBL620969,BAO_0000019,
4675,1,A,0,,,,22224,Vmax value was measured at 5 uM concentration of silyl ether.,,Sus scrofa,,,,9823.0,U,Autocuration,CHEMBL620970,BAO_0000019,
4676,1,B,9,,,,235,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL620971,BAO_0000357,
4677,1,A,0,,,,22224,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL620972,BAO_0000218,
4678,1,A,0,,,,22224,Compound was evaluated for area under the curve expressed as (h*ug/ml),,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL620973,BAO_0000019,
4679,1,A,0,,,,22224,Active metabolite of ifosfamide determined in humans; A-Active,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618243,BAO_0000019,
4680,1,A,0,,,,22224,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618244,BAO_0000019,
4681,1,A,0,,,,22224,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618245,BAO_0000019,
4682,1,A,0,,,,22224,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618246,BAO_0000019,
4683,1,A,0,,,,22224,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618247,BAO_0000019,
4684,1,A,0,,,,22224,Compound was evaluated for oral bioavailability in human,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618248,BAO_0000218,
4685,1,A,0,,,,22224,Metabolite of ifosfamide determined in urine; NF-Not found,1088.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618249,BAO_0000019,
4686,1,A,0,,,,22224,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618250,BAO_0000019,
4687,1,A,0,,,,22224,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL874598,BAO_0000019,
4688,1,A,0,,,,22224,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618251,BAO_0000019,
4689,1,A,0,,,,22224,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618252,BAO_0000019,
4690,1,A,0,,,,22224,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618253,BAO_0000019,
4691,1,A,0,,,,22224,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618254,BAO_0000019,
4692,1,A,0,,,,22224,Percent of compound in healthy individuals (Group D),,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618255,BAO_0000019,
4693,1,A,0,,,,22224,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,2107.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618983,BAO_0000251,
4694,1,A,0,,,,22224,Binding towards human plasma protein at 10 uM,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618984,BAO_0000019,
4695,1,A,0,,,,22224,Binding towards human plasma protein at 100 uM,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618985,BAO_0000019,
4696,1,A,0,,,,22224,Human plasma protein binding activity was determined,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618986,BAO_0000019,
4697,1,A,0,,,,22224,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618987,BAO_0000019,
4698,1,A,0,,,,22224,Percent binding of compound towards human plasma protein was determined,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618988,BAO_0000019,
4699,1,A,0,,,In vitro,22224,Plasma clearance in human liver microsomes,2107.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618989,BAO_0000251,
4700,1,A,0,,,In vitro,22224,In vitro intrinsic clearance in human liver microsome,2107.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618990,BAO_0000251,
4701,1,A,0,,,In vitro,22224,In vitro intrinsic clearance in human liver microsome,2107.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618991,BAO_0000251,
4702,1,A,0,,,In vitro,22224,In vitro microsome metabolism clearance in human was determined,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL876725,BAO_0000251,
4703,1,A,0,,,In vitro,22224,In vitro microsome metabolism clearance in human was determined; High,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618992,BAO_0000251,
4704,1,A,0,,,In vitro,22224,In vitro microsome metabolism clearance in human was determined; ND denotes no data,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618993,BAO_0000251,
4705,1,A,0,,,In vitro,22224,Pharmacokinetic property (clearance) in human liver microsome,2107.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618994,BAO_0000251,
4706,1,A,0,,,In vitro,22224,Plasma clearance in human liver microsomes,2107.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618995,BAO_0000251,
4707,1,A,0,,,In vitro,22224,In vitro clearance in human liver microsomes,2107.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618996,BAO_0000251,
4708,1,A,0,,,In vitro,22224,Intrinsic clearance in human liver microsomes was determined,2107.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618997,BAO_0000251,
4709,1,A,0,,,In vitro,22224,Intrinsic clearance in human liver microsomes was determined,2107.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618998,BAO_0000251,
4710,1,A,0,,,In vivo,22224,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618999,BAO_0000218,
4711,1,A,0,,,In vivo,22224,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL620223,BAO_0000218,
4712,1,A,0,,,,22224,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL620224,BAO_0000218,
4713,1,A,0,,,,22224,Stability in human plasma 2 hr after incubation expressed as percent concentration,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL620225,BAO_0000019,
4714,1,A,0,,,,22224,Stability in human plasma 4 hr after incubation expressed as percent concentration,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL620226,BAO_0000019,
4715,1,A,0,,,,22224,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1088.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL620227,BAO_0000019,
4716,1,A,0,,,,22224,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1088.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL876726,BAO_0000019,
4717,1,A,0,,,,22224,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1088.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL620228,BAO_0000019,
4718,1,A,0,,,,22224,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1088.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL620229,BAO_0000019,
4719,1,F,1,,,In vivo,50594,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620230,BAO_0000218,
4720,1,F,1,,,In vivo,50594,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620231,BAO_0000218,
4721,1,F,1,,,In vivo,50594,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620232,BAO_0000218,
4722,1,F,1,,,In vivo,50594,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620233,BAO_0000218,
4723,1,A,1,,,,50594,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620234,BAO_0000218,
4724,1,A,1,,,,50594,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620235,BAO_0000218,
4725,1,A,1,,,,50594,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620236,BAO_0000218,
4726,1,A,1,,,,50594,In vitro metabolic potential in mouse liver microsomes,2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620237,BAO_0000218,
4727,1,A,1,,,,50594,Ability of compound to bind to plasma protein was evaluated in HSA cells,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620238,BAO_0000218,
4728,1,A,1,,,,50594,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),2369.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620239,BAO_0000218,
4729,1,A,1,,,,50594,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620240,BAO_0000218,
4730,1,A,1,,,,50594,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620241,BAO_0000218,
4731,1,A,1,,,,50594,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL876727,BAO_0000218,
4732,1,A,1,,,,50594,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620242,BAO_0000218,
4733,1,A,1,,,,50594,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620243,BAO_0000218,
4734,1,A,1,,,,50594,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620244,BAO_0000218,
4735,1,A,1,,,,50594,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,1977.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620245,BAO_0000218,
4736,1,A,1,,,,50594,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,1977.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620246,BAO_0000218,
4737,1,A,1,,,,50594,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,1977.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620247,BAO_0000218,
4738,1,A,1,,,In vivo,50594,Half life of compound was determined in plasma of mice at 24 mg/Kg,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620248,BAO_0000218,
4739,1,A,1,,,In vivo,50594,Half life of compound was determined in plasma of mice at 40 mg/Kg,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL873497,BAO_0000218,
4740,1,A,1,,,In vivo,50594,Half life of compound was determined in plasma of mice at 5 mg/Kg,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620249,BAO_0000218,
4741,1,F,1,,,In vivo,50594,Half life after intraperitoneal administration in mice at 18 uM/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620250,BAO_0000218,
4742,1,F,1,,,In vivo,50594,Half life after intraperitoneal administration in mice at 23 uM/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620251,BAO_0000218,
4743,1,F,1,,,In vivo,50594,Half life after intraperitoneal administration in mice at 25 uM/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620252,BAO_0000218,
4744,1,F,1,,,In vivo,50594,Half life after intraperitoneal administration in mice at 26 uM/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620253,BAO_0000218,
4745,1,F,1,,,In vivo,50594,Half life after intravenous administration in mice at 23 uM/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620254,BAO_0000218,
4746,1,A,1,,,In vivo,50594,Half life after intravenous administration in mice at 24 uM/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620255,BAO_0000218,
4747,1,A,1,,,In vivo,50594,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620256,BAO_0000218,
4748,1,A,1,,,In vivo,50594,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL876728,BAO_0000218,
4749,1,A,1,,,In vivo,50594,Maximum time required to reach Cp max was evaluated in mice after oral administration,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620257,BAO_0000218,
4750,1,A,1,,,In vivo,50594,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620258,BAO_0000218,
4751,1,A,1,,,In vivo,50594,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620259,BAO_0000218,
4752,1,A,1,,,In vivo,50594,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620260,BAO_0000218,
4753,1,A,1,,,In vivo,50594,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620261,BAO_0000218,
4754,1,A,1,,,In vivo,50594,Half life at a dose of 10 mg/kg intravenous administration in mice.,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620262,BAO_0000218,
4755,1,A,1,,,In vivo,50594,Half life at a dose of 10 mg/kg peroral administration in mice.,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620263,BAO_0000218,
4756,1,A,1,,,,50594,Half life in ob/ob mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620264,BAO_0000218,
4757,1,A,1,,,In vivo,50594,Half-life at a single subcutaneous administration of 40 mg/kg in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620265,BAO_0000218,
4758,1,A,1,,,,50594,Half-life was measured in mouse,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620266,BAO_0000218,
4759,1,A,1,,,In vivo,50594,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620267,BAO_0000218,
4760,1,A,1,,,,50594,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619364,BAO_0000218,
4761,1,A,1,,,,50594,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619365,BAO_0000218,
4762,1,A,1,,,,50594,T2 in brain of mice at the oral dose of 50 mg/kg,955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619366,BAO_0000218,
4763,1,A,1,,,,50594,T2 in kidney of mice at the oral dose of 50 mg/kg,2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619367,BAO_0000218,
4764,1,A,1,,,,50594,T2 in liver of mice at the oral dose of 50 mg/kg,2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619368,BAO_0000218,
4765,1,A,1,,,,50594,T2 in lungs of mice at the oral dose of 50 mg/kg,2048.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619369,BAO_0000218,
4766,1,A,1,,,,50594,T2 in spleen of mice at the oral dose of 50 mg/kg,2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL876729,BAO_0000218,
4767,1,A,1,,,In vivo,50594,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619370,BAO_0000218,
4768,1,A,1,,,In vivo,50594,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619371,BAO_0000218,
4769,1,A,1,,,In vivo,50594,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619372,BAO_0000218,
4770,1,A,1,,,In vivo,50594,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620012,BAO_0000218,
4771,1,A,1,,,In vivo,50594,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620013,BAO_0000218,
4772,1,F,1,A2780,,,81034,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL620014,BAO_0000219,
4773,1,F,1,A2780,,,81034,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL620015,BAO_0000219,
4774,1,F,1,A2780,,,81034,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL621010,BAO_0000219,
4775,1,F,1,A2780,,,81034,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL621011,BAO_0000219,
4776,1,F,1,A2780,,,81034,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL621012,BAO_0000219,
4777,1,F,1,A2780,,,81034,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL621013,BAO_0000219,
4778,1,F,1,A2780,,,81034,In vitro cytotoxicity against A2780TAX cell line,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL621014,BAO_0000219,
4779,1,F,1,A2780cisR,,,80017,In vitro inhibitory activity against human tumor cell line A2780cis,,Homo sapiens,,481.0,,9606.0,N,Intermediate,CHEMBL618154,BAO_0000219,
4780,1,F,1,A2780,,,81034,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL618155,BAO_0000219,
4781,1,F,1,A2780cisR,,,80017,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,,Homo sapiens,,481.0,,9606.0,N,Intermediate,CHEMBL618156,BAO_0000219,
4782,1,F,1,A2780cisR,,,80017,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,Homo sapiens,,481.0,,9606.0,N,Intermediate,CHEMBL618157,BAO_0000219,
4783,1,F,1,A2780,,,81034,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL618328,BAO_0000219,
4784,1,F,1,A2780,,,81034,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL618329,BAO_0000219,
4785,1,F,1,A2780,,,81034,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL618330,BAO_0000219,
4786,1,F,1,A2780,,,81034,In vitro antitumor activity against A2780cisR cell line.,,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL618331,BAO_0000219,
4787,1,F,1,A2780,,,81034,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL618332,BAO_0000219,
4788,1,F,1,A2780,,,81034,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL618333,BAO_0000219,
4789,1,F,1,A2780cisR,,,80017,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,,Homo sapiens,,481.0,,9606.0,N,Intermediate,CHEMBL618334,BAO_0000219,
4790,1,F,1,A2780,,,81034,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL618335,BAO_0000219,
4791,1,B,9,,,,11736,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL618336,BAO_0000019,
4792,1,F,8,,,,11736,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,,,,,,H,Expert,CHEMBL618337,BAO_0000019,
4793,1,F,9,,,,11736,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL618338,BAO_0000019,
4794,1,F,9,HEK293,,,278,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,,Homo sapiens,,722.0,,9606.0,D,Expert,CHEMBL618339,BAO_0000219,
4795,1,F,9,HEK293,,,278,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,,Homo sapiens,,722.0,,9606.0,D,Expert,CHEMBL618340,BAO_0000219,
4796,1,B,9,,,,11831,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,,Mus musculus,,,,10090.0,D,Expert,CHEMBL618341,BAO_0000019,
4797,1,F,8,,,,11831,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,,,,,,H,Expert,CHEMBL618342,BAO_0000019,
4798,1,F,9,,,,11831,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,Mus musculus,,,,10090.0,D,Expert,CHEMBL618343,BAO_0000019,
4799,1,B,8,,,,280,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,,,,,,,H,Expert,CHEMBL621038,BAO_0000357,
4800,1,F,0,T-cells,,,22226,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),,Homo sapiens,,574.0,,9606.0,U,Autocuration,CHEMBL621039,BAO_0000219,
4801,1,F,0,T-cells,,,22226,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,,Homo sapiens,,574.0,,9606.0,U,Autocuration,CHEMBL621040,BAO_0000219,
4802,1,F,1,A-375,,,80018,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,,Homo sapiens,,455.0,,9606.0,N,Intermediate,CHEMBL621041,BAO_0000219,
4803,1,F,1,A-375,,,80018,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,,Homo sapiens,,455.0,,9606.0,N,Intermediate,CHEMBL621042,BAO_0000219,
4804,1,F,1,A-375,,,80018,In vitro antitumor activity against A375cell line extracted form melanoma,,Homo sapiens,,455.0,,9606.0,N,Intermediate,CHEMBL621043,BAO_0000219,
4805,1,F,1,A-375,,,80018,Inhibition of cell growth in (A375) melan cell line,,Homo sapiens,,455.0,,9606.0,N,Expert,CHEMBL621044,BAO_0000219,
4806,1,F,1,A-375,,,80018,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,,Homo sapiens,,455.0,,9606.0,N,Intermediate,CHEMBL621045,BAO_0000219,
4807,1,F,1,A-375,,,80018,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,,Homo sapiens,,455.0,,9606.0,N,Intermediate,CHEMBL621046,BAO_0000219,
4808,1,F,1,A-375,,,80018,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,,Homo sapiens,,455.0,,9606.0,N,Intermediate,CHEMBL621047,BAO_0000219,
4809,1,F,1,A-427,,,80019,Antiproliferative activity measured against A427 human lung carcinoma,,Homo sapiens,,797.0,,9606.0,N,Intermediate,CHEMBL621048,BAO_0000219,
4810,1,F,1,A-427,,,80019,Antiproliferative activity measured against A427 human lung carcinoma,,Homo sapiens,,797.0,,9606.0,N,Intermediate,CHEMBL883798,BAO_0000219,
4811,1,F,1,A-427,,,80019,Cytotoxicity against lung carcinoma A427 tumor cell lines,,Homo sapiens,,797.0,,9606.0,N,Intermediate,CHEMBL621049,BAO_0000219,
4812,1,F,1,A-427,,,80019,Inhibition of large cell lung carcinoma (A427),,Homo sapiens,,797.0,,9606.0,N,Intermediate,CHEMBL621050,BAO_0000219,
4813,1,F,1,A-427,,,80019,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,,Homo sapiens,,797.0,,9606.0,N,Intermediate,CHEMBL621051,BAO_0000219,
4814,1,F,1,A-427,,,80019,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,Homo sapiens,,797.0,,9606.0,N,Intermediate,CHEMBL621052,BAO_0000219,
4815,1,F,1,A-427,,,80019,Inhibitory concentration in human lung carcinoma A427 cell line,,Homo sapiens,,797.0,,9606.0,N,Intermediate,CHEMBL621053,BAO_0000219,
4816,1,F,1,A-427,,,80019,Inhibitory concentration in human lung carcinoma A427/VCR cell line,,Homo sapiens,,797.0,,9606.0,N,Intermediate,CHEMBL621054,BAO_0000219,
4817,1,A,0,,,In vivo,22224,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621055,BAO_0000218,
4818,1,A,0,,,In vivo,22224,Tested for volume of distribution upon iv administration to african green monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL876398,BAO_0000218,
4819,1,A,0,,,In vivo,22224,Volume of distribution in monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621056,BAO_0000218,
4820,1,A,0,,,In vivo,22224,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,Macaca mulatta,,,,9544.0,U,Autocuration,CHEMBL621057,BAO_0000218,
4821,1,A,0,,,In vivo,22224,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,,Macaca mulatta,,,,9544.0,U,Autocuration,CHEMBL621058,BAO_0000218,
4822,1,A,0,,,In vivo,22224,Pharmacokinetic property(Vdss) in cynomolgus monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621059,BAO_0000218,
4823,1,A,0,,,In vivo,22224,The distribution volume after intravenous administration in cynomolgus monkeys,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621060,BAO_0000218,
4824,1,A,0,,,In vivo,22224,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621061,BAO_0000218,
4825,1,A,0,,,In vivo,22224,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621062,BAO_0000218,
4826,1,A,0,,,In vivo,22224,Volume displacement was calculated in rhesus monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621063,BAO_0000218,
4827,1,A,0,,,In vivo,22224,Volume of distribution in steady state was determined in rhesus monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621064,BAO_0000218,
4828,1,A,0,,,In vivo,22224,Volume of distribution of compound was determined in monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621065,BAO_0000218,
4829,1,A,0,,,In vivo,22224,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621066,BAO_0000218,
4830,1,A,0,,,In vivo,22224,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621067,BAO_0000218,
4831,1,A,0,,,In vivo,22224,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621068,BAO_0000218,
4832,1,A,0,,,In vivo,22224,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL876399,BAO_0000218,
4833,1,A,0,,,In vivo,22224,Volume distribution in monkey after administration of 1 mg/kg iv,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621069,BAO_0000218,
4834,1,A,0,,,In vivo,22224,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621070,BAO_0000218,
4835,1,A,0,,,In vivo,22224,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621071,BAO_0000218,
4836,1,A,0,,,In vivo,22224,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621072,BAO_0000218,
4837,1,A,0,,,In vivo,22224,Oral systemic bioavailability upon iv administration to african green monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618209,BAO_0000218,
4838,1,A,0,,,In vivo,22224,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618210,BAO_0000218,
4839,1,A,0,,,,22224,Baboon plasma free fraction. ,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618211,BAO_0000019,
4840,1,A,0,,,,22224,Area under the curve was calculated in rhesus monkey after iv administration,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618212,BAO_0000218,
4841,1,A,0,,,,22224,Area under the curve was calculated in rhesus monkey after peroral administration,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618213,BAO_0000019,
4842,1,A,0,,,,22224,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618214,BAO_0000019,
4843,1,A,0,,,In vivo,22224,Half life period in monkey after 5 mg/kg dose,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL873492,BAO_0000218,
4844,1,A,0,,,In vivo,22224,Half-life was determined in monkey after 3 mg/kg of i.v. dose,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618272,BAO_0000218,
4845,1,A,0,,,In vivo,22224,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618273,BAO_0000218,
4846,1,A,0,,,In vivo,22224,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,1969.0,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618274,BAO_0000218,
4847,1,A,0,,,In vivo,22224,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618275,BAO_0000218,
4848,1,A,0,,,In vivo,22224,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618276,BAO_0000218,
4849,1,A,0,,,,22224,Compound was evaluated for terminal half life in monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618277,BAO_0000019,
4850,1,A,0,,,In vivo,22224,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618278,BAO_0000218,
4851,1,A,0,,,In vivo,22224,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,1969.0,Macaca mulatta,,,,9544.0,U,Autocuration,CHEMBL618279,BAO_0000218,
4852,1,A,0,,,,22224,Half life of compound was determined in squirrel monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618280,BAO_0000019,
4853,1,A,0,,,In vivo,22224,Half life after iv administration in cynomolgus monkey,,Macaca fascicularis,,,,9541.0,U,Autocuration,CHEMBL618281,BAO_0000218,
4854,1,A,0,,,In vivo,22224,Half life in monkey plasma after administration of 1 mg/kg iv,1969.0,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618282,BAO_0000218,
4855,1,A,0,,,,22224,Half life was calculated in rhesus monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618283,BAO_0000019,
4856,1,A,0,,,,22224,Half life in monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618284,BAO_0000019,
4857,1,A,0,,,In vivo,22224,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618285,BAO_0000218,
4858,1,A,0,,,,22224,Half life was evaluated in rhesus,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618286,BAO_0000019,
4859,1,A,0,,,In vivo,22224,Half life period after oral administration (2.5 mg/kg) in monkey was determined,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618287,BAO_0000218,
4860,1,A,0,,,In vivo,22224,Half life period was determine after peroral administration at 10 mpk in Rhesus,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618288,BAO_0000218,
4861,1,A,0,,,In vivo,22224,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL876393,BAO_0000218,
4862,1,A,0,,,In vivo,22224,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618289,BAO_0000218,
4863,1,A,0,,,In vivo,22224,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618290,BAO_0000218,
4864,1,A,0,,,,22224,Half-life was calculated in monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618291,BAO_0000019,
4865,1,A,0,,,,22224,Half-life in Squirrel monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618292,BAO_0000019,
4866,1,A,0,,,,22224,Half-life in rhesus monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618293,BAO_0000019,
4867,1,A,0,,,In vivo,22224,Half-life was measured in monkey after an iv dose of 1 mg/kg,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618294,BAO_0000218,
4868,1,A,0,,,In vivo,22224,Half-life period after intravenous administration in cynomolgus monkeys,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618295,BAO_0000218,
4869,1,A,0,,,In vivo,22224,Half-life period after oral administration in cynomolgus monkeys,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618296,BAO_0000218,
4870,1,A,0,,,In vivo,22224,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618297,BAO_0000218,
4871,1,A,0,,,,22224,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1088.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618298,BAO_0000019,
4872,1,A,0,,,,22224,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1088.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618299,BAO_0000019,
4873,1,A,0,,,,22224,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1088.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618300,BAO_0000019,
4874,1,A,0,,,,22224,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1088.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618301,BAO_0000019,
4875,1,A,0,,,,22224,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,1088.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618302,BAO_0000019,
4876,1,A,0,,,,22224,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,1088.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL876394,BAO_0000019,
4877,1,A,0,,,,22224,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,1088.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618303,BAO_0000019,
4878,1,A,0,,,,22224,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,1088.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618304,BAO_0000019,
4879,1,A,0,,,In vivo,22224,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618305,BAO_0000218,
4880,1,A,0,,,In vivo,22224,Oral bioavailability in human,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618306,BAO_0000218,
4881,1,A,0,,,,22224,Compound was tested for human plasma protein binding,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618307,BAO_0000019,
4882,1,A,0,,,,22224,Compound was tested for human plasma protein binding; Not determined,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618308,BAO_0000019,
4883,1,A,0,,,,22224,Protein binding activity of compound in human plasma; % Free,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618309,BAO_0000019,
4884,1,A,0,,,,22224,Unbound fraction (plasma),,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618310,BAO_0000019,
4885,1,A,0,,,,22224,Half life for the hydrolysis of compound in human blood serum,1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL873353,BAO_0000366,
4886,1,A,0,,,,22224,Half life period in human plasma using phosphate buffer (0.08 M),1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618311,BAO_0000366,
4887,1,A,0,,,,22224,Half life period in human plasma using phosphate buffer (0.1 M),1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618312,BAO_0000366,
4888,1,A,0,,,,22224,Half-life in human plasma was determined,1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618313,BAO_0000366,
4889,1,A,0,,,,22224,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618314,BAO_0000019,
4890,1,A,0,,,,22224,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618315,BAO_0000019,
4891,1,A,0,,,,22224,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618316,BAO_0000019,
4892,1,A,0,,,,22224,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618317,BAO_0000019,
4893,1,A,0,,,,22224,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL620138,BAO_0000019,
4894,1,A,0,,,,22224,Partition coefficient (logP),,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL858280,BAO_0000019,
4895,1,A,0,,,,22224,In vitro metabolic stability in human was measured as pmol/min/mg/protein,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL620139,BAO_0000019,
4896,1,A,0,,,,22224,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL620140,BAO_0000251,
4897,1,A,0,,,,22224,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL620141,BAO_0000019,
4898,1,A,0,,,,22224,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL620142,BAO_0000019,
4899,1,A,0,,,,22224,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL620143,BAO_0000019,
4900,1,A,0,,,,22224,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL620144,BAO_0000251,
4901,1,A,0,,,,22224,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL620145,BAO_0000251,
4902,1,A,0,,,,22224,Metabolism of compound in human microsomes; Trace,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL620146,BAO_0000251,
4903,1,A,0,,,,22224,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,2107.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL620147,BAO_0000251,
4904,1,A,0,,,,22224,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL620148,BAO_0000251,
4905,1,A,0,,,,22224,In vitro metabolic potential in human liver microsomes,2107.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL620149,BAO_0000251,
4906,1,A,0,,,,22224,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL876412,BAO_0000019,
4907,1,A,0,,,,22224,Tested for human plasma protein binding of the compound; Not tested,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL619352,BAO_0000019,
4908,1,A,0,,,,22224,Compound was tested for percent protein binding (PB) in human,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL619353,BAO_0000019,
4909,1,A,0,,,,22224,Protein binding in human plasma,1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL619354,BAO_0000019,
4910,1,A,0,,,,22224,Permeability coefficient (B to A) in Caco-2 cell,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL619355,BAO_0000019,
4911,1,A,0,,,,22224,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL619356,BAO_0000019,
4912,1,A,0,,,,22224,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL619357,BAO_0000019,
4913,1,A,0,,,,22224,In vitro rate of absorption observed as Caco-2 permeability in humans,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL619358,BAO_0000019,
4914,1,A,0,Caco-2,,,22224,Cellular permeability of compound was determined in Caco-2 cells; High,,Homo sapiens,,495.0,,9606.0,U,Autocuration,CHEMBL619359,BAO_0000219,
4915,1,A,0,Caco-2,,,22224,Permeability in Caco-2 cells of compound,,Homo sapiens,,495.0,,9606.0,U,Autocuration,CHEMBL619360,BAO_0000219,
4916,1,A,0,,,,22224,Permeability coefficient (A to B) in Caco-2 cell,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL619361,BAO_0000019,
4917,1,A,0,,,,22224,Permeability coefficient (B to A) in Caco-2 cell,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL619362,BAO_0000019,
4918,1,A,0,,,,22224,Permeability coefficient (Papp) (Caco-2 cell monolayer),,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL619363,BAO_0000019,
4919,1,A,0,,,,22224,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618942,BAO_0000019,
4920,1,A,0,,,,22224,Compound was tested for protein binding in human plasma,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618943,BAO_0000019,
4921,1,A,0,,,,22224,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618944,BAO_0000019,
4922,1,A,0,,,,22224,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,1088.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618945,BAO_0000019,
4923,1,A,1,,,In vivo,50594,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618946,BAO_0000218,
4924,1,A,1,,,In vivo,50594,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL876413,BAO_0000218,
4925,1,A,1,,,In vivo,50594,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618947,BAO_0000218,
4926,1,A,1,,,In vivo,50594,Time taken to reach maximum concentration in plasma upon oral administration in mouse,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618948,BAO_0000218,
4927,1,A,1,,,In vivo,50594,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618949,BAO_0000218,
4928,1,F,1,,,In vivo,50594,Tmax after intraperitoneal administration in mice at 23 uM/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618950,BAO_0000218,
4929,1,A,1,,,In vivo,50594,Tmax after oral administration at 30 mg/kg in ICR mouse,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618951,BAO_0000218,
4930,1,A,1,,,In vivo,50594,Tmax after peroral administration in mice at 2.4 uM/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618952,BAO_0000218,
4931,1,A,1,,,In vivo,50594,Tmax at a single subcutaneous administration of 40 mg/kg in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618953,BAO_0000218,
4932,1,A,1,,,In vivo,50594,Tmax in brain of mice at the oral dose of 50 mg/kg,955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618954,BAO_0000218,
4933,1,A,1,,,In vivo,50594,Tmax in kidney of mice at the oral dose of 50 mg/kg,2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618955,BAO_0000218,
4934,1,A,1,,,In vivo,50594,Tmax in liver of mice at the oral dose of 50 mg/kg,2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618956,BAO_0000218,
4935,1,A,1,,,In vivo,50594,Tmax in lungs of mice at the oral dose of 50 mg/kg,2048.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618957,BAO_0000218,
4936,1,F,1,,,In vivo,50594,Tmax in mice at 18 uM/kg i.p. administration,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618958,BAO_0000218,
4937,1,F,1,,,In vivo,50594,Tmax in mice at 23 uM/kg i.v. administration,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618959,BAO_0000218,
4938,1,F,1,,,In vivo,50594,Tmax in mice at 25 uM/kg i.p. administration,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618960,BAO_0000218,
4939,1,F,1,,,In vivo,50594,Tmax in mice at 26 uM/kg i.p. administration,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL876723,BAO_0000218,
4940,1,A,1,,,In vivo,50594,Tmax in spleen of mice at the oral dose of 50 mg/kg,2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618961,BAO_0000218,
4941,1,A,1,,,In vivo,50594,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618962,BAO_0000218,
4942,1,A,1,,,In vivo,50594,Tmax value at a dose of 10 mg/kg peroral administration in mice.,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618963,BAO_0000218,
4943,1,A,1,,,,50594,Tmax value in IRC mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618964,BAO_0000218,
4944,1,A,1,,,In vivo,50594,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618965,BAO_0000218,
4945,1,A,1,,,In vivo,50594,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618966,BAO_0000218,
4946,1,A,1,,,,50594,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),1088.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618967,BAO_0000218,
4947,1,A,1,,,,50594,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),1088.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618968,BAO_0000218,
4948,1,A,1,,,,50594,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),1088.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618969,BAO_0000218,
4949,1,A,1,,,,50594,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618970,BAO_0000218,
4950,1,A,1,,,,50594,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618971,BAO_0000218,
4951,1,A,1,,,In vivo,50594,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618972,BAO_0000218,
4952,1,A,1,,,In vivo,50594,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618973,BAO_0000218,
4953,1,A,1,,,In vivo,50594,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618974,BAO_0000218,
4954,1,A,1,,,In vivo,50594,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618975,BAO_0000218,
4955,1,A,1,,,In vivo,50594,Vd in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618976,BAO_0000218,
4956,1,A,1,,,In vivo,50594,Volume of distribution in mouse,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618977,BAO_0000218,
4957,1,A,1,,,In vivo,50594,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL876724,BAO_0000218,
4958,1,A,1,,,In vivo,50594,Volume of distribution of compound in plasma was determined at 24 mg/Kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618978,BAO_0000218,
4959,1,A,1,,,In vivo,50594,Volume of distribution of compound in plasma was determined at 40 mg/Kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618979,BAO_0000218,
4960,1,A,1,,,In vivo,50594,Volume of distribution of compound in plasma was determined at 5 mg/Kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618980,BAO_0000218,
4961,1,A,1,,,In vivo,50594,Pharmacokinetic property (vdss) was measured in mouse,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618981,BAO_0000218,
4962,1,A,1,,,In vivo,50594,Value distribution upon iv administration in mouse,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618982,BAO_0000218,
4963,1,A,1,,,In vivo,50594,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620150,BAO_0000218,
4964,1,A,1,,,In vivo,50594,Volume of distribution was evaluated in mice after intravenous administration,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620151,BAO_0000218,
4965,1,A,1,,,In vivo,50594,Volume of distribution was evaluated in mice after oral administration,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620152,BAO_0000218,
4966,1,A,1,,,In vivo,50594,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620153,BAO_0000218,
4967,1,A,1,,,In vivo,50594,Steady state volume of distribution was determined in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL876395,BAO_0000218,
4968,1,A,1,,,In vivo,50594,Volume distribution (steady state) of compound was determined in mouse,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620154,BAO_0000218,
4969,1,A,1,,,In vivo,50594,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620155,BAO_0000218,
4970,1,A,1,,,In vivo,50594,Vss value at a dose of 10 mg/kg intravenous administration in mice.,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620156,BAO_0000218,
4971,1,A,1,,,In vivo,50594,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620157,BAO_0000218,
4972,1,A,1,,,In vivo,50594,Biodistribution of compound (oxidized form) in in kidney tissue,2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620158,BAO_0000218,
4973,1,A,1,,,In vivo,50594,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620159,BAO_0000218,
4974,1,A,1,,,In vivo,50594,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620160,BAO_0000218,
4975,1,A,1,,,In vivo,50594,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620161,BAO_0000218,
4976,1,F,1,A-427,,,80019,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,,Homo sapiens,,797.0,,9606.0,N,Intermediate,CHEMBL620162,BAO_0000219,
4977,1,F,1,A-431,,,80852,Inhibition of A431 human squamous cell carcinoma cell proliferation,,Homo sapiens,,500.0,,9606.0,N,Expert,CHEMBL620163,BAO_0000219,
4978,1,F,1,A-431,,,80852,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,,Homo sapiens,,500.0,,9606.0,N,Expert,CHEMBL620833,BAO_0000219,
4979,1,F,1,A-431,,,80852,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,,Homo sapiens,,500.0,,9606.0,N,Expert,CHEMBL876396,BAO_0000219,
4980,1,F,1,A-431,,,80852,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,,Homo sapiens,,500.0,,9606.0,N,Expert,CHEMBL620834,BAO_0000219,
4981,1,F,1,A-431,,,80852,Inhibition of A431 human carcinoma cell proliferation,,Homo sapiens,,500.0,,9606.0,N,Expert,CHEMBL620835,BAO_0000219,
4982,1,F,1,A-431,,,80852,In vitro inhibition of A431 (human carcinoma) cell basal growth.,,Homo sapiens,,500.0,,9606.0,N,Expert,CHEMBL620836,BAO_0000219,
4983,1,F,1,A-431,,,80852,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,,Homo sapiens,,500.0,,9606.0,N,Intermediate,CHEMBL620837,BAO_0000219,
4984,1,F,1,A-431,,,80852,In vitro cytotoxicity against epidermoid carcinoma cell line,,Homo sapiens,,500.0,,9606.0,N,Intermediate,CHEMBL621017,BAO_0000219,
4985,1,F,9,A-431,,,9,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",,Homo sapiens,,500.0,,9606.0,D,Expert,CHEMBL621018,BAO_0000218,
4986,1,F,1,A-431,,,80852,Antiproliferative activity of compound was measured on human tumor cell line A431.,,Homo sapiens,,500.0,,9606.0,N,Intermediate,CHEMBL621019,BAO_0000219,
4987,1,F,1,A-431,,,80852,Antiproliferative effect of compound on A431 cell line expressing mutant p53,,Homo sapiens,,500.0,,9606.0,N,Intermediate,CHEMBL621020,BAO_0000219,
4988,1,F,1,A-431,,,80852,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,,Homo sapiens,,500.0,,9606.0,N,Intermediate,CHEMBL621021,BAO_0000219,
4989,1,F,8,A-431,,,9,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,,,,500.0,,,H,Expert,CHEMBL621022,BAO_0000219,
4990,1,F,1,A-431,,,80852,Tested for antiproliferative activity against human A431 cells,,Homo sapiens,,500.0,,9606.0,N,Expert,CHEMBL621023,BAO_0000219,
4991,1,F,9,A-431,,,9,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,,Homo sapiens,,500.0,,9606.0,D,Expert,CHEMBL621024,BAO_0000219,
4992,1,F,1,A-431,,,80852,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,,Homo sapiens,,500.0,,9606.0,N,Expert,CHEMBL621025,BAO_0000219,
4993,1,F,1,A-431,,,80852,Inhibition of A431 cell proliferation,,Homo sapiens,,500.0,,9606.0,N,Expert,CHEMBL621026,BAO_0000219,
4994,1,F,1,A-431,,,80852,Cytotoxic effect on A431 human epidermoid carcinoma cells,,Homo sapiens,,500.0,,9606.0,N,Expert,CHEMBL621027,BAO_0000219,
4995,1,F,1,A-431,,,80852,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),,Homo sapiens,,500.0,,9606.0,N,Expert,CHEMBL876397,BAO_0000219,
4996,1,F,1,A-431,,,80852,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,,Homo sapiens,,500.0,,9606.0,N,Intermediate,CHEMBL883797,BAO_0000219,
4997,1,F,1,A-431,,,80852,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,,Homo sapiens,,500.0,,9606.0,N,Intermediate,CHEMBL621028,BAO_0000219,
4998,1,F,1,A-431,,,80852,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,,Homo sapiens,,500.0,,9606.0,N,Intermediate,CHEMBL621029,BAO_0000219,
4999,1,F,1,A-431,,,80852,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,,Homo sapiens,,500.0,,9606.0,N,Intermediate,CHEMBL621030,BAO_0000219,
5000,1,F,8,A-431,,,9,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,,,,500.0,,,H,Expert,CHEMBL621147,BAO_0000219,
5001,1,F,1,A-431,,,80852,In vivo antiproliferative activity against A431 cell line,,Homo sapiens,,500.0,,9606.0,N,Intermediate,CHEMBL621148,BAO_0000218,
5002,1,F,9,A-431,,,9,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,,Homo sapiens,,500.0,,9606.0,D,Expert,CHEMBL621149,BAO_0000219,
5003,1,F,1,A-431,,,80852,Inhibition of A431 human epidermoid carcinoma cell proliferation,,Homo sapiens,,500.0,,9606.0,N,Expert,CHEMBL621150,BAO_0000219,
5004,1,F,9,A-431,,,9,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,,Homo sapiens,,500.0,,9606.0,D,Expert,CHEMBL621151,BAO_0000219,
5005,1,F,1,A-431,,,80852,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),,Homo sapiens,,500.0,,9606.0,N,Intermediate,CHEMBL621152,BAO_0000219,
5006,1,F,1,A-431,,,80852,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),,Homo sapiens,,500.0,,9606.0,N,Intermediate,CHEMBL621153,BAO_0000219,
5007,1,F,1,A-431,,,80852,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),,Homo sapiens,,500.0,,9606.0,N,Intermediate,CHEMBL884000,BAO_0000219,
5008,1,F,9,,,,9,Inhibition of EGFR overexpressing A431 cell proliferation,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL621154,BAO_0000019,
5009,1,F,1,A-431,,,80852,Inhibition of A431 cell proliferation,,Homo sapiens,,500.0,,9606.0,N,Expert,CHEMBL621155,BAO_0000219,
5010,1,F,9,A-431,,,9,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,,Homo sapiens,,500.0,,9606.0,D,Expert,CHEMBL621156,BAO_0000219,
5011,1,F,9,A-431,,,9,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",,Homo sapiens,,500.0,,9606.0,D,Expert,CHEMBL621157,BAO_0000219,
5012,1,F,8,A-431,,,9,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),,,,500.0,,,H,Expert,CHEMBL621158,BAO_0000219,
5013,1,F,1,A-431,,,80852,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,Homo sapiens,,500.0,,9606.0,N,Intermediate,CHEMBL621159,BAO_0000219,
5014,1,F,1,A-431,,,80852,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,Homo sapiens,,500.0,,9606.0,N,Intermediate,CHEMBL621160,BAO_0000219,
5015,1,F,1,A-431,,,80852,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,,Homo sapiens,,500.0,,9606.0,N,Intermediate,CHEMBL621161,BAO_0000219,
5016,1,F,1,A-431,,,80852,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,,Homo sapiens,,500.0,,9606.0,N,Intermediate,CHEMBL621162,BAO_0000219,
5017,1,F,1,A-431,,,80852,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,Homo sapiens,,500.0,,9606.0,N,Intermediate,CHEMBL621163,BAO_0000219,
5018,1,F,1,A-431,,,80852,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,,Homo sapiens,,500.0,,9606.0,N,Intermediate,CHEMBL621164,BAO_0000219,
5019,1,F,1,A-431,,,80852,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,,Homo sapiens,,500.0,,9606.0,N,Intermediate,CHEMBL621165,BAO_0000219,
5020,1,A,0,,,,22224,Half-life period in cynomolgus monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL619159,BAO_0000019,
5021,1,A,0,,,In vitro,22224,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",1969.0,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL619160,BAO_0000366,
5022,1,A,0,,,In vivo,22224,Longer half-life in monkey (i.v.) at 0.5 mpk,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL619161,BAO_0000218,
5023,1,A,0,,,,22224,Plasma half life in monkey,1969.0,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL619162,BAO_0000366,
5024,1,A,0,,,,22224,Plasma half-life in rhesus monkey,1969.0,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL619163,BAO_0000366,
5025,1,A,0,,,In vivo,22224,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),1969.0,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL619164,BAO_0000218,
5026,1,A,0,,,In vivo,22224,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),1969.0,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL619320,BAO_0000218,
5027,1,A,0,,,In vivo,22224,Tested for half life upon iv administration to african green monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL619321,BAO_0000218,
5028,1,A,0,,,In vivo,22224,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL873336,BAO_0000218,
5029,1,A,0,,,In vivo,22224,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL619322,BAO_0000218,
5030,1,A,0,,,In vivo,22224,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL619323,BAO_0000218,
5031,1,A,0,,,In vivo,22224,The time for peak concentration value after oral administration in cynomolgus monkeys,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL619324,BAO_0000218,
5032,1,A,0,,,,22224,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL619325,BAO_0000019,
5033,1,A,0,,,,22224,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL876411,BAO_0000019,
5034,1,A,0,,,,22224,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL619326,BAO_0000019,
5035,1,A,0,,,,22224,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL619327,BAO_0000019,
5036,1,A,0,,,,22224,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL619328,BAO_0000019,
5037,1,A,0,,,,22224,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL619329,BAO_0000019,
5038,1,A,0,,,,22224,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL619330,BAO_0000019,
5039,1,A,0,,,,22224,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL619331,BAO_0000019,
5040,1,A,0,,,,22224,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL619332,BAO_0000019,
5041,1,A,0,,,,22224,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL619333,BAO_0000019,
5042,1,A,0,,,,22224,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL619334,BAO_0000019,
5043,1,A,0,,,,22224,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL619335,BAO_0000019,
5044,1,A,0,,,,22224,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL619336,BAO_0000019,
5045,1,A,0,,,,22224,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL619337,BAO_0000019,
5046,1,A,0,,,,22224,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL619338,BAO_0000019,
5047,1,A,0,,,,22224,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL619339,BAO_0000019,
5048,1,A,1,,,In vivo,50597,Bioavailability in rat (cannulated) (dose 2 mg/kg),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619340,BAO_0000218,
5049,1,A,1,,,In vivo,50597,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL873496,BAO_0000218,
5050,1,A,1,,,,50597,AUC value in rat after IV administration at a dose of 10 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619341,BAO_0000218,
5051,1,A,1,,,,50597,AUC value in rat after oral administration at a dose of 10 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619342,BAO_0000218,
5052,1,A,1,,,In vivo,50597,Cmax value in rat after oral administration at a dose of 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619343,BAO_0000218,
5053,1,A,1,,,In vivo,50597,Bioavailability in rat after oral administration at a dose of 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619344,BAO_0000218,
5054,1,A,1,,,In vivo,50597,Tmax value in rat after oral administration at a dose of 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619345,BAO_0000218,
5055,1,A,1,,,,50597,Vc value in rat after IV administration at a dose of 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619346,BAO_0000218,
5056,1,A,1,,,In vivo,50597,Half life period in rat after IV administration at a dose of 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619347,BAO_0000218,
5057,1,A,0,,,,22224,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,Papio hamadryas,,,,9557.0,U,Autocuration,CHEMBL619348,BAO_0000019,
5058,1,A,0,,,,22224,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),,Papio hamadryas,,,,9557.0,U,Autocuration,CHEMBL619349,BAO_0000019,
5059,1,A,0,,,,22224,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),,Papio hamadryas,,,,9557.0,U,Autocuration,CHEMBL619350,BAO_0000019,
5060,1,A,0,,,,22224,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,,Papio hamadryas,,,,9557.0,U,Autocuration,CHEMBL619351,BAO_0000019,
5061,1,A,0,,,,22224,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,,Papio hamadryas,,,,9557.0,U,Autocuration,CHEMBL875953,BAO_0000019,
5062,1,A,0,,,,22224,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,,Papio hamadryas,,,,9557.0,U,Autocuration,CHEMBL621716,BAO_0000019,
5063,1,A,0,,,,22224,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,,Papio hamadryas,,,,9557.0,U,Autocuration,CHEMBL621717,BAO_0000019,
5064,1,A,0,,,,22224,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,Papio hamadryas,,,,9557.0,U,Autocuration,CHEMBL621718,BAO_0000019,
5065,1,A,0,,,,22224,Area under curve after 1 mpk peroral administration to beagles,,beagle,,,,9615.0,U,Autocuration,CHEMBL621719,BAO_0000019,
5066,1,A,0,,,,22224,Area under curve after 2 mpk peroral administration to beagles,,beagle,,,,9615.0,U,Autocuration,CHEMBL621720,BAO_0000019,
5067,1,A,0,,,In vivo,22224,Cmax value after 1 mpk peroral administration to beagles,,beagle,,,,9615.0,U,Autocuration,CHEMBL621721,BAO_0000218,
5068,1,A,0,,,,22224,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,1088.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL621722,BAO_0000019,
5069,1,A,0,,,,22224,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,1088.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL621723,BAO_0000019,
5070,1,A,0,,,,22224,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,1088.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL621724,BAO_0000019,
5071,1,A,0,,,,22224,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,1088.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL623443,BAO_0000019,
5072,1,A,0,,,,22224,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,1088.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL623444,BAO_0000019,
5073,1,A,0,,,,22224,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,1088.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL623445,BAO_0000019,
5074,1,A,0,,,,22224,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,1088.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL623446,BAO_0000019,
5075,1,A,0,,,,22224,Metabolic stability observed at 30 min after administration in human liver microsomes,2107.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL623447,BAO_0000251,
5076,1,A,0,,,,22224,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL623448,BAO_0000019,
5077,1,A,0,,,,22224,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL623449,BAO_0000019,
5078,1,A,0,,,,22224,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL623450,BAO_0000019,
5079,1,A,0,,,,22224,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",2107.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL623451,BAO_0000251,
5080,1,A,0,,,,22224,Metabolic stability (% remaining at 30 mins) in human S9.,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL623452,BAO_0000019,
5081,1,A,0,,,,22224,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL623453,BAO_0000019,
5082,1,A,0,,,,22224,Percent parent compound remaining after 20 min incubation with human liver microsomes,2107.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL623454,BAO_0000251,
5083,1,A,0,,,,22224,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,2107.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL623455,BAO_0000251,
5084,1,A,0,,,,22224,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,2107.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL624371,BAO_0000251,
5085,1,A,0,,,,22224,First pass metabolism and metabolic bioavailability using human hepatic microsomes,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL624372,BAO_0000218,
5086,1,A,0,,,,22224,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL624373,BAO_0000019,
5087,1,A,0,,,,22224,Percent remaining in human plasma after incubation for 60 min at 37 C.,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL624374,BAO_0000019,
5088,1,A,0,,,,22224,The percent remaining in human plasma after 30 min was determined,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL624556,BAO_0000019,
5089,1,A,0,,,,22224,Conversion rate of the prodrug in human plasma,1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL624557,BAO_0000366,
5090,1,A,0,,,,22224,Conversion rate of the prodrug in human plasma; ND means no data,1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL624558,BAO_0000366,
5091,1,A,0,,,,22224,Half life of compound was determined in human blood,178.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL624559,BAO_0000221,
5092,1,A,0,,,,22224,Half life of compound was determined in man with once daily dosing,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL624560,BAO_0000019,
5093,1,A,0,,,In vitro,22224,Half life in human microsomes,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL624561,BAO_0000251,
5094,1,A,0,,,,22224,Half life in human plasma,1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL624562,BAO_0000366,
5095,1,A,0,,,,22224,Half life in human plasma; Not detected,1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL624563,BAO_0000366,
5096,1,A,0,,,In vivo,22224,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL624564,BAO_0000218,
5097,1,A,0,,,In vitro,22224,Half-life for oxidative metabolic stability was determined using rat liver microsomes,2107.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL624565,BAO_0000251,
5098,1,A,0,,,,22224,Half-life in human plasma,1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL875152,BAO_0000366,
5099,1,A,0,,,,22224,Half-life of the parent prodrug in plasma,1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL624566,BAO_0000366,
5100,1,A,0,,,In vitro,22224,In vitro half life in human plasma was determined,1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL873805,BAO_0000366,
5101,1,A,0,,,In vitro,22224,The compound was tested In Vitro for half life in human liver microsomes.,2107.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL624567,BAO_0000251,
5102,1,A,0,,,In vivo,22224,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL624568,BAO_0000218,
5103,1,A,0,,,In vivo,22224,Observed volume of distribution,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL624569,BAO_0000218,
5104,1,A,0,,,In vivo,22224,Oral bioavailability in human,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL624570,BAO_0000218,
5105,1,A,0,,,,22224,Tested for human plasma protein binding of the compound,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL624571,BAO_0000019,
5106,1,A,0,,,,22224,"First order rate constant, k was determined in human plasma",,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL624572,BAO_0000019,
5107,1,A,0,,,,22224,Observed rate constant in 80% human plasma at 37 degree Centigrade,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL624573,BAO_0000019,
5108,1,A,0,,,,22224,Observed rate constant in 80% human plasma at 37 degree Centigrade,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL875153,BAO_0000019,
5109,1,A,0,,,,22224,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,2107.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL624574,BAO_0000251,
5110,1,A,0,,,,22224,The compound was tested for the plasma binding in human,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL624575,BAO_0000019,
5111,1,A,0,,,,22224,Plasma protein binding (human),,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL624576,BAO_0000019,
5112,1,A,0,,,In vitro,22224,Compound was evaluated for half-life in human liver microsomes,2107.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL624577,BAO_0000251,
5113,1,A,0,,,In vitro,22224,Half life measured in vitro for its stability in human blood,178.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL624578,BAO_0000221,
5114,1,A,0,,,,22224,Half life in human serum,1977.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL622796,BAO_0000019,
5115,1,A,0,,,,22224,Half life in human serum; ND=not determined,1977.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL622797,BAO_0000019,
5116,1,A,0,,,,22224,Half life were determined in CEM-SS cell extract in decomposition step 1,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL622798,BAO_0000019,
5117,1,A,0,,,,22224,Half life were determined in CEM-SS cell extract in decomposition step 2,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL622799,BAO_0000019,
5118,1,A,0,,,,22224,Half life of the in human plasma,1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL622800,BAO_0000366,
5119,1,A,0,,,In vitro,22224,Half life period in human hepatic S9 fraction was determined,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL622801,BAO_0000220,
5120,1,A,0,,,In vitro,22224,Half life period in human liver microsome was determined,2107.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL622802,BAO_0000251,
5121,1,A,0,,,,22224,Half life period was determined; 6-7,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL622803,BAO_0000019,
5122,1,A,0,,,,22224,Half life period was evaluated in human,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL875154,BAO_0000019,
5123,1,A,0,,,,22224,Half life time in human plasma,1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL622804,BAO_0000366,
5124,1,A,1,,,In vivo,50594,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622805,BAO_0000218,
5125,1,A,1,,,In vivo,50594,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622611,BAO_0000218,
5126,1,A,1,,,In vivo,50594,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622612,BAO_0000218,
5127,1,A,1,,,In vivo,50594,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL875160,BAO_0000218,
5128,1,A,1,,,In vivo,50594,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622613,BAO_0000218,
5129,1,A,1,,,In vivo,50594,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622614,BAO_0000218,
5130,1,A,1,,,In vivo,50594,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622615,BAO_0000218,
5131,1,A,1,,,In vivo,50594,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622616,BAO_0000218,
5132,1,A,1,,,In vivo,50594,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622617,BAO_0000218,
5133,1,A,1,,,In vivo,50594,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622618,BAO_0000218,
5134,1,A,1,,,In vivo,50594,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622619,BAO_0000218,
5135,1,A,1,,,In vivo,50594,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622620,BAO_0000218,
5136,1,A,1,,,In vivo,50594,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622621,BAO_0000218,
5137,1,A,1,,,In vivo,50594,Biodistribution of compound (oxidized form) in blood tissue,178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622622,BAO_0000218,
5138,1,A,1,,,In vivo,50594,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622623,BAO_0000218,
5139,1,A,1,,,In vivo,50594,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622624,BAO_0000218,
5140,1,A,1,,,In vivo,50594,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622625,BAO_0000218,
5141,1,A,1,,,In vivo,50594,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622626,BAO_0000218,
5142,1,A,1,,,In vivo,50594,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622627,BAO_0000218,
5143,1,A,1,,,In vivo,50594,Biodistribution of compound (oxidized form) in brain tissue of mice,955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622628,BAO_0000218,
5144,1,A,1,,,In vivo,50594,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622629,BAO_0000218,
5145,1,A,1,,,In vivo,50594,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622630,BAO_0000218,
5146,1,A,1,,,In vivo,50594,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622631,BAO_0000218,
5147,1,A,1,,,In vivo,50594,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622632,BAO_0000218,
5148,1,A,1,,,In vivo,50594,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622633,BAO_0000218,
5149,1,A,1,,,In vivo,50594,Biodistribution of compound (oxidized form) in heart tissue of mice,948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622634,BAO_0000218,
5150,1,A,1,,,In vivo,50594,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622635,BAO_0000218,
5151,1,A,1,,,In vivo,50594,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL875161,BAO_0000218,
5152,1,A,1,,,In vivo,50594,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622636,BAO_0000218,
5153,1,A,1,,,In vivo,50594,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623335,BAO_0000218,
5154,1,A,1,,,In vivo,50594,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623336,BAO_0000218,
5155,1,A,1,,,In vivo,50594,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623337,BAO_0000218,
5156,1,A,1,,,In vivo,50594,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623338,BAO_0000218,
5157,1,A,1,,,In vivo,50594,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623339,BAO_0000218,
5158,1,A,1,,,In vivo,50594,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623524,BAO_0000218,
5159,1,A,1,,,In vivo,50594,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623525,BAO_0000218,
5160,1,A,1,,,In vivo,50594,Biodistribution of compound (oxidized form) in liver tissue,2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623526,BAO_0000218,
5161,1,A,1,,,In vivo,50594,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623527,BAO_0000218,
5162,1,A,1,,,In vivo,50594,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623528,BAO_0000218,
5163,1,F,1,A-431,,,80852,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,,Homo sapiens,,500.0,,9606.0,N,Intermediate,CHEMBL624615,BAO_0000219,
5164,1,F,1,A-431,,,80852,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,Homo sapiens,,500.0,,9606.0,N,Intermediate,CHEMBL621672,BAO_0000219,
5165,1,F,1,A-431,,,80852,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",,,,500.0,,,N,Expert,CHEMBL621673,BAO_0000218,
5166,1,F,1,A-431,,,80852,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",,,,500.0,,,N,Expert,CHEMBL621674,BAO_0000218,
5167,1,F,9,A-431,,,9,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,Homo sapiens,,500.0,,9606.0,D,Expert,CHEMBL884002,BAO_0000219,
5168,1,F,1,A-431,,,80852,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",,Homo sapiens,,500.0,,9606.0,N,Intermediate,CHEMBL621850,BAO_0000219,
5169,1,F,1,A-431,,,80852,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,,Homo sapiens,,500.0,,9606.0,N,Intermediate,CHEMBL621851,BAO_0000219,
5170,1,F,9,A-431,,,9,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,,Homo sapiens,,500.0,,9606.0,D,Expert,CHEMBL621852,BAO_0000219,
5171,1,F,9,A-431,,,9,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,,Homo sapiens,,500.0,,9606.0,D,Expert,CHEMBL621853,BAO_0000219,
5172,1,F,1,A-431,,,80852,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",,,,500.0,,,N,Expert,CHEMBL621854,BAO_0000218,
5173,1,F,1,A-431,,,80852,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,,,500.0,,,N,Expert,CHEMBL621855,BAO_0000218,
5174,1,F,1,A-431,,,80852,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,,,500.0,,,N,Expert,CHEMBL623724,BAO_0000218,
5175,1,F,1,A-431,,,80852,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",,,,500.0,,,N,Expert,CHEMBL623725,BAO_0000218,
5176,1,F,1,A-431,,,80852,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",,,,500.0,,,N,Expert,CHEMBL623726,BAO_0000218,
5177,1,F,9,A-431,,,9,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",,Homo sapiens,,500.0,,9606.0,D,Expert,CHEMBL623727,BAO_0000219,
5178,1,F,8,A-431,,,9,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,,,,500.0,,,H,Expert,CHEMBL623728,BAO_0000219,
5179,1,F,1,A-431,,,80852,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",,,,500.0,,,N,Expert,CHEMBL623729,BAO_0000218,
5180,1,F,1,A-431,,,80852,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,,,500.0,,,N,Expert,CHEMBL623730,BAO_0000218,
5181,1,F,1,A-431,,,80852,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,,,500.0,,,N,Expert,CHEMBL623731,BAO_0000218,
5182,1,F,1,A-431,,,80852,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",,Mus musculus,,500.0,,10090.0,N,Expert,CHEMBL623732,BAO_0000218,
5183,1,F,1,A-431,,,80852,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",,Mus musculus,,500.0,,10090.0,N,Expert,CHEMBL623733,BAO_0000218,
5184,1,F,1,A-431,,,80852,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,Mus musculus,,500.0,,10090.0,N,Expert,CHEMBL623734,BAO_0000218,
5185,1,F,1,A-431,,,80852,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,Mus musculus,,500.0,,10090.0,N,Expert,CHEMBL623735,BAO_0000218,
5186,1,F,1,A-431,,,80852,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,,Homo sapiens,,500.0,,9606.0,N,Expert,CHEMBL623736,BAO_0000219,
5187,1,F,1,A-431,,,80852,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,,Homo sapiens,,500.0,,9606.0,N,Intermediate,CHEMBL623737,BAO_0000219,
5188,1,F,1,A-431,,,80852,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,,Homo sapiens,,500.0,,9606.0,N,Intermediate,CHEMBL623738,BAO_0000219,
5189,1,F,1,A-431,,,80852,Dose giving a 50% decrease in the living cell number (A437 cells),,Homo sapiens,,500.0,,9606.0,N,Intermediate,CHEMBL875168,BAO_0000219,
5190,1,F,1,A549,,,80682,In vitro inhibitory concentration against proliferation of A459 cell line.,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL623739,BAO_0000219,
5191,1,F,1,A549,,,80682,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL623740,BAO_0000219,
5192,1,F,1,A549,,,80682,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL624424,BAO_0000219,
5193,1,F,1,A498,,,80021,In vitro antitumor activity against renal A498 tumor cell lines,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL624425,BAO_0000219,
5194,1,F,1,A498,,,80021,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL624426,BAO_0000219,
5195,1,F,1,A498,,,80021,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL624427,BAO_0000219,
5196,1,F,1,A498,,,80021,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL624428,BAO_0000219,
5197,1,F,1,A498,,,80021,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL624429,BAO_0000219,
5198,1,F,1,A498,,,80021,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL624620,BAO_0000219,
5199,1,F,1,A498,,,80021,Cytotoxicity on kidney carcinoma (A-498) cell line,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL624621,BAO_0000219,
5200,1,F,1,A498,,,80021,Compound was evaluated against Human cell line renal A498,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL624622,BAO_0000219,
5201,1,F,1,A498,,,80021,Compound was tested for inhibition of A498 human renal cancer cell line,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL624623,BAO_0000219,
5202,1,F,1,A498,,,80021,Growth inhibitory activity against A498 human cancer cell line,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL874365,BAO_0000219,
5203,1,F,1,A498,,,80021,In vitro antitumor activity against human renal A498 cell line,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL624624,BAO_0000219,
5204,1,F,1,A498,,,80021,In vitro cytotoxic activity against renal (A498) cell line,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL624625,BAO_0000219,
5205,1,F,1,A498,,,80021,In vitro cytotoxic activity against human renal cancer (A498) cell line,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL624626,BAO_0000219,
5206,1,F,1,A498,,,80021,Tested for cytostatic activity against renal A498 cell line,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL624627,BAO_0000219,
5207,1,F,1,A498,,,80021,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL883157,BAO_0000219,
5208,1,F,1,A498,,,80021,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,,Homo sapiens,,624.0,,9606.0,N,Expert,CHEMBL624628,BAO_0000219,
5209,1,A,0,,,In vivo,22224,Cmax value after 2 mpk peroral administration to beagles,,beagle,,,,9615.0,U,Autocuration,CHEMBL624629,BAO_0000218,
5210,1,A,0,,,In vivo,22224,Bioavailability,,Canis lupus familiaris,beagle,,,9615.0,U,Autocuration,CHEMBL623551,BAO_0000218,
5211,1,A,0,,,In vivo,22224,Bioavailability after 1 mpk peroral administration to beagles,,Canis lupus familiaris,beagle,,,9615.0,U,Autocuration,CHEMBL623552,BAO_0000218,
5212,1,A,0,,,In vivo,22224,Bioavailability after 2 mpk peroral administration to beagles,,Canis lupus familiaris,beagle,,,9615.0,U,Autocuration,CHEMBL623553,BAO_0000218,
5213,1,A,0,,,,22224,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,,Bos taurus,,,,9913.0,U,Autocuration,CHEMBL623554,BAO_0000019,
5214,1,A,0,,,,22224,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,,Bos taurus,,,,9913.0,U,Autocuration,CHEMBL623555,BAO_0000019,
5215,1,A,0,,,,22224,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,,Bos taurus,,,,9913.0,U,Autocuration,CHEMBL623556,BAO_0000019,
5216,1,A,0,,,,22224,Solubility against bovine alpha-chymotrypsin,,Bos taurus,,,,9913.0,U,Autocuration,CHEMBL623557,BAO_0000019,
5217,1,A,0,,,,22224,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,Bos taurus,,,,9913.0,U,Autocuration,CHEMBL623558,BAO_0000019,
5218,1,A,0,,,,22224,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,Bos taurus,,,,9913.0,U,Autocuration,CHEMBL623559,BAO_0000019,
5219,1,A,0,,,,22224,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,2106.0,Bos taurus,,,,9913.0,U,Autocuration,CHEMBL623560,BAO_0000221,
5220,1,A,0,,,,22224,Half life in culture medium containing 10% of heat inactivated foetal calf serum,,Bos taurus,,,,9913.0,U,Autocuration,CHEMBL623561,BAO_0000019,
5221,1,A,0,,,,22224,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,,Bos taurus,,,,9913.0,U,Autocuration,CHEMBL623562,BAO_0000019,
5222,1,A,0,,,,22224,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,,Bos taurus,,,,9913.0,U,Autocuration,CHEMBL623563,BAO_0000019,
5223,1,A,0,,,,22224,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,2106.0,Bos taurus,,,,9913.0,U,Autocuration,CHEMBL623564,BAO_0000221,
5224,1,A,0,,,,22224,Half life in presence of 2 mg/mL BSA at pH 8.8,,Bos taurus,,,,9913.0,U,Autocuration,CHEMBL873806,BAO_0000019,
5225,1,A,0,,,,22224,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,,Bos taurus,,,,9913.0,U,Autocuration,CHEMBL623565,BAO_0000019,
5226,1,A,0,,,,22224,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,,Bos taurus,,,,9913.0,U,Autocuration,CHEMBL623566,BAO_0000019,
5227,1,A,0,,,,22224,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,,Bos taurus,,,,9913.0,U,Autocuration,CHEMBL623567,BAO_0000019,
5228,1,A,0,,,,22224,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),,Bos taurus,,,,9913.0,U,Autocuration,CHEMBL623568,BAO_0000019,
5229,1,A,1,,,,50588,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623569,BAO_0000218,
5230,1,A,1,,,,50588,AUC after administration at 100 mg/kg/day in dogs,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623570,BAO_0000218,
5231,1,A,1,,,,50588,AUC in dog at 0-24 hr by peroral administration at 3 mpk,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624254,BAO_0000218,
5232,1,A,1,,,,50588,AUC value after 15 mg/kg iv dose in Dogs,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624255,BAO_0000218,
5233,1,A,1,,,,50588,AUC value after 30 mg/kg po dose in Dogs,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624256,BAO_0000218,
5234,1,A,1,,,,50588,AUC value after administration of 4 mg/Kg oral dose in dog,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624257,BAO_0000218,
5235,1,A,1,,,,50588,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624258,BAO_0000218,
5236,1,A,1,,,,50588,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL875277,BAO_0000218,
5237,1,A,1,,,,50588,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622667,BAO_0000218,
5238,1,A,1,,,,50588,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622668,BAO_0000218,
5239,1,A,1,,,,50588,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622669,BAO_0000218,
5240,1,A,1,,,,50588,Area under curve determined in dogs after intravenous administration of 3 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622670,BAO_0000218,
5241,1,A,1,,,,50588,Area under curve determined in dogs after oral administration of 10 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622671,BAO_0000218,
5242,1,A,1,,,,50588,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622672,BAO_0000218,
5243,1,A,1,,,,50588,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Expert,CHEMBL622673,BAO_0000218,
5244,1,A,1,,,,50588,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Expert,CHEMBL622674,BAO_0000218,
5245,1,A,1,,,,50588,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622675,BAO_0000218,
5246,1,A,1,,,,50588,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622676,BAO_0000218,
5247,1,A,1,,,,50588,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622677,BAO_0000218,
5248,1,A,1,,,,50588,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622678,BAO_0000218,
5249,1,A,1,,,,50588,Area under curve in dog after administration of 20 mg/kg dose through peroral route,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622679,BAO_0000218,
5250,1,A,1,,,,50588,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622680,BAO_0000218,
5251,1,A,1,,,,50588,Area under curve was determine after peroral administration at 10 mpk in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622681,BAO_0000218,
5252,1,A,1,,,,50588,Area under curve was determine after peroral administration at 5 mpk in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL875278,BAO_0000218,
5253,1,A,1,,,,50588,Area under curve was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622682,BAO_0000218,
5254,1,A,1,,,,50588,Area under curve in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622683,BAO_0000218,
5255,1,A,1,,,,50588,Area under curve in dogs at 10 mg/kg dose fo oral administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622684,BAO_0000218,
5256,1,A,1,,,,50588,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622685,BAO_0000218,
5257,1,A,1,,,,50588,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622686,BAO_0000218,
5258,1,A,1,,,,50588,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618344,BAO_0000218,
5259,1,A,1,,,,50588,Area under curve value in dog at a dose of 5 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL875582,BAO_0000218,
5260,1,A,1,,,,50588,Area under curve was determined after 0.1 mg/kg iv administration in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618345,BAO_0000218,
5261,1,A,1,,,,50588,Area under curve was determined after 0.3 mg/kg po administration in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618346,BAO_0000218,
5262,1,A,1,,,,50588,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618347,BAO_0000218,
5263,1,A,1,,,,50588,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618348,BAO_0000218,
5264,1,A,0,,,,22224,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618349,BAO_0000019,
5265,1,A,0,,,,22224,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618350,BAO_0000019,
5266,1,A,0,,,,22224,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618351,BAO_0000019,
5267,1,A,0,,,,22224,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618352,BAO_0000019,
5268,1,A,0,,,,22224,Time taken to reduce 50% of the concentration of compound in blood plasma,178.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL873494,BAO_0000221,
5269,1,A,0,,,,22224,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618353,BAO_0000366,
5270,1,A,0,,,,22224,Half life in human plasma,1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618354,BAO_0000366,
5271,1,A,0,,,,22224,Half life in human plasma was reported,1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL875583,BAO_0000366,
5272,1,A,0,,,,22224,Half life in human serum,1977.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618355,BAO_0000019,
5273,1,A,0,,,,22224,Half life upon exposure to human plasma,1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618356,BAO_0000366,
5274,1,A,0,,,In vitro,22224,t1/2 in human microsomes,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618357,BAO_0000251,
5275,1,A,0,,,,22224,Half life period in 80% human plasma at 37 degree Centigrade,1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618358,BAO_0000366,
5276,1,A,0,,,,22224,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),14.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618359,BAO_0000221,
5277,1,A,0,,,In vitro,22224,Half-life measured in in vitro Cathepsin B assay in human plasma,1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618360,BAO_0000366,
5278,1,A,0,,,,22224,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618361,BAO_0000019,
5279,1,A,0,,,In vitro,22224,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,2107.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618362,BAO_0000251,
5280,1,A,0,,,,22224,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618363,BAO_0000366,
5281,1,A,0,,,,22224,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618364,BAO_0000366,
5282,1,A,0,,,,22224,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL875584,BAO_0000366,
5283,1,A,0,,,,22224,Half-life in the CEM cell extracts,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618365,BAO_0000019,
5284,1,A,0,,,,22224,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL873495,BAO_0000366,
5285,1,A,0,,,,22224,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618366,BAO_0000366,
5286,1,A,0,,,,22224,Half-life was determined,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618367,BAO_0000019,
5287,1,A,0,,,,22224,Half-life (human blood stability),178.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618368,BAO_0000221,
5288,1,A,0,,,,22224,Half-life (human blood stability); no data,178.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618369,BAO_0000221,
5289,1,A,0,,,,22224,Half-life in human plasma,1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618370,BAO_0000366,
5290,1,A,0,,,,22224,CYP3A4 metabolism half-life (t1/2),,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618371,BAO_0000019,
5291,1,A,0,,,,22224,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),178.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618372,BAO_0000221,
5292,1,A,0,,,In vitro,22224,In vitro half life in human plasma,1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618373,BAO_0000366,
5293,1,A,0,,,In vitro,22224,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618374,BAO_0000366,
5294,1,A,0,,,In vitro,22224,In vitro hydrolysis in human plasma,1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618375,BAO_0000366,
5295,1,A,0,,,In vitro,22224,In vitro hydrolysis in human plasma; no data,1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618376,BAO_0000366,
5296,1,A,0,,,In vitro,22224,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,2107.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618377,BAO_0000251,
5297,1,A,0,,,,22224,Plasma half life in human,1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618378,BAO_0000366,
5298,1,A,0,,,,22224,Stability after incubation with human plasma (at 37 degree C),1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618379,BAO_0000366,
5299,1,A,0,,,,22224,T1/2 was evaluated in human plasma,1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618380,BAO_0000366,
5300,1,A,0,,,,22224,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618381,BAO_0000366,
5301,1,A,0,,,,22224,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618382,BAO_0000366,
5302,1,A,0,,,,22224,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618383,BAO_0000019,
5303,1,A,0,,,In vitro,22224,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618384,BAO_0000019,
5304,1,A,0,,,In vitro,22224,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL618385,BAO_0000019,
5305,1,A,0,,,,22224,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL619099,BAO_0000366,
5306,1,A,0,,,,22224,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL619100,BAO_0000366,
5307,1,A,0,,,,22224,Time taken for 50% to be consumed by serum PON1 was determined,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL619101,BAO_0000019,
5308,1,A,0,,,,22224,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL619102,BAO_0000019,
5309,1,A,0,,,,22224,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,2107.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL619103,BAO_0000251,
5310,1,A,0,,,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,,Mus sp.,,,,10095.0,U,Autocuration,CHEMBL619268,BAO_0000218,
5311,1,A,0,,,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,,Mus sp.,,,,10095.0,U,Autocuration,CHEMBL619269,BAO_0000218,
5312,1,A,0,,,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,,Mus sp.,,,,10095.0,U,Autocuration,CHEMBL619270,BAO_0000218,
5313,1,A,0,,,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,,Mus sp.,,,,10095.0,U,Autocuration,CHEMBL619271,BAO_0000218,
5314,1,A,0,,,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,,Mus sp.,,,,10095.0,U,Autocuration,CHEMBL875585,BAO_0000218,
5315,1,A,0,,,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,,Mus sp.,,,,10095.0,U,Autocuration,CHEMBL619272,BAO_0000218,
5316,1,F,1,786-0,,,80640,Compound tested for growth inhibition of renal cancer cell line 786-0,,Homo sapiens,,391.0,,9606.0,N,Intermediate,CHEMBL619273,BAO_0000219,
5317,1,F,1,786-0,,,80640,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,,Homo sapiens,,391.0,,9606.0,N,Intermediate,CHEMBL619274,BAO_0000219,
5318,1,F,1,786-0,,,80640,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,,Homo sapiens,,391.0,,9606.0,N,Expert,CHEMBL619275,BAO_0000219,
5319,1,F,1,786-0,,,80640,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",,Homo sapiens,,391.0,,9606.0,N,Intermediate,CHEMBL619276,BAO_0000219,
5320,1,F,1,786-0,,,80640,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",,Homo sapiens,,391.0,,9606.0,N,Intermediate,CHEMBL619277,BAO_0000219,
5321,1,F,1,786-0,,,80640,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",,Homo sapiens,,391.0,,9606.0,N,Intermediate,CHEMBL619278,BAO_0000219,
5322,1,F,1,786-0,,,80640,Tested for cytotoxicity against 786-0 cell lines in renal cancer,,Homo sapiens,,391.0,,9606.0,N,Intermediate,CHEMBL619279,BAO_0000219,
5323,1,F,1,786-0,,,80640,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,,Homo sapiens,,391.0,,9606.0,N,Intermediate,CHEMBL858458,BAO_0000219,
5324,1,F,1,786-0,,,80640,Cytotoxic effect on renal cancer line 786-0,,Homo sapiens,,391.0,,9606.0,N,Expert,CHEMBL619280,BAO_0000219,
5325,1,F,1,786-0,,,80640,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,,Homo sapiens,,391.0,,9606.0,N,Intermediate,CHEMBL619281,BAO_0000219,
5326,1,F,1,786-0,,,80640,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,Homo sapiens,,391.0,,9606.0,N,Intermediate,CHEMBL619282,BAO_0000219,
5327,1,F,1,786-0,,,80640,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",,Homo sapiens,,391.0,,9606.0,N,Intermediate,CHEMBL619283,BAO_0000219,
5328,1,F,1,786-0,,,80640,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,,Homo sapiens,,391.0,,9606.0,N,Intermediate,CHEMBL619284,BAO_0000219,
5329,1,F,1,786-0,,,80640,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,Homo sapiens,,391.0,,9606.0,N,Intermediate,CHEMBL619285,BAO_0000219,
5330,1,F,1,786-0,,,80640,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),,Homo sapiens,,391.0,,9606.0,N,Intermediate,CHEMBL619286,BAO_0000219,
5331,1,F,1,786-0,,,80640,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,,Homo sapiens,,391.0,,9606.0,N,Intermediate,CHEMBL619287,BAO_0000219,
5332,1,F,1,786-0,,,80640,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,Homo sapiens,,391.0,,9606.0,N,Intermediate,CHEMBL857455,BAO_0000219,
5333,1,F,1,786-0,,,80640,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),,Homo sapiens,,391.0,,9606.0,N,Intermediate,CHEMBL883801,BAO_0000219,
5334,1,F,1,791T cell line,,,80641,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,,Homo sapiens,,972.0,,9606.0,N,Intermediate,CHEMBL619288,BAO_0000219,
5335,1,F,1,791T cell line,,,80641,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),,Homo sapiens,,972.0,,9606.0,N,Intermediate,CHEMBL619289,BAO_0000219,
5336,1,F,1,791T cell line,,,80641,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,,Homo sapiens,,972.0,,9606.0,N,Intermediate,CHEMBL619290,BAO_0000219,
5337,1,F,1,791T cell line,,,80641,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),,Homo sapiens,,972.0,,9606.0,N,Intermediate,CHEMBL619291,BAO_0000219,
5338,1,F,1,791T cell line,,,80641,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),,Homo sapiens,,972.0,,9606.0,N,Intermediate,CHEMBL619292,BAO_0000219,
5339,1,F,1,791T cell line,,,80641,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,,Homo sapiens,,972.0,,9606.0,N,Intermediate,CHEMBL619293,BAO_0000219,
5340,1,F,1,791T cell line,,,80641,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),,Homo sapiens,,972.0,,9606.0,N,Intermediate,CHEMBL619294,BAO_0000219,
5341,1,F,1,791T cell line,,,80641,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),,Homo sapiens,,972.0,,9606.0,N,Intermediate,CHEMBL619295,BAO_0000219,
5342,1,F,1,791T cell line,,,80641,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),,Homo sapiens,,972.0,,9606.0,N,Intermediate,CHEMBL619296,BAO_0000219,
5343,1,F,1,791T cell line,,,80641,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,,Homo sapiens,,972.0,,9606.0,N,Intermediate,CHEMBL619297,BAO_0000219,
5344,1,F,1,786-0,,,80640,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,,Homo sapiens,,391.0,,9606.0,N,Intermediate,CHEMBL619298,BAO_0000219,
5345,1,F,0,,,,22226,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,,,,,,,U,Intermediate,CHEMBL619299,BAO_0000019,
5346,1,F,1,RPMI-8226,,,80433,Inhibition of cell growth in drug resistant 8226 myeloma cell line,,Homo sapiens,,741.0,,9606.0,N,Expert,CHEMBL619300,BAO_0000219,
5347,1,F,1,RPMI-8226,,,80433,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,,Homo sapiens,,741.0,,9606.0,N,Expert,CHEMBL619301,BAO_0000219,
5348,1,F,1,RPMI-8226,,,80433,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,,Homo sapiens,,741.0,,9606.0,N,Intermediate,CHEMBL619302,BAO_0000219,
5349,1,F,1,RPMI-8226,,,80433,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,Homo sapiens,,741.0,,9606.0,N,Intermediate,CHEMBL619303,BAO_0000219,
5350,1,F,1,RPMI-8226,,,80433,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,Homo sapiens,,741.0,,9606.0,N,Intermediate,CHEMBL619304,BAO_0000219,
5351,1,F,1,RPMI-8226,,,80433,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,Homo sapiens,,741.0,,9606.0,N,Intermediate,CHEMBL857706,BAO_0000219,
5352,1,F,1,RPMI-8226,,,80433,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,Homo sapiens,,741.0,,9606.0,N,Intermediate,CHEMBL619305,BAO_0000219,
5353,1,F,1,RPMI-8226,,,80433,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,Homo sapiens,,741.0,,9606.0,N,Intermediate,CHEMBL619306,BAO_0000219,
5354,1,F,1,RPMI-8226,,,80433,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,Homo sapiens,,741.0,,9606.0,N,Intermediate,CHEMBL619307,BAO_0000219,
5355,1,F,1,RPMI-8226,,,80433,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,Homo sapiens,,741.0,,9606.0,N,Intermediate,CHEMBL619308,BAO_0000219,
5356,1,F,1,RPMI-8226,,,80433,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,Homo sapiens,,741.0,,9606.0,N,Intermediate,CHEMBL619309,BAO_0000219,
5357,1,F,1,RPMI-8226,,,80433,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,Homo sapiens,,741.0,,9606.0,N,Intermediate,CHEMBL619310,BAO_0000219,
5358,1,F,1,A498,,,80021,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL619311,BAO_0000219,
5359,1,F,1,A498,,,80021,Compound was tested for the growth inhibition of A498 renal tumor cell line,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL619312,BAO_0000219,
5360,1,F,1,A498,,,80021,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL619313,BAO_0000219,
5361,1,F,1,A498,,,80021,In vitro inhibitory concentration against renal cancer cell line A498,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL619314,BAO_0000219,
5362,1,F,1,A498,,,80021,Cytotoxicity against A 498 tumor cell line,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL619959,BAO_0000219,
5363,1,F,1,A498,,,80021,In vitro antitumor activity against A498 human cancer cell line,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL619960,BAO_0000219,
5364,1,F,1,A498,,,80021,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL619961,BAO_0000219,
5365,1,F,1,A498,,,80021,Inhibitory dose required against A498 human tumor cell lines,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL619962,BAO_0000219,
5366,1,F,1,A498,,,80021,Anticancer activity against one renal cancer (A498 cell line),,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL875586,BAO_0000219,
5367,1,F,1,A498,,,80021,In vitro cytotoxicity against melanoma A498 cell line,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL619963,BAO_0000219,
5368,1,F,1,A498,,,80021,Compound was tested for growth inhibitory activity against A498 cell line,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL619964,BAO_0000219,
5369,1,F,1,A498,,,80021,Compound tested for growth inhibition of renal cancer cell line A498,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL620108,BAO_0000219,
5370,1,F,1,A498,,,80021,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL620109,BAO_0000219,
5371,1,F,1,A498,,,80021,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL620110,BAO_0000219,
5372,1,F,1,A498,,,80021,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL620111,BAO_0000219,
5373,1,F,1,A498,,,80021,Tested for cytotoxicity against A498 cell lines in renal cancer,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL620112,BAO_0000219,
5374,1,F,1,A498,,,80021,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL620113,BAO_0000219,
5375,1,F,1,A498,,,80021,Cytotoxic effect on renal cancer lines A498,,Homo sapiens,,624.0,,9606.0,N,Expert,CHEMBL620114,BAO_0000219,
5376,1,F,1,A498,,,80021,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL620115,BAO_0000219,
5377,1,F,1,A498,,,80021,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL620116,BAO_0000219,
5378,1,F,1,A498,,,80021,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL620117,BAO_0000219,
5379,1,F,1,A498,,,80021,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL620118,BAO_0000219,
5380,1,F,1,A498,,,80021,Cytotoxicity against human kidney carcinoma cell lines A4982LM,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL620119,BAO_0000219,
5381,1,F,1,A498,,,80021,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL620120,BAO_0000219,
5382,1,F,1,A549,,,80682,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL620121,BAO_0000219,
5383,1,F,1,A549,,,80682,Antitumor activity against A549 human lung carcinoma cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620122,BAO_0000219,
5384,1,F,1,A549,,,80682,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620123,BAO_0000219,
5385,1,F,1,A549,,,80682,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620124,BAO_0000219,
5386,1,F,1,A549,,,80682,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620125,BAO_0000219,
5387,1,F,1,A549,,,80682,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL620126,BAO_0000219,
5388,1,F,1,A549,,,80682,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL883027,BAO_0000219,
5389,1,F,1,A549,,,80682,In vitro cytotoxic activity against human lung A549 cell line,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL620127,BAO_0000219,
5390,1,F,1,A549,,,80682,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620128,BAO_0000219,
5391,1,F,1,A549,,,80682,In vitro cytotoxic activity against human lung A549 cell line),,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620129,BAO_0000219,
5392,1,F,1,A549,,,80682,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620130,BAO_0000219,
5393,1,F,1,A549,,,80682,In vitro cytotoxicity against human non small-cell-lung cell line A549.,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL620131,BAO_0000219,
5394,1,F,1,A549,,,80682,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620132,BAO_0000219,
5395,1,F,1,A549,,,80682,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620133,BAO_0000219,
5396,1,F,1,A549,,,80682,Inhibition of A549 human lung carcinoma cell proliferation,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL620134,BAO_0000219,
5397,1,F,1,A549,,,80682,Inhibitory activity against A549 lung adenocarcinoma cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620135,BAO_0000219,
5398,1,F,1,A549,,,80682,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620136,BAO_0000219,
5399,1,F,1,A549,,,80682,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620137,BAO_0000219,
5400,1,F,1,A549,,,80682,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620268,BAO_0000219,
5401,1,F,1,A549,,,80682,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620269,BAO_0000219,
5402,1,F,1,A549,,,80682,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620270,BAO_0000219,
5403,1,F,1,A549,,,80682,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620271,BAO_0000219,
5404,1,F,1,A549,,,80682,Inhibition of A549 cancer cell proliferation,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL620272,BAO_0000219,
5405,1,F,1,A549,,,80682,Inhibition of A549 cancer cell proliferation (Not tested),,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL620273,BAO_0000219,
5406,1,F,1,A549,,,80682,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620274,BAO_0000219,
5407,1,F,1,A549,,,80682,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620275,BAO_0000219,
5408,1,F,1,A549,,,80682,Antiproliferative potency determined as inhibitory concentration against A549 cells,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620276,BAO_0000219,
5409,1,F,1,A549,,,80682,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620277,BAO_0000219,
5410,1,F,1,A549,,,80682,Cytotoxicity against Renal cell lines A549 was determined,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620278,BAO_0000219,
5411,1,A,1,,,,50588,Area under curve was determined in dog after a 3 mg/kg of oral dose,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL620279,BAO_0000218,
5412,1,A,1,,,,50588,Area under curve was determined in dog after oral administration at 1 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL620280,BAO_0000218,
5413,1,A,1,,,,50588,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL620281,BAO_0000218,
5414,1,A,1,,,,50588,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL620282,BAO_0000218,
5415,1,A,1,,,,50588,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621134,BAO_0000218,
5416,1,A,1,,,,50588,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621135,BAO_0000218,
5417,1,A,1,,,,50588,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621136,BAO_0000218,
5418,1,A,1,,,,50588,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621137,BAO_0000218,
5419,1,A,1,,,,50588,Area under plasma concentration time curve in dog upon oral administration,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621138,BAO_0000218,
5420,1,A,1,,,,50588,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL875587,BAO_0000218,
5421,1,A,1,,,,50588,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621139,BAO_0000218,
5422,1,A,1,,,,50588,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621140,BAO_0000218,
5423,1,A,1,,,,50588,Area under the curve for the compound was obtained when tested in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621141,BAO_0000218,
5424,1,A,1,,,,50588,Area under the curve at a dose of 1 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621142,BAO_0000218,
5425,1,A,1,,,,50588,Area under the curve at a dose of 1 mg/kg (oral),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621143,BAO_0000218,
5426,1,A,1,,,,50588,Area under the curve at i.v. dose of 0.2 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621144,BAO_0000218,
5427,1,A,1,,,,50588,Area under the curve was measured in dog after an iv dose of 1 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621145,BAO_0000218,
5428,1,A,1,,,,50588,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621146,BAO_0000218,
5429,1,A,1,,,,50588,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622567,BAO_0000218,
5430,1,A,1,,,,50588,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622568,BAO_0000218,
5431,1,A,1,,,,50588,Compound was evaluated for area under the curve in dog blood.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622569,BAO_0000218,
5432,1,A,1,,,,50588,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622570,BAO_0000218,
5433,1,A,1,,,,50588,AUC in dog after oral dose (1 mg/kg),1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622571,BAO_0000218,
5434,1,A,1,,,,50588,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622572,BAO_0000218,
5435,1,A,1,,,,50588,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622573,BAO_0000218,
5436,1,A,1,,,,50588,Pharmacokinetic parameter AUC after intravenous administration to dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622574,BAO_0000218,
5437,1,A,1,,,,50588,Pharmacokinetic parameter AUC after oral administration to dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622575,BAO_0000218,
5438,1,A,1,,,,50588,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622576,BAO_0000218,
5439,1,A,1,,,,50588,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622577,BAO_0000218,
5440,1,A,1,,,,50588,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622578,BAO_0000218,
5441,1,A,1,,,,50588,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622579,BAO_0000218,
5442,1,A,1,,,,50588,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622580,BAO_0000218,
5443,1,A,1,,,,50588,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622581,BAO_0000218,
5444,1,A,1,,,,50588,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622582,BAO_0000218,
5445,1,A,1,,,,50588,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622583,BAO_0000218,
5446,1,A,1,,,,50588,Oral AUCN in dog (dosed at 0.5 mpk iv ),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622584,BAO_0000218,
5447,1,A,1,,,,50588,Oral AUCN in dog (dosed at 0.5 mpk iv ),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622585,BAO_0000218,
5448,1,A,1,,,,50588,Compound was evaluated for oral bioavailability in dog; 90-100,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622586,BAO_0000218,
5449,1,A,1,,,,50588,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623281,BAO_0000218,
5450,1,A,1,,,,50588,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623282,BAO_0000218,
5451,1,A,1,,,,50588,PAPP (membrane permeability) in dog kidney cell monolayer assay,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623283,BAO_0000218,
5452,1,A,1,,,,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623284,BAO_0000218,
5453,1,A,1,,,,50588,Bioavailability administered orally at a dose of 10 mg/kg to dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623285,BAO_0000218,
5454,1,A,1,,,,50588,Plasma protein binding towards dog plasma at 10 uM,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623463,BAO_0000218,
5455,1,A,1,,,,50588,Plasma protein binding towards dog plasma at 100 uM,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL875952,BAO_0000218,
5456,1,A,1,,,In vivo,50588,Bioavailability in dog (dose 4 mg/kg p.o.),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621705,BAO_0000218,
5457,1,A,1,,,In vivo,50588,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621706,BAO_0000218,
5458,1,A,1,,,In vivo,50588,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621707,BAO_0000218,
5459,1,A,1,,,In vivo,50588,Bioavailability in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621708,BAO_0000218,
5460,1,A,1,,,In vivo,50588,Bioavailability,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621709,BAO_0000218,
5461,1,A,1,,,In vivo,50588,Oral bioavailability in dog (dose 10 mg/kg),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621710,BAO_0000218,
5462,1,A,1,,,In vivo,50588,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621711,BAO_0000218,
5463,1,A,1,,,In vivo,50588,Bioavailability in dog (dose 10.0 mg/kg p.o.),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621712,BAO_0000218,
5464,1,A,1,,,In vivo,50588,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621713,BAO_0000218,
5465,1,A,1,,,In vivo,50588,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621714,BAO_0000218,
5466,1,A,0,,,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,,Mus sp.,,,,10095.0,U,Autocuration,CHEMBL621715,BAO_0000218,
5467,1,A,0,,,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,2107.0,Mus sp.,,,,10095.0,U,Autocuration,CHEMBL623717,BAO_0000218,
5468,1,A,0,,,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,2107.0,Mus sp.,,,,10095.0,U,Autocuration,CHEMBL623718,BAO_0000218,
5469,1,A,0,,,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,2107.0,Mus sp.,,,,10095.0,U,Autocuration,CHEMBL623719,BAO_0000218,
5470,1,A,0,,,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,,Mus sp.,,,,10095.0,U,Autocuration,CHEMBL623720,BAO_0000218,
5471,1,A,0,,,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,,Mus sp.,,,,10095.0,U,Autocuration,CHEMBL623721,BAO_0000218,
5472,1,A,0,,,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,2385.0,Mus sp.,,,,10095.0,U,Autocuration,CHEMBL623722,BAO_0000218,
5473,1,A,0,,,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,2385.0,Mus sp.,,,,10095.0,U,Autocuration,CHEMBL623723,BAO_0000218,
5474,1,A,0,,,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,2385.0,Mus sp.,,,,10095.0,U,Autocuration,CHEMBL618543,BAO_0000218,
5475,1,A,0,,,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,2106.0,Mus sp.,,,,10095.0,U,Autocuration,CHEMBL618544,BAO_0000218,
5476,1,A,0,,,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,2106.0,Mus sp.,,,,10095.0,U,Autocuration,CHEMBL875155,BAO_0000218,
5477,1,A,0,,,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,,Mus sp.,,,,10095.0,U,Autocuration,CHEMBL618545,BAO_0000218,
5478,1,A,0,,,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,,Mus sp.,,,,10095.0,U,Autocuration,CHEMBL618546,BAO_0000218,
5479,1,A,0,,,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,,Mus sp.,,,,10095.0,U,Autocuration,CHEMBL623529,BAO_0000218,
5480,1,A,0,,,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,,Mus sp.,,,,10095.0,U,Autocuration,CHEMBL623530,BAO_0000218,
5481,1,A,0,,,,22224,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,,Mus sp.,,,,10095.0,U,Autocuration,CHEMBL621764,BAO_0000218,
5482,1,A,0,,,,22224,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621765,BAO_0000019,
5483,1,A,0,,,,22224,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),2037.0,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621766,BAO_0000019,
5484,1,A,0,,,,22224,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),1870.0,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621767,BAO_0000019,
5485,1,A,0,,,,22224,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621768,BAO_0000019,
5486,1,A,0,,,,22224,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),2435.0,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621769,BAO_0000019,
5487,1,A,0,,,,22224,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621770,BAO_0000019,
5488,1,A,0,,,,22224,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),2037.0,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621771,BAO_0000019,
5489,1,A,0,,,,22224,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),1870.0,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621772,BAO_0000019,
5490,1,A,0,,,,22224,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621773,BAO_0000019,
5491,1,A,0,,,,22224,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),2435.0,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621774,BAO_0000019,
5492,1,A,0,,,,22224,Compound was evaluated for oral bioavailability in rats,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621775,BAO_0000218,
5493,1,A,0,,,In vivo,22224,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,1969.0,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621776,BAO_0000218,
5494,1,A,0,,,,22224,Half life period was evaluated in monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621777,BAO_0000019,
5495,1,A,0,,,In vivo,22224,Half-life in rhesus monkeys by intravenous administration of dose,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL875162,BAO_0000218,
5496,1,A,1,,,,50594,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621778,BAO_0000218,
5497,1,A,1,,,,50594,AUC after intraperitoneal administration of 100 mg/kg in mice,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621779,BAO_0000218,
5498,1,A,1,,,,50594,AUC value was determined after oral administration,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622479,BAO_0000218,
5499,1,A,1,,,,50594,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622480,BAO_0000218,
5500,1,A,1,,,,50594,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622481,BAO_0000218,
5501,1,A,1,,,,50594,Area under curve by ioral administration in mouse,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622482,BAO_0000218,
5502,1,A,1,,,,50594,Area under curve by iv administration in mouse,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622483,BAO_0000218,
5503,1,A,1,,,,50594,Area under curve at 0-8 hr in IRC mice after peroral administration,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622484,BAO_0000218,
5504,1,A,1,,,,50594,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622641,BAO_0000218,
5505,1,A,1,,,,50594,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622642,BAO_0000218,
5506,1,A,1,,,,50594,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622643,BAO_0000218,
5507,1,A,1,,,,50594,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622644,BAO_0000218,
5508,1,F,1,RPMI-8226,,,80433,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,Homo sapiens,,741.0,,9606.0,N,Intermediate,CHEMBL622645,BAO_0000219,
5509,1,F,1,RPMI-8226,,,80433,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,Homo sapiens,,741.0,,9606.0,N,Intermediate,CHEMBL622646,BAO_0000219,
5510,1,F,1,RPMI-8226,,,80433,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,Homo sapiens,,741.0,,9606.0,N,Intermediate,CHEMBL621238,BAO_0000219,
5511,1,F,1,RPMI-8226,,,80433,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,Homo sapiens,,741.0,,9606.0,N,Intermediate,CHEMBL621239,BAO_0000219,
5512,1,F,1,RPMI-8226,,,80433,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,Homo sapiens,,741.0,,9606.0,N,Intermediate,CHEMBL621240,BAO_0000219,
5513,1,F,1,RPMI-8226,,,80433,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,Homo sapiens,,741.0,,9606.0,N,Intermediate,CHEMBL621241,BAO_0000219,
5514,1,F,1,RPMI-8226,,,80433,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,Homo sapiens,,741.0,,9606.0,N,Intermediate,CHEMBL621242,BAO_0000219,
5515,1,F,1,RPMI-8226,,,80433,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,Homo sapiens,,741.0,,9606.0,N,Intermediate,CHEMBL620350,BAO_0000219,
5516,1,F,1,RPMI-8226,,,80433,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,Homo sapiens,,741.0,,9606.0,N,Intermediate,CHEMBL620351,BAO_0000219,
5517,1,F,1,RPMI-8226,,,80433,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,Homo sapiens,,741.0,,9606.0,N,Intermediate,CHEMBL620352,BAO_0000219,
5518,1,F,1,RPMI-8226,,,80433,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,Homo sapiens,,741.0,,9606.0,N,Intermediate,CHEMBL620353,BAO_0000219,
5519,1,F,1,RPMI-8226,,,80433,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,Homo sapiens,,741.0,,9606.0,N,Intermediate,CHEMBL620354,BAO_0000219,
5520,1,F,1,RPMI-8226,,,80433,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,Homo sapiens,,741.0,,9606.0,N,Intermediate,CHEMBL620355,BAO_0000219,
5521,1,F,1,RPMI-8226,,,80433,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,Homo sapiens,,741.0,,9606.0,N,Intermediate,CHEMBL620356,BAO_0000219,
5522,1,F,1,RPMI-8226,,,80433,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,Homo sapiens,,741.0,,9606.0,N,Intermediate,CHEMBL620357,BAO_0000219,
5523,1,F,1,RPMI-8226,,,80433,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,Homo sapiens,,741.0,,9606.0,N,Intermediate,CHEMBL620358,BAO_0000219,
5524,1,F,1,RPMI-8226,,,80433,In vitro inhibition of human 8226 myeloma tumor cell line growth.,,Homo sapiens,,741.0,,9606.0,N,Expert,CHEMBL620359,BAO_0000219,
5525,1,F,1,RPMI-8226,,,80433,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,,Homo sapiens,,741.0,,9606.0,N,Intermediate,CHEMBL620360,BAO_0000219,
5526,1,F,1,RPMI-8226,,,80433,Cytotoxicity of compound against 8226/DOX1V cells,,Homo sapiens,,741.0,,9606.0,N,Intermediate,CHEMBL620361,BAO_0000219,
5527,1,F,1,RPMI-8226,,,80433,Cytotoxicity of compound against 8226/S cells,,Homo sapiens,,741.0,,9606.0,N,Intermediate,CHEMBL620362,BAO_0000219,
5528,1,F,1,RPMI-8226,,,80433,Inhibitory concentration against 8226 myeloma cancer cell line,,Homo sapiens,,741.0,,9606.0,N,Intermediate,CHEMBL620363,BAO_0000219,
5529,1,F,1,RPMI-8226,,,80433,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,,Homo sapiens,,741.0,,9606.0,N,Intermediate,CHEMBL620364,BAO_0000219,
5530,1,F,1,833K,,,80647,Inhibition of cell growth was studied in human teratocarcinoma (833K).,,Homo sapiens,,854.0,,9606.0,N,Intermediate,CHEMBL620365,BAO_0000219,
5531,1,F,1,833K,,,80647,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',,Homo sapiens,,854.0,,9606.0,N,Intermediate,CHEMBL620366,BAO_0000219,
5532,1,F,1,833K,,,80647,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,,Homo sapiens,,854.0,,9606.0,N,Expert,CHEMBL620367,BAO_0000219,
5533,1,F,1,833K,,,80647,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,,Homo sapiens,,854.0,,9606.0,N,Intermediate,CHEMBL620368,BAO_0000219,
5534,1,B,0,,,,22226,Inhibitory activity against caspase-1,,,,,,,U,Autocuration,CHEMBL620369,BAO_0000019,
5535,1,B,8,,,,45,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,,Enterococcus faecalis,,,,1351.0,H,Autocuration,CHEMBL620370,BAO_0000357,
5536,1,F,1,8701-BC,,,80648,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,,Homo sapiens,,705.0,,9606.0,N,Intermediate,CHEMBL620371,BAO_0000219,
5537,1,F,1,8701-BC,,,80648,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,,Homo sapiens,,705.0,,9606.0,N,Intermediate,CHEMBL620372,BAO_0000219,
5538,1,F,0,,,,22226,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,,,,,,,U,Intermediate,CHEMBL876492,BAO_0000019,
5539,1,F,0,,,,22226,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,,,,,,,U,Intermediate,CHEMBL620373,BAO_0000019,
5540,1,F,0,,,,22226,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,,,,,,,U,Intermediate,CHEMBL620374,BAO_0000019,
5541,1,B,0,,,,22226,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,,,,,,,U,Autocuration,CHEMBL620375,BAO_0000019,
5542,1,F,0,,,,22226,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,Streptococcus pyogenes,,,,1314.0,U,Autocuration,CHEMBL857902,BAO_0000019,
5543,1,F,0,,,,22226,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,Streptococcus pyogenes,,,,1314.0,U,Autocuration,CHEMBL620376,BAO_0000019,
5544,1,B,8,,,,11922,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,,,,,,,H,Autocuration,CHEMBL620377,BAO_0000357,
5545,1,F,1,KB ,,,81115,Tested for in vitro cytotoxic potency of compound in 9KB assay,,Homo sapiens,,324.0,,9606.0,N,Intermediate,CHEMBL620378,BAO_0000219,
5546,1,A,1,KB ,,,81115,Tested for in vitro cytotoxic potency of compound in 9KB assay,,Homo sapiens,,324.0,,9606.0,N,Intermediate,CHEMBL620379,BAO_0000219,
5547,1,F,0,,,,22226,In vitro cytotoxicity of compound was tested against 9KB cells.,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL620380,BAO_0000219,
5548,1,F,1,9L,,,80653,Cytotoxic concentration against 9L cells was determined on day 3,,Rattus norvegicus,,392.0,,10116.0,N,Intermediate,CHEMBL884006,BAO_0000219,
5549,1,F,1,9L,,,80653,Tested in vitro for anticancer activity against 9L cells,,Rattus norvegicus,,392.0,,10116.0,N,Expert,CHEMBL620381,BAO_0000219,
5550,1,F,1,9L,,,80653,Tested in vitro for anticancer activity against 9L cells; Not determined,,Rattus norvegicus,,392.0,,10116.0,N,Expert,CHEMBL620382,BAO_0000219,
5551,1,F,1,A549,,,80682,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620383,BAO_0000219,
5552,1,F,1,A549,,,80682,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL876493,BAO_0000219,
5553,1,F,1,A549,,,80682,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620384,BAO_0000219,
5554,1,F,1,A549,,,80682,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620385,BAO_0000219,
5555,1,F,1,A549,,,80682,Cytotoxicity against human lung carcinoma A549 cell line,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL620386,BAO_0000219,
5556,1,F,9,A549,,,25,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,,Homo sapiens,,646.0,,9606.0,D,Expert,CHEMBL620387,BAO_0000219,
5557,1,F,9,A549,,,25,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",,Homo sapiens,,646.0,,9606.0,D,Expert,CHEMBL621404,BAO_0000219,
5558,1,F,1,A549,,,80682,"In vitro growth inhibition of A549, lung carcinoma",,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621405,BAO_0000219,
5559,1,F,1,A549,,,80682,"In vitro growth inhibition of A549, lung carcinoma.",,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621406,BAO_0000219,
5560,1,F,1,A549,,,80682,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL621407,BAO_0000219,
5561,1,F,1,A549,,,80682,Cytotoxic activity against human lung cancer A549 cell line was determined,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621408,BAO_0000219,
5562,1,F,1,A549,,,80682,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL885345,BAO_0000219,
5563,1,F,1,A549,,,80682,Cytotoxicity concentration against human lung carcinoma A-549 cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621409,BAO_0000219,
5564,1,F,1,A549,,,80682,Cytotoxicity in A549 (human carcinoma) cell line.,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL876034,BAO_0000219,
5565,1,F,1,A549,,,80682,Cytotoxicity on lung carcinoma (A-549) cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621410,BAO_0000219,
5566,1,F,1,A549,,,80682,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL621411,BAO_0000219,
5567,1,F,1,A549,,,80682,Effective dose of compound against replication of A549 cell line was evaluated,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621412,BAO_0000219,
5568,1,F,1,A549,,,80682,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL621413,BAO_0000219,
5569,1,F,1,A549,,,80682,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621414,BAO_0000219,
5570,1,F,1,A549,,,80682,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621415,BAO_0000219,
5571,1,F,1,A549,,,80682,The compound was evaluated for antiproliferative activity against A549 cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621416,BAO_0000219,
5572,1,F,1,A549,,,80682,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621417,BAO_0000219,
5573,1,F,1,A549,,,80682,Concentration required for growth inhibition of human lung carcinoma cell line A549,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621418,BAO_0000219,
5574,1,F,1,A549,,,80682,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621419,BAO_0000219,
5575,1,F,1,A549,,,80682,Growth inhibition against A549 cell line was evaluated,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621420,BAO_0000219,
5576,1,F,1,A549,,,80682,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL875823,BAO_0000219,
5577,1,F,1,A549,,,80682,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL621421,BAO_0000219,
5578,1,F,1,A549,,,80682,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621422,BAO_0000219,
5579,1,F,1,A549,,,80682,Chemosensitivity against DT-diaphorase rich A549 cell lines,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL884014,BAO_0000219,
5580,1,F,1,A549,,,80682,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621423,BAO_0000219,
5581,1,F,1,A549,,,80682,In vitro cytotoxicity against human A549 (lung cancer) cell line.,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL621424,BAO_0000219,
5582,1,F,1,A549,,,80682,In vitro antitumor activity against A549 (lung) human tumor cell lines.,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621425,BAO_0000219,
5583,1,F,1,A549,,,80682,In vitro cytotoxic activity against human lung carcinoma A549 cell line,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL621426,BAO_0000219,
5584,1,F,1,A549,,,80682,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621427,BAO_0000219,
5585,1,F,1,A549,,,80682,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621428,BAO_0000219,
5586,1,F,1,A549,,,80682,Tested against A549 lung carcinoma in the sulforhodamine B assay.,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL621429,BAO_0000219,
5587,1,F,1,A549,,,80682,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621430,BAO_0000219,
5588,1,F,1,A549,,,80682,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621431,BAO_0000219,
5589,1,F,1,A549,,,80682,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621432,BAO_0000219,
5590,1,F,1,A549,,,80682,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL621433,BAO_0000219,
5591,1,F,1,A549,,,80682,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL875824,BAO_0000219,
5592,1,F,1,A549,,,80682,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621434,BAO_0000219,
5593,1,F,1,A549,,,80682,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621435,BAO_0000219,
5594,1,F,1,A549,,,80682,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621436,BAO_0000219,
5595,1,F,1,A549,,,80682,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621437,BAO_0000219,
5596,1,F,1,A549,,,80682,Compound was tested for the growth inhibition of A549 lung tumor cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621438,BAO_0000219,
5597,1,F,1,A549,,,80682,Growth inhibition of human non-small-lung carcinoma (A549) cell line,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL621439,BAO_0000219,
5598,1,F,1,A549,,,80682,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621440,BAO_0000219,
5599,1,A,1,,,In vivo,50588,Oral bioavailability in dog (conscious),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621441,BAO_0000218,
5600,1,A,1,,,In vivo,50588,Compound was evaluated for the oral bioavailability after oral administration in dog.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621442,BAO_0000218,
5601,1,A,1,,,In vivo,50588,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621443,BAO_0000218,
5602,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621444,BAO_0000218,
5603,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625133,BAO_0000218,
5604,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625134,BAO_0000218,
5605,1,A,1,,,In vivo,50588,Oral bioavailability in dog (fasted),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625135,BAO_0000218,
5606,1,A,1,,,In vivo,50588,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625136,BAO_0000218,
5607,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625137,BAO_0000218,
5608,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625138,BAO_0000218,
5609,1,A,1,,,In vivo,50588,Percent bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625139,BAO_0000218,
5610,1,A,1,,,In vivo,50588,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL872264,BAO_0000218,
5611,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625140,BAO_0000218,
5612,1,A,1,,,In vivo,50588,The compound was evaluated for bioavailability in dogs; 34-44,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624436,BAO_0000218,
5613,1,A,1,,,In vivo,50588,Bioavailability in dog (dose 4 mg/kg p.o.),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624437,BAO_0000218,
5614,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL872261,BAO_0000218,
5615,1,A,1,,,,50588,8 hour trough Blood level in dog was measured after administration of compound,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624438,BAO_0000218,
5616,1,A,1,,,In vivo,50588,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624439,BAO_0000218,
5617,1,A,1,,,,50588,C24 after oral administration at 5 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624440,BAO_0000218,
5618,1,A,1,,,,50588,Clearance after oral and iv dosing in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624441,BAO_0000218,
5619,1,A,1,,,,50588,Clearance of the drug was measured in the plasma of dog,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624442,BAO_0000218,
5620,1,A,1,,,,50588,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624443,BAO_0000218,
5621,1,A,1,,,In vivo,50588,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624444,BAO_0000218,
5622,1,A,1,,,In vivo,50588,Clearance of compound was determined in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624445,BAO_0000218,
5623,1,A,1,,,In vivo,50588,Clearance on i.v. administration of 2 mg/kg was measured in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624446,BAO_0000218,
5624,1,A,1,,,In vivo,50588,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624447,BAO_0000218,
5625,1,A,1,,,In vivo,50588,Plasma clearance in dog was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624448,BAO_0000218,
5626,1,A,1,,,In vivo,50588,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624449,BAO_0000218,
5627,1,A,1,,,In vivo,50588,Plasma clearance in dog after administration of 0.25 mg/kg iv,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624450,BAO_0000218,
5628,1,A,1,,,In vivo,50588,Plasma clearance in dog after administration of 1 mg/kg iv,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL875942,BAO_0000218,
5629,1,A,1,,,In vivo,50588,Plasma clearance in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624451,BAO_0000218,
5630,1,A,1,,,In vivo,50588,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624452,BAO_0000218,
5631,1,A,1,,,In vivo,50588,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624453,BAO_0000218,
5632,1,A,1,,,In vivo,50588,Plasma clearance after 15 mg/kg iv dose in Dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624454,BAO_0000218,
5633,1,A,1,,,In vivo,50588,Plasma clearance after 30 mg/kg po dose in Dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624455,BAO_0000218,
5634,1,A,1,,,In vivo,50588,Plasma administration to dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624456,BAO_0000218,
5635,1,A,1,,,In vivo,50588,Plasma clearance was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624457,BAO_0000218,
5636,1,A,1,,,In vivo,50588,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624458,BAO_0000218,
5637,1,A,1,,,In vivo,50588,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624459,BAO_0000218,
5638,1,A,2,,,In vitro,102164,Intrinsic clearance in human liver microsomes,2107.0,Homo sapiens,,,,9606.0,S,Intermediate,CHEMBL624460,BAO_0000251,
5639,1,A,2,,,In vitro,102164,Intrinsic clearance in human liver microsomes,2107.0,Homo sapiens,,,,9606.0,S,Intermediate,CHEMBL624461,BAO_0000251,
5640,1,A,1,,,In vivo,50588,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL875943,BAO_0000218,
5641,1,A,1,,,In vivo,50588,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624462,BAO_0000218,
5642,1,A,1,,,In vivo,50588,Clearance in dog (dose 1 mg/kg i.v.),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624463,BAO_0000218,
5643,1,A,1,,,In vivo,50588,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624464,BAO_0000218,
5644,1,A,1,,,In vivo,50588,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624465,BAO_0000218,
5645,1,A,1,,,In vivo,50588,Plasma clearance after peroral administration at 10 mpk in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624466,BAO_0000218,
5646,1,A,1,,,In vivo,50588,Plasma clearance after peroral administration at 5 mpk in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624467,BAO_0000218,
5647,1,A,1,,,In vivo,50588,Plasma clearance after peroral administration at 5 mg/kg in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624468,BAO_0000218,
5648,1,A,1,,,In vivo,50588,Plasma clearance was measured in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624469,BAO_0000218,
5649,1,A,1,,,In vivo,50588,Plasma clearance was measured in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624470,BAO_0000218,
5650,1,A,1,,,In vivo,50588,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624471,BAO_0000218,
5651,1,A,1,,,In vivo,50588,Total clearance was determined after 0.1 mg/kg iv administration in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624472,BAO_0000218,
5652,1,A,1,,,In vivo,50588,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622775,BAO_0000218,
5653,1,A,1,,,In vivo,50588,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622776,BAO_0000218,
5654,1,A,1,,,In vivo,50588,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622777,BAO_0000218,
5655,1,A,1,,,In vivo,50588,Clearance after peroral administration of 0.2 mg/kg in dog was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622778,BAO_0000218,
5656,1,A,1,,,In vivo,50588,Clearance by intravenous administration of 1.2 mg/kg in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622779,BAO_0000218,
5657,1,A,1,,,In vivo,50588,Clearance by iv administration in dogs at a dose of 1 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622780,BAO_0000218,
5658,1,A,1,,,In vivo,50588,Clearance value was evaluated in dog plasma,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622781,BAO_0000218,
5659,1,A,1,,,In vivo,50588,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622782,BAO_0000218,
5660,1,A,1,,,In vivo,50588,Compound was tested for plasma clearance in dog,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622783,BAO_0000218,
5661,1,A,1,,,In vivo,50588,Pharmacokinetic property (Plasma clearance) was measured in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622784,BAO_0000218,
5662,1,A,1,,,,50594,Area under curve when injected perorally in mice at a dose of 50 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622785,BAO_0000218,
5663,1,A,1,,,,50594,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622786,BAO_0000218,
5664,1,A,1,,,,50594,Area under curve value in mouse at a dose of 10 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622787,BAO_0000218,
5665,1,A,1,,,,50594,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL875949,BAO_0000218,
5666,1,A,1,,,,50594,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622788,BAO_0000218,
5667,1,F,1,,,,50594,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622789,BAO_0000218,
5668,1,F,1,,,,50594,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622790,BAO_0000218,
5669,1,F,1,,,,50594,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622791,BAO_0000218,
5670,1,F,1,,,,50594,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622792,BAO_0000218,
5671,1,A,1,,,,50594,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622793,BAO_0000218,
5672,1,A,1,,,,50594,Area under curve was determined for the compound at 24 mg/Kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622794,BAO_0000218,
5673,1,A,1,,,,50594,Area under curve was determined for the compound at 40 mg/Kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622795,BAO_0000218,
5674,1,A,1,,,,50594,Area under curve was determined for the compound at 5 mg/Kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621803,BAO_0000218,
5675,1,A,1,,,,50594,Area under the curve for the compound is obtained at dose 25 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621804,BAO_0000218,
5676,1,A,1,,,,50594,Area under the curve for the compound was obtained when tested in mouse,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621805,BAO_0000218,
5677,1,A,1,,,,50594,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621806,BAO_0000218,
5678,1,A,1,,,,50594,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621807,BAO_0000218,
5679,1,A,1,,,,50594,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621808,BAO_0000218,
5680,1,A,1,,,,50594,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621809,BAO_0000218,
5681,1,A,1,,,,50594,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621810,BAO_0000218,
5682,1,A,1,,,,50594,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL875164,BAO_0000218,
5683,1,A,1,,,,50594,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621811,BAO_0000218,
5684,1,A,1,,,,50594,"Compound was evaluated for the pharmacokinetic parameter, area under curve",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621812,BAO_0000218,
5685,1,A,1,,,,50594,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621813,BAO_0000218,
5686,1,A,1,,,,50594,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621814,BAO_0000218,
5687,1,A,1,,,,50594,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621815,BAO_0000218,
5688,1,A,1,,,,50594,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621816,BAO_0000218,
5689,1,A,1,,,,50594,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621817,BAO_0000218,
5690,1,A,1,,,,50594,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621818,BAO_0000218,
5691,1,A,1,,,,50594,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621819,BAO_0000218,
5692,1,A,1,,,,50594,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621820,BAO_0000218,
5693,1,A,1,,,,50594,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621821,BAO_0000218,
5694,1,A,1,,,,50594,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621822,BAO_0000218,
5695,1,A,1,,,,50594,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619474,BAO_0000218,
5696,1,A,1,,,,50594,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619475,BAO_0000218,
5697,1,A,1,,,,50594,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619476,BAO_0000218,
5698,1,A,1,,,,50594,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619477,BAO_0000218,
5699,1,A,1,,,,50594,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619478,BAO_0000218,
5700,1,A,1,,,,50594,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619479,BAO_0000218,
5701,1,A,1,,,,50594,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619480,BAO_0000218,
5702,1,A,1,,,,50594,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619481,BAO_0000218,
5703,1,A,1,,,,50594,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619482,BAO_0000218,
5704,1,A,1,,,,50594,Area under the curve was evaluated in mice after intravenous administration,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619483,BAO_0000218,
5705,1,A,1,,,,50594,Area under the curve was evaluated in mice after oral administration,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619484,BAO_0000218,
5706,1,A,1,,,,50594,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619485,BAO_0000218,
5707,1,A,1,,,,50594,AUC total value at a dose of 10 mg/kg peroral administration in mice.,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619486,BAO_0000218,
5708,1,A,1,,,,50594,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619487,BAO_0000218,
5709,1,A,1,,,,50594,AUMC after intraperitoneal administration of 100 mg/kg in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619488,BAO_0000218,
5710,1,A,1,,,In vivo,50594,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620106,BAO_0000218,
5711,1,F,1,9L,,,80653,The compound was tested in vitro for anticancer activity against 9L cells,,,,392.0,,,N,Intermediate,CHEMBL620107,BAO_0000219,
5712,1,F,0,,,,22226,Anti proliferation activity determined; Weak effect,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL620283,BAO_0000019,
5713,1,F,0,,,,22226,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL875176,BAO_0000219,
5714,1,F,0,,,,22226,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL620284,BAO_0000219,
5715,1,F,0,,,,22226,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL623515,BAO_0000219,
5716,1,F,0,,,,22226,The cytotoxic activity was in vitro tested by 9PS assay method,,Mus musculus,,,,10090.0,U,Autocuration,CHEMBL623516,BAO_0000019,
5717,1,F,0,,,,22226,The cytotoxic activity was in vitro tested by 9PS assay method.,,Mus musculus,,,,10090.0,U,Autocuration,CHEMBL623517,BAO_0000019,
5718,1,A,0,,,,22224,Partition coefficient (logD6.5),,,,,,,U,Autocuration,CHEMBL857878,BAO_0000019,
5719,1,F,1,A2780,,,81034,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL623518,BAO_0000219,
5720,1,F,1,A-375,,,80018,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),,Homo sapiens,,455.0,,9606.0,N,Intermediate,CHEMBL624195,BAO_0000219,
5721,1,F,1,A-431,,,80852,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,,Homo sapiens,,500.0,,9606.0,N,Expert,CHEMBL624196,BAO_0000219,
5722,1,F,9,A-431,,,9,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,Homo sapiens,,500.0,,9606.0,D,Expert,CHEMBL624197,BAO_0000219,
5723,1,F,1,A498,,,80021,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL624198,BAO_0000219,
5724,1,F,1,A498,,,80021,in vitro cytotoxicity against A 498 cancer cell line,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL621287,BAO_0000219,
5725,1,F,1,A498,,,80021,In vitro cytotoxic activity against renal (A 498) cancer cell line.,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL621288,BAO_0000219,
5726,1,F,1,A498,,,80021,Cytotoxic activity against A 498 renal cancer cell lines.,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL876496,BAO_0000219,
5727,1,F,1,A498,,,80021,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL621289,BAO_0000219,
5728,1,F,0,,,,22226,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,Staphylococcus aureus,,,,1280.0,U,Autocuration,CHEMBL621290,BAO_0000019,
5729,1,F,0,,,,22226,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,Staphylococcus aureus,,,,1280.0,U,Autocuration,CHEMBL621291,BAO_0000019,
5730,1,F,0,,,,22226,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,Staphylococcus aureus,,,,1280.0,U,Autocuration,CHEMBL621292,BAO_0000019,
5731,1,F,0,,,,22226,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,Staphylococcus aureus,,,,1280.0,U,Autocuration,CHEMBL621293,BAO_0000019,
5732,1,F,1,A549,,,80682,Inhibitory concentration required against A 549 lung cancer cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621294,BAO_0000219,
5733,1,F,1,A549,,,80682,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621295,BAO_0000219,
5734,1,F,1,A549,,,80682,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL884007,BAO_0000219,
5735,1,F,1,A549,,,80682,In vitro cytotoxicity against lung cancer A 549 cell lines,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621296,BAO_0000219,
5736,1,F,1,A549,,,80682,Compound was tested for its cytotoxicity against A 549 cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621297,BAO_0000219,
5737,1,F,1,A549,,,80682,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL839828,BAO_0000219,
5738,1,F,1,A549,,,80682,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620397,BAO_0000219,
5739,1,F,1,A549,,,80682,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL620398,BAO_0000219,
5740,1,F,1,A549,,,80682,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620399,BAO_0000219,
5741,1,F,1,A549,,,80682,In vitro inhibition of A549 (human lung cancer) cell growth.,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL620400,BAO_0000219,
5742,1,F,1,A549,,,80682,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620401,BAO_0000219,
5743,1,F,1,A549,,,80682,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL620402,BAO_0000219,
5744,1,F,1,A549,,,80682,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL620403,BAO_0000219,
5745,1,F,0,,,,22226,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,,,,,,,U,Autocuration,CHEMBL620404,BAO_0000218,
5746,1,F,4,,,In vivo,104694,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,,,,,,,H,Autocuration,CHEMBL620405,BAO_0000218,
5747,1,F,4,,,In vivo,104694,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,,,,,,,H,Autocuration,CHEMBL620406,BAO_0000218,
5748,1,F,4,,,In vivo,104694,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,,,,,,,H,Autocuration,CHEMBL620407,BAO_0000218,
5749,1,F,4,,,In vivo,104694,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,,,,,,,H,Autocuration,CHEMBL620408,BAO_0000218,
5750,1,F,4,,,In vivo,104694,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,,,,,,,H,Autocuration,CHEMBL620409,BAO_0000218,
5751,1,F,1,A498,,,80021,Inhibition of A-498 human Renal cell proliferation,,Homo sapiens,,624.0,,9606.0,N,Expert,CHEMBL620410,BAO_0000219,
5752,1,F,0,,,,22226,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL620411,BAO_0000019,
5753,1,F,0,,,,22226,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL620412,BAO_0000019,
5754,1,F,0,,,,22226,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL876596,BAO_0000019,
5755,1,F,1,A 172,,,80012,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,,Homo sapiens,,622.0,,9606.0,N,Expert,CHEMBL620413,BAO_0000219,
5756,1,F,1,A 172,,,80012,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,Homo sapiens,,622.0,,9606.0,N,Intermediate,CHEMBL620414,BAO_0000219,
5757,1,F,1,A 172,,,80012,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,Homo sapiens,,622.0,,9606.0,N,Intermediate,CHEMBL620415,BAO_0000219,
5758,1,F,1,A549,,,80682,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL620416,BAO_0000219,
5759,1,F,1,A549,,,80682,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620417,BAO_0000219,
5760,1,F,1,A549,,,80682,Cytotoxic activity evaluated against A549 tumor cells,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL620418,BAO_0000219,
5761,1,F,1,A549,,,80682,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620419,BAO_0000219,
5762,1,F,1,A549,,,80682,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620420,BAO_0000219,
5763,1,F,1,A549,,,80682,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620421,BAO_0000219,
5764,1,F,1,A549,,,80682,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620422,BAO_0000219,
5765,1,F,1,A549,,,80682,Cytotoxicity of compound against A549 cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620423,BAO_0000219,
5766,1,F,1,A549,,,80682,Cytotoxicity against human lung cell carcinoma A549 cell line,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL620424,BAO_0000219,
5767,1,F,1,A549,,,80682,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620425,BAO_0000219,
5768,1,F,1,A549,,,80682,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620426,BAO_0000219,
5769,1,F,1,A549,,,80682,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620427,BAO_0000219,
5770,1,F,1,A549,,,80682,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620428,BAO_0000219,
5771,1,F,1,A549,,,80682,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620429,BAO_0000219,
5772,1,F,1,A549,,,80682,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL620430,BAO_0000219,
5773,1,F,1,A549,,,80682,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL839887,BAO_0000219,
5774,1,F,1,A549,,,80682,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620431,BAO_0000219,
5775,1,F,1,A549,,,80682,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL884010,BAO_0000219,
5776,1,F,1,A549,,,80682,In vitro cytotoxicity against A549 (human lung cancer),,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620538,BAO_0000219,
5777,1,F,1,A549,,,80682,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL620539,BAO_0000219,
5778,1,F,1,A549,,,80682,In vivo antiproliferative activity against A549 cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL623373,BAO_0000218,
5779,1,F,1,A549,,,80682,Inhibition of non-small-cell lung adenocarcinoma (A549),,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL623374,BAO_0000219,
5780,1,F,1,A549,,,80682,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL623375,BAO_0000219,
5781,1,F,1,A549,,,80682,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL623376,BAO_0000219,
5782,1,F,1,A549,,,80682,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL623377,BAO_0000219,
5783,1,F,1,A549,,,80682,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL623378,BAO_0000219,
5784,1,F,1,A549,,,80682,Inhibitory activity of compound against human A549 lung carcinoma cell line.,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL623379,BAO_0000219,
5785,1,F,1,A549,,,80682,Inhibitory activity against A549 lung cancer cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL623380,BAO_0000219,
5786,1,F,1,A549,,,80682,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL623381,BAO_0000219,
5787,1,F,1,A549,,,80682,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL623382,BAO_0000219,
5788,1,F,1,A549,,,80682,Inhibitory concentration against A549 (lung cancer) cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL623383,BAO_0000219,
5789,1,F,1,A549,,,80682,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL623384,BAO_0000219,
5790,1,F,1,A549,,,80682,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL623385,BAO_0000219,
5791,1,F,1,A549,,,80682,Activity against A549 cancer cell line.,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL623386,BAO_0000219,
5792,1,F,1,A549,,,80682,The compound was evaluated for cytotoxicity against A549 cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL884105,BAO_0000219,
5793,1,F,1,A549,,,80682,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL623387,BAO_0000219,
5794,1,F,1,A549,,,80682,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621568,BAO_0000219,
5795,1,F,1,A549,,,80682,Growth inhibitory activity was measured for human A549 tumor cell line.,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621569,BAO_0000219,
5796,1,F,1,A549,,,80682,Inhibitory activity against A549 lung cancer cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621570,BAO_0000219,
5797,1,F,1,A549,,,80682,Inhibitory activity against A549 cell line; inactive,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621571,BAO_0000219,
5798,1,F,1,A549,,,80682,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL621572,BAO_0000219,
5799,1,F,1,A549,,,80682,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL621573,BAO_0000219,
5800,1,F,1,A549,,,80682,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621574,BAO_0000219,
5801,1,F,1,A549,,,80682,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621575,BAO_0000219,
5802,1,F,1,A549,,,80682,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621576,BAO_0000219,
5803,1,F,1,A549,,,80682,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621577,BAO_0000219,
5804,1,F,1,A549,,,80682,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621578,BAO_0000219,
5805,1,F,1,A549,,,80682,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621579,BAO_0000219,
5806,1,F,1,A549,,,80682,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621580,BAO_0000219,
5807,1,A,1,,,In vivo,50588,Plasma clearance (in vivo) in mongrel dogs was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621581,BAO_0000218,
5808,1,A,1,,,In vivo,50588,Plasma clearance was measured in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621582,BAO_0000218,
5809,1,A,1,,,In vivo,50588,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621583,BAO_0000218,
5810,1,A,1,,,In vivo,50588,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621584,BAO_0000218,
5811,1,A,1,,,In vivo,50588,Tested for plasma clearance in dog,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621585,BAO_0000218,
5812,1,A,1,,,In vivo,50588,The compound was tested for clearance in dog plasma.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621586,BAO_0000218,
5813,1,A,1,,,In vivo,50588,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL875835,BAO_0000218,
5814,1,A,1,,,In vivo,50588,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621587,BAO_0000218,
5815,1,A,1,,,In vivo,50588,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621588,BAO_0000218,
5816,1,A,1,,,In vitro,50588,In vitro clearance in dog liver microsomes,2107.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621589,BAO_0000218,
5817,1,A,1,,,In vivo,50588,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621590,BAO_0000218,
5818,1,A,1,,,In vivo,50588,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621591,BAO_0000218,
5819,1,A,1,,,In vivo,50588,Plasma clearance in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621592,BAO_0000218,
5820,1,A,1,,,In vivo,50588,Clearance rate in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621593,BAO_0000218,
5821,1,A,1,,,In vivo,50588,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621594,BAO_0000218,
5822,1,A,1,,,In vivo,50588,Clearance in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621595,BAO_0000218,
5823,1,A,1,,,In vivo,50588,Plasma clearance in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621596,BAO_0000218,
5824,1,A,1,,,In vivo,50588,Plasma clearance was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621597,BAO_0000218,
5825,1,A,1,,,In vivo,50588,Lower clearance in dog (i.v.) at 0.5 mpk,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621598,BAO_0000218,
5826,1,A,1,,,In vivo,50588,Plasma clearance in Beagle dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621599,BAO_0000218,
5827,1,A,1,,,In vivo,50588,Plasma clearance (Clp) in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL875836,BAO_0000218,
5828,1,A,1,,,In vivo,50588,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621600,BAO_0000218,
5829,1,A,1,,,In vivo,50588,Plasma clearance (pharmacokinetic parameter) in dog was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621601,BAO_0000218,
5830,1,A,1,,,In vivo,50588,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618474,BAO_0000218,
5831,1,A,1,,,In vivo,50588,Plasma clearance of compound was determined in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618475,BAO_0000218,
5832,1,A,1,,,In vivo,50588,Plasma clearance after intravenous administration of 1 mg/kg in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624524,BAO_0000218,
5833,1,A,1,,,In vivo,50588,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624525,BAO_0000218,
5834,1,A,1,,,In vivo,50588,Plasma clearance in dog was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624526,BAO_0000218,
5835,1,A,1,,,In vivo,50588,Plasma clearance was calculated in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624527,BAO_0000218,
5836,1,A,1,,,In vivo,50588,Plasma clearance at the dose of 2 mg/kg in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624528,BAO_0000218,
5837,1,A,1,,,In vivo,50588,Plasma clearance in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624529,BAO_0000218,
5838,1,A,1,,,In vivo,50588,Plasma clearance in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624530,BAO_0000218,
5839,1,A,1,,,In vivo,50588,Plasma clearance in dog; Unable to calculate,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624531,BAO_0000218,
5840,1,A,1,,,In vivo,50588,Plasma clearance in rhesus monkey,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624532,BAO_0000218,
5841,1,A,1,,,In vivo,50588,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624533,BAO_0000218,
5842,1,A,1,,,In vivo,50588,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624534,BAO_0000218,
5843,1,A,1,,,In vivo,50588,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624535,BAO_0000218,
5844,1,A,1,,,In vivo,50588,Plasma clearance was evaluated in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624536,BAO_0000218,
5845,1,A,1,,,In vivo,50588,Plasma clearance was evaluated in dog; Not tested,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624537,BAO_0000218,
5846,1,A,1,,,In vivo,50588,Plasma clearance was evaluated in rhesus,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624538,BAO_0000218,
5847,1,A,1,,,In vivo,50588,Plasma clearance was evaluated in rhesus; Not tested,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624539,BAO_0000218,
5848,1,A,1,,,In vivo,50588,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624540,BAO_0000218,
5849,1,A,1,,,In vivo,50588,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624541,BAO_0000218,
5850,1,A,1,,,In vivo,50588,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624542,BAO_0000218,
5851,1,A,1,,,In vivo,50588,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624543,BAO_0000218,
5852,1,A,1,,,In vivo,50588,Clearance value at a dose of 0.2 mg/kg i.v.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624544,BAO_0000218,
5853,1,A,1,,,In vivo,50588,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624545,BAO_0000218,
5854,1,A,1,,,In vivo,50588,Cmax after oral dose of compound at 3 mg/kg in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624546,BAO_0000218,
5855,1,A,1,,,In vivo,50588,Cmax after single intravenous bolus of 1 mg/kg in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL875957,BAO_0000218,
5856,1,A,1,,,In vivo,50588,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624547,BAO_0000218,
5857,1,A,1,,,In vivo,50588,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624548,BAO_0000218,
5858,1,A,1,,,In vivo,50588,Cmax in dog after administration of 1 mg/kg iv,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624549,BAO_0000218,
5859,1,A,1,,,In vivo,50588,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624550,BAO_0000218,
5860,1,A,1,,,In vivo,50588,Cmax on p.o. administration of 10 mg/kg was measured in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621613,BAO_0000218,
5861,1,A,1,,,In vivo,50588,Cmax was determine after peroral administration at 10 mpk in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621614,BAO_0000218,
5862,1,A,1,,,In vivo,50588,Cmax was determine after peroral administration at 5 mpk in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623431,BAO_0000218,
5863,1,A,1,,,In vivo,50588,Cmax was determine after peroral administration at 5 mg/kg in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623432,BAO_0000218,
5864,1,A,1,,,In vivo,50588,Cmax after 0.3 mg/kg po administration in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623433,BAO_0000218,
5865,1,A,1,,,In vivo,50588,Cmax after peroral administration in dogs at 2.4 uM/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623434,BAO_0000218,
5866,1,A,1,,,In vivo,50588,Cmax in dog after oral administration at 1 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623435,BAO_0000218,
5867,1,A,1,,,In vivo,50588,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623436,BAO_0000218,
5868,1,A,1,,,In vivo,50588,Cmax upon oral administration in male Beagle dog at 10 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL875958,BAO_0000218,
5869,1,A,1,,,In vivo,50588,Cmax value after 15 mg/kg iv dose in Dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623437,BAO_0000218,
5870,1,A,1,,,In vivo,50594,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623438,BAO_0000218,
5871,1,A,1,,,In vivo,50594,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623439,BAO_0000218,
5872,1,A,1,,,In vivo,50594,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,10000001.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623440,BAO_0000218,
5873,1,A,1,,,In vivo,50594,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,10000001.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623441,BAO_0000218,
5874,1,A,1,,,In vivo,50594,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,10000001.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623442,BAO_0000218,
5875,1,A,1,,,In vivo,50594,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623469,BAO_0000218,
5876,1,A,1,,,In vivo,50594,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623470,BAO_0000218,
5877,1,A,1,,,In vivo,50594,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623471,BAO_0000218,
5878,1,A,1,,,In vivo,50594,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623472,BAO_0000218,
5879,1,A,1,,,In vivo,50594,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623473,BAO_0000218,
5880,1,A,1,,,In vivo,50594,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623474,BAO_0000218,
5881,1,A,1,,,In vivo,50594,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623475,BAO_0000218,
5882,1,A,1,,,In vivo,50594,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623476,BAO_0000218,
5883,1,A,1,,,In vivo,50594,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623477,BAO_0000218,
5884,1,A,1,,,In vivo,50594,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,160.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621896,BAO_0000218,
5885,1,A,1,,,In vivo,50594,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,160.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621897,BAO_0000218,
5886,1,A,1,,,In vivo,50594,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,160.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621898,BAO_0000218,
5887,1,A,1,,,In vivo,50594,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621899,BAO_0000218,
5888,1,A,1,,,In vivo,50594,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621900,BAO_0000218,
5889,1,A,1,,,In vivo,50594,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621901,BAO_0000218,
5890,1,A,1,,,In vivo,50594,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,2048.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621902,BAO_0000218,
5891,1,A,1,,,In vivo,50594,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,2048.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621903,BAO_0000218,
5892,1,A,1,,,In vivo,50594,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,2048.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622587,BAO_0000218,
5893,1,A,1,,,In vivo,50594,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,2385.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620285,BAO_0000218,
5894,1,A,1,,,In vivo,50594,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,2385.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL875285,BAO_0000218,
5895,1,A,1,,,In vivo,50594,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,2385.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620286,BAO_0000218,
5896,1,A,1,,,In vivo,50594,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620287,BAO_0000218,
5897,1,A,1,,,In vivo,50594,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620288,BAO_0000218,
5898,1,A,1,,,In vivo,50594,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620289,BAO_0000218,
5899,1,A,1,,,In vivo,50594,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,160.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620290,BAO_0000218,
5900,1,A,1,,,In vivo,50594,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,160.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620291,BAO_0000218,
5901,1,A,1,,,In vivo,50594,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,160.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620292,BAO_0000218,
5902,1,A,1,,,In vivo,50594,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620293,BAO_0000218,
5903,1,A,1,,,In vivo,50594,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620294,BAO_0000218,
5904,1,A,1,,,In vivo,50594,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618614,BAO_0000218,
5905,1,A,1,,,In vivo,50594,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,945.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618615,BAO_0000218,
5906,1,A,1,,,In vivo,50594,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,945.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618616,BAO_0000218,
5907,1,F,1,A 172,,,80012,Cytotoxicity against A-172 human tumor cell lines,,Homo sapiens,,622.0,,9606.0,N,Expert,CHEMBL618617,BAO_0000219,
5908,1,F,1,A 172,,,80012,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,,Homo sapiens,,622.0,,9606.0,N,Intermediate,CHEMBL618618,BAO_0000219,
5909,1,F,1,A204,,,80014,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,,Homo sapiens,,623.0,,9606.0,N,Intermediate,CHEMBL618619,BAO_0000219,
5910,1,F,1,A2780,,,81034,Tested for antiproliferative activity against A-2780 tumoral cell line,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL618620,BAO_0000219,
5911,1,F,1,A-375,,,80018,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,,Homo sapiens,,455.0,,9606.0,N,Intermediate,CHEMBL618621,BAO_0000219,
5912,1,F,1,A-375,,,80018,Tested in vitro against A-375 cell line human melanoma,,Homo sapiens,,455.0,,9606.0,N,Intermediate,CHEMBL618622,BAO_0000219,
5913,1,F,1,A-427,,,80019,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,,Homo sapiens,,797.0,,9606.0,N,Expert,CHEMBL618623,BAO_0000219,
5914,1,F,1,A-427,,,80019,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,Homo sapiens,,797.0,,9606.0,N,Intermediate,CHEMBL618624,BAO_0000219,
5915,1,F,1,A-427,,,80019,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,,Homo sapiens,,797.0,,9606.0,N,Expert,CHEMBL618625,BAO_0000219,
5916,1,F,1,A-427,,,80019,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,Homo sapiens,,797.0,,9606.0,N,Intermediate,CHEMBL618626,BAO_0000219,
5917,1,F,1,A-427,,,80019,Antitumor activity on A-427 lung carcinoma cell lines,,Homo sapiens,,797.0,,9606.0,N,Intermediate,CHEMBL618627,BAO_0000219,
5918,1,F,1,A-427,,,80019,Cytotoxic activity against human A-427 lung tumor cell line,,Homo sapiens,,797.0,,9606.0,N,Intermediate,CHEMBL618628,BAO_0000219,
5919,1,F,1,A-427,,,80019,In vitro antitumor effects against human A-427 cell lines.,,Homo sapiens,,797.0,,9606.0,N,Expert,CHEMBL618629,BAO_0000219,
5920,1,F,1,A-427,,,80019,In vitro inhibition of A-427 (human lung cancer) cell growth.,,Homo sapiens,,797.0,,9606.0,N,Expert,CHEMBL618630,BAO_0000219,
5921,1,F,1,A-427,,,80019,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,,Homo sapiens,,797.0,,9606.0,N,Intermediate,CHEMBL618631,BAO_0000219,
5922,1,F,1,A-427,,,80019,Cytotoxic activity of compound against A-427 lung human tumor cell line,,Homo sapiens,,797.0,,9606.0,N,Intermediate,CHEMBL618632,BAO_0000219,
5923,1,F,1,A-431,,,80852,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,,Homo sapiens,,500.0,,9606.0,N,Expert,CHEMBL618633,BAO_0000219,
5924,1,F,1,A498,,,80021,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL619315,BAO_0000219,
5925,1,F,1,A498,,,80021,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,,Homo sapiens,,624.0,,9606.0,N,Expert,CHEMBL619316,BAO_0000219,
5926,1,F,1,A498,,,80021,Cytotoxicity against human kidney carcinoma A-498cell lines,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL619317,BAO_0000219,
5927,1,F,1,A498,,,80021,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL619318,BAO_0000219,
5928,1,F,1,A498,,,80021,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL619319,BAO_0000219,
5929,1,F,1,A498,,,80021,Antitumor cytotoxic activity against A-498 cell line was determined,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL619739,BAO_0000219,
5930,1,F,1,A498,,,80021,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL619740,BAO_0000219,
5931,1,F,1,A498,,,80021,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL883158,BAO_0000219,
5932,1,F,1,A498,,,80021,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL884012,BAO_0000219,
5933,1,F,1,A498,,,80021,In vitro inhibitory activity against A-498 ovarian cancer cell lines,,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL619741,BAO_0000219,
5934,1,F,1,A498,,,80021,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",,Homo sapiens,,624.0,,9606.0,N,Intermediate,CHEMBL619742,BAO_0000219,
5935,1,F,1,A549,,,80682,Inhibition of growth lung non-small cell carcinoma A-549 cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL876610,BAO_0000219,
5936,1,F,1,A549,,,80682,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619743,BAO_0000219,
5937,1,F,1,A549,,,80682,In vitro antiproliferative activity against human A-549 NSCL cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619744,BAO_0000219,
5938,1,F,1,A549,,,80682,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619745,BAO_0000219,
5939,1,F,1,A549,,,80682,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619746,BAO_0000219,
5940,1,F,1,A549,,,80682,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619747,BAO_0000219,
5941,1,F,1,A549,,,80682,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619748,BAO_0000219,
5942,1,F,1,A549,,,80682,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619749,BAO_0000219,
5943,1,F,1,A549,,,80682,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619750,BAO_0000219,
5944,1,F,1,A549,,,80682,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL624014,BAO_0000219,
5945,1,F,1,A549,,,80682,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL624015,BAO_0000219,
5946,1,F,1,A549,,,80682,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL885344,BAO_0000219,
5947,1,F,1,A549,,,80682,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL623224,BAO_0000219,
5948,1,F,1,A549,,,80682,Cytotoxic activity against A-549 cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL623225,BAO_0000219,
5949,1,F,1,A549,,,80682,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL622698,BAO_0000219,
5950,1,F,1,A549,,,80682,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL622699,BAO_0000219,
5951,1,F,1,A549,,,80682,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL622700,BAO_0000219,
5952,1,F,1,A549,,,80682,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL622701,BAO_0000219,
5953,1,F,1,A549,,,80682,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL622702,BAO_0000219,
5954,1,F,1,A549,,,80682,Cytotoxic activity against human lung carcinoma (A-549) cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL622703,BAO_0000219,
5955,1,F,1,A549,,,80682,Cytotoxic activity towards A-549 cells,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL622704,BAO_0000219,
5956,1,F,1,A549,,,80682,"In vitro percent inhibition of A549, lung carcinoma.",,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL622705,BAO_0000219,
5957,1,F,1,A549,,,80682,"In vitro percent inhibition of A549, lung carcinoma",,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL622706,BAO_0000219,
5958,1,F,1,A549,,,80682,"In vitro percent inhibition of A549, lung carcinoma.",,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL622707,BAO_0000219,
5959,1,F,1,A549,,,80682,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL622708,BAO_0000219,
5960,1,F,1,A549,,,80682,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL622709,BAO_0000219,
5961,1,F,1,A549,,,80682,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL622710,BAO_0000219,
5962,1,F,1,A549,,,80682,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL622711,BAO_0000219,
5963,1,F,1,A549,,,80682,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL622712,BAO_0000218,
5964,1,F,1,A549,,,80682,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL622713,BAO_0000218,
5965,1,F,1,A549,,,80682,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL622714,BAO_0000218,
5966,1,F,1,A549,,,80682,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL622715,BAO_0000218,
5967,1,F,1,A549,,,80682,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL622716,BAO_0000218,
5968,1,F,1,A549,,,80682,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL622717,BAO_0000219,
5969,1,F,1,A549,,,80682,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL622718,BAO_0000218,
5970,1,F,1,A549,,,80682,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL622719,BAO_0000219,
5971,1,F,1,A549,,,80682,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL622720,BAO_0000219,
5972,1,F,1,A549,,,80682,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL622721,BAO_0000219,
5973,1,F,1,A549,,,80682,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL622722,BAO_0000219,
5974,1,F,1,A549,,,80682,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL876030,BAO_0000219,
5975,1,F,1,A549,,,80682,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620206,BAO_0000219,
5976,1,F,1,A549,,,80682,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL620207,BAO_0000219,
5977,1,F,1,A549,,,80682,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL620208,BAO_0000219,
5978,1,F,1,A549,,,80682,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL620209,BAO_0000219,
5979,1,F,1,A549,,,80682,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL620210,BAO_0000219,
5980,1,F,1,A549,,,80682,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL621639,BAO_0000219,
5981,1,F,1,A549,,,80682,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621640,BAO_0000219,
5982,1,F,1,A549,,,80682,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL621641,BAO_0000219,
5983,1,F,1,A549,,,80682,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL621642,BAO_0000219,
5984,1,F,1,A549,,,80682,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621643,BAO_0000219,
5985,1,F,1,A549,,,80682,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621644,BAO_0000219,
5986,1,F,1,A549,,,80682,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL621645,BAO_0000219,
5987,1,F,1,A549,,,80682,In vitro antiproliferative activity against A549 cell line,,Mus musculus,,646.0,,10090.0,N,Intermediate,CHEMBL621646,BAO_0000219,
5988,1,F,1,A549,,,80682,Synergism with indomethacin in A549 cells,,,,646.0,,,N,Intermediate,CHEMBL621647,BAO_0000219,
5989,1,F,1,A549,,,80682,Synergism with tolmetin in A549 cells,,,,646.0,,,N,Intermediate,CHEMBL621648,BAO_0000219,
5990,1,F,1,A549,,,80682,Synergism with sulindac in A549 cells,,,,646.0,,,N,Intermediate,CHEMBL621649,BAO_0000219,
5991,1,F,1,A549,,,80682,Antagonism of indomethacin in A549 cells,,,,646.0,,,N,Intermediate,CHEMBL621650,BAO_0000219,
5992,1,F,1,A549,,,80682,Antagonism of sulindac in A549 cells,,,,646.0,,,N,Intermediate,CHEMBL621651,BAO_0000219,
5993,1,F,1,A549,,,80682,Antagonism of tolmetin in A549 cells,,,,646.0,,,N,Intermediate,CHEMBL621652,BAO_0000219,
5994,1,F,1,A549,,,80682,Synergism with indomethacin in A549 cells,,,,646.0,,,N,Intermediate,CHEMBL621653,BAO_0000219,
5995,1,F,1,A549,,,80682,Synergism with sulindac in A549 cells,,,,646.0,,,N,Intermediate,CHEMBL621654,BAO_0000219,
5996,1,F,1,A549,,,80682,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,,,,646.0,,,N,Intermediate,CHEMBL621655,BAO_0000219,
5997,1,A,1,,,In vivo,50588,Cmax value after 30 mg/kg po dose in Dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621656,BAO_0000218,
5998,1,A,1,,,In vivo,50588,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621657,BAO_0000218,
5999,1,A,1,,,In vivo,50588,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621658,BAO_0000218,
6000,1,A,1,,,In vivo,50588,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621659,BAO_0000218,
6001,1,A,1,,,In vivo,50588,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621660,BAO_0000218,
6002,1,A,1,,,In vivo,50588,Cmax value after administration of 4 mg/Kg oral dose in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621661,BAO_0000218,
6003,1,A,1,,,In vivo,50588,Cmax value in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621662,BAO_0000218,
6004,1,A,1,,,In vivo,50588,Cmax value in dogs after oral administration at 1 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621663,BAO_0000218,
6005,1,A,1,,,In vivo,50588,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621664,BAO_0000218,
6006,1,A,1,,,In vivo,50588,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621665,BAO_0000218,
6007,1,A,1,,,In vivo,50588,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621666,BAO_0000218,
6008,1,A,1,,,In vivo,50588,Concentration maxima after oral dosing in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621667,BAO_0000218,
6009,1,A,1,,,In vivo,50588,Concentration maxima after oral dosing in dogs; not available,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL876738,BAO_0000218,
6010,1,A,1,,,In vivo,50588,Concentration maxima after oral dosing in dogs; not available,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621668,BAO_0000218,
6011,1,A,1,,,In vivo,50588,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621669,BAO_0000218,
6012,1,A,1,,,In vivo,50588,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621670,BAO_0000218,
6013,1,A,1,,,In vivo,50588,In vivo maximal concentration was calculated at 1 mg/kg in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621671,BAO_0000218,
6014,1,A,1,,,In vivo,50588,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622360,BAO_0000218,
6015,1,A,1,,,In vivo,50588,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622361,BAO_0000218,
6016,1,A,1,,,In vivo,50588,Cmax in dog plasma after oral dose (1 mg/kg),1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622362,BAO_0000218,
6017,1,A,1,,,In vivo,50588,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622363,BAO_0000218,
6018,1,A,1,,,In vivo,50588,Maximal plasma concentration at a dose of 1 mg/kg,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622364,BAO_0000218,
6019,1,A,1,,,In vivo,50588,Maximal plasma concentration at a dose of 1 mg/kg (oral),1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622365,BAO_0000218,
6020,1,A,1,,,In vivo,50588,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622533,BAO_0000218,
6021,1,A,1,,,In vivo,50588,Maximum concentration of compound in dog was evaluated.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622534,BAO_0000218,
6022,1,A,1,,,In vivo,50588,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622535,BAO_0000218,
6023,1,A,1,,,In vivo,50588,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL876739,BAO_0000218,
6024,1,A,1,,,In vivo,50588,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622536,BAO_0000218,
6025,1,A,1,,,In vivo,50588,Maximum concentration obtained in dog plasma was determined,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622537,BAO_0000218,
6026,1,A,1,,,In vivo,50588,Maximum concentration was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622538,BAO_0000218,
6027,1,A,1,,,In vivo,50588,Maximum concentration at the dose of 2 mg/kg in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627867,BAO_0000218,
6028,1,A,1,,,In vivo,50588,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627868,BAO_0000218,
6029,1,A,1,,,In vivo,50588,Maximum concentration was evaluated in dog plasma,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627869,BAO_0000218,
6030,1,A,1,,,In vivo,50588,Maximum concentration was evaluated after 75 min after administration in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627870,BAO_0000218,
6031,1,A,1,,,In vivo,50588,Maximum plasma concentration determined in dog after oral administration of 17b,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627871,BAO_0000218,
6032,1,A,1,,,In vivo,50588,Maximum plasma concentration determined in dog after oral administration of 2b,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627872,BAO_0000218,
6033,1,A,1,,,In vivo,50588,Maximum plasma concentration in dog,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627873,BAO_0000218,
6034,1,A,1,,,In vivo,50588,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627874,BAO_0000218,
6035,1,A,1,,,In vivo,50588,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627875,BAO_0000218,
6036,1,A,1,,,In vivo,50588,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627876,BAO_0000218,
6037,1,A,1,,,In vivo,50588,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627877,BAO_0000218,
6038,1,A,1,,,In vivo,50588,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627878,BAO_0000218,
6039,1,A,1,,,In vivo,50588,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627879,BAO_0000218,
6040,1,A,1,,,In vivo,50588,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL875355,BAO_0000218,
6041,1,A,1,,,In vivo,50588,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627880,BAO_0000218,
6042,1,A,1,,,In vivo,50588,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627881,BAO_0000218,
6043,1,A,1,,,In vivo,50588,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627882,BAO_0000218,
6044,1,A,1,,,In vivo,50588,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627883,BAO_0000218,
6045,1,A,1,,,In vivo,50588,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628526,BAO_0000218,
6046,1,A,1,,,In vivo,50588,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628527,BAO_0000218,
6047,1,A,1,,,In vivo,50588,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628528,BAO_0000218,
6048,1,A,1,,,In vivo,50588,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628529,BAO_0000218,
6049,1,A,1,,,In vivo,50588,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628530,BAO_0000218,
6050,1,A,1,,,In vivo,50588,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625243,BAO_0000218,
6051,1,A,1,,,In vivo,50588,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,1969.0,Canis lupus familiaris,,,,9615.0,N,Expert,CHEMBL625244,BAO_0000218,
6052,1,A,1,,,In vivo,50588,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625245,BAO_0000218,
6053,1,A,1,,,In vivo,50588,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625246,BAO_0000218,
6054,1,A,1,,,In vivo,50594,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,945.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625247,BAO_0000218,
6055,1,A,1,,,In vivo,50594,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1088.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625248,BAO_0000218,
6056,1,A,1,,,In vivo,50594,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,1088.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625249,BAO_0000218,
6057,1,A,1,,,In vivo,50594,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,1088.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625250,BAO_0000218,
6058,1,A,1,,,,50594,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625251,BAO_0000218,
6059,1,A,1,,,,50594,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL875356,BAO_0000218,
6060,1,A,1,,,,50594,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625252,BAO_0000218,
6061,1,A,1,,,,50594,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625253,BAO_0000218,
6062,1,A,1,,,,50594,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625254,BAO_0000218,
6063,1,A,1,,,,50594,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625255,BAO_0000218,
6064,1,A,1,,,,50594,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625256,BAO_0000218,
6065,1,A,1,,,,50594,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625257,BAO_0000218,
6066,1,A,1,,,,50594,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625258,BAO_0000218,
6067,1,A,1,,,,50594,Compound was evaluated for washout rate in mice (Radiolabeled compound),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625259,BAO_0000218,
6068,1,A,1,,,,50594,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625260,BAO_0000218,
6069,1,A,1,,,,50594,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625261,BAO_0000218,
6070,1,A,1,,,,50594,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625262,BAO_0000218,
6071,1,A,1,,,,50594,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622639,BAO_0000218,
6072,1,A,1,,,,50594,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622640,BAO_0000218,
6073,1,A,1,,,,50594,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622812,BAO_0000218,
6074,1,A,1,,,,50594,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622813,BAO_0000218,
6075,1,A,1,,,,50594,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622814,BAO_0000218,
6076,1,A,1,,,,50594,Time at maximum activity in mice (Radiolabeled compound),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622815,BAO_0000218,
6077,1,A,1,,,,50594,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625342,BAO_0000218,
6078,1,A,1,,,,50594,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625343,BAO_0000218,
6079,1,A,1,,,,50594,Binding towards mouse plasma protein at 10 uM,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL877591,BAO_0000218,
6080,1,A,1,,,,50594,Binding towards mouse plasma protein at 100 uM,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625344,BAO_0000218,
6081,1,A,1,,,In vivo,50594,Bioavailability was evaluated in mice after intravenous administration,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625345,BAO_0000218,
6082,1,A,1,,,In vivo,50594,Bioavailability was evaluated in mice after oral administration,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625346,BAO_0000218,
6083,1,A,1,,,In vivo,50594,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625347,BAO_0000218,
6084,1,A,1,,,In vivo,50594,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625348,BAO_0000218,
6085,1,A,1,,,In vivo,50594,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625349,BAO_0000218,
6086,1,A,1,,,In vivo,50594,Oral bioavailability in mouse,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625350,BAO_0000218,
6087,1,A,1,,,In vivo,50594,Oral bioavailability after intravenous administration in mice at 24 uM/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL882952,BAO_0000218,
6088,1,A,1,,,In vivo,50594,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625351,BAO_0000218,
6089,1,A,1,,,In vivo,50594,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625352,BAO_0000218,
6090,1,A,1,,,In vivo,50594,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL877592,BAO_0000218,
6091,1,A,1,,,In vivo,50594,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625353,BAO_0000218,
6092,1,A,1,,,In vivo,50594,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625354,BAO_0000218,
6093,1,A,1,,,In vivo,50594,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626019,BAO_0000218,
6094,1,A,1,,,In vivo,50594,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626020,BAO_0000218,
6095,1,A,1,,,In vivo,50594,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626021,BAO_0000218,
6096,1,A,1,,,In vivo,50594,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626022,BAO_0000218,
6097,1,A,1,,,In vivo,50594,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626192,BAO_0000218,
6098,1,F,1,A549,,,80682,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL626193,BAO_0000219,
6099,1,F,1,A549,,,80682,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL626194,BAO_0000219,
6100,1,F,1,A549,,,80682,Cytotoxicity against human lung carcinoma A-549 cell lines,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL626195,BAO_0000219,
6101,1,F,1,A549,,,80682,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL626196,BAO_0000219,
6102,1,F,1,A549,,,80682,In vitro cytotoxicity against human lung carcinoma cell line A-549,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL626197,BAO_0000219,
6103,1,F,1,A549,,,80682,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL626198,BAO_0000219,
6104,1,F,1,A549,,,80682,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL626199,BAO_0000219,
6105,1,F,1,A549,,,80682,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL626200,BAO_0000219,
6106,1,F,1,A549,,,80682,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL626201,BAO_0000219,
6107,1,F,1,A549,,,80682,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL626202,BAO_0000219,
6108,1,F,1,A549,,,80682,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL626203,BAO_0000219,
6109,1,F,1,A549,,,80682,In vitro cytotoxicity against A-549 human lung cancer cells,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL626204,BAO_0000219,
6110,1,F,1,A549,,,80682,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL624701,BAO_0000219,
6111,1,F,1,A549,,,80682,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL624702,BAO_0000219,
6112,1,F,1,A549,,,80682,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL624703,BAO_0000219,
6113,1,F,1,A549,,,80682,Tested in vitro for cytotoxicity against A-549 lung cancer cells,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL624704,BAO_0000219,
6114,1,F,1,A549,,,80682,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL624705,BAO_0000219,
6115,1,F,1,A549,,,80682,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL624706,BAO_0000219,
6116,1,F,1,A549,,,80682,Antitumor cytotoxic activity against A-549 cell line was determined,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL624707,BAO_0000219,
6117,1,F,1,A549,,,80682,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL624708,BAO_0000219,
6118,1,F,1,A549,,,80682,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL624709,BAO_0000219,
6119,1,F,1,A549,,,80682,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL884107,BAO_0000219,
6120,1,F,1,A549,,,80682,Antitumoral activity was assayed against A-549 cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL624710,BAO_0000219,
6121,1,F,1,A549,,,80682,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL624711,BAO_0000219,
6122,1,F,1,A549,,,80682,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL624712,BAO_0000219,
6123,1,F,1,A549,,,80682,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL624713,BAO_0000219,
6124,1,F,1,A549,,,80682,Compound was tested for inhibition of cell growth of A-549 cells,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL624714,BAO_0000219,
6125,1,F,1,A549,,,80682,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL624715,BAO_0000219,
6126,1,F,1,A549,,,80682,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL624716,BAO_0000219,
6127,1,F,1,A549,,,80682,In vitro cytotoxicity against A549-human lung carcinoma cells.,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL619505,BAO_0000219,
6128,1,F,1,A549,,,80682,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL619506,BAO_0000219,
6129,1,F,1,A549,,,80682,Cytotoxic activity against A-549 cell lines.,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619507,BAO_0000219,
6130,1,F,1,A549,,,80682,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL619508,BAO_0000219,
6131,1,F,1,A549,,,80682,Cytotoxicity against human A549 non small cell lung cell lines,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619509,BAO_0000219,
6132,1,F,1,A549,,,80682,Inhibition of cell growth in (A-549) lung cell line,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL619510,BAO_0000219,
6133,1,F,1,A549,,,80682,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619511,BAO_0000219,
6134,1,F,1,A549,,,80682,In vitro antitumor activity against A-549 tumor cells.,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619512,BAO_0000219,
6135,1,F,1,A549,,,80682,In vitro antitumor effects against human A-549 cell lines.,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL619513,BAO_0000219,
6136,1,F,1,A549,,,80682,In vitro cytotoxic activity of compound against A-549 cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619514,BAO_0000219,
6137,1,F,1,A549,,,80682,In vitro cytotoxicity against human lung carcinoma A-549 cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619515,BAO_0000219,
6138,1,F,1,A549,,,80682,In vitro cytotoxicity against human non-small cell lung carcinoma A549,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619516,BAO_0000219,
6139,1,F,1,A549,,,80682,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL884005,BAO_0000219,
6140,1,F,1,A549,,,80682,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL619517,BAO_0000219,
6141,1,F,1,A549,,,80682,Inhibitory concentration of compound against A-549 cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619518,BAO_0000219,
6142,1,F,1,A549,,,80682,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619519,BAO_0000219,
6143,1,F,1,A549,,,80682,cytotoxic activity against leukemia (A-549) cancer cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL876489,BAO_0000219,
6144,1,F,1,A549,,,80682,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL619520,BAO_0000219,
6145,1,F,1,A549,,,80682,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619521,BAO_0000219,
6146,1,F,1,A549,,,80682,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619522,BAO_0000219,
6147,1,F,1,A549,,,80682,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619523,BAO_0000219,
6148,1,F,1,A549,,,80682,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619524,BAO_0000219,
6149,1,F,1,A549,,,80682,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619525,BAO_0000219,
6150,1,F,1,A549,,,80682,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,,,,646.0,,,N,Intermediate,CHEMBL619526,BAO_0000219,
6151,1,F,1,A549,,,80682,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619527,BAO_0000219,
6152,1,F,1,A549,,,80682,Cytotoxicity against A549 cells; No cytotoxicity,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619528,BAO_0000219,
6153,1,F,1,A549,,,80682,Cytotoxicity against human lung carcinoma (A549) cell lines,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL619529,BAO_0000219,
6154,1,F,1,A549,,,80682,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL619530,BAO_0000219,
6155,1,F,1,A549,,,80682,In vitro anticancer activity against human lung (A549) cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL876490,BAO_0000219,
6156,1,F,1,A549,,,80682,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619531,BAO_0000219,
6157,1,F,1,A549,,,80682,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619532,BAO_0000219,
6158,1,F,1,A549,,,80682,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619533,BAO_0000219,
6159,1,F,1,A549,,,80682,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619534,BAO_0000219,
6160,1,F,1,A549,,,80682,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620164,BAO_0000219,
6161,1,F,1,A549,,,80682,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620165,BAO_0000219,
6162,1,F,1,A549,,,80682,Inhibition of A549 human lung tumor cell proliferation,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL620166,BAO_0000219,
6163,1,F,1,A549,,,80682,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620167,BAO_0000219,
6164,1,F,1,A549,,,80682,In vitro cytotoxicity against human tumor cell line A549,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL620168,BAO_0000219,
6165,1,F,1,A549,,,80682,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620338,BAO_0000219,
6166,1,F,1,A549,,,80682,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620339,BAO_0000219,
6167,1,F,1,A549,,,80682,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620340,BAO_0000219,
6168,1,F,1,A549,,,80682,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620341,BAO_0000219,
6169,1,F,1,A549,,,80682,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL876491,BAO_0000219,
6170,1,F,1,A549,,,80682,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620342,BAO_0000219,
6171,1,F,1,A549,,,80682,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620343,BAO_0000219,
6172,1,F,1,A549,,,80682,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620344,BAO_0000219,
6173,1,F,1,A549,,,80682,In vitro anticancer activity against human lung (A549) cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620345,BAO_0000219,
6174,1,F,1,A549,,,80682,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620346,BAO_0000219,
6175,1,F,1,A549,,,80682,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620347,BAO_0000219,
6176,1,F,1,A549,,,80682,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620348,BAO_0000219,
6177,1,F,1,A549,,,80682,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620349,BAO_0000219,
6178,1,F,1,A549,,,80682,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL618667,BAO_0000219,
6179,1,F,1,A549,,,80682,Percentage inhibition of human lung carcinoma (A549) cell lines,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL618668,BAO_0000219,
6180,1,F,1,A549,,,80682,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL876031,BAO_0000219,
6181,1,F,1,A549,,,80682,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL618759,BAO_0000219,
6182,1,F,1,A549,,,80682,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL618760,BAO_0000219,
6183,1,F,1,A549,,,80682,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619000,BAO_0000219,
6184,1,F,1,A549,,,80682,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619001,BAO_0000219,
6185,1,F,1,A549,,,80682,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619002,BAO_0000219,
6186,1,F,1,A549,,,80682,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619003,BAO_0000219,
6187,1,F,1,A549,,,80682,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619597,BAO_0000219,
6188,1,F,1,A549,,,80682,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619598,BAO_0000219,
6189,1,F,1,A549,,,80682,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619599,BAO_0000219,
6190,1,F,1,A549,,,80682,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619600,BAO_0000219,
6191,1,F,1,A549,,,80682,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619601,BAO_0000219,
6192,1,F,1,A549,,,80682,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619602,BAO_0000219,
6193,1,F,1,A549,,,80682,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619603,BAO_0000219,
6194,1,F,1,A549,,,80682,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619604,BAO_0000219,
6195,1,F,1,A549,,,80682,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619605,BAO_0000219,
6196,1,A,1,,,In vivo,50588,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619606,BAO_0000218,
6197,1,A,1,,,In vivo,50588,Pharmacokinetic activity (Cmax) in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL876032,BAO_0000218,
6198,1,A,1,,,In vivo,50588,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619607,BAO_0000218,
6199,1,A,1,,,In vivo,50588,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619608,BAO_0000218,
6200,1,A,1,,,In vivo,50588,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619609,BAO_0000218,
6201,1,A,1,,,In vivo,50588,Cmax in dog plasma after 30mg/kg oral dose,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619610,BAO_0000218,
6202,1,A,1,,,In vivo,50588,Tested for the peak blood level in dog,178.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619611,BAO_0000218,
6203,1,A,1,,,In vivo,50588,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619612,BAO_0000218,
6204,1,A,1,,,In vivo,50588,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619613,BAO_0000218,
6205,1,A,1,,,In vivo,50588,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,178.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619614,BAO_0000218,
6206,1,A,1,,,,50588,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619615,BAO_0000218,
6207,1,A,1,,,,50588,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619616,BAO_0000218,
6208,1,A,1,,,,50588,Final plasma concentration in dogs after oral administration at 1 mg/kg,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619617,BAO_0000218,
6209,1,A,1,,,,50588,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619618,BAO_0000218,
6210,1,A,1,,,,50588,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL876033,BAO_0000218,
6211,1,A,1,,,,50588,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619619,BAO_0000218,
6212,1,A,1,,,,50588,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619620,BAO_0000218,
6213,1,A,1,,,,50588,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619621,BAO_0000218,
6214,1,A,1,,,,50588,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619622,BAO_0000218,
6215,1,A,1,,,,50588,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618874,BAO_0000218,
6216,1,A,1,,,In vivo,50588,Absolute bioavailability was evaluated in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618875,BAO_0000218,
6217,1,A,1,,,In vivo,50588,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618876,BAO_0000218,
6218,1,A,1,,,In vivo,50588,Bioavailability after peroral administration (1 mg/kg) was determined in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618877,BAO_0000218,
6219,1,A,1,,,In vivo,50588,Bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618878,BAO_0000218,
6220,1,A,1,,,In vivo,50588,Bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618879,BAO_0000218,
6221,1,A,1,,,In vivo,50588,Bioavailability after intravenous administration in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618880,BAO_0000218,
6222,1,A,1,,,In vivo,50588,Bioavailability after peroral administration in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618881,BAO_0000218,
6223,1,A,1,,,In vivo,50588,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618882,BAO_0000218,
6224,1,A,1,,,In vivo,50588,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624226,BAO_0000218,
6225,1,A,1,,,In vivo,50588,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624227,BAO_0000218,
6226,1,A,1,,,In vivo,50588,Bioavailability,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624228,BAO_0000218,
6227,1,A,1,,,In vivo,50588,Bioavailability,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624229,BAO_0000218,
6228,1,A,1,,,In vivo,50588,Bioavailability by intravenous administration of 1.2 mg/kg in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624230,BAO_0000218,
6229,1,A,1,,,In vivo,50588,Bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624231,BAO_0000218,
6230,1,A,1,,,In vivo,50588,Bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624232,BAO_0000218,
6231,1,A,1,,,In vivo,50588,Bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625127,BAO_0000218,
6232,1,A,1,,,In vivo,50588,Bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625128,BAO_0000218,
6233,1,A,1,,,In vivo,50588,Bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621675,BAO_0000218,
6234,1,A,1,,,In vivo,50588,Bioavailability in dog (p.o.) at 2.0 mpk,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621676,BAO_0000218,
6235,1,A,1,,,In vivo,50588,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621677,BAO_0000218,
6236,1,A,1,,,In vivo,50588,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621678,BAO_0000218,
6237,1,A,1,,,In vivo,50588,Bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621679,BAO_0000218,
6238,1,A,1,,,In vivo,50588,Bioavailability was evaluated after oral administration in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621680,BAO_0000218,
6239,1,A,1,,,In vivo,50588,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621681,BAO_0000218,
6240,1,A,1,,,In vivo,50588,Bioavailability was evaluated in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL876740,BAO_0000218,
6241,1,A,1,,,In vivo,50588,Bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621682,BAO_0000218,
6242,1,A,1,,,In vivo,50588,Bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621683,BAO_0000218,
6243,1,A,1,,,In vivo,50588,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621684,BAO_0000218,
6244,1,A,1,,,In vivo,50588,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621685,BAO_0000218,
6245,1,A,1,,,In vivo,50588,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621686,BAO_0000218,
6246,1,A,1,,,In vivo,50588,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621687,BAO_0000218,
6247,1,A,1,,,In vivo,50588,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621688,BAO_0000218,
6248,1,A,1,,,In vivo,50588,Bioavailability of compound in dog was determined after peroral administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621689,BAO_0000218,
6249,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621690,BAO_0000218,
6250,1,A,1,,,In vivo,50588,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621691,BAO_0000218,
6251,1,A,1,,,In vivo,50588,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL875941,BAO_0000218,
6252,1,A,1,,,In vivo,50588,Compound was evaluated for oral bioavailability in dogs; 37-38 %,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621692,BAO_0000218,
6253,1,A,1,,,In vivo,50588,Bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621693,BAO_0000218,
6254,1,A,1,,,In vivo,50588,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621694,BAO_0000218,
6255,1,A,1,,,In vivo,50594,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621695,BAO_0000218,
6256,1,A,1,,,In vivo,50594,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621696,BAO_0000218,
6257,1,A,1,,,In vivo,50594,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621697,BAO_0000218,
6258,1,A,1,,,In vivo,50594,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621698,BAO_0000218,
6259,1,A,1,,,In vivo,50594,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623420,BAO_0000218,
6260,1,A,1,,,In vivo,50594,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623421,BAO_0000218,
6261,1,A,1,,,In vivo,50594,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623422,BAO_0000218,
6262,1,A,1,,,In vivo,50594,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623423,BAO_0000218,
6263,1,A,1,,,In vivo,50594,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623424,BAO_0000218,
6264,1,A,1,,,In vivo,50594,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623425,BAO_0000218,
6265,1,A,1,,,In vivo,50594,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623426,BAO_0000218,
6266,1,A,1,,,In vivo,50594,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623427,BAO_0000218,
6267,1,A,1,,,In vivo,50594,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623428,BAO_0000218,
6268,1,A,1,,,In vivo,50594,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL875947,BAO_0000218,
6269,1,A,1,,,In vivo,50594,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,2048.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623429,BAO_0000218,
6270,1,A,1,,,In vivo,50594,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,2048.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623430,BAO_0000218,
6271,1,A,1,,,In vivo,50594,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,2048.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622588,BAO_0000218,
6272,1,A,1,,,In vivo,50594,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,2048.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622589,BAO_0000218,
6273,1,A,1,,,In vivo,50594,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,2048.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622751,BAO_0000218,
6274,1,A,1,,,In vivo,50594,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,2048.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622752,BAO_0000218,
6275,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL622753,BAO_0000218,
6276,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL622647,BAO_0000218,
6277,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL875163,BAO_0000218,
6278,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL622648,BAO_0000218,
6279,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL622649,BAO_0000218,
6280,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,955.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL622650,BAO_0000218,
6281,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,955.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL622651,BAO_0000218,
6282,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,955.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL622652,BAO_0000218,
6283,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,955.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL622653,BAO_0000218,
6284,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,955.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL622654,BAO_0000218,
6285,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,948.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL622655,BAO_0000218,
6286,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,948.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL622656,BAO_0000218,
6287,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,948.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL622657,BAO_0000218,
6288,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,948.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL622658,BAO_0000218,
6289,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,948.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL622659,BAO_0000218,
6290,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,2113.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL624630,BAO_0000218,
6291,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,2113.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL624631,BAO_0000218,
6292,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,2113.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL624632,BAO_0000218,
6293,1,F,1,A549,,,80682,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL624633,BAO_0000219,
6294,1,F,1,A549,,,80682,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL624634,BAO_0000219,
6295,1,F,1,A549,,,80682,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL624635,BAO_0000219,
6296,1,F,1,A549,,,80682,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL624636,BAO_0000219,
6297,1,F,1,A549,,,80682,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL857055,BAO_0000219,
6298,1,F,1,A549,,,80682,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL624637,BAO_0000219,
6299,1,F,1,A549,,,80682,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL624638,BAO_0000219,
6300,1,F,1,A549,,,80682,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL874366,BAO_0000219,
6301,1,F,1,A549,,,80682,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL624639,BAO_0000219,
6302,1,F,1,A549,,,80682,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL624640,BAO_0000219,
6303,1,F,1,A549,,,80682,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL624641,BAO_0000219,
6304,1,F,1,A549,,,80682,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL624642,BAO_0000219,
6305,1,F,1,A549,,,80682,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL624643,BAO_0000219,
6306,1,F,1,A549,,,80682,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL624644,BAO_0000219,
6307,1,F,1,A549,,,80682,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL624645,BAO_0000219,
6308,1,F,1,A549,,,80682,The compound was evaluated for its cytotoxic potency against A-549 cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619445,BAO_0000219,
6309,1,F,1,A549,,,80682,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL839886,BAO_0000219,
6310,1,F,1,A549,,,80682,Cytotoxic activity of compound against A-549 tumor cell line.,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619446,BAO_0000219,
6311,1,F,1,A549,,,80682,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619447,BAO_0000219,
6312,1,F,1,A549,,,80682,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619448,BAO_0000219,
6313,1,F,1,A549,,,80682,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619449,BAO_0000219,
6314,1,F,1,A549,,,80682,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619450,BAO_0000219,
6315,1,F,1,A549,,,80682,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619451,BAO_0000219,
6316,1,F,1,A549,,,80682,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL619452,BAO_0000219,
6317,1,F,1,A549,,,80682,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619453,BAO_0000219,
6318,1,F,1,A549,,,80682,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL874367,BAO_0000219,
6319,1,F,1,A549,,,80682,Cytotoxic concentration against A-549 tumor cells.,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619454,BAO_0000219,
6320,1,F,1,A549,,,80682,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619455,BAO_0000219,
6321,1,F,1,A549,,,80682,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619456,BAO_0000219,
6322,1,F,1,,,,50191,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,,Acinetobacter baumannii,,,,470.0,N,Expert,CHEMBL619457,BAO_0000218,
6323,1,F,1,,,,50192,Activity against Acinetobacter calcoaceticus (AC54),,Acinetobacter calcoaceticus,,,,471.0,N,Intermediate,CHEMBL619458,BAO_0000218,
6324,1,F,1,,,,50274,In vitro antifungal activity against Aspergillus flavus CM74,,Aspergillus flavus,,,,5059.0,N,Expert,CHEMBL619459,BAO_0000218,
6325,1,F,1,,,,50274,In vitro antifungal activity against Aspergillus flavus CM74,,Aspergillus flavus,,,,5059.0,N,Expert,CHEMBL619460,BAO_0000218,
6326,1,F,1,,,,50416,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,,Aspergillus fumigatus,,,,746128.0,N,Intermediate,CHEMBL619461,BAO_0000218,
6327,1,F,1,,,,50416,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),,Aspergillus fumigatus,,,,746128.0,N,Intermediate,CHEMBL619462,BAO_0000218,
6328,1,F,1,,,,50416,Antimicrobial activity against Aspergillus fumigatus (MIC),,Aspergillus fumigatus,,,,746128.0,N,Intermediate,CHEMBL620388,BAO_0000218,
6329,1,F,1,,,,50416,Antimicrobial activity against Aspergillus fumigatus (MIC),,Aspergillus fumigatus,,,,746128.0,N,Intermediate,CHEMBL620389,BAO_0000218,
6330,1,F,1,,,,50416,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),,Aspergillus fumigatus,,,,746128.0,N,Intermediate,CHEMBL620390,BAO_0000218,
6331,1,F,1,,,,50416,In vitro antifungal activity against Aspergillus fumigatus 48238E,,Aspergillus fumigatus,,,,746128.0,N,Expert,CHEMBL620391,BAO_0000218,
6332,1,F,1,,,,50416,In vitro antifungal activity against Aspergillus fumigatus 48238E,,Aspergillus fumigatus,,,,746128.0,N,Expert,CHEMBL621073,BAO_0000218,
6333,1,F,1,,,,50296,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,,Actinomyces naeslundii,,,,1655.0,N,Intermediate,CHEMBL621074,BAO_0000218,
6334,1,F,1,,,,50366,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,,Actinomyces viscosus,,,,1656.0,N,Intermediate,CHEMBL621075,BAO_0000218,
6335,1,F,1,,,,50535,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,Acanthocheilonema viteae,,,,6277.0,N,Intermediate,CHEMBL619554,BAO_0000218,
6336,1,F,1,,,,50535,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,Acanthocheilonema viteae,,,,6277.0,N,Intermediate,CHEMBL619555,BAO_0000218,
6337,1,F,1,,,,50169,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,,Aggregatibacter actinomycetemcomitans,,,,714.0,N,Intermediate,CHEMBL619556,BAO_0000218,
6338,1,F,1,,,,50169,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,,Aggregatibacter actinomycetemcomitans,,,,714.0,N,Intermediate,CHEMBL619557,BAO_0000218,
6339,1,F,1,,,,50169,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,,Aggregatibacter actinomycetemcomitans,,,,714.0,N,Intermediate,CHEMBL619558,BAO_0000218,
6340,1,F,1,A549,,,80682,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619559,BAO_0000219,
6341,1,F,1,A549,,,80682,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619560,BAO_0000219,
6342,1,F,1,A549,,,80682,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619561,BAO_0000219,
6343,1,F,1,A549,,,80682,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619562,BAO_0000219,
6344,1,F,1,A549,,,80682,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619563,BAO_0000219,
6345,1,F,1,A549,,,80682,GI values against A549 cells (lung cancer),,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL857457,BAO_0000219,
6346,1,F,1,A549,,,80682,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619564,BAO_0000219,
6347,1,F,1,A549,,,80682,Inhibitory activity against A549 human adenocarcinoma,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619565,BAO_0000219,
6348,1,F,1,A549,,,80682,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619566,BAO_0000218,
6349,1,F,1,A549,,,80682,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619567,BAO_0000218,
6350,1,F,1,A549,,,80682,Inhibitory activity against A549 lung adenocarcinoma cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619568,BAO_0000219,
6351,1,F,1,A549,,,80682,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619569,BAO_0000219,
6352,1,F,1,A549,,,80682,Cytotoxicity against human A549 lung cells,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619570,BAO_0000219,
6353,1,F,1,A549,,,80682,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619571,BAO_0000218,
6354,1,F,1,A549,,,80682,Growth inhibition of A549 (human lung carcinoma) cell line.,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL619572,BAO_0000219,
6355,1,F,1,A549,,,80682,Effective dose required for inhibitory activity against A549 human tumor cell line.,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL619573,BAO_0000219,
6356,1,F,1,A549,,,80682,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619574,BAO_0000219,
6357,1,F,1,A549,,,80682,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619575,BAO_0000219,
6358,1,F,1,A549,,,80682,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL619576,BAO_0000219,
6359,1,F,1,A549,,,80682,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619577,BAO_0000219,
6360,1,F,1,A549,,,80682,In vitro inhibitory activity against A549 tumor cell culture,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619578,BAO_0000219,
6361,1,F,1,A549,,,80682,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL884009,BAO_0000219,
6362,1,F,1,A549,,,80682,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619579,BAO_0000219,
6363,1,F,1,A549,,,80682,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619580,BAO_0000219,
6364,1,F,1,A549,,,80682,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619581,BAO_0000219,
6365,1,F,1,A549,,,80682,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619582,BAO_0000219,
6366,1,F,1,A549,,,80682,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619583,BAO_0000219,
6367,1,F,1,A549,,,80682,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL876502,BAO_0000219,
6368,1,F,1,A549,,,80682,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619584,BAO_0000219,
6369,1,F,1,A549,,,80682,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619585,BAO_0000219,
6370,1,F,1,A549,,,80682,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619586,BAO_0000219,
6371,1,F,1,A549,,,80682,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619587,BAO_0000219,
6372,1,F,1,A549,,,80682,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619588,BAO_0000219,
6373,1,F,1,A549,,,80682,Tested in vitro for cytotoxicity in A549/ATCC cell lines,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619589,BAO_0000219,
6374,1,F,1,A549,,,80682,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619590,BAO_0000219,
6375,1,F,1,A549,,,80682,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619591,BAO_0000219,
6376,1,F,1,A549,,,80682,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619592,BAO_0000219,
6377,1,F,1,A549,,,80682,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL619593,BAO_0000219,
6378,1,F,1,A549,,,80682,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620217,BAO_0000219,
6379,1,F,1,A549,,,80682,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620218,BAO_0000219,
6380,1,F,1,A549,,,80682,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620219,BAO_0000219,
6381,1,F,1,A549,,,80682,Antitumor activity against A549/ATCC cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL620220,BAO_0000219,
6382,1,F,1,A549,,,80682,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL625141,BAO_0000219,
6383,1,F,1,A549,,,80682,In vitro cytotoxicity against A549/ATCC cell line.,,Homo sapiens,,646.0,,9606.0,N,Expert,CHEMBL625142,BAO_0000219,
6384,1,F,1,A549,,,80682,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL625143,BAO_0000219,
6385,1,F,1,A549,,,80682,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL625144,BAO_0000219,
6386,1,F,1,A549,,,80682,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL622474,BAO_0000219,
6387,1,F,1,A549,,,80682,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,,Homo sapiens,,646.0,,9606.0,N,Intermediate,CHEMBL884104,BAO_0000219,
6388,1,F,0,,,,22226,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL622475,BAO_0000219,
6389,1,A,0,,,In vivo,22224,Compound was tested for oral bioavailability in dogs,,Canis lupus familiaris,,,,9615.0,U,Intermediate,CHEMBL622476,BAO_0000218,
6390,1,A,1,,,In vivo,50588,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL875831,BAO_0000218,
6391,1,A,1,,,In vivo,50588,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622477,BAO_0000218,
6392,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622478,BAO_0000218,
6393,1,A,1,,,In vivo,50588,Compound was tested for the oral bioavailability in dog; No availability,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623172,BAO_0000218,
6394,1,A,1,,,In vivo,50588,Oral bioavailability in dog (dose 5 mg/kg),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623173,BAO_0000218,
6395,1,A,1,,,In vivo,50588,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623174,BAO_0000218,
6396,1,A,1,,,In vivo,50588,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623175,BAO_0000218,
6397,1,A,1,,,In vivo,50588,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623340,BAO_0000218,
6398,1,A,1,,,In vivo,50588,Oral bioavailability in dog (dose 5 mg/kg),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623341,BAO_0000218,
6399,1,A,1,,,In vivo,50588,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623342,BAO_0000218,
6400,1,A,1,,,In vivo,50588,Oral bioavailability of active FTIs in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623343,BAO_0000218,
6401,1,A,1,,,In vivo,50588,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623344,BAO_0000218,
6402,1,A,1,,,In vivo,50588,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Expert,CHEMBL623345,BAO_0000218,
6403,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL875832,BAO_0000218,
6404,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623346,BAO_0000218,
6405,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623347,BAO_0000218,
6406,1,A,1,,,In vivo,50588,Oral bioavailability of compound was determined in dog; Not tested,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623348,BAO_0000218,
6407,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623349,BAO_0000218,
6408,1,A,1,,,In vivo,50588,Oral bioavailability (10 mg/kg) was determined in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623350,BAO_0000218,
6409,1,A,1,,,In vivo,50588,Oral bioavailability,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623351,BAO_0000218,
6410,1,A,1,,,In vivo,50588,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623352,BAO_0000218,
6411,1,A,1,,,In vivo,50588,Oral bioavailability administered in solution in rats,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623353,BAO_0000218,
6412,1,A,1,,,In vivo,50588,Oral bioavailability after 30 mg/kg po dose in Dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL875833,BAO_0000218,
6413,1,A,1,,,In vivo,50588,Oral bioavailability at a dose of 1 mg/kg in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623354,BAO_0000218,
6414,1,A,1,,,In vivo,50588,Oral bioavailability in dog (dose 1 mg/kg p.o.),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623355,BAO_0000218,
6415,1,A,1,,,In vivo,50588,Oral bioavailability in Dog; ND = not determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623356,BAO_0000218,
6416,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623357,BAO_0000218,
6417,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623358,BAO_0000218,
6418,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623359,BAO_0000218,
6419,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623360,BAO_0000218,
6420,1,A,1,,,In vivo,50588,Oral bioavailability in dogs; No data,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623361,BAO_0000218,
6421,1,A,1,,,In vivo,50588,Oral bioavailability measured in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623362,BAO_0000218,
6422,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623363,BAO_0000218,
6423,1,A,1,,,In vivo,50588,Oral bioavailability was calculated in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623364,BAO_0000218,
6424,1,A,1,,,In vivo,50588,Oral bioavailability after 0.3 mg/kg po administration in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL875834,BAO_0000218,
6425,1,A,1,,,In vivo,50588,Oral bioavailability in dog (i.v. dosing),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623365,BAO_0000218,
6426,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623366,BAO_0000218,
6427,1,A,1,,,In vivo,50588,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623367,BAO_0000218,
6428,1,A,1,,,In vivo,50588,Oral bioavailability in Beagle dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623368,BAO_0000218,
6429,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623369,BAO_0000218,
6430,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623370,BAO_0000218,
6431,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623371,BAO_0000218,
6432,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623372,BAO_0000218,
6433,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621351,BAO_0000218,
6434,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621352,BAO_0000218,
6435,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621353,BAO_0000218,
6436,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621354,BAO_0000218,
6437,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621355,BAO_0000218,
6438,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621356,BAO_0000218,
6439,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621357,BAO_0000218,
6440,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621358,BAO_0000218,
6441,1,A,1,,,In vivo,50588,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621359,BAO_0000218,
6442,1,A,1,,,In vivo,50588,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621360,BAO_0000218,
6443,1,A,1,,,In vivo,50588,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621361,BAO_0000218,
6444,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621362,BAO_0000218,
6445,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621363,BAO_0000218,
6446,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621364,BAO_0000218,
6447,1,A,1,,,In vivo,50588,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621166,BAO_0000218,
6448,1,A,1,,,In vivo,50588,Oral bioavailability in dog (dose 1 mg/kg i.v.),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621167,BAO_0000218,
6449,1,A,1,,,In vivo,50588,Oral bioavailability (F) in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621168,BAO_0000218,
6450,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621169,BAO_0000218,
6451,1,A,1,,,In vivo,50588,Bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL875950,BAO_0000218,
6452,1,A,1,,,In vivo,50588,Oral bioavailability in dog (dose 10 mg/kg),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621170,BAO_0000218,
6453,1,A,1,,,In vivo,50588,Oral bioavailability after peroral administration at 5 mpk in Dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621171,BAO_0000218,
6454,1,A,1,,,In vivo,50588,Oral bioavailability in dog (dose 5 mg/kg),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621172,BAO_0000218,
6455,1,A,1,,,In vivo,50588,Oral bioavailability in dog (dose 10 mg/kg),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621173,BAO_0000218,
6456,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,2113.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL621174,BAO_0000218,
6457,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,2113.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL621175,BAO_0000218,
6458,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,2107.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL621176,BAO_0000218,
6459,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,2107.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL621177,BAO_0000218,
6460,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,2107.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL621178,BAO_0000218,
6461,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,2107.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL621179,BAO_0000218,
6462,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,2107.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL621180,BAO_0000218,
6463,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,2048.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL875951,BAO_0000218,
6464,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,2048.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL621181,BAO_0000218,
6465,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,2048.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL621182,BAO_0000218,
6466,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,2048.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL621183,BAO_0000218,
6467,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,2048.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL621184,BAO_0000218,
6468,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL621185,BAO_0000218,
6469,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL621186,BAO_0000218,
6470,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL621187,BAO_0000218,
6471,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL621188,BAO_0000218,
6472,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL621189,BAO_0000218,
6473,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,2106.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL621190,BAO_0000218,
6474,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,2106.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL618520,BAO_0000218,
6475,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,2106.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL621739,BAO_0000218,
6476,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,2106.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL621740,BAO_0000218,
6477,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,2106.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL621741,BAO_0000218,
6478,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL621742,BAO_0000218,
6479,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL621743,BAO_0000218,
6480,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL621744,BAO_0000218,
6481,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL621745,BAO_0000218,
6482,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL621746,BAO_0000218,
6483,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL621747,BAO_0000218,
6484,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL621748,BAO_0000218,
6485,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL621749,BAO_0000218,
6486,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL621750,BAO_0000218,
6487,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL621751,BAO_0000218,
6488,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,948.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL621752,BAO_0000218,
6489,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,948.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL621753,BAO_0000218,
6490,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,948.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL875955,BAO_0000218,
6491,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,948.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL621754,BAO_0000218,
6492,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,948.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL621755,BAO_0000218,
6493,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,2107.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL621756,BAO_0000218,
6494,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,2107.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL624199,BAO_0000218,
6495,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,2107.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL624200,BAO_0000218,
6496,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,2107.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL624375,BAO_0000218,
6497,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,2107.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL624376,BAO_0000218,
6498,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,2048.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL624377,BAO_0000218,
6499,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,2048.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL624378,BAO_0000218,
6500,1,F,1,,,,50067,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,aeinetobacter anitrotap,,,,107673.0,N,Intermediate,CHEMBL857901,BAO_0000218,
6501,1,F,1,,,,50067,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,Acinetobacter calcoaceticus subsp. anitratus,,,,107673.0,N,Intermediate,CHEMBL875274,BAO_0000218,
6502,1,F,1,,,,50067,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,Acinetobacter calcoaceticus subsp. anitratus,,,,107673.0,N,Intermediate,CHEMBL624379,BAO_0000218,
6503,1,F,1,,,,50067,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,aeinetobacter anitrotap,,,,107673.0,N,Intermediate,CHEMBL624380,BAO_0000218,
6504,1,F,1,,,,50192,Activity against Acinetobacter calcoaceticus (AC54),,Acinetobacter calcoaceticus,,,,471.0,N,Intermediate,CHEMBL624381,BAO_0000218,
6505,1,F,1,,,,50714,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,,Anolis carolinensis,,,,28377.0,N,Intermediate,CHEMBL624382,BAO_0000218,
6506,1,F,1,,,,50714,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,,Anolis carolinensis,,,,28377.0,N,Intermediate,CHEMBL624383,BAO_0000218,
6507,1,F,1,,,,50296,Chlorohexidine coefficient for Actinomyces naeslundii 631,,Actinomyces naeslundii,,,,1655.0,N,Intermediate,CHEMBL624384,BAO_0000218,
6508,1,F,1,,,,50296,Chlorohexidine coefficient for Actinomyces naeslundii B74,,Actinomyces naeslundii,,,,1655.0,N,Intermediate,CHEMBL624385,BAO_0000218,
6509,1,F,1,,,,50296,Chlorohexidine coefficient for Actinomyces naeslundii N/3,,Actinomyces naeslundii,,,,1655.0,N,Intermediate,CHEMBL624386,BAO_0000218,
6510,1,F,1,,,,50296,Chlorohexidine coefficient for Actinomyces naeslundii N/9,,Actinomyces naeslundii,,,,1655.0,N,Intermediate,CHEMBL624387,BAO_0000218,
6511,1,F,1,,,,50296,Plaque bactericidal index against Actinomyces naeslundii 631,,Actinomyces naeslundii,,,,1655.0,N,Intermediate,CHEMBL624388,BAO_0000218,
6512,1,F,1,,,,50296,Plaque bactericidal index against Actinomyces naeslundii N/9,,Actinomyces naeslundii,,,,1655.0,N,Intermediate,CHEMBL624389,BAO_0000218,
6513,1,F,1,,,,50296,Plaque bactericidal index against Actinomyces naeslundii B74,,Actinomyces naeslundii,,,,1655.0,N,Intermediate,CHEMBL624390,BAO_0000218,
6514,1,F,1,,,,50296,Plaque bactericidal index against Actinomyces naeslundii N/3,,Actinomyces naeslundii,,,,1655.0,N,Intermediate,CHEMBL875275,BAO_0000218,
6515,1,F,1,,,,50056,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,,Artemia salina,,,,85549.0,N,Intermediate,CHEMBL624391,BAO_0000218,
6516,1,F,1,,,,50056,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",,Artemia salina,,,,85549.0,N,Intermediate,CHEMBL623636,BAO_0000218,
6517,1,F,1,,,,50532,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,,Ascaris suum,,,,6253.0,N,Intermediate,CHEMBL623637,BAO_0000218,
6518,1,F,1,,,,50532,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,,Ascaris suum,,,,6253.0,N,Intermediate,CHEMBL623638,BAO_0000218,
6519,1,F,1,,,,50532,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,,Ascaris suum,,,,6253.0,N,Intermediate,CHEMBL623639,BAO_0000218,
6520,1,F,1,,,,50532,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,,Ascaris suum,,,,6253.0,N,Intermediate,CHEMBL623640,BAO_0000218,
6521,1,F,1,,,,50532,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,,Ascaris suum,,,,6253.0,N,Intermediate,CHEMBL623641,BAO_0000218,
6522,1,F,1,,,,50532,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,,Ascaris suum,,,,6253.0,N,Intermediate,CHEMBL623642,BAO_0000218,
6523,1,F,1,,,,50532,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,,Ascaris suum,,,,6253.0,N,Intermediate,CHEMBL623643,BAO_0000218,
6524,1,F,1,,,,50532,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,,Ascaris suum,,,,6253.0,N,Intermediate,CHEMBL623644,BAO_0000218,
6525,1,F,1,,,,50532,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,,Ascaris suum,,,,6253.0,N,Intermediate,CHEMBL623645,BAO_0000218,
6526,1,F,1,,,,50532,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,,Ascaris suum,,,,6253.0,N,Intermediate,CHEMBL623646,BAO_0000218,
6527,1,F,1,,,,50532,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,,Ascaris suum,,,,6253.0,N,Intermediate,CHEMBL623647,BAO_0000218,
6528,1,F,1,,,,50532,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,,Ascaris suum,,,,6253.0,N,Intermediate,CHEMBL623648,BAO_0000218,
6529,1,F,1,,,,50366,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,Actinomyces viscosus,,,,1656.0,N,Intermediate,CHEMBL623649,BAO_0000218,
6530,1,F,1,,,,50366,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,Actinomyces viscosus,,,,1656.0,N,Intermediate,CHEMBL623650,BAO_0000218,
6531,1,F,1,,,,50366,Chlorohexidine coefficient for Actinomyces viscosus 8A06,,Actinomyces viscosus,,,,1656.0,N,Intermediate,CHEMBL623651,BAO_0000218,
6532,1,F,1,,,,50366,Chlorohexidine coefficient for Actinomyces viscosus M-100,,Actinomyces viscosus,,,,1656.0,N,Expert,CHEMBL623652,BAO_0000218,
6533,1,F,1,,,,50366,Chlorohexidine coefficient for Actinomyces viscosus M-626,,Actinomyces viscosus,,,,1656.0,N,Intermediate,CHEMBL623653,BAO_0000218,
6534,1,F,1,,,,50366,Chlorohexidine coefficient for Actinomyces viscosus T14V,,Actinomyces viscosus,,,,1656.0,N,Intermediate,CHEMBL623654,BAO_0000218,
6535,1,F,1,,,,50366,Plaque bactericidal index against Actinomyces viscosus 8A06,,Actinomyces viscosus,,,,1656.0,N,Intermediate,CHEMBL623655,BAO_0000218,
6536,1,F,1,,,,50366,Plaque bactericidal index against Actinomyces viscosus M-100,,Actinomyces viscosus,,,,1656.0,N,Intermediate,CHEMBL623656,BAO_0000218,
6537,1,F,1,,,,50366,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,,Actinomyces viscosus,,,,1656.0,N,Expert,CHEMBL623657,BAO_0000218,
6538,1,F,1,,,,50366,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,Actinomyces viscosus,,,,1656.0,N,Intermediate,CHEMBL623658,BAO_0000218,
6539,1,F,1,,,,50366,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,Actinomyces viscosus,,,,1656.0,N,Intermediate,CHEMBL623659,BAO_0000218,
6540,1,F,1,,,,50366,Plaque bactericidal index against Actinomyces viscosus 626,,Actinomyces viscosus,,,,1656.0,N,Intermediate,CHEMBL623660,BAO_0000218,
6541,1,F,1,,,,50366,Plaque bactericidal index against Actinomyces viscosus T14V,,Actinomyces viscosus,,,,1656.0,N,Intermediate,CHEMBL623661,BAO_0000218,
6542,1,F,1,,,,50535,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,,Acanthocheilonema viteae,,,,6277.0,N,Intermediate,CHEMBL875281,BAO_0000218,
6543,1,F,1,,,,50535,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,,Acanthocheilonema viteae,,,,6277.0,N,Intermediate,CHEMBL623662,BAO_0000218,
6544,1,F,1,,,,50535,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,,Acanthocheilonema viteae,,,,6277.0,N,Intermediate,CHEMBL623663,BAO_0000218,
6545,1,F,1,,,,50535,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,,Acanthocheilonema viteae,,,,6277.0,N,Intermediate,CHEMBL623664,BAO_0000218,
6546,1,F,1,,,,50535,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,,Acanthocheilonema viteae,,,,6277.0,N,Intermediate,CHEMBL623665,BAO_0000218,
6547,1,F,1,A673,,,80023,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,,Homo sapiens,,165.0,,9606.0,N,Intermediate,CHEMBL621856,BAO_0000219,
6548,1,F,1,A704,,,80661,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,,Homo sapiens,,645.0,,9606.0,N,Intermediate,CHEMBL620432,BAO_0000219,
6549,1,F,0,,,,22226,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL620433,BAO_0000219,
6550,1,F,1,A9,,,80024,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,Mus musculus,,625.0,,10090.0,N,Intermediate,CHEMBL620434,BAO_0000219,
6551,1,F,1,A9,,,80024,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,Mus musculus,,625.0,,10090.0,N,Intermediate,CHEMBL620435,BAO_0000219,
6552,1,F,1,A9,,,80024,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,,Homo sapiens,,625.0,,9606.0,N,Intermediate,CHEMBL620436,BAO_0000219,
6553,1,F,1,A9,,,80024,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,,Homo sapiens,,625.0,,9606.0,N,Intermediate,CHEMBL876597,BAO_0000219,
6554,1,F,1,Human ovarian carcinoma cell line,,,81037,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,,Homo sapiens,,874.0,,9606.0,N,Expert,CHEMBL620437,BAO_0000219,
6555,1,F,1,A9,,,80024,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",,Mus musculus,,625.0,,10090.0,N,Expert,CHEMBL620438,BAO_0000219,
6556,1,F,1,A9,,,80024,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,,Mus musculus,,625.0,,10090.0,N,Expert,CHEMBL620439,BAO_0000219,
6557,1,F,1,A9,,,80024,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,,Mus musculus,,625.0,,10090.0,N,Expert,CHEMBL619657,BAO_0000219,
6558,1,F,1,A9,,,80024,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,,Mus musculus,,625.0,,10090.0,N,Intermediate,CHEMBL619658,BAO_0000219,
6559,1,F,1,A9,,,80024,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,,Mus musculus,,625.0,,10090.0,N,Intermediate,CHEMBL619659,BAO_0000219,
6560,1,F,8,,,,10649,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",,,,,,,H,Expert,CHEMBL619660,BAO_0000019,
6561,1,F,1,A9,,,80024,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,,Mus musculus,,625.0,,10090.0,N,Intermediate,CHEMBL619661,BAO_0000219,
6562,1,F,1,A9,,,80024,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,,Mus musculus,,625.0,,10090.0,N,Intermediate,CHEMBL619662,BAO_0000219,
6563,1,F,1,AA6,,,80663,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,,Cricetulus griseus,,975.0,,10029.0,N,Intermediate,CHEMBL619663,BAO_0000219,
6564,1,F,0,,,,22226,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL619664,BAO_0000219,
6565,1,F,0,,,,22226,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL619665,BAO_0000219,
6566,1,F,1,AA5,,,80662,Anti -HIV activity was measured against AA5/HIV-1(IIIB),,Homo sapiens,,974.0,,9606.0,N,Intermediate,CHEMBL883244,BAO_0000219,
6567,1,F,1,AA5,,,80662,Cytotoxicity was measured against AA5/HIV-1(IIIB),,Homo sapiens,,974.0,,9606.0,N,Intermediate,CHEMBL884011,BAO_0000219,
6568,1,F,1,AA5,,,80662,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,,Homo sapiens,,974.0,,9606.0,N,Intermediate,CHEMBL619666,BAO_0000219,
6569,1,F,1,U-937,,,80566,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,,Homo sapiens,,379.0,,9606.0,N,Intermediate,CHEMBL619667,BAO_0000219,
6570,1,F,1,UV4,,,80578,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,,Cricetulus griseus,,274.0,,10029.0,N,Intermediate,CHEMBL619668,BAO_0000219,
6571,1,F,1,CHO-AA8,,,80089,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,Cricetulus griseus,,185.0,,10029.0,N,Expert,CHEMBL619669,BAO_0000219,
6572,1,F,1,CHO-AA8,,,80089,Average intracellular compound concentration when the hypoxic SER=1.6,,Cricetulus griseus,,185.0,,10029.0,N,Intermediate,CHEMBL876608,BAO_0000219,
6573,1,F,1,CHO-AA8,,,80089,Average intracellular compound concentration when the hypoxic SER=1.6.,,Cricetulus griseus,,185.0,,10029.0,N,Intermediate,CHEMBL619670,BAO_0000219,
6574,1,F,1,CHO-AA8,,,80089,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,,Cricetulus griseus,,185.0,,10029.0,N,Intermediate,CHEMBL619671,BAO_0000219,
6575,1,F,1,CHO-AA8,,,80089,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,,Cricetulus griseus,,185.0,,10029.0,N,Intermediate,CHEMBL619672,BAO_0000219,
6576,1,F,1,CHO-AA8,,,80089,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,,Cricetulus griseus,,185.0,,10029.0,N,Intermediate,CHEMBL619673,BAO_0000219,
6577,1,F,1,CHO-AA8,,,80089,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",,Cricetulus griseus,,185.0,,10029.0,N,Intermediate,CHEMBL619674,BAO_0000219,
6578,1,F,1,CHO-AA8,,,80089,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",,Cricetulus griseus,,185.0,,10029.0,N,Intermediate,CHEMBL619675,BAO_0000219,
6579,1,F,1,CHO-AA8,,,80089,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,,Cricetulus griseus,,185.0,,10029.0,N,Intermediate,CHEMBL619676,BAO_0000219,
6580,1,F,1,CHO-AA8,,,80089,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,Cricetulus griseus,,185.0,,10029.0,N,Intermediate,CHEMBL619677,BAO_0000219,
6581,1,A,1,CHO-AA8,,,80089,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,Cricetulus griseus,,185.0,,10029.0,N,Intermediate,CHEMBL619678,BAO_0000219,
6582,1,A,1,CHO-AA8,,,80089,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,,Cricetulus griseus,,185.0,,10029.0,N,Intermediate,CHEMBL619679,BAO_0000219,
6583,1,A,1,CHO-AA8,,,80089,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,,Cricetulus griseus,,185.0,,10029.0,N,Expert,CHEMBL619680,BAO_0000219,
6584,1,A,1,CHO-AA8,,,80089,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,,Cricetulus griseus,,185.0,,10029.0,N,Intermediate,CHEMBL621457,BAO_0000219,
6585,1,F,1,CHO-AA8,,,80089,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,,Cricetulus griseus,,185.0,,10029.0,N,Expert,CHEMBL876609,BAO_0000219,
6586,1,F,1,CHO-AA8,,,80089,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,,Cricetulus griseus,,185.0,,10029.0,N,Intermediate,CHEMBL621458,BAO_0000219,
6587,1,F,1,CHO-AA8,,,80089,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,,hampster,,185.0,,36483.0,N,Expert,CHEMBL621459,BAO_0000219,
6588,1,F,1,CHO-AA8,,,80089,Aerobic growth inhibition in Chinese hamster cell line AA8,,Cricetulus griseus,,185.0,,10029.0,N,Expert,CHEMBL621460,BAO_0000219,
6589,1,F,1,CHO-AA8,,,80089,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,,Cricetulus griseus,,185.0,,10029.0,N,Expert,CHEMBL621461,BAO_0000219,
6590,1,F,1,CHO-AA8,,,80089,Inhibition of growth under aerobic conditions in AA8 cells,,Cricetulus griseus,,185.0,,10029.0,N,Expert,CHEMBL621462,BAO_0000219,
6591,1,A,1,,,In vivo,50588,Oral bioavailability in dog (dose 10 mg/kg),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621463,BAO_0000218,
6592,1,A,1,,,In vivo,50588,Oral bioavailability in dog at 10 mg/kg of the compound,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621464,BAO_0000218,
6593,1,A,1,,,In vivo,50588,Oral bioavailability in dog (dose 5 uM/kg),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621465,BAO_0000218,
6594,1,A,1,,,In vivo,50588,Oral bioavailability in dog (dose 5 uM/kg),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621466,BAO_0000218,
6595,1,A,1,,,In vivo,50588,Oral bioavailability in dog (mongrel),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621467,BAO_0000218,
6596,1,A,1,,,In vivo,50588,Oral bioavailability in dog (dose 10 mg/kg),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621468,BAO_0000218,
6597,1,F,1,,,In vivo,50588,Oral bioavailability in dog (dose 10 mg/kg),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL876734,BAO_0000218,
6598,1,A,1,,,In vivo,50588,Bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618476,BAO_0000218,
6599,1,A,1,,,In vivo,50588,Bioavailability in dog (dose 1 mg/kg i.v.),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618477,BAO_0000218,
6600,1,A,1,,,In vivo,50588,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618478,BAO_0000218,
6601,1,A,1,,,In vivo,50588,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618479,BAO_0000218,
6602,1,A,1,,,In vivo,50588,Bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618480,BAO_0000218,
6603,1,A,1,,,In vivo,50588,Bioavailability in dog (dose 3-10 mg/kg),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618481,BAO_0000218,
6604,1,A,1,,,In vivo,50588,The compound was tested for bioavailability of compound in plasma of dog; Complete,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618482,BAO_0000218,
6605,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618483,BAO_0000218,
6606,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618484,BAO_0000218,
6607,1,A,1,,,In vivo,50588,Bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618485,BAO_0000218,
6608,1,A,1,,,In vivo,50588,oral bioavailability was measured in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618486,BAO_0000218,
6609,1,A,1,,,,50588,Compound was tested for plasma protein binding in dog; Not determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618487,BAO_0000218,
6610,1,A,1,,,,50588,Compound was tested for plasma protein binding of dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618488,BAO_0000218,
6611,1,A,1,,,,50588,Compound was tested for plasma protein binding of dog; Not determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL876735,BAO_0000218,
6612,1,A,1,,,,50588,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618489,BAO_0000218,
6613,1,A,1,,,In vivo,50588,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618490,BAO_0000218,
6614,1,A,1,,,,50588,Half life was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618491,BAO_0000218,
6615,1,A,1,,,In vivo,50588,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618492,BAO_0000218,
6616,1,A,1,,,,50588,Half life was evaluated in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL873354,BAO_0000218,
6617,1,A,1,,,,50588,Half life was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618493,BAO_0000218,
6618,1,A,1,,,In vivo,50588,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618494,BAO_0000218,
6619,1,A,1,,,In vivo,50588,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),948.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618495,BAO_0000218,
6620,1,A,1,,,In vivo,50588,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),2113.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618496,BAO_0000218,
6621,1,A,1,,,In vivo,50588,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),2107.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618497,BAO_0000218,
6622,1,A,1,,,In vivo,50588,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),2048.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618498,BAO_0000218,
6623,1,A,1,,,In vivo,50588,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),2106.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618499,BAO_0000218,
6624,1,A,1,,,,50588,LogP in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL876736,BAO_0000218,
6625,1,A,1,,,,50588,Partition coefficient (logP),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618500,BAO_0000218,
6626,1,A,1,,,,50588,Partition coefficient in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL857831,BAO_0000218,
6627,1,A,1,,,In vivo,50588,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618501,BAO_0000218,
6628,1,A,1,,,In vivo,50588,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618502,BAO_0000218,
6629,1,A,1,,,,50588,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618503,BAO_0000218,
6630,1,A,1,,,,50588,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618504,BAO_0000218,
6631,1,A,1,,,,50588,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618505,BAO_0000218,
6632,1,A,1,,,,50588,Metabolism of compound in dog S9 microsomes; Trace,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618506,BAO_0000218,
6633,1,A,1,,,,50588,In vitro metabolic potential in dog liver microsomes,2107.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618507,BAO_0000218,
6634,1,A,1,,,In vivo,50588,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL876737,BAO_0000218,
6635,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618508,BAO_0000218,
6636,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618509,BAO_0000218,
6637,1,A,1,,,In vivo,50588,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618510,BAO_0000218,
6638,1,A,1,,,In vivo,50588,The compound was tested for bioavailability in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618511,BAO_0000218,
6639,1,A,1,,,In vivo,50588,The compound was tested for oral bioavailability in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618512,BAO_0000218,
6640,1,A,1,,,In vivo,50588,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618513,BAO_0000218,
6641,1,A,1,,,,50588,Compound was tested for percent protein binding (PB) in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618514,BAO_0000218,
6642,1,A,1,,,,50588,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL620052,BAO_0000218,
6643,1,A,1,,,In vivo,50588,Compound was evaluated for plasma clearance.,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL620053,BAO_0000218,
6644,1,A,1,,,In vivo,50588,The compound was tested for plasma clearance in dog,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL620054,BAO_0000218,
6645,1,A,1,,,In vivo,50588,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL620055,BAO_0000218,
6646,1,A,1,,,,50588,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL620056,BAO_0000218,
6647,1,A,1,,,,50588,In vitro relative rate of metabolism was determined in dog liver microsomes,2107.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL620057,BAO_0000218,
6648,1,A,1,,,In vivo,50588,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618939,BAO_0000218,
6649,1,A,1,,,In vivo,50588,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618940,BAO_0000218,
6650,1,A,1,,,In vivo,50588,Half life after intravenous administration in dogs at 1.2 uM/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618941,BAO_0000218,
6651,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,2048.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL624473,BAO_0000218,
6652,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,2048.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL624474,BAO_0000218,
6653,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,2048.0,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL624475,BAO_0000218,
6654,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL624476,BAO_0000218,
6655,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL623478,BAO_0000218,
6656,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL623479,BAO_0000218,
6657,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL623480,BAO_0000218,
6658,1,A,1,CCRF S-180,,,50594,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,,Mus musculus,,42.0,,10090.0,N,Intermediate,CHEMBL623481,BAO_0000218,
6659,1,A,1,,,,50594,C2 in brain of mice at the oral dose of 50 mg/kg,955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623482,BAO_0000218,
6660,1,A,1,,,,50594,C2 in kidney of mice at the oral dose of 50 mg/kg,2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623483,BAO_0000218,
6661,1,A,1,,,,50594,C2 in liver of mice at the oral dose of 50 mg/kg,2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623484,BAO_0000218,
6662,1,A,1,,,,50594,C2 in lungs of mice at the oral dose of 50 mg/kg,2048.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623485,BAO_0000218,
6663,1,A,1,,,,50594,C2 in spleen of mice at the oral dose of 50 mg/kg,2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623486,BAO_0000218,
6664,1,A,1,,,In vivo,50594,Plasma clearance in mouse,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623487,BAO_0000218,
6665,1,A,1,,,In vivo,50594,Clearance of compound after intravenous administration in mice at 24 uM/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623488,BAO_0000218,
6666,1,A,1,,,In vivo,50594,Clearance from mouse blood following i.v. administration of 10 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623489,BAO_0000218,
6667,1,A,1,,,In vivo,50594,Clearance was evaluated in mice after intravenous administration,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL875157,BAO_0000218,
6668,1,A,1,,,In vivo,50594,Clearance was evaluated in mice after oral administration,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623490,BAO_0000218,
6669,1,A,1,,,In vivo,50594,Pharmacokinetic property (Plasma clearance) was measured in mouse,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623491,BAO_0000218,
6670,1,A,1,,,In vivo,50594,Plasma clearance of compound was determined at 40 mg/Kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623492,BAO_0000218,
6671,1,A,1,,,In vivo,50594,Plasma clearance of at 24 mg/Kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623493,BAO_0000218,
6672,1,A,1,,,In vivo,50594,Plasma clearance at 24 mg/Kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623494,BAO_0000218,
6673,1,A,1,,,In vivo,50594,Plasma clearance at 5 mg/Kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623495,BAO_0000218,
6674,1,A,1,,,In vivo,50594,Plasma clearance in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623496,BAO_0000218,
6675,1,A,1,,,In vivo,50594,Plasma clearance value upon iv administration in mouse,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623497,BAO_0000218,
6676,1,A,1,,,In vivo,50594,Total plasma clearance in mice,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623498,BAO_0000218,
6677,1,A,1,,,In vivo,50594,Clearance in mouse,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623499,BAO_0000218,
6678,1,A,1,,,In vivo,50594,Clearance value was determined,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623500,BAO_0000218,
6679,1,A,1,,,In vivo,50594,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623501,BAO_0000218,
6680,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Intermediate,CHEMBL875158,BAO_0000100,
6681,1,A,1,,,In vivo,50594,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623502,BAO_0000218,
6682,1,A,1,,,In vivo,50594,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623503,BAO_0000218,
6683,1,A,1,,,In vivo,50594,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623504,BAO_0000218,
6684,1,A,1,,,In vivo,50594,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623505,BAO_0000218,
6685,1,A,1,,,In vivo,50594,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623506,BAO_0000218,
6686,1,A,1,,,In vivo,50594,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623507,BAO_0000218,
6687,1,A,1,,,In vivo,50594,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623508,BAO_0000218,
6688,1,A,1,,,In vivo,50594,Cmax after oral administration at 30 mg/kg in ICR mouse,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623509,BAO_0000218,
6689,1,A,1,,,In vivo,50594,Cmax after peroral administration in mice at 2.4 uM/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL875159,BAO_0000218,
6690,1,A,1,,,In vivo,50594,Cmax in brain of mice at the oral dose of 50 mg/kg,955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623510,BAO_0000218,
6691,1,A,1,,,In vivo,50594,Cmax in kidney of mice at the oral dose of 50 mg/kg,2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623511,BAO_0000218,
6692,1,A,1,,,In vivo,50594,Cmax in liver of mice at the oral dose of 50 mg/kg,2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623512,BAO_0000218,
6693,1,A,1,,,In vivo,50594,Cmax in lungs of mice at the oral dose of 50 mg/kg,2048.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623513,BAO_0000218,
6694,1,F,1,,,In vivo,50594,Cmax in mice at 18 uM/kg i.p. administration,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623514,BAO_0000218,
6695,1,F,1,,,In vivo,50594,Cmax in mice at 23 uM/kg i.v. administration,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622609,BAO_0000218,
6696,1,F,1,,,In vivo,50594,Cmax in mice at 24 uM/kg i.p. administration,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622610,BAO_0000218,
6697,1,F,1,,,In vivo,50594,Cmax in mice at 25 uM/kg i.p. administration,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621823,BAO_0000218,
6698,1,F,1,,,In vivo,50594,Cmax in mice at 26 uM/kg i.p. administration,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621824,BAO_0000218,
6699,1,A,1,,,In vivo,50594,Cmax in spleen of mice at the oral dose of 50 mg/kg,2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621825,BAO_0000218,
6700,1,A,1,,,In vivo,50594,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621826,BAO_0000218,
6701,1,A,1,,,In vivo,50594,Cmax value at a dose of 10 mg/kg peroral administration in mice.,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621827,BAO_0000218,
6702,1,A,1,,,In vivo,50594,Cmax value was determined,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621828,BAO_0000218,
6703,1,A,1,,,In vivo,50594,Cmax value in IRC mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621829,BAO_0000218,
6704,1,A,1,,,In vivo,50594,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621830,BAO_0000218,
6705,1,A,1,,,In vivo,50594,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621831,BAO_0000218,
6706,1,A,1,,,In vivo,50594,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621832,BAO_0000218,
6707,1,A,1,,,In vivo,50594,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624579,BAO_0000218,
6708,1,A,1,,,In vivo,50594,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624580,BAO_0000218,
6709,1,F,1,,,,50535,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,,Acanthocheilonema viteae,,,,6277.0,N,Intermediate,CHEMBL624581,BAO_0000218,
6710,1,F,1,,,,50535,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,,Acanthocheilonema viteae,,,,6277.0,N,Intermediate,CHEMBL624582,BAO_0000218,
6711,1,F,1,,,,50535,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,,Acanthocheilonema viteae,,,,6277.0,N,Intermediate,CHEMBL624583,BAO_0000218,
6712,1,F,1,A-375,,,80018,Inhibitory activity against human tumor cell line A0375 melanoma.,,Homo sapiens,,455.0,,9606.0,N,Intermediate,CHEMBL624584,BAO_0000219,
6713,1,B,9,,,,12512,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,,Rattus norvegicus,,,,10116.0,D,Expert,CHEMBL624585,BAO_0000249,
6714,1,F,9,,,,114,Forskolin-induced cAMP production at human A1 adenosine receptor,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL875165,BAO_0000019,
6715,1,F,8,CHO,,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,,,,449.0,,,H,Autocuration,CHEMBL619490,BAO_0000219,
6716,1,F,8,CHO,,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,,,449.0,,,H,Autocuration,CHEMBL619491,BAO_0000219,
6717,1,F,8,CHO,,,114,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,,,,449.0,,,H,Expert,CHEMBL619492,BAO_0000219,
6718,1,F,8,CHO,,,114,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,,,,449.0,,,H,Expert,CHEMBL619493,BAO_0000219,
6719,1,F,8,CHO,,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,,,,449.0,,,H,Autocuration,CHEMBL619494,BAO_0000219,
6720,1,F,8,CHO,,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,,,,449.0,,,H,Autocuration,CHEMBL619495,BAO_0000219,
6721,1,F,8,CHO,,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,,,,449.0,,,H,Autocuration,CHEMBL619496,BAO_0000219,
6722,1,F,9,CHO,,,114,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,Homo sapiens,,449.0,,9606.0,D,Expert,CHEMBL619497,BAO_0000219,
6723,1,F,8,CHO,,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,,,,449.0,,,H,Autocuration,CHEMBL619498,BAO_0000219,
6724,1,F,8,CHO,,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,,,,449.0,,,H,Autocuration,CHEMBL619499,BAO_0000219,
6725,1,F,8,CHO,,,114,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,,,,449.0,,,H,Expert,CHEMBL619500,BAO_0000219,
6726,1,F,8,CHO,,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,,,,449.0,,,H,Autocuration,CHEMBL619501,BAO_0000219,
6727,1,F,8,CHO,,,114,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,,,,449.0,,,H,Expert,CHEMBL619502,BAO_0000219,
6728,1,F,8,CHO,,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,,,,449.0,,,H,Autocuration,CHEMBL619503,BAO_0000219,
6729,1,F,8,CHO,,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,,,449.0,,,H,Autocuration,CHEMBL619504,BAO_0000219,
6730,1,F,8,CHO,,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,,,,449.0,,,H,Autocuration,CHEMBL621298,BAO_0000219,
6731,1,F,8,CHO,,,114,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,,,,449.0,,,H,Expert,CHEMBL621299,BAO_0000219,
6732,1,F,8,CHO,,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,,,,449.0,,,H,Autocuration,CHEMBL621300,BAO_0000219,
6733,1,F,8,CHO,,,114,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,,,,449.0,,,H,Autocuration,CHEMBL621301,BAO_0000219,
6734,1,F,8,CHO,,,114,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,,,449.0,,,H,Expert,CHEMBL621302,BAO_0000219,
6735,1,F,1,A10,,,80013,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,,Oryctolagus cuniculus,,164.0,,9986.0,N,Intermediate,CHEMBL621303,BAO_0000219,
6736,1,F,0,A10,,,22226,In vitro potassium channel opening activity in A10 (smooth muscle) cells,,Rattus norvegicus,,164.0,,10116.0,U,Autocuration,CHEMBL621304,BAO_0000219,
6737,1,F,0,A10,,,22226,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,,Rattus norvegicus,,164.0,,10116.0,U,Autocuration,CHEMBL621305,BAO_0000219,
6738,1,F,1,A10,,,80013,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,,Rattus norvegicus,,164.0,,10116.0,N,Intermediate,CHEMBL621306,BAO_0000219,
6739,1,F,1,A10,,,80013,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,,Rattus norvegicus,,164.0,,10116.0,N,Intermediate,CHEMBL618444,BAO_0000219,
6740,1,F,1,A10,,,80013,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,,Rattus norvegicus,,164.0,,10116.0,N,Intermediate,CHEMBL618445,BAO_0000219,
6741,1,F,1,CHO-AA8,,,80089,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,,Cricetulus griseus,,185.0,,10029.0,N,Intermediate,CHEMBL618446,BAO_0000219,
6742,1,F,1,CHO-AA8,,,80089,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,,Cricetulus griseus,,185.0,,10029.0,N,Intermediate,CHEMBL618447,BAO_0000219,
6743,1,F,1,CHO-AA8,,,80089,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,,Cricetulus griseus,,185.0,,10029.0,N,Intermediate,CHEMBL618448,BAO_0000219,
6744,1,F,1,CHO-AA8,,,80089,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,,Cricetulus griseus,,185.0,,10029.0,N,Intermediate,CHEMBL618449,BAO_0000219,
6745,1,F,1,CHO-AA8,,,80089,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,Cricetulus griseus,,185.0,,10029.0,N,Intermediate,CHEMBL618637,BAO_0000219,
6746,1,F,1,CHO-AA8,,,80089,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",,Cricetulus griseus,,185.0,,10029.0,N,Intermediate,CHEMBL618638,BAO_0000219,
6747,1,F,1,CHO-AA8,,,80089,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),,Cricetulus griseus,,185.0,,10029.0,N,Intermediate,CHEMBL618639,BAO_0000219,
6748,1,F,1,CHO-AA8,,,80089,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",,Cricetulus griseus,,185.0,,10029.0,N,Expert,CHEMBL618640,BAO_0000219,
6749,1,F,1,CHO-AA8,,,80089,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,,Cricetulus griseus,,185.0,,10029.0,N,Expert,CHEMBL618641,BAO_0000219,
6750,1,F,1,CHO-AA8,,,80089,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,,Cricetulus griseus,,185.0,,10029.0,N,Intermediate,CHEMBL618642,BAO_0000219,
6751,1,F,1,CHO-AA8,,,80089,Inhibitory activity against aerobic growth of AA8 cells.,,Cricetulus griseus,,185.0,,10029.0,N,Intermediate,CHEMBL618643,BAO_0000219,
6752,1,A,1,CHO-AA8,,,80089,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,Cricetulus griseus,,185.0,,10029.0,N,Intermediate,CHEMBL884013,BAO_0000219,
6753,1,F,1,CHO-AA8,,,80089,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,Cricetulus griseus,,185.0,,10029.0,N,Expert,CHEMBL622723,BAO_0000219,
6754,1,F,1,CHO-AA8,,,80089,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,Cricetulus griseus,,185.0,,10029.0,N,Intermediate,CHEMBL622724,BAO_0000219,
6755,1,F,1,CHO-AA8,,,80089,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,,Cricetulus griseus,,185.0,,10029.0,N,Expert,CHEMBL622725,BAO_0000219,
6756,1,F,1,CHO-AA8,,,80089,Cytotoxicity against AA8 cell line,,Cricetulus griseus,,185.0,,10029.0,N,Expert,CHEMBL622726,BAO_0000219,
6757,1,F,1,CHO-AA8,,,80089,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),,Cricetulus griseus,,185.0,,10029.0,N,Intermediate,CHEMBL622727,BAO_0000219,
6758,1,A,1,CHO-AA8,,,80089,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,Cricetulus griseus,,185.0,,10029.0,N,Intermediate,CHEMBL622728,BAO_0000219,
6759,1,F,1,CHO-AA8,,,80089,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,Cricetulus griseus,,185.0,,10029.0,N,Intermediate,CHEMBL622729,BAO_0000219,
6760,1,A,1,CHO-AA8,,,80089,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,Cricetulus griseus,,185.0,,10029.0,N,Intermediate,CHEMBL622730,BAO_0000219,
6761,1,F,1,CHO-AA8,,,80089,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,,Cricetulus griseus,,185.0,,10029.0,N,Intermediate,CHEMBL622731,BAO_0000219,
6762,1,F,1,CHO-AA8,,,80089,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,Cricetulus griseus,,185.0,,10029.0,N,Intermediate,CHEMBL622732,BAO_0000219,
6763,1,F,1,CHO-AA8,,,80089,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,Cricetulus griseus,,185.0,,10029.0,N,Intermediate,CHEMBL622733,BAO_0000219,
6764,1,F,0,,,,22224,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),,Cricetulus griseus,,,,10029.0,U,Autocuration,CHEMBL622734,BAO_0000218,
6765,1,F,1,CHO-AA8,,,80089,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,,Cricetulus griseus,,185.0,,10029.0,N,Expert,CHEMBL622735,BAO_0000219,
6766,1,F,0,CHO-AA8,,,22224,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,,Cricetulus griseus,,185.0,,10029.0,U,Autocuration,CHEMBL618746,BAO_0000219,
6767,1,F,0,CHO-AA8,,,22224,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,,Cricetulus griseus,,185.0,,10029.0,U,Autocuration,CHEMBL618747,BAO_0000219,
6768,1,F,0,CHO-AA8,,,22224,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,,Cricetulus griseus,,185.0,,10029.0,U,Autocuration,CHEMBL620540,BAO_0000219,
6769,1,F,0,CHO-AA8,,,22224,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,,Cricetulus griseus,,185.0,,10029.0,U,Autocuration,CHEMBL620541,BAO_0000219,
6770,1,F,0,CHO-AA8,,,22224,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,,Cricetulus griseus,,185.0,,10029.0,U,Autocuration,CHEMBL620542,BAO_0000219,
6771,1,F,0,CHO-AA8,,,22224,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,,Cricetulus griseus,,185.0,,10029.0,U,Autocuration,CHEMBL620543,BAO_0000219,
6772,1,F,0,CHO-AA8,,,22224,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,,Cricetulus griseus,,185.0,,10029.0,U,Autocuration,CHEMBL618832,BAO_0000219,
6773,1,F,1,CHO-AA8,,,80089,Concentration required to reduce AA8 cell survival by 10%,,Cricetulus griseus,,185.0,,10029.0,N,Expert,CHEMBL618833,BAO_0000219,
6774,1,F,0,CHO-AA8,,,22224,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",,Cricetulus griseus,,185.0,,10029.0,U,Autocuration,CHEMBL618834,BAO_0000219,
6775,1,F,0,CHO-AA8,,,22224,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,Cricetulus griseus,,185.0,,10029.0,U,Autocuration,CHEMBL618835,BAO_0000219,
6776,1,F,0,CHO-AA8,,,22224,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,Cricetulus griseus,,185.0,,10029.0,U,Autocuration,CHEMBL618836,BAO_0000219,
6777,1,F,0,CHO-AA8,,,22224,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,,Cricetulus griseus,,185.0,,10029.0,U,Autocuration,CHEMBL618837,BAO_0000219,
6778,1,F,0,CHO-AA8,,,22224,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,,Cricetulus griseus,,185.0,,10029.0,U,Autocuration,CHEMBL618838,BAO_0000219,
6779,1,F,0,CHO-AA8,,,22224,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,,Cricetulus griseus,,185.0,,10029.0,U,Autocuration,CHEMBL618839,BAO_0000219,
6780,1,F,0,CHO-AA8,,,22224,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,,Cricetulus griseus,,185.0,,10029.0,U,Autocuration,CHEMBL618840,BAO_0000219,
6781,1,F,0,,,,22224,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,Cricetulus griseus,,,,10029.0,U,Autocuration,CHEMBL618841,BAO_0000019,
6782,1,F,0,CHO-AA8,,,22224,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,,Cricetulus griseus,,185.0,,10029.0,U,Autocuration,CHEMBL618842,BAO_0000219,
6783,1,F,0,CHO-AA8,,,22224,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,,Cricetulus griseus,,185.0,,10029.0,U,Autocuration,CHEMBL618843,BAO_0000219,
6784,1,A,1,,,In vivo,50588,Half life period after 15 mg/kg iv dose in Dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618844,BAO_0000218,
6785,1,A,1,,,In vivo,50588,Half life period after 30 mg/kg po dose in Dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618845,BAO_0000218,
6786,1,A,1,,,In vivo,50588,Half life was measured after oral 2b administration (tested in 6 dogs),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618846,BAO_0000218,
6787,1,A,1,,,In vivo,50588,Half life was measured in dog after oral 17b administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618847,BAO_0000218,
6788,1,A,1,,,In vivo,50588,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618848,BAO_0000218,
6789,1,A,1,,,In vivo,50588,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618849,BAO_0000218,
6790,1,A,1,,,In vivo,50588,Tmax value after 15 mg/kg iv dose in Dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618850,BAO_0000218,
6791,1,A,1,,,In vivo,50588,Tmax value after 30 mg/kg po dose in Dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618851,BAO_0000218,
6792,1,A,1,,,In vivo,50588,Compound was evaluated for its half life when administered intravenously in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL873815,BAO_0000218,
6793,1,A,1,,,In vivo,50588,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618852,BAO_0000218,
6794,1,A,1,,,,50588,Elimination Half-life of compound was determined in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618853,BAO_0000218,
6795,1,A,1,,,In vivo,50588,Half life of compound in dog following oral administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618854,BAO_0000218,
6796,1,A,1,,,,50588,Half life of compound was determined in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618855,BAO_0000218,
6797,1,A,1,,,,50588,Half life of compound was determined in dog blood,178.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618856,BAO_0000218,
6798,1,A,1,,,In vivo,50588,Half life after oral and iv dosing in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL875827,BAO_0000218,
6799,1,A,1,,,,50588,Half life in dogs in hours,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618857,BAO_0000218,
6800,1,A,1,,,In vivo,50588,Half life on i.v. administration of 2 mg/kg was measured in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618858,BAO_0000218,
6801,1,A,1,,,In vivo,50588,t1/2 in dog after oral dose (1 mg/kg),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618859,BAO_0000218,
6802,1,A,1,,,,50588,Half life was evaluated in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618860,BAO_0000218,
6803,1,A,1,,,In vivo,50588,Half life period of compound was determined after intravenous administration at 2 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618861,BAO_0000218,
6804,1,A,1,,,In vivo,50588,Half life period of compound was determined after peroral administration at 2 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622539,BAO_0000218,
6805,1,A,1,,,In vivo,50588,Half life period (10 mg/kg) was determined in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622540,BAO_0000218,
6806,1,A,1,,,In vivo,50588,Half life period (10 mg/kg) was determined in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL873803,BAO_0000218,
6807,1,A,1,,,In vivo,50588,Half life period by iv administration in dog at a dose of 0.3 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL873804,BAO_0000218,
6808,1,A,1,,,In vivo,50588,Half life period by po administration in dog at a dose of 0.3 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624311,BAO_0000218,
6809,1,A,1,,,,50588,Half life period in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624312,BAO_0000218,
6810,1,A,1,,,In vivo,50588,Half life period in dogs after oral administration at 1 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624313,BAO_0000218,
6811,1,A,1,,,In vivo,50588,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624314,BAO_0000218,
6812,1,A,1,,,,50588,Half-life of compound was determined in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624315,BAO_0000218,
6813,1,A,1,,,,50588,Half-life in dog plasma,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624316,BAO_0000218,
6814,1,A,1,,,,50588,Half-life in mongrel dogs was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624317,BAO_0000218,
6815,1,A,1,,,In vivo,50588,Half-life in dog upon oral administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624318,BAO_0000218,
6816,1,A,1,,,In vivo,50588,Half-life in dog upon oral administration; Unable to calculate,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624319,BAO_0000218,
6817,1,A,1,,,,50588,Half-life was measured in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624496,BAO_0000218,
6818,1,A,1,,,,50588,Half-life was measured in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624497,BAO_0000218,
6819,1,A,1,,,,50588,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624498,BAO_0000218,
6820,1,A,1,,,In vivo,50588,Oral half life was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624499,BAO_0000218,
6821,1,A,1,,,In vivo,50588,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624500,BAO_0000218,
6822,1,A,1,,,,50588,Plasma half life was evaluated,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624501,BAO_0000218,
6823,1,A,1,,,,50588,Plasma half life was evaluated in Dog,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623666,BAO_0000218,
6824,1,A,1,,,,50588,Plasma half life was evaluated in dog,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623667,BAO_0000218,
6825,1,A,1,,,In vivo,50588,T1/2 (Half-life) was after oral administration at 5 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623668,BAO_0000218,
6826,1,A,1,,,,50588,Tested for the half life value in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623669,BAO_0000218,
6827,1,A,1,,,In vivo,50588,Maximum time at the dose of 2 mg/kg in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623670,BAO_0000218,
6828,1,A,1,,,In vivo,50588,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623671,BAO_0000218,
6829,1,A,1,,,In vivo,50588,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,178.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL875945,BAO_0000218,
6830,1,A,1,,,In vivo,50588,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,178.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623672,BAO_0000218,
6831,1,A,1,,,In vivo,50588,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623673,BAO_0000218,
6832,1,A,1,,,In vivo,50588,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623674,BAO_0000218,
6833,1,A,1,,,In vivo,50588,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623675,BAO_0000218,
6834,1,A,1,,,,50588,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL872526,BAO_0000218,
6835,1,A,1,,,In vivo,50588,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623676,BAO_0000218,
6836,1,A,1,,,In vivo,50588,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623677,BAO_0000218,
6837,1,A,1,,,In vivo,50588,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623678,BAO_0000218,
6838,1,A,1,,,,50588,Time taken for maximum plasma concentration in dog,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623679,BAO_0000218,
6839,1,A,1,,,In vivo,50588,Time to reach Cmax after oral administration to dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623680,BAO_0000218,
6840,1,A,1,,,In vivo,50588,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623681,BAO_0000218,
6841,1,A,1,,,In vivo,50588,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623682,BAO_0000218,
6842,1,A,1,,,In vivo,50588,Tmax after peroral administration (1 mg/kg) was determined in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623683,BAO_0000218,
6843,1,A,1,,,In vivo,50588,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Expert,CHEMBL623684,BAO_0000218,
6844,1,A,1,,,In vivo,50588,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622745,BAO_0000218,
6845,1,A,1,,,In vivo,50588,Tmax after peroral administration in dogs at 2.4 uM/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622746,BAO_0000218,
6846,1,A,1,,,In vivo,50594,In vivo Cmax in mice at dose of 100 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622747,BAO_0000218,
6847,1,A,1,,,In vivo,50594,In vivo Cmax in mice at dose of 50 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622748,BAO_0000218,
6848,1,A,1,,,In vivo,50594,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622749,BAO_0000218,
6849,1,A,1,,,In vivo,50594,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622750,BAO_0000218,
6850,1,A,1,,,In vivo,50594,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623411,BAO_0000218,
6851,1,A,1,,,In vivo,50594,Maximum concentration obtained in mouse plasma was determined,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL875946,BAO_0000218,
6852,1,A,1,,,In vivo,50594,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623412,BAO_0000218,
6853,1,A,1,,,In vivo,50594,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623413,BAO_0000218,
6854,1,A,1,,,In vivo,50594,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623414,BAO_0000218,
6855,1,A,1,,,In vivo,50594,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623415,BAO_0000218,
6856,1,A,1,,,In vivo,50594,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623416,BAO_0000218,
6857,1,A,1,,,In vivo,50594,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623417,BAO_0000218,
6858,1,A,1,,,In vivo,50594,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623418,BAO_0000218,
6859,1,A,1,,,In vivo,50594,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623419,BAO_0000218,
6860,1,A,1,,,In vivo,50594,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622816,BAO_0000218,
6861,1,A,1,,,In vivo,50594,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623313,BAO_0000218,
6862,1,A,1,,,In vivo,50594,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623314,BAO_0000218,
6863,1,A,1,,,In vivo,50594,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL876788,BAO_0000218,
6864,1,A,1,,,In vivo,50594,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623315,BAO_0000218,
6865,1,A,1,,,In vivo,50594,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623316,BAO_0000218,
6866,1,A,1,,,In vivo,50594,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623317,BAO_0000218,
6868,1,A,1,,,In vivo,50594,Cmax in male mice after 2 mg/kg oral dose,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623319,BAO_0000218,
6869,1,A,1,,,In vivo,50594,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623320,BAO_0000218,
6870,1,A,1,,,In vivo,50594,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623321,BAO_0000218,
6871,1,A,1,,,,50594,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623322,BAO_0000218,
6872,1,A,1,,,,50594,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623323,BAO_0000218,
6873,1,A,1,,,,50594,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623324,BAO_0000218,
6874,1,A,1,,,,50594,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623325,BAO_0000218,
6875,1,A,1,,,,50594,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623326,BAO_0000218,
6876,1,A,1,,,,50594,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623327,BAO_0000218,
6877,1,A,1,,,,50594,Maximum concentration in plasma upon oral administration in mouse,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623328,BAO_0000218,
6878,1,A,1,,,,50594,Maximum plasma concentration was evaluated in mice after oral administration,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623329,BAO_0000218,
6879,1,A,1,,,In vivo,50594,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623330,BAO_0000218,
6880,1,A,1,,,,50594,Dose at which the compound induced fecal excretion in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL876789,BAO_0000218,
6893,1,F,1,A10,,,80013,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,,Rattus norvegicus,,164.0,,10116.0,N,Expert,CHEMBL623333,BAO_0000219,
6894,1,F,1,A10,,,80013,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,,Rattus norvegicus,,164.0,,10116.0,N,Expert,CHEMBL623334,BAO_0000219,
6895,1,F,1,A10,,,80013,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,,Rattus norvegicus,,164.0,,10116.0,N,Expert,CHEMBL627536,BAO_0000219,
6896,1,F,1,A10,,,80013,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,,Rattus norvegicus,,164.0,,10116.0,N,Expert,CHEMBL627537,BAO_0000219,
6897,1,F,1,A10,,,80013,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),,Rattus norvegicus,,164.0,,10116.0,N,Intermediate,CHEMBL627538,BAO_0000219,
6898,1,F,1,A121,,,80655,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,,Homo sapiens,,393.0,,9606.0,N,Intermediate,CHEMBL884106,BAO_0000219,
6899,1,F,1,A121,,,80655,Anticancer activity against human ovarian carcinoma A121 cells,,Homo sapiens,,393.0,,9606.0,N,Intermediate,CHEMBL625294,BAO_0000219,
6900,1,F,1,A121,,,80655,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,,Homo sapiens,,393.0,,9606.0,N,Intermediate,CHEMBL625295,BAO_0000219,
6901,1,F,1,A121,,,80655,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,,Homo sapiens,,393.0,,9606.0,N,Intermediate,CHEMBL625296,BAO_0000219,
6902,1,F,1,A121,,,80655,Growth inhibition of human ovarian carcinoma (A121) cell line,,Homo sapiens,,393.0,,9606.0,N,Expert,CHEMBL625297,BAO_0000219,
6903,1,F,1,A121,,,80655,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,,Homo sapiens,,393.0,,9606.0,N,Expert,CHEMBL625298,BAO_0000219,
6904,1,F,1,A121,,,80655,Cytotoxicity against human A121 ovarian cells,,Homo sapiens,,393.0,,9606.0,N,Intermediate,CHEMBL625960,BAO_0000219,
6905,1,F,1,A121,,,80655,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,,Homo sapiens,,393.0,,9606.0,N,Intermediate,CHEMBL625961,BAO_0000219,
6906,1,F,1,A121,,,80655,In vitro cytotoxicity against human ovarian carcinoma A21,,Homo sapiens,,393.0,,9606.0,N,Intermediate,CHEMBL625962,BAO_0000219,
6907,1,F,1,A121,,,80655,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,,Homo sapiens,,393.0,,9606.0,N,Intermediate,CHEMBL624717,BAO_0000219,
6908,1,F,1,A121,,,80655,Inhibitory activity of compound against human A121 ovarian cell line.,,Homo sapiens,,393.0,,9606.0,N,Intermediate,CHEMBL624718,BAO_0000219,
6909,1,F,1,A121,,,80655,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,,Homo sapiens,,393.0,,9606.0,N,Intermediate,CHEMBL624719,BAO_0000219,
6910,1,F,1,A121,,,80655,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,,Homo sapiens,,393.0,,9606.0,N,Intermediate,CHEMBL624720,BAO_0000219,
6911,1,F,1,A 172,,,80012,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,,Homo sapiens,,622.0,,9606.0,N,Intermediate,CHEMBL624721,BAO_0000219,
6912,1,F,1,A 172,,,80012,In vitro cytotoxicity against A172 human tumor cell lines.,,Homo sapiens,,622.0,,9606.0,N,Expert,CHEMBL624722,BAO_0000219,
6913,1,F,1,A 172,,,80012,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,,Homo sapiens,,622.0,,9606.0,N,Intermediate,CHEMBL877597,BAO_0000219,
6914,1,F,1,A 172,,,80012,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,,Homo sapiens,,622.0,,9606.0,N,Intermediate,CHEMBL624723,BAO_0000219,
6915,1,F,1,A 172,,,80012,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,,Homo sapiens,,622.0,,9606.0,N,Intermediate,CHEMBL624724,BAO_0000219,
6916,1,B,4,,,,104729,Association constant against A2 adenosine receptor,,Canis lupus familiaris,,,,9615.0,H,Autocuration,CHEMBL624725,BAO_0000224,
6917,1,F,1,A2,,,80656,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,,fish,,1085.0,,,N,Intermediate,CHEMBL624726,BAO_0000219,
6918,1,B,5,,,,104713,Ratio of Ki for adenosine A2 and A1 receptor binding,,Rattus norvegicus,,,,10116.0,D,Autocuration,CHEMBL857535,BAO_0000224,
6919,1,F,1,A204,,,80014,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,,Homo sapiens,,623.0,,9606.0,N,Expert,CHEMBL624727,BAO_0000219,
6920,1,F,1,A204,,,80014,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,,Homo sapiens,,623.0,,9606.0,N,Expert,CHEMBL624728,BAO_0000219,
6921,1,F,1,A2058,,,80015,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,,Homo sapiens,,404.0,,9606.0,N,Intermediate,CHEMBL624729,BAO_0000219,
6922,1,F,1,A253 cell line,,,80657,Growth inhibition against Human squamous cell line(A 253),,Homo sapiens,,973.0,,9606.0,N,Intermediate,CHEMBL624730,BAO_0000219,
6923,1,F,1,A253 cell line,,,80657,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,,Homo sapiens,,973.0,,9606.0,N,Intermediate,CHEMBL624731,BAO_0000219,
6924,1,F,1,A253 cell line,,,80657,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,,Homo sapiens,,973.0,,9606.0,N,Intermediate,CHEMBL624732,BAO_0000219,
6925,1,F,1,A253 cell line,,,80657,Growth inhibition of A253 cell lines.,,Homo sapiens,,973.0,,9606.0,N,Intermediate,CHEMBL883245,BAO_0000219,
6926,1,F,1,A253 cell line,,,80657,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),,Homo sapiens,,973.0,,9606.0,N,Intermediate,CHEMBL624733,BAO_0000219,
6927,1,F,1,A253 cell line,,,80657,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,Homo sapiens,,973.0,,9606.0,N,Intermediate,CHEMBL624734,BAO_0000219,
6928,1,F,1,A253 cell line,,,80657,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,Homo sapiens,,973.0,,9606.0,N,Intermediate,CHEMBL624735,BAO_0000219,
6929,1,F,1,A2780,,,81034,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL621780,BAO_0000219,
6930,1,F,1,A2780,,,81034,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL877598,BAO_0000219,
6931,1,F,1,A2780,,,81034,Cytotoxic activity against A2780 human ovarian carcinoma cell line,,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL621781,BAO_0000219,
6932,1,F,1,A2780,,,81034,Cytotoxicity against human cancer cell lines A2780 (ovarian),,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL621782,BAO_0000219,
6933,1,F,1,A2780,,,81034,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL621783,BAO_0000219,
6934,1,F,1,A2780,,,81034,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL621784,BAO_0000219,
6935,1,F,1,A2780,,,81034,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL621785,BAO_0000219,
6936,1,F,1,A2780,,,81034,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL621968,BAO_0000219,
6937,1,F,1,A2780,,,81034,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL621969,BAO_0000219,
6938,1,F,1,A2780,,,81034,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL621970,BAO_0000219,
6939,1,F,1,A2780,,,81034,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL621971,BAO_0000219,
6940,1,F,1,A2780,,,81034,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL621972,BAO_0000219,
6941,1,F,1,A2780,,,81034,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL884108,BAO_0000219,
6942,1,F,0,,,,22224,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,Cricetulus griseus,,,,10029.0,U,Autocuration,CHEMBL623826,BAO_0000019,
6943,1,A,0,CHO-AA8,,,22224,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,,Cricetulus griseus,,185.0,,10029.0,U,Autocuration,CHEMBL623827,BAO_0000219,
6944,1,F,0,CHO-AA8,,,22224,Evaluated for growth inhibition of AA8 cells under aerobic conditions,,Cricetulus griseus,,185.0,,10029.0,U,Autocuration,CHEMBL623828,BAO_0000219,
6945,1,F,0,CHO-AA8,,,22224,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,,Cricetulus griseus,,185.0,,10029.0,U,Autocuration,CHEMBL623829,BAO_0000219,
6946,1,F,0,CHO-AA8,,,22224,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),,Cricetulus griseus,,185.0,,10029.0,U,Autocuration,CHEMBL623830,BAO_0000219,
6947,1,F,0,,,,22224,Growth inhibition against CHO-derived cell line AA8,,Cricetulus griseus,,,,10029.0,U,Autocuration,CHEMBL623831,BAO_0000019,
6948,1,F,0,CHO-AA8,,,22224,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],,Cricetulus griseus,,185.0,,10029.0,U,Autocuration,CHEMBL623832,BAO_0000219,
6949,1,F,1,CHO-AA8,,,80089,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,,hampster,,185.0,,36483.0,N,Expert,CHEMBL623833,BAO_0000219,
6950,1,F,1,CHO-AA8,,,80089,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,,Cricetulus griseus,,185.0,,10029.0,N,Expert,CHEMBL623834,BAO_0000219,
6951,1,F,0,CHO-AA8,,,22224,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,,Cricetulus griseus,,185.0,,10029.0,U,Autocuration,CHEMBL623835,BAO_0000219,
6952,1,F,0,CHO-AA8,,,22224,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,,Cricetulus griseus,,185.0,,10029.0,U,Autocuration,CHEMBL623836,BAO_0000219,
6953,1,F,0,CHO-AA8,,,22224,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,,Cricetulus griseus,,185.0,,10029.0,U,Autocuration,CHEMBL623837,BAO_0000219,
6954,1,F,1,CHO-AA8,,,80089,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,,Cricetulus griseus,,185.0,,10029.0,N,Expert,CHEMBL623838,BAO_0000219,
6955,1,F,8,,,,12675,compound was evaluated for association constant (Ka) of isolated serum protein AAG,,,,,,,H,Autocuration,CHEMBL623839,BAO_0000019,
6956,1,F,8,,,,12675,Number of binding sites (n) of isolated serum protein AAG,,,,,,,H,Autocuration,CHEMBL623840,BAO_0000019,
6957,1,B,3,,,,22222,Association constant for binding to AATT duplex,,,,,,,M,Intermediate,CHEMBL623841,BAO_0000225,
6958,1,F,1,ABAE,,,100090,Inhibition of ABAE human fibroblast cell proliferation,,Homo sapiens,,416.0,,9606.0,N,Expert,CHEMBL623842,BAO_0000219,
6959,1,F,1,AC755,,,80668,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",,Mus musculus,,1064.0,,10090.0,N,Intermediate,CHEMBL623843,BAO_0000218,
6960,1,F,9,,,,102444,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,,Oryctolagus cuniculus,,,,9986.0,D,Expert,CHEMBL618669,BAO_0000218,
6961,1,F,9,,,In vivo,102444,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,,Oryctolagus cuniculus,,,,9986.0,D,Expert,CHEMBL618670,BAO_0000218,
6962,1,B,8,,,,69,Inhibitory activity against angiotensin-converting enzyme (ACE).,,,,,,,H,Autocuration,CHEMBL618671,BAO_0000357,
6963,1,B,8,,,,69,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,,,,,,,H,Autocuration,CHEMBL618672,BAO_0000357,
6964,1,F,1,ACH-2 cell line,,,80669,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,,Homo sapiens,,978.0,,9606.0,N,Intermediate,CHEMBL618673,BAO_0000219,
6965,1,F,1,ACH-2 cell line,,,80669,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),,Homo sapiens,,978.0,,9606.0,N,Intermediate,CHEMBL618674,BAO_0000219,
6966,1,F,0,T cell line,,,22224,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,,Human immunodeficiency virus 1,,998.0,,11676.0,U,Autocuration,CHEMBL618675,BAO_0000219,
6967,1,F,0,T cell line,,,22224,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),,Human immunodeficiency virus 1,,998.0,,11676.0,U,Autocuration,CHEMBL618676,BAO_0000219,
6968,1,F,0,T cell line,,,22224,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),,Human immunodeficiency virus 1,,998.0,,11676.0,U,Autocuration,CHEMBL618677,BAO_0000219,
6969,1,F,1,ACHN,,,80025,Inhibition of growth of renal cancer ACHN cell line,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL618678,BAO_0000219,
6970,1,F,1,ACHN,,,80025,Inhibition of growth of ACHN renal cancer cell line,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL618679,BAO_0000219,
6971,1,F,1,ACHN,,,80025,Inhibitory concentration required against ACHN renal cancer cell line,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL618680,BAO_0000219,
6972,1,F,1,ACHN,,,80025,Concentration required to inhibit growth of human renal (ACHN) cell line,,Homo sapiens,,626.0,,9606.0,N,Expert,CHEMBL618681,BAO_0000219,
6973,1,F,1,ACHN,,,80025,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL618682,BAO_0000219,
6974,1,F,1,ACHN,,,80025,Cytotoxic activity against ACHN Renal cancer cell line,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL618683,BAO_0000219,
6975,1,F,1,ACHN,,,80025,Cytotoxicity evaluation against ACHN renal cancer cells,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL618684,BAO_0000219,
6976,1,F,1,ACHN,,,80025,In vitro antitumor activity against human renal ACHN cell line,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL618685,BAO_0000219,
6977,1,F,1,ACHN,,,80025,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL876499,BAO_0000219,
6978,1,F,1,ACHN,,,80025,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL618686,BAO_0000219,
6979,1,F,1,ACHN,,,80025,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL618687,BAO_0000219,
6980,1,F,1,ACHN,,,80025,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL618688,BAO_0000219,
6981,1,F,1,ACHN,,,80025,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,Homo sapiens,,626.0,,9606.0,N,Expert,CHEMBL618689,BAO_0000219,
6982,1,F,1,ACHN,,,80025,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL618690,BAO_0000219,
6983,1,F,1,ACHN,,,80025,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL618691,BAO_0000219,
6984,1,F,1,ACHN,,,80025,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL619373,BAO_0000219,
6985,1,F,1,ACHN,,,80025,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL884008,BAO_0000219,
6986,1,F,1,ACHN,,,80025,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL619374,BAO_0000219,
6987,1,F,1,ACHN,,,80025,Compound was tested for the growth inhibition of ACHN renal tumor cell line,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL619375,BAO_0000219,
6988,1,F,1,ACHN,,,80025,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL619376,BAO_0000219,
6989,1,F,1,ACHN,,,80025,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL619377,BAO_0000219,
6990,1,F,1,ACHN,,,80025,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL619378,BAO_0000219,
6991,1,A,1,,,In vivo,50588,Tmax value after administration of 4 mg/Kg oral dose in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL872527,BAO_0000218,
6992,1,A,1,,,,50588,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL876500,BAO_0000218,
6993,1,A,1,,,,50588,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619379,BAO_0000218,
6994,1,A,1,,,In vivo,50588,Volume distribution after 15 mg/kg iv dose in Dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619538,BAO_0000218,
6995,1,A,1,,,In vivo,50588,Volume distribution after 30 mg/kg po dose in Dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619539,BAO_0000218,
6996,1,A,1,,,In vivo,50588,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619540,BAO_0000218,
6997,1,A,1,,,In vivo,50588,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619541,BAO_0000218,
6998,1,A,1,,,In vivo,50588,Volume of distribution was evaluated in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619542,BAO_0000218,
6999,1,A,1,,,In vivo,50588,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619543,BAO_0000218,
7000,1,A,1,,,,50588,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Expert,CHEMBL619544,BAO_0000218,
7001,1,A,1,,,In vivo,50588,The compound was tested for volume of distribution in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619545,BAO_0000218,
7002,1,A,1,,,In vivo,50588,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619546,BAO_0000218,
7003,1,A,1,,,In vivo,50588,Vd (1 mg/kg) was determined in dog (in vivo),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619547,BAO_0000218,
7004,1,A,1,,,In vivo,50588,Vd in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619548,BAO_0000218,
7005,1,A,1,,,In vivo,50588,Volume distribution was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619549,BAO_0000218,
7006,1,A,1,,,In vivo,50588,Volume of distribution in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619550,BAO_0000218,
7007,1,A,1,,,In vivo,50588,Volume of distribution by as 4 fold increase by iv administration in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL876501,BAO_0000218,
7008,1,A,1,,,In vivo,50588,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619551,BAO_0000218,
7009,1,A,1,,,In vivo,50588,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619552,BAO_0000218,
7010,1,A,1,,,In vivo,50588,Volume distribution at the dose of 2 mg/kg in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619553,BAO_0000218,
7011,1,A,1,,,In vivo,50588,Steady state volume of distribution was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618722,BAO_0000218,
7012,1,A,1,,,In vivo,50588,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618723,BAO_0000218,
7013,1,A,1,,,In vivo,50588,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618724,BAO_0000218,
7014,1,A,1,,,In vivo,50588,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618725,BAO_0000218,
7015,1,A,1,,,In vivo,50588,Bioavailability in dog (dose 1 mg/kg i.v.),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618726,BAO_0000218,
7016,1,A,1,,,In vivo,50588,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618727,BAO_0000218,
7017,1,A,1,,,In vivo,50588,Pharmacokinetic property (vdss) was measured in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624233,BAO_0000218,
7018,1,A,1,,,In vivo,50588,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624234,BAO_0000218,
7019,1,A,1,,,In vivo,50588,Vdss was determined after iv 0.1 mg/kg administration in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624235,BAO_0000218,
7020,1,A,1,,,In vivo,50588,Volume displacement was calculated in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624236,BAO_0000218,
7021,1,A,1,,,In vivo,50588,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624237,BAO_0000218,
7022,1,A,1,,,In vivo,50588,Volume distribution constant was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624238,BAO_0000218,
7023,1,A,1,,,In vivo,50588,Volume distribution at a dose of 1 uM/kg in dog was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624239,BAO_0000218,
7024,1,A,1,,,In vivo,50588,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL875829,BAO_0000218,
7025,1,A,1,,,In vivo,50588,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624240,BAO_0000218,
7026,1,A,1,,,In vivo,50588,Volume distribution (Vdss) was measured in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624241,BAO_0000218,
7027,1,A,1,,,In vivo,50588,Volume distribution (Vdss) was measured in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624242,BAO_0000218,
7028,1,A,1,,,In vivo,50588,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624243,BAO_0000218,
7029,1,A,1,,,In vivo,50588,Volume of distribution in steady state was determined in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624244,BAO_0000218,
7030,1,A,1,,,In vivo,50588,Volume of distribution of compound was determined in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624245,BAO_0000218,
7031,1,A,1,,,In vivo,50588,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624246,BAO_0000218,
7032,1,A,1,,,In vivo,50588,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624247,BAO_0000218,
7033,1,A,1,,,In vivo,50588,Volume of distribution (Vdss) was measured in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624248,BAO_0000218,
7034,1,A,1,,,In vivo,50588,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624249,BAO_0000218,
7035,1,A,1,,,In vivo,50588,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624250,BAO_0000218,
7036,1,A,1,,,In vivo,50588,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624251,BAO_0000218,
7037,1,A,1,,,,50588,Maximum rate of depolarization of the upstroke of the action potential,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624252,BAO_0000218,
7038,1,A,1,,,In vivo,50588,Steady state volume distribution in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624253,BAO_0000218,
7039,1,A,1,,,In vivo,50588,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624950,BAO_0000218,
7040,1,A,1,,,In vivo,50588,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624951,BAO_0000218,
7041,1,A,1,,,In vivo,50588,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL875830,BAO_0000218,
7042,1,A,1,,,In vivo,50588,Volume distribution in dog after administration of 1 mg/kg iv,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624952,BAO_0000218,
7043,1,A,1,,,In vivo,50588,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624953,BAO_0000218,
7044,1,A,1,,,In vivo,50588,Vss after intravenous administration (0.5 mg/kg) was determined in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624954,BAO_0000218,
7045,1,A,1,,,In vivo,50588,Vss on i.v. administration of 2 mg/kg was measured in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624955,BAO_0000218,
7046,1,A,1,,,,50588,Vss was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624956,BAO_0000218,
7047,1,A,1,,,,50588,Vss in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625129,BAO_0000218,
7048,1,A,1,,,In vivo,50588,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625130,BAO_0000218,
7049,1,A,1,,,In vivo,50588,Volume distribution in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625131,BAO_0000218,
7050,1,A,1,,,In vivo,50588,Volume of distribution in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625132,BAO_0000218,
7051,1,A,1,,,In vivo,50588,Tested for the oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL872263,BAO_0000218,
7060,1,A,1,,,In vivo,50594,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624336,BAO_0000218,
7061,1,A,1,,,In vivo,50594,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624337,BAO_0000218,
7062,1,A,1,,,In vivo,50594,Bioavailability after peroral administration of 50 mg/kg of dose in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624338,BAO_0000218,
7063,1,A,1,,,In vivo,50594,Bioavailability was measured in mouse,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624339,BAO_0000218,
7064,1,A,1,,,In vivo,50594,Bioavailability in mouse,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624340,BAO_0000218,
7065,1,A,1,,,In vivo,50594,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624341,BAO_0000218,
7066,1,A,1,,,In vivo,50594,Bioavailability in mouse,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624342,BAO_0000218,
7067,1,A,1,,,In vivo,50594,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624343,BAO_0000218,
7068,1,A,1,,,In vivo,50594,Oral bioavailability in mouse,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624344,BAO_0000218,
7069,1,A,1,,,In vivo,50594,Oral availability at 50 mg/kg po in male mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624345,BAO_0000218,
7070,1,A,1,,,In vivo,50594,Oral bioavailability in mouse (dose 10 mg/kg),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624346,BAO_0000218,
7071,1,A,1,,,In vivo,50594,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,,Mus musculus,,,,10090.0,N,Expert,CHEMBL624347,BAO_0000218,
7072,1,A,1,,,In vivo,50594,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624348,BAO_0000218,
7074,1,A,1,,,In vivo,50594,Oral bioavailability in mouse,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622754,BAO_0000218,
7075,1,A,1,,,In vivo,50594,Oral bioavailability in vivo in mice;ND=Not determined,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622755,BAO_0000218,
7076,1,A,1,,,In vivo,50594,Oral bioavailability in mouse at 10 mg/kg of the compound,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622756,BAO_0000218,
7077,1,A,1,,,In vivo,50594,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622757,BAO_0000218,
7078,1,A,1,,,In vivo,50594,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622758,BAO_0000218,
7079,1,A,1,,,In vivo,50594,Tested for bioavailability of the compound,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622759,BAO_0000218,
7080,1,A,1,,,In vivo,50594,Tested for half life at the dose of 10 mg/kg when administered intravenously,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622760,BAO_0000218,
7081,1,A,1,,,,50594,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622761,BAO_0000218,
7082,1,A,1,,,,50594,The plasma half life of compound was determined on heparin prepared by human plasma. ,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622762,BAO_0000218,
7083,1,A,1,,,,50594,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622763,BAO_0000218,
7084,1,A,1,,,,50594,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622764,BAO_0000218,
7085,1,A,1,,,,50594,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622765,BAO_0000218,
7086,1,F,1,,,,50594,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622766,BAO_0000218,
7087,1,A,1,,,,50594,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622767,BAO_0000218,
7088,1,A,1,,,,50594,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622768,BAO_0000218,
7089,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL875948,BAO_0000218,
7090,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622769,BAO_0000218,
7091,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622770,BAO_0000218,
7092,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622771,BAO_0000218,
7093,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622772,BAO_0000218,
7094,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622773,BAO_0000218,
7095,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622774,BAO_0000218,
7096,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10000001.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621725,BAO_0000218,
7097,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,10000001.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621726,BAO_0000218,
7098,1,F,1,A2780,,,81034,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL621727,BAO_0000219,
7099,1,F,1,A2780,,,81034,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL622413,BAO_0000219,
7100,1,F,1,A2780,,,81034,Compound was evaluated for cytotoxicity against A2780 cell line,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL622414,BAO_0000219,
7101,1,F,1,A2780,,,81034,Inhibition of A2780 cell clonogenic assay,,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL622415,BAO_0000219,
7102,1,F,1,A2780,,,81034,Cytotoxic effect on ovarian cancer cell line (A2780),,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL884001,BAO_0000219,
7103,1,F,1,A2780,,,81034,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL622416,BAO_0000219,
7104,1,F,1,A2780,,,81034,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL622417,BAO_0000219,
7105,1,F,1,A2780,,,81034,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL622590,BAO_0000219,
7106,1,F,1,A2780,,,81034,Antiproliferative activity against human A2780 cells,,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL622591,BAO_0000219,
7107,1,F,1,A2780,,,81034,Inhibition of human A2780 cell proliferation,,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL622592,BAO_0000219,
7108,1,F,1,A2780,,,81034,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL622593,BAO_0000219,
7109,1,F,1,A2780,,,81034,Inhibition of human A2780 cell proliferation (No data),,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL622594,BAO_0000219,
7110,1,F,1,A2780,,,81034,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL622595,BAO_0000219,
7111,1,F,1,A2780,,,81034,Compound was evaluated against human Ovarian carcinoma cell line A2780,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL622596,BAO_0000219,
7112,1,F,1,A2780,,,81034,Growth inhibition against A2780 wild-type ovarian cell lines,,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL622597,BAO_0000219,
7113,1,F,1,A2780,,,81034,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL622598,BAO_0000219,
7114,1,F,5,,,,104766,Inhibition of tubulin polymerization in human ovarian cancer cell lines,,Homo sapiens,,,,9606.0,D,Autocuration,CHEMBL622599,BAO_0000019,
7115,1,F,1,A2780,,,81034,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL622600,BAO_0000219,
7116,1,F,1,A2780,,,81034,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL622601,BAO_0000219,
7117,1,F,1,A2780,,,81034,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL622602,BAO_0000219,
7118,1,F,1,A2780,,,81034,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL622603,BAO_0000219,
7119,1,F,1,A2780,,,81034,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL622604,BAO_0000219,
7120,1,F,1,A2780,,,81034,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL622605,BAO_0000219,
7121,1,F,1,A2780,,,81034,In vitro inhibition of human ovarian cell line A2780,,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL622606,BAO_0000219,
7122,1,F,1,A2780,,,81034,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL619463,BAO_0000219,
7123,1,F,1,A2780,,,81034,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619464,BAO_0000219,
7124,1,F,1,A2780,,,81034,Concentration required to inhibit A2780-cell growth by 50%,,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL619465,BAO_0000219,
7125,1,F,1,A2780,,,81034,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL619466,BAO_0000219,
7126,1,F,1,A2780,,,81034,Cytotoxic effect on human ovarian (A2780) cancer cell line,,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL619467,BAO_0000219,
7127,1,F,1,A2780,,,81034,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619468,BAO_0000219,
7128,1,F,1,A2780,,,81034,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL619469,BAO_0000219,
7129,1,F,1,A2780,,,81034,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL619470,BAO_0000219,
7130,1,F,1,A2780,,,81034,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619471,BAO_0000219,
7131,1,F,1,A2780,,,81034,Cytotoxicity against human ovarian carcinoma A2780 cell line,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619472,BAO_0000219,
7132,1,F,1,A2780,,,81034,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL619473,BAO_0000219,
7133,1,F,1,A2780,,,81034,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL874368,BAO_0000219,
7134,1,F,1,A2780,,,81034,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL884003,BAO_0000219,
7135,1,F,1,A2780,,,81034,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL622690,BAO_0000219,
7136,1,F,1,A2780,,,81034,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL622691,BAO_0000219,
7137,1,F,1,A2780,,,81034,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL622692,BAO_0000219,
7138,1,F,1,A2780,,,81034,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL623406,BAO_0000219,
7139,1,F,1,A2780,,,81034,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL884004,BAO_0000219,
7140,1,F,1,A2780,,,81034,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL623407,BAO_0000219,
7141,1,F,1,A2780,,,81034,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL623408,BAO_0000219,
7142,1,F,1,A2780,,,81034,In vitro antitumor activity against A2780 cell line.,,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL623409,BAO_0000219,
7143,1,F,1,A2780,,,81034,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL623410,BAO_0000219,
7144,1,F,1,A2780,,,81034,In vitro cytotoxicity against A2780 human ovarian cancer cell line,,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL623576,BAO_0000219,
7145,1,F,1,ACHN,,,80025,Inhibitory activity against kidney A-CHN tumor cell growth in culture,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL623577,BAO_0000219,
7146,1,F,1,ACHN,,,80025,The IC50 value was measured on ACHN cell line in renal tumor type.,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL623578,BAO_0000219,
7147,1,F,1,ACHN,,,80025,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL623579,BAO_0000219,
7148,1,F,1,ACHN,,,80025,In vitro lethal concentration against most sensitive ACHN cell line,,Homo sapiens,,626.0,,9606.0,N,Expert,CHEMBL623580,BAO_0000219,
7149,1,F,1,ACHN,,,80025,Tested for cytotoxic activity against renal cancer ACHN cell line,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL623581,BAO_0000219,
7150,1,F,1,ACHN,,,80025,Compound tested for growth inhibition of renal cancer cell line ACHN,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL857456,BAO_0000219,
7151,1,F,1,ACHN,,,80025,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL623582,BAO_0000219,
7152,1,F,1,ACHN,,,80025,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL623583,BAO_0000219,
7153,1,F,1,ACHN,,,80025,In vitro anticancer activity against ACHN renal cancer cell line,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL623584,BAO_0000219,
7154,1,F,1,ACHN,,,80025,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL623585,BAO_0000219,
7155,1,F,1,ACHN,,,80025,Percent selectivity was evaluated in renal ACHN cell lines,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL623586,BAO_0000219,
7156,1,F,1,ACHN,,,80025,In vitro inhibitory activity against renal ACHN cancer cell line,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL623587,BAO_0000219,
7157,1,F,1,ACHN,,,80025,Tested for cytotoxicity against ACHN cell lines in renal cancer,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL875279,BAO_0000219,
7158,1,F,1,ACHN,,,80025,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL623588,BAO_0000219,
7159,1,F,1,ACHN,,,80025,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL623589,BAO_0000219,
7160,1,F,1,ACHN,,,80025,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL623590,BAO_0000219,
7161,1,F,1,ACHN,,,80025,Cytotoxic effect on renal cancer line ACHN,,Homo sapiens,,626.0,,9606.0,N,Expert,CHEMBL623591,BAO_0000219,
7162,1,F,1,ACHN,,,80025,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL623592,BAO_0000219,
7163,1,F,1,ACHN,,,80025,In vitro inhibition of Renal Cancer ACHN cell lines,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL623593,BAO_0000219,
7164,1,F,1,ACHN,,,80025,Antitumor activity against human renal adenocarcinoma ACHN cells,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL623594,BAO_0000219,
7165,1,F,1,ACHN,,,80025,Antitumor activity against human renal adenocarcinoma ACHN cells.,,Homo sapiens,,626.0,,9606.0,N,Expert,CHEMBL621833,BAO_0000219,
7166,1,F,1,ACHN,,,80025,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL621834,BAO_0000219,
7167,1,F,1,ACHN,,,80025,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL621835,BAO_0000219,
7168,1,F,1,ACHN,,,80025,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL621836,BAO_0000219,
7169,1,F,1,ACHN,,,80025,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL621837,BAO_0000219,
7170,1,F,1,ACHN,,,80025,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL875280,BAO_0000219,
7171,1,F,1,ACHN,,,80025,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL621838,BAO_0000219,
7172,1,F,1,ACHN,,,80025,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,,Homo sapiens,,626.0,,9606.0,N,Intermediate,CHEMBL621839,BAO_0000219,
7173,1,A,0,,,,22224,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,,,,,,U,Autocuration,CHEMBL621840,BAO_0000019,
7174,1,F,8,,,,10647,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,,,,,,,H,Autocuration,CHEMBL621841,BAO_0000019,
7175,1,F,1,HEL,,,50529,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,,Cytomegalovirus,,468.0,,10358.0,N,Expert,CHEMBL622979,BAO_0000218,
7176,1,F,1,,,,50529,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,,Cytomegalovirus,,,,10358.0,N,Intermediate,CHEMBL876595,BAO_0000218,
7177,1,B,8,,,,12159,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),,,,,,,H,Autocuration,CHEMBL620221,BAO_0000357,
7178,1,B,8,,,,12159,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),,,,,,,H,Autocuration,CHEMBL620222,BAO_0000357,
7179,1,F,1,ADDP cell line,,,80670,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,,Bos taurus,,979.0,,9913.0,N,Intermediate,CHEMBL620506,BAO_0000219,
7180,1,F,1,ADJ/PC6,,,80671,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,,Mus musculus,,980.0,,10090.0,N,Intermediate,CHEMBL620507,BAO_0000219,
7181,1,F,1,ADJ/PC6,,,80671,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,,Mus musculus,,980.0,,10090.0,N,Intermediate,CHEMBL620508,BAO_0000219,
7182,1,F,1,ADJ/PC6,,,80671,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",,Mus musculus,,980.0,,10090.0,N,Intermediate,CHEMBL620509,BAO_0000219,
7183,1,F,1,ADJ/PC6,,,80671,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,,Mus musculus,,980.0,,10090.0,N,Intermediate,CHEMBL620510,BAO_0000219,
7184,1,A,1,ADJ/PC6,,,80671,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,,Mus musculus,,980.0,,10090.0,N,Intermediate,CHEMBL620511,BAO_0000219,
7185,1,F,1,ADJ/PC6,,,80671,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,,Mus musculus,,980.0,,10090.0,N,Intermediate,CHEMBL620512,BAO_0000219,
7186,1,F,0,,,,22224,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,,Mus musculus,,,,10090.0,U,Autocuration,CHEMBL620513,BAO_0000019,
7187,1,F,0,,,,22224,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,,Mus musculus,,,,10090.0,U,Autocuration,CHEMBL620514,BAO_0000019,
7188,1,F,0,,,,22224,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,,Mus musculus,,,,10090.0,U,Autocuration,CHEMBL620515,BAO_0000019,
7189,1,A,0,,,In vivo,22224,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,Bacillus subtilis,,,,1423.0,U,Autocuration,CHEMBL620516,BAO_0000218,
7190,1,A,1,,,,50588,AUC value in dog after IV administration at a dose of 5 mg/kg,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL620517,BAO_0000218,
7191,1,A,1,,,,50588,AUC value in dog after oral administration at a dose of 5 mg/kg,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL620518,BAO_0000218,
7192,1,A,1,,,In vivo,50588,Cmax value in dog after oral administration at a dose of 5 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL620519,BAO_0000218,
7193,1,A,1,,,In vivo,50588,Bioavailability in dog after oral administration at a dose of 5 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621386,BAO_0000218,
7194,1,A,1,,,In vivo,50588,Tmax value in dog after oral administration at a dose of 5 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621387,BAO_0000218,
7195,1,A,1,,,In vivo,50588,Compound was evaluated for its clearance when administered intravenously in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621388,BAO_0000218,
7196,1,A,1,,,In vivo,50588,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621389,BAO_0000218,
7197,1,A,1,,,In vivo,50588,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621390,BAO_0000218,
7198,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Intermediate,CHEMBL621391,BAO_0000100,
7199,1,A,1,,,,50588,Half life in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621392,BAO_0000218,
7200,1,A,1,,,,50588,Time taken for EC90 was determined when tested in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621393,BAO_0000218,
7201,1,A,1,,,,50588,Half life (iv) was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621394,BAO_0000218,
7202,1,A,1,,,,50588,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,2107.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621395,BAO_0000218,
7203,1,A,1,,,,50588,Area under the curve was calculated in dog after iv administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621396,BAO_0000218,
7204,1,A,1,,,,50588,Area under the curve was calculated in dog after peroral administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621397,BAO_0000218,
7205,1,A,1,,,,50588,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621398,BAO_0000218,
7206,1,A,1,,,,50588,pKa was evaluated in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618818,BAO_0000218,
7207,1,A,1,,,,50588,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618819,BAO_0000218,
7208,1,A,1,,,In vivo,50588,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618820,BAO_0000218,
7209,1,A,1,,,In vivo,50588,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL873810,BAO_0000218,
7210,1,A,1,,,In vivo,50588,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL876606,BAO_0000218,
7211,1,A,1,,,,50588,Compound was evaluated for the half-life (t 1/2) in hours,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618821,BAO_0000218,
7212,1,A,1,,,In vivo,50588,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,178.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618822,BAO_0000218,
7213,1,A,1,,,In vivo,50588,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,178.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618823,BAO_0000218,
7214,1,A,1,,,In vivo,50588,Half life after intravenous administration of 1 mg/kg in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618824,BAO_0000218,
7215,1,A,1,,,,50588,Half life was measured in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618825,BAO_0000218,
7216,1,A,1,,,In vivo,50588,Half life period in dog after 5 mg/kg dose,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618826,BAO_0000218,
7217,1,A,1,,,,50588,Half life period was evaluated in dog; 4-4.8,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618827,BAO_0000218,
7218,1,A,1,,,In vivo,50588,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618828,BAO_0000218,
7219,1,A,1,,,In vivo,50588,Half-life was determined in dog after a3 mg/kg of iv dose,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618829,BAO_0000218,
7220,1,A,1,,,,50588,Half-life was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618830,BAO_0000218,
7221,1,A,1,,,,50588,Half life in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618831,BAO_0000218,
7222,1,A,1,,,In vivo,50588,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619489,BAO_0000218,
7223,1,A,1,,,In vivo,50588,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619649,BAO_0000218,
7224,1,A,1,,,In vivo,50588,Compound was evaluated for the half life period after iv administration in Beagle dog.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL876607,BAO_0000218,
7225,1,A,1,,,In vivo,50588,Compound was evaluated for the half life period after oral administration in conscious dog.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619650,BAO_0000218,
7226,1,A,1,,,,50588,Compound was tested for half life in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619651,BAO_0000218,
7227,1,A,1,,,,50588,Compound was tested for its half life in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619652,BAO_0000218,
7228,1,A,1,,,In vivo,50588,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619653,BAO_0000218,
7229,1,A,1,,,,50588,Half life of compound in dog was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619654,BAO_0000218,
7230,1,A,1,,,In vivo,50588,Half life (iv) was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619655,BAO_0000218,
7231,1,A,1,,,,50588,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),178.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619656,BAO_0000218,
7232,1,A,1,,,In vivo,50588,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL873812,BAO_0000218,
7233,1,F,1,,,In vivo,50588,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621365,BAO_0000218,
7234,1,A,1,,,,50588,Half life in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621366,BAO_0000218,
7235,1,A,1,,,,50588,Half life in dog plasma,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621367,BAO_0000218,
7236,1,A,1,,,In vivo,50588,Half life in dog plasma after administration of 0.25 mg/kg iv,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621368,BAO_0000218,
7237,1,A,1,,,In vivo,50588,Half life in dog plasma after administration of 1 mg/kg iv,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621369,BAO_0000218,
7238,1,A,1,,,In vivo,50588,Half life in dog plasma was determined at dose 10 mg/kg,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621370,BAO_0000218,
7239,1,A,1,,,,50588,Half life in dog was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621371,BAO_0000218,
7240,1,A,1,,,In vivo,50588,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621372,BAO_0000218,
7241,1,A,1,,,,50588,Half life upon exposure to human plasma,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621373,BAO_0000218,
7242,1,A,1,,,,50588,Half life was calculated in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621374,BAO_0000218,
7243,1,A,1,,,,50588,Half life was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621375,BAO_0000218,
7244,1,A,1,,,,50588,Half life was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621376,BAO_0000218,
7245,1,A,1,,,In vivo,50588,Half life by intravenous administration of 1.2 mg/kg in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619624,BAO_0000218,
7246,1,A,1,,,,50588,Half life in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL875840,BAO_0000218,
7247,1,A,1,,,,50588,Half life in dog after intra venous administration of the compound,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619625,BAO_0000218,
7248,1,A,1,,,,50588,Half life in dog after intra venous administration of the compound; ND means Not determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619626,BAO_0000218,
7249,1,A,1,,,In vivo,50588,Half life in dog after po administration of the compound,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619627,BAO_0000218,
7250,1,A,1,,,In vivo,50588,Half life in dog after po administration of the compound; ND means Not determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL873817,BAO_0000218,
7251,1,A,1,,,In vivo,50588,Half life in dog at the single oral dose of 1 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619628,BAO_0000218,
7252,1,A,1,,,,50588,Half life in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619629,BAO_0000218,
7253,1,A,1,,,In vivo,50588,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619630,BAO_0000218,
7254,1,A,1,,,,50588,Half life in rat,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619631,BAO_0000218,
7255,1,A,1,,,In vivo,50588,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL619632,BAO_0000218,
7256,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10000001.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619633,BAO_0000218,
7257,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10000001.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL875841,BAO_0000218,
7258,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10000001.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619634,BAO_0000218,
7259,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10000001.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619635,BAO_0000218,
7260,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10000001.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619636,BAO_0000218,
7261,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10000004.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619637,BAO_0000218,
7262,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,10000004.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619638,BAO_0000218,
7263,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10000004.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619639,BAO_0000218,
7264,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10000004.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619640,BAO_0000218,
7265,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10000004.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619641,BAO_0000218,
7266,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10000004.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619642,BAO_0000218,
7267,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10000004.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619643,BAO_0000218,
7268,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619644,BAO_0000218,
7269,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621112,BAO_0000218,
7270,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621113,BAO_0000218,
7271,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621114,BAO_0000218,
7272,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621115,BAO_0000218,
7273,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621116,BAO_0000218,
7274,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621117,BAO_0000218,
7275,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621118,BAO_0000218,
7276,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621119,BAO_0000218,
7277,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621120,BAO_0000218,
7278,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621757,BAO_0000218,
7279,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621758,BAO_0000218,
7280,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621759,BAO_0000218,
7281,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621760,BAO_0000218,
7282,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621761,BAO_0000218,
7283,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621762,BAO_0000218,
7284,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621763,BAO_0000218,
7285,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624502,BAO_0000218,
7286,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624503,BAO_0000218,
7287,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624504,BAO_0000218,
7288,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624505,BAO_0000218,
7289,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,2048.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624506,BAO_0000218,
7290,1,F,1,A2780,,,81034,In vitro cytotoxicity against A2780 (human ovarian cancer),,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL624507,BAO_0000219,
7291,1,F,1,A2780,,,81034,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL624508,BAO_0000219,
7292,1,F,1,A2780,,,81034,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL624509,BAO_0000219,
7293,1,F,1,A2780,,,81034,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL624510,BAO_0000219,
7294,1,F,1,A2780,,,81034,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL875956,BAO_0000219,
7295,1,F,1,A2780,,,81034,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL839885,BAO_0000219,
7296,1,F,1,A2780,,,81034,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL624511,BAO_0000219,
7297,1,F,1,A2780,,,81034,In vitro cytotoxicity against A2780 cell line,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL624512,BAO_0000219,
7298,1,F,1,A2780,,,81034,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL624513,BAO_0000219,
7299,1,F,1,A2780,,,81034,In vitro inhibitory activity against human ovarian cancer A2780 cell line,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL624514,BAO_0000219,
7300,1,F,1,A2780,,,81034,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL618547,BAO_0000218,
7301,1,F,1,A2780,,,81034,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL618548,BAO_0000219,
7302,1,F,1,A2780,,,81034,Inhibition of tubulin polymerization in analogy of ca.,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL618549,BAO_0000219,
7303,1,F,1,A2780,,,81034,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL618550,BAO_0000219,
7304,1,F,1,A2780,,,81034,Cytotoxic effect in ovarian cancer cell line (A2780),,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL618551,BAO_0000219,
7305,1,F,1,A2780,,,81034,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL618552,BAO_0000219,
7306,1,F,1,A2780,,,81034,Tested for the cytotoxicity in A2780 ovarian cell line,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL618553,BAO_0000219,
7307,1,F,1,A2780,,,81034,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL618554,BAO_0000219,
7308,1,F,1,A2780,,,81034,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL618555,BAO_0000219,
7309,1,F,1,A2780cisR,,,80017,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,,,,481.0,,,N,Intermediate,CHEMBL618556,BAO_0000219,
7310,1,F,1,A2780cisR,,,80017,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,,,481.0,,,N,Intermediate,CHEMBL618557,BAO_0000219,
7311,1,F,1,A2780cisR,,,80017,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,,,,481.0,,,N,Intermediate,CHEMBL618558,BAO_0000219,
7312,1,F,1,A2780cisR,,,80017,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),,,,481.0,,,N,Intermediate,CHEMBL618559,BAO_0000219,
7313,1,F,1,A2780,,,81034,In vivo log of cells killed after administration of compound in A2780 cell line,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL618560,BAO_0000218,
7314,1,F,1,A2780,,In vivo,81034,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL618561,BAO_0000218,
7315,1,F,1,A2780,,,81034,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL618562,BAO_0000219,
7316,1,F,1,A2780,,,81034,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL618563,BAO_0000219,
7317,1,F,1,A2780,,,81034,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL618564,BAO_0000219,
7318,1,F,1,A2780,,,81034,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL618565,BAO_0000219,
7319,1,F,1,A2780,,,81034,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL618566,BAO_0000218,
7320,1,F,1,A2780,,,81034,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL618567,BAO_0000219,
7321,1,F,1,A2780,,,81034,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL618568,BAO_0000219,
7322,1,F,1,A2780,,,81034,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL618569,BAO_0000219,
7323,1,F,1,A2780,,,81034,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL621857,BAO_0000219,
7324,1,F,1,A2780,,,81034,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL621858,BAO_0000219,
7325,1,F,1,A2780,,,81034,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL621859,BAO_0000219,
7326,1,F,1,A2780,,,81034,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL621860,BAO_0000219,
7327,1,F,1,A2780,,,81034,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL621861,BAO_0000219,
7328,1,F,1,A2780,,,81034,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",,Homo sapiens,,478.0,,9606.0,N,Expert,CHEMBL621862,BAO_0000219,
7329,1,F,1,A2780,,,81034,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL621863,BAO_0000219,
7330,1,F,1,A2780,,,81034,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL621864,BAO_0000219,
7331,1,F,1,A2780,,,81034,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL621865,BAO_0000219,
7332,1,F,1,A2780,,,81034,In vitro antiproliferative activity against A2780 cell line,,Mus musculus,,478.0,,10090.0,N,Intermediate,CHEMBL621866,BAO_0000219,
7333,1,F,1,A2780,,,81034,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,,Mus musculus,,478.0,,10090.0,N,Expert,CHEMBL621867,BAO_0000219,
7334,1,F,1,A2780,,,81034,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL621868,BAO_0000219,
7335,1,F,1,A2780,,,81034,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,,Homo sapiens,,478.0,,9606.0,N,Intermediate,CHEMBL875282,BAO_0000219,
7336,1,A,1,,,,50588,Vc value in dog after IV administration at a dose of 5 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621869,BAO_0000218,
7337,1,A,1,,,In vivo,50588,Half life period in dog after IV administration at a dose of 5 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621870,BAO_0000218,
7338,1,A,0,,,,22224,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621871,BAO_0000019,
7339,1,A,0,,,,22224,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1969.0,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621243,BAO_0000218,
7340,1,A,0,,,,22224,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1969.0,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621244,BAO_0000218,
7341,1,A,0,,,In vivo,22224,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,Macaca fascicularis,,,,9541.0,U,Autocuration,CHEMBL621245,BAO_0000218,
7342,1,A,0,,,In vivo,22224,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,,Macaca fascicularis,,,,9541.0,U,Autocuration,CHEMBL621246,BAO_0000218,
7343,1,A,0,,,In vivo,22224,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,,Macaca fascicularis,,,,9541.0,U,Autocuration,CHEMBL621247,BAO_0000218,
7344,1,A,0,,,In vivo,22224,Oral Bioavailability in rat,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL618386,BAO_0000218,
7345,1,A,0,,,,22224,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618387,BAO_0000218,
7346,1,A,0,,,,22224,Area under curve value in monkey at a dose of 5 mg/kg,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618388,BAO_0000218,
7347,1,A,0,,,,22224,Area under curve was determined in monkey after a 3 mg/kg of oral dose,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618389,BAO_0000218,
7348,1,A,0,,,,22224,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618574,BAO_0000019,
7349,1,A,0,,,,22224,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618575,BAO_0000019,
7350,1,A,0,,,,22224,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618576,BAO_0000019,
7351,1,A,0,,,,22224,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618577,BAO_0000218,
7352,1,A,0,,,,22224,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL876487,BAO_0000218,
7353,1,A,0,,,,22224,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618578,BAO_0000218,
7354,1,A,0,,,,22224,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618579,BAO_0000218,
7355,1,A,0,,,,22224,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618580,BAO_0000019,
7356,1,A,0,,,,22224,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618581,BAO_0000218,
7357,1,A,0,,,,22224,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618582,BAO_0000218,
7358,1,A,0,,,,22224,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618583,BAO_0000218,
7359,1,A,0,,,,22224,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618584,BAO_0000218,
7360,1,A,0,,,In vivo,22224,Oral AUCN in monkey (dosed at 0.5 mpk iv ),,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618585,BAO_0000218,
7361,1,A,0,,,,22224,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618586,BAO_0000218,
7362,1,A,0,,,In vivo,22224,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618587,BAO_0000218,
7363,1,A,0,,,In vivo,22224,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618588,BAO_0000218,
7364,1,A,0,,,,22224,Binding towards monkey plasma protein at 10 uM,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618589,BAO_0000019,
7365,1,A,0,,,,22224,Binding towards monkey plasma protein at 100 uM,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618590,BAO_0000019,
7366,1,A,0,,,In vivo,22224,Apparent bioavailability in squirrel monkey was determined,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL872262,BAO_0000218,
7367,1,A,0,,,In vivo,22224,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618591,BAO_0000218,
7368,1,A,0,,,In vivo,22224,Bioavailability in monkey (dose 2 mg/kg),,monkey,,,,9443.0,U,Autocuration,CHEMBL618592,BAO_0000218,
7369,1,A,0,,,In vivo,22224,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL876488,BAO_0000218,
7370,1,A,0,,,In vivo,22224,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618593,BAO_0000218,
7371,1,A,0,,,In vivo,22224,Bioavailability in monkey (i.d. dosing),,monkey,,,,9443.0,U,Autocuration,CHEMBL618594,BAO_0000218,
7372,1,A,0,,,In vivo,22224,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL618595,BAO_0000218,
7373,1,A,0,,,,22224,Clearance of the drug was measured in cynomolgus,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621469,BAO_0000019,
7374,1,A,0,,,In vivo,22224,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621470,BAO_0000218,
7375,1,A,0,,,In vivo,22224,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621471,BAO_0000218,
7376,1,A,0,,,In vivo,22224,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,1969.0,Macaca mulatta,,,,9544.0,U,Autocuration,CHEMBL621472,BAO_0000218,
7377,1,A,0,,,In vivo,22224,Plasma clearance in rhesus monkey was determined,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621473,BAO_0000218,
7378,1,A,0,,,In vivo,22224,Plasma clearance in monkey after administration of 1 mg/kg iv,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621474,BAO_0000218,
7379,1,A,0,,,In vivo,22224,Plasma clearance in cynomolgus monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621475,BAO_0000218,
7380,1,A,0,,,In vivo,22224,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL621476,BAO_0000218,
7381,1,A,0,,,In vivo,22224,Plasma clearance after peroral administration at 10 mpk in Rhesus,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL624290,BAO_0000218,
7382,1,A,0,,,In vivo,22224,The total clearance was determined after intravenous administration in cynomolgus monkeys,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL624291,BAO_0000218,
7383,1,A,0,,,In vivo,22224,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL624292,BAO_0000218,
7384,1,A,0,,,In vivo,22224,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL624293,BAO_0000218,
7385,1,A,0,,,In vivo,22224,Tested for Clearance upon iv administration to african green monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL624294,BAO_0000218,
7386,1,A,0,,,In vivo,22224,Clearance in monkey,,Cercopithecidae,,,,9527.0,U,Autocuration,CHEMBL624295,BAO_0000218,
7387,1,A,1,,,In vivo,50588,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624296,BAO_0000218,
7388,1,A,1,,,In vivo,50588,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624297,BAO_0000218,
7389,1,A,1,,,In vivo,50588,Half life was evaluated after intravenous administration to dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624298,BAO_0000218,
7390,1,A,1,,,,50588,Half life was evaluated in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624299,BAO_0000218,
7391,1,A,1,,,,50588,Half life was evaluated in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624300,BAO_0000218,
7392,1,A,1,,,In vivo,50588,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624301,BAO_0000218,
7393,1,A,1,,,In vivo,50588,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624302,BAO_0000218,
7394,1,A,1,,,In vivo,50588,Half life period after intravenous administration in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL876026,BAO_0000218,
7395,1,A,1,,,In vivo,50588,Half life period after oral administration (2.5 mg/kg) in dog was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624303,BAO_0000218,
7396,1,A,1,,,,50588,Half life period at a dose of 1 uM/kg in dog was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624304,BAO_0000218,
7397,1,A,1,,,In vivo,50588,Half life period was determine after peroral administration at 10 mpk in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624305,BAO_0000218,
7398,1,A,1,,,In vivo,50588,Half life period was determine after peroral administration at 5 mpk in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624306,BAO_0000218,
7399,1,A,1,,,,50588,Half life period was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624307,BAO_0000218,
7400,1,A,1,,,,50588,Half life period was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624308,BAO_0000218,
7401,1,A,1,,,In vivo,50588,Half life period by iv administration in dog at a dose of 6 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624309,BAO_0000218,
7402,1,A,1,,,,50588,Half life period was evaluated in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624310,BAO_0000218,
7403,1,A,1,,,In vivo,50588,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625003,BAO_0000218,
7404,1,A,1,,,In vivo,50588,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625004,BAO_0000218,
7405,1,A,1,,,In vivo,50588,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625005,BAO_0000218,
7406,1,A,1,,,In vivo,50588,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL873813,BAO_0000218,
7407,1,A,1,,,In vivo,50588,Half-life after oral dose of compound at 3 mg/kg in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625006,BAO_0000218,
7408,1,A,1,,,In vivo,50588,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625007,BAO_0000218,
7409,1,A,1,,,In vivo,50588,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL876027,BAO_0000218,
7410,1,A,1,,,In vivo,50588,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625008,BAO_0000218,
7411,1,A,1,,,In vivo,50588,Half-life of compound in dog following p.o. administration of 1 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625009,BAO_0000218,
7412,1,A,1,,,,50588,Half-life of compound in plasma of dog was determined,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625010,BAO_0000218,
7413,1,A,1,,,,50588,Half-life of compound was determined in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625011,BAO_0000218,
7414,1,A,1,,,In vivo,50588,Half-life after administration of 4 mg/Kg oral dose in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621553,BAO_0000218,
7415,1,A,1,,,In vivo,50588,Half-life after intravenous administration of 1 mg/kg/h in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621554,BAO_0000218,
7416,1,A,1,,,,50588,Half-life in Dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621555,BAO_0000218,
7417,1,A,1,,,,50588,Half-life in Dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621556,BAO_0000218,
7418,1,A,1,,,,50588,Half-life in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621557,BAO_0000218,
7419,1,A,1,,,In vivo,50588,Half-life in dog after oral administration at 1 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621558,BAO_0000218,
7420,1,A,1,,,In vivo,50588,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621559,BAO_0000218,
7421,1,A,1,,,,50588,Half-life in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621560,BAO_0000218,
7422,1,A,1,,,,50588,Half-life in dogs; ND indicates not determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL876028,BAO_0000218,
7423,1,A,1,,,,50588,Half-life in plasma of dog,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621561,BAO_0000218,
7424,1,A,1,,,,50588,Half-life in plasma of dog at dose of 3-10 mgkg,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621562,BAO_0000218,
7425,1,A,1,,,In vivo,50588,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621563,BAO_0000218,
7426,1,A,1,,,In vivo,50588,Half-life was measured in dog after an iv dose of 1 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621564,BAO_0000218,
7427,1,A,1,,,In vivo,50588,Half-life was measured in dogs after an oral dose of 10 uM/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621565,BAO_0000218,
7428,1,A,1,,,In vivo,50588,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621566,BAO_0000218,
7429,1,A,1,,,In vivo,50588,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621567,BAO_0000218,
7430,1,A,1,,,In vivo,50588,Half-life of the compound after 0.3 mg/kg po administration in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622978,BAO_0000218,
7431,1,A,1,,,In vivo,50588,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL873814,BAO_0000218,
7432,1,A,1,,,In vivo,50588,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623219,BAO_0000218,
7433,1,A,1,,,In vivo,50588,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624477,BAO_0000218,
7434,1,A,1,,,,50588,t1/2 in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624478,BAO_0000218,
7435,1,A,1,,,,50588,Half-life period measured in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624479,BAO_0000218,
7436,1,A,1,,,In vivo,50588,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624480,BAO_0000218,
7437,1,A,1,,,In vivo,50588,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623595,BAO_0000218,
7438,1,A,1,,,In vivo,50588,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623596,BAO_0000218,
7439,1,A,1,,,In vitro,50588,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623597,BAO_0000218,
7440,1,A,1,,,In vivo,50588,In vivo half life period was calculated at 1 mg/kg in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623598,BAO_0000218,
7441,1,A,1,,,In vivo,50588,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623599,BAO_0000218,
7442,1,A,1,,,In vivo,50588,Longer half-life in dog (i.v.) at 0.5 mpk,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623600,BAO_0000218,
7443,1,A,1,,,In vivo,50588,Oral bioavailability in dog (dose 5 uM/kg),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623601,BAO_0000218,
7444,1,A,1,,,In vivo,50588,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623602,BAO_0000218,
7445,1,A,1,,,In vivo,50588,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623603,BAO_0000218,
7446,1,A,1,,,In vivo,50588,Bioavailability in dog (dose 1 mg/kg i.v.),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623604,BAO_0000218,
7447,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,2048.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623605,BAO_0000218,
7448,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,2048.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623606,BAO_0000218,
7449,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,2048.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623607,BAO_0000218,
7450,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,2048.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623608,BAO_0000218,
7451,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,2048.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623609,BAO_0000218,
7452,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,2048.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623610,BAO_0000218,
7453,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,2385.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623611,BAO_0000218,
7454,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,2385.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623612,BAO_0000218,
7455,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,2385.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623613,BAO_0000218,
7456,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,2385.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623614,BAO_0000218,
7457,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,2385.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623615,BAO_0000218,
7458,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,2385.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623616,BAO_0000218,
7459,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,2385.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623617,BAO_0000218,
7460,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,14.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL875944,BAO_0000218,
7461,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,14.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623618,BAO_0000218,
7462,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,14.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623619,BAO_0000218,
7463,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,14.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623620,BAO_0000218,
7464,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,14.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623621,BAO_0000218,
7465,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,14.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623622,BAO_0000218,
7466,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,14.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623623,BAO_0000218,
7467,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623624,BAO_0000218,
7468,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618521,BAO_0000218,
7469,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618522,BAO_0000218,
7470,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618523,BAO_0000218,
7471,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618524,BAO_0000218,
7472,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618525,BAO_0000218,
7473,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624586,BAO_0000218,
7474,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,945.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624587,BAO_0000218,
7475,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,945.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624588,BAO_0000218,
7476,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,945.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624589,BAO_0000218,
7477,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,945.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624590,BAO_0000218,
7478,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,945.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624591,BAO_0000218,
7479,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,945.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624592,BAO_0000218,
7480,1,A,1,,,In vivo,50594,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,945.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624593,BAO_0000218,
7481,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624594,BAO_0000218,
7482,1,A,1,,,In vivo,50597,Tested for the bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624595,BAO_0000218,
7483,1,A,1,,,In vivo,50597,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624596,BAO_0000218,
7484,1,A,1,,,In vivo,50597,Bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624597,BAO_0000218,
7485,1,A,1,,,In vivo,50597,Bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624598,BAO_0000218,
7486,1,A,1,,,In vivo,50597,Bioavailability in rat (dose 3-10 mg/kg),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624599,BAO_0000218,
7487,1,A,1,,,In vivo,50597,Bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875166,BAO_0000218,
7488,1,A,1,,,In vivo,50597,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624600,BAO_0000218,
7489,1,A,1,,,In vivo,50597,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624601,BAO_0000218,
7490,1,A,1,,,In vivo,50597,Half life after oral administration was determined in rats at 6 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624602,BAO_0000218,
7491,1,A,1,,,,50597,Half life was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624603,BAO_0000218,
7492,1,A,1,,,In vivo,50597,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624604,BAO_0000218,
7493,1,A,1,,,In vivo,50597,Plasma half life in rat at oral dose 2.8 mg/mk body weight,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624605,BAO_0000218,
7494,1,A,1,,,,50597,Half life in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624606,BAO_0000218,
7495,1,A,1,,,In vivo,50597,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624607,BAO_0000218,
7496,1,A,1,,,,50597,Hill coefficient of the compound,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624608,BAO_0000218,
7497,1,A,1,,,,50597,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624609,BAO_0000218,
7498,1,A,1,,,,50597,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624610,BAO_0000218,
7499,1,A,1,,,,50597,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624611,BAO_0000218,
7500,1,A,1,,,,50597,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624612,BAO_0000218,
7501,1,A,1,,,,50597,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875167,BAO_0000218,
7502,1,A,1,,,,50597,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624613,BAO_0000218,
7503,1,A,1,,,,50597,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624614,BAO_0000218,
7504,1,A,1,,,,50597,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624392,BAO_0000218,
7505,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624393,BAO_0000218,
7506,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624394,BAO_0000218,
7507,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624395,BAO_0000218,
7508,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624396,BAO_0000218,
7509,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624397,BAO_0000218,
7510,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624398,BAO_0000218,
7511,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624399,BAO_0000218,
7512,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624400,BAO_0000218,
7513,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624401,BAO_0000218,
7514,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624402,BAO_0000218,
7515,1,A,1,,,In vivo,50597,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624403,BAO_0000218,
7516,1,A,1,,,In vivo,50597,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624404,BAO_0000218,
7517,1,A,1,,,In vivo,50597,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624405,BAO_0000218,
7518,1,A,1,,,In vivo,50597,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624406,BAO_0000218,
7519,1,A,1,,,In vivo,50597,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624407,BAO_0000218,
7520,1,A,1,,,In vivo,50597,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624408,BAO_0000218,
7521,1,A,1,,,In vivo,50597,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618644,BAO_0000218,
7522,1,A,1,,,In vivo,50597,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618645,BAO_0000218,
7523,1,A,1,,,In vivo,50597,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618646,BAO_0000218,
7524,1,A,1,,,In vivo,50597,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618647,BAO_0000218,
7525,1,A,1,,,In vivo,50597,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618648,BAO_0000218,
7526,1,A,1,,,In vivo,50597,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618649,BAO_0000218,
7527,1,A,1,,,In vivo,50597,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618650,BAO_0000218,
7528,1,A,1,,,In vivo,50597,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618651,BAO_0000218,
7529,1,A,1,,,In vivo,50597,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876497,BAO_0000218,
7530,1,A,1,,,In vivo,50597,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618652,BAO_0000218,
7531,1,A,1,,,In vivo,50597,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618653,BAO_0000218,
7532,1,A,1,,,In vivo,50597,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618654,BAO_0000218,
7533,1,A,1,,,,50597,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618655,BAO_0000218,
7534,1,A,1,,,,50597,Compound was tested for solubility in water,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618656,BAO_0000218,
7535,1,P,0,,,,22229,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),,,,,,,U,Intermediate,CHEMBL618657,BAO_0000100,
7536,1,A,1,,,,50597,Solubility was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618658,BAO_0000218,
7537,1,A,1,,,,50597,solubility in water (ug/mL) at 37 degree C.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618659,BAO_0000218,
7538,1,A,1,,,,50597,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618660,BAO_0000218,
7539,1,A,1,,,,50597,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618661,BAO_0000218,
7540,1,A,1,,,,50597,Half life in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL873807,BAO_0000218,
7541,1,A,1,,,,50597,Half life in Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618662,BAO_0000218,
7542,1,A,1,,,In vivo,50597,Half life period after 3 mg/kg iv administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618663,BAO_0000218,
7543,1,A,1,,,In vivo,50597,Half life period after 3 mg/kg iv administration in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618664,BAO_0000218,
7544,1,A,1,,,In vivo,50597,Half life period after 3 mg/kg iv administration in the rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618665,BAO_0000218,
7545,1,A,1,,,,50597,Half life period in female Sprague-Dawley rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876498,BAO_0000218,
7546,1,A,1,,,,50597,Half life period in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618666,BAO_0000218,
7547,1,A,1,,,,50597,Half-life in rats was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620440,BAO_0000218,
7548,1,A,1,,,,50597,Half-life in rats with metabolic oxidation,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620441,BAO_0000218,
7549,1,A,1,,,,50597,Half-life in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620442,BAO_0000218,
7550,1,A,1,,,In vivo,50597,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620443,BAO_0000218,
7551,1,A,1,,,In vivo,50597,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620444,BAO_0000218,
7552,1,A,1,,,In vivo,50597,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620445,BAO_0000218,
7553,1,A,1,,,In vivo,50597,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620446,BAO_0000218,
7554,1,A,1,,,,50597,Biological half-life measured in plasma of rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620447,BAO_0000218,
7555,1,A,1,,,,50597,Biological half-life measured in plasma of rat; 22-25,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621129,BAO_0000218,
7556,1,A,1,,,,50597,Biological half-life measured in plasma of rat; 9-16,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621130,BAO_0000218,
7557,1,A,1,,,In vivo,50597,Compound was evaluated for its half life when administered intravenously in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL873808,BAO_0000218,
7558,1,A,1,,,In vivo,50597,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876598,BAO_0000218,
7559,1,A,1,,,In vivo,50597,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621131,BAO_0000218,
7560,1,A,1,,,In vivo,50597,Half life (T1/2) after oral administration in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621132,BAO_0000218,
7561,1,A,1,,,In vivo,50597,Half life of compound after iv administration of 20 mg/kg dose in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621133,BAO_0000218,
7562,1,A,1,,,In vivo,50597,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Expert,CHEMBL621312,BAO_0000218,
7563,1,A,1,,,,50597,Half life of compound was determined in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621313,BAO_0000218,
7564,1,A,1,,,,50597,Half life of compound was determined in rat blood,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621314,BAO_0000218,
7565,1,A,1,,,In vivo,50597,Half life at 1 mg/kg was determined in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621315,BAO_0000218,
7566,1,A,1,,,In vivo,50597,Half life at 10 mg/kg was determined in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621316,BAO_0000218,
7567,1,A,1,,,,50597,Half life in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621317,BAO_0000218,
7568,1,A,1,,,,50597,Half life in rats in hours,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621318,BAO_0000218,
7569,1,A,1,,,In vivo,50597,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621319,BAO_0000218,
7570,1,A,1,,,In vivo,50597,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621377,BAO_0000218,
7571,1,A,1,,,,50597,Half life was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621378,BAO_0000218,
7572,1,A,1,,,In vivo,50597,Half life after i.v. administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876599,BAO_0000218,
7573,1,A,1,,,In vivo,50597,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621379,BAO_0000218,
7574,1,A,1,,,,50597,Half life in rat plasma,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621380,BAO_0000218,
7575,1,A,1,,,,50597,Half life in rat plasma; Not detected,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621381,BAO_0000218,
7576,1,A,1,,,,50597,Half life in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618515,BAO_0000218,
7577,1,A,1,,,In vivo,50597,Half life period of compound was determined after peroral administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618516,BAO_0000218,
7578,1,A,1,,,In vivo,50597,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618517,BAO_0000218,
7579,1,A,1,,,,50597,Half life period in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618518,BAO_0000218,
7580,1,A,1,,,In vivo,50597,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618519,BAO_0000218,
7581,1,A,1,,,In vivo,50597,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618698,BAO_0000218,
7582,1,A,1,,,In vivo,50597,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618862,BAO_0000218,
7583,1,A,1,,,In vivo,50597,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618863,BAO_0000218,
7584,1,A,1,,,In vivo,50597,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618864,BAO_0000218,
7585,1,A,1,,,In vivo,50597,Half life time in rat the dose of 2 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618865,BAO_0000218,
7586,1,A,1,,,In vivo,50597,Half-life 24 hr after 10 mg/kg iv administration in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618866,BAO_0000218,
7587,1,A,1,,,In vivo,50597,Half-life 24 hr after 2 mg/kg iv administration in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618867,BAO_0000218,
7588,1,A,1,,,,50597,Half-life consistent with the observed metabolic steady state in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875828,BAO_0000218,
7589,1,A,1,,,In vivo,50597,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618868,BAO_0000218,
7590,1,A,1,,,,50597,Half-life for oxidative metabolic stability was determined using male human,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618869,BAO_0000218,
7591,1,A,1,,,In vivo,50597,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618870,BAO_0000218,
7592,1,A,1,,,,50597,Half-life in rat plasma,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618871,BAO_0000218,
7593,1,A,1,,,,50597,Half-life in rat plasma was determined,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618872,BAO_0000218,
7594,1,A,1,,,,50597,Half-life in rats was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL873816,BAO_0000218,
7595,1,A,0,,,,22224,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,,,,,,,U,Autocuration,CHEMBL618873,BAO_0000218,
7596,1,A,0,,,,22224,Area under curve after oral dose of 0.1 mg//kg,,,,,,,U,Autocuration,CHEMBL621602,BAO_0000019,
7597,1,A,0,,,,22224,Area under curve after oral dose of 0.3 mg/kg,,,,,,,U,Autocuration,CHEMBL621603,BAO_0000218,
7598,1,A,0,,,,22224,Area under curve after oral dose of 1 mg/kg,,,,,,,U,Autocuration,CHEMBL621604,BAO_0000218,
7599,1,A,0,,,,22224,Area under curve after oral dose of 10 mg/kg,,,,,,,U,Autocuration,CHEMBL621605,BAO_0000218,
7600,1,A,0,,,,22224,Area under curve after oral dose of 23.4 mg/kg,,,,,,,U,Autocuration,CHEMBL621606,BAO_0000218,
7601,1,A,0,,,,22224,Area under curve after oral dose of 3 mg/kg,,,,,,,U,Autocuration,CHEMBL621607,BAO_0000218,
7602,1,A,0,,,,22224,Area under curve after oral dose of 3.87 mg/kg,,,,,,,U,Autocuration,CHEMBL621608,BAO_0000218,
7603,1,A,0,,,,22224,Area under curve was determined,,,,,,,U,Autocuration,CHEMBL621609,BAO_0000019,
7604,1,A,0,,,,22224,Area under curve at a dose of 10 mg/kg,,,,,,,U,Autocuration,CHEMBL621610,BAO_0000218,
7605,1,A,1,,,,50597,Area under curve was determined; ND=No data,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621611,BAO_0000218,
7606,1,A,1,,,,50597,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621612,BAO_0000218,
7607,1,A,1,,,,50597,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622308,BAO_0000218,
7608,1,A,1,,,,50597,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622309,BAO_0000218,
7609,1,A,1,,,,50597,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622310,BAO_0000218,
7610,1,A,1,,,,50597,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622311,BAO_0000218,
7611,1,A,1,,,,50597,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622312,BAO_0000218,
7612,1,A,1,,,,50597,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622931,BAO_0000218,
7613,1,A,1,,,,50597,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622932,BAO_0000218,
7614,1,A,1,,,,50597,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622736,BAO_0000218,
7615,1,A,1,,,,50597,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622737,BAO_0000218,
7616,1,A,1,,,,50597,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622738,BAO_0000218,
7617,1,A,1,,,,50597,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622739,BAO_0000218,
7618,1,A,1,,,,50597,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622740,BAO_0000218,
7619,1,A,1,,,,50597,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622741,BAO_0000218,
7620,1,A,1,,,,50597,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622742,BAO_0000218,
7621,1,A,1,,,,50597,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622743,BAO_0000218,
7622,1,A,1,,,,50594,AUC in mice,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622744,BAO_0000218,
7623,1,A,0,,,,22224,Area under curve was measured from the graph obtained from concentration Vs time,,,,,,,U,Autocuration,CHEMBL624134,BAO_0000019,
7624,1,A,0,,,,22224,Area under curve value of compound per hour after oral administration,,,,,,,U,Autocuration,CHEMBL624135,BAO_0000019,
7625,1,A,1,,,,50597,Area under curve was determined after oral administration in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624136,BAO_0000218,
7626,1,A,1,,,,50597,Area under curve was determined after oral administration in rats; No data,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624137,BAO_0000218,
7627,1,A,1,,,,50597,Area under curve was determined after oral administration in rats;No data,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624320,BAO_0000218,
7628,1,A,1,,,,50588,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624321,BAO_0000218,
7629,1,A,1,,,,50597,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624322,BAO_0000218,
7630,1,A,1,,,,50597,Area under curve was determined for the compound after iv dose of 5.06 in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624323,BAO_0000218,
7631,1,A,1,,,,50597,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624324,BAO_0000218,
7632,1,A,1,,,,50597,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624325,BAO_0000218,
7633,1,A,1,,,,50597,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624326,BAO_0000218,
7634,1,A,1,,,,50597,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624327,BAO_0000218,
7635,1,A,1,,,,50597,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624328,BAO_0000218,
7636,1,A,1,,,,50588,Area under curve was determined in Dogs after peroral administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627848,BAO_0000218,
7637,1,A,1,,,,50597,Area under curve was determined in Rats after peroral administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627849,BAO_0000218,
7638,1,A,1,,,,50597,Area under curve was determined in carotid blood of rat when administered intradermally,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627850,BAO_0000218,
7639,1,A,1,,,,50597,Area under curve was determined in portal blood of rat when administered intradermally,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627851,BAO_0000218,
7640,1,A,1,,,,50594,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627852,BAO_0000218,
7641,1,A,1,,,,50594,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627853,BAO_0000218,
7642,1,A,1,,,,50594,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627854,BAO_0000218,
7643,1,A,1,,,,50594,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627855,BAO_0000218,
7644,1,A,1,,,,50594,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627856,BAO_0000218,
7645,1,A,1,,,,50594,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL875339,BAO_0000218,
7646,1,A,1,,,,50594,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627857,BAO_0000218,
7647,1,A,1,,,In vivo,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627858,BAO_0000218,
7648,1,A,1,,,,50597,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627859,BAO_0000218,
7649,1,A,1,,,,50597,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627860,BAO_0000218,
7650,1,A,1,,,,50597,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627019,BAO_0000218,
7651,1,A,1,,,,50597,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627020,BAO_0000218,
7652,1,A,1,,,,50597,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627021,BAO_0000218,
7653,1,A,1,,,,50597,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627022,BAO_0000218,
7654,1,A,1,,,,50597,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627023,BAO_0000218,
7655,1,A,1,,,,50597,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627024,BAO_0000218,
7656,1,A,1,,,,50597,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627025,BAO_0000218,
7657,1,A,1,,,,50597,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627026,BAO_0000218,
7658,1,A,1,,,,50597,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627027,BAO_0000218,
7659,1,A,1,,,,50597,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627028,BAO_0000218,
7660,1,A,1,,,,50597,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627029,BAO_0000218,
7661,1,A,1,,,,50597,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627030,BAO_0000218,
7662,1,A,1,,,,50597,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627031,BAO_0000218,
7663,1,A,1,,,,50597,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627032,BAO_0000218,
7664,1,A,1,,,,50597,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627033,BAO_0000218,
7665,1,A,1,,,,50597,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627034,BAO_0000218,
7666,1,A,1,,,,50597,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627035,BAO_0000218,
7667,1,A,1,,,,50597,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627036,BAO_0000218,
7668,1,A,1,,,,50597,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875340,BAO_0000218,
7669,1,A,1,,,,50597,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627037,BAO_0000218,
7670,1,A,1,,,,50597,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627038,BAO_0000218,
7671,1,A,1,,,,50597,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627039,BAO_0000218,
7672,1,A,1,,,,50597,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627040,BAO_0000218,
7673,1,A,1,,,,50597,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624663,BAO_0000218,
7674,1,A,1,,,,50597,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625963,BAO_0000218,
7675,1,A,1,,,,50597,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876799,BAO_0000218,
7676,1,A,1,,,,50597,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626133,BAO_0000218,
7677,1,A,1,,,,50597,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626134,BAO_0000218,
7678,1,A,1,,,,50597,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626135,BAO_0000218,
7679,1,A,1,,,,50597,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626136,BAO_0000218,
7680,1,A,1,,,,50597,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626137,BAO_0000218,
7681,1,A,1,,,,50597,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626138,BAO_0000218,
7682,1,A,1,,,,50597,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626139,BAO_0000218,
7683,1,A,1,,,In vivo,50597,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626140,BAO_0000218,
7684,1,A,1,,,In vivo,50597,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626141,BAO_0000218,
7685,1,A,1,,,,50597,C24h in rat p.o. at 20 mg/kg concentration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626142,BAO_0000218,
7686,1,A,1,,,In vivo,50597,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627930,BAO_0000218,
7687,1,A,1,,,In vivo,50597,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627931,BAO_0000218,
7688,1,A,1,,,In vivo,50597,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627932,BAO_0000218,
7689,1,A,1,,,In vivo,50597,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627933,BAO_0000218,
7690,1,A,1,,,In vivo,50597,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627934,BAO_0000218,
7691,1,A,1,,,In vivo,50597,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627935,BAO_0000218,
7692,1,A,1,,,In vivo,50597,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627936,BAO_0000218,
7693,1,A,1,,,In vivo,50597,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627937,BAO_0000218,
7694,1,A,1,,,In vivo,50597,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627938,BAO_0000218,
7695,1,A,1,,,In vivo,50597,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627939,BAO_0000218,
7696,1,A,1,,,In vivo,50597,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627940,BAO_0000218,
7697,1,A,1,,,In vivo,50597,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627941,BAO_0000218,
7698,1,A,1,,,In vivo,50597,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876800,BAO_0000218,
7699,1,A,1,,,In vivo,50597,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627942,BAO_0000218,
7700,1,A,1,,,In vivo,50597,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627943,BAO_0000218,
7701,1,A,1,,,In vivo,50597,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627944,BAO_0000218,
7702,1,A,1,,,In vivo,50597,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627945,BAO_0000218,
7703,1,A,1,,,In vivo,50597,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628584,BAO_0000218,
7704,1,A,1,,,In vivo,50597,Biodistribution in rat blood in the presence of GdDTPA at 15 min,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628585,BAO_0000218,
7705,1,A,1,,,In vivo,50597,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628586,BAO_0000218,
7706,1,A,1,,,In vivo,50597,Biodistribution in rat blood in the presence of GdDTPA at 30 min,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628587,BAO_0000218,
7707,1,A,1,,,In vivo,50597,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628588,BAO_0000218,
7708,1,A,1,,,In vivo,50597,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628589,BAO_0000218,
7709,1,A,1,,,In vivo,50597,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625304,BAO_0000218,
7710,1,A,1,,,In vivo,50597,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625305,BAO_0000218,
7711,1,A,1,,,In vivo,50597,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625306,BAO_0000218,
7712,1,A,1,,,In vivo,50597,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625307,BAO_0000218,
7713,1,A,1,,,In vivo,50597,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625308,BAO_0000218,
7714,1,A,1,,,In vivo,50597,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627740,BAO_0000218,
7715,1,A,1,,,In vivo,50597,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627741,BAO_0000218,
7716,1,A,1,,,In vivo,50597,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627742,BAO_0000218,
7717,1,A,1,,,In vivo,50597,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627743,BAO_0000218,
7718,1,A,1,,,In vivo,50597,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627744,BAO_0000218,
7719,1,A,1,,,In vivo,50597,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627745,BAO_0000218,
7720,1,A,1,,,In vivo,50597,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627746,BAO_0000218,
7721,1,A,1,,,In vivo,50597,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627747,BAO_0000218,
7722,1,A,1,,,In vivo,50597,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876810,BAO_0000218,
7723,1,A,1,,,In vivo,50597,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627748,BAO_0000218,
7724,1,A,1,,,In vivo,50597,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627749,BAO_0000218,
7725,1,A,1,,,In vivo,50597,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627750,BAO_0000218,
7726,1,A,1,,,In vivo,50597,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618728,BAO_0000218,
7727,1,A,1,,,In vivo,50597,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618729,BAO_0000218,
7728,1,A,1,,,In vivo,50597,Biodistribution in rat bone in the presence of GdDTPA at 15 min,10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618730,BAO_0000218,
7729,1,A,1,,,In vivo,50597,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618731,BAO_0000218,
7730,1,A,1,,,In vivo,50597,Biodistribution in rat bone in the presence of GdDTPA at 30 min,10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618732,BAO_0000218,
7731,1,A,1,,,In vivo,50597,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618733,BAO_0000218,
7732,1,A,1,,,In vivo,50597,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618734,BAO_0000218,
7733,1,A,1,,,In vivo,50597,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618735,BAO_0000218,
7734,1,A,1,,,In vivo,50597,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876602,BAO_0000218,
7735,1,A,1,,,In vivo,50597,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618736,BAO_0000218,
7736,1,A,1,,,In vivo,50597,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618737,BAO_0000218,
7737,1,A,1,,,In vivo,50597,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618738,BAO_0000218,
7738,1,A,1,,,In vivo,50597,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618739,BAO_0000218,
7739,1,A,1,,,In vivo,50597,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618740,BAO_0000218,
7740,1,A,1,,,In vivo,50597,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618741,BAO_0000218,
7741,1,A,1,,,In vivo,50597,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618742,BAO_0000218,
7742,1,A,1,,,In vivo,50597,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618743,BAO_0000218,
7743,1,A,1,,,In vivo,50597,Half-life from rat plasma at a single oral dose of 25 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618744,BAO_0000218,
7744,1,A,1,,,,50597,Half-life in male rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618745,BAO_0000218,
7745,1,A,1,,,In vivo,50597,Half-life in rat after peroral administration at 10 mg/kg concentration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620479,BAO_0000218,
7746,1,A,1,,,In vivo,50597,Half-life in rat after peroral administration at 5 mg/kg concentration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620480,BAO_0000218,
7747,1,A,1,,,In vivo,50597,Half-life in rat at a dose of 3 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620481,BAO_0000218,
7748,1,A,1,,,,50597,Half-life was evaluated in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620482,BAO_0000218,
7749,1,A,1,,,,50597,Half-life was measured in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876603,BAO_0000218,
7750,1,A,1,,,In vivo,50597,Half-life period for the compound was determined in rats at 50 mg/kg dose,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620483,BAO_0000218,
7751,1,A,1,,,In vivo,50597,Half-life period in rats after intravenous administration at 5 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620484,BAO_0000218,
7752,1,A,1,,,In vivo,50597,Half-life period in rat at 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620485,BAO_0000218,
7753,1,A,1,,,In vivo,50597,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620486,BAO_0000218,
7754,1,A,1,,,In vivo,50597,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620487,BAO_0000218,
7755,1,A,1,,,In vivo,50597,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620488,BAO_0000218,
7756,1,A,1,,,In vivo,50597,Half-life time in rat the dose of 2 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620489,BAO_0000218,
7757,1,A,1,,,In vivo,50597,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620490,BAO_0000218,
7758,1,A,1,,,In vivo,50597,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620491,BAO_0000218,
7759,1,A,1,,,In vivo,50597,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876604,BAO_0000218,
7760,1,A,1,,,In vivo,50597,Oral half life was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620492,BAO_0000218,
7761,1,A,1,,,In vivo,50597,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620493,BAO_0000218,
7762,1,A,1,,,In vivo,50597,Pharmacokinetic property (t1/2) in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620494,BAO_0000218,
7763,1,A,1,,,,50597,Plasma elimination half-life was determined,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620495,BAO_0000218,
7764,1,A,1,,,In vivo,50597,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620496,BAO_0000218,
7765,1,A,1,,,In vivo,50597,Plasma half life was observed after intravenous administration in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620497,BAO_0000218,
7766,1,A,1,,,,50597,Plasma half-life was determined,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620498,BAO_0000218,
7767,1,A,1,,,In vivo,50597,Plasma half-life following oral administration in Fisher rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620499,BAO_0000218,
7768,1,A,1,,,,50597,Plasma half-life in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620500,BAO_0000218,
7769,1,A,1,,,In vivo,50597,Plasmatic Half-life after intravenous administration to rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL873809,BAO_0000218,
7770,1,A,1,,,In vivo,50597,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620501,BAO_0000218,
7771,1,A,1,,,In vivo,50597,Terminal half life after intravenous administration (1 mg/kg) in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620502,BAO_0000218,
7772,1,A,1,,,In vivo,50597,Terminal half life in Rat at a oral dose of 5 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620503,BAO_0000218,
7773,1,A,1,,,In vivo,50597,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620504,BAO_0000218,
7774,1,A,1,,,In vivo,50597,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876605,BAO_0000218,
7775,1,A,1,,,In vivo,50597,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620505,BAO_0000218,
7776,1,A,1,,,In vivo,50597,plasma half life was observed after intravenous administration in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL873811,BAO_0000218,
7777,1,A,1,,,In vivo,50597,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Expert,CHEMBL624016,BAO_0000218,
7778,1,A,1,,,,50597,Half life of compound determined in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624017,BAO_0000218,
7779,1,A,1,,,,50597,Mean residence time determined in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624018,BAO_0000218,
7780,1,A,1,,,,50597,Plasma half life determined in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624019,BAO_0000218,
7781,1,A,1,,,In vivo,50597,Compound was evaluated for Tmax in brain after intravenous administration in male rats,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624020,BAO_0000218,
7782,1,A,1,,,In vivo,50597,Compound was evaluated for pharmacokinetic parameter maximum time period,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624201,BAO_0000218,
7783,1,A,1,,,In vivo,50597,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL872528,BAO_0000218,
7784,1,A,1,,,In vivo,50597,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624202,BAO_0000218,
7785,1,A,1,,,In vivo,50597,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624203,BAO_0000218,
7786,1,A,1,,,In vivo,50597,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624350,BAO_0000218,
7787,1,A,1,,,In vivo,50597,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621320,BAO_0000218,
7788,1,A,1,,,In vivo,50597,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621321,BAO_0000218,
7789,1,A,1,,,,50597,Maximum time (Tmax) required to reach Cmax in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621322,BAO_0000218,
7790,1,A,1,,,In vivo,50597,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621323,BAO_0000218,
7791,1,A,1,,,In vivo,50597,Maximum time of clearance of compound in rats after peroral administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621324,BAO_0000218,
7792,1,A,1,,,,50597,Maximum time at the dose of 2 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621325,BAO_0000218,
7793,1,A,1,,,In vivo,50597,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875837,BAO_0000218,
7794,1,A,1,,,In vivo,50597,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621326,BAO_0000218,
7795,1,A,1,,,In vivo,50597,Tmax in Guinea pig (PO dose),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621327,BAO_0000218,
7796,1,A,1,,,In vivo,50597,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621328,BAO_0000218,
7797,1,A,1,,,In vivo,50597,Pharmacokinetic parameter (Tmax) in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621329,BAO_0000218,
7798,1,A,1,,,In vivo,50597,Pharmacokinetic parameter (Tmax) was estimated,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621330,BAO_0000218,
7799,1,A,1,,,In vivo,50597,Pharmacokinetic property (Tmax) in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621331,BAO_0000218,
7800,1,A,1,,,In vivo,50597,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621332,BAO_0000218,
7801,1,A,1,,,In vivo,50597,T max in Rat at a oral dose of 5 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621333,BAO_0000218,
7802,1,A,1,,,In vivo,50597,T max was determined at 10 mg/kg po dose in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621334,BAO_0000218,
7803,1,A,1,,,,50594,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621335,BAO_0000218,
7804,1,A,1,,,,50588,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621336,BAO_0000218,
7805,1,A,1,,,,50597,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621337,BAO_0000218,
7806,1,A,1,,,,50588,Area under curve was measured after i.v. administration into Beagle dog.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621338,BAO_0000218,
7807,1,A,1,,,,50588,Area under curve was measured after iv administration into Beagle dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL875838,BAO_0000218,
7808,1,A,1,,,,50588,Area under curve was measured after po administration into Beagle dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621339,BAO_0000218,
7809,1,A,1,,,,50588,Area under curve was measured after po administration into Beagle dog.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621340,BAO_0000218,
7810,1,A,0,,,,22224,Area under curve was measured at peroral dose of 3 mg/kg,,,,,,,U,Autocuration,CHEMBL621341,BAO_0000218,
7811,1,A,0,,,,22224,Area under curve was measured by using concentration Vs time,,,,,,,U,Autocuration,CHEMBL621342,BAO_0000019,
7812,1,A,0,,,,22224,Area under curve was measured by using concentration Vs time; not tested,,,,,,,U,Autocuration,CHEMBL621343,BAO_0000019,
7813,1,A,1,,,,50594,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621344,BAO_0000218,
7814,1,A,1,,,,50594,Area under curve(AUC) was measured in mice after oral administration.,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621345,BAO_0000218,
7815,1,A,0,,,,22224,Area under curve(AUC) value of the compound,,,,,,,U,Autocuration,CHEMBL621346,BAO_0000019,
7816,1,A,0,,,,22224,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,,,,,,,U,Autocuration,CHEMBL621347,BAO_0000218,
7817,1,A,1,,,,50588,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621348,BAO_0000218,
7818,1,A,0,,,,22224,Area under curve(carotid artery) was determined by the availability in blood,178.0,,,,,,U,Autocuration,CHEMBL621349,BAO_0000019,
7819,1,A,0,,,,22224,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,178.0,,,,,,U,Autocuration,CHEMBL621350,BAO_0000019,
7820,1,A,0,,,,22224,Area under curve(carotid artery) was determined by the availability in blood; No data,178.0,,,,,,U,Autocuration,CHEMBL875839,BAO_0000019,
7821,1,A,0,,,,22224,Area under curve(portal vein) was determined by the availability in blood,178.0,,,,,,U,Autocuration,CHEMBL620211,BAO_0000019,
7822,1,A,0,,,,22224,Area under curve(portal vein) was determined by the availability in blood; ND means no data,178.0,,,,,,U,Autocuration,CHEMBL620212,BAO_0000019,
7823,1,A,0,,,,22224,Area under curve(portal vein) was determined by the availability in blood; No data,178.0,,,,,,U,Autocuration,CHEMBL620213,BAO_0000019,
7824,1,A,1,,,,50797,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",1969.0,Macaca mulatta,,,,9544.0,N,Intermediate,CHEMBL620214,BAO_0000218,
7825,1,A,1,,,,50797,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",1969.0,Macaca mulatta,,,,9544.0,N,Intermediate,CHEMBL620215,BAO_0000218,
7826,1,A,1,,,,50797,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,1969.0,Macaca mulatta,,,,9544.0,N,Intermediate,CHEMBL620216,BAO_0000218,
7827,1,A,1,,,,50588,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL620888,BAO_0000218,
7828,1,A,1,,,,50588,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL620889,BAO_0000218,
7829,1,A,0,,,,22224,Area under plasma concentration vs time curve observed in rats for 0-3 h,1969.0,,,,,,U,Autocuration,CHEMBL620890,BAO_0000019,
7830,1,A,1,,,,50597,Area under plasma time curve determined in male rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620891,BAO_0000218,
7831,1,A,0,,,,22224,Area under the MAP curve measured over 5 min.,,,,,,,U,Autocuration,CHEMBL620892,BAO_0000019,
7832,1,A,1,,,,50594,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621079,BAO_0000218,
7833,1,A,1,,,,50594,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621080,BAO_0000218,
7834,1,A,1,,,,50588,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621081,BAO_0000218,
7835,1,A,1,,,,100712,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,,Cricetinae,,,,10026.0,N,Intermediate,CHEMBL621082,BAO_0000218,
7836,1,A,1,,,,50597,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621083,BAO_0000218,
7837,1,A,1,,,,50588,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621084,BAO_0000218,
7838,1,A,1,,,,50588,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621085,BAO_0000218,
7839,1,A,1,,,,50588,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621086,BAO_0000218,
7840,1,A,1,,,,50588,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621087,BAO_0000218,
7841,1,A,1,,,,50588,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622607,BAO_0000218,
7842,1,A,1,,,,50588,Serum AUC in marmosets (IV dose),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622608,BAO_0000218,
7843,1,A,0,,,,22224,Area under the curve after intravenous administration at a dose of 10 umol/kg,,,,,,,U,Autocuration,CHEMBL624481,BAO_0000019,
7844,1,A,0,,,,22224,Area under the curve after intravenous administration at a dose of 2 umol/kg,,,,,,,U,Autocuration,CHEMBL624482,BAO_0000019,
7845,1,A,0,,,,22224,Area under the curve after intravenous administration at a dose of 4 umol/kg,,,,,,,U,Autocuration,CHEMBL624483,BAO_0000019,
7846,1,A,0,,,,22224,Area under the curve after intravenous administration at a dose of 40 umol/kg,,,,,,,U,Autocuration,CHEMBL624484,BAO_0000019,
7847,1,A,0,,,,22224,Area under the curve after intravenous administration at a dose of 5 umol/kg,,,,,,,U,Autocuration,CHEMBL624485,BAO_0000019,
7848,1,A,1,,,,50597,Area under the curve for fumarate salt was evaluated in F344 Rats.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624486,BAO_0000218,
7849,1,A,0,,,,22224,Area under the curve for the compound was calculated.,,,,,,,U,Autocuration,CHEMBL624487,BAO_0000019,
7850,1,A,0,,,,22224,Area under the curve in concentration/ time,,,,,,,U,Autocuration,CHEMBL624488,BAO_0000019,
7851,1,A,1,,,,50597,Area under the curve administered intraintestinal in rats.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624489,BAO_0000218,
7852,1,A,1,,,,50597,Area under the curve administered intravenously in rats.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625184,BAO_0000218,
7853,1,A,0,,,,22224,Area under the curve during intravenous administration,,,,,,,U,Autocuration,CHEMBL625185,BAO_0000019,
7854,1,A,0,,,,22224,Area under the curve during intravenous administration; Not determined,,,,,,,U,Autocuration,CHEMBL875954,BAO_0000019,
7855,1,A,0,,,,22224,Area under the curve during systemic administration,,,,,,,U,Autocuration,CHEMBL625186,BAO_0000019,
7856,1,A,0,,,,22224,Area under the curve during systemic administration; Not determined,,,,,,,U,Autocuration,CHEMBL625187,BAO_0000019,
7857,1,A,0,,,,22224,Area under the curve was calculated for the compound.,,,,,,,U,Autocuration,CHEMBL625188,BAO_0000019,
7858,1,A,1,,,,50588,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625189,BAO_0000218,
7859,1,A,1,,,,50588,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625190,BAO_0000218,
7860,1,A,1,,,,50597,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621733,BAO_0000218,
7861,1,A,1,,,,50597,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621734,BAO_0000218,
7862,1,A,1,,,,50597,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621735,BAO_0000218,
7863,1,A,1,,,,50597,Clearance of the drug was measured in the plasma of rat; No data,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621736,BAO_0000218,
7864,1,A,1,,,,50597,The pharmacokinetic parameter plasma clearance in vivo in rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621737,BAO_0000218,
7865,1,A,1,,,,50597,Plasma clearance at the dose of 2 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621738,BAO_0000218,
7866,1,A,1,,,In vivo,50597,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622806,BAO_0000218,
7867,1,A,1,,,In vivo,50597,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623519,BAO_0000218,
7868,1,A,1,,,In vivo,50597,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623520,BAO_0000218,
7869,1,A,1,,,In vivo,50597,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623521,BAO_0000218,
7870,1,A,1,,,In vivo,50597,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623522,BAO_0000218,
7871,1,A,1,,,In vivo,50597,Clearance rate in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623523,BAO_0000218,
7872,1,A,1,,,In vivo,50597,Clearance rate in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623690,BAO_0000218,
7873,1,A,1,,,In vivo,50597,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623691,BAO_0000218,
7874,1,A,1,,,In vivo,50597,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623692,BAO_0000218,
7875,1,A,1,,,In vivo,50597,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623693,BAO_0000218,
7876,1,A,1,,,In vivo,50597,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623694,BAO_0000218,
7877,1,A,1,,,In vivo,50597,Clearance of compound after iv administration of 20 mg/kg dose in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623695,BAO_0000218,
7878,1,A,1,,,In vivo,50597,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623696,BAO_0000218,
7879,1,A,1,,,In vivo,50597,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623697,BAO_0000218,
7880,1,A,0,,,In vivo,22224,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,1969.0,Macaca mulatta,,,,9544.0,U,Intermediate,CHEMBL623698,BAO_0000218,
7881,1,A,0,,,In vivo,22224,Compound was tested for its plasma clearance rate in Sprague Dawley rats,1969.0,Rattus norvegicus,,,,10116.0,U,Intermediate,CHEMBL623699,BAO_0000218,
7882,1,A,1,,,In vivo,50597,Mean (%CV) PK parameters for CL(mL/min/kg).,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623700,BAO_0000218,
7883,1,A,1,,,In vivo,50597,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623701,BAO_0000218,
7884,1,A,1,,,In vivo,50597,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623702,BAO_0000218,
7885,1,A,1,,,In vivo,50597,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623703,BAO_0000218,
7886,1,A,1,,,In vivo,50597,Plasma clearance in rat was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623704,BAO_0000218,
7887,1,A,1,,,In vivo,50597,Plasma clearance in rat after administration of 2 mg/kg iv,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623705,BAO_0000218,
7888,1,A,1,,,In vivo,50597,Plasma clearance in rat after administration of 2 mg/kg iv,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623706,BAO_0000218,
7889,1,A,1,,,In vivo,50597,Plasma clearance was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623707,BAO_0000218,
7890,1,A,1,,,In vivo,50597,Plasma clearance in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623708,BAO_0000218,
7891,1,A,1,,,In vivo,50597,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623709,BAO_0000218,
7892,1,A,1,,,In vivo,50597,Plasma clearance in rat by iv administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623710,BAO_0000218,
7893,1,A,1,,,In vivo,50597,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623711,BAO_0000218,
7894,1,A,1,,,In vivo,50597,Plasma clearance in rat p.o.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623712,BAO_0000218,
7895,1,A,1,,,In vivo,50597,Plasma clearance in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623713,BAO_0000218,
7896,1,A,1,,,In vivo,50597,Plasma clearance was determined; ND denotes no data,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623714,BAO_0000218,
7897,1,A,1,,,In vivo,50597,Plasma clearance was determined; ND denotes not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623715,BAO_0000218,
7898,1,A,1,,,In vivo,50597,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623716,BAO_0000218,
7899,1,A,1,,,In vivo,50597,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622980,BAO_0000218,
7900,1,A,1,,,In vivo,50597,Plasma administration to rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622981,BAO_0000218,
7901,1,A,1,,,In vivo,50597,Plasma clearance of the compound in female Sprague-Dawley rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622982,BAO_0000218,
7902,1,A,1,,,In vivo,50597,Plasma clearance was observed after intravenous administration in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622983,BAO_0000218,
7903,1,A,1,,,In vivo,50597,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622984,BAO_0000218,
7904,1,A,1,,,In vivo,50597,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622985,BAO_0000218,
7905,1,A,1,,,In vivo,50597,plasma clearance was observed after intravenous administration in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623631,BAO_0000218,
7906,1,A,1,,,In vivo,50597,In vivo CL/F determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623632,BAO_0000218,
7907,1,A,1,,,In vivo,50597,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623633,BAO_0000218,
7908,1,A,1,,,In vivo,50597,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623634,BAO_0000218,
7909,1,A,1,,,In vivo,50597,Compound was tested for the lower blood clearance in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623635,BAO_0000218,
7910,1,A,1,,,In vivo,50597,Evaluated for the low clearance in rat (in vivo),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621195,BAO_0000218,
7911,1,A,1,,,In vivo,50597,Pharmacokinetic property (CLb)of the compound was determined in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621196,BAO_0000218,
7912,1,A,1,,,In vivo,50597,Rapid clearance after intravenous administration in rat was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875287,BAO_0000218,
7913,1,A,1,,,In vivo,50597,Clearance measured in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621197,BAO_0000218,
7914,1,A,1,,,In vivo,50597,Compound was evaluated for plasma clearance in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621198,BAO_0000218,
7915,1,A,1,,,In vivo,50597,Low plasma clearance was calculated in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621199,BAO_0000218,
7916,1,A,1,,,In vivo,50597,Pharmacokinetic property (Clp) in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621200,BAO_0000218,
7917,1,A,1,,,In vivo,50597,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621201,BAO_0000218,
7918,1,A,1,,,In vivo,50597,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621202,BAO_0000218,
7919,1,A,1,,,In vivo,50597,Plasma clearance after IV dosing at 0.5 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621203,BAO_0000218,
7920,1,A,1,,,In vivo,50597,Plasma clearance after IV dosing at 1 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621204,BAO_0000218,
7921,1,A,1,,,In vivo,50597,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621205,BAO_0000218,
7922,1,A,1,,,In vivo,50597,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621206,BAO_0000218,
7923,1,A,1,,,In vivo,50597,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621207,BAO_0000218,
7924,1,A,1,,,In vivo,50597,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621208,BAO_0000218,
7925,1,A,1,,,In vivo,50597,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621209,BAO_0000218,
7926,1,A,1,,,In vivo,50597,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876484,BAO_0000218,
7927,1,A,1,,,In vivo,50597,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621210,BAO_0000218,
7928,1,A,1,,,In vivo,50597,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621211,BAO_0000218,
7929,1,A,1,,,In vivo,50597,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621212,BAO_0000218,
7930,1,A,1,,,In vivo,50597,Biodistribution in rat heart in the presence of GdDTPA at 15 min,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621213,BAO_0000218,
7931,1,A,1,,,In vivo,50597,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621214,BAO_0000218,
7932,1,A,1,,,In vivo,50597,Biodistribution in rat heart in the presence of GdDTPA at 30 min,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621215,BAO_0000218,
7933,1,A,1,,,In vivo,50597,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621216,BAO_0000218,
7934,1,A,1,,,In vivo,50597,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621217,BAO_0000218,
7935,1,A,1,,,In vivo,50597,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621218,BAO_0000218,
7936,1,A,1,,,In vivo,50597,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621219,BAO_0000218,
7937,1,A,1,,,In vivo,50597,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621220,BAO_0000218,
7938,1,A,1,,,In vivo,50597,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621221,BAO_0000218,
7939,1,A,1,,,In vivo,50597,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621222,BAO_0000218,
7940,1,A,1,,,In vivo,50597,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621223,BAO_0000218,
7941,1,A,1,,,In vivo,50597,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876485,BAO_0000218,
7942,1,A,1,,,In vivo,50597,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621224,BAO_0000218,
7943,1,A,1,,,In vivo,50597,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621225,BAO_0000218,
7944,1,A,1,,,In vivo,50597,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621226,BAO_0000218,
7945,1,A,1,,,In vivo,50597,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621227,BAO_0000218,
7946,1,A,1,,,In vivo,50597,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621228,BAO_0000218,
7947,1,A,1,,,In vivo,50597,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621229,BAO_0000218,
7948,1,A,1,,,In vivo,50597,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621230,BAO_0000218,
7949,1,A,1,,,In vivo,50597,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621231,BAO_0000218,
7950,1,A,1,,,In vivo,50597,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621232,BAO_0000218,
7951,1,A,1,,,In vivo,50597,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621233,BAO_0000218,
7952,1,A,1,,,In vivo,50597,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621234,BAO_0000218,
7953,1,A,1,,,In vivo,50597,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621235,BAO_0000218,
7954,1,A,1,,,In vivo,50597,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621236,BAO_0000218,
7955,1,A,1,,,In vivo,50597,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621237,BAO_0000218,
7956,1,A,1,,,In vivo,50597,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876486,BAO_0000218,
7957,1,A,1,,,In vivo,50597,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,160.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622436,BAO_0000218,
7958,1,A,1,,,In vivo,50597,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,160.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622437,BAO_0000218,
7959,1,A,1,,,In vivo,50597,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,160.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622438,BAO_0000218,
7960,1,A,1,,,In vivo,50597,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622439,BAO_0000218,
7961,1,A,1,,,In vivo,50597,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622440,BAO_0000218,
7962,1,A,1,,,In vivo,50597,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622441,BAO_0000218,
7963,1,A,1,,,In vivo,50597,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622442,BAO_0000218,
7964,1,A,1,,,In vivo,50597,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622443,BAO_0000218,
7965,1,A,1,,,In vivo,50597,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622444,BAO_0000218,
7966,1,A,1,,,In vivo,50597,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622445,BAO_0000218,
7967,1,A,1,,,In vivo,50597,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622446,BAO_0000218,
7968,1,A,1,,,In vivo,50597,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622447,BAO_0000218,
7969,1,A,1,,,In vivo,50597,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622448,BAO_0000218,
7970,1,A,1,,,In vivo,50597,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622449,BAO_0000218,
7971,1,A,1,,,In vivo,50597,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622450,BAO_0000218,
7972,1,A,1,,,In vivo,50597,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622451,BAO_0000218,
7973,1,A,1,,,In vivo,50597,Biodistribution in rat liver in the presence of GdDTPA at 15 min,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622452,BAO_0000218,
7974,1,A,1,,,In vivo,50597,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622453,BAO_0000218,
7975,1,A,1,,,In vivo,50597,Biodistribution in rat liver in the presence of GdDTPA at 30 min,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622454,BAO_0000218,
7976,1,A,1,,,In vivo,50597,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622455,BAO_0000218,
7977,1,A,1,,,In vivo,50597,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876024,BAO_0000218,
7978,1,A,1,,,In vivo,50597,T max was determined at 3 mg/kg po dose in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622456,BAO_0000218,
7979,1,A,1,,,In vivo,50597,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622457,BAO_0000218,
7980,1,A,1,,,In vivo,50597,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622458,BAO_0000218,
7981,1,A,1,,,,50597,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622459,BAO_0000218,
7982,1,A,1,,,,50597,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL873343,BAO_0000218,
7983,1,A,1,,,,50597,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622460,BAO_0000218,
7984,1,A,1,,,,50597,Time for maximum plasma concentration determined in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622461,BAO_0000218,
7985,1,A,1,,,In vivo,50597,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622462,BAO_0000218,
7986,1,A,1,,,In vivo,50597,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622463,BAO_0000218,
7987,1,A,1,,,In vivo,50597,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622464,BAO_0000218,
7988,1,A,1,,,In vivo,50597,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622465,BAO_0000218,
7989,1,A,1,,,In vivo,50597,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622466,BAO_0000218,
7990,1,A,1,,,In vivo,50597,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622467,BAO_0000218,
7991,1,A,1,,,,50597,Time of maximum plasma concentration in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622468,BAO_0000218,
7992,1,A,1,,,,50597,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876025,BAO_0000218,
7993,1,A,1,,,,50597,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622469,BAO_0000218,
7994,1,A,1,,,,50597,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622470,BAO_0000218,
7995,1,A,1,,,In vivo,50597,Time required to reach maximum concentration (Cmax) after oral administration in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622471,BAO_0000218,
7996,1,A,1,,,,50597,Time required to reach maximum concentration in rat plasma,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622472,BAO_0000218,
7997,1,A,1,,,In vivo,50597,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622473,BAO_0000218,
7998,1,A,1,,,In vivo,50597,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624282,BAO_0000218,
7999,1,A,1,,,In vivo,50597,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624283,BAO_0000218,
8000,1,A,1,,,In vivo,50597,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624284,BAO_0000218,
8001,1,A,1,,,In vivo,50597,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624285,BAO_0000218,
8002,1,A,1,,,In vivo,50597,Time to reach Cmax after oral administration to rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624286,BAO_0000218,
8003,1,A,1,,,In vivo,50597,Time to reach Cmax when a dose of 1 mg/kg is administered orally,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624287,BAO_0000218,
8004,1,A,1,,,,50597,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624288,BAO_0000218,
8005,1,A,1,,,In vivo,50597,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624289,BAO_0000218,
8006,1,A,1,,,In vivo,50597,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL873344,BAO_0000218,
8007,1,A,1,,,In vivo,50597,Tmax after peroral administration (10 mg/kg) was determined in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619623,BAO_0000218,
8008,1,A,1,,,In vivo,50597,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Expert,CHEMBL621399,BAO_0000218,
8009,1,A,1,,,In vivo,50597,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621400,BAO_0000218,
8010,1,A,1,,,In vivo,50597,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621401,BAO_0000218,
8011,1,A,1,,,,50597,Tmax was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621402,BAO_0000218,
8012,1,A,1,,,,50597,Tmax was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621403,BAO_0000218,
8013,1,A,1,,,In vivo,50597,Tmax after oral administration in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621121,BAO_0000218,
8014,1,A,1,,,In vivo,50597,Tmax after peroral administration in rats at 2.4 uM/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL872525,BAO_0000218,
8015,1,A,1,,,,50597,Tmax in male rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621122,BAO_0000218,
8016,1,A,1,,,In vivo,50597,Tmax in rat at 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621123,BAO_0000218,
8017,1,A,1,,,In vivo,50597,Tmax in rat by po administration at a dose of 40 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621124,BAO_0000218,
8018,1,A,1,,,,50597,Tmax in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621125,BAO_0000218,
8019,1,A,1,,,In vivo,50597,Tmax was measured in rats after peroral administration at 5 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621126,BAO_0000218,
8020,1,A,1,,,In vivo,50597,Tmax value after oral dose at a dose of 10 mg/kg in rats.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621127,BAO_0000218,
8021,1,A,1,,,In vivo,50597,Tmax value after administration of 20 mg/Kg oral dose in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621128,BAO_0000218,
8022,1,A,1,,,In vivo,50597,Tmax value at a dose of 10 mg/kg in male SD rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618263,BAO_0000218,
8023,1,A,1,,,In vivo,50597,Tmax value at a dose of 100 mg/kg in male SD rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618264,BAO_0000218,
8024,1,A,1,,,In vivo,50597,Tmax value at a dose of 50 mg/kg in male SD rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618265,BAO_0000218,
8025,1,A,1,,,In vivo,50597,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618266,BAO_0000218,
8026,1,A,1,,,In vivo,50597,time required to reach maximum concentration (Cmax) after oral administration in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618267,BAO_0000218,
8027,1,A,1,,,,50597,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618450,BAO_0000218,
8028,1,A,1,,,,50597,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618451,BAO_0000218,
8029,1,A,1,,,,50597,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618452,BAO_0000218,
8030,1,A,1,,,,50597,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618453,BAO_0000218,
8031,1,A,1,,,,50597,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618454,BAO_0000218,
8032,1,A,1,,,,50597,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618455,BAO_0000218,
8033,1,A,1,,,In vivo,50597,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618456,BAO_0000218,
8034,1,A,1,,,In vivo,50597,Compound distribution in rat tissues was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618457,BAO_0000218,
8035,1,A,1,,,In vivo,50597,Volume of distribution was evaluated in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618458,BAO_0000218,
8036,1,A,1,,,,50597,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618459,BAO_0000218,
8037,1,A,1,,,,50597,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876733,BAO_0000218,
8038,1,A,1,,,,50588,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618460,BAO_0000218,
8039,1,A,1,,,,50597,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618461,BAO_0000218,
8040,1,A,0,,,,22224,Area under the curve was determined after oral administration (300 uM/Kg),,,,,,,U,Autocuration,CHEMBL618462,BAO_0000019,
8041,1,A,1,,,,50597,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618463,BAO_0000218,
8042,1,A,1,,,,50597,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618464,BAO_0000218,
8043,1,A,1,,,,50597,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618465,BAO_0000218,
8044,1,A,1,,,,50597,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618466,BAO_0000218,
8045,1,A,1,,,,50597,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618467,BAO_0000218,
8046,1,A,1,,,,50597,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618468,BAO_0000218,
8047,1,A,1,,,,50588,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618469,BAO_0000218,
8048,1,A,1,,,,50588,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL618470,BAO_0000218,
8049,1,A,0,,,,22224,Plasma drug AUC in rat (PO dose),,,,,,,U,Autocuration,CHEMBL618471,BAO_0000218,
8050,1,A,1,,,,50594,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618472,BAO_0000218,
8051,1,A,0,,,,22224,Area under was determined at a dose of 30 mg/kg,,,,,,,U,Autocuration,CHEMBL618473,BAO_0000218,
8052,1,A,1,,,,50506,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,,Mustela putorius furo,,,,9669.0,N,Intermediate,CHEMBL621699,BAO_0000218,
8053,1,A,1,,,,50597,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621700,BAO_0000218,
8054,1,A,1,,,,50597,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621701,BAO_0000218,
8055,1,A,1,,,,50506,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,,Mustela putorius furo,,,,9669.0,N,Intermediate,CHEMBL621702,BAO_0000218,
8056,1,A,1,,,,50588,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621703,BAO_0000218,
8057,1,A,1,,,,50588,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621704,BAO_0000218,
8058,1,A,1,,,,50597,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624259,BAO_0000218,
8059,1,A,1,,,,50597,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624260,BAO_0000218,
8060,1,A,1,,,,50597,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624430,BAO_0000218,
8061,1,A,1,,,,50597,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624431,BAO_0000218,
8062,1,A,1,,,,50597,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624432,BAO_0000218,
8063,1,A,1,,,,50597,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624433,BAO_0000218,
8064,1,A,1,,,,50597,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624434,BAO_0000218,
8065,1,A,1,,,,50597,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624435,BAO_0000218,
8066,1,A,1,,,,50594,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618570,BAO_0000218,
8067,1,A,1,,,,50594,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618571,BAO_0000218,
8068,1,A,1,,,,50594,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618572,BAO_0000218,
8069,1,A,1,,,,50594,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618573,BAO_0000218,
8070,1,A,1,,,,50594,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619267,BAO_0000218,
8071,1,A,1,,,,50594,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619431,BAO_0000218,
8072,1,A,1,,,,50594,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619432,BAO_0000218,
8073,1,A,1,,,,50594,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619433,BAO_0000218,
8074,1,A,0,,,,22224,AUC in mice after oral dose (50 mg/kg),1969.0,,,,,,U,Autocuration,CHEMBL619434,BAO_0000218,
8075,1,A,1,,,,50594,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,1977.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619435,BAO_0000218,
8076,1,A,0,,,,22224,AUC (0-4 hr) ug/ml/h,1969.0,,,,,,U,Autocuration,CHEMBL619436,BAO_0000019,
8077,1,A,1,,,,50597,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619437,BAO_0000218,
8078,1,A,0,,,,22224,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,,,,,,,U,Autocuration,CHEMBL619438,BAO_0000218,
8079,1,A,1,,,,50594,Compound was evaluated for Area under curve in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619439,BAO_0000218,
8080,1,A,1,,,,50597,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619440,BAO_0000218,
8081,1,F,0,,,,22224,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,,,,,,U,Autocuration,CHEMBL619441,BAO_0000218,
8082,1,A,1,,,,50597,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619442,BAO_0000218,
8083,1,A,0,,,,22224,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,,,,,,,U,Autocuration,CHEMBL875156,BAO_0000019,
8084,1,A,0,,,,22224,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,,,,,,,U,Autocuration,CHEMBL619443,BAO_0000019,
8085,1,A,0,,,,22224,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,,,,,,,U,Autocuration,CHEMBL619444,BAO_0000019,
8086,1,A,0,,,,22224,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,,,,,,,U,Autocuration,CHEMBL623464,BAO_0000019,
8087,1,A,1,,,,50594,Compound was evaluated for area under curve when administered through oral route in mouse,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623465,BAO_0000218,
8088,1,A,1,,,In vivo,50597,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623466,BAO_0000218,
8089,1,A,1,,,In vivo,50597,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623467,BAO_0000218,
8090,1,A,1,,,In vivo,50597,Plasma clearance in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623468,BAO_0000218,
8091,1,A,1,,,In vivo,50597,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622660,BAO_0000218,
8092,1,A,1,,,In vivo,50597,Plasma clearance rate in Sprague-Dawley rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622661,BAO_0000218,
8093,1,F,1,,,In vivo,50597,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622662,BAO_0000218,
8094,1,A,1,,,In vivo,50597,Pharmacokinetic property (total body clearance) in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622663,BAO_0000218,
8095,1,A,1,,,In vivo,50597,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622664,BAO_0000218,
8096,1,A,1,,,,50597,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622665,BAO_0000218,
8097,1,A,1,,,,50597,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622666,BAO_0000218,
8098,1,A,1,,,In vivo,50597,Cl in rat i.v. at 2 mg/kg concentration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621615,BAO_0000218,
8099,1,A,1,,,In vivo,50597,Clearance of compound after intravenous administration in rats at 24 uM/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621616,BAO_0000218,
8100,1,A,1,,,In vivo,50597,Clearance was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621617,BAO_0000218,
8101,1,A,1,,,In vivo,50597,Clearance by intravenous administration of 3.4 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621618,BAO_0000218,
8102,1,A,1,,,In vivo,50597,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621619,BAO_0000218,
8103,1,A,1,,,In vivo,50597,Clearance rate after i.v. administration in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621620,BAO_0000218,
8104,1,A,1,,,In vivo,50597,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621786,BAO_0000218,
8105,1,A,1,,,In vivo,50597,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621787,BAO_0000218,
8106,1,A,1,,,In vivo,50597,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621788,BAO_0000218,
8107,1,A,1,,,In vivo,50597,Clearance (Cl) after oral administration in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621789,BAO_0000218,
8108,1,A,1,,,In vivo,50597,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621790,BAO_0000218,
8109,1,A,1,,,In vivo,50597,Compound was tested for plasma clearance in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621791,BAO_0000218,
8110,1,A,1,,,In vitro,50597,In vitro microsome metabolism clearance in rat was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621792,BAO_0000218,
8111,1,A,1,,,In vitro,50597,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621793,BAO_0000218,
8112,1,A,1,,,In vivo,50597,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621794,BAO_0000218,
8113,1,A,1,,,In vivo,50597,In vivo plasma clearance was determined,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621795,BAO_0000218,
8114,1,A,1,,,In vivo,50597,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621796,BAO_0000218,
8115,1,A,1,Hepatocyte,,In vivo,50597,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,2107.0,Rattus norvegicus,,401.0,,10116.0,N,Intermediate,CHEMBL621797,BAO_0000218,
8116,1,A,1,,,In vivo,50597,Pharmacokinetic property (Plasma clearance) was measured in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621798,BAO_0000218,
8117,1,A,1,,,In vivo,50597,Pharmacokinetic property (clearance) in rat i.v.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621799,BAO_0000218,
8118,1,A,1,,,In vivo,50597,"Plasma Clearance was evaluated in rats, iv",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621800,BAO_0000218,
8119,1,A,1,,,In vivo,50597,Plasma clearance (in vivo) in rats was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621801,BAO_0000218,
8120,1,A,1,,,In vivo,50597,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621802,BAO_0000218,
8121,1,A,1,,,In vivo,50597,Plasma clearance was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618596,BAO_0000218,
8122,1,A,1,,,In vivo,50597,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618597,BAO_0000218,
8123,1,A,1,,,In vivo,50597,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618598,BAO_0000218,
8124,1,A,1,,,In vivo,50597,Plasma clearance in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618599,BAO_0000218,
8125,1,A,1,,,In vivo,50597,Plasma clearance rate determined in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618600,BAO_0000218,
8126,1,A,1,,,In vivo,50597,Plasma clearance was determined in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618601,BAO_0000218,
8127,1,A,1,,,In vivo,50597,Plasma clearance was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618602,BAO_0000218,
8128,1,A,1,,,In vivo,50597,Plasma clearance value in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618603,BAO_0000218,
8129,1,A,1,,,Ex vivo,50597,Clearance rate constant using isolated perfused rat liver (IPRL) assay,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618604,BAO_0000218,
8130,1,A,1,,,In vivo,50597,Clearance in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618605,BAO_0000218,
8131,1,A,1,,,In vivo,50597,Total body clearance in rat i.v. at 2 mg/kg concentration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618606,BAO_0000218,
8132,1,A,1,,,In vivo,50597,Clearance of compound in rats after intravenous administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618607,BAO_0000218,
8133,1,A,1,,,In vivo,50597,Clearance after iv administration to rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618608,BAO_0000218,
8134,1,A,1,,,In vivo,50597,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618609,BAO_0000218,
8135,1,A,1,,,In vivo,50597,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618610,BAO_0000218,
8136,1,A,1,,,In vivo,50597,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618611,BAO_0000218,
8137,1,A,1,,,In vivo,50597,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618612,BAO_0000218,
8138,1,A,1,,,In vivo,50597,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618613,BAO_0000218,
8139,1,A,1,,,In vivo,50597,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621076,BAO_0000218,
8140,1,A,1,,,In vivo,50597,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621077,BAO_0000218,
8141,1,A,1,,,In vivo,50597,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621078,BAO_0000218,
8142,1,A,1,,,In vivo,50597,Clearance in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621251,BAO_0000218,
8143,1,A,1,,,In vivo,50597,Clearance in rat after oral administration at 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621252,BAO_0000218,
8144,1,A,1,,,In vivo,50597,Clearance in rat.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621253,BAO_0000218,
8145,1,A,1,,,In vivo,50597,Clearance rate following an oral dose of 20 mg/kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621254,BAO_0000218,
8146,1,A,1,,,In vivo,50597,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621255,BAO_0000218,
8147,1,A,1,,,In vivo,50597,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621256,BAO_0000218,
8148,1,A,1,,,In vivo,50597,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621257,BAO_0000218,
8149,1,A,1,,,In vivo,50597,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621258,BAO_0000218,
8150,1,A,1,,,In vivo,50597,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621259,BAO_0000218,
8151,1,A,1,,,In vivo,50597,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621260,BAO_0000218,
8152,1,A,1,,,In vivo,50597,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876494,BAO_0000218,
8153,1,A,1,,,In vivo,50597,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621261,BAO_0000218,
8154,1,A,1,,,In vivo,50597,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621262,BAO_0000218,
8155,1,A,1,,,In vivo,50597,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621263,BAO_0000218,
8156,1,A,1,,,In vivo,50597,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621264,BAO_0000218,
8157,1,A,1,,,In vivo,50597,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621265,BAO_0000218,
8158,1,A,1,,,In vivo,50597,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621266,BAO_0000218,
8159,1,A,1,,,In vivo,50597,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621267,BAO_0000218,
8160,1,A,1,,,In vivo,50597,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621268,BAO_0000218,
8161,1,A,1,,,In vivo,50597,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621269,BAO_0000218,
8162,1,A,1,,,In vivo,50597,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621270,BAO_0000218,
8163,1,A,1,,,In vivo,50597,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621271,BAO_0000218,
8164,1,A,1,,,In vivo,50597,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621272,BAO_0000218,
8165,1,A,1,,,In vivo,50597,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621273,BAO_0000218,
8166,1,A,1,,,In vivo,50597,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621274,BAO_0000218,
8167,1,A,1,,,In vivo,50597,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876495,BAO_0000218,
8168,1,A,1,,,In vivo,50597,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621275,BAO_0000218,
8169,1,A,1,,,In vivo,50597,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621276,BAO_0000218,
8170,1,A,1,,,In vivo,50597,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621277,BAO_0000218,
8171,1,A,1,,,In vivo,50597,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,160.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621278,BAO_0000218,
8172,1,A,1,,,In vivo,50597,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,160.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621279,BAO_0000218,
8173,1,A,1,,,In vivo,50597,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),160.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621280,BAO_0000218,
8174,1,A,1,,,In vivo,50597,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621281,BAO_0000218,
8175,1,A,1,,,In vivo,50597,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621282,BAO_0000218,
8176,1,A,1,,,In vivo,50597,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621283,BAO_0000218,
8177,1,A,1,,,In vivo,50597,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621284,BAO_0000218,
8178,1,A,1,,,In vivo,50597,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621285,BAO_0000218,
8179,1,A,1,,,In vivo,50597,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621286,BAO_0000218,
8180,1,A,1,,,In vivo,50597,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623220,BAO_0000218,
8181,1,A,1,,,In vivo,50597,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623221,BAO_0000218,
8182,1,A,1,,,In vivo,50597,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876029,BAO_0000218,
8183,1,A,1,,,In vivo,50597,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,945.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623222,BAO_0000218,
8184,1,A,1,,,In vivo,50597,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,945.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623223,BAO_0000218,
8185,1,A,1,,,In vivo,50597,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,945.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621445,BAO_0000218,
8186,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621446,BAO_0000218,
8187,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621447,BAO_0000218,
8188,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619681,BAO_0000218,
8189,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619682,BAO_0000218,
8190,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619683,BAO_0000218,
8191,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619684,BAO_0000218,
8192,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619685,BAO_0000218,
8193,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619686,BAO_0000218,
8194,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619687,BAO_0000218,
8195,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619688,BAO_0000218,
8196,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619689,BAO_0000218,
8197,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619690,BAO_0000218,
8198,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619691,BAO_0000218,
8199,1,A,1,,,In vivo,50597,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619692,BAO_0000218,
8200,1,A,1,,,,50597,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Expert,CHEMBL619693,BAO_0000218,
8201,1,A,1,,,In vivo,50597,Vc value after IV dose at a dose of 5 mg/kg in rats.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619694,BAO_0000218,
8202,1,A,1,,,In vivo,50597,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619695,BAO_0000218,
8203,1,A,1,,,In vivo,50597,Compound was evaluated for pharmacokinetic parameter volume of distribution,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619696,BAO_0000218,
8204,1,A,1,,,In vivo,50597,Compound was evaluated for volume of distribution in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619697,BAO_0000218,
8205,1,A,1,,,In vivo,50597,Steady state volume distribution was determined; steady state(ss),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619698,BAO_0000218,
8206,1,A,1,,,In vivo,50597,Steady state volume of distribution after iv administration to rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619699,BAO_0000218,
8207,1,A,1,,,In vivo,50597,Steady state volume of distribution dosing at 3 mg/kg iv,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619700,BAO_0000218,
8208,1,A,1,,,In vivo,50597,The compound was evaluated for volume of distribution in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619701,BAO_0000218,
8209,1,A,1,,,In vivo,50597,The compound was tested for volume of distribution in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619702,BAO_0000218,
8210,1,A,1,,,In vivo,50597,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620335,BAO_0000218,
8211,1,A,1,,,In vivo,50597,Volume distribution (VD) after oral administration in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620336,BAO_0000218,
8212,1,A,1,,,In vivo,50597,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620337,BAO_0000218,
8213,1,A,1,,,In vivo,50597,Volume distribution in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620520,BAO_0000218,
8214,1,A,1,,,In vivo,50597,Volume distribution in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620521,BAO_0000218,
8215,1,A,1,,,In vivo,50597,Volume distribution in rat after peroral administration at 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875825,BAO_0000218,
8216,1,A,1,,,In vivo,50597,Volume distribution in rat after peroral administration at 5 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620522,BAO_0000218,
8217,1,A,1,,,In vivo,50597,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620523,BAO_0000218,
8218,1,A,1,,,In vivo,50597,Volume of distribution in rat.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620524,BAO_0000218,
8219,1,A,1,,,In vivo,50597,Volume of distribution in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620525,BAO_0000218,
8220,1,A,1,,,In vivo,50597,Volume of distribution in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620526,BAO_0000218,
8221,1,A,1,,,In vivo,50597,Volume of distribution in rat by iv administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620527,BAO_0000218,
8222,1,A,1,,,In vivo,50597,Volume of distribution in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620528,BAO_0000218,
8223,1,A,1,,,In vivo,50597,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620529,BAO_0000218,
8224,1,A,1,,,,50597,Volume distribution at the dose of 2 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620530,BAO_0000218,
8225,1,A,1,,,In vivo,50597,Steady state volume of distribution was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620531,BAO_0000218,
8226,1,A,0,,,In vivo,22224,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,Macaca mulatta,,,,9544.0,U,Intermediate,CHEMBL620532,BAO_0000218,
8227,1,A,0,,,In vivo,22224,Compound was tested for its plasma volume distribution in Sprague Dawley rats,,Rattus norvegicus,,,,10116.0,U,Intermediate,CHEMBL620533,BAO_0000218,
8228,1,A,0,,,In vivo,22224,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,,Rattus norvegicus,,,,10116.0,U,Intermediate,CHEMBL620534,BAO_0000218,
8229,1,A,1,,,In vivo,50597,Mean (%CV) PK parameters for Vdss(mL/kg).,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620535,BAO_0000218,
8230,1,A,1,,,In vivo,50597,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875826,BAO_0000218,
8231,1,A,1,,,In vivo,50597,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620536,BAO_0000218,
8232,1,A,1,,,In vivo,50597,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620537,BAO_0000218,
8233,1,A,1,,,In vivo,50597,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618526,BAO_0000218,
8234,1,A,1,,,In vivo,50597,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618527,BAO_0000218,
8235,1,A,1,,,In vivo,50597,Pharmacokinetic property (Vdss) in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618528,BAO_0000218,
8236,1,A,1,,,In vivo,50597,Pharmacokinetic property (vdss) was measured in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618529,BAO_0000218,
8237,1,A,1,,,In vivo,50597,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618530,BAO_0000218,
8238,1,A,1,,,In vivo,50597,Volume of distribution in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618531,BAO_0000218,
8239,1,A,1,,,In vivo,50597,The pharmacokinetic parameter volume of distribution in vivo in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618532,BAO_0000218,
8240,1,F,1,,,In vivo,50597,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618533,BAO_0000218,
8241,1,A,1,,,In vivo,50597,Vdss in rat i.v. at 2 mg/kg concentration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618534,BAO_0000218,
8242,1,A,1,,,In vivo,50597,Volume distribution after intravenous administration (1 mg/kg) in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618535,BAO_0000218,
8243,1,A,1,,,In vivo,50597,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618536,BAO_0000218,
8244,1,A,1,,,In vivo,50597,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618537,BAO_0000218,
8245,1,A,1,,,In vivo,50597,Volume distribution at a dose of 10 uM/kg in rat was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618538,BAO_0000218,
8246,1,A,1,,,In vivo,50597,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618539,BAO_0000218,
8247,1,A,1,,,In vivo,50597,Volume distribution was calculated in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618540,BAO_0000218,
8248,1,A,1,,,In vivo,50597,Volume distribution was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618541,BAO_0000218,
8249,1,A,1,,,In vivo,50597,Volume of distribution after intravenous administration was evaluated in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618542,BAO_0000218,
8250,1,A,1,,,In vivo,50597,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622544,BAO_0000218,
8251,1,A,1,,,In vivo,50597,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622545,BAO_0000218,
8252,1,A,1,,,In vivo,50597,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622546,BAO_0000218,
8253,1,A,1,,,In vivo,50597,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622547,BAO_0000218,
8254,1,A,1,,,In vivo,50597,Volume of distribution in steady state was determined in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622548,BAO_0000218,
8255,1,A,1,,,In vivo,50597,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622549,BAO_0000218,
8256,1,A,1,,,In vivo,50597,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622550,BAO_0000218,
8257,1,A,1,,,,50594,Compound was evaluated for area under curve when administered through oral route to mouse,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622551,BAO_0000218,
8258,1,A,1,,,,50597,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622552,BAO_0000218,
8259,1,A,1,,,,50597,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622553,BAO_0000218,
8260,1,F,0,,,In vivo,22224,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,,,,,,,U,Autocuration,CHEMBL622554,BAO_0000218,
8261,1,A,1,,,,50588,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622555,BAO_0000218,
8262,1,A,1,,,,50594,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622556,BAO_0000218,
8263,1,A,1,,,,50594,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622557,BAO_0000218,
8264,1,A,1,,,,50594,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622558,BAO_0000218,
8265,1,A,1,,,,50594,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622559,BAO_0000218,
8266,1,A,1,,,,50588,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622560,BAO_0000218,
8267,1,A,1,,,,50597,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622561,BAO_0000218,
8268,1,A,1,,,,50597,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622562,BAO_0000218,
8269,1,A,1,,,,50597,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622563,BAO_0000218,
8270,1,A,0,,,,22224,Concentration of compound in Central nervous system,,,,,,,U,Autocuration,CHEMBL622564,BAO_0000019,
8271,1,A,0,,,,22224,Concentration of compound in Central nervous system; Not detectable,,,,,,,U,Autocuration,CHEMBL622565,BAO_0000019,
8272,1,A,1,,,,50594,"Concentration of diester in the blood, following oral administration in mice",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622566,BAO_0000218,
8273,1,A,1,,,,50594,"Concentration of monoester in the blood, following oral administration in mice",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624515,BAO_0000218,
8274,1,A,1,,,,50594,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624516,BAO_0000218,
8275,1,A,0,,,,22224,Evaluated for Pharmacokinetic property: Area under the curve,,,,,,,U,Autocuration,CHEMBL624517,BAO_0000019,
8276,1,A,1,,,,50594,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624518,BAO_0000218,
8277,1,A,1,,,,100710,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL624519,BAO_0000218,
8278,1,A,1,,,,100710,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL624520,BAO_0000218,
8279,1,A,1,,,,100710,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL624521,BAO_0000218,
8280,1,A,1,,,,100710,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL624522,BAO_0000218,
8281,1,A,1,,,,100710,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL624523,BAO_0000218,
8282,1,A,1,,,,100710,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL624409,BAO_0000218,
8283,1,A,1,,,,100710,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL624410,BAO_0000218,
8284,1,A,1,,,,100710,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL624411,BAO_0000218,
8285,1,A,1,,,,100710,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL623531,BAO_0000218,
8286,1,A,1,,,,100710,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL623532,BAO_0000218,
8287,1,A,1,,,,100710,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL623533,BAO_0000218,
8288,1,A,1,,,,100710,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL623534,BAO_0000218,
8289,1,A,1,,,,50594,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623535,BAO_0000218,
8290,1,A,1,,,,50594,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623536,BAO_0000218,
8291,1,A,1,,,,50594,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623537,BAO_0000218,
8292,1,A,1,,,,50594,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623538,BAO_0000218,
8293,1,A,1,,,,50594,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623539,BAO_0000218,
8294,1,A,1,,,,50594,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623540,BAO_0000218,
8295,1,A,1,,,,50594,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623541,BAO_0000218,
8296,1,A,1,,,,50594,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623542,BAO_0000218,
8297,1,A,1,,,,50594,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623543,BAO_0000218,
8298,1,A,1,,,,50594,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623544,BAO_0000218,
8299,1,A,1,,,,50594,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623545,BAO_0000218,
8300,1,A,1,,,,50594,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623546,BAO_0000218,
8301,1,A,1,,,In vivo,50597,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623547,BAO_0000218,
8302,1,A,1,,,In vivo,50597,High i.v. clearance in Dawley rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623548,BAO_0000218,
8303,1,A,1,,,In vitro,50597,In vitro clearance in rat liver microsomes,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623549,BAO_0000218,
8304,1,A,1,,,In vitro,50597,Intrinsic clearance in rat liver microsomes was determined,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623550,BAO_0000218,
8305,1,A,1,Hepatocyte,,In vitro,50597,Intrinsic clearance in rat hepatocytes was determined,2107.0,Rattus norvegicus,,401.0,,10116.0,N,Intermediate,CHEMBL875276,BAO_0000218,
8306,1,A,1,,,In vivo,50597,Plasma Clearance was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621872,BAO_0000218,
8307,1,A,1,,,In vivo,50597,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621873,BAO_0000218,
8308,1,A,1,,,In vivo,50597,Plasma clearance in rat.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621874,BAO_0000218,
8309,1,A,1,,,In vivo,50597,Plasma clearance in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621875,BAO_0000218,
8310,1,A,1,,,In vivo,50597,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621876,BAO_0000218,
8311,1,A,1,,,In vivo,50597,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621877,BAO_0000218,
8312,1,A,1,,,In vivo,50597,Plasma clearance was measured in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621878,BAO_0000218,
8313,1,A,1,,,In vivo,50597,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621879,BAO_0000218,
8314,1,A,1,,,In vivo,50597,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621880,BAO_0000218,
8315,1,A,1,,,In vivo,50597,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621881,BAO_0000218,
8316,1,A,1,,,In vivo,50597,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621882,BAO_0000218,
8317,1,A,1,,,In vivo,50597,Total clearance at 1 mg/kg was determined in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875283,BAO_0000218,
8318,1,A,1,,,In vivo,50597,Total clearance at 10 mg/kg was determined in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621883,BAO_0000218,
8319,1,A,1,,,In vivo,50597,Clearance in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621884,BAO_0000218,
8320,1,A,1,,,In vivo,50597,Plasma clearance rate determined in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621885,BAO_0000218,
8321,1,A,1,,,In vivo,50597,Clearance of compound in rat was evaluated,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621886,BAO_0000218,
8322,1,A,1,,,In vivo,50597,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621887,BAO_0000218,
8323,1,A,1,,,In vivo,50597,Pharmacokinetic property (blood clearance) in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621888,BAO_0000218,
8324,1,A,1,,,In vivo,50597,Plasma clearance in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621889,BAO_0000218,
8325,1,A,1,,,In vivo,50597,Plasma clearance in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621890,BAO_0000218,
8326,1,A,1,,,In vitro,50597,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621891,BAO_0000218,
8327,1,A,1,,,In vivo,50597,Clearance in Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621892,BAO_0000218,
8328,1,A,1,,,In vivo,50597,Clearance rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621893,BAO_0000218,
8329,1,A,1,,,In vivo,50597,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621894,BAO_0000218,
8330,1,A,1,,,In vivo,50597,Clearance rat; Not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621895,BAO_0000218,
8331,1,A,1,,,In vivo,50597,Clearance rate was determined in rat at a dose of 1 mpk i.v.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875284,BAO_0000218,
8332,1,A,1,,,In vivo,50597,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618699,BAO_0000218,
8333,1,A,1,,,In vivo,50597,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618700,BAO_0000218,
8334,1,A,1,,,In vivo,50597,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618701,BAO_0000218,
8335,1,A,1,,,In vivo,50597,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876600,BAO_0000218,
8336,1,A,1,,,In vivo,50597,Clearance of compound in rat after 1 mg/kg i.v. administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618702,BAO_0000218,
8337,1,A,1,,,In vivo,50597,Compound was evaluated for Hepatic clearance in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618703,BAO_0000218,
8338,1,A,1,,,In vivo,50597,In vivo clearance after 5 mg/kg dose,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618704,BAO_0000218,
8339,1,A,1,,,In vivo,50597,Compound was tested for plasma clearance in rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618705,BAO_0000218,
8340,1,A,1,,,In vivo,50597,Hepatic clearance after intravenous administration was evaluated in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618706,BAO_0000218,
8341,1,A,1,,,In vivo,50597,Lower clearance in rat (i.v.) at 0.5 mpk,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618707,BAO_0000218,
8342,1,A,1,,,In vivo,50597,Pharmacokinetic parameter expressed as plasma clearance in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618708,BAO_0000218,
8343,1,A,1,,,In vivo,50597,Pharmacokinetic property (Clp) in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618709,BAO_0000218,
8344,1,A,1,,,In vivo,50597,Plasma clearance in Sprague-Dawley rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618710,BAO_0000218,
8345,1,A,1,,,In vivo,50597,Plasma clearance (Clp) in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618711,BAO_0000218,
8346,1,A,1,,,In vivo,50597,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618712,BAO_0000218,
8347,1,A,1,,,In vivo,50597,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618713,BAO_0000218,
8348,1,A,1,,,In vivo,50597,Plasma clearance after intravenous administration of 1 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618714,BAO_0000218,
8349,1,A,1,,,In vivo,50597,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618715,BAO_0000218,
8350,1,A,1,,,In vivo,50597,Plasma clearance in rat was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618716,BAO_0000218,
8351,1,A,1,,,In vivo,50597,Plasma clearance measured in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876601,BAO_0000218,
8352,1,A,1,,,In vivo,50597,Plasma clearance was calculated in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618717,BAO_0000218,
8353,1,A,1,,,In vivo,50597,Plasma clearance in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618718,BAO_0000218,
8354,1,A,1,,,In vivo,50597,Plasma clearance in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618719,BAO_0000218,
8355,1,A,1,,,In vivo,50597,Plasma clearance in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618720,BAO_0000218,
8356,1,A,1,,,In vivo,50597,Plasma clearance in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618721,BAO_0000218,
8357,1,A,1,,,In vivo,50597,Plasma clearance in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621477,BAO_0000218,
8358,1,A,1,,,In vivo,50597,Plasma clearance in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621478,BAO_0000218,
8359,1,A,1,,,In vivo,50597,Plasma clearance was evaluated in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621479,BAO_0000218,
8360,1,A,1,,,In vivo,50597,Plasma clearance was evaluated in rat; Not tested,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621480,BAO_0000218,
8361,1,A,1,,,In vivo,50597,Plasma clearance rate was determined for the compound in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621481,BAO_0000218,
8362,1,A,1,,,In vivo,50597,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621482,BAO_0000218,
8363,1,A,1,,,In vivo,50597,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621483,BAO_0000218,
8364,1,A,1,,,In vivo,50597,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621484,BAO_0000218,
8365,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621485,BAO_0000218,
8366,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621486,BAO_0000218,
8367,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,160.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621487,BAO_0000218,
8368,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,160.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621488,BAO_0000218,
8369,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,160.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621489,BAO_0000218,
8370,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,160.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621490,BAO_0000218,
8371,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,160.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621491,BAO_0000218,
8372,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621492,BAO_0000218,
8373,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621493,BAO_0000218,
8374,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621494,BAO_0000218,
8375,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621495,BAO_0000218,
8376,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621496,BAO_0000218,
8377,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621497,BAO_0000218,
8378,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621498,BAO_0000218,
8379,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621499,BAO_0000218,
8380,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618634,BAO_0000218,
8381,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618635,BAO_0000218,
8382,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618636,BAO_0000218,
8383,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619737,BAO_0000218,
8384,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619738,BAO_0000218,
8385,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624329,BAO_0000218,
8386,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624330,BAO_0000218,
8387,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624331,BAO_0000218,
8388,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624332,BAO_0000218,
8389,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624333,BAO_0000218,
8390,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624334,BAO_0000218,
8391,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624335,BAO_0000218,
8392,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620016,BAO_0000218,
8393,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620169,BAO_0000218,
8394,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620170,BAO_0000218,
8395,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620171,BAO_0000218,
8396,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620172,BAO_0000218,
8397,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,945.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620173,BAO_0000218,
8398,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,945.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620174,BAO_0000218,
8399,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,945.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620175,BAO_0000218,
8400,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,945.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620176,BAO_0000218,
8401,1,A,1,,,In vivo,50597,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,945.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620177,BAO_0000218,
8402,1,A,1,,,,50597,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,2037.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620178,BAO_0000218,
8403,1,A,1,,,,50597,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,2037.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620179,BAO_0000218,
8404,1,A,1,,,,50597,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620180,BAO_0000218,
8405,1,A,1,,,In vivo,50597,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620181,BAO_0000218,
8406,1,A,1,,,In vivo,50597,Volume of distribution of compound in rats after intravenous administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620182,BAO_0000218,
8407,1,A,1,,,In vivo,50597,Volume of distribution in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620183,BAO_0000218,
8408,1,A,1,,,In vivo,50597,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620184,BAO_0000218,
8409,1,A,1,,,In vivo,50597,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620185,BAO_0000218,
8410,1,A,1,,,In vivo,50597,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620186,BAO_0000218,
8411,1,A,1,,,In vivo,50597,Volume of distribution was determined in Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620187,BAO_0000218,
8412,1,A,1,,,In vivo,50597,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620188,BAO_0000218,
8413,1,A,1,,,In vivo,50597,Volume of distribution was reported in Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620189,BAO_0000218,
8414,1,A,1,,,In vivo,50597,Volumes of distribution in rat after peroral administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620190,BAO_0000218,
8415,1,A,1,,,In vivo,50597,Volumes of distribution in rat after po administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620191,BAO_0000218,
8416,1,A,1,,,In vivo,50597,Volumes of distribution in rat after po administration; Not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620192,BAO_0000218,
8417,1,A,1,,,In vivo,50597,Pharmacokinetic property (Volume) in rat i.v.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620193,BAO_0000218,
8418,1,A,1,,,In vivo,50597,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620194,BAO_0000218,
8419,1,A,1,,,In vivo,50597,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876730,BAO_0000218,
8420,1,A,1,,,In vivo,50597,Volume distribution in rat after oral administration at 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620195,BAO_0000218,
8421,1,A,1,,,In vivo,50597,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620196,BAO_0000218,
8422,1,A,1,,,In vivo,50597,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620197,BAO_0000218,
8423,1,A,1,,,In vivo,50597,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620198,BAO_0000218,
8424,1,A,1,,,In vivo,50597,Volume of distribution in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620199,BAO_0000218,
8425,1,A,1,,,In vivo,50597,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620200,BAO_0000218,
8426,1,A,1,,,In vivo,50597,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620201,BAO_0000218,
8427,1,A,1,,,In vivo,50597,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620202,BAO_0000218,
8428,1,A,1,,,In vivo,50597,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620203,BAO_0000218,
8429,1,A,1,,,In vivo,50597,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620204,BAO_0000218,
8430,1,A,1,,,In vivo,50597,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620205,BAO_0000218,
8431,1,A,1,,,In vivo,50597,Pharmacokinetic parameter (Vss) in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624664,BAO_0000218,
8432,1,A,1,,,In vivo,50597,Pharmacokinetic property (Volume) in rat i.v.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624665,BAO_0000218,
8433,1,A,1,,,,50597,Pharmacokinetic property (Vss) in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624666,BAO_0000218,
8434,1,A,1,,,In vivo,50597,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624667,BAO_0000218,
8435,1,A,1,,,In vivo,50597,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624668,BAO_0000218,
8436,1,A,1,,,In vivo,50597,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624669,BAO_0000218,
8437,1,A,1,,,In vivo,50597,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624670,BAO_0000218,
8438,1,A,1,,,In vivo,50597,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624671,BAO_0000218,
8439,1,A,1,,,In vivo,50597,Steady state volume distribution in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624672,BAO_0000218,
8440,1,A,1,,,In vivo,50597,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624673,BAO_0000218,
8441,1,A,1,,,In vivo,50597,Steady state volume of distribution determined in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624674,BAO_0000218,
8442,1,A,1,,,In vivo,50597,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624675,BAO_0000218,
8443,1,A,1,,,In vivo,50597,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621728,BAO_0000218,
8444,1,A,1,,,,50597,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621729,BAO_0000218,
8445,1,A,1,,,,50597,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621730,BAO_0000218,
8446,1,A,1,,,In vivo,50597,Volume distribution in rat after administration of 2 mg/kg iv,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621731,BAO_0000218,
8447,1,A,1,,,In vivo,50597,Volume distribution in rat after administration of 2 mg/kg iv,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621732,BAO_0000218,
8448,1,A,1,,,In vivo,50597,Volume in steady state distribution value was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621908,BAO_0000218,
8449,1,A,1,,,In vivo,50597,Volume in steady state distribution value was determined; ND denotes no data,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875347,BAO_0000218,
8450,1,A,1,,,In vivo,50597,Volume in steady state distribution value was determined; ND denotes not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621909,BAO_0000218,
8451,1,A,1,,,In vivo,50597,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621910,BAO_0000218,
8452,1,A,1,,,In vivo,50597,Volume of distribution at steady state was evaluated in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621911,BAO_0000218,
8453,1,A,1,,,In vivo,50597,Volume of distribution at steady state was observed after intravenous administration in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621912,BAO_0000218,
8454,1,A,1,,,In vivo,50597,Volume of distribution in steady state was determined in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621913,BAO_0000218,
8455,1,A,1,,,In vivo,50597,Volume of distribution in steady state was determined in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621914,BAO_0000218,
8456,1,A,1,,,In vivo,50597,Volume of distribution after i.v. administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621915,BAO_0000218,
8457,1,A,1,,,In vivo,50597,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621916,BAO_0000218,
8458,1,A,1,,,In vivo,50594,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621917,BAO_0000218,
8459,1,A,1,,,In vivo,50594,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621918,BAO_0000218,
8460,1,A,1,,,In vivo,50594,Biodistribution of compound (oxidized form) in spleen tissue,2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621919,BAO_0000218,
8461,1,A,1,,,In vivo,50594,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621920,BAO_0000218,
8462,1,A,1,,,In vivo,50594,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621921,BAO_0000218,
8463,1,A,1,,,In vivo,50594,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622401,BAO_0000218,
8464,1,A,1,,,In vivo,50594,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL875348,BAO_0000218,
8465,1,A,1,,,In vivo,50594,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622402,BAO_0000218,
8466,1,A,1,,,In vivo,50594,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622403,BAO_0000218,
8467,1,A,1,,,In vivo,50594,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622404,BAO_0000218,
8468,1,A,1,,,In vivo,50594,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622405,BAO_0000218,
8469,1,A,1,,,In vivo,50594,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622406,BAO_0000218,
8470,1,A,1,,,In vivo,50594,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622407,BAO_0000218,
8471,1,A,1,,,In vivo,50594,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622408,BAO_0000218,
8472,1,A,1,,,In vivo,50594,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622409,BAO_0000218,
8473,1,A,1,,,In vivo,50594,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622410,BAO_0000218,
8474,1,A,1,,,In vivo,50594,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622411,BAO_0000218,
8475,1,A,1,,,In vivo,50594,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627864,BAO_0000218,
8476,1,A,1,,,In vivo,50594,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627865,BAO_0000218,
8477,1,A,1,,,In vivo,50594,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627866,BAO_0000218,
8478,1,A,1,,,In vivo,50594,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627751,BAO_0000218,
8479,1,A,1,,,In vivo,50594,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627752,BAO_0000218,
8480,1,A,1,,,In vivo,50594,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627753,BAO_0000218,
8481,1,A,1,,,In vivo,50594,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627754,BAO_0000218,
8482,1,A,1,,,,50594,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627755,BAO_0000218,
8483,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627756,BAO_0000218,
8484,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627757,BAO_0000218,
8485,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627758,BAO_0000218,
8486,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627759,BAO_0000218,
8487,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627760,BAO_0000218,
8488,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627761,BAO_0000218,
8489,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL876811,BAO_0000218,
8490,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627762,BAO_0000218,
8491,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627763,BAO_0000218,
8492,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627764,BAO_0000218,
8493,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627765,BAO_0000218,
8494,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627766,BAO_0000218,
8495,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627767,BAO_0000218,
8496,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627768,BAO_0000218,
8497,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL628422,BAO_0000218,
8498,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL628423,BAO_0000218,
8499,1,A,1,,,In vivo,50597,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628424,BAO_0000218,
8500,1,A,1,,,In vivo,50597,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628425,BAO_0000218,
8501,1,A,1,,,In vivo,50597,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628426,BAO_0000218,
8502,1,A,1,,,In vivo,50597,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628427,BAO_0000218,
8503,1,A,1,,,In vivo,50597,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626938,BAO_0000218,
8504,1,A,1,,,In vivo,50597,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626939,BAO_0000218,
8505,1,A,1,,,In vivo,50597,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626940,BAO_0000218,
8506,1,A,1,,,In vivo,50597,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626941,BAO_0000218,
8507,1,A,1,,,In vivo,50597,Plasma clearance was reported in Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626942,BAO_0000218,
8508,1,A,1,,,In vivo,50597,Plasma clearance after intravenous administration (1 mg/kg) in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876812,BAO_0000218,
8509,1,A,1,,,In vivo,50597,Plasma clearance of compound in rats was evaluated,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626943,BAO_0000218,
8510,1,A,1,,,In vivo,50597,Plasma clearance of compound in rats was evaluated; ND indicates not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626944,BAO_0000218,
8511,1,A,1,,,In vivo,50597,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626945,BAO_0000218,
8512,1,A,1,,,In vivo,50597,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626946,BAO_0000218,
8513,1,A,1,,,In vivo,50597,Plasma clearance rate in Sprague-Dawley rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626856,BAO_0000218,
8514,1,A,1,,,In vivo,50597,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626857,BAO_0000218,
8515,1,A,1,,,In vivo,50597,The compound was evaluated for plasma clearance in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626858,BAO_0000218,
8516,1,A,1,,,In vivo,50597,Total plasma clearance in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627018,BAO_0000218,
8517,1,A,1,,,In vivo,50597,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625331,BAO_0000218,
8518,1,A,1,,,In vivo,50597,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625332,BAO_0000218,
8519,1,A,1,,,In vivo,50597,C max was determined at 10 mg/kg po dose in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL877590,BAO_0000218,
8520,1,A,1,,,In vivo,50597,C max was determined at 3 mg/kg po dose in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625333,BAO_0000218,
8521,1,A,1,,,In vivo,50597,Cmax after repeated oral dose of compound at 1 mg/kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625334,BAO_0000218,
8522,1,A,1,,,In vivo,50597,Cmax after single intravenous bolus of 1 mg/kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625335,BAO_0000218,
8523,1,A,1,,,In vivo,50597,Cmax of compound at 5 mg/kg after po administration was determined in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625336,BAO_0000218,
8524,1,A,1,,,In vivo,50597,Cmax 24 hr after 10 mg/kg oral administration in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625337,BAO_0000218,
8525,1,A,1,,,In vivo,50597,Cmax 24 hr after 2 mg/kg oral administration in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625338,BAO_0000218,
8526,1,A,1,,,In vivo,50597,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625339,BAO_0000218,
8527,1,A,1,,,In vivo,50597,Cmax in rat after administration of 2 mg/kg iv,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625340,BAO_0000218,
8528,1,A,1,,,In vivo,50597,Cmax in rat after administration of 2 mg/kg iv,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625341,BAO_0000218,
8529,1,A,1,,,In vivo,50597,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622687,BAO_0000218,
8530,1,A,1,,,In vivo,50597,Cmax wa determined in rat plasma at 30 mg/kg after po administration,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622688,BAO_0000218,
8531,1,A,1,,,In vivo,50597,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622689,BAO_0000218,
8532,1,A,1,,,In vivo,50597,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620295,BAO_0000218,
8533,1,A,1,,,In vivo,50597,Cmax after 10 mg/kg oral administration in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620296,BAO_0000218,
8534,1,A,1,,,In vivo,50597,Cmax after IV dosing at 0.5 mg/kg in rat; no data,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620297,BAO_0000218,
8535,1,A,1,,,In vivo,50597,Cmax after IV dosing at 1 mg/kg in rat; no data,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620298,BAO_0000218,
8536,1,A,1,,,In vivo,50597,Cmax after oral administration at 20 mpk in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620299,BAO_0000218,
8537,1,A,1,,,In vivo,50597,Cmax after oral administration at 20 mpk in rats; Not performed.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620300,BAO_0000218,
8538,1,A,1,,,In vivo,50597,Cmax after oral administration at 20 mpk in rats d; Not performed.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620301,BAO_0000218,
8539,1,A,1,,,In vivo,50597,Cmax after oral administration in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620302,BAO_0000218,
8540,1,A,1,,,In vivo,50597,Cmax after oral administration at a dose of 2 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620303,BAO_0000218,
8541,1,A,1,,,In vivo,50597,Cmax after oral administration at a dose of 4 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620304,BAO_0000218,
8542,1,A,1,,,In vivo,50597,Cmax in rats after 20 mg/kg oral dose,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620305,BAO_0000218,
8543,1,A,1,,,In vivo,50597,Cmax after peroral administration in rats at 2.4 uM/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620306,BAO_0000218,
8544,1,A,1,,,In vivo,50597,Cmax at the dose of 2 mg/Kg administered perorally in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620307,BAO_0000218,
8545,1,A,1,,,In vivo,50597,Cmax at the dose of 5 mg/Kg administered perorally in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620308,BAO_0000218,
8546,1,A,1,,,In vivo,50597,Cmax by administering at 20 mg/kg p.o. in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620309,BAO_0000218,
8547,1,A,1,,,In vivo,50597,Cmax in male rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620310,BAO_0000218,
8548,1,A,1,,,In vivo,50597,Cmax in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620311,BAO_0000218,
8549,1,A,1,,,In vivo,50597,Cmax in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620312,BAO_0000218,
8550,1,A,1,,,In vivo,50597,Cmax in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620313,BAO_0000218,
8551,1,A,1,,,In vivo,50597,Cmax in rat at 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620314,BAO_0000218,
8552,1,A,1,,,In vivo,50597,Cmax in rat at the dose of 1 mg/kg i.v.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620315,BAO_0000218,
8553,1,A,1,,,In vivo,50597,Cmax in rat by po administration at a dose of 40 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620316,BAO_0000218,
8554,1,A,1,,,In vivo,50597,Cmax in rat p.o. at 20 mg/kg concentration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620317,BAO_0000218,
8555,1,A,1,,,In vivo,50597,Cmax in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620318,BAO_0000218,
8556,1,A,1,,,In vivo,50597,Cmax in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620319,BAO_0000218,
8557,1,A,1,,,In vivo,50597,Cmax was evaluated after 20 uM/kg of peroral administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620320,BAO_0000218,
8558,1,A,1,,,In vivo,50597,Cmax was measured in rats after peroral administration at 3 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620321,BAO_0000218,
8559,1,A,1,,,In vivo,50597,Cmax value after oral dose at a dose of 10 mg/kg in rats.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620322,BAO_0000218,
8560,1,A,1,,,,50597,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620323,BAO_0000218,
8561,1,A,1,,,,50597,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,1870.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620324,BAO_0000218,
8562,1,A,1,,,,50597,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,1870.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620325,BAO_0000218,
8563,1,A,1,,,,50597,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,10000000.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620326,BAO_0000218,
8564,1,A,1,,,,50597,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,10000000.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620327,BAO_0000218,
8565,1,A,1,,,,50597,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620328,BAO_0000218,
8566,1,A,1,,,,50597,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620329,BAO_0000218,
8567,1,A,1,,,,50597,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,1891.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620330,BAO_0000218,
8568,1,A,1,,,,50597,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,1891.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875286,BAO_0000218,
8569,1,A,1,,,,50597,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620331,BAO_0000218,
8570,1,A,1,,,,50597,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620332,BAO_0000218,
8571,1,A,1,,,,50597,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,2435.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620333,BAO_0000218,
8572,1,A,1,,,,50597,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,2435.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620334,BAO_0000218,
8573,1,A,1,,,,50597,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621015,BAO_0000218,
8574,1,A,1,,,,50597,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621016,BAO_0000218,
8575,1,A,1,,,,50597,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621191,BAO_0000218,
8576,1,A,1,,,,50597,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621192,BAO_0000218,
8577,1,A,1,,,,50597,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621193,BAO_0000218,
8578,1,A,1,,,,50597,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621194,BAO_0000218,
8579,1,A,1,,,,50597,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624204,BAO_0000218,
8580,1,A,1,,,,50597,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624205,BAO_0000218,
8581,1,A,1,,,,50597,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624206,BAO_0000218,
8582,1,A,1,,,,50597,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624207,BAO_0000218,
8583,1,A,1,,,,50597,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624208,BAO_0000218,
8584,1,A,1,,,,50597,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624209,BAO_0000218,
8585,1,A,1,,,,50597,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624210,BAO_0000218,
8586,1,A,1,,,,50597,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624211,BAO_0000218,
8587,1,A,1,,,,50597,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624212,BAO_0000218,
8588,1,A,1,,,,50597,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624213,BAO_0000218,
8589,1,A,1,,,,50597,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876611,BAO_0000218,
8590,1,A,1,,,,50597,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624214,BAO_0000218,
8591,1,A,1,,,,50597,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624215,BAO_0000218,
8592,1,A,1,,,,50597,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624216,BAO_0000218,
8593,1,A,1,,,,50597,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624217,BAO_0000218,
8594,1,A,1,,,,50597,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624218,BAO_0000218,
8595,1,A,1,,,,50597,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624219,BAO_0000218,
8596,1,A,1,,,,50597,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624220,BAO_0000218,
8597,1,A,1,,,,50597,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624221,BAO_0000218,
8598,1,A,1,,,,50597,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624222,BAO_0000218,
8599,1,A,1,,,,50597,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624223,BAO_0000218,
8600,1,A,1,,,,50597,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624224,BAO_0000218,
8601,1,A,1,,,,50597,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624225,BAO_0000218,
8602,1,A,1,,,In vivo,50597,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622420,BAO_0000218,
8603,1,A,1,,,In vivo,50597,Volume of steady state distribution after i.v. administration in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622421,BAO_0000218,
8604,1,A,1,,,In vivo,50597,Vss after intravenous administration (5.0 mg/kg) was determined in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622422,BAO_0000218,
8605,1,A,1,,,In vivo,50597,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622423,BAO_0000218,
8606,1,A,1,,,In vivo,50597,Vss was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622424,BAO_0000218,
8607,1,A,1,,,In vivo,50597,Vss in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622425,BAO_0000218,
8608,1,A,1,,,In vivo,50597,Vss was evaluated after 10 uM/kg of intra arterial administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876612,BAO_0000218,
8609,1,A,1,,,In vivo,50597,volume of distribution at steady state was observed after intravenous administration in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622426,BAO_0000218,
8610,1,A,1,,,In vivo,50597,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622427,BAO_0000218,
8611,1,A,1,,,In vivo,50597,Pharmacokinetic (PK) parameter Vz in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622428,BAO_0000218,
8612,1,A,1,,,In vivo,50597,Volume distribution in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622429,BAO_0000218,
8613,1,A,1,,,In vivo,50597,Volume of distribution in rat; No data,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622430,BAO_0000218,
8614,1,A,1,,,In vivo,50597,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622431,BAO_0000218,
8615,1,A,1,,,,50597,% absorption predicted from in vitro rat ileum transport studies,2116.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622432,BAO_0000218,
8616,1,A,1,,,In vivo,50597,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622433,BAO_0000218,
8617,1,A,1,,,In vivo,50597,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622434,BAO_0000218,
8618,1,A,1,,,In vivo,50597,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622435,BAO_0000218,
8619,1,A,1,,,In vivo,50597,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618748,BAO_0000218,
8620,1,A,1,,,In vivo,50597,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618749,BAO_0000218,
8621,1,A,1,,,In vivo,50597,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618750,BAO_0000218,
8622,1,A,1,,,In vivo,50597,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618751,BAO_0000218,
8623,1,A,1,,,In vivo,50597,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618752,BAO_0000218,
8624,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618753,BAO_0000218,
8625,1,A,1,,,In vivo,50597,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618754,BAO_0000218,
8626,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618755,BAO_0000218,
8627,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618756,BAO_0000218,
8628,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618757,BAO_0000218,
8629,1,A,1,,,In vivo,50597,Bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618758,BAO_0000218,
8630,1,A,1,,,In vivo,50597,Oral bioavailability in rat (dose 30 mg/kg),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621088,BAO_0000218,
8631,1,A,1,,,,50597,Pharmacokinetic property (cLogP) in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621089,BAO_0000218,
8632,1,F,1,,,,50597,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621090,BAO_0000218,
8633,1,F,1,,,,50597,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621091,BAO_0000218,
8634,1,A,1,,,In vivo,50597,Clearance in rat.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876731,BAO_0000218,
8635,1,A,1,,,In vivo,50597,Compound was evaluated for its clearance when administered intravenously in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621092,BAO_0000218,
8636,1,A,1,,,In vivo,50597,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621093,BAO_0000218,
8637,1,A,1,,,,50597,Blood: Brain distribution ratio is determined in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621094,BAO_0000218,
8638,1,A,1,,,,50597,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621095,BAO_0000218,
8639,1,A,1,,,,50597,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621096,BAO_0000218,
8640,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621097,BAO_0000218,
8641,1,F,1,,,,50597,Percent dose excreted in 0-48 hours administered ip to male rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621098,BAO_0000218,
8642,1,A,1,,,,50597,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),2037.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621099,BAO_0000218,
8643,1,A,1,,,,50597,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),2037.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621100,BAO_0000218,
8644,1,A,1,,,,50597,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),2037.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621101,BAO_0000218,
8645,1,A,1,,,,50597,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),2037.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621102,BAO_0000218,
8646,1,A,1,,,,50597,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),2037.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876732,BAO_0000218,
8647,1,A,1,,,,50597,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621103,BAO_0000218,
8648,1,A,1,,,,50597,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621104,BAO_0000218,
8649,1,A,1,,,,50597,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621105,BAO_0000218,
8650,1,A,1,,,,50597,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621106,BAO_0000218,
8651,1,A,1,,,,50597,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621107,BAO_0000218,
8652,1,A,1,,,,50597,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621108,BAO_0000218,
8653,1,A,1,,,,50597,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621109,BAO_0000218,
8654,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621110,BAO_0000218,
8655,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621111,BAO_0000218,
8656,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622541,BAO_0000218,
8657,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622542,BAO_0000218,
8658,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622543,BAO_0000218,
8659,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624412,BAO_0000218,
8660,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624413,BAO_0000218,
8661,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624414,BAO_0000218,
8662,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),2048.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624415,BAO_0000218,
8663,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),2048.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624416,BAO_0000218,
8664,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),2048.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624417,BAO_0000218,
8665,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),2048.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624418,BAO_0000218,
8666,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),2048.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624419,BAO_0000218,
8667,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),2048.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624420,BAO_0000218,
8668,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),2385.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624421,BAO_0000218,
8669,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),2385.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624422,BAO_0000218,
8670,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),2385.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624423,BAO_0000218,
8671,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),2385.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625123,BAO_0000218,
8672,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),2385.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625124,BAO_0000218,
8673,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),2385.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625125,BAO_0000218,
8674,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),14.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625126,BAO_0000218,
8675,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),14.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626947,BAO_0000218,
8676,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),14.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626948,BAO_0000218,
8677,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),14.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626949,BAO_0000218,
8678,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),14.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626950,BAO_0000218,
8679,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),14.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626951,BAO_0000218,
8680,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626952,BAO_0000218,
8681,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626953,BAO_0000218,
8682,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626954,BAO_0000218,
8683,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626955,BAO_0000218,
8684,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626956,BAO_0000218,
8685,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626957,BAO_0000218,
8686,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626958,BAO_0000218,
8687,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626959,BAO_0000218,
8688,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626960,BAO_0000218,
8689,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626961,BAO_0000218,
8690,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627589,BAO_0000218,
8691,1,A,1,,,In vivo,50594,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627590,BAO_0000218,
8692,1,A,1,,,,50594,Time taken for EC90 was determined when tested in mouse,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627591,BAO_0000218,
8693,1,A,1,,,,50594,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627592,BAO_0000218,
8694,1,A,1,,,In vivo,50594,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627593,BAO_0000218,
8695,1,A,1,,,,50594,Half life in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627594,BAO_0000218,
8696,1,A,1,,,In vivo,50594,Half life period in mouse after 10 mg/Kg dose,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL876813,BAO_0000218,
8697,1,A,1,,,In vivo,50594,Half life period in mouse after 10 mg/kg dose,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627595,BAO_0000218,
8698,1,A,1,,,In vivo,50594,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627596,BAO_0000218,
8699,1,A,1,,,In vivo,50597,Cmax value at 5 mg/kg po was determined in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627597,BAO_0000218,
8700,1,A,1,,,In vivo,50597,Cmax value evaluated in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627598,BAO_0000218,
8701,1,A,1,,,In vivo,50597,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627599,BAO_0000218,
8702,1,A,1,,,In vivo,50597,Cmax value after administration of 20 mg/Kg oral dose in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627600,BAO_0000218,
8703,1,A,1,,,In vivo,50597,Cmax value at 1 mg/kg po in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627601,BAO_0000218,
8704,1,A,1,,,In vivo,50597,Cmax value at 5 mg/kg po in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627776,BAO_0000218,
8705,1,A,1,,,In vivo,50597,Cmax value at a dose of 10 mg/kg in male SD rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627777,BAO_0000218,
8706,1,A,1,,,In vivo,50597,Cmax value at a dose of 100 mg/kg in male SD rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627778,BAO_0000218,
8707,1,A,1,,,In vivo,50597,Cmax value at a dose of 50 mg/kg in male SD rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627779,BAO_0000218,
8708,1,A,1,,,In vivo,50597,Cmax value in rats at 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876814,BAO_0000218,
8709,1,A,1,,,In vivo,50597,Cmax value was evaluated in rats at a dose of 20 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627780,BAO_0000218,
8710,1,A,1,,,In vivo,50597,Cmax value was determined after peroral administration of 20 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627781,BAO_0000218,
8711,1,A,1,,,In vivo,50597,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627782,BAO_0000218,
8712,1,A,1,,,In vivo,50597,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627783,BAO_0000218,
8713,1,A,1,,,In vivo,50597,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627784,BAO_0000218,
8714,1,A,1,,,In vivo,50597,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627785,BAO_0000218,
8715,1,A,1,,,In vivo,50597,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627786,BAO_0000218,
8716,1,A,1,,,In vivo,50597,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627787,BAO_0000218,
8717,1,A,1,,,In vivo,50597,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627788,BAO_0000218,
8718,1,A,1,,,In vivo,50597,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626579,BAO_0000218,
8719,1,A,1,,,In vivo,50597,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626580,BAO_0000218,
8720,1,A,1,,,In vivo,50597,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876815,BAO_0000218,
8721,1,A,1,,,In vivo,50597,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626581,BAO_0000218,
8722,1,A,1,,,In vivo,50597,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626582,BAO_0000218,
8723,1,A,1,,,In vivo,50597,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626583,BAO_0000218,
8724,1,A,1,,,In vivo,50597,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626205,BAO_0000218,
8725,1,A,1,,,In vivo,50597,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626206,BAO_0000218,
8726,1,A,1,,,In vivo,50597,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626207,BAO_0000218,
8727,1,A,1,,,In vivo,50597,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623882,BAO_0000218,
8728,1,A,1,,,In vivo,50597,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623883,BAO_0000218,
8729,1,A,1,,,In vivo,50597,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623884,BAO_0000218,
8730,1,A,1,,,In vivo,50597,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623885,BAO_0000218,
8731,1,A,1,,,In vivo,50597,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623886,BAO_0000218,
8732,1,A,1,,,In vivo,50597,Maximal concentration in rat was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623887,BAO_0000218,
8733,1,A,1,,,In vivo,50597,Maximal concentration after i.v. administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623888,BAO_0000218,
8734,1,A,1,,,In vivo,50597,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623889,BAO_0000218,
8735,1,A,1,,,In vivo,50597,Maximal plasma concentration in rat after oral administration at 50 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623890,BAO_0000218,
8736,1,A,1,,,In vivo,50597,Cmax in rat plasma after oral dose (50 mg/Kg),1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623891,BAO_0000218,
8737,1,A,1,,,In vivo,50597,Maximal plasma concentration was determined.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623892,BAO_0000218,
8738,1,A,1,,,In vivo,50597,Maximal plasma drug concentration was determined,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623893,BAO_0000218,
8739,1,A,1,,,In vivo,50597,Maximal concentration in rats after peroral administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL877616,BAO_0000218,
8740,1,A,1,,,In vivo,50597,Maximum concentration in rat after 2 mg/kg peroral administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623894,BAO_0000218,
8741,1,A,1,,,In vivo,50597,Maximum concentration in rat plasma after 5 mg/kg oral gavage,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623895,BAO_0000218,
8742,1,A,1,,,In vivo,50597,Maximum concentration of compound in rat was evaluated.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623896,BAO_0000218,
8743,1,A,1,,,In vivo,50597,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623897,BAO_0000218,
8744,1,A,1,,,In vivo,50597,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623898,BAO_0000218,
8745,1,A,1,,,In vivo,50597,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623899,BAO_0000218,
8746,1,A,1,,,In vivo,50597,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623900,BAO_0000218,
8747,1,A,1,,,In vivo,50597,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623901,BAO_0000218,
8748,1,A,1,,,In vivo,50597,Maximum concentration was evaluated in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623902,BAO_0000218,
8749,1,A,1,,,In vivo,50597,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,1359.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623903,BAO_0000218,
8750,1,A,1,,,In vivo,50597,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623904,BAO_0000218,
8751,1,A,1,,,In vivo,50597,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL877617,BAO_0000218,
8752,1,A,1,,,In vivo,50597,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623905,BAO_0000218,
8753,1,A,1,,,In vivo,50597,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623906,BAO_0000218,
8754,1,A,1,,,In vivo,50597,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623907,BAO_0000218,
8755,1,A,1,,,,50597,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623908,BAO_0000218,
8756,1,A,1,,,,50597,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623909,BAO_0000218,
8757,1,A,1,,,,50597,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623910,BAO_0000218,
8758,1,A,1,,,,50597,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623911,BAO_0000218,
8759,1,A,1,,,,50597,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623912,BAO_0000218,
8760,1,A,1,,,,50597,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624616,BAO_0000218,
8761,1,A,1,,,,50597,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624617,BAO_0000218,
8762,1,A,1,,,,50597,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624618,BAO_0000218,
8763,1,A,1,,,,50597,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624619,BAO_0000218,
8764,1,A,1,,,,50597,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624794,BAO_0000218,
8765,1,A,1,,,,50597,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624795,BAO_0000218,
8766,1,A,1,,,,50597,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623921,BAO_0000218,
8767,1,A,1,,,,50597,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623922,BAO_0000218,
8768,1,A,1,,,,50597,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623923,BAO_0000218,
8769,1,A,1,,,,50597,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623924,BAO_0000218,
8770,1,A,1,,,,50597,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623925,BAO_0000218,
8771,1,A,1,,,,50597,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623926,BAO_0000218,
8772,1,A,1,,,,50597,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623927,BAO_0000218,
8773,1,A,1,,,,50597,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623928,BAO_0000218,
8774,1,A,1,,,,50597,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623929,BAO_0000218,
8775,1,A,1,,,,50597,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623930,BAO_0000218,
8776,1,A,1,,,,50597,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623931,BAO_0000218,
8777,1,A,1,,,,50597,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622165,BAO_0000218,
8778,1,A,1,,,,50597,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621249,BAO_0000218,
8779,1,A,1,,,,50597,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621250,BAO_0000218,
8780,1,A,1,,,,50597,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621448,BAO_0000218,
8781,1,A,1,,,,50597,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621449,BAO_0000218,
8782,1,A,1,,,,50597,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621450,BAO_0000218,
8783,1,A,1,,,,50597,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621451,BAO_0000218,
8784,1,A,1,,,,50597,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621452,BAO_0000218,
8785,1,A,1,,,,50597,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621453,BAO_0000218,
8786,1,A,1,,,,50597,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621454,BAO_0000218,
8787,1,A,1,,,,50597,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621455,BAO_0000218,
8788,1,A,1,,,,50597,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621456,BAO_0000218,
8789,1,A,1,,,,50597,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625145,BAO_0000218,
8790,1,A,1,,,,50597,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875847,BAO_0000218,
8791,1,A,1,,,,50597,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625146,BAO_0000218,
8792,1,A,1,,,,50597,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625147,BAO_0000218,
8793,1,A,1,,,,50597,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625148,BAO_0000218,
8794,1,A,1,,,,50597,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625149,BAO_0000218,
8795,1,A,1,,,,50597,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625150,BAO_0000218,
8796,1,A,1,,,,50597,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625151,BAO_0000218,
8797,1,A,1,,,,50597,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625152,BAO_0000218,
8798,1,A,1,,,,50597,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625153,BAO_0000218,
8799,1,A,1,,,,50597,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625154,BAO_0000218,
8800,1,A,1,,,,50597,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625155,BAO_0000218,
8801,1,A,1,,,,50597,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625156,BAO_0000218,
8802,1,A,1,,,,50597,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624354,BAO_0000218,
8803,1,A,1,,,,50597,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),10000000.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624355,BAO_0000218,
8804,1,A,1,,,,50597,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),10000000.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624356,BAO_0000218,
8805,1,A,1,,,,50597,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),10000000.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624357,BAO_0000218,
8806,1,A,1,,,,50597,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),10000000.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624358,BAO_0000218,
8807,1,A,1,,,,50597,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),2435.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624359,BAO_0000218,
8808,1,A,1,,,,50597,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),2435.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624360,BAO_0000218,
8809,1,A,1,,,,50597,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),2435.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624361,BAO_0000218,
8810,1,A,1,,,,50597,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),2435.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624362,BAO_0000218,
8811,1,A,1,,,,50597,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),2435.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624363,BAO_0000218,
8812,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624364,BAO_0000218,
8813,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624365,BAO_0000218,
8814,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624366,BAO_0000218,
8815,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624367,BAO_0000218,
8816,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624368,BAO_0000218,
8817,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624369,BAO_0000218,
8818,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624370,BAO_0000218,
8819,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625069,BAO_0000218,
8820,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625070,BAO_0000218,
8821,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626051,BAO_0000218,
8822,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626052,BAO_0000218,
8823,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626053,BAO_0000218,
8824,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626054,BAO_0000218,
8825,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626055,BAO_0000218,
8826,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626056,BAO_0000218,
8827,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626057,BAO_0000218,
8828,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625193,BAO_0000218,
8829,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625194,BAO_0000218,
8830,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625195,BAO_0000218,
8831,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625196,BAO_0000218,
8832,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625197,BAO_0000218,
8833,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625198,BAO_0000218,
8834,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627929,BAO_0000218,
8835,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627074,BAO_0000218,
8836,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627075,BAO_0000218,
8837,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627076,BAO_0000218,
8838,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627077,BAO_0000218,
8839,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627078,BAO_0000218,
8840,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627079,BAO_0000218,
8841,1,A,1,,,In vivo,50594,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL873824,BAO_0000218,
8842,1,A,1,,,In vivo,50594,Half life in mouse plasma was determined at dose 25 mg/kg,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627080,BAO_0000218,
8843,1,A,1,,,,50594,Half life was determined,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627081,BAO_0000218,
8844,1,A,1,,,In vivo,50594,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627082,BAO_0000218,
8845,1,A,1,,,In vivo,50594,Half-life in male mice after 1 mg/kg intravenous dose,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627083,BAO_0000218,
8847,1,A,1,,,,50594,Half life in mice plasma,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627085,BAO_0000218,
8848,1,A,1,,,,50594,Half life in mouse,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627086,BAO_0000218,
8849,1,A,1,,,In vivo,50594,Half life in mouse plasma at dose 25 mg/kg,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627087,BAO_0000218,
8850,1,A,1,,,In vivo,50594,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627088,BAO_0000218,
8851,1,A,1,,,In vivo,50594,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627089,BAO_0000218,
8852,1,A,1,,,In vivo,50594,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627090,BAO_0000218,
8853,1,A,1,,,In vivo,50594,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627091,BAO_0000218,
8854,1,A,1,,,In vivo,50594,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627092,BAO_0000218,
8855,1,A,1,,,In vivo,50594,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL876785,BAO_0000218,
8856,1,A,1,,,In vivo,50594,Half-life by iv administration in mouse,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627093,BAO_0000218,
8857,1,A,1,,,In vivo,50594,Half-life by oral administration in mouse,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627094,BAO_0000218,
8858,1,A,1,,,,50594,Half-life in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627095,BAO_0000218,
8859,1,A,1,,,,50594,Half-life using mouse brain homogenate,955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627096,BAO_0000218,
8860,1,A,1,,,,50594,Half-life was measured in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627097,BAO_0000218,
8861,1,A,1,,,In vivo,50594,Half-life was measured in mouse after an iv dose of 1 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627098,BAO_0000218,
8862,1,A,1,,,,50594,Half-life period was determined in mouse blood,178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627099,BAO_0000218,
8863,1,A,1,,,,50594,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627100,BAO_0000218,
8864,1,A,1,,,,50594,Plasma half life in mouse,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627101,BAO_0000218,
8865,1,A,1,,,,50594,Stability of the peptide in the presence of mouse serum,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627102,BAO_0000218,
8866,1,A,1,,,,50594,Terminal half life of compound was determined in mouse,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627103,BAO_0000218,
8867,1,A,1,,,In vivo,50594,Terminal half life was evaluated in mice after intravenous administration,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627104,BAO_0000218,
8868,1,A,1,,,In vivo,50594,Terminal half life was evaluated in mice after oral administration,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627105,BAO_0000218,
8869,1,A,1,,,,50594,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL876786,BAO_0000218,
8870,1,A,1,,,,50594,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL873825,BAO_0000218,
8871,1,A,1,,,,50594,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627106,BAO_0000218,
8872,1,A,1,,,In vivo,50594,half life period is evaluated by administering intravenously at 25 mg/kg in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626336,BAO_0000218,
8873,1,A,1,,,In vivo,50594,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL877462,BAO_0000218,
8874,1,A,1,,,In vivo,50594,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626337,BAO_0000218,
8875,1,A,1,,,,50594,Half life after intraperitoneal administration of 100 mg/kg in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626338,BAO_0000218,
8876,1,A,1,,,In vivo,50594,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626339,BAO_0000218,
8877,1,A,1,,,In vivo,50594,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626340,BAO_0000218,
8878,1,A,1,,,In vivo,50594,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625377,BAO_0000218,
8879,1,A,1,,,In vivo,50594,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625378,BAO_0000218,
8880,1,A,1,,,In vivo,50594,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625379,BAO_0000218,
8881,1,A,0,,,,22224,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),,Sus scrofa,,,,9823.0,U,Autocuration,CHEMBL625380,BAO_0000251,
8882,1,A,0,,,,22224,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),,Sus scrofa,,,,9823.0,U,Autocuration,CHEMBL625381,BAO_0000251,
8883,1,A,0,,,,22224,Stability to porcine renal DHP-I,,Sus scrofa,,,,9823.0,U,Autocuration,CHEMBL625382,BAO_0000019,
8884,1,A,0,,,In vivo,22224,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,,Sus scrofa,,,,9823.0,U,Autocuration,CHEMBL873828,BAO_0000218,
8885,1,A,0,,,In vivo,22224,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,,Sus scrofa,,,,9823.0,U,Autocuration,CHEMBL625383,BAO_0000218,
8886,1,A,0,,,,22224,Half-life of the parent prodrug in porcine esterase solution,,Sus scrofa,,,,9823.0,U,Autocuration,CHEMBL625384,BAO_0000019,
8887,1,A,0,,,,22224,"First order rate constant, k was determined in in pig liver Esterase",,Sus scrofa,,,,9823.0,U,Autocuration,CHEMBL625385,BAO_0000019,
8888,1,A,0,,,,22224,Half life of the in pig liver Esterase,2107.0,Sus scrofa,,,,9823.0,U,Autocuration,CHEMBL625386,BAO_0000221,
8889,1,A,0,,,,22224,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,2107.0,Sus scrofa,,,,9823.0,U,Autocuration,CHEMBL623571,BAO_0000221,
8890,1,A,0,,,,22224,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,2107.0,Sus scrofa,,,,9823.0,U,Autocuration,CHEMBL623572,BAO_0000221,
8891,1,A,0,,,,22224,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,2107.0,Sus scrofa,,,,9823.0,U,Autocuration,CHEMBL623573,BAO_0000221,
8892,1,A,0,,,,22224,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,2107.0,Sus scrofa,,,,9823.0,U,Autocuration,CHEMBL623574,BAO_0000221,
8893,1,A,0,,,,22224,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,2107.0,Sus scrofa,,,,9823.0,U,Autocuration,CHEMBL623575,BAO_0000221,
8894,1,A,0,,,,22224,Half-life in the presence of pig liver esterase(PLE) was evaluated.,2107.0,Sus scrofa,,,,9823.0,U,Autocuration,CHEMBL623749,BAO_0000221,
8895,1,A,0,,,,22224,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,2107.0,Sus scrofa,,,,9823.0,U,Autocuration,CHEMBL623750,BAO_0000221,
8896,1,A,0,,,In vitro,22224,Half-life in vitro in pig liver,2107.0,Sus scrofa,,,,9823.0,U,Autocuration,CHEMBL623751,BAO_0000221,
8897,1,A,0,,,,22224,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,2107.0,Sus scrofa,,,,9823.0,U,Autocuration,CHEMBL623752,BAO_0000221,
8898,1,A,1,,,In vivo,50597,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623753,BAO_0000218,
8899,1,A,1,,,In vivo,50597,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623754,BAO_0000218,
8900,1,A,1,,,In vivo,50597,Maximum concentration in rat plasma was determined,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623755,BAO_0000218,
8901,1,A,1,,,In vivo,50597,Maximum concentration in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623756,BAO_0000218,
8902,1,A,1,,,In vivo,50597,Maximum concentration in rats at 1-2 hours,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623757,BAO_0000218,
8903,1,A,1,,,In vivo,50597,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623758,BAO_0000218,
8904,1,A,1,,,In vivo,50597,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623759,BAO_0000218,
8905,1,A,1,,,In vivo,50597,Maximum concentration at the dose of 2 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623760,BAO_0000218,
8906,1,A,1,,,In vivo,50597,Maximum concentration was evaluated in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623761,BAO_0000218,
8907,1,A,1,,,In vivo,50597,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623762,BAO_0000218,
8908,1,A,1,,,In vivo,50597,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL877594,BAO_0000218,
8909,1,A,1,,,In vivo,50597,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623763,BAO_0000218,
8910,1,A,1,,,In vivo,50597,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623764,BAO_0000218,
8911,1,A,1,,,In vivo,50597,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623765,BAO_0000218,
8912,1,A,1,,,In vivo,50597,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623766,BAO_0000218,
8913,1,A,1,,,In vivo,50597,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623767,BAO_0000218,
8914,1,A,1,,,In vivo,50597,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623768,BAO_0000218,
8915,1,A,1,,,In vivo,50597,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623769,BAO_0000218,
8916,1,A,1,,,In vivo,50597,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623770,BAO_0000218,
8917,1,A,1,,,In vivo,50597,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623771,BAO_0000218,
8918,1,A,1,,,In vivo,50597,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623772,BAO_0000218,
8919,1,A,1,,,In vivo,50597,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623773,BAO_0000218,
8920,1,A,1,,,In vivo,50597,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623774,BAO_0000218,
8921,1,A,1,,,In vivo,50597,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623775,BAO_0000218,
8922,1,A,1,,,In vivo,50597,Cmax in rat (PO dose),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623776,BAO_0000218,
8923,1,A,1,,,In vivo,50597,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622191,BAO_0000218,
8924,1,A,1,,,In vivo,50597,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622192,BAO_0000218,
8925,1,A,1,,,In vivo,50597,Maximum plasma concentration determined in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622193,BAO_0000218,
8926,1,A,1,,,In vivo,50597,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622194,BAO_0000218,
8927,1,A,1,,,In vivo,50597,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622195,BAO_0000218,
8928,1,A,1,,,In vivo,50597,Maximum plasma concentration in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622196,BAO_0000218,
8929,1,A,1,,,In vivo,50597,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622197,BAO_0000218,
8930,1,A,1,,,In vivo,50597,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622198,BAO_0000218,
8931,1,A,1,,,In vivo,50597,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622199,BAO_0000218,
8932,1,A,1,,,In vivo,50597,Maximum plasma concentration of compound was measured in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622200,BAO_0000218,
8933,1,A,1,,,In vivo,50597,Maximum plasma concentration after 20 mg/kg oral administration in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622201,BAO_0000218,
8934,1,A,1,,,In vivo,50597,Maximum plasma concentration after oral administration to rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623990,BAO_0000218,
8935,1,A,1,,,In vivo,50597,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623991,BAO_0000218,
8936,1,A,1,,,In vivo,50597,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623992,BAO_0000218,
8937,1,A,1,,,In vivo,50597,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623993,BAO_0000218,
8938,1,A,1,,,In vivo,50597,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623994,BAO_0000218,
8939,1,F,1,,,In vivo,50597,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623995,BAO_0000218,
8940,1,F,1,,,In vivo,50597,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623996,BAO_0000218,
8941,1,F,1,,,In vivo,50597,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623997,BAO_0000218,
8942,1,A,1,,,In vivo,50597,Maximum plasma concentration dosed orally in rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623998,BAO_0000218,
8943,1,A,1,,,In vivo,50597,Maximum plasma concentration dosed orally in rats after 6 hours,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623999,BAO_0000218,
8944,1,A,1,,,In vivo,50597,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624000,BAO_0000218,
8945,1,A,1,,,In vivo,50597,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624001,BAO_0000218,
8946,1,A,1,,,In vivo,50597,Maximum plasma concentration in rat after po administration,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624002,BAO_0000218,
8947,1,A,1,,,In vivo,50597,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624003,BAO_0000218,
8948,1,A,1,,,In vivo,50597,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624004,BAO_0000218,
8949,1,A,1,,,,50597,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624005,BAO_0000218,
8950,1,A,1,,,,50597,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624006,BAO_0000218,
8951,1,A,1,,,,50597,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624007,BAO_0000218,
8952,1,A,1,,,,50597,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624008,BAO_0000218,
8953,1,A,1,,,,50597,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624009,BAO_0000218,
8954,1,A,1,,,,50597,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874387,BAO_0000218,
8955,1,A,1,,,,50597,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624010,BAO_0000218,
8956,1,A,1,,,,50597,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624011,BAO_0000218,
8957,1,A,1,,,,50597,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624012,BAO_0000218,
8958,1,A,1,,,,50597,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624013,BAO_0000218,
8959,1,A,1,,,,50597,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624736,BAO_0000218,
8960,1,A,1,,,,50597,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624737,BAO_0000218,
8961,1,A,1,,,,50597,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624738,BAO_0000218,
8962,1,A,1,,,,50597,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624739,BAO_0000218,
8963,1,A,1,,,,50597,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624740,BAO_0000218,
8964,1,A,1,,,,50597,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624896,BAO_0000218,
8965,1,A,1,,,,50597,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624897,BAO_0000218,
8966,1,A,1,,,,50597,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624108,BAO_0000218,
8967,1,A,1,,,,50597,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624109,BAO_0000218,
8968,1,A,1,,,,50597,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624110,BAO_0000218,
8969,1,A,1,,,,50597,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624111,BAO_0000218,
8970,1,A,1,,,,50597,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624112,BAO_0000218,
8971,1,A,1,,,,50597,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624113,BAO_0000218,
8972,1,A,1,,,,50597,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619709,BAO_0000218,
8973,1,A,1,,,,50597,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619710,BAO_0000218,
8974,1,A,1,,,,50597,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619711,BAO_0000218,
8975,1,A,1,,,,50597,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619712,BAO_0000218,
8976,1,A,1,,,,50597,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619713,BAO_0000218,
8977,1,A,1,,,,50597,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619714,BAO_0000218,
8978,1,A,1,,,,50597,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619715,BAO_0000218,
8979,1,A,1,,,,50597,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619716,BAO_0000218,
8980,1,A,1,,,,50597,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619717,BAO_0000218,
8981,1,A,1,,,,50597,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619718,BAO_0000218,
8982,1,A,1,,,,50597,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619719,BAO_0000218,
8983,1,A,1,,,,50597,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875329,BAO_0000218,
8984,1,A,1,,,,50597,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619720,BAO_0000218,
8985,1,A,1,,,,50597,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619721,BAO_0000218,
8986,1,A,1,,,,50597,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619722,BAO_0000218,
8987,1,A,1,,,,50597,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619723,BAO_0000218,
8988,1,A,1,,,,50597,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619724,BAO_0000218,
8989,1,A,1,,,,50597,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619725,BAO_0000218,
8990,1,A,1,,,,50597,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619726,BAO_0000218,
8991,1,A,1,,,,50597,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619727,BAO_0000218,
8992,1,A,1,,,,50597,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619728,BAO_0000218,
8993,1,A,1,,,,50597,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619729,BAO_0000218,
8994,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619730,BAO_0000218,
8995,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619731,BAO_0000218,
8996,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619732,BAO_0000218,
8997,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619733,BAO_0000218,
8998,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619734,BAO_0000218,
8999,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),14.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619735,BAO_0000218,
9000,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),14.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875330,BAO_0000218,
9001,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),14.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628465,BAO_0000218,
9002,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),14.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628466,BAO_0000218,
9003,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),14.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628467,BAO_0000218,
9004,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628468,BAO_0000218,
9005,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628469,BAO_0000218,
9006,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628470,BAO_0000218,
9007,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628471,BAO_0000218,
9008,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628472,BAO_0000218,
9009,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625191,BAO_0000218,
9010,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625192,BAO_0000218,
9011,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875337,BAO_0000218,
9012,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626341,BAO_0000218,
9013,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626342,BAO_0000218,
9014,1,A,1,,,In vivo,50597,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621943,BAO_0000218,
9015,1,A,1,,,,50597,Half life in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621944,BAO_0000218,
9016,1,A,1,,,,50597,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621945,BAO_0000218,
9017,1,A,1,,,,50597,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621946,BAO_0000218,
9018,1,A,1,,,,50597,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621947,BAO_0000218,
9019,1,A,1,,,,50597,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621948,BAO_0000218,
9020,1,A,1,,,,50597,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621949,BAO_0000218,
9021,1,A,1,,,,50597,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621950,BAO_0000218,
9022,1,A,1,,,,50597,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621951,BAO_0000218,
9023,1,A,1,,,In vivo,50597,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621952,BAO_0000218,
9024,1,A,1,,,,50597,Stability (%) in rat liver microsomes,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621953,BAO_0000218,
9025,1,A,1,,,,50597,Area under curve was calculated after intravenous administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621954,BAO_0000218,
9026,1,A,1,,,,50597,Area under the curve was calculated after iv administration in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621955,BAO_0000218,
9027,1,A,1,,,,50597,Area under the curve was calculated in rat after peroral administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621956,BAO_0000218,
9028,1,A,1,,,,50597,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621957,BAO_0000218,
9029,1,A,1,,,,50597,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621958,BAO_0000218,
9030,1,A,1,,,,50597,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621959,BAO_0000218,
9031,1,A,1,,,,50597,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621960,BAO_0000218,
9032,1,A,1,,,,50597,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621961,BAO_0000218,
9033,1,A,1,,,,50597,p value of the compound,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621962,BAO_0000218,
9034,1,F,1,,,,50597,p value of the compound,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876787,BAO_0000218,
9035,1,A,1,,,,50597,p value of the compound,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621963,BAO_0000218,
9036,1,A,1,,,,50597,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),945.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622637,BAO_0000218,
9037,1,A,1,,,,50597,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),945.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622638,BAO_0000218,
9038,1,A,1,,,,50597,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),945.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626561,BAO_0000218,
9039,1,F,0,,,,22224,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL626562,BAO_0000019,
9040,1,A,0,,,,22224,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL626563,BAO_0000218,
9041,1,A,0,,,,22224,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL626564,BAO_0000218,
9042,1,A,0,,,In vivo,22224,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL626565,BAO_0000218,
9043,1,A,0,,,In vivo,22224,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL626566,BAO_0000218,
9044,1,A,0,,,In vivo,22224,Clearance rate in rabbits,,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL626567,BAO_0000218,
9045,1,A,0,,,In vivo,22224,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL626568,BAO_0000218,
9046,1,A,0,,,In vivo,22224,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL626569,BAO_0000218,
9047,1,A,0,,,In vivo,22224,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL626570,BAO_0000218,
9048,1,A,0,,,In vivo,22224,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL626571,BAO_0000218,
9049,1,A,0,,,In vivo,22224,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL626572,BAO_0000218,
9050,1,A,0,,,In vivo,22224,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,1969.0,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL626573,BAO_0000218,
9051,1,A,0,,,,22224,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,2107.0,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL626574,BAO_0000251,
9052,1,A,0,,,,22224,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,2107.0,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL626575,BAO_0000251,
9053,1,A,0,,,,22224,Dose at which bioavailability of intravenously administered compound was tested in rabbit,,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL626576,BAO_0000218,
9054,1,A,0,,,,22224,Dose at which bioavailability of perorally administered compound was tested in rabbit,,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL626577,BAO_0000218,
9055,1,A,0,,,In vivo,22224,The compound was tested for its bioavailability in rabbit (by oral dosage).,,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL626578,BAO_0000218,
9056,1,A,0,,,In vivo,22224,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL625263,BAO_0000218,
9057,1,A,0,,,In vivo,22224,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL625264,BAO_0000218,
9058,1,A,0,,,In vivo,22224,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL625265,BAO_0000218,
9059,1,A,0,,,,22224,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL625266,BAO_0000251,
9060,1,A,0,,,,22224,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL876796,BAO_0000251,
9061,1,A,0,,,In vivo,22224,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL625267,BAO_0000218,
9062,1,A,0,,,In vivo,22224,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,1969.0,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL625268,BAO_0000218,
9063,1,A,0,,,In vivo,22224,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,1969.0,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL625269,BAO_0000218,
9064,1,A,0,,,In vivo,22224,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,1969.0,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL624689,BAO_0000218,
9065,1,A,0,,,In vivo,22224,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL624690,BAO_0000218,
9066,1,A,0,,,,22224,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),1088.0,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL624691,BAO_0000218,
9067,1,A,0,,,,22224,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),1088.0,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL624692,BAO_0000218,
9068,1,A,0,,,In vivo,22224,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL624693,BAO_0000218,
9069,1,A,0,,,In vivo,22224,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL624694,BAO_0000218,
9070,1,A,0,,,In vitro,22224,In vitro Biological half-life in crude homogenate of rabbit renal cortex,,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL877596,BAO_0000221,
9071,1,A,0,,,,22224,Time within which only 10% of the drug was degraded,,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL624695,BAO_0000019,
9072,1,A,0,,,,22224,Half life period in rabbit liver homogenate,2107.0,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL624696,BAO_0000221,
9073,1,A,0,,,,22224,Half life value in rabbits,,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL624697,BAO_0000019,
9074,1,A,0,,,In vivo,22224,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,178.0,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL624698,BAO_0000218,
9075,1,A,0,,,In vivo,22224,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,178.0,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL624699,BAO_0000218,
9076,1,A,0,,,In vivo,22224,Half-life period in rabbits following intravenous administration at 2 mg/kg,,Oryctolagus cuniculus,,,,9986.0,U,Autocuration,CHEMBL624700,BAO_0000218,
9077,1,A,1,,,,50597,AUC 0-8 hr value in rats at 10 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622903,BAO_0000218,
9078,1,A,1,,,,50597,AUC after administration at 2000 mg/kg/day in rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622904,BAO_0000218,
9079,1,A,1,,,,50597,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622905,BAO_0000218,
9080,1,A,1,,,,50597,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622906,BAO_0000218,
9081,1,A,1,,,,50597,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622907,BAO_0000218,
9082,1,A,1,,,,50597,AUC in rat after oral administration at 10.5 mg/kg dose,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622908,BAO_0000218,
9083,1,A,1,,,,50597,AUC in rat after oral administration at 11.2 mg/kg dose,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622909,BAO_0000218,
9084,1,A,1,,,,50597,AUC in rat after oral administration at 9.7 mg/kg dose,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622910,BAO_0000218,
9085,1,A,1,,,,50597,AUC in rat brain after oral administration at 10 mg/kg,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622911,BAO_0000218,
9086,1,A,1,,,,50597,AUC in rat p.o.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622912,BAO_0000218,
9087,1,A,1,,,,50597,AUC in rat p.o. at 20 mg/kg concentration,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622913,BAO_0000218,
9088,1,A,1,,,,50597,AUC in rat plasma after oral administration at 10 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622914,BAO_0000218,
9089,1,A,1,,,,50597,AUC in rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622915,BAO_0000218,
9090,1,A,1,,,,50597,AUC value after IV dose at a dose of 5 mg/kg in rats.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622916,BAO_0000218,
9091,1,A,1,,,,50597,AUC value after oral dose at a dose of 10 mg/kg in rats.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622917,BAO_0000218,
9092,1,A,1,,,In vivo,50597,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622918,BAO_0000218,
9093,1,A,1,,,In vivo,50597,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622919,BAO_0000218,
9094,1,A,1,,,In vivo,50597,Maximum plasma concentration was evaluated in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622920,BAO_0000218,
9095,1,A,1,,,In vivo,50597,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622921,BAO_0000218,
9096,1,A,1,,,In vivo,50597,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622922,BAO_0000218,
9097,1,A,1,,,In vivo,50597,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622923,BAO_0000218,
9098,1,A,1,,,In vivo,50597,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL877604,BAO_0000218,
9099,1,A,1,,,In vivo,50597,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622924,BAO_0000218,
9100,1,A,1,,,In vivo,50597,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622925,BAO_0000218,
9101,1,A,1,,,In vivo,50597,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622926,BAO_0000218,
9102,1,A,1,,,In vivo,50597,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623625,BAO_0000218,
9103,1,A,1,,,In vivo,50597,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Expert,CHEMBL623626,BAO_0000218,
9104,1,A,1,,,In vivo,50597,Maximum plasma drug concentration was determined,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623627,BAO_0000218,
9105,1,A,1,,,In vivo,50597,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623628,BAO_0000218,
9106,1,A,1,,,In vivo,50597,Mean peak plasma concentration was observed after intravenous administration in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623629,BAO_0000218,
9107,1,A,1,,,In vivo,50597,Mean peak plasma concentration was observed after oral administration in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623630,BAO_0000218,
9108,1,A,1,,,In vivo,50597,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623804,BAO_0000218,
9109,1,A,1,,,In vivo,50597,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623805,BAO_0000218,
9110,1,A,1,,,In vivo,50597,Peak oral plasma concentration was determined in rats by oral administration,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623806,BAO_0000218,
9111,1,A,1,,,In vivo,50597,Peak plasma concentration (Cmax) was determined,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623807,BAO_0000218,
9112,1,A,1,,,In vivo,50597,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623808,BAO_0000218,
9113,1,A,1,,,In vivo,50597,Peak plasma concentration (Cmax) in rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623809,BAO_0000218,
9114,1,A,1,,,In vivo,50597,Peak plasma concentration at 1 mg/kg peroral administration,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623810,BAO_0000218,
9115,1,A,1,,,In vivo,50597,Peak plasma concentration in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623811,BAO_0000218,
9116,1,A,1,,,In vivo,50597,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623812,BAO_0000218,
9117,1,A,1,,,In vivo,50597,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL877605,BAO_0000218,
9118,1,A,1,,,In vivo,50597,Pharmacokinetic property (Cmax) in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623813,BAO_0000218,
9119,1,A,1,,,In vivo,50597,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623814,BAO_0000218,
9120,1,A,1,,,In vivo,50597,Cmax in rat after 3mg/kg oral dose,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623815,BAO_0000218,
9121,1,A,1,,,In vivo,50597,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,,Rattus norvegicus,Sprague-Dawley,,,10116.0,N,Intermediate,CHEMBL623816,BAO_0000218,
9122,1,A,1,,,In vivo,50597,Cmax in rats after 20 mg/kg oral dose,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623145,BAO_0000218,
9123,1,A,1,,,In vivo,50597,Cmax in rat plasma after 30mg/kg oral dose,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623146,BAO_0000218,
9124,1,A,1,,,In vivo,50597,Plasma concentration after oral administration of 100 mg/kg to rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623147,BAO_0000218,
9125,1,A,1,,,In vivo,50597,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623042,BAO_0000218,
9126,1,A,1,,,In vivo,50597,Tested for the Cmax in rat at 10 mg/kg per orally,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623043,BAO_0000218,
9127,1,A,1,,,In vivo,50597,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623044,BAO_0000218,
9128,1,A,1,,,In vivo,50597,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623045,BAO_0000218,
9129,1,A,1,,,In vivo,50597,Bioavailability as oral Cmax in rats at 30 mins,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623046,BAO_0000218,
9130,1,A,1,,,In vivo,50597,Bioavailability as oral Cmax in rats at 6hr,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623226,BAO_0000218,
9131,1,A,1,,,In vivo,50597,The maximum concentration of compound was measured at the dose of 100 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623227,BAO_0000218,
9132,1,A,1,,,In vivo,50597,The maximum concentration of compound was measured at the dose of 300 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623228,BAO_0000218,
9133,1,A,1,,,In vivo,50597,The maximum concentration of compound was measured at the dose of 30 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623229,BAO_0000218,
9134,1,A,1,,,In vivo,50597,The maximum plasma levels for the compounds were determined by LC-MS.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623230,BAO_0000218,
9135,1,A,1,,,In vivo,50597,mean peak plasma concentration was observed after intravenous administration in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623231,BAO_0000218,
9136,1,A,1,,,In vivo,50597,mean peak plasma concentration was observed after oral administration in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623232,BAO_0000218,
9137,1,A,1,,,,50597,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623233,BAO_0000218,
9138,1,A,1,,,,50597,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623234,BAO_0000218,
9139,1,A,1,,,,50597,Concentration in plasma (portal) following oral dose in rats at 1 hr,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623235,BAO_0000218,
9140,1,A,1,,,,50597,Concentration in plasma (portal) following oral dose in rats at 2 hr,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623236,BAO_0000218,
9141,1,A,1,,,,50597,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623237,BAO_0000218,
9142,1,A,1,,,,50597,Concentration in plasma (systemic) following oral dose in rats at 1 hr,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623238,BAO_0000218,
9143,1,A,1,,,,50597,Concentration in plasma (systemic) following oral dose in rats at 2 hr,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623239,BAO_0000218,
9144,1,A,0,,,In vivo,22224,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,1969.0,Rattus norvegicus,,,,10116.0,U,Intermediate,CHEMBL623240,BAO_0000218,
9145,1,A,1,,,,50597,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",1898.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623241,BAO_0000218,
9146,1,A,1,,,,50597,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",1898.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623242,BAO_0000218,
9147,1,A,1,,,,50597,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874394,BAO_0000218,
9148,1,A,1,,,,50597,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623243,BAO_0000218,
9149,1,A,1,,,,50597,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623244,BAO_0000218,
9150,1,A,1,,,,50597,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623245,BAO_0000218,
9151,1,A,1,,,,50597,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623246,BAO_0000218,
9152,1,A,1,,,,50597,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623247,BAO_0000218,
9153,1,A,1,,,,50597,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623248,BAO_0000218,
9154,1,A,1,,,,50597,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623249,BAO_0000218,
9155,1,A,1,,,,50597,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625072,BAO_0000218,
9156,1,A,1,,,,50597,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625073,BAO_0000218,
9157,1,A,1,,,,50597,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625074,BAO_0000218,
9158,1,A,1,,,,50597,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625075,BAO_0000218,
9159,1,A,1,,,,50597,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625076,BAO_0000218,
9160,1,A,1,,,,50597,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625077,BAO_0000218,
9161,1,A,1,,,,50597,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625078,BAO_0000218,
9162,1,A,1,,,,50597,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874395,BAO_0000218,
9163,1,A,1,,,,50597,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625079,BAO_0000218,
9164,1,A,1,,,,50597,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625080,BAO_0000218,
9165,1,A,1,,,,50597,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625081,BAO_0000218,
9166,1,A,1,,,,50597,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625082,BAO_0000218,
9167,1,A,1,,,,50597,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625083,BAO_0000218,
9168,1,A,1,,,,50597,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625084,BAO_0000218,
9169,1,A,1,,,,50597,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625085,BAO_0000218,
9170,1,A,1,,,,50597,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625086,BAO_0000218,
9171,1,A,1,,,,50597,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625087,BAO_0000218,
9172,1,A,1,,,,50597,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625088,BAO_0000218,
9173,1,A,1,,,,50597,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622205,BAO_0000218,
9174,1,A,1,,,,50597,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622206,BAO_0000218,
9175,1,A,1,,,,50597,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622207,BAO_0000218,
9176,1,A,1,,,,50597,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622366,BAO_0000218,
9177,1,A,1,,,,50597,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622367,BAO_0000218,
9178,1,A,1,,,,50597,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875331,BAO_0000218,
9179,1,A,1,,,,50597,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622368,BAO_0000218,
9180,1,A,1,,,,50597,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622369,BAO_0000218,
9181,1,A,1,,,,50597,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622370,BAO_0000218,
9182,1,A,1,,,,50597,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622371,BAO_0000218,
9183,1,A,1,,,,50597,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622372,BAO_0000218,
9184,1,A,1,,,,50597,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622373,BAO_0000218,
9185,1,A,1,,,,50597,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622374,BAO_0000218,
9186,1,A,1,,,,50597,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622375,BAO_0000218,
9187,1,A,1,,,,50597,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622376,BAO_0000218,
9188,1,A,1,,,,50597,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622377,BAO_0000218,
9189,1,A,1,,,,50597,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622378,BAO_0000218,
9190,1,A,1,,,,50597,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622379,BAO_0000218,
9191,1,A,1,,,,50597,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622380,BAO_0000218,
9192,1,A,1,,,,50597,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622381,BAO_0000218,
9193,1,A,1,,,,50597,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622382,BAO_0000218,
9194,1,A,1,,,,50597,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622383,BAO_0000218,
9195,1,A,1,,,,50597,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),945.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875332,BAO_0000218,
9196,1,A,1,,,,50597,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),945.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622384,BAO_0000218,
9197,1,A,1,,,,50597,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),945.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622385,BAO_0000218,
9198,1,A,1,,,,50597,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),945.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622386,BAO_0000218,
9199,1,A,1,,,,50597,The compound was tested for the plasma binding in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622387,BAO_0000218,
9200,1,A,1,,,,50597,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622388,BAO_0000218,
9201,1,A,1,,,,50597,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622389,BAO_0000218,
9202,1,A,1,,,,50597,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622390,BAO_0000218,
9203,1,A,1,,,,50597,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622391,BAO_0000218,
9204,1,A,1,,,,50597,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622392,BAO_0000218,
9205,1,A,1,,,,50597,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622393,BAO_0000218,
9206,1,A,1,,,,50597,Plasma level at 2 hr after administration of the compound,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622394,BAO_0000218,
9207,1,A,1,,,,50597,plasma level at 2 hr after administration of the compound,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622395,BAO_0000218,
9208,1,A,1,,,,50597,Stability in rat serum measured as % recovery at 1 min,1977.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622396,BAO_0000218,
9209,1,A,1,,,,50597,Stability in rat serum measured as % recovery at 10 min,1977.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624894,BAO_0000218,
9210,1,A,1,,,,50597,Stability in rat serum measured as % recovery at 10 mins,1977.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624895,BAO_0000218,
9211,1,A,1,,,,50597,Stability in rat serum measured as % recovery at 2 hr,1977.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624058,BAO_0000218,
9212,1,A,1,,,,50597,Stability in rat serum measured as % recovery at 3 min,1977.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624059,BAO_0000218,
9213,1,A,1,,,,50597,Stability in rat serum measured as % recovery at 3 mins,1977.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624060,BAO_0000218,
9214,1,A,1,,,,50597,Stability in rat serum measured as % recovery at 5 min,1977.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624061,BAO_0000218,
9215,1,A,1,,,,50597,Stability in rat serum measured as % recovery at 5 mins,1977.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624062,BAO_0000218,
9216,1,A,1,,,In vivo,50597,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624063,BAO_0000218,
9217,1,A,1,,,In vivo,50597,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624064,BAO_0000218,
9218,1,A,1,,,,50597,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624065,BAO_0000218,
9219,1,A,1,,,,50597,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624066,BAO_0000218,
9220,1,A,1,,,In vivo,50597,Half life tested in mature male rat at a dose of 30 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL877490,BAO_0000218,
9221,1,A,1,,,In vivo,50597,Half life after intravenous administration of 1 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874442,BAO_0000218,
9222,1,A,1,,,In vivo,50597,Half life period after administration (30 mg/kg) in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626890,BAO_0000218,
9223,1,A,1,,,In vivo,50597,Half life period in rat after 5 mg/Kg dose,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626891,BAO_0000218,
9224,1,A,1,,,In vivo,50597,Half life period in rat after 5 mg/kg dose,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626892,BAO_0000218,
9225,1,A,1,,,,50597,Half life period was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626893,BAO_0000218,
9226,1,A,1,,,,50597,Half life period was evaluated in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626894,BAO_0000218,
9227,1,A,1,,,,50597,Half life period was evaluated in rat; 0.5-1.0,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626895,BAO_0000218,
9228,1,A,1,,,,50597,Half life period was evaluated in rat; 5.9-7.5,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626896,BAO_0000218,
9229,1,A,1,,,,50597,Half-life in rat plasma,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626897,BAO_0000218,
9230,1,A,1,,,,50597,Half-life time in rat was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626898,BAO_0000218,
9231,1,A,1,,,In vivo,50597,Terminal half-life after iv administration to rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626899,BAO_0000218,
9232,1,A,1,,,In vivo,50597,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626900,BAO_0000218,
9233,1,A,1,,,,50597,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626901,BAO_0000218,
9234,1,A,1,,,In vivo,50597,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626902,BAO_0000218,
9235,1,A,1,,,In vivo,50597,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626903,BAO_0000218,
9236,1,A,1,,,In vivo,50597,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874443,BAO_0000218,
9237,1,A,1,,,In vivo,50597,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626904,BAO_0000218,
9238,1,A,1,,,,50597,Half life in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626905,BAO_0000218,
9239,1,A,1,,,In vivo,50597,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL873830,BAO_0000218,
9240,1,A,1,,,In vivo,50597,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626906,BAO_0000218,
9241,1,A,1,,,In vivo,50597,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631076,BAO_0000218,
9242,1,A,1,,,,50597,Biological half-life was measured in plasma of rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631077,BAO_0000218,
9243,1,A,1,,,In vivo,50597,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631078,BAO_0000218,
9244,1,A,1,,,In vivo,50597,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631079,BAO_0000218,
9245,1,A,1,,,In vivo,50597,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631080,BAO_0000218,
9246,1,A,1,,,In vivo,50597,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631081,BAO_0000218,
9247,1,A,1,,,In vivo,50597,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631239,BAO_0000218,
9248,1,A,1,,,,50597,Compound was evaluated for plasma half life in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631240,BAO_0000218,
9249,1,A,1,,,,50597,AUC value at a dose of 5 mg/kg (p.o.) in rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631241,BAO_0000218,
9250,1,A,1,,,,50597,AUC value after administration of 20 mg/Kg oral dose in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631242,BAO_0000218,
9251,1,A,1,,,,50597,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631243,BAO_0000218,
9252,1,A,1,,,,50597,AUC0-96 after administration at 50 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874444,BAO_0000218,
9253,1,A,1,,,,50597,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631244,BAO_0000218,
9254,1,A,1,,,,50597,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631245,BAO_0000218,
9255,1,A,1,,,,50597,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627162,BAO_0000218,
9256,1,A,1,,,,50597,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627163,BAO_0000218,
9257,1,A,1,,,,50597,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627164,BAO_0000218,
9258,1,A,1,,,,50597,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627165,BAO_0000218,
9259,1,A,1,,,,50597,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627166,BAO_0000218,
9260,1,A,1,,,,50597,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627167,BAO_0000218,
9261,1,A,1,,,,50597,Area under curve (AUC) at a dose of 30 mg/kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627822,BAO_0000218,
9262,1,A,1,,,,50597,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627823,BAO_0000218,
9263,1,A,1,,,,50597,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627824,BAO_0000218,
9264,1,A,1,,,,50597,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627825,BAO_0000218,
9265,1,A,1,,,,50597,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627826,BAO_0000218,
9266,1,A,1,,,,50597,Area under curve (Pharmacokinetic property) was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627827,BAO_0000218,
9267,1,A,1,,,,50597,Area under curve (Pharmacokinetic property) of the compound; Not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627828,BAO_0000218,
9268,1,A,1,,,,50597,Area under curve after intravenous administration (1 mg/kg) in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627829,BAO_0000218,
9269,1,A,1,,,,50597,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627830,BAO_0000218,
9270,1,A,1,,,,50597,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627831,BAO_0000218,
9271,1,A,1,,,,50597,Area under curve in male SD rats was observed after oral administration in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627832,BAO_0000218,
9272,1,A,1,,,,50597,Area under curve of compound after iv administration of 20 mg/kg dose in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627833,BAO_0000218,
9273,1,A,1,,,,50597,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Expert,CHEMBL627834,BAO_0000218,
9274,1,A,1,,,,50597,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Expert,CHEMBL628004,BAO_0000218,
9275,1,A,1,,,,50597,Area under curve at 5 mg/kg po was determined in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628005,BAO_0000218,
9276,1,A,1,,,,50597,Area under curve in Rat at a oral dose of 5 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628006,BAO_0000218,
9277,1,A,1,,,,50597,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628007,BAO_0000218,
9278,1,A,1,,,,50597,Area under curve was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625676,BAO_0000218,
9279,1,A,1,,,,50597,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631309,BAO_0000218,
9280,1,A,1,,,,50597,Area under curve after intravenous administration at 3 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631310,BAO_0000218,
9281,1,A,1,,,,50597,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631311,BAO_0000218,
9282,1,A,1,,,,50597,Area under curve at 4 hr in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631312,BAO_0000218,
9283,1,A,1,,,,50597,Area under curve at a dose of 30 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631313,BAO_0000218,
9284,1,A,1,,,,50597,Area under curve at the dose of 2 mg/Kg administered perorally in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631314,BAO_0000218,
9285,1,A,1,,,,50597,Area under curve at the dose of 5 mg/Kg administered perorally in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631315,BAO_0000218,
9286,1,A,1,,,,50597,Area under curve for a 2-mpk po dose in SD rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631316,BAO_0000218,
9287,1,A,1,,,,50597,Area under curve in SD rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631317,BAO_0000218,
9288,1,A,1,,,,50597,Area under curve in rat after oral administration at 13 mg/kg dose,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874471,BAO_0000218,
9289,1,A,1,,,,50597,Area under curve in rat by po administration at 0-24 hr,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631318,BAO_0000218,
9290,1,A,1,,,,50597,Area under curve in rat plasma,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631319,BAO_0000218,
9291,1,A,1,,,,50597,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631320,BAO_0000218,
9292,1,A,1,,,,50597,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631321,BAO_0000218,
9293,1,A,1,,,,50597,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631322,BAO_0000218,
9294,1,A,1,,,,50597,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631323,BAO_0000218,
9295,1,A,1,,,,50597,Area under curve value in rat at a dose of 5 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631324,BAO_0000218,
9296,1,A,1,,,,50597,Area under curve was determined after oral administration in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631325,BAO_0000218,
9297,1,A,1,,,,50597,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631326,BAO_0000218,
9298,1,A,1,,,,50597,Area under curve was determined after peroral administration in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631327,BAO_0000218,
9299,1,A,1,,,,50597,Area under curve was determined at a dose 30 mpk administered orally.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631328,BAO_0000218,
9300,1,A,1,,,,50597,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631329,BAO_0000218,
9301,1,A,1,,,,50597,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627217,BAO_0000218,
9302,1,A,1,,,,50597,Area under curve was determined in male rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626352,BAO_0000218,
9303,1,A,1,,,,50597,Area under curve was determined in rat after PO administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626353,BAO_0000218,
9304,1,A,1,,,,50597,Area under curve was determined in rat after a 3 mg/kg of oral dose,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626354,BAO_0000218,
9305,1,A,1,,,,50597,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626355,BAO_0000218,
9306,1,A,1,,,,50597,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626356,BAO_0000218,
9307,1,A,1,,,,50597,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626357,BAO_0000218,
9308,1,A,1,,,,50597,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626358,BAO_0000218,
9309,1,A,1,,,,50597,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626359,BAO_0000218,
9310,1,A,1,,,,50597,Peak plasma concentration in rat at a dose of 3 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626360,BAO_0000218,
9311,1,A,1,,,,50597,Plasma concentration at 2 hr in rats was evaluated.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626361,BAO_0000218,
9312,1,A,1,,,,50597,Plasma concentration at 2 hr in rats was evaluated; Not available,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626362,BAO_0000218,
9313,1,A,1,,,,50597,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626363,BAO_0000218,
9314,1,A,1,,,,50597,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626970,BAO_0000218,
9315,1,A,1,,,,50597,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626971,BAO_0000218,
9316,1,A,1,,,,50597,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626972,BAO_0000218,
9317,1,A,1,,,,50597,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626973,BAO_0000218,
9318,1,A,1,,,,50597,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626974,BAO_0000218,
9319,1,A,1,,,,50597,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874592,BAO_0000218,
9320,1,A,1,,,,50597,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626975,BAO_0000218,
9321,1,A,1,,,,50597,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626976,BAO_0000218,
9322,1,A,1,,,,50597,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626977,BAO_0000218,
9323,1,A,1,,,,50597,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626978,BAO_0000218,
9324,1,A,1,,,,50597,PK study was carried to determine the relative absorption ranking in rat.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626979,BAO_0000218,
9325,1,A,1,,,In vivo,50597,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626980,BAO_0000218,
9326,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626981,BAO_0000218,
9327,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626982,BAO_0000218,
9328,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626983,BAO_0000218,
9329,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622522,BAO_0000218,
9330,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622523,BAO_0000218,
9331,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622524,BAO_0000218,
9332,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622525,BAO_0000218,
9333,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622526,BAO_0000218,
9334,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619849,BAO_0000218,
9335,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619850,BAO_0000218,
9336,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623864,BAO_0000218,
9337,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623865,BAO_0000218,
9338,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623866,BAO_0000218,
9339,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623867,BAO_0000218,
9340,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL877615,BAO_0000218,
9341,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623868,BAO_0000218,
9342,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623869,BAO_0000218,
9343,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623870,BAO_0000218,
9344,1,A,1,,,,50597,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623871,BAO_0000218,
9345,1,A,1,,,,50597,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623872,BAO_0000218,
9346,1,A,1,,,,50597,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622129,BAO_0000218,
9347,1,A,1,,,,50597,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622130,BAO_0000218,
9348,1,A,1,,,,50597,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622131,BAO_0000218,
9349,1,A,1,,,,50597,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622132,BAO_0000218,
9350,1,A,1,,,,50597,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622133,BAO_0000218,
9351,1,A,1,,,,50597,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622134,BAO_0000218,
9352,1,A,1,,,,50597,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622135,BAO_0000218,
9353,1,A,1,,,,50597,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622136,BAO_0000218,
9354,1,A,1,,,,50597,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622137,BAO_0000218,
9355,1,A,1,,,,50597,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622138,BAO_0000218,
9356,1,A,1,,,,50597,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623017,BAO_0000218,
9357,1,A,1,,,,50597,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623018,BAO_0000218,
9358,1,A,1,,,,50597,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623019,BAO_0000218,
9359,1,A,1,,,,50597,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623020,BAO_0000218,
9360,1,A,1,,,,50597,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623021,BAO_0000218,
9361,1,A,1,,,,50597,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623022,BAO_0000218,
9362,1,A,1,,,,50597,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623023,BAO_0000218,
9363,1,A,1,,,,50597,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623024,BAO_0000218,
9364,1,A,1,,,,50597,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623025,BAO_0000218,
9365,1,A,1,,,,50597,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620545,BAO_0000218,
9366,1,A,1,,,,50597,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620546,BAO_0000218,
9367,1,A,1,,,,50597,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620547,BAO_0000218,
9368,1,A,1,,,,50597,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620548,BAO_0000218,
9369,1,A,1,,,,50597,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620549,BAO_0000218,
9370,1,A,1,,,,50597,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620550,BAO_0000218,
9371,1,A,1,,,,50597,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620551,BAO_0000218,
9372,1,A,1,,,,50597,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620552,BAO_0000218,
9373,1,A,1,,,,50597,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620553,BAO_0000218,
9374,1,A,1,,,,50597,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620554,BAO_0000218,
9375,1,A,1,,,,50597,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875845,BAO_0000218,
9376,1,A,1,,,,50597,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620555,BAO_0000218,
9377,1,A,1,,,,50597,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620556,BAO_0000218,
9378,1,A,1,,,,50597,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620557,BAO_0000218,
9379,1,A,1,,,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620558,BAO_0000218,
9380,1,A,1,,,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620559,BAO_0000218,
9381,1,A,1,,,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622939,BAO_0000218,
9382,1,A,1,,,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622940,BAO_0000218,
9383,1,A,1,,,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622941,BAO_0000218,
9384,1,A,1,,,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622942,BAO_0000218,
9385,1,A,1,,,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622943,BAO_0000218,
9386,1,A,1,,,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622944,BAO_0000218,
9387,1,A,1,,,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622945,BAO_0000218,
9388,1,A,1,,,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622946,BAO_0000218,
9389,1,A,1,,,,50597,Compound was evaluated for terminal half life in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622947,BAO_0000218,
9390,1,A,1,,,In vivo,50597,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622948,BAO_0000218,
9391,1,A,1,,,In vivo,50597,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622949,BAO_0000218,
9392,1,A,1,,,,50597,Compound was tested for its half life in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622950,BAO_0000218,
9393,1,A,0,,,In vivo,22224,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,1969.0,Macaca mulatta,,,,9544.0,U,Intermediate,CHEMBL622951,BAO_0000218,
9394,1,A,0,,,,22224,Compound was tested for its plasma half life in Sprague Dawley rats,1969.0,Rattus norvegicus,,,,10116.0,U,Intermediate,CHEMBL622952,BAO_0000366,
9395,1,A,0,,,,22224,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,1969.0,Rattus norvegicus,,,,10116.0,U,Intermediate,CHEMBL622953,BAO_0000366,
9396,1,A,1,,,,50597,Compound was tested for plasma half-life period in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL873818,BAO_0000218,
9397,1,A,1,,,In vivo,50597,Elimination half life after i.v. administration of compound in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622954,BAO_0000218,
9398,1,A,1,,,In vivo,50597,Elimination half-life after IV dosing at 0.5 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622955,BAO_0000218,
9399,1,A,1,,,In vivo,50597,Elimination half-life after IV dosing at 1 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875229,BAO_0000218,
9400,1,A,1,,,In vivo,50597,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622956,BAO_0000218,
9401,1,A,1,,,In vivo,50597,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622957,BAO_0000218,
9402,1,A,1,,,In vivo,50597,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622958,BAO_0000218,
9403,1,A,1,,,In vivo,50597,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622959,BAO_0000218,
9404,1,A,1,,,In vivo,50597,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622960,BAO_0000218,
9405,1,A,1,,,In vivo,50597,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622961,BAO_0000218,
9406,1,A,1,,,In vivo,50597,Evaluated for the half life in rat (in vivo),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622962,BAO_0000218,
9407,1,A,1,,,,50597,Hafl life in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622963,BAO_0000218,
9408,1,A,1,,,,50597,Hafl life rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622964,BAO_0000218,
9409,1,A,1,,,,50597,Hafl life rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622965,BAO_0000218,
9410,1,A,1,,,,50597,Hafl life rat; Not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622966,BAO_0000218,
9411,1,A,1,,,,50597,Hafl life rat; Not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622967,BAO_0000218,
9412,1,A,1,,,In vivo,50597,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622968,BAO_0000218,
9413,1,A,1,,,In vivo,50597,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622969,BAO_0000218,
9414,1,A,1,,,In vivo,50597,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875327,BAO_0000218,
9415,1,A,1,,,In vivo,50597,Half life in rat after 1 mg/kg i.v. administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628638,BAO_0000218,
9416,1,A,1,,,In vivo,50597,Half life in rat after 2 mg/kg peroral administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628639,BAO_0000218,
9417,1,A,1,,,In vivo,50597,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625840,BAO_0000218,
9418,1,A,1,,,In vivo,50597,Half life of 10 mg/kg oral dose determined in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625841,BAO_0000218,
9419,1,A,1,,,In vivo,50597,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625842,BAO_0000218,
9420,1,A,1,,,In vivo,50597,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625843,BAO_0000218,
9421,1,A,1,,,In vivo,50597,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625844,BAO_0000218,
9422,1,A,1,,,In vivo,50597,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL873822,BAO_0000218,
9423,1,A,1,,,In vivo,50597,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625845,BAO_0000218,
9424,1,A,1,,,In vivo,50597,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627059,BAO_0000218,
9425,1,A,1,,,In vivo,50597,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627060,BAO_0000218,
9426,1,A,1,,,In vivo,50597,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627061,BAO_0000218,
9427,1,A,1,,,In vivo,50597,Half life of compound at 5 mg/kg after po administration was determined in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627709,BAO_0000218,
9428,1,A,1,,,In vivo,50597,Half life of compound determined after intravenous administration to rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627710,BAO_0000218,
9429,1,A,1,,,,50597,Half life of compound was determined in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627711,BAO_0000218,
9430,1,A,1,,,In vivo,50597,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627712,BAO_0000218,
9431,1,A,1,,,In vivo,50597,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627713,BAO_0000218,
9432,1,A,1,,,In vivo,50597,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627714,BAO_0000218,
9433,1,A,0,,,In vivo,22224,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,Macaca fascicularis,,,,9541.0,U,Intermediate,CHEMBL627889,BAO_0000218,
9434,1,A,0,,,In vivo,22224,Half life determined in rat by intravenous administration,,Rattus norvegicus,,,,10116.0,U,Intermediate,CHEMBL627890,BAO_0000218,
9435,1,A,1,,,In vivo,50597,Half life determined in rats after iv administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627891,BAO_0000218,
9436,1,A,1,,,In vivo,50597,Half life in rat plasma after administration of 2 mg/kg iv,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627892,BAO_0000218,
9437,1,A,1,,,In vivo,50597,Half life in rat plasma after administration of 2 mg/kg iv,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627893,BAO_0000218,
9438,1,A,1,,,,50597,Half life in rat plasma was determined,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627894,BAO_0000218,
9439,1,A,1,,,,50597,Half life in rat plasma was determined; NA means not applicable,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627895,BAO_0000218,
9440,1,A,1,,,,50597,Half life in rat was tested,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627896,BAO_0000218,
9441,1,A,1,,,,50597,Half life measured in rat plasma,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627897,BAO_0000218,
9442,1,A,1,,,,50597,Half life recorded in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627898,BAO_0000218,
9443,1,A,1,,,,50597,Half life was calculated,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627899,BAO_0000218,
9444,1,A,1,,,,50597,Half life was calculated in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL873823,BAO_0000218,
9445,1,A,1,,,,50597,Half life was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627900,BAO_0000218,
9446,1,A,1,,,In vivo,50597,Half life after 10 mg/kg oral administration in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627901,BAO_0000218,
9447,1,A,1,,,In vivo,50597,Half life after administering orally a dose of 10 mg/kg to a fasting rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627902,BAO_0000218,
9448,1,A,1,,,In vivo,50597,Half life after administering orally a dose of 30 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627903,BAO_0000218,
9449,1,A,1,,,,50597,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627904,BAO_0000218,
9450,1,A,1,,,,50597,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627905,BAO_0000218,
9451,1,A,1,,,,50597,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627906,BAO_0000218,
9452,1,A,1,,,,50597,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627907,BAO_0000218,
9453,1,A,1,,,,50597,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876783,BAO_0000218,
9454,1,A,1,,,,50597,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627908,BAO_0000218,
9455,1,A,1,,,,50597,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627909,BAO_0000218,
9456,1,A,1,,,,50597,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627910,BAO_0000218,
9457,1,A,1,,,,50597,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627911,BAO_0000218,
9458,1,A,1,,,,50597,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627912,BAO_0000218,
9459,1,A,1,,,,50597,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627913,BAO_0000218,
9460,1,A,1,,,,50597,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627914,BAO_0000218,
9461,1,A,1,,,,50597,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627915,BAO_0000218,
9462,1,A,1,,,,50597,Area under the curve was evaluated after 20 uM/kg of peroral administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627916,BAO_0000218,
9463,1,A,1,,,,50597,Area under the curve was measured in rat after an iv dose of 1 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627917,BAO_0000218,
9464,1,A,1,,,,50597,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627918,BAO_0000218,
9465,1,A,1,,,,50597,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627919,BAO_0000218,
9466,1,A,1,,,,50597,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627920,BAO_0000218,
9467,1,A,1,,,,50597,Area under the curve was evaluated at an oral dose of 30 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627921,BAO_0000218,
9468,1,A,1,,,,50597,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627922,BAO_0000218,
9469,1,A,1,,,,50597,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876784,BAO_0000218,
9470,1,A,1,,,,50597,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627923,BAO_0000218,
9471,1,A,1,,,,50597,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626208,BAO_0000218,
9472,1,A,1,,,,50597,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626209,BAO_0000218,
9473,1,A,1,,,,50597,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626210,BAO_0000218,
9474,1,A,1,,,,50597,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627994,BAO_0000218,
9475,1,A,1,,,,50597,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627995,BAO_0000218,
9476,1,A,1,,,,50597,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627996,BAO_0000218,
9477,1,A,1,,,,50597,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627997,BAO_0000218,
9478,1,A,1,,,,50597,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627998,BAO_0000218,
9479,1,A,1,,,,50597,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628640,BAO_0000218,
9480,1,A,1,,,,50597,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628641,BAO_0000218,
9481,1,A,1,,,,50597,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628642,BAO_0000218,
9482,1,A,1,,,,50597,Compound was evaluated for area under the curve expressed as (h*ug/ml),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628643,BAO_0000218,
9483,1,A,1,,,,50597,Compound was tested for area under curve in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628644,BAO_0000218,
9484,1,A,1,,,,50597,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628645,BAO_0000218,
9485,1,A,1,,,,50597,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628646,BAO_0000218,
9486,1,A,1,,,,50597,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628647,BAO_0000218,
9487,1,A,1,,,,50597,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628648,BAO_0000218,
9488,1,A,1,,,,50597,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625358,BAO_0000218,
9489,1,A,1,,,,50597,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625359,BAO_0000218,
9490,1,A,1,,,,50597,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625360,BAO_0000218,
9491,1,A,1,,,,50597,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625361,BAO_0000218,
9492,1,A,1,,,,50597,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625362,BAO_0000218,
9493,1,A,1,,,,50597,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625363,BAO_0000218,
9494,1,A,1,,,,50597,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625364,BAO_0000218,
9495,1,A,1,,,,50597,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625365,BAO_0000218,
9496,1,A,1,,,,50597,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625366,BAO_0000218,
9497,1,A,1,,,,50597,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625367,BAO_0000218,
9498,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625368,BAO_0000218,
9499,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625369,BAO_0000218,
9500,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625370,BAO_0000218,
9501,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625371,BAO_0000218,
9502,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625372,BAO_0000218,
9503,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625373,BAO_0000218,
9504,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625374,BAO_0000218,
9505,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL877593,BAO_0000218,
9506,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625375,BAO_0000218,
9507,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625376,BAO_0000218,
9508,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621973,BAO_0000218,
9509,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621974,BAO_0000218,
9510,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621975,BAO_0000218,
9511,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622166,BAO_0000218,
9512,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622167,BAO_0000218,
9513,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622168,BAO_0000218,
9514,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622169,BAO_0000218,
9515,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622170,BAO_0000218,
9516,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622171,BAO_0000218,
9517,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622172,BAO_0000218,
9518,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622173,BAO_0000218,
9519,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622174,BAO_0000218,
9520,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622175,BAO_0000218,
9521,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622176,BAO_0000218,
9522,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622177,BAO_0000218,
9523,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622178,BAO_0000218,
9524,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622179,BAO_0000218,
9525,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622180,BAO_0000218,
9526,1,A,1,,,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622181,BAO_0000218,
9527,1,A,1,,,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622182,BAO_0000218,
9528,1,A,1,,,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622183,BAO_0000218,
9529,1,A,1,,,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622184,BAO_0000218,
9530,1,A,1,,,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622185,BAO_0000218,
9531,1,A,1,,,,50597,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622186,BAO_0000218,
9532,1,A,1,,,,50597,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622187,BAO_0000218,
9533,1,A,1,,,,50597,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625002,BAO_0000218,
9534,1,A,1,,,,50597,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622090,BAO_0000218,
9535,1,A,1,,,,50597,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622091,BAO_0000218,
9536,1,A,1,,,,50597,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622092,BAO_0000218,
9537,1,A,1,,,,50597,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622093,BAO_0000218,
9538,1,A,1,,,,50597,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622094,BAO_0000218,
9539,1,A,1,,,,50597,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622095,BAO_0000218,
9540,1,A,1,,,,50597,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622264,BAO_0000218,
9541,1,A,1,,,,50597,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622265,BAO_0000218,
9542,1,A,1,,,,50597,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622266,BAO_0000218,
9543,1,A,1,,,,50597,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622267,BAO_0000218,
9544,1,A,1,,,,50597,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622268,BAO_0000218,
9545,1,A,1,,,,50597,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622269,BAO_0000218,
9546,1,A,1,,,,50597,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625071,BAO_0000218,
9547,1,A,1,,,,50597,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621621,BAO_0000218,
9548,1,A,1,,,,50597,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621622,BAO_0000218,
9549,1,A,1,,,,50597,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621623,BAO_0000218,
9550,1,A,1,,,,50597,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621624,BAO_0000218,
9551,1,A,1,,,,50597,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621625,BAO_0000218,
9552,1,A,1,,,,50597,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621626,BAO_0000218,
9553,1,A,1,,,,50597,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621627,BAO_0000218,
9554,1,A,1,,,,50597,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621628,BAO_0000218,
9555,1,A,1,,,,50597,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875328,BAO_0000218,
9556,1,A,1,,,,50597,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621629,BAO_0000218,
9557,1,A,1,,,,50597,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621630,BAO_0000218,
9558,1,A,1,,,,50597,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621631,BAO_0000218,
9559,1,A,1,,,,50597,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621632,BAO_0000218,
9560,1,A,1,,,,50597,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621633,BAO_0000218,
9561,1,A,1,,,,50597,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621634,BAO_0000218,
9562,1,A,1,,,,50597,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621635,BAO_0000218,
9563,1,A,1,,,,50597,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621636,BAO_0000218,
9564,1,A,1,,,,50597,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621637,BAO_0000218,
9565,1,A,1,,,,50597,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621638,BAO_0000218,
9566,1,A,1,,,,50597,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618883,BAO_0000218,
9567,1,A,1,,,,50597,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618884,BAO_0000218,
9568,1,A,1,,,,50597,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628627,BAO_0000218,
9569,1,A,1,,,,50597,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628628,BAO_0000218,
9570,1,A,1,,,,50597,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628629,BAO_0000218,
9571,1,A,1,,,In vivo,50597,Half life after administering orally a dose of 3 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628630,BAO_0000218,
9572,1,A,1,,,In vivo,50597,Half life after administering orally a dose of 3 mg/kg to a fasting rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628631,BAO_0000218,
9573,1,A,1,,,In vivo,50597,Half life after administering intravenously a dose of 1 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628632,BAO_0000218,
9574,1,A,1,,,In vivo,50597,Half life after oral dosing in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628633,BAO_0000218,
9575,1,A,1,,,In vivo,50597,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628634,BAO_0000218,
9576,1,A,1,,,In vivo,50597,Half life by intravenous administration of 3.4 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627789,BAO_0000218,
9577,1,A,1,,,,50597,Half life in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627790,BAO_0000218,
9578,1,A,1,,,,50597,Half life in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627791,BAO_0000218,
9579,1,A,1,,,,50597,Half life in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627792,BAO_0000218,
9580,1,A,1,,,In vivo,50597,Half life in rat after intravenous administration of the compound,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627793,BAO_0000218,
9581,1,A,1,,,In vivo,50597,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627794,BAO_0000218,
9582,1,A,1,,,In vivo,50597,Half life in rat after po administration of the compound,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627795,BAO_0000218,
9583,1,A,1,,,In vivo,50597,Half life in rat after po administration of the compound; ND means Not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627796,BAO_0000218,
9584,1,A,1,,,In vivo,50597,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875335,BAO_0000218,
9585,1,A,1,,,In vivo,50597,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627797,BAO_0000218,
9586,1,A,1,,,In vivo,50597,Half life in rat i.v.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627798,BAO_0000218,
9587,1,A,1,,,In vivo,50597,Half life in rat i.v. at 2 mg/kg concentration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627799,BAO_0000218,
9588,1,A,1,,,,50597,Half life in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627800,BAO_0000218,
9589,1,A,1,,,In vivo,50597,Half life in rats after intravenous administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627801,BAO_0000218,
9590,1,A,1,,,In vivo,50597,Half life in rats at the dose of 1.0 mpk by i.v. administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627802,BAO_0000218,
9591,1,A,1,,,,50597,Half life in rat,,Rattus norvegicus,,,,10116.0,N,Expert,CHEMBL627803,BAO_0000218,
9592,1,A,1,,,In vivo,50597,Half life was evaluated after intravenous administration to rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL873820,BAO_0000218,
9593,1,A,1,,,,50597,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627804,BAO_0000218,
9594,1,A,1,,,,50597,Half life was evaluated in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627805,BAO_0000218,
9595,1,A,1,,,,50597,Half life was evaluated in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627806,BAO_0000218,
9596,1,A,1,,,,50597,Half life was evaluated in rat; Not tested,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627107,BAO_0000218,
9597,1,A,1,,,In vivo,50597,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627108,BAO_0000218,
9598,1,A,1,,,In vivo,50597,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627109,BAO_0000218,
9599,1,A,1,,,In vivo,50597,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627110,BAO_0000218,
9600,1,A,0,,,In vivo,22224,Half life was measured in monkey at dose of 10 mg/kg by po administration,,Primates,,,,9443.0,U,Intermediate,CHEMBL627111,BAO_0000218,
9601,1,A,0,,,In vivo,22224,Half life was measured in monkey at dose of 10 mg/kg by po administration,,Primates,,,,9443.0,U,Intermediate,CHEMBL627112,BAO_0000218,
9602,1,A,0,,,In vivo,22224,Half life was measured in rat at dose of 30 mg/kg by iv administration,,Rattus norvegicus,,,,10116.0,U,Intermediate,CHEMBL627113,BAO_0000218,
9603,1,A,0,,,In vivo,22224,Half life was measured in rat at dose of 30 mg/kg by po administration,,Rattus norvegicus,,,,10116.0,U,Intermediate,CHEMBL627114,BAO_0000218,
9604,1,A,1,,,,50597,Half life (t1/2) was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627115,BAO_0000218,
9605,1,A,1,,,,50597,Half life period at a dose of 10 uM/kg in rat was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627116,BAO_0000218,
9606,1,A,1,,,In vivo,50597,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627117,BAO_0000218,
9607,1,A,1,,,,50597,Half life period was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627118,BAO_0000218,
9608,1,A,1,,,In vivo,50597,Half life period after intravenous administration at 20 mpk in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627119,BAO_0000218,
9609,1,A,1,,,In vivo,50597,Half life period after intravenous administration at 20 mpk in rats; Not performed.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627120,BAO_0000218,
9610,1,A,1,,,In vivo,50597,Half life period after intravenous administration in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626922,BAO_0000218,
9611,1,A,1,,,In vivo,50597,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626923,BAO_0000218,
9612,1,A,1,,,In vivo,50597,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626924,BAO_0000218,
9613,1,A,1,,,,50597,Half life period in 80% rat plasma at 37 degree Centigrade,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626925,BAO_0000218,
9614,1,A,1,,,,50597,Half life period in SD rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626926,BAO_0000218,
9615,1,A,1,,,,50597,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626927,BAO_0000218,
9616,1,A,1,,,,50597,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626928,BAO_0000218,
9617,1,A,1,,,,50597,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626929,BAO_0000218,
9618,1,A,1,,,,50597,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626930,BAO_0000218,
9619,1,A,1,,,,50597,Half life period in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626931,BAO_0000218,
9620,1,A,1,,,,50597,Half life period in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626932,BAO_0000218,
9621,1,A,1,,,,50597,Half life period in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626933,BAO_0000218,
9622,1,A,1,,,In vivo,50597,Half life period in rat after oral administration at 10.5 mg/kg dose,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL873826,BAO_0000218,
9623,1,A,1,,,In vivo,50597,Half life period in rat after oral administration at 11.2 mg/kg dose,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626934,BAO_0000218,
9624,1,A,1,,,In vivo,50597,Half life period in rat after oral administration at 13 mg/kg dose,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626935,BAO_0000218,
9625,1,A,1,,,In vivo,50597,Half life period in rat after oral administration at 9.7 mg/kg dose,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626936,BAO_0000218,
9626,1,A,1,,,,50597,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626937,BAO_0000218,
9627,1,A,1,,,,50597,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625906,BAO_0000218,
9628,1,A,1,,,,50597,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625907,BAO_0000218,
9629,1,A,1,,,,50597,PK study was carried to determine AUC (area under curve) value in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625908,BAO_0000218,
9630,1,A,1,,,,50597,Pharmacokinetic parameter AUC after intravenous administration to rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625909,BAO_0000218,
9631,1,A,1,,,,50597,Pharmacokinetic parameter AUC after oral administration to rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625910,BAO_0000218,
9632,1,A,1,,,,50597,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625911,BAO_0000218,
9633,1,A,1,,,,50597,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625912,BAO_0000218,
9634,1,A,1,,,,50597,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626538,BAO_0000218,
9635,1,A,1,,,,50597,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876794,BAO_0000218,
9636,1,A,1,,,,50597,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626539,BAO_0000218,
9637,1,A,1,,,,50597,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626540,BAO_0000218,
9638,1,A,1,,,,50597,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626541,BAO_0000218,
9639,1,A,1,,,,50597,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626542,BAO_0000218,
9640,1,A,1,,,,50597,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626543,BAO_0000218,
9641,1,A,1,,,,50597,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626544,BAO_0000218,
9642,1,A,1,,,,50597,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626545,BAO_0000218,
9643,1,A,1,,,,50597,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626546,BAO_0000218,
9644,1,A,1,,,,50597,Pharmacokinetic parameter area under curve was reported,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626547,BAO_0000218,
9645,1,A,1,,,,50597,Pharmacokinetic property (AUC) in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626548,BAO_0000218,
9646,1,A,1,,,,50597,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626549,BAO_0000218,
9647,1,A,1,,,,50597,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626550,BAO_0000218,
9648,1,A,1,,,,50597,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626551,BAO_0000218,
9649,1,A,1,,,,50597,Pharmacokinetic property was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623777,BAO_0000218,
9650,1,A,1,,,,50597,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623778,BAO_0000218,
9651,1,A,1,,,,50597,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623779,BAO_0000218,
9652,1,A,1,,,,50597,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623780,BAO_0000218,
9653,1,A,1,,,,50597,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622015,BAO_0000218,
9654,1,A,1,,,,50597,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622016,BAO_0000218,
9655,1,A,1,,,,50597,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622017,BAO_0000218,
9656,1,A,1,,,,50597,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622018,BAO_0000218,
9657,1,A,1,,,,50597,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622019,BAO_0000218,
9658,1,A,1,,,,50597,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622020,BAO_0000218,
9659,1,A,1,,,,50597,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622021,BAO_0000218,
9660,1,A,1,,,,50597,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622022,BAO_0000218,
9661,1,A,1,,,,50597,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622023,BAO_0000218,
9662,1,A,1,,,,50597,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622024,BAO_0000218,
9663,1,A,1,,,,50597,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622693,BAO_0000218,
9664,1,A,1,,,,50597,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622694,BAO_0000218,
9665,1,A,1,,,,50597,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622695,BAO_0000218,
9666,1,A,1,,,,50597,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622696,BAO_0000218,
9667,1,A,1,,,,50597,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622697,BAO_0000218,
9668,1,A,1,,,,50597,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622874,BAO_0000218,
9669,1,A,1,,,,50597,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622875,BAO_0000218,
9670,1,A,1,,,,50597,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622876,BAO_0000218,
9671,1,A,1,,,,50597,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622877,BAO_0000218,
9672,1,A,1,,,,50597,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622878,BAO_0000218,
9673,1,A,1,,,,50597,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622879,BAO_0000218,
9674,1,A,1,,,,50597,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL877602,BAO_0000218,
9675,1,A,1,,,,50597,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622880,BAO_0000218,
9676,1,A,1,,,,50597,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622881,BAO_0000218,
9677,1,A,1,,,,50597,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622882,BAO_0000218,
9678,1,A,1,,,,50597,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622883,BAO_0000218,
9679,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622884,BAO_0000218,
9680,1,A,1,,,,50597,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622885,BAO_0000218,
9681,1,A,1,,,,50597,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622886,BAO_0000218,
9682,1,A,1,,,,50597,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622887,BAO_0000218,
9683,1,A,1,,,,50597,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622888,BAO_0000218,
9684,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622889,BAO_0000218,
9685,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622890,BAO_0000218,
9686,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622891,BAO_0000218,
9687,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL877603,BAO_0000218,
9688,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622892,BAO_0000218,
9689,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622893,BAO_0000218,
9690,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622894,BAO_0000218,
9691,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622895,BAO_0000218,
9692,1,A,1,,,In vivo,50597,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622896,BAO_0000218,
9693,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622897,BAO_0000218,
9694,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622898,BAO_0000218,
9695,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622899,BAO_0000218,
9696,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622900,BAO_0000218,
9697,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624114,BAO_0000218,
9698,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624115,BAO_0000218,
9699,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624116,BAO_0000218,
9700,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624117,BAO_0000218,
9701,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624118,BAO_0000218,
9702,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624119,BAO_0000218,
9703,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624120,BAO_0000218,
9704,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624121,BAO_0000218,
9705,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624122,BAO_0000218,
9706,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624123,BAO_0000218,
9707,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624124,BAO_0000218,
9708,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624125,BAO_0000218,
9709,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624126,BAO_0000218,
9710,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624127,BAO_0000218,
9711,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624128,BAO_0000218,
9712,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",14.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624129,BAO_0000218,
9713,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",14.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624130,BAO_0000218,
9714,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",14.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622340,BAO_0000218,
9715,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",14.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622341,BAO_0000218,
9716,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",160.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622342,BAO_0000218,
9717,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",160.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622343,BAO_0000218,
9718,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",160.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622344,BAO_0000218,
9719,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",160.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622345,BAO_0000218,
9720,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622346,BAO_0000218,
9721,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622347,BAO_0000218,
9722,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622348,BAO_0000218,
9723,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622349,BAO_0000218,
9724,1,A,1,,,,50597,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622350,BAO_0000218,
9725,1,A,1,,,,50597,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622351,BAO_0000218,
9726,1,A,1,,,,50597,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622352,BAO_0000218,
9727,1,A,1,,,,50597,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622353,BAO_0000218,
9728,1,A,1,,,,50597,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622354,BAO_0000218,
9729,1,A,1,,,,50597,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622355,BAO_0000218,
9730,1,A,1,,,,50597,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622356,BAO_0000218,
9731,1,A,1,,,,50597,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622357,BAO_0000218,
9732,1,A,1,,,,50597,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622358,BAO_0000218,
9733,1,A,1,,,,50597,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622359,BAO_0000218,
9734,1,A,1,,,,50597,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874393,BAO_0000218,
9735,1,A,1,,,,50597,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622872,BAO_0000218,
9736,1,A,1,,,,50597,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622873,BAO_0000218,
9737,1,A,1,,,,50597,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623047,BAO_0000218,
9738,1,A,1,,,,50597,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623048,BAO_0000218,
9739,1,A,1,,,,50597,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623049,BAO_0000218,
9740,1,A,1,,,,50597,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623050,BAO_0000218,
9741,1,A,1,,,,50597,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623051,BAO_0000218,
9742,1,A,1,,,,50597,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623052,BAO_0000218,
9743,1,A,1,,,,50597,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626343,BAO_0000218,
9744,1,A,1,,,,50597,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626344,BAO_0000218,
9745,1,A,1,,,,50597,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626345,BAO_0000218,
9746,1,A,1,,,,50597,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626346,BAO_0000218,
9747,1,A,1,,,,50597,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626347,BAO_0000218,
9748,1,A,1,,,,50597,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626348,BAO_0000218,
9749,1,A,1,,,,50597,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626349,BAO_0000218,
9750,1,F,1,,,,50597,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626350,BAO_0000218,
9751,1,A,1,,,,50597,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626351,BAO_0000218,
9752,1,A,1,,,,50597,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627650,BAO_0000218,
9753,1,F,1,,,,50597,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627651,BAO_0000218,
9754,1,A,1,,,,50597,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627652,BAO_0000218,
9755,1,A,1,,,,50597,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627653,BAO_0000218,
9756,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627654,BAO_0000218,
9757,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627835,BAO_0000218,
9758,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627836,BAO_0000218,
9759,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627837,BAO_0000218,
9760,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627838,BAO_0000218,
9761,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875338,BAO_0000218,
9762,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627839,BAO_0000218,
9763,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627840,BAO_0000218,
9764,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627841,BAO_0000218,
9765,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627842,BAO_0000218,
9766,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627843,BAO_0000218,
9767,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627844,BAO_0000218,
9768,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627845,BAO_0000218,
9769,1,A,1,,,In vivo,50597,Half life period in rat by iv administration at a dose of 3 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627846,BAO_0000218,
9770,1,A,1,,,,50597,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627847,BAO_0000218,
9771,1,A,1,,,,50597,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL873821,BAO_0000218,
9772,1,A,1,,,,50597,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626079,BAO_0000218,
9773,1,A,1,,,,50597,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626080,BAO_0000218,
9774,1,A,1,,,,50597,Half life period was evaluated in rat plasma,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626081,BAO_0000218,
9775,1,A,1,,,,50597,Half life period was evaluated in rat plasma; Not tested,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875344,BAO_0000218,
9776,1,A,1,,,,50597,Half life period was evaluated in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626082,BAO_0000218,
9777,1,A,1,,,In vivo,50597,"Half life period was evaluated in rats, iv",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626250,BAO_0000218,
9778,1,A,1,,,In vivo,50597,Half life period after intravenous administration at 5 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626251,BAO_0000218,
9779,1,A,1,,,In vivo,50597,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626252,BAO_0000218,
9780,1,A,1,,,In vivo,50597,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626253,BAO_0000218,
9781,1,A,1,,,,50597,Half life stability of compound was evaluated in rat plasma,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626254,BAO_0000218,
9782,1,A,1,,,In vivo,50597,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626255,BAO_0000218,
9783,1,A,1,,,In vivo,50597,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626256,BAO_0000218,
9784,1,A,1,,,In vivo,50597,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626257,BAO_0000218,
9785,1,A,1,,,In vivo,50597,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626258,BAO_0000218,
9786,1,A,1,,,In vivo,50597,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626259,BAO_0000218,
9787,1,A,1,,,In vivo,50597,Half in rat i.v.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626260,BAO_0000218,
9788,1,A,1,,,In vivo,50597,Half period in rat after intravenous administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875345,BAO_0000218,
9789,1,A,1,,,In vivo,50597,Half-life after repeated oral dose of compound at 1 mg/kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626261,BAO_0000218,
9790,1,A,1,,,In vitro,50597,Half-life measured in in vitro Cathepsin B assay in rat liver,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626262,BAO_0000218,
9791,1,A,1,,,,50597,Half-life of compound was determined in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626263,BAO_0000218,
9792,1,A,1,,,In vivo,50597,Half-life at 10 mg/kg in rat upon intravenous administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625270,BAO_0000218,
9793,1,A,1,,,,50597,Half-life determined in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625271,BAO_0000218,
9794,1,A,1,,,,50597,Half-life determined in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625272,BAO_0000218,
9795,1,A,1,,,In vivo,50597,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625273,BAO_0000218,
9796,1,A,1,,,,50597,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625274,BAO_0000218,
9797,1,A,1,,,In vivo,50597,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625275,BAO_0000218,
9798,1,A,1,,,In vivo,50597,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625276,BAO_0000218,
9799,1,A,1,,,,50597,Half-life in rat plasma,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625277,BAO_0000218,
9800,1,A,1,,,,50597,Half-life in rat plasma was determined,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625278,BAO_0000218,
9801,1,A,1,,,,50597,Half-life in rat plasma; Not tested,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625279,BAO_0000218,
9802,1,A,1,,,,50597,Half-life in rat serum,1977.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625280,BAO_0000218,
9803,1,A,1,,,,50597,Half-life in rat serum; na is not available,1977.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876797,BAO_0000218,
9804,1,A,1,,,,50597,Half-life was calculated in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625281,BAO_0000218,
9805,1,A,1,,,,50597,Half-life was calculated in rat plasma,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL873827,BAO_0000218,
9806,1,A,1,,,,50597,Half-life was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625282,BAO_0000218,
9807,1,A,1,,,,50597,Half-life was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625283,BAO_0000218,
9808,1,A,1,,,In vivo,50597,Half-life after administration of 20 mg/Kg oral dose in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625284,BAO_0000218,
9809,1,A,1,,,In vivo,50597,Half-life after administration of 3.2 mg/kg intravenously in male rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625285,BAO_0000218,
9810,1,A,1,,,In vivo,50597,Half-life after intravenous administration in female rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625286,BAO_0000218,
9811,1,A,1,,,In vivo,50597,Half-life after intravenous administration in male rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625287,BAO_0000218,
9812,1,A,1,,,In vivo,50597,Half-life after intravenous dose in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625288,BAO_0000218,
9813,1,A,1,,,,50597,Half-life in a rat liver homogenate preparation,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625289,BAO_0000218,
9814,1,A,1,,,,50597,Half-life in plasma of rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625290,BAO_0000218,
9815,1,A,1,,,,50597,Half-life in plasma of rat at dose of 3-10 mgkg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876798,BAO_0000218,
9816,1,A,1,,,,50597,Half-life in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625291,BAO_0000218,
9817,1,A,1,,,,50597,Half-life in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625292,BAO_0000218,
9818,1,A,1,,,,50597,Half-life in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625293,BAO_0000218,
9819,1,A,1,,,,50597,Half-life in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622832,BAO_0000218,
9820,1,A,1,,,,50597,Half-life in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622833,BAO_0000218,
9821,1,A,1,,,,50597,Half-life in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622834,BAO_0000218,
9822,1,A,1,,,In vivo,50597,Half-life in rat after oral administration at 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622835,BAO_0000218,
9823,1,A,1,,,In vivo,50597,Half-life in rat after po administration at a dose of 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622836,BAO_0000218,
9824,1,A,1,,,In vivo,50597,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622837,BAO_0000218,
9825,1,A,1,,,In vivo,50597,Half-life in rat at 3 mg/kg dose administered intravenously,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622838,BAO_0000218,
9826,1,A,1,,,,50597,Half-life in rat brain homogenate,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622839,BAO_0000218,
9827,1,A,1,,,,50597,Half-life in rat plasma,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622840,BAO_0000218,
9828,1,A,1,,,,50597,Half-life in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622841,BAO_0000218,
9829,1,A,1,,,,50597,Half-life in Dawley rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622842,BAO_0000218,
9830,1,A,1,,,In vitro,50597,Half-life in vitro in rat plasma,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622843,BAO_0000218,
9831,1,A,1,,,In vitro,50597,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622844,BAO_0000218,
9832,1,A,1,,,,50597,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622845,BAO_0000218,
9833,1,A,1,,,,50597,The area under the curve of compound was measured at the dose of 100 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622846,BAO_0000218,
9834,1,A,1,,,,50597,The area under the curve of compound was measured at the dose of 300 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622847,BAO_0000218,
9835,1,A,1,,,,50597,The area under the curve of compound was measured at the dose of 30 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622848,BAO_0000218,
9836,1,A,1,,,In vivo,50597,Bioavailability as oral AUC in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622849,BAO_0000218,
9837,1,A,1,,,,50597,The plasma concentration versus time curve (AUC) was determined,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622850,BAO_0000218,
9838,1,A,1,,,,50597,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876807,BAO_0000218,
9839,1,A,1,,,,50597,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622851,BAO_0000218,
9840,1,A,1,,,,50597,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622852,BAO_0000218,
9841,1,A,1,,,,50597,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622853,BAO_0000218,
9842,1,A,1,,,,50597,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622854,BAO_0000218,
9843,1,A,1,,,,50597,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622855,BAO_0000218,
9844,1,A,1,,,,50597,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622856,BAO_0000218,
9845,1,A,1,,,,50597,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622857,BAO_0000218,
9846,1,A,1,,,,50597,AUC in rat after po administration at a dose of 10 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622858,BAO_0000218,
9847,1,A,1,,,,50597,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622859,BAO_0000218,
9848,1,A,1,,,,50597,Area under curve value 24 hr after 10 mg/kg iv administration in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622860,BAO_0000218,
9849,1,A,1,,,,50597,Area under curve value 24 hr after 10 mg/kg oral administration in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622861,BAO_0000218,
9850,1,A,1,,,,50597,Area under curve value 24 hr after 2 mg/kg iv administration in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622862,BAO_0000218,
9851,1,A,1,,,,50597,Area under curve value 24 hr after 2 mg/kg oral administration in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622863,BAO_0000218,
9852,1,A,1,,,,50597,Area under curve value 6 hr after po administration in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623817,BAO_0000218,
9853,1,A,1,,,,50597,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623818,BAO_0000218,
9854,1,A,1,,,,50597,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623819,BAO_0000218,
9855,1,A,1,,,,50597,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623820,BAO_0000218,
9856,1,A,1,,,,50597,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623821,BAO_0000218,
9857,1,A,1,,,,50597,AUC normalized for dose (AUCN) in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623822,BAO_0000218,
9858,1,A,1,,,,50597,Area under curve in rat after p.o. administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623823,BAO_0000218,
9859,1,A,1,,,,50597,Area under curve in rat after p.o. administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623824,BAO_0000218,
9860,1,A,1,,,,50597,Area under curve in rat after p.o. administration; Not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623825,BAO_0000218,
9861,1,A,1,,,,50597,Area under curve in rat after peroral administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622070,BAO_0000218,
9862,1,A,1,,,,50597,Area under curve (carotid artery) value of the compound,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622071,BAO_0000218,
9863,1,A,1,,,,50597,Bioavailability expressed as the area under curve of rat carotid artery,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622072,BAO_0000218,
9864,1,A,1,,,,50597,Area under curve in male SD rats was observed after intravenous administration in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622073,BAO_0000218,
9865,1,A,1,,,,50597,Area under curve of the compound was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622074,BAO_0000218,
9866,1,A,1,,,,50597,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622075,BAO_0000218,
9867,1,A,1,,,,50597,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622076,BAO_0000218,
9868,1,A,1,,,,50597,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622077,BAO_0000218,
9869,1,A,1,,,,50597,Area under curve (portal vein) value of the compound,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622078,BAO_0000218,
9870,1,A,1,,,,50597,Bioavailability expressed as the area under curve of rat portal vein,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622079,BAO_0000218,
9871,1,A,1,,,,50597,Area Under plasma concentration time curve in rat upon peroral administration,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622080,BAO_0000218,
9872,1,A,1,,,,50597,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL877612,BAO_0000218,
9873,1,A,1,,,,50597,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622081,BAO_0000218,
9874,1,A,1,,,,50597,Compound was evaluated for oral bioavailability in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622082,BAO_0000218,
9875,1,A,1,,,,50597,Compound was evaluated for oral bioavailability in rats after iv administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622083,BAO_0000218,
9876,1,A,1,,,,50597,Compound was evaluated for oral bioavailability in rats; 30-80,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622084,BAO_0000218,
9877,1,A,1,,,,50597,Compound was evaluated for oral bioavailability in rats; 50-60,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622085,BAO_0000218,
9878,1,A,1,,,,50597,Compound was evaluated for oral bioavailability in rats; no data,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622086,BAO_0000218,
9879,1,A,1,,,,50597,Compound was evaluated for oral bioavailability in rats; peptide,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622087,BAO_0000218,
9880,1,A,1,,,,50597,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622088,BAO_0000218,
9881,1,A,1,,,,50597,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622089,BAO_0000218,
9882,1,A,1,,,,50597,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623685,BAO_0000218,
9883,1,A,1,,,,50597,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623686,BAO_0000218,
9884,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",945.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623687,BAO_0000218,
9885,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",945.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623688,BAO_0000218,
9886,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",945.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623689,BAO_0000218,
9887,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",945.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622485,BAO_0000218,
9888,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622486,BAO_0000218,
9889,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL877613,BAO_0000218,
9890,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622487,BAO_0000218,
9891,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622488,BAO_0000218,
9892,1,A,1,,,In vivo,50597,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622489,BAO_0000218,
9893,1,A,1,,,,50597,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622490,BAO_0000218,
9894,1,A,1,,,,50597,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622491,BAO_0000218,
9895,1,A,1,,,,50597,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622492,BAO_0000218,
9896,1,A,1,,,,50597,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622493,BAO_0000218,
9897,1,A,1,,,,50597,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622494,BAO_0000218,
9898,1,A,1,,,,50597,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622495,BAO_0000218,
9899,1,A,1,,,,50597,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622496,BAO_0000218,
9900,1,A,1,,,,50597,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622497,BAO_0000218,
9901,1,A,1,,,,50597,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622498,BAO_0000218,
9902,1,A,1,,,,50597,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624918,BAO_0000218,
9903,1,A,1,,,,50597,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624919,BAO_0000218,
9904,1,A,1,,,In vivo,50597,Biodistribution of compound in rat blood after 5 min of administration,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624920,BAO_0000218,
9905,1,A,1,,,In vivo,50597,Biodistribution of compound in rat blood after 5 min of administration.,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624921,BAO_0000218,
9906,1,A,1,,,In vivo,50597,Biodistribution of compound in rat brain after 5 min of administration,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624922,BAO_0000218,
9907,1,A,1,,,In vivo,50597,Biodistribution of compound in rat heart after 5 min of administration,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624923,BAO_0000218,
9908,1,A,1,,,In vivo,50597,Biodistribution of compound in rat heart after 5 min of administration.,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624924,BAO_0000218,
9909,1,A,1,,,In vivo,50597,Biodistribution of compound in rat kidney after 5 min of administration,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624925,BAO_0000218,
9910,1,A,1,,,In vivo,50597,Biodistribution of compound in rat kidney after 5 min of administration.,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624926,BAO_0000218,
9911,1,A,1,,,In vivo,50597,Biodistribution of compound in rat liver after 5 min of administration,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624927,BAO_0000218,
9912,1,A,1,,,In vivo,50597,Biodistribution of compound in rat liver after 5 min of administration.,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874402,BAO_0000218,
9913,1,A,1,,,In vivo,50597,Biodistribution of compound in rat lung after 5 min of administration,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624928,BAO_0000218,
9914,1,A,1,,,In vivo,50597,Biodistribution of compound in rat lung after 5 min of administration.,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624929,BAO_0000218,
9915,1,A,1,,,In vivo,50597,Biodistribution of compound in rat muscle after 5 min of administration,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624930,BAO_0000218,
9916,1,A,1,,,In vivo,50597,Biodistribution of compound in rat muscle after 5 min of administration.,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624931,BAO_0000218,
9917,1,A,1,,,,50597,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624932,BAO_0000218,
9918,1,A,1,,,,50597,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624933,BAO_0000218,
9919,1,A,1,,,,50597,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624934,BAO_0000218,
9920,1,A,1,,,,50597,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624935,BAO_0000218,
9921,1,A,1,,,,50597,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624936,BAO_0000218,
9922,1,A,1,,,,50597,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624937,BAO_0000218,
9923,1,A,1,,,,50597,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624938,BAO_0000218,
9924,1,A,1,,,,50597,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624939,BAO_0000218,
9925,1,A,1,,,,50597,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624940,BAO_0000218,
9926,1,A,1,,,,50597,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874403,BAO_0000218,
9927,1,A,1,,,,50597,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624941,BAO_0000218,
9928,1,A,1,,,,50597,Dose required to lower urine osmolality to 300 mOsm/kg in rat,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624942,BAO_0000218,
9929,1,A,1,,,,50597,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624943,BAO_0000218,
9930,1,A,1,,,In vivo,50597,% Bioavailability after 1 day of the drug administration in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624944,BAO_0000218,
9931,1,A,1,,,In vivo,50597,% Bioavailability after 4 day of the drug administration in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624945,BAO_0000218,
9932,1,A,1,,,In vivo,50597,Absolute bioavailability was evaluated in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624946,BAO_0000218,
9933,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624947,BAO_0000218,
9934,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624948,BAO_0000218,
9935,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624949,BAO_0000218,
9936,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622025,BAO_0000218,
9937,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622026,BAO_0000218,
9938,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622027,BAO_0000218,
9939,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622028,BAO_0000218,
9940,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622029,BAO_0000218,
9941,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622208,BAO_0000218,
9942,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622209,BAO_0000218,
9943,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622210,BAO_0000218,
9944,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622211,BAO_0000218,
9945,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622212,BAO_0000218,
9946,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622213,BAO_0000218,
9947,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874404,BAO_0000218,
9948,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620452,BAO_0000218,
9949,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620453,BAO_0000218,
9950,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620454,BAO_0000218,
9951,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624067,BAO_0000218,
9952,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624068,BAO_0000218,
9953,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,992.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624069,BAO_0000218,
9954,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,992.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624070,BAO_0000218,
9955,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,992.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624071,BAO_0000218,
9956,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,995.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624072,BAO_0000218,
9957,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,995.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624073,BAO_0000218,
9958,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,995.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624788,BAO_0000218,
9959,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,995.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624789,BAO_0000218,
9960,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624790,BAO_0000218,
9961,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624791,BAO_0000218,
9962,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624792,BAO_0000218,
9963,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624793,BAO_0000218,
9964,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL877491,BAO_0000218,
9965,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624957,BAO_0000218,
9966,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624958,BAO_0000218,
9967,1,A,1,,,,50597,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624959,BAO_0000218,
9968,1,A,1,,,,50597,Dissociation constant was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624960,BAO_0000218,
9969,1,A,1,,,,50597,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624961,BAO_0000218,
9970,1,A,1,,,,50597,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624962,BAO_0000218,
9971,1,A,1,,,,50597,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624963,BAO_0000218,
9972,1,A,1,,,,50597,Observed rate constant in 80% rat plasma at 37 degree Centigrade,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624964,BAO_0000218,
9973,1,A,1,,,,50597,LogP value was evaluated in the in situ rat gut perfusion assay,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624965,BAO_0000218,
9974,1,A,1,,,In vivo,50597,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624966,BAO_0000218,
9975,1,A,1,,,In vivo,50597,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624967,BAO_0000218,
9976,1,A,1,,,In vivo,50597,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624968,BAO_0000218,
9977,1,A,1,,,,50597,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624969,BAO_0000218,
9978,1,F,1,,,,50597,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,,Rattus norvegicus,,,,10116.0,N,Expert,CHEMBL624970,BAO_0000218,
9979,1,A,1,,,,50597,Half-life was evaluated after 10 uM/kg of intra arterial administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624971,BAO_0000218,
9980,1,A,1,,,In vivo,50597,Half-life was evaluated after 20 uM/kg of peroral administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624972,BAO_0000218,
9981,1,A,1,,,In vivo,50597,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624973,BAO_0000218,
9982,1,A,1,,,,50597,Half-life was evaluated in plasma of rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624974,BAO_0000218,
9983,1,A,1,,,In vivo,50597,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624975,BAO_0000218,
9984,1,A,1,,,In vivo,50597,Half-life was evaluated in rats at an oral dose of 30 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL877492,BAO_0000218,
9985,1,A,1,,,In vivo,50597,Half-life was measured in rat after an iv dose of 1 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624976,BAO_0000218,
9986,1,A,1,,,In vivo,50597,Half-life period of compound in rats after peroral administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624977,BAO_0000218,
9987,1,A,1,,,,50597,Half-life period of compound was measured in rat plasma.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626848,BAO_0000218,
9988,1,A,1,,,,50597,Half-life period of compound was measured in rat plasma; ND is not determined,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626849,BAO_0000218,
9989,1,A,1,,,,50597,Half-life period of compound was measured in rat plasma; not determined,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626850,BAO_0000218,
9990,1,A,1,,,In vivo,50597,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626851,BAO_0000218,
9991,1,A,1,,,In vivo,50597,Half-life period in rat by iv administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626852,BAO_0000218,
9992,1,A,1,,,In vivo,50597,Half-life period in rats following intravenous administration at 2 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626853,BAO_0000218,
9993,1,A,1,,,In vivo,50597,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626854,BAO_0000218,
9994,1,A,1,,,,50597,Half-life period was determined for the compound in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627486,BAO_0000218,
9995,1,A,1,,,In vivo,50597,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627487,BAO_0000218,
9996,1,A,1,,,In vivo,50597,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627488,BAO_0000218,
9997,1,A,1,,,In vivo,50597,Half-life value after IV dose at a dose of 5 mg/kg in rats.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627489,BAO_0000218,
9998,1,A,1,,,In vivo,50597,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627490,BAO_0000218,
9999,1,A,1,,,In vivo,50597,Half-life was determined in rat after intravenous administration (0.5 mg/kg),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL873829,BAO_0000218,
10000,1,A,1,,,In vivo,50597,Half-life was determined in rat at a dose of 1 mpk i.v.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627655,BAO_0000218,
10001,1,A,1,,,In vivo,50597,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625994,BAO_0000218,
10002,1,A,1,,,In vivo,50597,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625995,BAO_0000218,
10003,1,A,1,,,,50597,Half-life in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625996,BAO_0000218,
10004,1,A,1,,,In vitro,50597,In vitro half life in rat plasma,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625850,BAO_0000218,
10005,1,A,1,,,In vitro,50597,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625851,BAO_0000218,
10006,1,A,1,,,In vitro,50597,In vitro half life in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625852,BAO_0000218,
10007,1,A,1,,,In vivo,50597,In vivo half life period after intravenous administration in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625853,BAO_0000218,
10008,1,A,1,,,In vivo,50597,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625854,BAO_0000218,
10009,1,A,1,,,In vivo,50597,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874450,BAO_0000218,
10010,1,A,1,,,In vivo,50597,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625855,BAO_0000218,
10011,1,A,1,,,In vivo,50597,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625856,BAO_0000218,
10012,1,A,1,,,In vivo,50597,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625857,BAO_0000218,
10013,1,A,1,,,In vivo,50597,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL873831,BAO_0000218,
10014,1,A,1,,,In vivo,50597,Longer half-life in rat (i.v.) at 0.5 mpk,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625858,BAO_0000218,
10015,1,A,1,,,In vivo,50597,Longer half-life in rat (p.o.) at 2.0 mpk,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625859,BAO_0000218,
10016,1,A,1,,,,50597,Pharmacokinetic property (half life) in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625860,BAO_0000218,
10017,1,A,1,,,In vivo,50597,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625861,BAO_0000218,
10018,1,A,1,,,In vivo,50597,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625862,BAO_0000218,
10019,1,A,1,,,In vivo,50597,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625863,BAO_0000218,
10020,1,A,1,,,In vivo,50597,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625864,BAO_0000218,
10021,1,A,1,,,In vivo,50597,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625865,BAO_0000218,
10022,1,A,1,,,In vivo,50597,Pharmacokinetic half time was determined intravenously in rats.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625866,BAO_0000218,
10023,1,A,1,,,In vivo,50597,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625867,BAO_0000218,
10024,1,A,1,,,,50597,Plasma half life of hydrolysis of the compound,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625868,BAO_0000218,
10025,1,A,1,,,In vivo,50597,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625869,BAO_0000218,
10026,1,A,1,,,,50597,Plasma half life period was calculated in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874451,BAO_0000218,
10027,1,A,1,,,,50597,Plasma half-life in Sprague-Dawley rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625870,BAO_0000218,
10028,1,A,1,,,,50597,Plasma half-life in Sprague-Dawley rats; Not determined,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625871,BAO_0000218,
10029,1,A,1,,,,50597,Plasma half-life in rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625872,BAO_0000218,
10030,1,A,1,,,,50597,Plasma half-life in rats; <MQL,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625873,BAO_0000218,
10031,1,A,1,,,,50597,Plasma half-life period (0-8 h) was determined,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625874,BAO_0000218,
10032,1,A,1,,,,50597,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625875,BAO_0000218,
10033,1,A,1,,,In vivo,50597,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625876,BAO_0000218,
10034,1,A,1,,,In vivo,50597,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631258,BAO_0000218,
10035,1,A,1,,,,50597,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631259,BAO_0000218,
10036,1,A,1,,,,50597,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631260,BAO_0000218,
10037,1,A,1,,,,50597,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631261,BAO_0000218,
10038,1,A,1,,,,50597,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631262,BAO_0000218,
10039,1,A,1,,,,50597,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631263,BAO_0000218,
10040,1,A,1,,,,50597,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631264,BAO_0000218,
10041,1,A,1,,,,50597,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631265,BAO_0000218,
10042,1,A,1,,,,50597,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631266,BAO_0000218,
10043,1,A,1,,,,50597,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631267,BAO_0000218,
10044,1,A,1,,,,50597,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631268,BAO_0000218,
10045,1,A,1,,,,50597,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631269,BAO_0000218,
10046,1,A,1,,,,50597,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631270,BAO_0000218,
10047,1,A,1,,,,50597,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631271,BAO_0000218,
10048,1,A,1,,,,50597,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631272,BAO_0000218,
10049,1,A,1,,,,50597,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631273,BAO_0000218,
10050,1,A,1,,,,50597,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631274,BAO_0000218,
10051,1,A,1,,,,50597,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631275,BAO_0000218,
10052,1,A,1,,,,50597,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626984,BAO_0000218,
10053,1,A,1,,,,50597,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626985,BAO_0000218,
10054,1,A,1,,,,50597,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626986,BAO_0000218,
10055,1,A,1,,,,50597,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626987,BAO_0000218,
10056,1,A,1,,,,50597,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626988,BAO_0000218,
10057,1,A,1,,,,50597,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626989,BAO_0000218,
10058,1,A,1,,,,50597,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626990,BAO_0000218,
10059,1,A,1,,,,50597,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626991,BAO_0000218,
10060,1,A,1,,,,50597,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626992,BAO_0000218,
10061,1,A,1,,,,50597,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626993,BAO_0000218,
10062,1,A,1,,,,50597,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874593,BAO_0000218,
10063,1,A,1,,,,50597,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626994,BAO_0000218,
10064,1,A,1,,,,50597,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626995,BAO_0000218,
10065,1,A,1,,,,50597,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626190,BAO_0000218,
10066,1,A,1,,,,50597,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626191,BAO_0000218,
10067,1,A,1,,,,50597,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626364,BAO_0000218,
10068,1,A,1,,,,50597,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626365,BAO_0000218,
10069,1,A,1,,,,50597,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626366,BAO_0000218,
10070,1,A,1,,,,50597,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626367,BAO_0000218,
10071,1,A,1,,,,50597,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626368,BAO_0000218,
10072,1,A,1,,,,50597,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626369,BAO_0000218,
10073,1,A,1,,,,50597,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626370,BAO_0000218,
10074,1,A,1,,,In vivo,50597,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626371,BAO_0000218,
10075,1,A,1,,,In vivo,50597,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626372,BAO_0000218,
10076,1,A,1,,,In vivo,50597,Bioavailability after a dose of 10 mg/kg p.o.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626373,BAO_0000218,
10077,1,A,1,,,In vivo,50597,Bioavailability after peroral administration (10 mg/kg) was determined in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626374,BAO_0000218,
10078,1,A,1,,,In vivo,50597,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626375,BAO_0000218,
10079,1,A,1,,,In vivo,50597,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626376,BAO_0000218,
10080,1,A,1,,,In vivo,50597,Bioavailability in rat po was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626377,BAO_0000218,
10081,1,A,1,,,In vivo,50597,Bioavailability of compound at 10 mg/kg in rat after oral administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626378,BAO_0000218,
10082,1,A,1,,,In vivo,50597,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626379,BAO_0000218,
10083,1,A,1,,,In vivo,50597,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626380,BAO_0000218,
10084,1,A,1,,,In vivo,50597,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626381,BAO_0000218,
10085,1,A,1,,,In vivo,50597,Bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626382,BAO_0000218,
10086,1,A,1,,,In vivo,50597,Bioavailability in rat (Sprague-Dawley) (female),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626383,BAO_0000218,
10087,1,A,1,,,In vivo,50597,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874652,BAO_0000218,
10088,1,A,1,,,In vivo,50597,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626384,BAO_0000218,
10089,1,A,1,,,In vivo,50597,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626385,BAO_0000218,
10090,1,A,1,,,In vivo,50597,Bioavailability in rat at an oral dose of 2 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626386,BAO_0000218,
10091,1,A,1,,,In vivo,50597,Bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626387,BAO_0000218,
10092,1,A,1,,,In vivo,50597,Bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626388,BAO_0000218,
10093,1,A,1,,,In vivo,50597,Bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626389,BAO_0000218,
10094,1,A,1,,,In vivo,50597,Bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626390,BAO_0000218,
10095,1,A,1,,,In vivo,50597,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626391,BAO_0000218,
10096,1,A,1,,,In vivo,50597,Bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626392,BAO_0000218,
10097,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626393,BAO_0000218,
10098,1,A,1,,,In vivo,50597,Bioavailability was determined in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623026,BAO_0000218,
10099,1,A,1,,,In vivo,50597,Bioavailability,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623027,BAO_0000218,
10100,1,A,1,,,In vivo,50597,Bioavailability,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623028,BAO_0000218,
10101,1,A,1,,,In vivo,50597,Bioavailability in rat after 1 day dosing,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623029,BAO_0000218,
10102,1,A,1,,,In vivo,50597,Bioavailability in rat after 4 day dosing,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623030,BAO_0000218,
10103,1,A,1,,,In vivo,50597,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623031,BAO_0000218,
10104,1,A,1,,,In vivo,50597,Bioavailability after IV dosing at 1 mg/kg in rat; no data,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623032,BAO_0000218,
10105,1,A,1,,,In vivo,50597,Bioavailability after oral administration at a dose of 2 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623033,BAO_0000218,
10106,1,A,1,,,In vivo,50597,Bioavailability after oral administration at a dose of 4 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623034,BAO_0000218,
10107,1,A,1,,,In vivo,50597,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623035,BAO_0000218,
10108,1,A,1,,,In vivo,50597,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623036,BAO_0000218,
10109,1,A,1,,,In vivo,50597,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623037,BAO_0000218,
10110,1,A,1,,,In vivo,50597,Bioavailability by intravenous administration of 3.4 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623038,BAO_0000218,
10111,1,A,1,,,In vivo,50597,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874385,BAO_0000218,
10112,1,A,1,,,In vivo,50597,Bioavailability in rat (Fisher) (fasted),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623039,BAO_0000218,
10113,1,A,0,,,In vivo,22224,Bioavailability in monkey after po administration of 10 mg/kg dose,,Primates,,,,9443.0,U,Intermediate,CHEMBL623040,BAO_0000218,
10114,1,A,0,,,In vivo,22224,Oral bioavailability in monkey (dose 10 mg/kg),,Primates,,,,9443.0,U,Intermediate,CHEMBL623041,BAO_0000218,
10115,1,A,1,,,In vivo,50597,Bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623741,BAO_0000218,
10116,1,A,1,,,In vivo,50597,Bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623742,BAO_0000218,
10117,1,A,1,,,In vivo,50597,Bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623743,BAO_0000218,
10118,1,A,1,,,In vivo,50597,Bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623744,BAO_0000218,
10119,1,A,1,,,In vivo,50597,Bioavailability in rat (dose 2.0 mg/kg p.o.),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623745,BAO_0000218,
10120,1,A,1,,,In vivo,50597,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623746,BAO_0000218,
10121,1,A,1,,,In vivo,50597,Oral bioavailability in rat (dose 5 mg/kg p.o.),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623747,BAO_0000218,
10122,1,A,0,,,In vivo,22224,Bioavailability in rat after po administration of 30 mg/kg dose,,Rattus norvegicus,,,,10116.0,U,Intermediate,CHEMBL623748,BAO_0000218,
10123,1,A,0,,,In vivo,22224,Bioavailability in rat after po administration of 30 mg/kg dose,,Rattus norvegicus,,,,10116.0,U,Intermediate,CHEMBL623916,BAO_0000218,
10124,1,A,1,,,In vivo,50597,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623917,BAO_0000218,
10125,1,A,1,,,In vivo,50597,Bioavailability in rat (dose 2 mg/kg i.v.),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623918,BAO_0000218,
10126,1,A,1,,,In vivo,50597,Bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874386,BAO_0000218,
10127,1,A,1,,,In vivo,50597,Bioavailability in rat; Only traces detected in rat plasma,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623919,BAO_0000218,
10128,1,A,1,,,In vivo,50597,Bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623920,BAO_0000218,
10129,1,A,1,,,In vivo,50597,Bioavailability upon oral administration of compound,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623148,BAO_0000218,
10130,1,A,1,,,In vivo,50597,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623149,BAO_0000218,
10131,1,A,1,,,In vivo,50597,Bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623150,BAO_0000218,
10132,1,A,1,,,In vivo,50597,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623151,BAO_0000218,
10133,1,A,1,,,In vivo,50597,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623152,BAO_0000218,
10134,1,F,1,,,,50597,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,,Rattus norvegicus,,,,10116.0,N,Expert,CHEMBL623153,BAO_0000218,
10135,1,F,1,,,,50597,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,,Rattus norvegicus,,,,10116.0,N,Expert,CHEMBL623154,BAO_0000218,
10136,1,A,1,,,,50597,In vitro and metabolic stability was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623155,BAO_0000218,
10137,1,A,1,,,,50597,In vitro metabolic stability in rat hepatocytes,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623156,BAO_0000218,
10138,1,A,1,,,,50597,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623157,BAO_0000218,
10139,1,A,1,Hepatocyte,,In vitro,50597,Metabolic rate for compound was observed in rat hepatocytes,2107.0,Rattus norvegicus,,401.0,,10116.0,N,Intermediate,CHEMBL623158,BAO_0000218,
10140,1,A,1,,,,50597,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623159,BAO_0000218,
10141,1,A,1,,,,50597,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874390,BAO_0000218,
10142,1,A,1,,,,50597,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623160,BAO_0000218,
10143,1,A,1,,,,50597,Metabolism of compound in rat S9 microsomes; Trace,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623161,BAO_0000218,
10144,1,A,1,,,,50597,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623162,BAO_0000218,
10145,1,A,1,,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623163,BAO_0000218,
10146,1,A,1,,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623164,BAO_0000218,
10147,1,A,1,,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623165,BAO_0000218,
10148,1,A,1,,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623166,BAO_0000218,
10149,1,A,1,,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624983,BAO_0000218,
10150,1,A,1,,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624984,BAO_0000218,
10151,1,A,1,,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624985,BAO_0000218,
10152,1,A,1,,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622970,BAO_0000218,
10153,1,A,1,,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622971,BAO_0000218,
10154,1,A,1,,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622972,BAO_0000218,
10155,1,A,1,,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622973,BAO_0000218,
10156,1,A,1,,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622974,BAO_0000218,
10157,1,A,1,,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622975,BAO_0000218,
10158,1,A,1,,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622976,BAO_0000218,
10159,1,A,1,,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622977,BAO_0000218,
10160,1,A,1,,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624351,BAO_0000218,
10161,1,A,1,,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624352,BAO_0000218,
10162,1,A,1,,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624353,BAO_0000218,
10163,1,A,1,,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622397,BAO_0000218,
10164,1,A,1,,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622398,BAO_0000218,
10165,1,A,1,,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622399,BAO_0000218,
10166,1,A,1,,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622400,BAO_0000218,
10167,1,A,1,,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628428,BAO_0000218,
10168,1,A,1,,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628590,BAO_0000218,
10169,1,A,1,,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628591,BAO_0000218,
10170,1,A,1,,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628592,BAO_0000218,
10171,1,A,1,,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628593,BAO_0000218,
10172,1,A,1,,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875333,BAO_0000218,
10173,1,A,1,,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628594,BAO_0000218,
10174,1,A,1,,,,50597,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628595,BAO_0000218,
10175,1,A,1,,,,50597,Stability in rat plasma was determined,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628596,BAO_0000218,
10176,1,A,1,,,,50597,Stability in rat plasma was determined; ND= no data,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628597,BAO_0000218,
10177,1,A,1,,,,50597,Tested for plasma half life period in rat (0-8 hr),1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628598,BAO_0000218,
10178,1,A,1,,,,50597,Tested for plasma half life period in rat (0-8 hr); Not determined,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628599,BAO_0000218,
10179,1,A,1,,,In vivo,50597,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628600,BAO_0000218,
10180,1,A,1,,,In vivo,50597,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628601,BAO_0000218,
10181,1,A,1,,,,50597,Tested for the half life in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628602,BAO_0000218,
10182,1,A,1,,,In vitro,50597,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628603,BAO_0000218,
10183,1,A,1,,,In vitro,50597,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628604,BAO_0000218,
10184,1,A,1,,,In vitro,50597,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628605,BAO_0000218,
10185,1,A,1,,,In vitro,50597,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628606,BAO_0000218,
10186,1,A,1,,,In vitro,50597,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628607,BAO_0000218,
10187,1,A,1,,,,50597,The biological half life the compound was measured at the dose of 100 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628608,BAO_0000218,
10188,1,A,1,,,,50597,The biological half life the compound was measured at the dose of 30 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628609,BAO_0000218,
10189,1,A,1,,,,50597,The compound was evaluated for plasma half life period in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628610,BAO_0000218,
10190,1,A,1,,,In vivo,50597,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL873819,BAO_0000218,
10191,1,A,1,,,In vivo,50597,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628611,BAO_0000218,
10192,1,A,1,,,In vivo,50597,The pharmacokinetic parameter half-life period in vivo in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628612,BAO_0000218,
10193,1,A,1,,,In vivo,50597,"The pharmacokinetic property, Half-life was determined",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628613,BAO_0000218,
10194,1,A,1,,,In vivo,50597,"The pharmacokinetic property, Half-life in rat in vivo",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628614,BAO_0000218,
10195,1,A,1,,,In vivo,50597,"The pharmacokinetic property, Half-life was determined; ND denotes no data",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628615,BAO_0000218,
10196,1,A,1,,,In vivo,50597,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628616,BAO_0000218,
10197,1,A,1,,,,50597,The plasma half life period in rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627924,BAO_0000218,
10198,1,A,1,,,,50597,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627925,BAO_0000218,
10199,1,A,1,,,In vivo,50597,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627926,BAO_0000218,
10200,1,A,1,,,,50597,t1/2 (apparent elimination)of the compound was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627927,BAO_0000218,
10201,1,A,1,,,,50597,t1/2 value in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627928,BAO_0000218,
10202,1,A,1,,,,50597,Half life in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627539,BAO_0000218,
10203,1,A,1,,,In vivo,50597,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876790,BAO_0000218,
10204,1,A,1,,,In vivo,50597,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL858186,BAO_0000218,
10205,1,A,1,,,,50597,Half-life period in fasted rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627540,BAO_0000218,
10206,1,A,1,,,In vivo,50597,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627541,BAO_0000218,
10207,1,A,1,,,In vivo,50597,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627715,BAO_0000218,
10208,1,A,1,,,In vivo,50597,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627716,BAO_0000218,
10209,1,A,1,,,,50597,Maximum time required to achieve Cmax was determined in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627717,BAO_0000218,
10210,1,A,1,,,In vivo,50597,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627718,BAO_0000218,
10211,1,A,1,,,In vivo,50597,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627719,BAO_0000218,
10212,1,A,1,,,In vivo,50597,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627720,BAO_0000218,
10213,1,A,1,,,In vivo,50597,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627721,BAO_0000218,
10214,1,A,1,,,In vivo,50597,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627722,BAO_0000218,
10215,1,A,1,,,In vivo,50597,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627723,BAO_0000218,
10216,1,A,1,,,In vivo,50597,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626058,BAO_0000218,
10217,1,A,1,,,In vivo,50597,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626059,BAO_0000218,
10218,1,A,1,,,In vivo,50597,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626060,BAO_0000218,
10219,1,A,1,,,In vivo,50597,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626061,BAO_0000218,
10220,1,A,1,,,In vivo,50597,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876791,BAO_0000218,
10221,1,A,1,,,In vivo,50597,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626062,BAO_0000218,
10222,1,A,1,,,In vivo,50597,Tmax at the dose of 2 mg/Kg administered perorally in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626063,BAO_0000218,
10223,1,A,1,,,In vivo,50597,Tmax at the dose of 5 mg/Kg administered perorally in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626064,BAO_0000218,
10224,1,A,1,,,In vivo,50597,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626065,BAO_0000218,
10225,1,A,1,,,In vivo,50597,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626066,BAO_0000218,
10226,1,A,1,,,In vivo,50597,tmax upon peroral administration of 10.0 mg/Kg dose in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626067,BAO_0000218,
10227,1,F,1,,,,50597,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626068,BAO_0000218,
10228,1,F,1,,,,50597,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626069,BAO_0000218,
10229,1,F,1,,,,50597,Percent total excretion of 3-methoxyacetaminophen glucuronide,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626070,BAO_0000218,
10230,1,F,1,,,,50597,Percent total excretion of N-methoxyacetaminophen glucuronide,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626071,BAO_0000218,
10231,1,F,1,,,,50597,Percent total excretion of N-methoxyacetaminophen sulfate,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626072,BAO_0000218,
10232,1,F,1,,,,50597,Percent total excretion of acetaminophen,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626073,BAO_0000218,
10233,1,A,1,,,,50597,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626741,BAO_0000218,
10234,1,A,1,,,,50597,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626742,BAO_0000218,
10235,1,A,1,,,,50597,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626743,BAO_0000218,
10236,1,A,1,,,,50597,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876792,BAO_0000218,
10237,1,A,1,,,,50597,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626744,BAO_0000218,
10238,1,A,1,,,,50597,Compound was tested for antidiuretic activity in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626745,BAO_0000218,
10239,1,A,1,,,In vivo,50597,AUC in rat after 3mg/kg oral dose,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626746,BAO_0000218,
10240,1,A,1,,,,50597,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626747,BAO_0000218,
10241,1,A,1,,,,50597,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626748,BAO_0000218,
10242,1,A,1,,,,50597,Bioavailability administered orally at a dose of 10 mg/kg to rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626749,BAO_0000218,
10243,1,A,1,,,,50597,Oral Bioavailability was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626750,BAO_0000218,
10244,1,A,1,,,,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626751,BAO_0000218,
10245,1,A,1,,,,50597,Oral bioavailability in rat; Not performed.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626913,BAO_0000218,
10246,1,A,1,,,,50597,Bioavailability,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626914,BAO_0000218,
10247,1,A,1,,,,50597,Bioavailability was determined; ND denotes no data,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626915,BAO_0000218,
10248,1,A,1,,,,50597,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626916,BAO_0000218,
10249,1,A,1,,,,50597,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626917,BAO_0000218,
10250,1,A,1,,,,50597,Binding towards rat plasma protein at 10 uM,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626918,BAO_0000218,
10251,1,A,1,,,,50597,Binding towards rat plasma protein at 100 uM,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626919,BAO_0000218,
10252,1,A,1,,,In vivo,50597,Bioavailability in rat (dose 20 mg/kg p.o.),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626920,BAO_0000218,
10253,1,A,1,,,In vivo,50597,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621976,BAO_0000218,
10254,1,A,1,,,In vivo,50597,Bioavailability in rat after 5 mg/kg oral gavage,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL877599,BAO_0000218,
10255,1,A,1,,,In vivo,50597,Bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621977,BAO_0000218,
10256,1,A,1,,,In vivo,50597,Bioavailability in rat (dose 1 mg/kg i.v.),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621978,BAO_0000218,
10257,1,A,1,,,In vivo,50597,Bioavailability in rat (dose 3 mg/kg p.o.),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621979,BAO_0000218,
10258,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621980,BAO_0000218,
10259,1,A,1,,,In vivo,50597,Bioavailability of the compound in rats after administration of 30 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621981,BAO_0000218,
10260,1,A,1,,,In vivo,50597,Bioavailability after administration of 10 mg/kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621982,BAO_0000218,
10261,1,A,1,,,In vivo,50597,Bioavailability after administration of 2 mg/kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL882953,BAO_0000218,
10262,1,A,1,,,In vivo,50597,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621983,BAO_0000218,
10263,1,A,1,,,In vivo,50597,Bioavailability in dogs was determined; high,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621984,BAO_0000218,
10264,1,A,1,,,In vivo,50597,Bioavailability in monkey after intravenous administration at 1 mpk,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621985,BAO_0000218,
10265,1,A,1,,,In vivo,50597,Bioavailability in monkey after peroral administration at 10 mpk,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621986,BAO_0000218,
10266,1,A,1,,,In vivo,50597,Bioavailability in rat after intravenous administration at 1 mpk,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621987,BAO_0000218,
10267,1,F,1,,,In vivo,50597,Bioavailability in rat after intravenous administration at 2 mpk,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL877600,BAO_0000218,
10268,1,A,1,,,In vivo,50597,Bioavailability in rat after peroral administration at 30 mpk,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621988,BAO_0000218,
10269,1,F,1,,,In vivo,50597,Bioavailability in rat after peroral administration at at 100 mpk,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621989,BAO_0000218,
10270,1,A,1,,,In vivo,50597,Bioavailability in rats was evaluated,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621990,BAO_0000218,
10271,1,A,1,,,In vivo,50597,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621991,BAO_0000218,
10272,1,A,1,,,In vivo,50597,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621992,BAO_0000218,
10273,1,A,1,,,In vivo,50597,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621993,BAO_0000218,
10274,1,A,1,,,In vivo,50597,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621994,BAO_0000218,
10275,1,A,1,,,In vivo,50597,Bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621995,BAO_0000218,
10276,1,A,1,,,In vivo,50597,Bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621996,BAO_0000218,
10277,1,A,1,,,In vivo,50597,Oral bioavailability in rat (dose 10 mg/kg),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621997,BAO_0000218,
10278,1,A,1,,,In vivo,50597,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621998,BAO_0000218,
10279,1,A,1,,,In vivo,50597,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621999,BAO_0000218,
10280,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622000,BAO_0000218,
10281,1,A,1,,,In vivo,50597,Bioavailability was measured in rat after oral administration; 2-4,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622001,BAO_0000218,
10282,1,A,1,,,In vivo,50597,Bioavailability was measured in rat after oral administration; 3-7,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622002,BAO_0000218,
10283,1,A,1,,,In vivo,50597,Bioavailability in rat (intraduodenal administration),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622003,BAO_0000218,
10284,1,A,1,,,In vivo,50597,Bioavailability in rat (intraduodenal administration),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL877601,BAO_0000218,
10285,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624871,BAO_0000218,
10286,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622004,BAO_0000218,
10287,1,A,1,,,In vivo,50597,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL882954,BAO_0000218,
10288,1,A,1,,,In vivo,50597,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622005,BAO_0000218,
10289,1,A,1,,,In vivo,50597,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622006,BAO_0000218,
10290,1,A,1,,,In vivo,50597,Bioavailability was measured in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622007,BAO_0000218,
10291,1,A,1,,,In vivo,50597,Bioavailability was reported,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622008,BAO_0000218,
10292,1,A,1,,,In vivo,50597,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622009,BAO_0000218,
10293,1,A,1,,,In vivo,50597,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622010,BAO_0000218,
10294,1,A,1,,,In vivo,50597,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622011,BAO_0000218,
10295,1,A,1,,,In vivo,50597,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622012,BAO_0000218,
10296,1,A,1,,,In vivo,50597,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622013,BAO_0000218,
10297,1,A,1,,,In vivo,50597,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622014,BAO_0000218,
10298,1,A,1,,,In vivo,50597,Bioavailability was determined at 3 mg/kg po dose in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624749,BAO_0000218,
10299,1,A,1,,,In vivo,50597,Oral bioavailability in rat (dose 2 mg/kg),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624750,BAO_0000218,
10300,1,A,1,,,In vivo,50597,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624751,BAO_0000218,
10301,1,A,1,,,In vivo,50597,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624752,BAO_0000218,
10302,1,A,1,,,In vivo,50597,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624753,BAO_0000218,
10303,1,A,1,,,In vivo,50597,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624754,BAO_0000218,
10304,1,A,1,,,In vivo,50597,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624755,BAO_0000218,
10305,1,A,1,,,In vivo,50597,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624756,BAO_0000218,
10306,1,A,1,,,In vivo,50597,Bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624757,BAO_0000218,
10307,1,A,1,,,In vivo,50597,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624758,BAO_0000218,
10308,1,A,1,,,In vivo,50597,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622270,BAO_0000218,
10309,1,A,1,,,In vivo,50597,Bioavailability in rat (Sprague-Dawley),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622271,BAO_0000218,
10310,1,A,1,,,In vivo,50597,Bioavailability in rat at the dose of 2 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622272,BAO_0000218,
10311,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622273,BAO_0000218,
10312,1,A,1,,,In vivo,50597,Bioavailability in rat (cannulated) (dose 2 mg/kg),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622274,BAO_0000218,
10313,1,A,1,,,In vivo,50597,Bioavailability value of compound in rats was determined after peroral administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622275,BAO_0000218,
10314,1,A,1,,,In vivo,50597,Oral bioavailability in rat (dose 20 mg/kg),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622276,BAO_0000218,
10315,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622277,BAO_0000218,
10316,1,A,1,,,In vivo,50597,Oral bioavailability in rat (dose 5 mg/kg),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622278,BAO_0000218,
10317,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622279,BAO_0000218,
10318,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622280,BAO_0000218,
10319,1,A,1,,,In vivo,50597,Compound was evaluated for oral bioavailability in rats; 15-27 %,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624083,BAO_0000218,
10320,1,A,1,,,In vivo,50597,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624084,BAO_0000218,
10321,1,A,1,,,In vivo,50597,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624085,BAO_0000218,
10322,1,A,1,,,In vivo,50597,Compound was tested for bioavailability in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624086,BAO_0000218,
10323,1,A,1,,,In vivo,50597,Bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624087,BAO_0000218,
10324,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624088,BAO_0000218,
10325,1,A,0,,,In vivo,22224,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,,Macaca mulatta,,,,9544.0,U,Intermediate,CHEMBL624089,BAO_0000218,
10326,1,A,0,,,In vivo,22224,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,Rattus norvegicus,,,,10116.0,U,Intermediate,CHEMBL624090,BAO_0000218,
10327,1,A,1,,,In vivo,50597,Evaluated for the bioavailability in rat (in vivo),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624091,BAO_0000218,
10328,1,A,1,,,In vivo,50597,F value of compound in rats was determined after peroral administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624092,BAO_0000218,
10329,1,A,1,,,In vivo,50597,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624093,BAO_0000218,
10330,1,A,1,,,In vivo,50597,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624094,BAO_0000218,
10331,1,A,1,,,In vivo,50597,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624095,BAO_0000218,
10332,1,A,1,,,In vivo,50597,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624096,BAO_0000218,
10333,1,A,1,,,In vivo,50597,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624097,BAO_0000218,
10334,1,A,1,,,In vivo,50597,Maximum fall in carotid flow in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624098,BAO_0000218,
10335,1,A,1,,,In vivo,50597,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874392,BAO_0000218,
10336,1,A,1,,,In vivo,50597,Oral bioavailability in rat (dose 5 mg/kg),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624099,BAO_0000218,
10337,1,A,1,,,In vivo,50597,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624100,BAO_0000218,
10338,1,A,1,,,In vivo,50597,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624101,BAO_0000218,
10339,1,A,1,,,In vivo,50597,Oral bioavailability in rat (male Wistar),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624102,BAO_0000218,
10340,1,A,1,,,In vivo,50597,Oral bioavailability after administration (30 mg/kg) in rat; good,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624103,BAO_0000218,
10341,1,A,1,,,In vivo,50597,Oral bioavailability at the dose of 2 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624104,BAO_0000218,
10342,1,A,1,,,In vivo,50597,Oral bioavailability determined in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624105,BAO_0000218,
10343,1,A,1,,,In vivo,50597,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624106,BAO_0000218,
10344,1,A,1,,,In vivo,50597,Oral bioavailability in rat (dose single 10 mg/kg),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624107,BAO_0000218,
10345,1,A,1,,,In vivo,50597,Oral bioavailability in rat (dose single 10 mg/kg),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623943,BAO_0000218,
10346,1,A,1,,,In vivo,50597,Oral bioavailability in rat (dose 5 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623944,BAO_0000218,
10347,1,A,1,,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623945,BAO_0000218,
10348,1,A,1,,,,50597,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623946,BAO_0000218,
10349,1,A,1,,,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623947,BAO_0000218,
10350,1,A,1,,,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623948,BAO_0000218,
10351,1,A,1,,,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623949,BAO_0000218,
10352,1,A,1,,,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623950,BAO_0000218,
10353,1,A,1,,,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874398,BAO_0000218,
10354,1,A,1,,,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623951,BAO_0000218,
10355,1,A,1,,,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623952,BAO_0000218,
10356,1,A,1,,,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623953,BAO_0000218,
10357,1,A,1,,,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623954,BAO_0000218,
10358,1,A,1,,,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623955,BAO_0000218,
10359,1,A,1,,,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623956,BAO_0000218,
10360,1,A,1,,,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627807,BAO_0000218,
10361,1,A,1,,,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627808,BAO_0000218,
10362,1,A,1,,,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627809,BAO_0000218,
10363,1,A,1,,,,50597,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627810,BAO_0000218,
10364,1,A,1,,,,50597,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627811,BAO_0000218,
10365,1,A,1,,,,50597,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627812,BAO_0000218,
10366,1,A,1,,,,50597,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627813,BAO_0000218,
10367,1,A,1,,,,50597,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627814,BAO_0000218,
10368,1,A,1,,,,50597,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875336,BAO_0000218,
10369,1,A,1,,,,50597,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627815,BAO_0000218,
10370,1,A,1,,,,50597,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627816,BAO_0000218,
10371,1,A,1,,,,50597,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627817,BAO_0000218,
10372,1,A,1,,,,50597,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627818,BAO_0000218,
10373,1,A,1,,,,50597,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627819,BAO_0000218,
10374,1,A,1,,,,50597,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627820,BAO_0000218,
10375,1,A,1,,,,50597,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627821,BAO_0000218,
10376,1,A,1,,,,50597,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628464,BAO_0000218,
10377,1,A,1,,,,50597,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626239,BAO_0000218,
10378,1,A,1,,,,50597,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626240,BAO_0000218,
10379,1,A,1,,,,50597,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626241,BAO_0000218,
10380,1,A,1,,,,50597,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626242,BAO_0000218,
10381,1,A,1,,,,50597,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626243,BAO_0000218,
10382,1,A,1,,,,50597,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626244,BAO_0000218,
10383,1,A,1,,,,50597,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626907,BAO_0000218,
10384,1,A,1,,,,50597,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626908,BAO_0000218,
10385,1,A,1,,,,50597,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626909,BAO_0000218,
10386,1,A,1,,,,50597,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626910,BAO_0000218,
10387,1,F,1,,,,50597,Percent total excretion of acetaminophen cysteine conjugate,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875342,BAO_0000218,
10388,1,F,1,,,,50597,Percent total excretion of acetaminophen glucuronide,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626911,BAO_0000218,
10389,1,F,1,,,,50597,Percent total excretion of acetaminophen sulfate,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626912,BAO_0000218,
10390,1,F,1,,,,50597,Percent total excretion of acetaminophen-mercapturic acid,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627065,BAO_0000218,
10391,1,A,1,,,,50597,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627066,BAO_0000218,
10392,1,A,1,,,In vivo,50597,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627067,BAO_0000218,
10393,1,A,0,,,In vivo,22224,Biodistribution of compound in rat muscle after 5 min of administration,2385.0,ratrat,,,,8656.0,U,Autocuration,CHEMBL627068,BAO_0000218,
10394,1,A,0,,,In vivo,22224,Biodistribution of compound in rat muscle after 5 min of administration.,2385.0,ratrat,,,,8656.0,U,Autocuration,CHEMBL627069,BAO_0000218,
10395,1,A,0,,,In vivo,22224,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,Ovis aries,,,,9940.0,U,Autocuration,CHEMBL627070,BAO_0000218,
10396,1,A,0,,,In vivo,22224,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,Ovis aries,,,,9940.0,U,Autocuration,CHEMBL627071,BAO_0000218,
10397,1,A,0,,,In vivo,22224,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,Ovis aries,,,,9940.0,U,Autocuration,CHEMBL627072,BAO_0000218,
10398,1,A,0,,,In vivo,22224,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,Ovis aries,,,,9940.0,U,Autocuration,CHEMBL627073,BAO_0000218,
10399,1,A,0,,,In vivo,22224,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,Ovis aries,,,,9940.0,U,Autocuration,CHEMBL625387,BAO_0000218,
10400,1,A,0,,,In vivo,22224,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,Ovis aries,,,,9940.0,U,Autocuration,CHEMBL625388,BAO_0000218,
10401,1,A,0,,,In vivo,22224,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),1969.0,Ovis aries,,,,9940.0,U,Autocuration,CHEMBL625389,BAO_0000218,
10402,1,A,0,,,In vivo,22224,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),1969.0,Ovis aries,,,,9940.0,U,Autocuration,CHEMBL875343,BAO_0000218,
10403,1,A,1,,,,50497,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),,Serpentes,,,,8570.0,N,Intermediate,CHEMBL876795,BAO_0000218,
10404,1,A,1,,,,50497,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,,Serpentes,,,,8570.0,N,Intermediate,CHEMBL626552,BAO_0000218,
10405,1,A,1,,,,50497,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,,Serpentes,,,,8570.0,N,Intermediate,CHEMBL626553,BAO_0000218,
10406,1,A,0,,,,22224,The human biological plasma half life of the compound,1969.0,Homo sapiens,,,,9606.0,U,Autocuration,CHEMBL626554,BAO_0000366,
10407,1,A,1,,,,50597,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626555,BAO_0000218,
10408,1,A,1,,,,50597,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626556,BAO_0000218,
10409,1,A,1,,,,50597,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626557,BAO_0000218,
10410,1,A,1,,,,50597,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626558,BAO_0000218,
10411,1,A,1,,,,50597,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626559,BAO_0000218,
10412,1,A,1,,,,50597,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626560,BAO_0000218,
10413,1,A,1,,,,50597,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876803,BAO_0000218,
10414,1,A,1,,,,50597,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627964,BAO_0000218,
10415,1,A,1,,,,50597,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627965,BAO_0000218,
10416,1,A,1,,,,50597,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627966,BAO_0000218,
10417,1,A,1,,,,50597,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627967,BAO_0000218,
10418,1,A,1,,,,50597,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627968,BAO_0000218,
10419,1,A,1,,,,50597,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627969,BAO_0000218,
10420,1,A,1,,,,50597,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627970,BAO_0000218,
10421,1,A,1,,,,50597,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627971,BAO_0000218,
10422,1,A,1,,,,50597,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627972,BAO_0000218,
10423,1,B,9,,,,180,Dissociation constant against binding to human cyclophilin A,,Homo sapiens,,,,9606.0,D,Expert,CHEMBL856029,BAO_0000357,
10424,1,B,8,,,,11591,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,,Bos taurus,,,,9913.0,H,Expert,CHEMBL627973,BAO_0000019,
10425,1,A,0,,,,22224,-Log C was determined by performing the electroshock minimum test,,,,,,,U,Autocuration,CHEMBL627974,BAO_0000019,
10426,1,A,0,,,,22224,-Log C was determined by performing the foot shock test,,,,,,,U,Autocuration,CHEMBL627975,BAO_0000019,
10427,1,A,0,,,,22224,-Log C was determined by performing the incl screen test,,,,,,,U,Autocuration,CHEMBL627976,BAO_0000019,
10428,1,A,0,,,,22224,-Log C was determined by performing the maximum electroshock test,,,,,,,U,Autocuration,CHEMBL627977,BAO_0000019,
10429,1,A,0,,,,22224,-Log C was determined by performing the pentylenetetrazole test,,,,,,,U,Autocuration,CHEMBL627978,BAO_0000019,
10430,1,A,0,,,,22224,Tested for experimental arotinoid inhibitory dose,,,,,,,U,Autocuration,CHEMBL627979,BAO_0000019,
10431,1,A,0,,,,22224,Negative log transformed activity,,,,,,,U,Autocuration,CHEMBL876804,BAO_0000019,
10432,1,A,0,,,,22224,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",,,,,,,U,Autocuration,CHEMBL627980,BAO_0000019,
10433,1,A,1,,,,50512,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,,Cavia porcellus,,,,10141.0,N,Intermediate,CHEMBL627981,BAO_0000218,
10434,1,A,1,,,,50512,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,,Cavia porcellus,,,,10141.0,N,Intermediate,CHEMBL627982,BAO_0000218,
10435,1,A,1,,,,50512,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,,Cavia porcellus,,,,10141.0,N,Intermediate,CHEMBL627983,BAO_0000218,
10436,1,A,1,,,,50512,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,2116.0,Cavia porcellus,,,,10141.0,N,Intermediate,CHEMBL627984,BAO_0000218,
10437,1,P,0,,,,22229,Solubility in water was determined; values expressed as -log,,,,,,,U,Autocuration,CHEMBL627985,BAO_0000100,
10438,1,A,0,,,,22224,Ratio of Kcat to that of Km was determined,,,,,,,U,Autocuration,CHEMBL627986,BAO_0000019,
10439,1,A,0,,,,22224,Observed first order rate constant,,,,,,,U,Autocuration,CHEMBL627987,BAO_0000019,
10440,1,A,0,,,,22224,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,,,,,,,U,Autocuration,CHEMBL627988,BAO_0000019,
10441,1,A,1,,,In vivo,50597,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627989,BAO_0000218,
10442,1,A,1,,,In vivo,50597,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627990,BAO_0000218,
10443,1,A,1,,,In vivo,50597,Oral Bioavailability after administration of 10 mg/kg in male rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876805,BAO_0000218,
10444,1,A,1,,,In vivo,50597,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627991,BAO_0000218,
10445,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627992,BAO_0000218,
10446,1,A,1,,,In vivo,50597,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627993,BAO_0000218,
10447,1,A,1,,,In vivo,50597,Oral bioavailability at 1 mg/kg was determined in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622817,BAO_0000218,
10448,1,A,1,,,In vivo,50597,Oral bioavailability at 10 mg/kg was determined in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622818,BAO_0000218,
10449,1,A,1,,,In vivo,50597,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622819,BAO_0000218,
10450,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL872267,BAO_0000218,
10451,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622820,BAO_0000218,
10452,1,A,1,,,In vivo,50597,Oral bioavailability after intravenous administration in rats at 24 uM/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622821,BAO_0000218,
10453,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622822,BAO_0000218,
10454,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622823,BAO_0000218,
10455,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622824,BAO_0000218,
10456,1,A,1,,,In vivo,50597,Oral bioavailability in rat at a dose of 3 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622825,BAO_0000218,
10457,1,A,1,,,In vivo,50597,Oral bioavailability in rat after oral administration at 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622901,BAO_0000218,
10458,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622902,BAO_0000218,
10459,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621844,BAO_0000218,
10460,1,A,1,,,In vivo,50597,Oral bioavailability in Dawley rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621845,BAO_0000218,
10461,1,A,1,,,In vivo,50597,Oral bioavailability,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621846,BAO_0000218,
10462,1,A,1,,,In vivo,50597,Oral bioavailability in rat (dose 30 mg/kg),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621847,BAO_0000218,
10463,1,A,1,,,In vivo,50597,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL877609,BAO_0000218,
10464,1,A,1,,,In vivo,50597,Bioavailability in rat (dose 3 mg/kg i.v.),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621848,BAO_0000218,
10465,1,A,1,,,In vivo,50597,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621849,BAO_0000218,
10466,1,A,1,,,In vivo,50597,Oral bioavailability in rat (dose 60 mg/kg p.o.),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622030,BAO_0000218,
10467,1,A,1,,,In vivo,50597,Percent oral bioavailability determined in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622031,BAO_0000218,
10468,1,A,1,,,In vivo,50597,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622032,BAO_0000218,
10469,1,A,1,,,In vivo,50597,The compound was evaluated for bioavailability in rats; 32-51,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622033,BAO_0000218,
10470,1,A,1,,,In vivo,50597,Bioavailability in rat (dose 20 mg/kg p.o.),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622034,BAO_0000218,
10471,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622035,BAO_0000218,
10472,1,A,1,,,In vivo,50597,Bioavailability percent in rat at the dose of 2 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL882966,BAO_0000218,
10473,1,A,1,,,In vivo,50597,Bioavailability was evaluated after 20 uM/kg of peroral administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622036,BAO_0000218,
10474,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622037,BAO_0000218,
10475,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622038,BAO_0000218,
10476,1,A,1,,,In vivo,50597,Bioavailability in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622039,BAO_0000218,
10477,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622040,BAO_0000218,
10478,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622041,BAO_0000218,
10479,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622042,BAO_0000218,
10480,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622043,BAO_0000218,
10481,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622044,BAO_0000218,
10482,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622045,BAO_0000218,
10483,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622046,BAO_0000218,
10484,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622047,BAO_0000218,
10485,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL877610,BAO_0000218,
10486,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622048,BAO_0000218,
10487,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622049,BAO_0000218,
10488,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622050,BAO_0000218,
10489,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622051,BAO_0000218,
10490,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622052,BAO_0000218,
10491,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622053,BAO_0000218,
10492,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622054,BAO_0000218,
10493,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622055,BAO_0000218,
10494,1,A,1,,,In vivo,50597,Oral bioavailability in rats was determined; High,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622056,BAO_0000218,
10495,1,A,1,,,In vivo,50597,Oral bioavailability in the rat was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622057,BAO_0000218,
10496,1,A,1,,,In vivo,50597,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628008,BAO_0000218,
10497,1,A,1,,,In vivo,50597,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622058,BAO_0000218,
10498,1,A,1,,,In vivo,50597,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622059,BAO_0000218,
10499,1,A,1,,,In vivo,50597,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622060,BAO_0000218,
10500,1,A,1,,,In vivo,50597,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622061,BAO_0000218,
10501,1,A,1,,,In vivo,50597,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622062,BAO_0000218,
10502,1,A,1,,,In vivo,50597,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622063,BAO_0000218,
10503,1,A,1,,,In vivo,50597,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Expert,CHEMBL877611,BAO_0000218,
10504,1,A,1,,,In vivo,50597,Oral bioavailability of compound in Sprague Dawley rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622064,BAO_0000218,
10505,1,A,1,,,In vivo,50597,Oral bioavailability of compound in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622065,BAO_0000218,
10506,1,A,1,,,In vivo,50597,Oral bioavailability in rat (dose 2 mg/kg),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622066,BAO_0000218,
10507,1,A,1,,,In vivo,50597,Oral bioavailability of compound in rat was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622067,BAO_0000218,
10508,1,A,1,,,In vivo,50597,Oral bioavailability of compound in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622068,BAO_0000218,
10509,1,A,1,,,In vivo,50597,Oral bioavailability of compound was determined in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622069,BAO_0000218,
10510,1,A,1,,,In vivo,50597,Oral bioavailability at a dose of 30 mg/kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624796,BAO_0000218,
10511,1,A,1,,,In vivo,50597,Oral bioavailability in rat (dose 10 mg/kg),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624797,BAO_0000218,
10512,1,A,1,,,In vivo,50597,Oral bioavailability in rat (dose 10 mg/kg),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623053,BAO_0000218,
10513,1,A,1,,,In vivo,50597,Oral bioavailability evaluated in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623054,BAO_0000218,
10514,1,A,1,,,In vivo,50597,Oral bioavailability in fasted rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623055,BAO_0000218,
10515,1,A,1,,,In vivo,50597,Oral bioavailability in fed rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623056,BAO_0000218,
10516,1,A,1,,,In vivo,50597,Oral bioavailability in rat (mature male) (dose 30 mg/kg),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623057,BAO_0000218,
10517,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623058,BAO_0000218,
10518,1,A,1,,,In vivo,50597,Oral bioavailability in rat (dose 10 mg/kg p.o.),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623059,BAO_0000218,
10519,1,A,1,,,In vivo,50597,Oral bioavailability in rat after administration of 10 mg/kg po,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623060,BAO_0000218,
10520,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623061,BAO_0000218,
10521,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623062,BAO_0000218,
10522,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623063,BAO_0000218,
10523,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623064,BAO_0000218,
10524,1,A,1,,,In vivo,50597,Oral bioavailability in ratrs,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623065,BAO_0000218,
10525,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623066,BAO_0000218,
10526,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623067,BAO_0000218,
10527,1,A,1,,,In vivo,50597,Oral bioavailability in rats was determined; High,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623068,BAO_0000218,
10528,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623069,BAO_0000218,
10529,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623070,BAO_0000218,
10530,1,A,1,,,In vivo,50597,Oral bioavailability was calculated in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623071,BAO_0000218,
10531,1,A,1,,,In vivo,50597,Oral bioavailability,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623072,BAO_0000218,
10532,1,A,1,,,In vivo,50597,Oral bioavailability,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623073,BAO_0000218,
10533,1,A,1,,,In vivo,50597,Oral bioavailability,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623074,BAO_0000218,
10534,1,A,1,,,In vivo,50597,Oral bioavailability,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623075,BAO_0000218,
10535,1,A,1,,,In vivo,50597,Oral bioavailability after i.v. administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623076,BAO_0000218,
10536,1,A,1,,,In vivo,50597,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623077,BAO_0000218,
10537,1,A,1,,,In vivo,50597,Oral bioavailability in rat (Sprague-Dawley),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623078,BAO_0000218,
10538,1,A,1,,,In vivo,50597,Oral bioavailability in Sprague-Dawley rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623079,BAO_0000218,
10539,1,A,1,,,In vivo,50597,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623080,BAO_0000218,
10540,1,A,1,,,In vivo,50597,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623081,BAO_0000218,
10541,1,A,1,,,In vivo,50597,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623082,BAO_0000218,
10542,1,A,1,,,In vivo,50597,Oral bioavailability in fasted rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874400,BAO_0000218,
10543,1,A,1,,,In vivo,50597,Oral bioavailability in fed rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623083,BAO_0000218,
10544,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623084,BAO_0000218,
10545,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623085,BAO_0000218,
10546,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623086,BAO_0000218,
10547,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623087,BAO_0000218,
10548,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623088,BAO_0000218,
10549,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623089,BAO_0000218,
10550,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623090,BAO_0000218,
10551,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623091,BAO_0000218,
10552,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623092,BAO_0000218,
10553,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623093,BAO_0000218,
10554,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874401,BAO_0000218,
10555,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623094,BAO_0000218,
10556,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623095,BAO_0000218,
10557,1,A,1,,,In vivo,50597,Oral bioavailability in rat after peroral administration at 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623096,BAO_0000218,
10558,1,A,1,,,In vivo,50597,Oral bioavailability in rat after peroral administration at 5 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624913,BAO_0000218,
10559,1,A,1,,,In vivo,50597,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624914,BAO_0000218,
10560,1,A,1,,,In vivo,50597,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624915,BAO_0000218,
10561,1,A,1,,,In vivo,50597,Oral bioavailability in rat; Not measured,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624916,BAO_0000218,
10562,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624917,BAO_0000218,
10563,1,A,1,,,,50597,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625157,BAO_0000218,
10564,1,A,1,,,,50597,In vitro metabolic potential in rat liver microsomes,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625158,BAO_0000218,
10565,1,A,1,,,In vivo,50597,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625159,BAO_0000218,
10566,1,A,1,,,In vivo,50597,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625160,BAO_0000218,
10567,1,A,1,,,In vivo,50597,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625161,BAO_0000218,
10568,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625162,BAO_0000218,
10569,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625163,BAO_0000218,
10570,1,A,1,,,In vivo,50597,Oral bioavailability in rats at 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625164,BAO_0000218,
10571,1,A,1,,,In vivo,50597,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625165,BAO_0000218,
10572,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625166,BAO_0000218,
10573,1,A,1,,,,50597,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625167,BAO_0000218,
10574,1,A,1,,,,50597,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625168,BAO_0000218,
10575,1,A,1,,,In vivo,50597,Plasma clearance of the compound,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625169,BAO_0000218,
10576,1,A,1,,,In vivo,50597,Plasma clearance at 10 mg/kg in rat upon intravenous administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626264,BAO_0000218,
10577,1,A,1,,,In vivo,50597,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626265,BAO_0000218,
10578,1,A,1,,,In vivo,50597,The compound was tested for plasma clearance in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626266,BAO_0000218,
10579,1,A,1,,,In vivo,50597,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626267,BAO_0000218,
10580,1,A,1,,,,50597,Plasma concentration upon oral administration of 1 mg/Kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626268,BAO_0000218,
10581,1,A,1,,,,50597,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626269,BAO_0000218,
10582,1,A,1,,,,50597,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626270,BAO_0000218,
10583,1,A,1,,,,50597,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626271,BAO_0000218,
10584,1,A,1,,,,50597,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626272,BAO_0000218,
10585,1,A,1,,,,50597,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626273,BAO_0000218,
10586,1,A,1,,,,50597,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875346,BAO_0000218,
10587,1,A,1,,,,50597,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626274,BAO_0000218,
10588,1,A,1,,,,50597,Compound was tested for protein binding in rat plasma,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626275,BAO_0000218,
10589,1,A,1,,,,50597,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624646,BAO_0000218,
10590,1,A,1,,,,50597,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624647,BAO_0000218,
10591,1,A,1,,,,50597,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624648,BAO_0000218,
10592,1,A,1,,,,50597,Area under curve ratio was determined (po/iv) in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624649,BAO_0000218,
10593,1,A,1,,,,50597,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624650,BAO_0000218,
10594,1,A,1,,,,50597,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624651,BAO_0000218,
10595,1,A,1,,,,50597,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624652,BAO_0000218,
10596,1,A,1,,,,50597,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624653,BAO_0000218,
10597,1,A,1,,,,50597,Ratio of AUCbrain to AUCplasma,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624654,BAO_0000218,
10598,1,A,1,,,,50597,Ratio of brain to plasma,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624655,BAO_0000218,
10599,1,A,1,,,,50597,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624656,BAO_0000218,
10600,1,A,1,,,,50597,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624657,BAO_0000218,
10601,1,A,1,,,,50597,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624658,BAO_0000218,
10602,1,A,1,,,,50597,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624659,BAO_0000218,
10603,1,A,1,,,,50597,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624660,BAO_0000218,
10604,1,A,1,,,,50597,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624661,BAO_0000218,
10605,1,A,1,,,,50597,Steady state brain :blood ratio was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624662,BAO_0000218,
10606,1,A,1,,,,50597,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625199,BAO_0000218,
10607,1,A,1,,,,50597,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625200,BAO_0000218,
10608,1,A,1,,,,50597,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625201,BAO_0000218,
10609,1,A,1,,,,50597,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625202,BAO_0000218,
10610,1,A,1,,,,50597,Percentage recovery after 3h incubation with rat hapatocytes was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625203,BAO_0000218,
10611,1,A,1,,,,50597,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625204,BAO_0000218,
10612,1,A,1,,,,50597,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625205,BAO_0000218,
10613,1,A,1,,,,50597,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625206,BAO_0000218,
10614,1,A,0,,,,22224,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",,,,,,,U,Autocuration,CHEMBL625207,BAO_0000019,
10615,1,A,0,,,,22224,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,,,,,,,U,Autocuration,CHEMBL625208,BAO_0000019,
10616,1,A,1,Caco-2,,,50587,In vivo absorption in Caco-2 cell line monolayers was determined,,Homo sapiens,,495.0,,9606.0,N,Intermediate,CHEMBL625209,BAO_0000218,
10617,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL625210,BAO_0000100,
10618,1,A,1,,,,50597,Area under curve was determine after peroral administration at 10 mpk in Rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625211,BAO_0000218,
10619,1,A,1,,,,50797,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,Macaca mulatta,,,,9544.0,N,Intermediate,CHEMBL625212,BAO_0000218,
10620,1,A,1,,,,50597,Area under curve was determine after peroral administration at 160 mpk in Rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625213,BAO_0000218,
10621,1,A,1,,,,50597,Area under curve was determine after peroral administration at 20 mpk in Rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625214,BAO_0000218,
10622,1,A,1,,,,50597,Area under curve was determine after peroral administration at 50 mpk in Rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874542,BAO_0000218,
10623,1,P,0,,,,22229,Calculated partition coefficient (clogP) (AlogP),,,,,,,U,Autocuration,CHEMBL625215,BAO_0000100,
10624,1,A,0,,,,22224,Activated partial thromboplastin time measured,,,,,,,U,Autocuration,CHEMBL625216,BAO_0000019,
10625,1,P,0,,,,22224,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),,,,,,,U,Autocuration,CHEMBL625217,BAO_0000100,
10626,1,P,0,,,,22224,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),,,,,,,U,Autocuration,CHEMBL625218,BAO_0000100,
10627,1,A,1,,,,50588,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622864,BAO_0000218,
10628,1,A,1,,,,50597,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622865,BAO_0000218,
10629,1,A,1,,,,50597,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622866,BAO_0000218,
10630,1,A,1,,,,50588,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622867,BAO_0000218,
10631,1,A,1,,,,50512,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,1969.0,Cavia porcellus,,,,10141.0,N,Intermediate,CHEMBL876808,BAO_0000218,
10632,1,A,0,,,,22224,AUC in brain,955.0,,,,,,U,Autocuration,CHEMBL627725,BAO_0000019,
10633,1,A,0,,,,22224,AUC in serum,1977.0,,,,,,U,Autocuration,CHEMBL627726,BAO_0000019,
10634,1,A,0,,,,22224,AUC was determined,1969.0,,,,,,U,Autocuration,CHEMBL627727,BAO_0000019,
10635,1,A,0,,,,22224,AUC of the compound.,1969.0,,,,,,U,Autocuration,CHEMBL627728,BAO_0000019,
10636,1,A,0,,,,22224,AUC value (0-4 hr),1969.0,,,,,,U,Autocuration,CHEMBL627729,BAO_0000019,
10637,1,A,0,,,,22224,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",1969.0,,,,,,U,Autocuration,CHEMBL627730,BAO_0000019,
10638,1,A,0,,,,22224,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,1969.0,,,,,,U,Autocuration,CHEMBL627731,BAO_0000019,
10639,1,A,0,,,,22224,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",1969.0,,,,,,U,Autocuration,CHEMBL627732,BAO_0000019,
10640,1,A,0,,,,22224,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",1969.0,,,,,,U,Autocuration,CHEMBL627733,BAO_0000019,
10641,1,A,1,,,,50597,AUC(area under curve) was determined after intravenous administration in rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627734,BAO_0000218,
10642,1,A,1,,,,50597,AUC(area under curve) was determined after oral administration in rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627735,BAO_0000218,
10643,1,A,1,,,,50512,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,1969.0,Cavia porcellus,,,,10141.0,N,Intermediate,CHEMBL627736,BAO_0000218,
10644,1,A,1,,,,50597,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876809,BAO_0000218,
10645,1,A,0,,,,22224,Area Under Curve after oral dosing of 100 uM/Kg,,,,,,,U,Autocuration,CHEMBL627737,BAO_0000019,
10646,1,A,0,,,,22224,Area Under Curve after oral dosing of 30 uM/Kg,,,,,,,U,Autocuration,CHEMBL627738,BAO_0000019,
10647,1,A,0,,,,22224,Area Under Curve was measured by ploting the graph between concentration verses time,,,,,,,U,Autocuration,CHEMBL627739,BAO_0000019,
10648,1,A,1,,,,50588,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626143,BAO_0000218,
10649,1,A,0,,,,22224,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL626144,BAO_0000218,
10650,1,A,1,,,,50592,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL626145,BAO_0000218,
10651,1,A,1,,,,50597,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626146,BAO_0000218,
10652,1,A,1,,,,50597,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626147,BAO_0000218,
10653,1,A,0,,,,22224,Area under curve (AUC) was determined,,,,,,,U,Autocuration,CHEMBL626148,BAO_0000019,
10654,1,A,0,,,,22224,Area under curve (AUC) following ip administration at 1 mg/kg,,,,,,,U,Autocuration,CHEMBL626149,BAO_0000218,
10655,1,A,0,,,,22224,Area under curve (AUC) was determined; ND is Not determined,,,,,,,U,Autocuration,CHEMBL626150,BAO_0000019,
10656,1,A,1,,,,50588,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626151,BAO_0000218,
10657,1,A,1,,,,50588,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626152,BAO_0000218,
10658,1,A,1,,,,50588,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626153,BAO_0000218,
10659,1,A,0,,,,22224,Area under curve (AUR) was determined,,,,,,,U,Autocuration,CHEMBL626154,BAO_0000019,
10660,1,A,0,,,,22224,Area under curve at 1 uM/dg administered intravenously,,,,,,,U,Autocuration,CHEMBL626155,BAO_0000019,
10661,1,A,0,,,,22224,Area under curve at 10 uM/dg administered perorally,,,,,,,U,Autocuration,CHEMBL626156,BAO_0000019,
10662,1,A,0,,,,22224,Area under curve at 2 uM/dg administered intravenously,,,,,,,U,Autocuration,CHEMBL626157,BAO_0000019,
10663,1,A,0,,,,22224,Area under curve at 20 uM/dg administered perorally,,,,,,,U,Autocuration,CHEMBL626158,BAO_0000019,
10664,1,A,1,,,,50588,Area under curve at a peroral dose of 3 mg/kg in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626159,BAO_0000218,
10665,1,A,1,,,,50597,Area under curve at a peroral dose of 3 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626160,BAO_0000218,
10666,1,A,1,,,,50588,Area under curve at an iv dose of 1 mg/kg in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626161,BAO_0000218,
10667,1,A,1,,,,50597,Area under curve at an iv dose of 1 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626162,BAO_0000218,
10668,1,A,0,,,,22224,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,,,,,,,U,Autocuration,CHEMBL626163,BAO_0000019,
10669,1,A,0,,,,22224,Area under curve gives the effective duration for the angiotensin II antagonist effect.,,,,,,,U,Autocuration,CHEMBL626164,BAO_0000019,
10670,1,A,1,,,,50594,Area under curve measured as conc vs time after intravenous administration to mice.,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626165,BAO_0000218,
10671,1,A,1,,,,50594,Area under curve measured as conc vs time after peroral administration to mice.,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626166,BAO_0000218,
10672,1,A,1,,,,50588,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626167,BAO_0000218,
10673,1,A,1,,,,50588,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626168,BAO_0000218,
10674,1,A,1,,,,50588,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL877463,BAO_0000218,
10675,1,A,1,,,,50588,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626169,BAO_0000218,
10676,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626170,BAO_0000218,
10677,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626171,BAO_0000218,
10678,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626172,BAO_0000218,
10679,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626173,BAO_0000218,
10680,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626174,BAO_0000218,
10681,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626175,BAO_0000218,
10682,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626176,BAO_0000218,
10683,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626177,BAO_0000218,
10684,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622499,BAO_0000218,
10685,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622500,BAO_0000218,
10686,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622501,BAO_0000218,
10687,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622502,BAO_0000218,
10688,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622503,BAO_0000218,
10689,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL877614,BAO_0000218,
10690,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624839,BAO_0000218,
10691,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624840,BAO_0000218,
10692,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624841,BAO_0000218,
10693,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624842,BAO_0000218,
10694,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624843,BAO_0000218,
10695,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624844,BAO_0000218,
10696,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624845,BAO_0000218,
10697,1,A,1,,,In vivo,50597,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621904,BAO_0000218,
10698,1,A,1,,,In vivo,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621905,BAO_0000218,
10699,1,A,1,,,In vivo,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874382,BAO_0000218,
10700,1,A,1,,,In vivo,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621906,BAO_0000218,
10701,1,A,1,,,In vivo,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621907,BAO_0000218,
10702,1,A,1,,,In vivo,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622096,BAO_0000218,
10703,1,A,1,,,In vivo,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622097,BAO_0000218,
10704,1,A,1,,,In vivo,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622098,BAO_0000218,
10705,1,A,1,,,In vivo,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622099,BAO_0000218,
10706,1,A,1,,,In vivo,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622100,BAO_0000218,
10707,1,A,1,,,In vivo,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622101,BAO_0000218,
10708,1,A,1,,,In vivo,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622102,BAO_0000218,
10709,1,A,1,,,In vivo,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622103,BAO_0000218,
10710,1,A,1,,,In vivo,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622104,BAO_0000218,
10711,1,A,1,,,In vivo,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622105,BAO_0000218,
10712,1,A,1,,,In vivo,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622106,BAO_0000218,
10713,1,A,1,,,In vivo,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622107,BAO_0000218,
10714,1,A,1,,,In vivo,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622108,BAO_0000218,
10715,1,A,1,,,In vivo,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622109,BAO_0000218,
10716,1,A,1,,,In vivo,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622110,BAO_0000218,
10717,1,A,1,,,In vivo,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622111,BAO_0000218,
10718,1,A,1,,,In vivo,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874383,BAO_0000218,
10719,1,A,1,,,In vivo,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,14.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622112,BAO_0000218,
10720,1,A,1,,,In vivo,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,14.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622113,BAO_0000218,
10721,1,A,1,,,In vivo,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,14.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622114,BAO_0000218,
10722,1,A,1,,,In vivo,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622115,BAO_0000218,
10723,1,A,1,,,In vivo,50597,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622116,BAO_0000218,
10724,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622117,BAO_0000218,
10725,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622118,BAO_0000218,
10726,1,A,1,,,In vivo,50597,Oral bioavailability in rats at 6 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622119,BAO_0000218,
10727,1,A,1,,,In vivo,50597,Oral bioavailability in rat (dose 6 mg/kg),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622120,BAO_0000218,
10728,1,A,1,,,In vivo,50597,Oral bioavailability in rats at 6 mg/kg dose; Not tested,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622121,BAO_0000218,
10729,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622122,BAO_0000218,
10730,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622123,BAO_0000218,
10731,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622124,BAO_0000218,
10732,1,A,1,,,In vivo,50597,Bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622125,BAO_0000218,
10733,1,A,1,,,In vivo,50597,Oral bioavailability,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622126,BAO_0000218,
10734,1,A,1,,,In vivo,50597,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620455,BAO_0000218,
10735,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620456,BAO_0000218,
10736,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620457,BAO_0000218,
10737,1,A,1,,,In vivo,50597,Oral bioavailability was evaluated; Not tested,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620458,BAO_0000218,
10738,1,A,1,,,In vivo,50597,Oral bioavailability,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620459,BAO_0000218,
10739,1,A,1,,,In vivo,50597,Oral bioavailability in rat by oral dosing,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620460,BAO_0000218,
10740,1,A,1,,,In vivo,50597,Oral bioavailability in rat (dose 10 mg/kg p.o.),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620461,BAO_0000218,
10741,1,A,1,,,In vivo,50597,Oral bioavailability in rat (Sprague-Dawley),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620462,BAO_0000218,
10742,1,A,1,,,In vivo,50597,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620463,BAO_0000218,
10743,1,A,1,,,In vivo,50597,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620464,BAO_0000218,
10744,1,A,1,,,In vivo,50597,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620465,BAO_0000218,
10745,1,A,1,,,In vivo,50597,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620466,BAO_0000218,
10746,1,A,1,,,In vivo,50597,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620467,BAO_0000218,
10747,1,A,1,,,In vivo,50597,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620468,BAO_0000218,
10748,1,A,1,,,In vivo,50597,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620469,BAO_0000218,
10749,1,A,1,,,In vivo,50597,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620470,BAO_0000218,
10750,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620471,BAO_0000218,
10751,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620472,BAO_0000218,
10752,1,A,1,,,In vivo,50597,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620473,BAO_0000218,
10753,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620474,BAO_0000218,
10754,1,A,1,,,In vivo,50597,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620475,BAO_0000218,
10755,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620476,BAO_0000218,
10756,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620477,BAO_0000218,
10757,1,A,1,,,In vivo,50597,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620478,BAO_0000218,
10758,1,A,1,,,In vivo,50597,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618768,BAO_0000218,
10759,1,A,1,,,In vivo,50597,Oral bioavailability in rat after oral administration at 13 mg/kg dose,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618769,BAO_0000218,
10760,1,A,1,,,In vivo,50597,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618770,BAO_0000218,
10761,1,A,1,,,In vivo,50597,Oral bioavailability (dose 20 mg/kg p.o.),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618771,BAO_0000218,
10762,1,A,1,,,In vivo,50597,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618772,BAO_0000218,
10763,1,A,1,,,In vivo,50597,Oral bioavailability in rat at 10 mg/kg of the compound,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618773,BAO_0000218,
10764,1,A,1,,,In vivo,50597,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875842,BAO_0000218,
10765,1,A,1,,,In vivo,50597,Bioavailability in rat (dose 3 mg/kg i.v.),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618774,BAO_0000218,
10766,1,A,1,,,In vivo,50597,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618775,BAO_0000218,
10767,1,A,1,,,In vivo,50597,Oral bioavailability in rat (dose 60 mg/kg p.o.),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618776,BAO_0000218,
10768,1,A,1,,,In vivo,50597,Percent bioavailability (F) in rats after iv administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618777,BAO_0000218,
10769,1,A,1,,,In vivo,50597,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618778,BAO_0000218,
10770,1,A,1,,,In vivo,50597,Bioavailability in rat (dose 5 uM/kg p.o.),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618779,BAO_0000218,
10771,1,A,1,,,In vivo,50597,Oral bioavailability,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618780,BAO_0000218,
10772,1,A,1,,,In vivo,50597,Bioavailability in rat (dose 2 mg/kg p.o.),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618781,BAO_0000218,
10773,1,A,1,,,In vivo,50597,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618782,BAO_0000218,
10774,1,A,1,,,In vivo,50597,Oral bioavailability in rat (dose 20 mg/kg),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618783,BAO_0000218,
10775,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618784,BAO_0000218,
10776,1,A,1,,,In vivo,50597,Percent oral bioavailability evaluated in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618785,BAO_0000218,
10777,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618786,BAO_0000218,
10778,1,A,1,,,In vivo,50597,Percent oral bioavailability in rat; Not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618787,BAO_0000218,
10779,1,A,1,,,In vivo,50597,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618788,BAO_0000218,
10780,1,A,1,,,In vivo,50597,Bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618789,BAO_0000218,
10781,1,A,1,,,In vivo,50597,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618790,BAO_0000218,
10782,1,A,1,,,In vivo,50597,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618791,BAO_0000218,
10783,1,A,1,,,In vivo,50597,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875843,BAO_0000218,
10784,1,A,1,,,In vivo,50597,Oral bioavailability in rat (dose 20 mg/kg p.o.),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL618792,BAO_0000218,
10785,1,A,1,,,In vivo,50597,Cmax at a dose of 30 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623395,BAO_0000218,
10786,1,A,0,,,In vivo,22224,Cmax in monkeys at a dose of 1 mg/kg,,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL623396,BAO_0000218,
10787,1,A,1,,,In vivo,50597,Cmax in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623397,BAO_0000218,
10788,1,A,1,,,In vivo,50597,Cmax in rats at a dose of 1 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623398,BAO_0000218,
10789,1,A,1,,,In vivo,50594,Cmax was measured in mice after an oral dose of 50 mg/kg.,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623399,BAO_0000218,
10790,1,A,0,,,In vivo,22224,"Cmax value at a dose of 12.7 uM/kg, po",,,,,,,U,Autocuration,CHEMBL623400,BAO_0000218,
10791,1,A,0,,,In vivo,22224,"Cmax value at a dose of 6.3 uM/kg, iv",,,,,,,U,Autocuration,CHEMBL623401,BAO_0000218,
10792,1,A,0,,,In vivo,22224,"Cmax value at a dose of 7.1 uM/kg, iv",,,,,,,U,Autocuration,CHEMBL623402,BAO_0000218,
10793,1,A,0,,,In vivo,22224,Cmax value of compound was determined after 1 hr,,,,,,,U,Autocuration,CHEMBL623403,BAO_0000218,
10794,1,A,0,,,In vivo,22224,Cmax value of the compound,,,,,,,U,Autocuration,CHEMBL623404,BAO_0000218,
10795,1,A,1,,,In vivo,50597,Cmax value administered intraintestinal in rats.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625997,BAO_0000218,
10796,1,A,1,,,In vivo,50597,Cmax value administered perorally was determined in rat; Not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625998,BAO_0000218,
10797,1,A,0,,,In vivo,22224,Cmax value at the dose of 2.3 mg/kg,,,,,,,U,Autocuration,CHEMBL625999,BAO_0000218,
10798,1,A,0,,,In vivo,22224,Cmax value at the dose of 5 mg/kg,,,,,,,U,Autocuration,CHEMBL626000,BAO_0000218,
10799,1,A,0,,,In vivo,22224,Cmax value in the period of 8 hr after dosing. ,,,,,,,U,Autocuration,CHEMBL626001,BAO_0000218,
10800,1,A,0,,,In vivo,22224,Cmax value at a oral dose of 20 mg/kg; Not tested,,,,,,,U,Autocuration,CHEMBL626002,BAO_0000218,
10801,1,A,0,,,In vivo,22224,Cmax value at a oral dose of 20 mg/kg,,,,,,,U,Autocuration,CHEMBL626003,BAO_0000218,
10802,1,A,1,,,In vivo,50597,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626004,BAO_0000218,
10803,1,A,1,,,In vivo,50512,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,,Cavia porcellus,,,,10141.0,N,Intermediate,CHEMBL626005,BAO_0000218,
10804,1,A,1,,,In vivo,50597,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626006,BAO_0000218,
10805,1,A,1,,,In vivo,50597,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626007,BAO_0000218,
10806,1,A,1,,,In vivo,50594,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626008,BAO_0000218,
10807,1,A,1,,,In vivo,50588,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,2107.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626009,BAO_0000218,
10808,1,A,1,,,In vivo,50588,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626010,BAO_0000218,
10809,1,A,1,,,In vivo,50594,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626011,BAO_0000218,
10810,1,A,1,,,In vivo,50594,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626012,BAO_0000218,
10811,1,A,1,,,In vivo,50594,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626013,BAO_0000218,
10812,1,A,1,,,In vivo,50594,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626014,BAO_0000218,
10813,1,A,1,,,In vivo,50594,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL877496,BAO_0000218,
10814,1,F,1,,,In vivo,50588,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626015,BAO_0000218,
10815,1,F,1,,,In vivo,50588,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626016,BAO_0000218,
10816,1,F,1,,,In vivo,50588,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626017,BAO_0000218,
10817,1,A,1,,,In vivo,50588,Bioavailability as maximal plasma concentration in dogs,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626018,BAO_0000218,
10818,1,A,1,,,In vivo,50588,Bioavailability as maximal plasma concentration in dogs,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626692,BAO_0000218,
10819,1,A,1,,,In vivo,50597,Bioavailability as maximal plasma concentration in rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626693,BAO_0000218,
10820,1,A,0,,,In vivo,22224,Bioavailability as maximal plasma concentration in rats,1969.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL626694,BAO_0000218,
10821,1,A,1,,,In vivo,50588,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,178.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626695,BAO_0000218,
10822,1,A,1,,,In vivo,50588,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,178.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626696,BAO_0000218,
10823,1,A,1,,,In vivo,50588,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,178.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626697,BAO_0000218,
10824,1,A,1,,,In vivo,50588,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,178.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626859,BAO_0000218,
10825,1,A,1,,,In vivo,50588,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,178.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626860,BAO_0000218,
10826,1,A,1,,,In vivo,50588,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,178.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626861,BAO_0000218,
10827,1,A,1,,,In vivo,50597,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626296,BAO_0000218,
10828,1,A,0,,,In vivo,22224,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,,,,,,,U,Autocuration,CHEMBL626297,BAO_0000218,
10829,1,A,0,,,In vivo,22224,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,1969.0,,,,,,U,Autocuration,CHEMBL626298,BAO_0000218,
10830,1,A,1,,,In vivo,50597,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626299,BAO_0000218,
10831,1,A,1,,,In vivo,50597,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626300,BAO_0000218,
10832,1,A,1,,,In vivo,50597,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626301,BAO_0000218,
10833,1,A,1,,,In vivo,50597,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626962,BAO_0000218,
10834,1,A,1,,,In vivo,50597,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626963,BAO_0000218,
10835,1,A,1,,,In vivo,50597,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626964,BAO_0000218,
10836,1,A,1,,,In vivo,100710,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,1969.0,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL626965,BAO_0000218,
10837,1,A,1,,,In vivo,50594,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626966,BAO_0000218,
10838,1,A,1,,,In vivo,50594,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626967,BAO_0000218,
10839,1,A,1,,,In vivo,100710,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,1969.0,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL626968,BAO_0000218,
10840,1,A,1,,,,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626969,BAO_0000218,
10841,1,A,1,,,,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627126,BAO_0000218,
10842,1,A,1,,,,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631276,BAO_0000218,
10843,1,A,1,,,,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631277,BAO_0000218,
10844,1,A,1,,,,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631278,BAO_0000218,
10845,1,A,1,,,,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874457,BAO_0000218,
10846,1,A,1,,,,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631279,BAO_0000218,
10847,1,A,1,,,,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631280,BAO_0000218,
10848,1,A,1,,,,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631281,BAO_0000218,
10849,1,A,1,,,,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631968,BAO_0000218,
10850,1,A,1,,,,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631969,BAO_0000218,
10851,1,A,1,,,,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631970,BAO_0000218,
10852,1,A,1,,,,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631971,BAO_0000218,
10853,1,A,1,,,,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631972,BAO_0000218,
10854,1,A,1,,,,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630435,BAO_0000218,
10855,1,A,1,,,,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630436,BAO_0000218,
10856,1,A,1,,,,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630437,BAO_0000218,
10857,1,A,1,,,,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630438,BAO_0000218,
10858,1,A,1,,,,50597,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630439,BAO_0000218,
10859,1,A,1,,,,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630440,BAO_0000218,
10860,1,A,1,,,,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630441,BAO_0000218,
10861,1,A,1,,,,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630442,BAO_0000218,
10862,1,A,1,,,,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625234,BAO_0000218,
10863,1,A,1,,,,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625235,BAO_0000218,
10864,1,A,1,,,,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625236,BAO_0000218,
10865,1,A,1,,,,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625237,BAO_0000218,
10866,1,A,1,,,,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626125,BAO_0000218,
10867,1,A,1,,,,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626126,BAO_0000218,
10868,1,A,1,,,,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626127,BAO_0000218,
10869,1,A,1,,,,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626128,BAO_0000218,
10870,1,A,1,,,,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626129,BAO_0000218,
10871,1,A,1,,,,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626130,BAO_0000218,
10872,1,A,1,,,,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626131,BAO_0000218,
10873,1,A,1,,,,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626132,BAO_0000218,
10874,1,A,1,,,,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626752,BAO_0000218,
10875,1,A,1,,,,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626753,BAO_0000218,
10876,1,A,1,,,,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626754,BAO_0000218,
10877,1,A,1,,,,50597,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626755,BAO_0000218,
10878,1,A,1,,,,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626756,BAO_0000218,
10879,1,A,1,,,,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626757,BAO_0000218,
10880,1,A,1,,,,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626758,BAO_0000218,
10881,1,A,1,,,,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626759,BAO_0000218,
10882,1,A,1,,,,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626760,BAO_0000218,
10883,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626394,BAO_0000218,
10884,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626395,BAO_0000218,
10885,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626396,BAO_0000218,
10886,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626397,BAO_0000218,
10887,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626398,BAO_0000218,
10888,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626399,BAO_0000218,
10889,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874653,BAO_0000218,
10890,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626400,BAO_0000218,
10891,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626401,BAO_0000218,
10892,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626402,BAO_0000218,
10893,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626403,BAO_0000218,
10894,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626404,BAO_0000218,
10895,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626405,BAO_0000218,
10896,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625529,BAO_0000218,
10897,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625530,BAO_0000218,
10898,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625531,BAO_0000218,
10899,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625532,BAO_0000218,
10900,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625533,BAO_0000218,
10901,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875474,BAO_0000218,
10902,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625534,BAO_0000218,
10903,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625535,BAO_0000218,
10904,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625536,BAO_0000218,
10905,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625537,BAO_0000218,
10906,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625538,BAO_0000218,
10907,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625539,BAO_0000218,
10908,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625540,BAO_0000218,
10909,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625541,BAO_0000218,
10910,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625542,BAO_0000218,
10911,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625543,BAO_0000218,
10912,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625544,BAO_0000218,
10913,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625545,BAO_0000218,
10914,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625546,BAO_0000218,
10915,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625547,BAO_0000218,
10916,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625548,BAO_0000218,
10917,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625549,BAO_0000218,
10918,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625550,BAO_0000218,
10919,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625551,BAO_0000218,
10920,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL875475,BAO_0000218,
10921,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625552,BAO_0000218,
10922,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625553,BAO_0000218,
10923,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625554,BAO_0000218,
10924,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625555,BAO_0000218,
10925,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625556,BAO_0000218,
10926,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624986,BAO_0000218,
10927,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624987,BAO_0000218,
10928,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624988,BAO_0000218,
10929,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,1637.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624989,BAO_0000218,
10930,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,1637.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624990,BAO_0000218,
10931,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,1637.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL874391,BAO_0000218,
10932,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,1637.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624991,BAO_0000218,
10933,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,1637.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624992,BAO_0000218,
10934,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,1637.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624993,BAO_0000218,
10935,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,1637.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624994,BAO_0000218,
10936,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,1637.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624995,BAO_0000218,
10937,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,1637.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624996,BAO_0000218,
10938,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,1637.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624997,BAO_0000218,
10939,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,1637.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624998,BAO_0000218,
10940,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,1637.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624999,BAO_0000218,
10941,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,1637.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL882955,BAO_0000218,
10942,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,1637.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625000,BAO_0000218,
10943,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,1637.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625001,BAO_0000218,
10944,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,1637.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625089,BAO_0000218,
10945,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,1637.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625090,BAO_0000218,
10946,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,1637.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625091,BAO_0000218,
10947,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,1637.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625092,BAO_0000218,
10948,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,1637.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625093,BAO_0000218,
10949,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,1637.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625094,BAO_0000218,
10950,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,1637.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625095,BAO_0000218,
10951,1,A,1,,,In vivo,50588,Compound was evaluated for its bioavailability in the dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625096,BAO_0000218,
10952,1,A,1,,,In vivo,50597,Compound was evaluated for its bioavailability in the rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625097,BAO_0000218,
10953,1,A,0,,,In vivo,22224,Compound was evaluated for oral bioavailability,,,,,,,U,Autocuration,CHEMBL882956,BAO_0000218,
10954,1,A,1,,,In vivo,50597,Compound was evaluated for percentage of Oral bioavailability in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625098,BAO_0000218,
10955,1,A,0,,,In vivo,22224,Bioavailability in guinea pig,,Cavia porcellus,,,,10141.0,U,Autocuration,CHEMBL625099,BAO_0000218,
10956,1,A,1,,,In vivo,50597,Compound was evaluated for the oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625100,BAO_0000218,
10957,1,A,1,,,In vivo,50588,Compound was evaluated for the oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625101,BAO_0000218,
10958,1,A,1,,,In vivo,50597,Compound was evaluated for the oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874396,BAO_0000218,
10959,1,F,0,,,In vivo,22224,Bioavailability in dog (dosed i.v.),,Canis lupus familiaris,,,,9615.0,U,Autocuration,CHEMBL625102,BAO_0000218,
10960,1,A,1,,,In vivo,50588,Compound was tested for in vivo bioavailability in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625103,BAO_0000218,
10961,1,A,1,,,In vivo,100712,Compound was tested for in vivo bioavailability in hamsters,,Cricetinae,,,,10026.0,N,Intermediate,CHEMBL625104,BAO_0000218,
10962,1,A,0,,,In vivo,22224,Compound was tested for in vivo bioavailability in monkey,,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL625105,BAO_0000218,
10963,1,A,1,,,In vivo,50597,Compound was tested for in vivo bioavailability in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625106,BAO_0000218,
10964,1,A,0,,,In vivo,22224,Oral bioavailability in mouse,,Mus musculus,,,,10090.0,U,Autocuration,CHEMBL625107,BAO_0000218,
10965,1,A,1,,,In vivo,50594,Compound was tested for percent of oral bioavailability in mice; 56-74,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625108,BAO_0000218,
10966,1,A,0,,,In vivo,22224,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),,Mus musculus,,,,10090.0,U,Autocuration,CHEMBL625109,BAO_0000218,
10967,1,A,0,,,In vivo,22224,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),,Macaca fascicularis,,,,9541.0,U,Autocuration,CHEMBL625110,BAO_0000218,
10968,1,A,0,,,In vivo,22224,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),,Macaca fascicularis,,,,9541.0,U,Autocuration,CHEMBL625111,BAO_0000218,
10969,1,A,1,,,In vivo,50594,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625112,BAO_0000218,
10970,1,A,1,,,In vivo,50594,Oral bioavailability in nude mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL875334,BAO_0000218,
10971,1,A,0,,,In vivo,22224,Bioavailability in monkey (i.d. dosing),,Primates,,,,9443.0,U,Autocuration,CHEMBL628617,BAO_0000218,
10972,1,A,0,,,In vivo,22224,Bioavailability in rat,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL628618,BAO_0000218,
10973,1,A,0,,,In vivo,22224,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,,,,,,,U,Autocuration,CHEMBL628619,BAO_0000218,
10974,1,A,0,,,In vivo,22224,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,,,,,,,U,Autocuration,CHEMBL628620,BAO_0000218,
10975,1,A,1,,,In vivo,100710,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL628621,BAO_0000218,
10976,1,A,1,,,In vivo,100710,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL628622,BAO_0000218,
10977,1,A,1,,,In vivo,100710,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL628623,BAO_0000218,
10978,1,A,1,,,In vivo,100710,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,1969.0,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL628624,BAO_0000218,
10979,1,A,1,,,In vivo,50594,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL628625,BAO_0000218,
10980,1,A,1,,,In vivo,100710,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,1969.0,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL628626,BAO_0000218,
10981,1,A,1,,,In vivo,50594,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627041,BAO_0000218,
10982,1,A,1,,,In vivo,50594,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627042,BAO_0000218,
10983,1,A,1,,,In vivo,50594,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627043,BAO_0000218,
10984,1,A,0,,,In vivo,22224,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,1969.0,,,,,,U,Autocuration,CHEMBL627044,BAO_0000218,
10985,1,A,1,,,In vivo,50594,Cmax in mouse plasma,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627045,BAO_0000218,
10986,1,A,0,,,In vivo,22224,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,1969.0,,,,,,U,Autocuration,CHEMBL627046,BAO_0000218,
10987,1,A,1,,,In vivo,50597,Maximal plasma concentration in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627047,BAO_0000218,
10988,1,A,1,,,In vivo,50597,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627048,BAO_0000218,
10989,1,A,1,,,In vivo,50597,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627049,BAO_0000218,
10990,1,A,1,,,In vivo,50597,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627050,BAO_0000218,
10991,1,A,1,,,In vivo,50597,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627051,BAO_0000218,
10992,1,A,1,,,In vivo,50597,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627052,BAO_0000218,
10993,1,A,1,,,In vivo,50597,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627053,BAO_0000218,
10994,1,A,1,,,In vivo,50597,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627054,BAO_0000218,
10995,1,A,1,,,In vivo,50594,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627055,BAO_0000218,
10996,1,A,1,,,In vivo,50594,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627056,BAO_0000218,
10997,1,A,1,,,In vivo,50594,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627057,BAO_0000218,
10998,1,A,1,,,In vivo,50594,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627058,BAO_0000218,
10999,1,A,1,,,In vivo,50594,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626211,BAO_0000218,
11000,1,A,0,,,In vivo,22224,Maximum Concentration of the compound.,,,,,,,U,Autocuration,CHEMBL626212,BAO_0000218,
11001,1,A,1,,,In vivo,50588,Maximum Concentration was measured after iv administration into Beagle dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626213,BAO_0000218,
11002,1,A,1,,,In vivo,50588,Maximum Concentration was measured after iv administration into Beagle dog.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626214,BAO_0000218,
11003,1,A,1,,,In vivo,50588,Maximum Concentration was measured after po administration into Beagle dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626215,BAO_0000218,
11004,1,A,1,,,In vivo,50588,Maximum Concentration was measured after po administration into Beagle dog.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626216,BAO_0000218,
11005,1,A,0,,,In vivo,22224,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,178.0,,,,,,U,Autocuration,CHEMBL626217,BAO_0000218,
11006,1,A,0,,,In vivo,22224,Maximum blood level reached after an iv dose of 12.2 uM/kg,178.0,,,,,,U,Autocuration,CHEMBL626218,BAO_0000218,
11007,1,A,0,,,In vivo,22224,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,178.0,,,,,,U,Autocuration,CHEMBL626219,BAO_0000218,
11008,1,A,0,,,In vivo,22224,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,178.0,,,,,,U,Autocuration,CHEMBL626220,BAO_0000218,
11009,1,A,0,,,In vivo,22224,Maximum blood level reached after an oral dose of 5.0 mg/kg,178.0,,,,,,U,Autocuration,CHEMBL626221,BAO_0000218,
11010,1,A,0,,,In vivo,22224,Maximum blood level reached at dose of 10.6 uM/kg orally,178.0,,,,,,U,Autocuration,CHEMBL626222,BAO_0000218,
11011,1,A,1,,,In vivo,50512,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,,Cavia porcellus,,,,10141.0,N,Intermediate,CHEMBL626223,BAO_0000218,
11012,1,A,1,,,In vivo,50512,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,,Cavia porcellus,,,,10141.0,N,Intermediate,CHEMBL626224,BAO_0000218,
11013,1,A,1,,,In vivo,50597,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626225,BAO_0000218,
11014,1,A,1,,,In vivo,50597,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626226,BAO_0000218,
11015,1,A,1,,,In vivo,50597,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626227,BAO_0000218,
11016,1,A,1,,,In vivo,50597,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626228,BAO_0000218,
11017,1,A,1,,,In vivo,50597,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626229,BAO_0000218,
11018,1,A,1,,,In vivo,50597,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626921,BAO_0000218,
11019,1,A,1,,,In vivo,50597,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876793,BAO_0000218,
11020,1,A,1,,,In vivo,50597,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625309,BAO_0000218,
11021,1,A,1,,,In vivo,50278,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,Bacillus subtilis,,,,1423.0,N,Intermediate,CHEMBL625310,BAO_0000218,
11022,1,A,0,,,In vivo,22224,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL625311,BAO_0000218,
11023,1,A,1,,,In vivo,50597,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625312,BAO_0000218,
11024,1,A,0,,,In vivo,22224,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,,,,,,,U,Autocuration,CHEMBL625313,BAO_0000218,
11025,1,A,1,,,In vivo,50594,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625314,BAO_0000218,
11026,1,A,1,,,In vivo,50597,Maximum concentration in male rats after iv administration of 20 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625315,BAO_0000218,
11027,1,A,1,,,,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625316,BAO_0000218,
11028,1,A,1,,,,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625317,BAO_0000218,
11029,1,A,1,,,,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625318,BAO_0000218,
11030,1,A,1,,,,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625319,BAO_0000218,
11031,1,A,1,,,,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625320,BAO_0000218,
11032,1,A,1,,,,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625321,BAO_0000218,
11033,1,A,1,,,,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625322,BAO_0000218,
11034,1,A,1,,,,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876801,BAO_0000218,
11035,1,A,1,,,,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625323,BAO_0000218,
11036,1,A,1,,,,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625324,BAO_0000218,
11037,1,A,1,,,,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625325,BAO_0000218,
11038,1,A,1,,,,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625326,BAO_0000218,
11039,1,A,1,,,,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625327,BAO_0000218,
11040,1,A,1,,,,50597,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625328,BAO_0000218,
11041,1,A,1,,,,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625329,BAO_0000218,
11042,1,A,1,,,,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625330,BAO_0000218,
11043,1,A,1,,,,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627774,BAO_0000218,
11044,1,A,1,,,,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627775,BAO_0000218,
11045,1,A,1,,,,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627949,BAO_0000218,
11046,1,A,1,,,,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627950,BAO_0000218,
11047,1,A,1,,,,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627951,BAO_0000218,
11048,1,A,1,,,,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627952,BAO_0000218,
11049,1,A,1,,,,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627953,BAO_0000218,
11050,1,A,1,,,,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627954,BAO_0000218,
11051,1,A,1,,,,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627955,BAO_0000218,
11052,1,A,1,,,,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627956,BAO_0000218,
11053,1,A,1,,,,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876802,BAO_0000218,
11054,1,A,1,,,,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627957,BAO_0000218,
11055,1,A,1,,,,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627958,BAO_0000218,
11056,1,A,1,,,,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627959,BAO_0000218,
11057,1,A,1,,,,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627960,BAO_0000218,
11058,1,A,1,,,,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627961,BAO_0000218,
11059,1,A,1,,,,50597,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627962,BAO_0000218,
11060,1,A,1,,,,50597,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627963,BAO_0000218,
11061,1,A,1,,,,50597,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624759,BAO_0000218,
11062,1,A,1,,,,50597,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624760,BAO_0000218,
11063,1,A,1,,,,50597,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624761,BAO_0000218,
11064,1,A,1,,,,50597,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL877607,BAO_0000218,
11065,1,A,1,,,,50597,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624762,BAO_0000218,
11066,1,A,1,,,,50597,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624763,BAO_0000218,
11067,1,A,1,,,,50597,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624764,BAO_0000218,
11068,1,A,1,,,,50597,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624765,BAO_0000218,
11069,1,A,1,,,,50597,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624766,BAO_0000218,
11070,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624767,BAO_0000218,
11071,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624768,BAO_0000218,
11072,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624769,BAO_0000218,
11073,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624770,BAO_0000218,
11074,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624771,BAO_0000218,
11075,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624772,BAO_0000218,
11076,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624773,BAO_0000218,
11077,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624774,BAO_0000218,
11078,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624775,BAO_0000218,
11079,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624776,BAO_0000218,
11080,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624777,BAO_0000218,
11081,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624778,BAO_0000218,
11082,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624779,BAO_0000218,
11083,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624780,BAO_0000218,
11084,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624781,BAO_0000218,
11085,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL877608,BAO_0000218,
11086,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624782,BAO_0000218,
11087,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624783,BAO_0000218,
11088,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624784,BAO_0000218,
11089,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624785,BAO_0000218,
11090,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624786,BAO_0000218,
11091,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624787,BAO_0000218,
11092,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628676,BAO_0000218,
11093,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621842,BAO_0000218,
11094,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621843,BAO_0000218,
11095,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623873,BAO_0000218,
11096,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623874,BAO_0000218,
11097,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623875,BAO_0000218,
11098,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623876,BAO_0000218,
11099,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623877,BAO_0000218,
11100,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623878,BAO_0000218,
11101,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623879,BAO_0000218,
11102,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623880,BAO_0000218,
11103,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623881,BAO_0000218,
11104,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623957,BAO_0000218,
11105,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623958,BAO_0000218,
11106,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623959,BAO_0000218,
11107,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623960,BAO_0000218,
11108,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623961,BAO_0000218,
11109,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623962,BAO_0000218,
11110,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624676,BAO_0000218,
11111,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624677,BAO_0000218,
11112,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624678,BAO_0000218,
11113,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624679,BAO_0000218,
11114,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624680,BAO_0000218,
11115,1,A,0,,,In vivo,22224,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,,,,,,,U,Autocuration,CHEMBL624849,BAO_0000218,
11116,1,A,0,,,In vivo,22224,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,,,,,,,U,Autocuration,CHEMBL624850,BAO_0000218,
11117,1,A,0,,,In vivo,22224,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,,,,,,,U,Autocuration,CHEMBL874399,BAO_0000218,
11118,1,A,0,,,In vivo,22224,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,,,,,,,U,Autocuration,CHEMBL624851,BAO_0000218,
11119,1,A,0,,,In vivo,22224,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,,,,,,,U,Autocuration,CHEMBL624852,BAO_0000218,
11120,1,A,0,,,In vivo,22224,Oral bioavailability in rat (dose 10 mg/kg),,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL624853,BAO_0000218,
11121,1,A,0,,,In vivo,22224,Oral bioavailability in rat (Sprague-Dawley),,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL624854,BAO_0000218,
11122,1,A,0,,,In vivo,22224,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL624855,BAO_0000218,
11123,1,A,0,,,In vivo,22224,Oral bioavailability in rats was determined in vivo,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL624856,BAO_0000218,
11124,1,A,0,,,In vivo,22224,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,U,Autocuration,CHEMBL882957,BAO_0000218,
11125,1,A,0,,,In vivo,22224,Oral bioavailability of compound in monkey,,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL624857,BAO_0000218,
11126,1,A,1,,,In vivo,50597,Oral bioavailability of compound in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622202,BAO_0000218,
11127,1,A,0,,,In vivo,22224,Bioavailability in rat of PMEA prodrug,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL622203,BAO_0000218,
11128,1,A,1,,,In vivo,50597,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625522,BAO_0000218,
11129,1,A,0,,,In vivo,22224,Serum conc at 3 hours following 25 mg/kg dose,,Macaca mulatta,,,,9544.0,U,Autocuration,CHEMBL622868,BAO_0000218,
11130,1,A,0,,,In vivo,22224,Urine conc 0-5 hours following 25 mg/kg dose,1088.0,Macaca mulatta,,,,9544.0,U,Autocuration,CHEMBL622869,BAO_0000218,
11131,1,A,0,,,In vivo,22224,Urine conc 0-24 hours following 25 mg/kg dose,1088.0,Macaca mulatta,,,,9544.0,U,Autocuration,CHEMBL622870,BAO_0000218,
11132,1,A,0,,,In vivo,22224,Oral bioavailability in African green monkeys; 20-25,,Chlorocebus aethiops,,,,9534.0,U,Autocuration,CHEMBL622871,BAO_0000218,
11133,1,A,1,,,In vivo,100710,Oral bioavailability in cynomolgus monkey.,,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL620560,BAO_0000218,
11134,1,A,0,,,In vivo,22224,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,U,Autocuration,CHEMBL620561,BAO_0000218,
11135,1,A,1,,,In vivo,50588,Oral bioavailability in dog at 10 mg/kg oral dose,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL620562,BAO_0000218,
11136,1,A,1,,,In vivo,100712,Oral bioavailability in hamster at 10 mg/kg oral dose,,Cricetinae,,,,10026.0,N,Intermediate,CHEMBL620563,BAO_0000218,
11137,1,A,1,,,In vivo,50597,Oral bioavailability in rat at 10 mg/kg oral dose,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL620564,BAO_0000218,
11138,1,A,0,,,In vivo,22224,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL872265,BAO_0000218,
11139,1,A,0,,,In vivo,22224,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL620565,BAO_0000218,
11140,1,A,0,,,In vivo,22224,Oral bioavailability,,Eutheria,,,,9347.0,U,Autocuration,CHEMBL620566,BAO_0000218,
11141,1,A,0,,,In vivo,22224,Oral bioavailability was determined; range 49-102%,,,,,,,U,Autocuration,CHEMBL620567,BAO_0000218,
11142,1,A,1,,,In vivo,50588,Oral bioavailability was determined in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL620568,BAO_0000218,
11143,1,A,0,,,In vivo,22224,Oral bioavailability in rat,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL620569,BAO_0000218,
11144,1,A,0,,,In vivo,22224,Oral bioavailability,,Eutheria,,,,9347.0,U,Autocuration,CHEMBL620570,BAO_0000218,
11145,1,A,0,,,In vivo,22224,Oral bioavailability was determined; Not orally available,,,,,,,U,Autocuration,CHEMBL620571,BAO_0000218,
11146,1,A,1,,,In vivo,50594,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620572,BAO_0000218,
11147,1,A,0,,,In vivo,22224,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),,Mus musculus,,,,10090.0,U,Autocuration,CHEMBL620573,BAO_0000218,
11148,1,A,0,,,In vivo,22224,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,,Mus musculus,,,,10090.0,U,Autocuration,CHEMBL620574,BAO_0000218,
11149,1,A,0,,,In vivo,22224,Oral bioavailability in Rhesus monkey,,Macaca mulatta,,,,9544.0,U,Autocuration,CHEMBL620575,BAO_0000218,
11150,1,A,0,,,In vivo,22224,Oral bioavailability in dog (female mongrel),,Canis lupus familiaris,,,,9615.0,U,Autocuration,CHEMBL620576,BAO_0000218,
11151,1,A,0,,,In vivo,22224,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,,,,,,,U,Autocuration,CHEMBL875846,BAO_0000218,
11152,1,A,0,,,In vivo,22224,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,U,Autocuration,CHEMBL620577,BAO_0000218,
11153,1,A,0,,,In vivo,22224,Percentage Bioavailability was evaluated.,,,,,,,U,Autocuration,CHEMBL620578,BAO_0000218,
11154,1,A,0,,,In vivo,22224,Bioavailability in rat administered i.d.,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL620579,BAO_0000218,
11155,1,A,0,,,In vivo,22224,Bioavailability,,Eutheria,,,,9347.0,U,Autocuration,CHEMBL621248,BAO_0000218,
11156,1,A,0,,,In vivo,22224,Bioavailability in dog (male Beagle) i.v. administration,,Canis lupus familiaris,,,,9615.0,U,Autocuration,CHEMBL625390,BAO_0000218,
11157,1,A,0,,,In vivo,22224,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL625391,BAO_0000218,
11158,1,A,0,,,In vivo,22224,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),,Primates,,,,9443.0,U,Autocuration,CHEMBL872266,BAO_0000218,
11159,1,A,0,,,In vivo,22224,Oral bioavailability in rat (Sprague-Dawley) (male),,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL625392,BAO_0000218,
11160,1,A,1,,,In vivo,50597,The oral bioavailability was measured on rats after oral administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625393,BAO_0000218,
11161,1,A,1,,,In vivo,50597,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625394,BAO_0000218,
11162,1,A,1,,,In vivo,50797,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,,Macaca mulatta,,,,9544.0,N,Intermediate,CHEMBL625395,BAO_0000218,
11163,1,A,0,,,In vivo,22224,Bioavailability in rat (dose 10 mg/kg i.d.),,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL625396,BAO_0000218,
11164,1,A,0,,,In vivo,22224,Bioavailability in dog (male Beagle) i.v. administration,,Canis lupus familiaris,,,,9615.0,U,Autocuration,CHEMBL625397,BAO_0000218,
11165,1,A,1,,,In vivo,50594,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625398,BAO_0000218,
11166,1,A,1,,,In vivo,50594,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625399,BAO_0000218,
11167,1,A,1,,,In vivo,50594,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),2037.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626074,BAO_0000218,
11168,1,A,1,,,In vivo,50594,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626075,BAO_0000218,
11169,1,A,1,,,In vivo,50597,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626076,BAO_0000218,
11170,1,A,1,,,In vivo,50797,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,1969.0,Macaca mulatta,,,,9544.0,N,Intermediate,CHEMBL626077,BAO_0000218,
11171,1,A,1,,,In vivo,50597,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626078,BAO_0000218,
11172,1,A,0,,,In vivo,22224,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),178.0,,,,,,U,Autocuration,CHEMBL625846,BAO_0000218,
11173,1,A,0,,,In vivo,22224,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),178.0,,,,,,U,Autocuration,CHEMBL625847,BAO_0000218,
11174,1,A,1,,,In vivo,50597,Maximum concentration observed in rats at an oral dose of 50 mg/kg,,Rattus norvegicus,,,,10116.0,N,Expert,CHEMBL625848,BAO_0000218,
11175,1,A,1,,,In vivo,50597,Maximum concentration of compound in plasma administered orally to rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625849,BAO_0000218,
11176,1,A,1,,,In vivo,50588,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626023,BAO_0000218,
11177,1,A,1,,,In vivo,50588,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626024,BAO_0000218,
11178,1,A,1,,,In vivo,50588,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626025,BAO_0000218,
11179,1,A,0,,,In vivo,22224,Maximum concentration after 10 mg/kg by oral administration,,,,,,,U,Autocuration,CHEMBL626026,BAO_0000218,
11180,1,A,0,,,In vivo,22224,Maximum concentration at a dose of 1.5 mg/kg,,,,,,,U,Autocuration,CHEMBL626027,BAO_0000218,
11181,1,A,0,,,In vivo,22224,Maximum concentration at a dose of 2.0 mg/kg,,,,,,,U,Autocuration,CHEMBL626028,BAO_0000218,
11182,1,A,1,,,In vivo,50588,Maximum concentration in dog plasma,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626029,BAO_0000218,
11183,1,A,0,,,In vivo,22224,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,1969.0,,,,,,U,Autocuration,CHEMBL626030,BAO_0000218,
11184,1,A,0,,,In vivo,22224,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,1969.0,,,,,,U,Autocuration,CHEMBL626031,BAO_0000218,
11185,1,A,0,,,In vivo,22224,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,1969.0,,,,,,U,Autocuration,CHEMBL626032,BAO_0000218,
11186,1,A,0,,,In vivo,22224,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,1969.0,,,,,,U,Autocuration,CHEMBL626033,BAO_0000218,
11187,1,A,0,,,In vivo,22224,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,1969.0,,,,,,U,Autocuration,CHEMBL626034,BAO_0000218,
11188,1,A,1,,,In vivo,50588,Maximum concentration in plasma after oral administration in dog (25 mg/kg),1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626035,BAO_0000218,
11189,1,A,0,,,In vivo,22224,Maximum concentration in plasma at Tmax,1969.0,,,,,,U,Autocuration,CHEMBL626036,BAO_0000218,
11190,1,A,1,,,In vivo,50588,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,1969.0,Canis lupus familiaris,,,,9615.0,N,Expert,CHEMBL626037,BAO_0000218,
11191,1,A,1,,,In vivo,100712,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,1969.0,Cricetinae,,,,10026.0,N,Intermediate,CHEMBL626038,BAO_0000218,
11192,1,A,1,,,In vivo,50597,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626039,BAO_0000218,
11193,1,A,1,,,In vivo,50597,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626040,BAO_0000218,
11194,1,A,1,,,In vivo,50592,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,1969.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL626041,BAO_0000218,
11195,1,A,0,,,In vivo,22224,Maximum concentration was calculated,,,,,,,U,Autocuration,CHEMBL626042,BAO_0000218,
11196,1,A,0,,,In vivo,22224,Maximum concentration was calculated.,,,,,,,U,Autocuration,CHEMBL626043,BAO_0000218,
11197,1,A,0,,,In vivo,22224,Maximum concentration at a peroral dose of 10 mg/kg,,,,,,,U,Autocuration,CHEMBL626044,BAO_0000218,
11198,1,A,0,,,In vivo,22224,Maximum concentration of the drug at 10 uM/dg administered perorally,,,,,,,U,Autocuration,CHEMBL626045,BAO_0000218,
11199,1,A,0,,,In vivo,22224,Maximum concentration of the drug at 2 uM/dg administered intravenously,,,,,,,U,Autocuration,CHEMBL626046,BAO_0000218,
11200,1,A,1,,,In vivo,50588,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626047,BAO_0000218,
11201,1,A,1,,,In vivo,100712,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",1969.0,Cricetinae,,,,10026.0,N,Intermediate,CHEMBL626048,BAO_0000218,
11202,1,A,1,,,In vivo,50597,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626049,BAO_0000218,
11203,1,A,1,,,In vivo,50597,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626050,BAO_0000218,
11204,1,A,1,,,In vivo,50588,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL874541,BAO_0000218,
11205,1,A,1,,,In vivo,100712,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,1969.0,Cricetinae,,,,10026.0,N,Intermediate,CHEMBL622826,BAO_0000218,
11206,1,A,1,,,In vivo,100712,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,1969.0,Cricetinae,,,,10026.0,N,Intermediate,CHEMBL622827,BAO_0000218,
11207,1,A,1,,,In vivo,50597,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622828,BAO_0000218,
11208,1,A,1,,,In vivo,50597,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622829,BAO_0000218,
11209,1,A,1,,,In vivo,50597,Maximum concentration reached following intravenous administration in male rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876806,BAO_0000218,
11210,1,A,1,,,In vivo,50588,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622830,BAO_0000218,
11211,1,A,1,,,In vivo,50597,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622831,BAO_0000218,
11212,1,A,1,,,In vivo,50588,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626794,BAO_0000218,
11213,1,A,1,,,In vivo,50597,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626795,BAO_0000218,
11214,1,A,1,,,In vivo,50597,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626796,BAO_0000218,
11215,1,A,1,,,In vivo,50597,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626797,BAO_0000218,
11216,1,A,1,,,In vivo,50597,Maximum drug concentration is determined after oral dosing in rats.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626798,BAO_0000218,
11217,1,A,1,,,In vivo,50588,Maximum observed concentration in oral (5 mg/kg) fasted dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626799,BAO_0000218,
11218,1,A,1,,,In vivo,50588,Maximum observed concentration in oral (5 mg/kg) fed dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626800,BAO_0000218,
11219,1,A,0,,,In vivo,22224,Maximum plasma concentration,1969.0,,,,,,U,Autocuration,CHEMBL626801,BAO_0000218,
11220,1,A,1,,,In vivo,50597,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876816,BAO_0000218,
11221,1,A,1,,,In vivo,50597,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626802,BAO_0000218,
11222,1,A,1,,,In vivo,50588,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626803,BAO_0000218,
11223,1,A,0,,,In vivo,22224,Maximum plasma concentration following oral administration of 30 umol/kg,1969.0,,,,,,U,Autocuration,CHEMBL626804,BAO_0000218,
11224,1,A,1,,,,50597,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626805,BAO_0000218,
11225,1,A,1,,,,50597,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626309,BAO_0000218,
11226,1,A,1,,,,50597,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626310,BAO_0000218,
11227,1,A,1,,,,50597,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626311,BAO_0000218,
11228,1,A,1,,,,50597,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626312,BAO_0000218,
11229,1,A,1,,,,50597,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,995.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626313,BAO_0000218,
11230,1,A,1,,,,50597,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,995.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626314,BAO_0000218,
11231,1,A,1,,,,50597,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,995.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626315,BAO_0000218,
11232,1,A,1,,,,50597,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,995.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626316,BAO_0000218,
11233,1,A,1,,,,50597,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,995.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626317,BAO_0000218,
11234,1,A,1,,,,50597,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626318,BAO_0000218,
11235,1,A,1,,,,50597,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626319,BAO_0000218,
11236,1,A,1,,,,50597,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626320,BAO_0000218,
11237,1,A,1,,,,50597,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875053,BAO_0000218,
11238,1,A,1,,,,50597,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626321,BAO_0000218,
11239,1,A,1,,,,50597,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626322,BAO_0000218,
11240,1,A,1,,,,50597,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626323,BAO_0000218,
11241,1,A,1,,,,50597,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626324,BAO_0000218,
11242,1,A,1,,,,50597,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626325,BAO_0000218,
11243,1,A,1,,,,50597,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626326,BAO_0000218,
11244,1,A,1,,,,50597,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626327,BAO_0000218,
11245,1,A,1,,,,50597,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626328,BAO_0000218,
11246,1,A,1,,,,50597,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626329,BAO_0000218,
11247,1,A,1,,,,50597,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626330,BAO_0000218,
11248,1,A,1,,,,50597,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626331,BAO_0000218,
11249,1,A,1,,,,50597,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626332,BAO_0000218,
11250,1,A,1,,,,50597,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626333,BAO_0000218,
11251,1,A,1,,,,50597,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626334,BAO_0000218,
11252,1,A,1,,,,50597,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626335,BAO_0000218,
11253,1,A,1,,,,50597,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624798,BAO_0000218,
11254,1,A,1,,,,50597,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624799,BAO_0000218,
11255,1,A,1,,,,50597,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624800,BAO_0000218,
11256,1,A,1,,,,50597,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624801,BAO_0000218,
11257,1,A,1,,,,50597,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624802,BAO_0000218,
11258,1,A,1,,,,50597,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624803,BAO_0000218,
11259,1,A,1,,,,50597,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624804,BAO_0000218,
11260,1,A,1,,,,50597,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624805,BAO_0000218,
11261,1,A,1,,,,50597,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624806,BAO_0000218,
11262,1,A,1,,,,50597,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624807,BAO_0000218,
11263,1,A,1,,,,50597,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624808,BAO_0000218,
11264,1,A,1,,,,50597,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624809,BAO_0000218,
11265,1,A,1,,,,50597,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624810,BAO_0000218,
11266,1,A,1,,,,50597,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL877618,BAO_0000218,
11267,1,A,1,,,,50597,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624811,BAO_0000218,
11268,1,A,1,,,,50597,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624812,BAO_0000218,
11269,1,A,1,,,,50597,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624813,BAO_0000218,
11270,1,A,1,,,,50597,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624814,BAO_0000218,
11271,1,A,1,,,,50597,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624815,BAO_0000218,
11272,1,A,1,,,,50597,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624816,BAO_0000218,
11273,1,A,1,,,,50597,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624817,BAO_0000218,
11274,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624818,BAO_0000218,
11275,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624819,BAO_0000218,
11276,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624820,BAO_0000218,
11277,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624821,BAO_0000218,
11278,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624822,BAO_0000218,
11279,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624823,BAO_0000218,
11280,1,A,1,,,,50212,Observed diffusion coefficient in organic solvent for Escherichia coli,,Escherichia coli,,,,562.0,N,Intermediate,CHEMBL624824,BAO_0000218,
11281,1,A,1,,,,50597,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624825,BAO_0000218,
11282,1,A,1,,,,50597,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624826,BAO_0000218,
11283,1,A,1,,,,50597,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",2081.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876817,BAO_0000218,
11284,1,A,1,,,,50597,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",2081.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624827,BAO_0000218,
11285,1,A,1,,,,50597,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624828,BAO_0000218,
11286,1,A,1,,,,50597,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624829,BAO_0000218,
11287,1,A,1,,,,50597,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624830,BAO_0000218,
11288,1,A,1,,,,50597,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624831,BAO_0000218,
11289,1,A,1,,,,50597,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",2081.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624832,BAO_0000218,
11290,1,A,1,,,,50597,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",2081.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624833,BAO_0000218,
11291,1,A,1,,,,50597,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624834,BAO_0000218,
11292,1,A,1,,,,50597,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624835,BAO_0000218,
11293,1,A,1,,,,50597,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624836,BAO_0000218,
11294,1,A,1,,,,50597,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624837,BAO_0000218,
11295,1,A,1,,,,50597,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624838,BAO_0000218,
11296,1,A,1,,,,50597,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622188,BAO_0000218,
11297,1,A,1,,,,50597,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622189,BAO_0000218,
11298,1,A,1,,,,50597,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622190,BAO_0000218,
11299,1,A,1,,,,50597,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625170,BAO_0000218,
11300,1,A,1,,,,50597,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625171,BAO_0000218,
11301,1,A,1,,,,50597,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625172,BAO_0000218,
11302,1,A,1,,,,50597,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625173,BAO_0000218,
11303,1,A,1,,,,50597,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625174,BAO_0000218,
11304,1,A,1,,,,50597,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625175,BAO_0000218,
11305,1,A,1,,,,50597,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625176,BAO_0000218,
11306,1,A,1,,,,50597,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625177,BAO_0000218,
11307,1,A,1,,,,50597,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625178,BAO_0000218,
11308,1,A,1,,,,50597,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625179,BAO_0000218,
11309,1,A,1,,,,50597,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625180,BAO_0000218,
11310,1,A,0,,,,22224,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",,,,,,,U,Autocuration,CHEMBL625181,BAO_0000218,
11311,1,A,1,,,,50594,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,1088.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625182,BAO_0000218,
11312,1,A,1,,,,50597,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625183,BAO_0000218,
11313,1,A,1,,,,50597,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875848,BAO_0000218,
11314,1,A,1,,,,50597,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622260,BAO_0000218,
11315,1,A,1,,,,50597,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622261,BAO_0000218,
11316,1,A,1,,,,50597,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622262,BAO_0000218,
11317,1,A,1,,,,50597,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622263,BAO_0000218,
11318,1,A,1,,,,50597,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622418,BAO_0000218,
11319,1,A,1,,,,50597,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622419,BAO_0000218,
11320,1,A,1,,,In vivo,50594,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623388,BAO_0000218,
11321,1,A,1,,,In vivo,50594,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623389,BAO_0000218,
11322,1,A,1,,,In vivo,50594,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623390,BAO_0000218,
11323,1,A,1,,,In vivo,50594,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623391,BAO_0000218,
11324,1,A,1,,,In vivo,50594,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623392,BAO_0000218,
11325,1,A,1,,,In vivo,50594,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),2037.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623393,BAO_0000218,
11326,1,A,1,,,In vivo,50594,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623394,BAO_0000218,
11327,1,A,1,,,In vivo,50594,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618885,BAO_0000218,
11328,1,A,1,,,In vivo,50594,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618886,BAO_0000218,
11329,1,A,1,,,In vivo,50594,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618887,BAO_0000218,
11330,1,A,1,,,In vivo,50594,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619535,BAO_0000218,
11331,1,A,1,,,In vivo,50594,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619536,BAO_0000218,
11332,1,A,1,,,In vivo,50594,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),2037.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619537,BAO_0000218,
11333,1,A,1,,,In vivo,50594,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619705,BAO_0000218,
11334,1,A,1,,,In vivo,50594,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619706,BAO_0000218,
11335,1,A,1,,,In vivo,50594,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619707,BAO_0000218,
11336,1,A,1,,,In vivo,50594,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL619708,BAO_0000218,
11337,1,A,1,,,In vivo,50594,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625219,BAO_0000218,
11338,1,A,1,,,In vivo,50594,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625220,BAO_0000218,
11339,1,A,1,,,In vivo,50594,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),2037.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625221,BAO_0000218,
11340,1,A,1,,,In vivo,50594,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625222,BAO_0000218,
11341,1,A,1,,,In vivo,50594,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625223,BAO_0000218,
11342,1,A,1,,,In vivo,50594,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625224,BAO_0000218,
11343,1,A,1,,,In vivo,50594,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625225,BAO_0000218,
11344,1,A,1,,,In vivo,50597,Biodistribution in Rat blood after 24 hours of iv administration,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625226,BAO_0000218,
11345,1,A,1,,,In vivo,50597,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625227,BAO_0000218,
11346,1,A,1,,,In vivo,50597,Biodistribution in Rat blood after 30 minutes of iv administration,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625228,BAO_0000218,
11347,1,A,1,,,In vivo,50597,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875354,BAO_0000218,
11348,1,A,1,,,In vivo,50597,Biodistribution in Rat blood after 5 minutes of iv administration,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625229,BAO_0000218,
11349,1,A,1,,,In vivo,50597,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625230,BAO_0000218,
11350,1,A,1,,,In vivo,50597,Biodistribution in Rat heart after 24 hours of iv administration,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625231,BAO_0000218,
11351,1,A,1,,,In vivo,50597,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625900,BAO_0000218,
11352,1,A,1,,,In vivo,50597,Biodistribution in Rat heart after 30 minutes of iv administration,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625901,BAO_0000218,
11353,1,A,1,,,In vivo,50597,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625902,BAO_0000218,
11354,1,A,1,,,In vivo,50597,Biodistribution in Rat heart after 5 minutes of iv administration,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625903,BAO_0000218,
11355,1,A,1,,,In vivo,50597,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625904,BAO_0000218,
11356,1,A,1,,,In vivo,50597,Biodistribution in Rat liver after 24 hours of iv administration,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625905,BAO_0000218,
11357,1,A,1,,,In vivo,50597,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627861,BAO_0000218,
11358,1,A,1,,,In vivo,50597,Biodistribution in Rat liver after 30 minutes of iv administration,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627862,BAO_0000218,
11359,1,A,1,,,In vivo,50597,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627863,BAO_0000218,
11360,1,A,1,,,In vivo,50597,Biodistribution in Rat liver after 30 minutes of iv administration,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627769,BAO_0000218,
11361,1,A,1,,,In vivo,50588,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627770,BAO_0000218,
11362,1,A,1,,,In vivo,100710,Cmax in cynomolgus monkey (PO dose),,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL627771,BAO_0000218,
11363,1,A,1,,,In vivo,50597,Cmax in rat (PO dose),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627772,BAO_0000218,
11364,1,A,1,,,In vivo,50597,Cmax in rat (PO dose),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627773,BAO_0000218,
11365,1,A,1,,,In vivo,50597,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621922,BAO_0000218,
11366,1,A,1,,,In vivo,50597,Cmax in rat plasma after oral dose (10 mg/kg),1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621923,BAO_0000218,
11367,1,A,0,,,In vivo,22224,Cmax in plasma after oral dose (10 mg/kg),1969.0,,,,,,U,Autocuration,CHEMBL621924,BAO_0000218,
11368,1,A,1,,,In vivo,50588,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621925,BAO_0000218,
11369,1,A,0,,,In vivo,22224,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,1969.0,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL621926,BAO_0000218,
11370,1,A,1,,,In vivo,50592,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,1969.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL621927,BAO_0000218,
11371,1,A,1,,,In vivo,50597,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621928,BAO_0000218,
11372,1,A,1,,,In vivo,50597,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621929,BAO_0000218,
11373,1,A,1,,,In vivo,50594,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL621930,BAO_0000218,
11374,1,A,1,,,In vivo,50597,Maximum plasma concentration after oral dosing in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621931,BAO_0000218,
11375,1,A,0,,,In vivo,22224,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,1969.0,,,,,,U,Autocuration,CHEMBL621932,BAO_0000218,
11376,1,A,0,,,In vivo,22224,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,1969.0,,,,,,U,Autocuration,CHEMBL621933,BAO_0000218,
11377,1,A,1,,,In vivo,50588,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621934,BAO_0000218,
11378,1,A,1,,,In vivo,50588,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL621935,BAO_0000218,
11379,1,A,1,,,In vivo,50597,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621936,BAO_0000218,
11380,1,A,0,,,In vivo,22224,Maximum plasma concentration was determined,1969.0,,,,,,U,Autocuration,CHEMBL621937,BAO_0000218,
11381,1,A,0,,,In vivo,22224,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,1969.0,,,,,,U,Autocuration,CHEMBL621938,BAO_0000218,
11382,1,A,0,,,In vivo,22224,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,1969.0,,,,,,U,Autocuration,CHEMBL621939,BAO_0000218,
11383,1,A,0,,,In vivo,22224,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,1969.0,,,,,,U,Autocuration,CHEMBL621940,BAO_0000218,
11384,1,A,0,,,In vivo,22224,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,1969.0,,,,,,U,Autocuration,CHEMBL621941,BAO_0000218,
11385,1,A,0,,,In vivo,22224,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,1969.0,,,,,,U,Autocuration,CHEMBL621942,BAO_0000218,
11386,1,A,0,,,In vivo,22224,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,1969.0,,,,,,U,Autocuration,CHEMBL626178,BAO_0000218,
11387,1,A,0,,,In vivo,22224,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,1969.0,,,,,,U,Autocuration,CHEMBL626179,BAO_0000218,
11388,1,A,0,,,In vivo,22224,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,1969.0,,,,,,U,Autocuration,CHEMBL626180,BAO_0000218,
11389,1,A,1,,,In vivo,50597,Plasma Cmax in rat (PO dose),1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626181,BAO_0000218,
11390,1,A,1,,,In vivo,50597,Maximum serum concentration after po dose of 5.22 mg/kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626182,BAO_0000218,
11391,1,A,1,,,In vivo,50597,Maximum serum concentration after po dose of 5.46 mg/kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626183,BAO_0000218,
11392,1,A,1,,,In vivo,50597,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626184,BAO_0000218,
11393,1,A,1,,,In vivo,50597,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626185,BAO_0000218,
11394,1,A,1,,,In vivo,50588,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626186,BAO_0000218,
11395,1,A,1,,,In vivo,50588,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL877589,BAO_0000218,
11396,1,A,0,,,In vivo,22224,Maximum concentration of the drug at 1 uM/dg administered intravenously,,,,,,,U,Autocuration,CHEMBL626187,BAO_0000218,
11397,1,A,0,,,In vivo,22224,Maximum concentration of the drug at 20 uM/dg administered perorally,,,,,,,U,Autocuration,CHEMBL626188,BAO_0000218,
11398,1,A,0,,,In vivo,22224,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,,,,,,,U,Autocuration,CHEMBL626189,BAO_0000218,
11399,1,A,0,,,In vivo,22224,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,178.0,,,,,,U,Autocuration,CHEMBL626855,BAO_0000218,
11400,1,A,0,,,In vivo,22224,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,178.0,,,,,,U,Autocuration,CHEMBL623781,BAO_0000218,
11401,1,A,0,,,In vivo,22224,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,178.0,,,,,,U,Autocuration,CHEMBL623782,BAO_0000218,
11402,1,A,1,,,In vivo,50597,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623783,BAO_0000218,
11403,1,A,1,,,In vivo,50588,Cmax in dog plasma after 1mg/kg oral dose,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623784,BAO_0000218,
11404,1,A,1,,,In vivo,50588,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623785,BAO_0000218,
11405,1,A,1,,,In vivo,50597,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623786,BAO_0000218,
11406,1,A,1,,,In vivo,50597,Oral maximum concentration in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623787,BAO_0000218,
11407,1,A,1,,,In vivo,50597,Oral maximum concentration in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623788,BAO_0000218,
11408,1,A,1,,,In vivo,50594,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623789,BAO_0000218,
11409,1,A,1,,,In vivo,50594,Peak concentration in blood after intravenous administration to mice,178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623790,BAO_0000218,
11410,1,A,1,,,In vivo,50594,Peak concentration in blood after peroral administration to mice,178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623791,BAO_0000218,
11411,1,A,1,,,In vivo,50597,Peak concentration in rat plasma was determined,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623792,BAO_0000218,
11412,1,A,0,,,In vivo,22224,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,1969.0,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL623793,BAO_0000218,
11413,1,A,1,,,In vivo,50594,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623794,BAO_0000218,
11414,1,A,1,,,In vivo,50597,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623795,BAO_0000218,
11415,1,A,1,,,,50597,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623796,BAO_0000218,
11416,1,A,1,,,,50597,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623797,BAO_0000218,
11417,1,A,1,,,,50597,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623798,BAO_0000218,
11418,1,A,1,,,,50597,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623799,BAO_0000218,
11419,1,A,1,,,,50597,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",160.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624490,BAO_0000218,
11420,1,A,1,,,,50597,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",160.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624491,BAO_0000218,
11421,1,A,1,,,,50597,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",160.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624492,BAO_0000218,
11422,1,A,1,,,,50597,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",160.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624493,BAO_0000218,
11423,1,A,1,,,,50597,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",160.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL877595,BAO_0000218,
11424,1,A,1,,,,50597,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",160.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624494,BAO_0000218,
11425,1,A,1,,,,50597,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",160.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624495,BAO_0000218,
11426,1,A,1,,,,50597,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",160.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624681,BAO_0000218,
11427,1,A,1,,,,50597,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624682,BAO_0000218,
11428,1,A,1,,,,50597,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624683,BAO_0000218,
11429,1,A,1,,,,50597,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624684,BAO_0000218,
11430,1,A,1,,,,50597,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624685,BAO_0000218,
11431,1,A,1,,,,50597,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624686,BAO_0000218,
11432,1,A,1,,,,50597,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624687,BAO_0000218,
11433,1,A,1,,,,50597,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624688,BAO_0000218,
11434,1,A,1,,,,50597,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627161,BAO_0000218,
11435,1,A,1,,,,50597,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622127,BAO_0000218,
11436,1,A,1,,,,50597,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622128,BAO_0000218,
11437,1,A,1,,,,50597,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874384,BAO_0000218,
11438,1,A,1,,,,50597,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624898,BAO_0000218,
11439,1,A,1,,,,50597,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624899,BAO_0000218,
11440,1,A,1,,,,50597,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624900,BAO_0000218,
11441,1,A,1,,,,50597,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624901,BAO_0000218,
11442,1,A,1,,,,50597,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624902,BAO_0000218,
11443,1,A,1,,,,50597,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624903,BAO_0000218,
11444,1,A,1,,,,50597,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624904,BAO_0000218,
11445,1,A,1,,,,50597,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624905,BAO_0000218,
11446,1,A,1,,,,50597,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624906,BAO_0000218,
11447,1,A,1,,,,50597,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624907,BAO_0000218,
11448,1,A,1,,,,50597,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624908,BAO_0000218,
11449,1,A,1,,,,50597,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624909,BAO_0000218,
11450,1,A,1,,,,50597,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624910,BAO_0000218,
11451,1,A,1,,,,50597,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624911,BAO_0000218,
11452,1,A,1,,,,50597,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874388,BAO_0000218,
11453,1,A,1,,,,50597,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624912,BAO_0000218,
11454,1,A,1,,,,50597,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622930,BAO_0000218,
11455,1,A,1,,,,50597,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623121,BAO_0000218,
11456,1,A,1,,,,50597,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623122,BAO_0000218,
11457,1,A,1,,,,50597,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623123,BAO_0000218,
11458,1,A,1,,,,50597,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623124,BAO_0000218,
11459,1,A,1,,,,50597,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623125,BAO_0000218,
11460,1,A,1,,,,50597,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623126,BAO_0000218,
11461,1,A,1,,,,50597,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623127,BAO_0000218,
11462,1,A,1,,,,50597,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623128,BAO_0000218,
11463,1,A,1,,,,50597,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623129,BAO_0000218,
11464,1,A,1,,,,50597,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623130,BAO_0000218,
11465,1,A,1,,,,50597,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623131,BAO_0000218,
11466,1,A,1,,,,50597,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623132,BAO_0000218,
11467,1,A,1,,,,50597,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623133,BAO_0000218,
11468,1,A,1,,,,50597,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623134,BAO_0000218,
11469,1,A,1,,,,50597,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874389,BAO_0000218,
11470,1,A,1,,,,50597,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623135,BAO_0000218,
11471,1,A,1,,,,50597,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623136,BAO_0000218,
11472,1,A,1,,,,50597,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623137,BAO_0000218,
11473,1,A,1,,,,50597,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623138,BAO_0000218,
11474,1,A,1,,,,50597,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623139,BAO_0000218,
11475,1,A,1,,,,50597,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623140,BAO_0000218,
11476,1,A,1,,,,50597,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623141,BAO_0000218,
11477,1,A,1,,,,50597,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623142,BAO_0000218,
11478,1,A,1,,,,50597,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623143,BAO_0000218,
11479,1,A,1,,,,50594,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,1088.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623144,BAO_0000218,
11480,1,A,1,,,,50597,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623405,BAO_0000218,
11481,1,A,1,,,,50597,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624074,BAO_0000218,
11482,1,A,1,,,,50597,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624075,BAO_0000218,
11483,1,A,1,,,,50597,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624076,BAO_0000218,
11484,1,A,1,,,,50597,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624077,BAO_0000218,
11485,1,A,1,,,,50597,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624078,BAO_0000218,
11486,1,A,1,,,,50597,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624079,BAO_0000218,
11487,1,A,1,,,,50597,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624261,BAO_0000218,
11488,1,A,1,,,,50597,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624262,BAO_0000218,
11489,1,A,1,,,,50597,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624263,BAO_0000218,
11490,1,A,1,,,,50597,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624264,BAO_0000218,
11491,1,A,1,,,,50597,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624265,BAO_0000218,
11492,1,A,1,,,,50597,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624266,BAO_0000218,
11493,1,A,1,,,,50597,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624267,BAO_0000218,
11494,1,A,1,,,,50597,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624268,BAO_0000218,
11495,1,A,1,,,,50597,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875227,BAO_0000218,
11496,1,A,1,,,,50597,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624269,BAO_0000218,
11497,1,A,1,,,,50597,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624270,BAO_0000218,
11498,1,A,1,,,,50597,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624271,BAO_0000218,
11499,1,A,1,,,,50597,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624272,BAO_0000218,
11500,1,A,1,,,,50597,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624273,BAO_0000218,
11501,1,A,1,,,,50597,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624274,BAO_0000218,
11502,1,A,1,,,,50597,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624275,BAO_0000218,
11503,1,A,1,,,,50597,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624276,BAO_0000218,
11504,1,A,1,,,,50597,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624277,BAO_0000218,
11505,1,A,0,,,,22224,% dose converted to 2-amino-5-chlorophenyl sulfate,,,,,,,U,Autocuration,CHEMBL624278,BAO_0000019,
11506,1,A,0,,,,22224,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),,,,,,,U,Autocuration,CHEMBL624279,BAO_0000019,
11507,1,A,1,,,,50597,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",1988.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624280,BAO_0000218,
11508,1,A,1,,,,50597,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",1988.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624281,BAO_0000218,
11509,1,A,1,,,,50597,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",1988.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622933,BAO_0000218,
11510,1,A,1,,,,50597,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",1988.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622934,BAO_0000218,
11511,1,A,1,,,In vivo,50597,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622935,BAO_0000218,
11512,1,A,1,,,In vivo,50597,Biodistribution in Rat liver after 5 minutes of iv administration,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622936,BAO_0000218,
11513,1,A,1,,,In vivo,50597,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875228,BAO_0000218,
11514,1,A,1,,,In vivo,50597,Biodistribution in Rat lung after 24 hours of iv administration,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622937,BAO_0000218,
11515,1,A,1,,,In vivo,50597,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622938,BAO_0000218,
11516,1,A,1,,,In vivo,50597,Biodistribution in Rat lung after 30 minutes of iv administration,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL619736,BAO_0000218,
11517,1,A,1,,,In vivo,50597,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625117,BAO_0000218,
11518,1,A,1,,,In vivo,50597,Biodistribution in Rat lung after 5 minutes of iv administration,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625118,BAO_0000218,
11519,1,A,1,,,In vivo,50597,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625119,BAO_0000218,
11520,1,A,1,,,In vivo,50597,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",2037.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625120,BAO_0000218,
11521,1,A,1,,,In vivo,50597,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625121,BAO_0000218,
11522,1,A,1,,,In vivo,50597,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",10000006.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625122,BAO_0000218,
11523,1,A,1,,,In vivo,50597,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622204,BAO_0000218,
11524,1,A,1,,,In vivo,50597,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL877503,BAO_0000218,
11525,1,A,1,,,In vivo,50597,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627127,BAO_0000218,
11526,1,A,0,,,In vivo,22224,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,10000000.0,,,,,,U,Autocuration,CHEMBL627128,BAO_0000218,
11527,1,A,0,,,In vivo,22224,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,10000000.0,,,,,,U,Autocuration,CHEMBL627129,BAO_0000218,
11528,1,A,0,,,In vivo,22224,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,10000000.0,,,,,,U,Autocuration,CHEMBL627130,BAO_0000218,
11529,1,A,1,,,In vivo,50597,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627131,BAO_0000218,
11530,1,A,1,,,In vivo,50597,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627132,BAO_0000218,
11531,1,A,1,,,In vivo,50597,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627133,BAO_0000218,
11532,1,A,1,,,In vivo,50597,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,2037.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627134,BAO_0000218,
11533,1,A,1,,,In vivo,50597,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,2037.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627135,BAO_0000218,
11534,1,A,1,,,In vivo,50597,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,2037.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627136,BAO_0000218,
11535,1,A,1,,,In vivo,50597,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628435,BAO_0000218,
11536,1,A,1,,,In vivo,50597,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628436,BAO_0000218,
11537,1,A,1,,,In vivo,50597,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628437,BAO_0000218,
11538,1,A,1,,,In vivo,50597,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628438,BAO_0000218,
11539,1,A,1,,,In vivo,50597,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628439,BAO_0000218,
11540,1,A,1,,,In vivo,50597,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628440,BAO_0000218,
11541,1,A,1,,,In vivo,50597,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,10000000.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628441,BAO_0000218,
11542,1,A,1,,,In vivo,50597,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,10000000.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628442,BAO_0000218,
11543,1,A,1,,,In vivo,50597,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,10000000.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628443,BAO_0000218,
11544,1,A,1,,,In vivo,50597,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628444,BAO_0000218,
11545,1,A,1,,,In vivo,50597,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628445,BAO_0000218,
11546,1,A,1,,,In vivo,50597,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL877504,BAO_0000218,
11547,1,A,1,,,In vivo,50597,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628446,BAO_0000218,
11548,1,A,1,,,In vivo,50597,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626874,BAO_0000218,
11549,1,A,1,,,In vivo,50597,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626875,BAO_0000218,
11550,1,A,1,,,In vivo,50597,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626876,BAO_0000218,
11551,1,A,1,,,In vivo,50597,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626877,BAO_0000218,
11552,1,A,1,,,In vivo,50597,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626878,BAO_0000218,
11553,1,A,1,,,In vivo,50597,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626879,BAO_0000218,
11554,1,A,0,,,In vivo,22224,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,1969.0,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL626880,BAO_0000218,
11555,1,A,1,,,In vivo,50594,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626881,BAO_0000218,
11556,1,A,1,,,In vivo,50597,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626882,BAO_0000218,
11557,1,A,1,,,In vivo,50588,Peak plasma concentration was measured in dogs,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626883,BAO_0000218,
11558,1,A,1,,,In vivo,50597,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626884,BAO_0000218,
11559,1,A,1,,,In vivo,50597,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626885,BAO_0000218,
11560,1,A,1,,,In vivo,50597,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626886,BAO_0000218,
11561,1,A,1,,,In vivo,50597,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626887,BAO_0000218,
11562,1,A,1,,,In vivo,50597,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626888,BAO_0000218,
11563,1,A,1,,,In vivo,50588,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626889,BAO_0000218,
11564,1,A,0,,,In vivo,22224,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL626761,BAO_0000218,
11565,1,A,1,,,In vivo,50588,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626762,BAO_0000218,
11566,1,A,1,,,In vivo,50588,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626763,BAO_0000218,
11567,1,A,1,,,In vivo,50597,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626764,BAO_0000218,
11568,1,A,1,,,In vivo,50597,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626765,BAO_0000218,
11569,1,A,1,,,In vivo,50588,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626766,BAO_0000218,
11570,1,A,1,,,In vivo,50597,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626767,BAO_0000218,
11571,1,A,1,,,In vivo,50597,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626768,BAO_0000218,
11572,1,A,1,,,In vivo,50588,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626769,BAO_0000218,
11573,1,A,1,,,In vivo,50588,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL874463,BAO_0000218,
11574,1,A,0,,,In vivo,22224,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL626770,BAO_0000218,
11575,1,A,0,,,In vivo,22224,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL626771,BAO_0000218,
11576,1,A,1,,,In vivo,50597,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626772,BAO_0000218,
11577,1,A,1,,,In vivo,100710,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL626773,BAO_0000218,
11578,1,A,1,,,In vivo,50594,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626774,BAO_0000218,
11579,1,A,1,,,In vivo,50588,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626775,BAO_0000218,
11580,1,A,1,,,In vivo,50588,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626776,BAO_0000218,
11581,1,A,1,,,In vivo,50597,Maximum concentration (Cmax) in rat when administered orally,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626777,BAO_0000218,
11582,1,A,0,,,In vivo,22224,Maximal concentration in monkey plasma after 25 mg/kg oral dose,1969.0,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL626778,BAO_0000218,
11583,1,A,0,,,In vivo,22224,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL626779,BAO_0000218,
11584,1,A,0,,,In vivo,22224,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL626780,BAO_0000218,
11585,1,A,0,,,In vivo,22224,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,1969.0,,,,,,U,Autocuration,CHEMBL626781,BAO_0000218,
11586,1,A,1,,,In vivo,50597,Pharmacokinetic profile Cmax was evaluated in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632164,BAO_0000218,
11587,1,A,1,,,In vivo,50588,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL632165,BAO_0000218,
11588,1,A,1,,,In vivo,50594,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL632166,BAO_0000218,
11589,1,A,1,,,In vivo,50588,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL632167,BAO_0000218,
11590,1,A,1,,,In vivo,50594,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL632168,BAO_0000218,
11591,1,A,0,,,In vivo,22224,Cmax in rat plasma,1969.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL632169,BAO_0000218,
11592,1,A,1,,,In vivo,50588,Cmax in dog plasma after 30mg/kg oral dose,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL632170,BAO_0000218,
11593,1,A,1,,,In vivo,50597,Cmax in rat plasma after 30mg/kg oral dose,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632171,BAO_0000218,
11594,1,A,1,,,In vivo,50597,Plasma level in rats at 30 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632172,BAO_0000218,
11595,1,A,1,,,In vivo,50594,Tested for maximum plasma concentration in mice,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL632173,BAO_0000218,
11596,1,A,1,,,In vivo,50597,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632174,BAO_0000218,
11597,1,A,1,,,In vivo,50597,The Cmax values in female wistar rats.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632175,BAO_0000218,
11598,1,A,1,,,In vivo,50588,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL632176,BAO_0000218,
11599,1,A,1,,,In vivo,50597,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632177,BAO_0000218,
11600,1,A,1,,,In vivo,50597,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632178,BAO_0000218,
11601,1,A,1,,,In vivo,50597,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632179,BAO_0000218,
11602,1,A,1,,,In vivo,50597,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632180,BAO_0000218,
11603,1,A,1,,,In vivo,50597,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632181,BAO_0000218,
11604,1,A,1,,,In vivo,50597,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632182,BAO_0000218,
11605,1,A,0,,,In vivo,22224,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,178.0,Mus musculus,,,,10090.0,U,Autocuration,CHEMBL632183,BAO_0000218,
11606,1,A,1,,,In vivo,50588,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL632184,BAO_0000218,
11607,1,A,1,,,In vivo,50597,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874470,BAO_0000218,
11608,1,A,1,,,,50597,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631302,BAO_0000218,
11609,1,A,1,,,,50597,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631303,BAO_0000218,
11610,1,A,1,,,,50597,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631304,BAO_0000218,
11611,1,A,1,,,,50597,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631305,BAO_0000218,
11612,1,A,1,,,,50597,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631306,BAO_0000218,
11613,1,A,1,,,,50597,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631307,BAO_0000218,
11614,1,A,1,,,,50597,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631308,BAO_0000218,
11615,1,A,1,,,,50597,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625557,BAO_0000218,
11616,1,A,1,,,,50597,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625558,BAO_0000218,
11617,1,A,1,,,,50597,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625559,BAO_0000218,
11618,1,A,1,,,,50597,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625560,BAO_0000218,
11619,1,A,1,,,,50597,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625561,BAO_0000218,
11620,1,A,1,,,,50597,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625562,BAO_0000218,
11621,1,A,1,,,,50597,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875320,BAO_0000218,
11622,1,A,1,,,,50597,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625563,BAO_0000218,
11623,1,A,1,,,,50597,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625564,BAO_0000218,
11624,1,A,1,,,,50597,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",995.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625565,BAO_0000218,
11625,1,A,1,,,,50597,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",995.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625566,BAO_0000218,
11626,1,A,1,,,,50597,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",995.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625567,BAO_0000218,
11627,1,A,1,,,,50597,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",995.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625568,BAO_0000218,
11628,1,A,1,,,,50597,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",995.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628217,BAO_0000218,
11629,1,A,1,,,,50597,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",995.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628218,BAO_0000218,
11630,1,A,1,,,,50597,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",995.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628219,BAO_0000218,
11631,1,A,1,,,,50597,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",995.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628220,BAO_0000218,
11632,1,A,0,,,,22224,Distribution in the blood after 120 min of intravenous administration,,,,,,,U,Autocuration,CHEMBL628221,BAO_0000019,
11633,1,A,0,,,,22224,Distribution in the blood after 15 min of intravenous administration,,,,,,,U,Autocuration,CHEMBL628222,BAO_0000019,
11634,1,A,0,,,,22224,Distribution in the blood after 30 min of intravenous administration,,,,,,,U,Autocuration,CHEMBL628223,BAO_0000019,
11635,1,A,0,,,,22224,Distribution in the blood after 5 min of intravenous administration,,,,,,,U,Autocuration,CHEMBL628224,BAO_0000019,
11636,1,A,0,,,,22224,Distribution in the blood after 60 min of intravenous administration,,,,,,,U,Autocuration,CHEMBL628225,BAO_0000019,
11637,1,A,0,,,,22224,Distribution in the blood after 90 min of intravenous administration,,,,,,,U,Autocuration,CHEMBL628226,BAO_0000019,
11638,1,A,0,,,,22224,Distribution in the bone after 120 min of intravenous administration,,,,,,,U,Autocuration,CHEMBL628227,BAO_0000019,
11639,1,A,0,,,,22224,Distribution in the bone after 15 min of intravenous administration,,,,,,,U,Autocuration,CHEMBL875481,BAO_0000019,
11640,1,A,0,,,,22224,Distribution in the bone after 30 min of intravenous administration,,,,,,,U,Autocuration,CHEMBL628228,BAO_0000019,
11641,1,A,0,,,,22224,Distribution in the bone after 5 min of intravenous administration,,,,,,,U,Autocuration,CHEMBL628229,BAO_0000019,
11642,1,A,0,,,,22224,Distribution in the bone after 60 min of intravenous administration,,,,,,,U,Autocuration,CHEMBL628230,BAO_0000019,
11643,1,A,0,,,,22224,Distribution in the bone after 90 min of intravenous administration,,,,,,,U,Autocuration,CHEMBL628231,BAO_0000019,
11644,1,A,0,,,,22224,Distribution in the heart after 120 min of intravenous administration,,,,,,,U,Autocuration,CHEMBL628232,BAO_0000019,
11645,1,A,0,,,,22224,Distribution in the heart after 15 min of intravenous administration,,,,,,,U,Autocuration,CHEMBL628233,BAO_0000019,
11646,1,A,0,,,,22224,Distribution in the heart after 30 min of intravenous administration,,,,,,,U,Autocuration,CHEMBL628234,BAO_0000019,
11647,1,A,0,,,,22224,Distribution in the heart after 5 min of intravenous administration,,,,,,,U,Autocuration,CHEMBL628235,BAO_0000019,
11648,1,A,0,,,,22224,Distribution in the heart after 60 min of intravenous administration,,,,,,,U,Autocuration,CHEMBL628236,BAO_0000019,
11649,1,A,0,,,,22224,Distribution in the heart after 90 min of intravenous administration,,,,,,,U,Autocuration,CHEMBL628237,BAO_0000019,
11650,1,A,0,,,,22224,Distribution in the kidneys after 120 min of intravenous administration,,,,,,,U,Autocuration,CHEMBL628238,BAO_0000019,
11651,1,A,0,,,,22224,Distribution in the kidneys after 15 min of intravenous administration,,,,,,,U,Autocuration,CHEMBL628239,BAO_0000019,
11652,1,A,0,,,,22224,Distribution in the kidneys after 30 min of intravenous administration,,,,,,,U,Autocuration,CHEMBL628240,BAO_0000019,
11653,1,A,0,,,,22224,Distribution in the kidneys after 5 min of intravenous administration,,,,,,,U,Autocuration,CHEMBL628241,BAO_0000019,
11654,1,A,0,,,,22224,Distribution in the kidneys after 60 min of intravenous administration,,,,,,,U,Autocuration,CHEMBL628242,BAO_0000019,
11655,1,A,0,,,,22224,Distribution in the kidneys after 90 min of intravenous administration,,,,,,,U,Autocuration,CHEMBL875482,BAO_0000019,
11656,1,A,0,,,,22224,Distribution in the liver after 120 min of intravenous administration,,,,,,,U,Autocuration,CHEMBL628243,BAO_0000019,
11657,1,A,0,,,,22224,Distribution in the liver after 15 min of intravenous administration,,,,,,,U,Autocuration,CHEMBL628244,BAO_0000019,
11658,1,A,0,,,,22224,Distribution in the liver after 30 min of intravenous administration,,,,,,,U,Autocuration,CHEMBL628245,BAO_0000019,
11659,1,A,0,,,,22224,Distribution in the liver after 5 min of intravenous administration,,,,,,,U,Autocuration,CHEMBL628246,BAO_0000019,
11660,1,A,0,,,,22224,Distribution in the liver after 60 min of intravenous administration,,,,,,,U,Autocuration,CHEMBL628247,BAO_0000019,
11661,1,A,0,,,,22224,Distribution in the liver after 90 min of intravenous administration,,,,,,,U,Autocuration,CHEMBL628248,BAO_0000019,
11662,1,A,0,,,,22224,Distribution in the lung after 120 min of intravenous administration,,,,,,,U,Autocuration,CHEMBL628249,BAO_0000019,
11663,1,A,1,,,,50594,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625452,BAO_0000218,
11664,1,A,1,,,,50594,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625453,BAO_0000218,
11665,1,A,1,,,,50594,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625454,BAO_0000218,
11666,1,A,1,,,,50594,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623844,BAO_0000218,
11667,1,A,1,,,,50597,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623845,BAO_0000218,
11668,1,A,1,,,,50597,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623846,BAO_0000218,
11669,1,A,0,,,,22224,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,,,,,,,U,Autocuration,CHEMBL623847,BAO_0000218,
11670,1,A,1,,,,100710,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL623848,BAO_0000218,
11671,1,A,1,,,,100710,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL623849,BAO_0000218,
11672,1,A,1,,,,100710,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL623850,BAO_0000218,
11673,1,A,1,,,,100710,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL623851,BAO_0000218,
11674,1,A,0,,,,22224,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL623852,BAO_0000218,
11675,1,A,1,,,,50506,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,,Mustela putorius furo,,,,9669.0,N,Intermediate,CHEMBL624551,BAO_0000218,
11676,1,A,1,,,,50506,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",,Mustela putorius furo,,,,9669.0,N,Intermediate,CHEMBL624552,BAO_0000218,
11677,1,A,0,,,,22224,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL624553,BAO_0000218,
11678,1,A,0,,,,22224,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL624554,BAO_0000218,
11679,1,A,1,,,,50597,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624555,BAO_0000218,
11680,1,A,1,,,,50597,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624741,BAO_0000218,
11681,1,A,1,,,,50588,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624742,BAO_0000218,
11682,1,A,1,,,,100712,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",,Cricetinae,,,,10026.0,N,Intermediate,CHEMBL624743,BAO_0000218,
11683,1,A,1,,,,50597,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL877606,BAO_0000218,
11684,1,A,0,,,,22224,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,,,,,,,U,Autocuration,CHEMBL624744,BAO_0000218,
11685,1,A,0,,,,22224,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,178.0,,,,,,U,Autocuration,CHEMBL624745,BAO_0000218,
11686,1,A,0,,,,22224,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,178.0,,,,,,U,Autocuration,CHEMBL624746,BAO_0000218,
11687,1,A,0,,,,22224,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,178.0,,,,,,U,Autocuration,CHEMBL624747,BAO_0000218,
11688,1,A,0,,,,22224,Oral absorption expressed as Area under curve was determined,,,,,,,U,Autocuration,CHEMBL624748,BAO_0000019,
11689,1,A,1,,,,50588,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622504,BAO_0000218,
11690,1,A,1,,,,50588,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622505,BAO_0000218,
11691,1,A,1,,,,100712,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",,Cricetinae,,,,10026.0,N,Intermediate,CHEMBL622506,BAO_0000218,
11692,1,A,1,,,,100712,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",,Cricetinae,,,,10026.0,N,Intermediate,CHEMBL622507,BAO_0000218,
11693,1,A,1,,,,50597,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622508,BAO_0000218,
11694,1,A,0,,,,22224,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,,,,,,,U,Autocuration,CHEMBL622509,BAO_0000019,
11695,1,A,1,,,,50597,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622510,BAO_0000218,
11696,1,A,1,,,,50597,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622511,BAO_0000218,
11697,1,A,1,,,,100710,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL622512,BAO_0000218,
11698,1,A,1,,,,100710,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL622513,BAO_0000218,
11699,1,A,1,,,,100710,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL622514,BAO_0000218,
11700,1,A,1,,,,50588,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622515,BAO_0000218,
11701,1,A,1,,,,50588,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622516,BAO_0000218,
11702,1,A,1,,,,50597,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622517,BAO_0000218,
11703,1,A,1,,,,50597,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622518,BAO_0000218,
11704,1,A,1,,,,50597,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622519,BAO_0000218,
11705,1,A,1,,,In vivo,50597,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622520,BAO_0000218,
11706,1,A,1,,,In vivo,50597,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622521,BAO_0000218,
11707,1,A,1,,,In vivo,50594,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,14.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625113,BAO_0000218,
11708,1,A,1,,,In vivo,50597,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,14.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625114,BAO_0000218,
11709,1,A,1,,,In vivo,50597,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,14.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874397,BAO_0000218,
11710,1,A,1,,,In vivo,50597,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625115,BAO_0000218,
11711,1,A,1,,,In vivo,50597,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625116,BAO_0000218,
11712,1,A,1,,,In vivo,50597,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623932,BAO_0000218,
11713,1,A,1,,,In vivo,50597,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,2435.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623933,BAO_0000218,
11714,1,A,1,,,In vivo,50597,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,2435.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623934,BAO_0000218,
11715,1,A,1,,,In vivo,50597,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,2435.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623935,BAO_0000218,
11716,1,A,1,,,In vivo,50597,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623936,BAO_0000218,
11717,1,A,1,,,In vivo,50597,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623937,BAO_0000218,
11718,1,A,1,,,In vivo,50597,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623938,BAO_0000218,
11719,1,A,1,,,,50594,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623939,BAO_0000218,
11720,1,A,1,,,,50594,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623940,BAO_0000218,
11721,1,A,1,,,,50594,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623941,BAO_0000218,
11722,1,A,1,,,,50594,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627216,BAO_0000218,
11723,1,A,1,,,,50594,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623942,BAO_0000218,
11724,1,A,1,,,,50594,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618793,BAO_0000218,
11725,1,A,1,,,,50594,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618794,BAO_0000218,
11726,1,A,1,,,,50594,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618795,BAO_0000218,
11727,1,A,1,,,,50594,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618796,BAO_0000218,
11728,1,A,1,,,,50594,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618797,BAO_0000218,
11729,1,A,1,,,,50594,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618798,BAO_0000218,
11730,1,A,1,,,,50594,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618799,BAO_0000218,
11731,1,A,1,,,,50594,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618800,BAO_0000218,
11732,1,A,1,,,,50594,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618801,BAO_0000218,
11733,1,A,1,,,,50594,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618802,BAO_0000218,
11734,1,A,1,,,,50594,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618803,BAO_0000218,
11735,1,A,1,,,,50594,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618804,BAO_0000218,
11736,1,A,1,,,,50594,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618805,BAO_0000218,
11737,1,A,1,,,,50594,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618806,BAO_0000218,
11738,1,A,1,,,,50594,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618807,BAO_0000218,
11739,1,A,1,,,,50594,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618808,BAO_0000218,
11740,1,A,1,,,,50594,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618809,BAO_0000218,
11741,1,A,1,,,,50594,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,2385.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618810,BAO_0000218,
11742,1,A,1,,,,50594,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,2385.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618811,BAO_0000218,
11743,1,A,1,,,,50594,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,2385.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL875844,BAO_0000218,
11744,1,A,1,,,,50594,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,2385.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618812,BAO_0000218,
11745,1,A,1,,,,50594,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,2385.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618813,BAO_0000218,
11746,1,A,1,,,,50594,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618814,BAO_0000218,
11747,1,A,1,,,,50594,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618815,BAO_0000218,
11748,1,A,1,,,,50594,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618816,BAO_0000218,
11749,1,A,1,,,,50594,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL618817,BAO_0000218,
11750,1,A,1,,,,50594,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL620544,BAO_0000218,
11751,1,A,1,,,In vivo,50597,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626230,BAO_0000218,
11752,1,A,1,,,In vivo,50597,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626231,BAO_0000218,
11753,1,A,1,,,In vivo,50597,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626232,BAO_0000218,
11754,1,A,1,,,In vivo,50588,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626233,BAO_0000218,
11755,1,A,1,,,In vivo,50597,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626234,BAO_0000218,
11756,1,A,1,,,In vivo,50597,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875341,BAO_0000218,
11757,1,A,1,,,In vivo,50587,The maximum plasma concentration (100 mg/kg) administered orally in human,1969.0,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL626235,BAO_0000218,
11758,1,A,0,,,In vivo,22224,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,1969.0,Callithrix,,,,9481.0,U,Autocuration,CHEMBL626236,BAO_0000218,
11759,1,A,0,,,In vivo,22224,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,1969.0,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL626237,BAO_0000218,
11760,1,A,1,,,In vivo,50588,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626238,BAO_0000218,
11761,1,A,1,,,In vivo,50587,The maximum plasma concentration (200 mg/kg) administered orally in human,1969.0,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL622412,BAO_0000218,
11762,1,A,1,,,In vivo,50597,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623114,BAO_0000218,
11763,1,A,0,,,In vivo,22224,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,1969.0,Callithrix,,,,9481.0,U,Autocuration,CHEMBL623115,BAO_0000218,
11764,1,A,0,,,In vivo,22224,The maximum plasma concentration (25 mg/kg) administered orally in monkey,1969.0,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL623116,BAO_0000218,
11765,1,A,0,,,In vivo,22224,The maximum plasma concentration (30 mg/kg) administered orally in dog,1969.0,Canis lupus familiaris,,,,9615.0,U,Autocuration,CHEMBL623117,BAO_0000218,
11766,1,A,1,,,In vivo,50587,The maximum plasma concentration (400 mg/kg) administered orally in human,1969.0,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL623118,BAO_0000218,
11767,1,A,1,,,In vivo,50597,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623119,BAO_0000218,
11768,1,A,1,,,In vivo,50597,The maximum plasma concentration (50 mg/kg) administered orally in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623120,BAO_0000218,
11769,1,A,1,,,In vivo,50587,The maximum plasma concentration (800 mg/kg) administered orally in human,1969.0,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL623286,BAO_0000218,
11770,1,A,1,,,In vivo,50597,The maximum plasma concentration was measured on rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623287,BAO_0000218,
11771,1,A,1,,,In vivo,50597,The maximum plasma concentration was measured on rats after oral administration,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623288,BAO_0000218,
11772,1,A,1,,,In vivo,50597,Plasma drug Cmax in rat (PO dose),1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623289,BAO_0000218,
11773,1,A,0,,,In vivo,22224,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,,,,,,,U,Autocuration,CHEMBL623290,BAO_0000218,
11774,1,A,1,,,In vivo,50588,maximum Plasma concentration in Dog was determined after Peroral administration,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623291,BAO_0000218,
11775,1,A,1,,,In vivo,50597,maximum Plasma concentration in Rats was determined after Peroral administration,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623292,BAO_0000218,
11776,1,A,1,,,In vivo,50588,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623293,BAO_0000218,
11777,1,A,0,,,In vivo,22224,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,1969.0,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL623294,BAO_0000218,
11778,1,A,1,,,In vivo,50597,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623295,BAO_0000218,
11779,1,A,1,,,In vivo,50594,maximum concentration was measured when administered through oral route in mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623296,BAO_0000218,
11780,1,A,1,,,,50594,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL875349,BAO_0000218,
11781,1,A,0,,,,22224,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL623297,BAO_0000019,
11782,1,A,0,,,,22224,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL623298,BAO_0000019,
11783,1,A,0,,,,22224,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL623299,BAO_0000019,
11784,1,A,1,,,,50597,Pharmacokinetic parameter was evaluated in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623300,BAO_0000218,
11785,1,A,1,,,,50594,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623301,BAO_0000218,
11786,1,A,1,,,,50594,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623302,BAO_0000218,
11787,1,A,1,,,,50594,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623303,BAO_0000218,
11788,1,A,1,,,,50594,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623304,BAO_0000218,
11789,1,A,1,,,,50594,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623305,BAO_0000218,
11790,1,A,1,,,,50597,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623306,BAO_0000218,
11791,1,A,1,,,,50597,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623307,BAO_0000218,
11792,1,A,1,,,,50597,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623308,BAO_0000218,
11793,1,A,1,,,,50594,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623309,BAO_0000218,
11794,1,A,1,,,,50594,Plasma Concentration after 120 min of oral administration to mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623310,BAO_0000218,
11795,1,A,1,,,,50594,Plasma Concentration after 30 min of oral administration to mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623311,BAO_0000218,
11796,1,A,1,,,,100710,Plasma Concentration after 60 min of oral administration to mice,,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL623312,BAO_0000218,
11797,1,A,1,,,,50594,Plasma Concentration after 60 min of oral administration to mice; Not determined,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL875350,BAO_0000218,
11798,1,A,1,,,,50594,Plasma Concentration after 90 min of oral administration to mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL628635,BAO_0000218,
11799,1,A,1,,,,50597,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628636,BAO_0000218,
11800,1,A,1,,,,50597,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628637,BAO_0000218,
11801,1,A,1,,,,50597,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628058,BAO_0000218,
11802,1,A,1,,,,50597,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628059,BAO_0000218,
11803,1,A,1,,,,50597,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628060,BAO_0000218,
11804,1,A,0,,,,22224,Distribution in the lung after 15 min of intravenous administration,,,,,,,U,Autocuration,CHEMBL628061,BAO_0000019,
11805,1,A,0,,,,22224,Distribution in the lung after 30 min of intravenous administration,,,,,,,U,Autocuration,CHEMBL628062,BAO_0000019,
11806,1,A,0,,,,22224,Distribution in the lung after 5 min of intravenous administration,,,,,,,U,Autocuration,CHEMBL628063,BAO_0000019,
11807,1,A,0,,,,22224,Distribution in the lung after 60 min of intravenous administration,,,,,,,U,Autocuration,CHEMBL628064,BAO_0000019,
11808,1,A,0,,,,22224,Distribution in the lung after 90 min of intravenous administration,,,,,,,U,Autocuration,CHEMBL628065,BAO_0000019,
11809,1,A,0,,,,22224,Distribution in the muscle after 120 min of intravenous administration,2385.0,,,,,,U,Autocuration,CHEMBL628066,BAO_0000019,
11810,1,A,0,,,,22224,Distribution in the muscle after 15 min of intravenous administration,2385.0,,,,,,U,Autocuration,CHEMBL628067,BAO_0000019,
11811,1,A,1,,,,50594,Distribution in the muscle after 30 min of intravenous administration,2385.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL874646,BAO_0000218,
11812,1,A,0,,,,22224,Distribution in the muscle after 5 min of intravenous administration,2385.0,,,,,,U,Autocuration,CHEMBL628068,BAO_0000019,
11813,1,A,0,,,,22224,Distribution in the muscle after 60 min of intravenous administration,2385.0,,,,,,U,Autocuration,CHEMBL628069,BAO_0000019,
11814,1,A,0,,,,22224,Distribution in the muscle after 90 min of intravenous administration,2385.0,,,,,,U,Autocuration,CHEMBL628070,BAO_0000019,
11815,1,A,0,,,,22224,Distribution in the spleen after 120 min of intravenous administration,2106.0,,,,,,U,Autocuration,CHEMBL628071,BAO_0000019,
11816,1,A,0,,,,22224,Distribution in the spleen after 15 min of intravenous administration,2106.0,,,,,,U,Autocuration,CHEMBL628072,BAO_0000019,
11817,1,A,0,,,,22224,Distribution in the spleen after 30 min of intravenous administration,2106.0,,,,,,U,Autocuration,CHEMBL628073,BAO_0000019,
11818,1,A,0,,,,22224,Distribution in the spleen after 5 min of intravenous administration,2106.0,,,,,,U,Autocuration,CHEMBL628074,BAO_0000019,
11819,1,A,0,,,,22224,Distribution in the spleen after 60 min of intravenous administration,2106.0,,,,,,U,Autocuration,CHEMBL628075,BAO_0000019,
11820,1,A,0,,,,22224,Distribution in the spleen after 90 min of intravenous administration,2106.0,,,,,,U,Autocuration,CHEMBL628076,BAO_0000019,
11821,1,A,1,,,,50597,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,1235.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628077,BAO_0000218,
11822,1,A,1,,,,50597,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628078,BAO_0000218,
11823,1,A,1,,,,50597,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628079,BAO_0000218,
11824,1,A,1,,,,50597,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,992.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628080,BAO_0000218,
11825,1,A,1,,,,50597,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628081,BAO_0000218,
11826,1,A,1,,,,50597,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,1235.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628082,BAO_0000218,
11827,1,A,1,,,,50597,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874647,BAO_0000218,
11828,1,A,1,,,,50597,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626406,BAO_0000218,
11829,1,A,1,,,,50597,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,992.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626407,BAO_0000218,
11830,1,A,1,,,,50597,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626408,BAO_0000218,
11831,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626409,BAO_0000218,
11832,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626410,BAO_0000218,
11833,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626411,BAO_0000218,
11834,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626412,BAO_0000218,
11835,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626413,BAO_0000218,
11836,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626414,BAO_0000218,
11837,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626415,BAO_0000218,
11838,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626416,BAO_0000218,
11839,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627062,BAO_0000218,
11840,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627063,BAO_0000218,
11841,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627064,BAO_0000218,
11842,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627227,BAO_0000218,
11843,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627228,BAO_0000218,
11844,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627229,BAO_0000218,
11845,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625792,BAO_0000218,
11846,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625793,BAO_0000218,
11847,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625794,BAO_0000218,
11848,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625795,BAO_0000218,
11849,1,A,1,,,,50594,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625796,BAO_0000218,
11850,1,A,1,,,,50588,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625797,BAO_0000218,
11851,1,A,1,,,,50588,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625798,BAO_0000218,
11852,1,A,0,,,,22224,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,,,,,,U,Autocuration,CHEMBL875613,BAO_0000218,
11853,1,A,0,,,,22224,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,,,,,,U,Autocuration,CHEMBL625799,BAO_0000218,
11854,1,A,0,,,,22224,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,,,,,,,U,Autocuration,CHEMBL625800,BAO_0000218,
11855,1,A,0,,,,22224,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,,,,,,,U,Autocuration,CHEMBL625801,BAO_0000218,
11856,1,A,0,,,,22224,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,,,,,,,U,Autocuration,CHEMBL625802,BAO_0000218,
11857,1,A,0,,,,22224,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,,,,,,,U,Autocuration,CHEMBL625803,BAO_0000218,
11858,1,A,0,,,,22224,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,,,,,,,U,Autocuration,CHEMBL625804,BAO_0000019,
11859,1,A,0,,,,22224,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,,,,,,,U,Autocuration,CHEMBL622530,BAO_0000218,
11860,1,A,1,,,,50594,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622531,BAO_0000218,
11861,1,A,1,,,,50594,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622532,BAO_0000218,
11862,1,A,1,,,,50594,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623176,BAO_0000218,
11863,1,A,1,,,,50594,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623177,BAO_0000218,
11864,1,A,1,,,,50594,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623178,BAO_0000218,
11865,1,A,1,,,,50594,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623179,BAO_0000218,
11866,1,A,1,,,,50594,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623180,BAO_0000218,
11867,1,A,1,,,,50594,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623181,BAO_0000218,
11868,1,A,1,,,,50594,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624131,BAO_0000218,
11869,1,A,1,,,,50594,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624132,BAO_0000218,
11870,1,A,1,,,,50594,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624133,BAO_0000218,
11871,1,A,1,,,,50594,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624846,BAO_0000218,
11872,1,A,1,,,,50594,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624847,BAO_0000218,
11873,1,A,1,,,,50594,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL624848,BAO_0000218,
11874,1,A,1,,,,50594,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625012,BAO_0000218,
11875,1,A,1,,,,50594,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625013,BAO_0000218,
11876,1,A,1,,,,50594,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625014,BAO_0000218,
11877,1,A,1,,,,50594,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625015,BAO_0000218,
11878,1,A,1,,,,50594,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625016,BAO_0000218,
11879,1,A,1,,,,50594,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625017,BAO_0000218,
11880,1,A,1,,,,50594,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625018,BAO_0000218,
11881,1,A,1,,,,50594,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625019,BAO_0000218,
11882,1,A,1,,,,50594,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625020,BAO_0000218,
11883,1,A,1,,,,50594,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625021,BAO_0000218,
11884,1,A,1,,,,50597,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625022,BAO_0000218,
11885,1,A,1,,,,50594,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625023,BAO_0000218,
11886,1,A,1,,,,100710,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL625024,BAO_0000218,
11887,1,A,1,,,,100710,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL627626,BAO_0000218,
11888,1,A,0,,,,22224,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,955.0,,,,,,U,Autocuration,CHEMBL627627,BAO_0000218,
11889,1,A,0,,,,22224,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,1977.0,,,,,,U,Autocuration,CHEMBL627628,BAO_0000218,
11890,1,A,0,,,,22224,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,955.0,,,,,,U,Autocuration,CHEMBL627629,BAO_0000218,
11891,1,A,0,,,,22224,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,1977.0,,,,,,U,Autocuration,CHEMBL627630,BAO_0000218,
11892,1,A,0,,,,22224,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),,,,,,,U,Autocuration,CHEMBL627631,BAO_0000019,
11893,1,A,0,,,,22224,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),,,,,,,U,Autocuration,CHEMBL629515,BAO_0000218,
11894,1,A,1,,,,50594,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL629516,BAO_0000218,
11895,1,A,1,,,,50594,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL629517,BAO_0000218,
11896,1,A,1,,,,50594,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL629518,BAO_0000218,
11897,1,A,1,,,,50594,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL877499,BAO_0000218,
11898,1,A,1,,,,50594,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL629519,BAO_0000218,
11899,1,A,1,,,,50594,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL629520,BAO_0000218,
11900,1,A,1,,,,50594,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL629521,BAO_0000218,
11901,1,A,1,,,,50594,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL629522,BAO_0000218,
11902,1,A,1,,,,50594,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL629523,BAO_0000218,
11903,1,A,1,,,,50594,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL629524,BAO_0000218,
11904,1,A,1,,,,50594,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL629525,BAO_0000218,
11905,1,A,1,,,,50594,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL629526,BAO_0000218,
11906,1,A,1,,,,50594,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL629527,BAO_0000218,
11907,1,A,1,,,,50594,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL629528,BAO_0000218,
11908,1,A,1,,,,50594,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL629529,BAO_0000218,
11909,1,A,1,,,,50594,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL629530,BAO_0000218,
11910,1,A,1,,,,50594,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL629531,BAO_0000218,
11911,1,A,1,,,,50594,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL628656,BAO_0000218,
11912,1,A,1,,,,50594,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL628657,BAO_0000218,
11913,1,A,1,,,In vivo,50597,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628658,BAO_0000218,
11914,1,A,1,,,In vivo,50597,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628659,BAO_0000218,
11915,1,A,1,,,In vivo,50597,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL877500,BAO_0000218,
11916,1,A,1,,,In vivo,50597,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628660,BAO_0000218,
11917,1,A,1,,,In vivo,50597,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628661,BAO_0000218,
11918,1,A,1,,,In vivo,50597,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628662,BAO_0000218,
11919,1,A,1,,,In vivo,50597,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628663,BAO_0000218,
11920,1,A,1,,,In vivo,50597,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628664,BAO_0000218,
11921,1,A,1,,,In vivo,50597,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628665,BAO_0000218,
11922,1,A,1,,,In vivo,50597,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628666,BAO_0000218,
11923,1,A,1,,,In vivo,50597,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628667,BAO_0000218,
11924,1,A,1,,,In vivo,50597,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628668,BAO_0000218,
11925,1,A,1,,,In vivo,50597,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628669,BAO_0000218,
11926,1,A,1,,,In vivo,50597,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628670,BAO_0000218,
11927,1,A,1,,,In vivo,50597,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628671,BAO_0000218,
11928,1,A,1,,,In vivo,50597,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628672,BAO_0000218,
11929,1,A,1,,,In vivo,50597,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630300,BAO_0000218,
11930,1,A,1,,,In vivo,50597,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629787,BAO_0000218,
11931,1,A,1,,,In vivo,50597,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629788,BAO_0000218,
11932,1,A,1,,,In vivo,50597,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629789,BAO_0000218,
11933,1,A,1,,,In vivo,50597,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629790,BAO_0000218,
11934,1,A,1,,,In vivo,50597,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629791,BAO_0000218,
11935,1,A,1,,,In vivo,50597,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629792,BAO_0000218,
11936,1,A,1,,,In vivo,50597,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629793,BAO_0000218,
11937,1,A,1,,,In vivo,50597,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629794,BAO_0000218,
11938,1,A,1,,,,50597,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874459,BAO_0000218,
11939,1,A,1,,,,50597,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629795,BAO_0000218,
11940,1,A,1,,,,50597,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629796,BAO_0000218,
11941,1,A,1,,,,50597,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629797,BAO_0000218,
11942,1,A,1,,,,50597,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629798,BAO_0000218,
11943,1,A,1,,,In vivo,50597,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,2369.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629799,BAO_0000218,
11944,1,A,1,,,In vivo,50597,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,2369.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629800,BAO_0000218,
11945,1,A,1,,,In vivo,50597,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,2369.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629801,BAO_0000218,
11946,1,A,1,,,In vivo,50597,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,2369.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629802,BAO_0000218,
11947,1,A,1,,,In vivo,50597,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,2369.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629803,BAO_0000218,
11948,1,A,1,,,In vivo,50597,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629804,BAO_0000218,
11949,1,A,1,,,In vivo,50597,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629805,BAO_0000218,
11950,1,A,1,,,In vivo,50597,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629806,BAO_0000218,
11951,1,A,1,,,In vivo,50597,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629807,BAO_0000218,
11952,1,A,1,,,In vivo,50597,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629808,BAO_0000218,
11953,1,A,1,,,In vivo,50597,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629809,BAO_0000218,
11954,1,A,1,,,In vivo,50597,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629810,BAO_0000218,
11955,1,A,1,,,In vivo,50597,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629811,BAO_0000218,
11956,1,A,1,,,In vivo,50597,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629812,BAO_0000218,
11957,1,A,1,,,In vivo,50597,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629813,BAO_0000218,
11958,1,A,1,,,In vivo,50597,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874460,BAO_0000218,
11959,1,A,1,,,In vivo,50597,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629814,BAO_0000218,
11960,1,A,1,,,In vivo,50597,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629815,BAO_0000218,
11961,1,A,1,,,In vivo,50597,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629816,BAO_0000218,
11962,1,A,1,,,In vivo,50597,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629817,BAO_0000218,
11963,1,A,1,,,In vivo,50597,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626643,BAO_0000218,
11964,1,A,1,,,In vivo,50597,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626644,BAO_0000218,
11965,1,A,1,,,In vivo,50597,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626806,BAO_0000218,
11966,1,A,1,,,In vivo,50597,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626807,BAO_0000218,
11967,1,A,1,,,In vivo,50597,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627261,BAO_0000218,
11968,1,A,1,,,In vivo,50597,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627262,BAO_0000218,
11969,1,A,1,,,In vivo,50597,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627263,BAO_0000218,
11970,1,A,1,,,In vivo,50597,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627264,BAO_0000218,
11971,1,A,1,,,In vivo,50597,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627265,BAO_0000218,
11972,1,A,1,,,In vivo,50597,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627266,BAO_0000218,
11973,1,A,1,,,In vivo,50597,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627267,BAO_0000218,
11974,1,A,1,,,In vivo,50597,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627268,BAO_0000218,
11975,1,A,1,,,In vivo,50597,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627269,BAO_0000218,
11976,1,A,1,,,In vivo,50597,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627270,BAO_0000218,
11977,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627271,BAO_0000218,
11978,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627946,BAO_0000218,
11979,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875472,BAO_0000218,
11980,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627947,BAO_0000218,
11981,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627948,BAO_0000218,
11982,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628113,BAO_0000218,
11983,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628114,BAO_0000218,
11984,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628115,BAO_0000218,
11985,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628116,BAO_0000218,
11986,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628117,BAO_0000218,
11987,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628118,BAO_0000218,
11988,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628119,BAO_0000218,
11989,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628120,BAO_0000218,
11990,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628121,BAO_0000218,
11991,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628122,BAO_0000218,
11992,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627297,BAO_0000218,
11993,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627298,BAO_0000218,
11994,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627299,BAO_0000218,
11995,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627300,BAO_0000218,
11996,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627301,BAO_0000218,
11997,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627302,BAO_0000218,
11998,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627303,BAO_0000218,
11999,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627304,BAO_0000218,
12000,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627305,BAO_0000218,
12001,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627306,BAO_0000218,
12002,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623982,BAO_0000218,
12003,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623983,BAO_0000218,
12004,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623984,BAO_0000218,
12005,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623985,BAO_0000218,
12006,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623986,BAO_0000218,
12007,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623987,BAO_0000218,
12008,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623988,BAO_0000218,
12009,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623989,BAO_0000218,
12010,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622215,BAO_0000218,
12011,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622216,BAO_0000218,
12012,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL877481,BAO_0000218,
12013,1,A,0,,,,22224,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),,,,,,,U,Autocuration,CHEMBL622217,BAO_0000218,
12014,1,A,1,,,,50594,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622218,BAO_0000218,
12015,1,A,1,,,,50597,Pharmacokinetic profile AUC was evaluated in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622219,BAO_0000218,
12016,1,A,0,,,,22224,Pharmacokinetic property (Area under curve),,,,,,,U,Autocuration,CHEMBL622220,BAO_0000019,
12017,1,A,1,,,,50588,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622221,BAO_0000218,
12018,1,A,1,,,,50594,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622222,BAO_0000218,
12019,1,A,1,,,,50588,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622223,BAO_0000218,
12020,1,A,1,,,,50594,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622224,BAO_0000218,
12021,1,A,0,,,,22224,Plasma concentration (AUC) was determined,,,,,,,U,Autocuration,CHEMBL622225,BAO_0000019,
12022,1,A,0,,,,22224,Plasma concentration (AUC) was determined; Not detectable,,,,,,,U,Autocuration,CHEMBL622226,BAO_0000019,
12023,1,A,1,,,,50512,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),,Cavia porcellus,,,,10141.0,N,Intermediate,CHEMBL624154,BAO_0000218,
12024,1,A,1,,,,50597,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624155,BAO_0000218,
12025,1,A,1,,,,50597,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624156,BAO_0000218,
12026,1,A,1,,,,50597,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624157,BAO_0000218,
12027,1,A,1,,,,50597,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624158,BAO_0000218,
12028,1,A,1,,,,50597,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624159,BAO_0000218,
12029,1,A,1,,,,50597,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624160,BAO_0000218,
12030,1,A,1,,,,50597,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624161,BAO_0000218,
12031,1,A,1,,,,50597,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624162,BAO_0000218,
12032,1,A,1,,,,50588,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624163,BAO_0000218,
12033,1,A,1,,,,50597,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624164,BAO_0000218,
12034,1,A,1,,,,50597,The AUC(0-infinity) values in female wistar rats.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624165,BAO_0000218,
12035,1,A,1,,,,50597,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624166,BAO_0000218,
12036,1,A,1,,,,50597,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624167,BAO_0000218,
12037,1,A,1,,,,50597,The AUC(0-t)values in female wistar rats.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624168,BAO_0000218,
12038,1,A,1,,,,50597,The Area under the concentration time curve of compound was measured on rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624169,BAO_0000218,
12039,1,A,1,,,,50587,The area under curve (100 mg/kg) administered orally in humans,,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL624170,BAO_0000218,
12040,1,A,0,,,,22224,The area under curve (12.5 mg/kg) administered intravenously in marmoset,,Callithrix,,,,9481.0,U,Autocuration,CHEMBL624171,BAO_0000218,
12041,1,A,0,,,,22224,The area under curve (12.5 mg/kg) administered intravenously in monkey,,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL624172,BAO_0000218,
12042,1,A,1,,,,50588,The area under curve (15 mg/kg) administered intravenously in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624173,BAO_0000218,
12043,1,A,1,,,,50587,The area under curve (200 mg/kg) administered orally in humans,,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL877488,BAO_0000218,
12044,1,A,1,,,,50597,The area under curve (25 mg/kg) administered intravenously in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624174,BAO_0000218,
12045,1,A,0,,,,22224,The area under curve (25 mg/kg) administered orally in marmoset,,Callithrix,,,,9481.0,U,Autocuration,CHEMBL624175,BAO_0000218,
12046,1,A,0,,,,22224,The area under curve (25 mg/kg) administered orally in monkey,,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL624176,BAO_0000218,
12047,1,A,1,,,,50588,The area under curve (30 mg/kg) administered orally in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624177,BAO_0000218,
12048,1,A,1,,,,50587,The area under curve (400 mg/kg) administered orally in humans,,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL624178,BAO_0000218,
12049,1,A,1,,,,50597,The area under curve (50 mg/kg) administered orally in fasted rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624179,BAO_0000218,
12050,1,A,1,,,,50597,The area under curve (50 mg/kg) administered orally in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627689,BAO_0000218,
12051,1,A,1,,,,50587,The area under curve (800 mg/kg) administered orally in humans,,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL627690,BAO_0000218,
12052,1,A,0,,,,22224,The compound was evaluated for area under the curve,,,,,,,U,Autocuration,CHEMBL627691,BAO_0000019,
12053,1,A,0,,,,22224,The compound was evaluated for area under the curve in marmosets,,Callithrix,,,,9481.0,U,Autocuration,CHEMBL627692,BAO_0000019,
12054,1,A,0,,,,22224,The compound was evaluated for area under the curve in marmosets,,Callithrix,,,,9481.0,U,Autocuration,CHEMBL627693,BAO_0000019,
12055,1,A,1,,,,50597,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627694,BAO_0000218,
12056,1,A,1,,,,50597,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627695,BAO_0000218,
12057,1,A,0,,,,22224,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),,,,,,,U,Autocuration,CHEMBL627696,BAO_0000218,
12058,1,A,1,,,,50597,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627697,BAO_0000218,
12059,1,A,1,,,,50597,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627698,BAO_0000218,
12060,1,A,1,,,,50597,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627699,BAO_0000218,
12061,1,A,1,,,,50597,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627700,BAO_0000218,
12062,1,A,1,,,,50597,Total drug exposure is determined after oral dosing in rats.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627701,BAO_0000218,
12063,1,A,0,,,,22224,Total drug exposure (5 mg/kg) when administered intravenously,,,,,,,U,Autocuration,CHEMBL627702,BAO_0000218,
12064,1,A,0,,,,22224,Total drug exposure (5 mg/kg) when administered orally,,,,,,,U,Autocuration,CHEMBL627703,BAO_0000218,
12065,1,A,0,,,,22224,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL626873,BAO_0000218,
12066,1,A,1,,,,50597,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629583,BAO_0000218,
12067,1,A,1,,,,50588,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL629584,BAO_0000218,
12068,1,A,1,,,,50588,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL629585,BAO_0000218,
12069,1,A,1,,,In vivo,50597,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629586,BAO_0000218,
12070,1,A,1,,,In vivo,50597,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629587,BAO_0000218,
12071,1,A,1,,,In vivo,50597,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629588,BAO_0000218,
12072,1,A,1,,,In vivo,50597,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629589,BAO_0000218,
12073,1,A,1,,,In vivo,50597,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629590,BAO_0000218,
12074,1,A,1,,,In vivo,50597,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629591,BAO_0000218,
12075,1,A,1,,,In vivo,50597,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629592,BAO_0000218,
12076,1,A,1,,,In vivo,50597,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629593,BAO_0000218,
12077,1,A,1,,,In vivo,50597,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629594,BAO_0000218,
12078,1,A,1,,,In vivo,50597,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629595,BAO_0000218,
12079,1,A,1,,,In vivo,50597,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630290,BAO_0000218,
12080,1,A,1,,,In vivo,50597,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627137,BAO_0000218,
12081,1,A,1,,,In vivo,50597,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627138,BAO_0000218,
12082,1,A,1,,,In vivo,50597,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627139,BAO_0000218,
12083,1,A,1,,,In vivo,50597,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627140,BAO_0000218,
12084,1,A,1,,,In vivo,50597,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627141,BAO_0000218,
12085,1,A,1,,,In vivo,50597,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627142,BAO_0000218,
12086,1,A,1,,,In vivo,50597,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627143,BAO_0000218,
12087,1,A,1,,,In vivo,50597,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874449,BAO_0000218,
12088,1,A,1,,,In vivo,50597,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627144,BAO_0000218,
12089,1,A,1,,,In vivo,50597,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627145,BAO_0000218,
12090,1,A,1,,,In vivo,50597,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627146,BAO_0000218,
12091,1,A,1,,,In vivo,50597,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627147,BAO_0000218,
12092,1,A,1,,,In vivo,50597,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627148,BAO_0000218,
12093,1,A,1,,,In vivo,50597,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627149,BAO_0000218,
12094,1,A,1,,,In vivo,50597,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632160,BAO_0000218,
12095,1,A,1,,,In vivo,50597,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632161,BAO_0000218,
12096,1,A,1,,,In vivo,50597,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632162,BAO_0000218,
12097,1,A,1,,,In vivo,50597,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632163,BAO_0000218,
12098,1,A,1,,,In vivo,50597,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874469,BAO_0000218,
12099,1,A,1,,,In vivo,50597,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627182,BAO_0000218,
12100,1,A,1,,,In vivo,50597,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627183,BAO_0000218,
12101,1,A,1,,,In vivo,50597,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627184,BAO_0000218,
12102,1,A,1,,,In vivo,50597,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627185,BAO_0000218,
12103,1,A,1,,,In vivo,50597,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627186,BAO_0000218,
12104,1,A,1,,,In vivo,50597,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627187,BAO_0000218,
12105,1,A,1,,,In vivo,50597,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627188,BAO_0000218,
12106,1,A,1,,,In vivo,50597,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627189,BAO_0000218,
12107,1,A,1,,,In vivo,50597,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627190,BAO_0000218,
12108,1,A,1,,,In vivo,50597,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627191,BAO_0000218,
12109,1,A,1,,,In vivo,50597,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627192,BAO_0000218,
12110,1,A,1,,,In vivo,50597,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627193,BAO_0000218,
12111,1,A,1,,,In vivo,50597,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874590,BAO_0000218,
12112,1,A,1,,,In vivo,50597,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627194,BAO_0000218,
12113,1,A,1,,,In vivo,50597,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627195,BAO_0000218,
12114,1,A,1,,,In vivo,50597,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,992.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627196,BAO_0000218,
12115,1,A,1,,,In vivo,50597,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,992.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627197,BAO_0000218,
12116,1,A,1,,,In vivo,50597,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,992.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627198,BAO_0000218,
12117,1,A,1,,,In vivo,50597,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,992.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627199,BAO_0000218,
12118,1,A,1,,,In vivo,50597,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,992.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627200,BAO_0000218,
12119,1,A,1,,,In vivo,50597,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627201,BAO_0000218,
12120,1,A,1,,,In vivo,50597,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627202,BAO_0000218,
12121,1,A,1,,,In vivo,50597,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627203,BAO_0000218,
12122,1,A,1,,,In vivo,50597,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627204,BAO_0000218,
12123,1,A,1,,,In vivo,50597,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627205,BAO_0000218,
12124,1,A,1,,,In vivo,50597,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627206,BAO_0000218,
12125,1,A,1,,,In vivo,50597,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627207,BAO_0000218,
12126,1,A,1,,,In vivo,50597,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627208,BAO_0000218,
12127,1,A,1,,,In vivo,50597,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627209,BAO_0000218,
12128,1,A,1,,,In vivo,50597,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627210,BAO_0000218,
12129,1,A,1,,,In vivo,50597,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627211,BAO_0000218,
12130,1,A,1,,,In vivo,50597,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627212,BAO_0000218,
12131,1,A,1,,,In vivo,50597,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,995.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627213,BAO_0000218,
12132,1,A,1,,,In vivo,50597,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,995.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626599,BAO_0000218,
12133,1,A,1,,,In vivo,50597,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,995.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626600,BAO_0000218,
12134,1,A,1,,,In vivo,50597,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,995.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626601,BAO_0000218,
12135,1,A,0,,,,22224,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,,,,,,,U,Autocuration,CHEMBL627484,BAO_0000019,
12136,1,A,1,,,,100710,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),1969.0,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL627485,BAO_0000218,
12137,1,A,1,,,,100710,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,1969.0,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL628147,BAO_0000218,
12138,1,A,1,,,,100710,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,1969.0,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL628148,BAO_0000218,
12139,1,A,1,,,,50588,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628149,BAO_0000218,
12140,1,A,1,,,,50588,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628150,BAO_0000218,
12141,1,A,1,,,,50588,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628318,BAO_0000218,
12142,1,A,1,,,,50588,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628319,BAO_0000218,
12143,1,A,1,,,,50588,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL875609,BAO_0000218,
12144,1,A,0,,,,22224,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,,,,,,,U,Autocuration,CHEMBL628320,BAO_0000019,
12145,1,A,0,,,,22224,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,,,,,,,U,Autocuration,CHEMBL628321,BAO_0000019,
12146,1,A,0,,,,22224,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,,,,,,,U,Autocuration,CHEMBL628322,BAO_0000019,
12147,1,A,0,,,,22224,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,,,,,,,U,Autocuration,CHEMBL628323,BAO_0000019,
12148,1,A,0,,,,22224,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,,,,,,,U,Autocuration,CHEMBL628324,BAO_0000019,
12149,1,A,0,,,,22224,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,,,,,,,U,Autocuration,CHEMBL628325,BAO_0000019,
12150,1,A,0,,,,22224,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,,,,,,,U,Autocuration,CHEMBL628326,BAO_0000019,
12151,1,A,1,,,,50588,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",1236.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628327,BAO_0000218,
12152,1,A,1,,,,50588,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",1236.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628328,BAO_0000218,
12153,1,A,1,,,,50588,"Concentration of compound in blood of dog 1, after administering intravenously",178.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628329,BAO_0000218,
12154,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628330,BAO_0000218,
12155,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628331,BAO_0000218,
12156,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628332,BAO_0000218,
12157,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628333,BAO_0000218,
12158,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628334,BAO_0000218,
12159,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628335,BAO_0000218,
12160,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628336,BAO_0000218,
12161,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628337,BAO_0000218,
12162,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628338,BAO_0000218,
12163,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875610,BAO_0000218,
12164,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628339,BAO_0000218,
12165,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628340,BAO_0000218,
12166,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628341,BAO_0000218,
12167,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622214,BAO_0000218,
12168,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623167,BAO_0000218,
12169,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623168,BAO_0000218,
12170,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623169,BAO_0000218,
12171,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623170,BAO_0000218,
12172,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627224,BAO_0000218,
12173,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875634,BAO_0000218,
12174,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627225,BAO_0000218,
12175,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627226,BAO_0000218,
12176,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626083,BAO_0000218,
12177,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626084,BAO_0000218,
12178,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626085,BAO_0000218,
12179,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626086,BAO_0000218,
12180,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626087,BAO_0000218,
12181,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626088,BAO_0000218,
12182,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626089,BAO_0000218,
12183,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626090,BAO_0000218,
12184,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626091,BAO_0000218,
12185,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626092,BAO_0000218,
12186,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626093,BAO_0000218,
12187,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626094,BAO_0000218,
12188,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626095,BAO_0000218,
12189,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626096,BAO_0000218,
12190,1,A,0,,,,22224,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL626097,BAO_0000218,
12191,1,A,1,,,,50597,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626098,BAO_0000218,
12192,1,A,0,,,,22224,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,1969.0,,,,,,U,Autocuration,CHEMBL626099,BAO_0000218,
12193,1,A,0,,,,22224,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,1969.0,,,,,,U,Autocuration,CHEMBL626100,BAO_0000218,
12194,1,A,1,,,,50588,AUC 0-inf in dog,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626101,BAO_0000218,
12195,1,A,1,,,,50512,AUC 0-inf in guinea pig,1969.0,Cavia porcellus,,,,10141.0,N,Intermediate,CHEMBL626102,BAO_0000218,
12196,1,A,1,,,,50588,AUC 0-t in dog,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626103,BAO_0000218,
12197,1,A,1,,,,50512,AUC 0-t in guinea pig,1969.0,Cavia porcellus,,,,10141.0,N,Intermediate,CHEMBL628391,BAO_0000218,
12198,1,A,1,,,,50597,The compound was tested for brain to plasma partition in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628392,BAO_0000218,
12199,1,A,1,,,,50597,The compound was tested for brain to plasma partition in rat.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628393,BAO_0000218,
12200,1,A,0,,,,22224,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,178.0,,,,,,U,Autocuration,CHEMBL628394,BAO_0000019,
12201,1,A,1,,,,50588,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628395,BAO_0000218,
12202,1,A,0,,,,22224,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL628396,BAO_0000218,
12203,1,A,1,,,,50592,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL628397,BAO_0000218,
12204,1,A,1,,,,50597,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628398,BAO_0000218,
12205,1,A,1,,,,50797,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,,Macaca mulatta,,,,9544.0,N,Intermediate,CHEMBL628399,BAO_0000218,
12206,1,A,1,,,,50588,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628400,BAO_0000218,
12207,1,A,1,,,,50597,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874907,BAO_0000218,
12208,1,A,0,,,,22224,Area under curve of the compound was determined,,,,,,,U,Autocuration,CHEMBL628401,BAO_0000019,
12209,1,A,0,,,,22224,AUC in monkeys at a dose of 1 mg/kg,1969.0,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL628402,BAO_0000218,
12210,1,A,1,,,,50597,AUC in rats at a dose of 1 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628403,BAO_0000218,
12211,1,A,0,,,,22224,Compound was evaluated for the overall absorbance loss at pH of 2,,,,,,,U,Autocuration,CHEMBL628404,BAO_0000019,
12212,1,A,0,,,,22224,Compound was evaluated for the overall absorbance loss at pH of 4,,,,,,,U,Autocuration,CHEMBL628405,BAO_0000019,
12213,1,A,0,,,,22224,Compound was evaluated for the overall absorbance loss at pH of 7,,,,,,,U,Autocuration,CHEMBL628406,BAO_0000019,
12214,1,A,1,,,,50597,Compound was evaluated for its absorption in the rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628407,BAO_0000218,
12215,1,A,1,,,,50597,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628408,BAO_0000218,
12216,1,A,1,,,,50597,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629171,BAO_0000218,
12217,1,A,1,,,,50597,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629172,BAO_0000218,
12218,1,A,1,,,,50597,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629173,BAO_0000218,
12219,1,A,1,,,,50597,In vitro percent permeability into rat ileum,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629174,BAO_0000218,
12220,1,A,1,,,,50597,In vitro percent permeability into rat ileum; Range is 10-17,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629175,BAO_0000218,
12221,1,A,1,,,,50597,In vitro percent permeability into rat ileum; Range is 10-18,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629176,BAO_0000218,
12222,1,A,1,,,,50597,In vitro percent permeability into rat ileum; Range is 10-19,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629177,BAO_0000218,
12223,1,A,1,,,,50597,In vitro percent permeability into rat ileum; Range is 12-15,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629178,BAO_0000218,
12224,1,A,1,,,,50597,In vitro percent permeability into rat ileum; Range is 13-19,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631869,BAO_0000218,
12225,1,A,1,,,,50597,In vitro percent permeability into rat ileum; Range is 14-17,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631870,BAO_0000218,
12226,1,A,1,,,,50597,In vitro percent permeability into rat ileum; Range is 15-18,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631871,BAO_0000218,
12227,1,A,1,,,,50597,In vitro percent permeability into rat ileum; Range is 2-5,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631872,BAO_0000218,
12228,1,A,0,,,,22224,In vitro percent permeability into rat ileum; Range is 23-42,2116.0,,,,,,U,Autocuration,CHEMBL875775,BAO_0000221,
12229,1,A,1,,,,50597,In vitro percent permeability into rat ileum; Range is 28-36,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631873,BAO_0000218,
12230,1,A,1,,,,50597,In vitro percent permeability into rat ileum; Range is 29-35,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631874,BAO_0000218,
12231,1,A,1,,,,50597,In vitro percent permeability into rat ileum; Range is 46-66,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631875,BAO_0000218,
12232,1,A,1,,,,50597,In vitro percent permeability into rat ileum; Range is 50-68,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631876,BAO_0000218,
12233,1,A,1,,,,50597,In vitro percent permeability into rat ileum; Range is 78-81,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631877,BAO_0000218,
12234,1,A,1,,,,50597,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631878,BAO_0000218,
12235,1,A,1,,,,50597,In vitro percent permeability into rat ileum; nd indicates not detected,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631879,BAO_0000218,
12236,1,A,1,,,,50597,In vitro percent permeability into rat ileum; nt indicates not detected,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631880,BAO_0000218,
12237,1,A,1,,,,50597,In vitro percent permeability into rat ileum; nt indicates not tested,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631881,BAO_0000218,
12238,1,A,1,,,,50597,Compound was tested for oral absorption in bile-duct cannulated rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631882,BAO_0000218,
12239,1,A,1,,,,50597,Compound was tested for oral absorption in bile-duct cannulated rats.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630749,BAO_0000218,
12240,1,A,1,,,,50587,Oral absorption using Caco-2 cell monolayers.,,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL630750,BAO_0000218,
12241,1,A,1,,,,50587,Percent of the drug absorbed after administration to humans was determined,,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL630253,BAO_0000218,
12242,1,A,1,,,,50597,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630254,BAO_0000218,
12243,1,A,1,,,,50597,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630255,BAO_0000218,
12244,1,A,1,,,,50597,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630256,BAO_0000218,
12245,1,A,1,,,In vivo,50597,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875781,BAO_0000218,
12246,1,A,1,,,In vivo,50597,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630257,BAO_0000218,
12247,1,A,1,,,In vivo,50597,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630258,BAO_0000218,
12248,1,A,1,,,,50597,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630259,BAO_0000218,
12249,1,A,1,,,,50597,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",2435.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630260,BAO_0000218,
12250,1,A,1,,,,50597,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",2435.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630261,BAO_0000218,
12251,1,A,1,,,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630262,BAO_0000218,
12252,1,A,1,,,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630263,BAO_0000218,
12253,1,A,1,,,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630264,BAO_0000218,
12254,1,A,1,,,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630265,BAO_0000218,
12255,1,A,1,,,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630266,BAO_0000218,
12256,1,A,1,,,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630267,BAO_0000218,
12257,1,A,1,,,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630268,BAO_0000218,
12258,1,A,1,,,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630269,BAO_0000218,
12259,1,A,1,,,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630270,BAO_0000218,
12260,1,A,1,,,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630141,BAO_0000218,
12261,1,A,1,,,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630142,BAO_0000218,
12262,1,A,1,,,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630143,BAO_0000218,
12263,1,A,1,,,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630144,BAO_0000218,
12264,1,A,1,,,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,2367.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630145,BAO_0000218,
12265,1,A,1,,,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,2367.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630146,BAO_0000218,
12266,1,A,1,,,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630147,BAO_0000218,
12267,1,A,1,,,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630148,BAO_0000218,
12268,1,A,1,,,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630149,BAO_0000218,
12269,1,A,1,,,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630150,BAO_0000218,
12270,1,A,1,,,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630151,BAO_0000218,
12271,1,A,1,,,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632031,BAO_0000218,
12272,1,A,1,,,,50597,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632032,BAO_0000218,
12273,1,A,1,,,,50597,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632033,BAO_0000218,
12274,1,A,1,,,,50597,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632034,BAO_0000218,
12275,1,A,1,,,,50597,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632035,BAO_0000218,
12276,1,A,1,,,,50597,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632036,BAO_0000218,
12277,1,A,1,,,,50597,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632037,BAO_0000218,
12278,1,A,1,,,,50597,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632038,BAO_0000218,
12279,1,A,1,,,,50597,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632039,BAO_0000218,
12280,1,A,1,,,,50597,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632040,BAO_0000218,
12281,1,A,1,,,,50597,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632041,BAO_0000218,
12282,1,A,1,,,,50588,"Concentration of compound in blood of dog 2, after administering intravenously",178.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL632042,BAO_0000218,
12283,1,A,1,,,,50588,"Concentration of compound in left ventricle of dog 1, after administering intravenously",,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL632043,BAO_0000218,
12284,1,A,1,,,,50588,"Concentration of compound in left ventricle of dog 2, after administering intravenously",,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL632044,BAO_0000218,
12285,1,A,1,,,,50588,"Concentration of compound in liver of dog 1, after administering intravenously",2107.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL632045,BAO_0000218,
12286,1,A,1,,,,50588,"Concentration of compound in liver of dog 2, after administering intravenously",2107.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL632046,BAO_0000218,
12287,1,A,1,,,,50588,"Concentration of compound in lung of dog 1, after administering intravenously",2048.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL632047,BAO_0000218,
12288,1,A,1,,,,50588,"Concentration of compound in lung of dog 2, after administering intravenously",2048.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL632048,BAO_0000218,
12289,1,A,1,,,,50588,"Concentration of compound in muscle of dog 1, after administering intravenously",2385.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL632049,BAO_0000218,
12290,1,A,1,,,,50588,"Concentration of compound in muscle of dog 2, after administering intravenously",2385.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL876418,BAO_0000218,
12291,1,A,1,,,,50588,"Concentration of compound in spleen of dog 1,after administering intravenously",2106.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL632050,BAO_0000218,
12292,1,A,1,,,,50588,"Concentration of compound in spleen of dog 2, after administering intravenously",2106.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL632051,BAO_0000218,
12293,1,F,0,,,,22224,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,,,,,,,U,Autocuration,CHEMBL632052,BAO_0000218,
12294,1,F,0,,,,22224,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,,,,,,,U,Autocuration,CHEMBL632053,BAO_0000218,
12295,1,A,0,,,,22224,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,,,,,,,U,Autocuration,CHEMBL632054,BAO_0000218,
12296,1,F,0,,,,22224,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,,,,,,,U,Autocuration,CHEMBL632055,BAO_0000218,
12297,1,F,0,,,,22224,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,,,,,,,U,Autocuration,CHEMBL631181,BAO_0000218,
12298,1,A,0,,,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,,,,,,,U,Autocuration,CHEMBL631182,BAO_0000218,
12299,1,A,0,,,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,,,,,,U,Autocuration,CHEMBL631183,BAO_0000218,
12300,1,A,0,,,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,,,,,,U,Autocuration,CHEMBL631184,BAO_0000218,
12301,1,A,0,,,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,,,,,,U,Autocuration,CHEMBL629774,BAO_0000218,
12302,1,A,0,,,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,,,,,,U,Autocuration,CHEMBL629775,BAO_0000218,
12303,1,A,0,,,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,,,,,,U,Autocuration,CHEMBL876549,BAO_0000218,
12304,1,A,0,,,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,,,,,,U,Autocuration,CHEMBL628172,BAO_0000218,
12305,1,A,0,,,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,,,,,,U,Autocuration,CHEMBL628173,BAO_0000218,
12306,1,A,0,,,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,,,,,,,U,Autocuration,CHEMBL628174,BAO_0000218,
12307,1,A,0,,,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,,,,,,,U,Autocuration,CHEMBL628175,BAO_0000218,
12308,1,A,0,,,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,,,,,,U,Autocuration,CHEMBL628176,BAO_0000218,
12309,1,A,0,,,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,,,,,,U,Autocuration,CHEMBL628177,BAO_0000218,
12310,1,A,0,,,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,,,,,,U,Autocuration,CHEMBL628178,BAO_0000218,
12311,1,A,0,,,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,,,,,,U,Autocuration,CHEMBL628179,BAO_0000218,
12312,1,A,0,,,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,,,,,,,U,Autocuration,CHEMBL628180,BAO_0000218,
12313,1,A,0,,,,22224,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,,,,,,,U,Autocuration,CHEMBL628181,BAO_0000218,
12314,1,A,0,,,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,,,,,,U,Autocuration,CHEMBL628182,BAO_0000218,
12315,1,A,0,,,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,,,,,,U,Autocuration,CHEMBL628183,BAO_0000218,
12316,1,A,0,,,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,,,,,,,U,Autocuration,CHEMBL628184,BAO_0000218,
12317,1,A,0,,,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,,,,,,U,Autocuration,CHEMBL628185,BAO_0000218,
12318,1,A,0,,,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,,,,,,U,Autocuration,CHEMBL875617,BAO_0000218,
12319,1,A,0,,,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,,,,,,,U,Autocuration,CHEMBL628186,BAO_0000218,
12320,1,A,0,,,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,,,,,,U,Autocuration,CHEMBL628187,BAO_0000218,
12321,1,A,0,,,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,,,,,,U,Autocuration,CHEMBL628188,BAO_0000218,
12322,1,A,0,,,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,,,,,,,U,Autocuration,CHEMBL628189,BAO_0000218,
12323,1,A,0,,,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,,,,,,,U,Autocuration,CHEMBL628190,BAO_0000218,
12324,1,A,0,,,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,,,,,,U,Autocuration,CHEMBL628191,BAO_0000218,
12325,1,A,0,,,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,,,,,,,U,Autocuration,CHEMBL626513,BAO_0000218,
12326,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626514,BAO_0000218,
12327,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626515,BAO_0000218,
12328,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626516,BAO_0000218,
12329,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626517,BAO_0000218,
12330,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626518,BAO_0000218,
12331,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626519,BAO_0000218,
12332,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626520,BAO_0000218,
12333,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626521,BAO_0000218,
12334,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626522,BAO_0000218,
12335,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626523,BAO_0000218,
12336,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626524,BAO_0000218,
12337,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626688,BAO_0000218,
12338,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626689,BAO_0000218,
12339,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626690,BAO_0000218,
12340,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626691,BAO_0000218,
12341,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627319,BAO_0000218,
12342,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624052,BAO_0000218,
12343,1,A,1,,,,50597,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624053,BAO_0000218,
12344,1,A,1,,,,50597,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624054,BAO_0000218,
12345,1,A,1,,,,50597,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624055,BAO_0000218,
12346,1,A,1,,,,50597,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624056,BAO_0000218,
12347,1,A,1,,,,50597,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,995.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624057,BAO_0000218,
12348,1,A,1,,,,50597,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,995.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622281,BAO_0000218,
12349,1,A,1,,,,50597,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,995.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622282,BAO_0000218,
12350,1,A,1,,,,50597,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,995.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622283,BAO_0000218,
12351,1,A,1,,,,50597,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,995.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622284,BAO_0000218,
12352,1,A,1,,,,50597,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,995.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622285,BAO_0000218,
12353,1,A,1,,,,50597,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,995.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622286,BAO_0000218,
12354,1,P,0,,,,22224,Distribution coefficient (D %) between octanol and buffer of pH 7.4,,,,,,,U,Autocuration,CHEMBL622287,BAO_0000100,
12355,1,A,1,,,,50594,Partition coefficient (logD7.4),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622288,BAO_0000218,
12356,1,A,1,,,,50594,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622289,BAO_0000218,
12357,1,A,1,,,,50594,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622290,BAO_0000218,
12358,1,A,1,,,,50594,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622291,BAO_0000218,
12359,1,A,1,,,,50594,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622292,BAO_0000218,
12360,1,A,1,,,,50594,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622293,BAO_0000218,
12361,1,A,1,,,,50594,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622294,BAO_0000218,
12362,1,A,1,,,,50594,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL622295,BAO_0000218,
12363,1,A,1,,,,50597,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622296,BAO_0000218,
12364,1,A,1,,,,50597,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874409,BAO_0000218,
12365,1,A,1,,,,50597,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622297,BAO_0000218,
12366,1,A,1,,,,50597,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622298,BAO_0000218,
12367,1,A,1,,,,50597,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622299,BAO_0000218,
12368,1,A,1,,,,50597,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622300,BAO_0000218,
12369,1,A,1,,,,50597,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622301,BAO_0000218,
12370,1,A,1,,,,50597,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622302,BAO_0000218,
12371,1,A,1,,,,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622303,BAO_0000218,
12372,1,A,1,,,,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622304,BAO_0000218,
12373,1,A,1,,,,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622305,BAO_0000218,
12374,1,A,1,,,,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622306,BAO_0000218,
12375,1,A,1,,,,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626864,BAO_0000218,
12376,1,A,1,,,,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626865,BAO_0000218,
12377,1,A,1,,,,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626866,BAO_0000218,
12378,1,A,1,,,,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626867,BAO_0000218,
12379,1,A,1,,,,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626868,BAO_0000218,
12380,1,A,1,,,,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626869,BAO_0000218,
12381,1,A,1,,,,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626870,BAO_0000218,
12382,1,A,1,,,,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626871,BAO_0000218,
12383,1,A,1,,,,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626872,BAO_0000218,
12384,1,A,1,,,,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632185,BAO_0000218,
12385,1,A,1,,,,50597,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632186,BAO_0000218,
12386,1,A,0,,,,22224,Amount of acetic acid produced by the compound,,,,,,,U,Autocuration,CHEMBL629310,BAO_0000019,
12387,1,A,0,,,,22224,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,,,,,,,U,Autocuration,CHEMBL629311,BAO_0000019,
12388,1,A,1,,,,50597,Log of (Cbrain/Cblood) in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629312,BAO_0000218,
12389,1,A,0,,,,22224,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),,,,,,,U,Autocuration,CHEMBL629313,BAO_0000221,
12390,1,A,0,,,,22224,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,,,,,,U,Autocuration,CHEMBL629314,BAO_0000221,
12391,1,A,0,,,,22224,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),,,,,,,U,Autocuration,CHEMBL629315,BAO_0000221,
12392,1,B,0,,,,22224,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),,,,,,,U,Autocuration,CHEMBL629316,BAO_0000219,
12393,1,A,0,,,,22224,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,,,,,,U,Autocuration,CHEMBL629317,BAO_0000221,
12394,1,A,0,,,,22224,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),,,,,,,U,Autocuration,CHEMBL629318,BAO_0000019,
12395,1,A,0,,,,22224,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),,,,,,,U,Autocuration,CHEMBL877497,BAO_0000019,
12396,1,A,0,,,,22224,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),,,,,,,U,Autocuration,CHEMBL629319,BAO_0000019,
12397,1,A,0,,,,22224,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,,,,,,U,Autocuration,CHEMBL629320,BAO_0000019,
12398,1,A,0,,,,22224,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),,,,,,,U,Autocuration,CHEMBL629496,BAO_0000019,
12399,1,A,0,,,,22224,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),,,,,,,U,Autocuration,CHEMBL629497,BAO_0000019,
12400,1,A,0,,,,22224,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),,,,,,,U,Autocuration,CHEMBL629498,BAO_0000019,
12401,1,A,0,,,,22224,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),,,,,,,U,Autocuration,CHEMBL629499,BAO_0000019,
12402,1,A,0,,,,22224,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),,,,,,,U,Autocuration,CHEMBL629500,BAO_0000019,
12403,1,A,0,,,,22224,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),,,,,,,U,Autocuration,CHEMBL629501,BAO_0000019,
12404,1,A,0,,,,22224,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),,,,,,,U,Autocuration,CHEMBL629502,BAO_0000019,
12405,1,F,0,,,In vivo,22224,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,,,,,,,U,Autocuration,CHEMBL629503,BAO_0000218,
12406,1,A,1,,,,50588,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL629504,BAO_0000218,
12407,1,A,0,,,,22224,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,,,,,,,U,Autocuration,CHEMBL629505,BAO_0000019,
12408,1,A,0,,,,22224,Compound was evaluated for total body clearance,,,,,,,U,Autocuration,CHEMBL629506,BAO_0000019,
12409,1,A,0,,,,22224,Compound was evaluated for volume of distribution at steady state,,,,,,,U,Autocuration,CHEMBL629507,BAO_0000019,
12410,1,A,0,,,,22224,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,,,,,,,U,Autocuration,CHEMBL877498,BAO_0000019,
12411,1,A,0,,,,22224,Percentage of the diamine which is monoprotonated at pH 7.4,,,,,,,U,Autocuration,CHEMBL629508,BAO_0000019,
12412,1,A,0,,,,22224,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,,,,,,,U,Autocuration,CHEMBL629509,BAO_0000019,
12413,1,A,1,,,,50597,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629510,BAO_0000218,
12414,1,A,1,,,,50597,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629511,BAO_0000218,
12415,1,A,1,,,,50597,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629512,BAO_0000218,
12416,1,A,1,,,,50597,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629513,BAO_0000218,
12417,1,A,1,,,,50597,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629514,BAO_0000218,
12418,1,A,1,,,,50597,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628447,BAO_0000218,
12419,1,A,1,,,,50597,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628448,BAO_0000218,
12420,1,A,1,,,,50597,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628449,BAO_0000218,
12421,1,A,1,,,,50597,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631119,BAO_0000218,
12422,1,A,1,,,,50597,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631120,BAO_0000218,
12423,1,A,1,,,,50597,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631121,BAO_0000218,
12424,1,A,1,,,,50597,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874458,BAO_0000218,
12425,1,A,1,,,,50597,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631122,BAO_0000218,
12426,1,A,1,,,,50597,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631123,BAO_0000218,
12427,1,A,1,,,,50597,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631124,BAO_0000218,
12428,1,A,1,,,,50597,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631125,BAO_0000218,
12429,1,A,1,,,,50597,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631290,BAO_0000218,
12430,1,A,1,,,,50597,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631291,BAO_0000218,
12431,1,A,1,,,,50597,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631292,BAO_0000218,
12432,1,A,1,,,,50597,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631293,BAO_0000218,
12433,1,A,1,,,,50597,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631294,BAO_0000218,
12434,1,A,1,,,,50597,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631295,BAO_0000218,
12435,1,A,1,,,,50597,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631296,BAO_0000218,
12436,1,A,1,,,,50597,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631297,BAO_0000218,
12437,1,A,0,,,,22224,Maximum biodistribution (Bmax) was determined.,,,,,,,U,Autocuration,CHEMBL631298,BAO_0000218,
12438,1,A,1,,,,50594,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL631299,BAO_0000218,
12439,1,A,1,,,,50594,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL631300,BAO_0000218,
12440,1,A,1,,,,50594,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL631301,BAO_0000218,
12441,1,A,1,,,,50594,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630291,BAO_0000218,
12442,1,A,0,,,,22224,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,,,,,,,U,Autocuration,CHEMBL630292,BAO_0000218,
12443,1,A,0,,,,22224,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,,,,,,,U,Autocuration,CHEMBL630293,BAO_0000218,
12444,1,A,0,,,,22224,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,,,,,,,U,Autocuration,CHEMBL630294,BAO_0000218,
12445,1,A,0,,,,22224,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,,,,,,,U,Autocuration,CHEMBL630295,BAO_0000218,
12446,1,A,0,,,,22224,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,,,,,,,U,Autocuration,CHEMBL630296,BAO_0000218,
12447,1,A,0,,,,22224,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,,,,,,,U,Autocuration,CHEMBL626782,BAO_0000218,
12448,1,A,0,,,,22224,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,,,,,,,U,Autocuration,CHEMBL626783,BAO_0000218,
12449,1,A,0,,,,22224,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,,,,,,,U,Autocuration,CHEMBL626784,BAO_0000218,
12450,1,A,0,,,,22224,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,,,,,,,U,Autocuration,CHEMBL626785,BAO_0000218,
12451,1,A,0,,,,22224,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,,,,,,,U,Autocuration,CHEMBL626786,BAO_0000218,
12452,1,A,0,,,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,,,,,,U,Autocuration,CHEMBL626787,BAO_0000218,
12453,1,A,0,,,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,,,,,,,U,Autocuration,CHEMBL626788,BAO_0000218,
12454,1,A,0,,,,22224,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,,,,,,U,Autocuration,CHEMBL625927,BAO_0000218,
12455,1,A,1,,,,50597,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625928,BAO_0000218,
12456,1,A,1,,,,50597,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625929,BAO_0000218,
12457,1,A,1,,,,50597,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625930,BAO_0000218,
12458,1,A,1,,,,50597,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625931,BAO_0000218,
12459,1,A,1,,,,50597,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627230,BAO_0000218,
12460,1,A,1,,,,50597,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627231,BAO_0000218,
12461,1,A,1,,,,50597,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627232,BAO_0000218,
12462,1,A,1,,,,50597,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627233,BAO_0000218,
12463,1,A,1,,,,50597,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875470,BAO_0000218,
12464,1,A,1,,,,50597,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627234,BAO_0000218,
12465,1,A,1,,,,50597,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627235,BAO_0000218,
12466,1,A,1,,,,50597,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627236,BAO_0000218,
12467,1,A,1,,,,50597,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627237,BAO_0000218,
12468,1,A,1,,,,50597,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627238,BAO_0000218,
12469,1,A,1,,,,50597,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627239,BAO_0000218,
12470,1,A,1,,,,50597,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627240,BAO_0000218,
12471,1,A,1,,,,50597,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627241,BAO_0000218,
12472,1,A,1,,,,50597,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627242,BAO_0000218,
12473,1,A,1,,,,50597,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627243,BAO_0000218,
12474,1,A,1,,,,50597,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627244,BAO_0000218,
12475,1,A,1,,,,50597,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627245,BAO_0000218,
12476,1,A,1,,,,50597,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627246,BAO_0000218,
12477,1,A,1,,,,50597,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627247,BAO_0000218,
12478,1,A,1,,,,50597,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627248,BAO_0000218,
12479,1,A,1,,,,50597,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627249,BAO_0000218,
12480,1,A,1,,,,50597,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625569,BAO_0000218,
12481,1,A,1,,,,50597,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625570,BAO_0000218,
12482,1,A,1,,,,50597,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625571,BAO_0000218,
12483,1,A,1,,,,50597,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625572,BAO_0000218,
12484,1,A,1,,,,50597,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625573,BAO_0000218,
12485,1,A,1,,,,50597,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625574,BAO_0000218,
12486,1,A,1,,,,50597,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626245,BAO_0000218,
12487,1,A,1,,,,50597,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626246,BAO_0000218,
12488,1,A,0,,,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,,,,,,U,Autocuration,CHEMBL626247,BAO_0000218,
12489,1,A,0,,,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,,,,,,U,Autocuration,CHEMBL626248,BAO_0000218,
12490,1,A,0,,,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,,,,,,,U,Autocuration,CHEMBL626249,BAO_0000218,
12491,1,A,0,,,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,,,,,,U,Autocuration,CHEMBL626420,BAO_0000218,
12492,1,A,0,,,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,,,,,,U,Autocuration,CHEMBL626421,BAO_0000218,
12493,1,A,0,,,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,,,,,,U,Autocuration,CHEMBL626422,BAO_0000218,
12494,1,A,0,,,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,,,,,,U,Autocuration,CHEMBL626423,BAO_0000218,
12495,1,A,0,,,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,,,,,,U,Autocuration,CHEMBL626424,BAO_0000218,
12496,1,A,1,,,,50588,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626425,BAO_0000218,
12497,1,A,1,,,,50597,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875476,BAO_0000218,
12498,1,A,1,,,,100710,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL626426,BAO_0000218,
12499,1,P,0,,,,22224,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,,,,,,,U,Autocuration,CHEMBL626427,BAO_0000100,
12500,1,P,0,,,,22224,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,,,,,,,U,Autocuration,CHEMBL626428,BAO_0000100,
12501,1,A,0,,,,22224,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,,,,,,,U,Autocuration,CHEMBL626429,BAO_0000019,
12502,1,A,0,,,,22224,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,1088.0,,,,,,U,Autocuration,CHEMBL625025,BAO_0000019,
12503,1,A,1,,,,50597,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625026,BAO_0000218,
12504,1,A,1,,,,50597,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625027,BAO_0000218,
12505,1,A,1,,,,50597,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874410,BAO_0000218,
12506,1,A,1,,,,50597,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625028,BAO_0000218,
12507,1,A,1,,,,50597,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625029,BAO_0000218,
12508,1,A,1,,,,50597,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625030,BAO_0000218,
12509,1,A,1,,,,50597,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625031,BAO_0000218,
12510,1,A,1,,,,50597,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625032,BAO_0000218,
12511,1,A,1,,,,50597,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625033,BAO_0000218,
12512,1,A,1,,,,50597,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625034,BAO_0000218,
12513,1,A,1,,,,50597,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624872,BAO_0000218,
12514,1,A,1,,,,50597,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624873,BAO_0000218,
12515,1,A,1,,,,50597,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624874,BAO_0000218,
12516,1,A,1,,,,50597,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624875,BAO_0000218,
12517,1,A,1,,,,50597,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624876,BAO_0000218,
12518,1,A,1,,,,50597,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624877,BAO_0000218,
12519,1,A,1,,,,50597,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624878,BAO_0000218,
12520,1,A,1,,,,50597,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624879,BAO_0000218,
12521,1,A,1,,,,50597,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624880,BAO_0000218,
12522,1,A,1,,,,50597,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624881,BAO_0000218,
12523,1,A,1,,,,50597,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624882,BAO_0000218,
12524,1,A,1,,,,50597,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624883,BAO_0000218,
12525,1,A,1,,,,50597,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624884,BAO_0000218,
12526,1,A,1,,,,50597,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624885,BAO_0000218,
12527,1,A,1,,,,50597,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624886,BAO_0000218,
12528,1,A,1,,,,50597,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624887,BAO_0000218,
12529,1,A,1,,,,50597,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624888,BAO_0000218,
12530,1,A,1,,,,50597,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624889,BAO_0000218,
12531,1,A,1,,,,50597,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624890,BAO_0000218,
12532,1,A,1,,,,50597,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621964,BAO_0000218,
12533,1,A,1,,,,50597,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621965,BAO_0000218,
12534,1,A,1,,,,50597,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621966,BAO_0000218,
12535,1,A,1,,,,50597,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL621967,BAO_0000218,
12536,1,A,1,,,,50597,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622164,BAO_0000218,
12537,1,A,0,,,,22224,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),,,,,,,U,Autocuration,CHEMBL623097,BAO_0000019,
12538,1,A,0,,,,22224,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),,,,,,,U,Autocuration,CHEMBL623098,BAO_0000019,
12539,1,A,0,,,,22224,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,,,,,,,U,Autocuration,CHEMBL623099,BAO_0000019,
12540,1,A,0,,,,22224,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,,,,,,,U,Autocuration,CHEMBL623100,BAO_0000019,
12541,1,A,1,,,,50597,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628673,BAO_0000218,
12542,1,A,1,,,,50597,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628674,BAO_0000218,
12543,1,A,1,,,,50597,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628675,BAO_0000218,
12544,1,A,1,,,,50597,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627644,BAO_0000218,
12545,1,A,1,,,,50597,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627645,BAO_0000218,
12546,1,A,1,,,,50597,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627646,BAO_0000218,
12547,1,A,1,,,,50597,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627647,BAO_0000218,
12548,1,A,1,,,,50597,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627648,BAO_0000218,
12549,1,A,1,,,,50597,Free level in rat plasma,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627649,BAO_0000218,
12550,1,A,0,,,,22224,Level reaching in blood plasma of rat or human was determined,,,,,,,U,Autocuration,CHEMBL628313,BAO_0000019,
12551,1,A,1,,,,50597,Log (Cbrain/Cblood) in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628314,BAO_0000218,
12552,1,A,0,,,,22224,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,,,,,,,U,Autocuration,CHEMBL628315,BAO_0000019,
12553,1,A,0,,,,22224,Mean percentage of compound transport through membrane; expressed as membrane transport,,,,,,,U,Autocuration,CHEMBL628316,BAO_0000019,
12554,1,A,0,,,,22224,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,,,,,,,U,Autocuration,CHEMBL628317,BAO_0000218,
12555,1,A,0,,,,22224,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,,,,,,,U,Autocuration,CHEMBL628473,BAO_0000019,
12556,1,A,0,,,,22224,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",,,,,,,U,Autocuration,CHEMBL628474,BAO_0000019,
12557,1,A,0,,,,22224,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,,,,,,,U,Autocuration,CHEMBL628475,BAO_0000019,
12558,1,A,0,,,,22224,Net water uptake by a carrier mediated transport (%cm) mechanism,,,,,,,U,Autocuration,CHEMBL628476,BAO_0000019,
12559,1,A,0,,,,22224,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL628477,BAO_0000218,
12560,1,A,1,,,,50506,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,,Mustela putorius furo,,,,9669.0,N,Intermediate,CHEMBL628478,BAO_0000218,
12561,1,A,1,,,,50506,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",,Mustela putorius furo,,,,9669.0,N,Intermediate,CHEMBL628479,BAO_0000218,
12562,1,A,0,,,,22224,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL628480,BAO_0000218,
12563,1,A,0,,,,22224,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL628481,BAO_0000218,
12564,1,A,1,,,,50597,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628482,BAO_0000218,
12565,1,A,1,,,,50597,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628483,BAO_0000218,
12566,1,A,1,,,,50597,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628484,BAO_0000218,
12567,1,A,1,,,,50597,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628485,BAO_0000218,
12568,1,A,1,,,,100710,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",1969.0,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL628486,BAO_0000218,
12569,1,A,1,,,,50587,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",1969.0,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL628487,BAO_0000218,
12570,1,A,1,,,,50597,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628488,BAO_0000218,
12571,1,A,1,,,,50597,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628489,BAO_0000218,
12572,1,A,1,,,,50597,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628490,BAO_0000218,
12573,1,A,1,,,,100710,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL628491,BAO_0000218,
12574,1,A,1,,,,100710,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL877507,BAO_0000218,
12575,1,A,0,,,,22224,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,,,,,,U,Autocuration,CHEMBL628492,BAO_0000218,
12576,1,A,0,,,,22224,% metabolized in monkey S-9 after 2 hours (10 ug/mL),,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL628493,BAO_0000019,
12577,1,A,0,,,,22224,% metabolized in monkey S-9 after 2 hours (1 ug/ml),,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL628494,BAO_0000019,
12578,1,A,0,,,,22224,% metabolized in monkey S-9 after 2 hours (10 ug/ml),,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL628495,BAO_0000019,
12579,1,A,1,,,,50587,Permeability in Caco-2 assay at 10E-6,,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL628496,BAO_0000218,
12580,1,A,0,,,,22224,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,955.0,,,,,,U,Autocuration,CHEMBL628497,BAO_0000218,
12581,1,A,0,,,,22224,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,955.0,,,,,,U,Autocuration,CHEMBL628498,BAO_0000218,
12582,1,A,0,,,,22224,Plasma protein binding was determined,,,,,,,U,Autocuration,CHEMBL628499,BAO_0000019,
12583,1,A,0,,,,22224,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,,,,,,,U,Autocuration,CHEMBL627656,BAO_0000218,
12584,1,A,0,,,,22224,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,,,,,,,U,Autocuration,CHEMBL627657,BAO_0000218,
12585,1,A,0,,,,22224,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,,,,,,,U,Autocuration,CHEMBL626808,BAO_0000218,
12586,1,A,0,,,,22224,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,,,,,,,U,Autocuration,CHEMBL626809,BAO_0000218,
12587,1,A,0,,,,22224,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,,,,,,,U,Autocuration,CHEMBL626810,BAO_0000218,
12588,1,A,0,,,,22224,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,,,,,,,U,Autocuration,CHEMBL626811,BAO_0000218,
12589,1,A,0,,,,22224,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,,,,,,,U,Autocuration,CHEMBL874465,BAO_0000218,
12590,1,A,0,,,,22224,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,,,,,,,U,Autocuration,CHEMBL626812,BAO_0000218,
12591,1,A,0,,,,22224,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,,,,,,,U,Autocuration,CHEMBL626813,BAO_0000218,
12592,1,A,0,,,,22224,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,,,,,,,U,Autocuration,CHEMBL626814,BAO_0000218,
12593,1,A,0,,,,22224,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,,,,,,,U,Autocuration,CHEMBL626815,BAO_0000019,
12594,1,A,0,,,,22224,Partition coefficient (logP),,,,,,,U,Autocuration,CHEMBL628566,BAO_0000019,
12595,1,P,0,,,,22229,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,,,,,,U,Autocuration,CHEMBL628567,BAO_0000100,
12596,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL628568,BAO_0000100,
12597,1,A,1,,,In vivo,50588,C max in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628569,BAO_0000218,
12598,1,A,1,,,In vivo,50512,C max in guinea pig,,Cavia porcellus,,,,10141.0,N,Intermediate,CHEMBL628570,BAO_0000218,
12599,1,A,0,,,In vivo,22224,C max value was evaluated,,,,,,,U,Autocuration,CHEMBL628571,BAO_0000218,
12600,1,A,0,,,In vivo,22224,Cmax value after oral dose of 0.1 mg//kg,,,,,,,U,Autocuration,CHEMBL628572,BAO_0000218,
12601,1,A,0,,,In vivo,22224,Cmax value after oral dose of 0.3 mg/kg,,,,,,,U,Autocuration,CHEMBL628573,BAO_0000218,
12602,1,A,0,,,In vivo,22224,Cmax value after oral dose of 1 mg/kg,,,,,,,U,Autocuration,CHEMBL628574,BAO_0000218,
12603,1,A,0,,,In vivo,22224,Cmax value after oral dose of 10 mg/kg,,,,,,,U,Autocuration,CHEMBL628575,BAO_0000218,
12604,1,A,0,,,In vivo,22224,Cmax value after oral dose of 23.4 mg/kg,,,,,,,U,Autocuration,CHEMBL628576,BAO_0000218,
12605,1,A,0,,,In vivo,22224,Cmax value after oral dose of 3 mg/kg,,,,,,,U,Autocuration,CHEMBL628577,BAO_0000218,
12606,1,A,0,,,In vivo,22224,Cmax value after oral dose of 3.87 mg/kg,,,,,,,U,Autocuration,CHEMBL628578,BAO_0000218,
12607,1,A,1,,,In vivo,50588,Cmax value in female Beagle dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL874466,BAO_0000218,
12608,1,A,1,,,In vivo,50597,Cmax value in male rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628579,BAO_0000218,
12609,1,A,1,,,In vivo,50597,Cmax value in rat plasma when administered 20 mg/kg perorally,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628580,BAO_0000218,
12610,1,A,1,,,In vivo,50588,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628581,BAO_0000218,
12611,1,A,1,,,In vivo,50588,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628582,BAO_0000218,
12612,1,A,1,,,,50588,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628583,BAO_0000218,
12613,1,A,0,,,,22224,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL625782,BAO_0000218,
12614,1,A,1,,,,50592,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL625783,BAO_0000218,
12615,1,A,1,,,,50597,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625784,BAO_0000218,
12616,1,A,1,,,,50797,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,1969.0,Macaca mulatta,,,,9544.0,N,Intermediate,CHEMBL625785,BAO_0000218,
12617,1,A,1,,,,50597,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625786,BAO_0000218,
12618,1,A,0,,,,22224,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,,,,,,,U,Autocuration,CHEMBL874467,BAO_0000019,
12619,1,A,1,,,,50588,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625787,BAO_0000218,
12620,1,A,1,,,,50677,cytotoxicity against HIV protease enzyme.,,Human immunodeficiency virus,,,,12721.0,N,Intermediate,CHEMBL625964,BAO_0000218,
12621,1,A,1,,,,50594,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625965,BAO_0000218,
12622,1,A,1,,,,50594,Apparent clearance in mice after oral administration of 100 mg/kg of dose,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625966,BAO_0000218,
12623,1,A,1,,,In vivo,50588,The plasma clearance in dog.,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625967,BAO_0000218,
12624,1,A,1,,,In vivo,50597,The plasma clearance in rat.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625968,BAO_0000218,
12625,1,A,1,,,In vivo,50597,Clearance from plasma in male Sprague-Dawley rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625969,BAO_0000218,
12626,1,A,1,,,In vivo,100710,Clearance from plasma in male cynomolgus monkeys,1969.0,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL625970,BAO_0000218,
12627,1,A,1,,,In vivo,50588,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625971,BAO_0000218,
12628,1,A,1,,,In vivo,50588,Clearance of compound in dog plasma,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625972,BAO_0000218,
12629,1,A,1,,,In vivo,50587,Clearance of compound in human plasma,1969.0,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL625973,BAO_0000218,
12630,1,A,1,,,In vivo,50588,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625974,BAO_0000218,
12631,1,A,1,,,In vivo,50588,Clearance of compound when administered intravenously as an individual dose to a single dog.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625975,BAO_0000218,
12632,1,A,1,,,In vivo,50588,"Clearance (10 mg/kg, intravenously) in dog plasma",1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625976,BAO_0000218,
12633,1,A,1,,,In vivo,50588,Clearance value in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625977,BAO_0000218,
12634,1,A,1,,,In vivo,50512,Clearance value in guinea pig,,Cavia porcellus,,,,10141.0,N,Intermediate,CHEMBL625978,BAO_0000218,
12635,1,A,1,,,In vivo,50597,Clearance values in rats after iv administration.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874468,BAO_0000218,
12636,1,A,0,,,In vivo,22224,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,1969.0,,,,,,U,Autocuration,CHEMBL625421,BAO_0000218,
12637,1,A,1,,,In vivo,50592,In vivo clearance (5 mg/kg) was determined in rabbits,,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL625422,BAO_0000218,
12638,1,A,1,,,In vivo,50597,Plasma Clearance rate was determined for the compound in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625423,BAO_0000218,
12639,1,A,0,,,In vivo,22224,Plasma Clearance rate was determined for the compound in squirrel monkeys,,Saimiri,,,,9520.0,U,Autocuration,CHEMBL625424,BAO_0000218,
12640,1,A,1,,,In vivo,50597,Plasma clearance in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625425,BAO_0000218,
12641,1,A,0,,,In vivo,22224,Plasma clearance of the compound,,,,,,,U,Autocuration,CHEMBL625426,BAO_0000218,
12642,1,A,1,,,In vivo,50512,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,,Cavia porcellus,,,,10141.0,N,Intermediate,CHEMBL625427,BAO_0000218,
12643,1,A,1,,,In vivo,50512,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,,Cavia porcellus,,,,10141.0,N,Intermediate,CHEMBL625428,BAO_0000218,
12644,1,A,0,,,In vivo,22224,Plasma clearance was determined,,,,,,,U,Autocuration,CHEMBL625429,BAO_0000218,
12645,1,A,1,,,In vivo,50588,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625430,BAO_0000218,
12646,1,A,1,,,In vivo,50597,Plasma clearance rate was determined for the compound in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625431,BAO_0000218,
12647,1,A,0,,,In vivo,22224,Plasma clearance rate was determined for the compound in squirrel monkeys,,Saimiri,,,,9520.0,U,Autocuration,CHEMBL627307,BAO_0000218,
12648,1,A,0,,,In vivo,22224,Slow clearance (CL) was determined,,,,,,,U,Autocuration,CHEMBL627308,BAO_0000218,
12649,1,A,0,,,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,,,,,,U,Autocuration,CHEMBL627309,BAO_0000218,
12650,1,A,0,,,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,,,,,,,U,Autocuration,CHEMBL627310,BAO_0000218,
12651,1,A,0,,,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,,,,,,,U,Autocuration,CHEMBL627311,BAO_0000218,
12652,1,A,0,,,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,,,,,,U,Autocuration,CHEMBL627312,BAO_0000218,
12653,1,A,0,,,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,,,,,,,U,Autocuration,CHEMBL627313,BAO_0000218,
12654,1,A,0,,,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,,,,,,U,Autocuration,CHEMBL627314,BAO_0000218,
12655,1,A,0,,,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,,,,,,U,Autocuration,CHEMBL627315,BAO_0000218,
12656,1,A,0,,,,22224,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,,,,,,U,Autocuration,CHEMBL627316,BAO_0000218,
12657,1,A,0,,,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,,,,,,U,Autocuration,CHEMBL627317,BAO_0000218,
12658,1,A,0,,,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,,,,,,U,Autocuration,CHEMBL627318,BAO_0000218,
12659,1,A,0,,,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,,,,,,,U,Autocuration,CHEMBL627999,BAO_0000218,
12660,1,A,0,,,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,,,,,,U,Autocuration,CHEMBL628000,BAO_0000218,
12661,1,A,0,,,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,,,,,,U,Autocuration,CHEMBL628001,BAO_0000218,
12662,1,A,0,,,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,,,,,,U,Autocuration,CHEMBL628002,BAO_0000218,
12663,1,A,0,,,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,,,,,,U,Autocuration,CHEMBL625610,BAO_0000218,
12664,1,A,0,,,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,,,,,,U,Autocuration,CHEMBL625611,BAO_0000218,
12665,1,A,0,,,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,,,,,,,U,Autocuration,CHEMBL625612,BAO_0000218,
12666,1,A,0,,,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,,,,,,,U,Autocuration,CHEMBL625613,BAO_0000218,
12667,1,A,0,,,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,,,,,,U,Autocuration,CHEMBL875479,BAO_0000218,
12668,1,A,0,,,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,,,,,,U,Autocuration,CHEMBL625614,BAO_0000218,
12669,1,A,0,,,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,,,,,,U,Autocuration,CHEMBL625615,BAO_0000218,
12670,1,A,0,,,,22224,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,,,,,,,U,Autocuration,CHEMBL626302,BAO_0000218,
12671,1,A,1,,,,50597,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626303,BAO_0000218,
12672,1,A,1,,,,50597,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627420,BAO_0000218,
12673,1,A,1,,,,50597,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627421,BAO_0000218,
12674,1,A,1,,,,50597,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625695,BAO_0000218,
12675,1,A,1,,,,50597,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625696,BAO_0000218,
12676,1,A,1,,,,50594,Distribution of compound in mice brain was measured after 1 hr,955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL875606,BAO_0000218,
12677,1,A,1,,,,50594,Distribution of compound in mice brain was measured after 24 hr r,955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625697,BAO_0000218,
12678,1,A,1,,,,50594,Distribution of compound in mice brain was measured after 2 hr,955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625698,BAO_0000218,
12679,1,A,1,,,,50594,Distribution of compound in mice brain was measured after 3 hr,955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625699,BAO_0000218,
12680,1,A,1,,,,50594,Distribution of compound in mice brain was measured after 6 hr,955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625700,BAO_0000218,
12681,1,A,1,,,,50594,Distribution of compound in mice liver was measured after 1 hr,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625701,BAO_0000218,
12682,1,A,1,,,,50594,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625702,BAO_0000218,
12683,1,A,1,,,,50594,Distribution of compound in mice liver was measured after 2 hr,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625703,BAO_0000218,
12684,1,A,1,,,,50594,Distribution of compound in mice liver was measured after 3 hr,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625704,BAO_0000218,
12685,1,A,1,,,,50594,Distribution of compound in mice liver was measured after 6 hr,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625705,BAO_0000218,
12686,1,A,1,,,,50588,Distribution in dog adrenal medulla 30 min after administration.,1236.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625706,BAO_0000218,
12687,1,A,1,,,,50588,Distribution in dog adrenal medulla 72 hours after administration.,1236.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625707,BAO_0000218,
12688,1,A,1,,,,50588,Distribution in female dog Ovary 24 hours after administration.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625708,BAO_0000218,
12689,1,A,1,,,,50588,Distribution in female dog Ovary 72 hours after administration.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625709,BAO_0000218,
12690,1,A,1,,,,50588,Distribution in female dog adipose 24 hours after administration.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624180,BAO_0000218,
12691,1,A,1,,,,50588,Distribution in female dog adipose 72 hours after administration.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624181,BAO_0000218,
12692,1,A,1,,,,50588,Distribution in female dog adrenal cortex 72 hours after administration.,1235.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624182,BAO_0000218,
12693,1,A,1,,,,50588,Distribution in female dog adrenal cortex 72 hours after administration.,1235.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624183,BAO_0000218,
12694,1,A,1,,,,50597,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624184,BAO_0000218,
12695,1,A,1,,,,50597,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL877489,BAO_0000218,
12696,1,A,1,,,,50597,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624185,BAO_0000218,
12697,1,A,1,,,,50597,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624186,BAO_0000218,
12698,1,A,1,,,,50597,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624187,BAO_0000218,
12699,1,A,1,,,,50597,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624188,BAO_0000218,
12700,1,A,1,,,,50597,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624189,BAO_0000218,
12701,1,A,1,,,,50597,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624190,BAO_0000218,
12702,1,A,1,,,,50597,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624191,BAO_0000218,
12703,1,A,1,,,,50597,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624192,BAO_0000218,
12704,1,A,1,,,,50597,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624193,BAO_0000218,
12705,1,A,1,,,,50597,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624194,BAO_0000218,
12706,1,A,1,,,,50597,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624891,BAO_0000218,
12707,1,A,1,,,,50597,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624892,BAO_0000218,
12708,1,A,1,,,,50597,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624893,BAO_0000218,
12709,1,A,1,,,,50597,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627632,BAO_0000218,
12710,1,A,1,,,,50597,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627633,BAO_0000218,
12711,1,A,1,,,,50597,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627634,BAO_0000218,
12712,1,A,1,,,,50597,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627635,BAO_0000218,
12713,1,A,1,,,,50597,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627636,BAO_0000218,
12714,1,A,1,,,,50597,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626816,BAO_0000218,
12715,1,A,1,,,,50597,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626817,BAO_0000218,
12716,1,A,1,,,,50597,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626818,BAO_0000218,
12717,1,A,1,,,,50597,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626819,BAO_0000218,
12718,1,A,1,,,,50597,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626820,BAO_0000218,
12719,1,A,1,,,,50597,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626821,BAO_0000218,
12720,1,A,1,,,,50597,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626822,BAO_0000218,
12721,1,A,1,,,,50597,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626823,BAO_0000218,
12722,1,A,1,,,,50597,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626824,BAO_0000218,
12723,1,A,1,,,,50597,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626825,BAO_0000218,
12724,1,A,1,,,,50597,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626826,BAO_0000218,
12725,1,A,1,,,,50597,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626827,BAO_0000218,
12726,1,A,1,,,,50597,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626828,BAO_0000218,
12727,1,A,1,,,,50597,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626829,BAO_0000218,
12728,1,A,1,,,,50597,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626830,BAO_0000218,
12729,1,A,1,,,,50597,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627150,BAO_0000218,
12730,1,A,1,,,,50597,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627151,BAO_0000218,
12731,1,A,1,,,,50597,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627152,BAO_0000218,
12732,1,A,1,,,,50597,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627153,BAO_0000218,
12733,1,A,0,,,,22224,Rate of acetate production by the compound was determined,,,,,,,U,Autocuration,CHEMBL627154,BAO_0000019,
12734,1,A,0,,,,22224,Rate of acetate production by the compound was determined; Not determined,,,,,,,U,Autocuration,CHEMBL627155,BAO_0000019,
12735,1,A,0,,,,22224,Rate of hydrolysis of nitrocefin by compound was evaluated in water,,,,,,,U,Autocuration,CHEMBL627156,BAO_0000019,
12736,1,A,0,,,,22224,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,,,,,,,U,Autocuration,CHEMBL627157,BAO_0000019,
12737,1,A,1,,,,50592,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL627158,BAO_0000218,
12738,1,A,1,,,,50592,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,1969.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL627159,BAO_0000218,
12739,1,A,1,,,,50594,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627160,BAO_0000218,
12740,1,A,1,,,,50597,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628540,BAO_0000218,
12741,1,A,1,,,,50597,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628541,BAO_0000218,
12742,1,A,1,,,,50597,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628542,BAO_0000218,
12743,1,P,0,,,,22229,Solubility after at a pH 1.2,,,,,,,U,Autocuration,CHEMBL628543,BAO_0000100,
12744,1,P,0,,,,22229,Solubility after at pH 1.2,,,,,,,U,Autocuration,CHEMBL628544,BAO_0000100,
12745,1,P,0,,,,22229,Solubility after injection of water,,,,,,,U,Autocuration,CHEMBL628545,BAO_0000100,
12746,1,A,0,,,,22224,Statistical significance of IC 50 values; Expressed as R value,,,,,,,U,Autocuration,CHEMBL628546,BAO_0000019,
12747,1,A,0,,,,22224,Systemic availability with respect to methyldopa was determined,,,,,,,U,Autocuration,CHEMBL874455,BAO_0000019,
12748,1,A,1,,,,50597,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628547,BAO_0000218,
12749,1,A,1,,,,50597,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628548,BAO_0000218,
12750,1,A,1,,,,50592,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",1988.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL628549,BAO_0000218,
12751,1,A,1,,,,50592,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",1988.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL628550,BAO_0000218,
12752,1,A,1,,,,50592,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",1988.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL628551,BAO_0000218,
12753,1,A,1,,,,50592,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",1088.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL628552,BAO_0000218,
12754,1,A,1,,,,50592,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",1088.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL628553,BAO_0000218,
12755,1,A,1,,,,50592,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",1088.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL628554,BAO_0000218,
12756,1,A,1,,,,50592,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",1088.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL628555,BAO_0000218,
12757,1,A,1,,,,50592,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",1088.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL628556,BAO_0000218,
12758,1,A,1,,,,50592,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",2113.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL628557,BAO_0000218,
12759,1,A,1,,,,50592,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",1988.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL628558,BAO_0000218,
12760,1,A,1,,,,50592,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",1988.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL628559,BAO_0000218,
12761,1,A,1,,,,50592,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",1988.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL628560,BAO_0000218,
12762,1,A,1,,,,50592,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",1088.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL874456,BAO_0000218,
12763,1,A,1,,,,50592,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",1988.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL628561,BAO_0000218,
12764,1,A,1,,,,50592,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",1988.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL628562,BAO_0000218,
12765,1,A,1,,,,50592,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",1088.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL628563,BAO_0000218,
12766,1,A,1,,,,50592,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",1088.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL628564,BAO_0000218,
12767,1,A,1,,,,50592,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",1088.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL628565,BAO_0000218,
12768,1,A,1,,,,50592,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",1088.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL631248,BAO_0000218,
12769,1,A,1,,,,50592,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",1088.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL631249,BAO_0000218,
12770,1,A,1,,,,50592,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",2113.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL627214,BAO_0000218,
12771,1,A,1,,,,50592,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",1988.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL874591,BAO_0000218,
12772,1,A,1,,,,50592,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",1988.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL627215,BAO_0000218,
12773,1,A,1,,,,50592,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,1988.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL625471,BAO_0000218,
12774,1,A,1,,,,50592,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL625472,BAO_0000218,
12775,1,A,1,,,,50592,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL625473,BAO_0000218,
12776,1,A,1,,,In vivo,50588,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625474,BAO_0000218,
12777,1,A,1,,,In vivo,50588,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625475,BAO_0000218,
12778,1,A,1,,,In vivo,50597,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625476,BAO_0000218,
12779,1,A,1,,,In vivo,50597,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625477,BAO_0000218,
12780,1,A,1,,,In vivo,50597,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625478,BAO_0000218,
12781,1,A,1,,,In vitro,50597,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625479,BAO_0000218,
12782,1,A,1,,,In vitro,50597,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625480,BAO_0000218,
12783,1,A,1,,,In vivo,50597,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625481,BAO_0000218,
12784,1,A,1,,,In vivo,50597,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625482,BAO_0000218,
12785,1,A,1,,,In vivo,50597,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625483,BAO_0000218,
12786,1,A,1,,,In vivo,50597,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625484,BAO_0000218,
12787,1,A,1,,,In vivo,50597,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625485,BAO_0000218,
12788,1,A,1,,,In vivo,50588,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625486,BAO_0000218,
12789,1,A,1,,,In vivo,50597,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625487,BAO_0000218,
12790,1,A,1,,,In vivo,50597,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625488,BAO_0000218,
12791,1,A,1,,,In vivo,50597,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625489,BAO_0000218,
12792,1,A,1,,,In vivo,50597,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625490,BAO_0000218,
12793,1,A,1,,,In vivo,50588,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625491,BAO_0000218,
12794,1,A,1,,,In vivo,50597,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625492,BAO_0000218,
12795,1,A,1,,,In vivo,50587,plasma clearance in human,1969.0,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL625493,BAO_0000218,
12796,1,A,1,,,In vivo,50597,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625494,BAO_0000218,
12797,1,A,1,,,In vivo,50597,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625495,BAO_0000218,
12798,1,A,1,,,In vivo,50597,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625496,BAO_0000218,
12799,1,P,0,,,,22229,1-Octanol/water partition coefficient measured at 7.4,,,,,,,U,Autocuration,CHEMBL625497,BAO_0000100,
12800,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL625498,BAO_0000100,
12801,1,A,0,,,,22224,Partition coefficient (logP),,,,,,,U,Autocuration,CHEMBL625499,BAO_0000019,
12802,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL625500,BAO_0000100,
12803,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL625501,BAO_0000100,
12804,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL625502,BAO_0000100,
12805,1,P,0,,,,22229,Calculated partition coefficient (clogP) (relative to BAY K 8644),,,,,,,U,Autocuration,CHEMBL625503,BAO_0000100,
12806,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL625504,BAO_0000100,
12807,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL625505,BAO_0000100,
12808,1,P,0,,,,22229,Calculated partition coefficient of the compound,,,,,,,U,Autocuration,CHEMBL625506,BAO_0000100,
12809,1,A,0,,,,22224,Partition coefficient (logP),,,,,,,U,Autocuration,CHEMBL625507,BAO_0000019,
12810,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL625508,BAO_0000100,
12811,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL625509,BAO_0000100,
12812,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL625510,BAO_0000100,
12813,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL883125,BAO_0000100,
12814,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL625511,BAO_0000100,
12815,1,A,0,,,,22224,Partition coefficient of the compound,,,,,,,U,Autocuration,CHEMBL874650,BAO_0000019,
12816,1,A,0,,,,22224,Partition coefficient of the compound,,,,,,,U,Autocuration,CHEMBL625512,BAO_0000019,
12817,1,A,0,,,,22224,Partition coefficient of compound was determined,,,,,,,U,Autocuration,CHEMBL625513,BAO_0000019,
12818,1,A,0,,,,22224,Partition coefficient was determined,,,,,,,U,Autocuration,CHEMBL625514,BAO_0000019,
12819,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL625515,BAO_0000100,
12820,1,P,0,,,,22229,partition coefficient of compound was determined,,,,,,,U,Autocuration,CHEMBL625516,BAO_0000100,
12821,1,A,1,,,In vivo,50588,The total body administered intravenously in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625517,BAO_0000218,
12822,1,A,1,,,In vivo,50597,The total body administered intravenously in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625518,BAO_0000218,
12823,1,A,1,,,,50594,Time taken for the administration to female NIH mice weighing 25-30 g.,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625519,BAO_0000218,
12824,1,A,0,,,,22224,Time taken for the administration,,,,,,,U,Autocuration,CHEMBL625520,BAO_0000019,
12825,1,A,1,,,In vivo,50588,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL874651,BAO_0000218,
12826,1,A,0,,,In vivo,22224,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL625521,BAO_0000218,
12827,1,A,1,,,In vivo,50592,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL623171,BAO_0000218,
12828,1,A,1,,,In vivo,50597,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623853,BAO_0000218,
12829,1,A,0,,,,22224,Plasma clearance for the compound was determined.,,,,,,,U,Autocuration,CHEMBL623854,BAO_0000019,
12830,1,P,0,,,,22224,CLog P value of the compound,,,,,,,U,Autocuration,CHEMBL874405,BAO_0000100,
12831,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL623855,BAO_0000100,
12832,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL623856,BAO_0000100,
12833,1,P,0,,,,22224,ClogP value of the compound; nd ='no data',,,,,,,U,Autocuration,CHEMBL623857,BAO_0000100,
12834,1,P,0,,,,22224,ClogP value of the compound; nd ='not determined',,,,,,,U,Autocuration,CHEMBL623858,BAO_0000100,
12835,1,P,0,,,,22224,CLog P was determined,,,,,,,U,Autocuration,CHEMBL623859,BAO_0000100,
12836,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL839829,BAO_0000100,
12837,1,A,0,,,,22224,CLogP was calculated,,,,,,,U,Autocuration,CHEMBL623860,BAO_0000019,
12838,1,A,0,,,,22224,CLogP value was determined,,,,,,,U,Autocuration,CHEMBL623861,BAO_0000019,
12839,1,A,0,,,,22224,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,,,,,,,U,Autocuration,CHEMBL623862,BAO_0000019,
12840,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL874406,BAO_0000100,
12841,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL623863,BAO_0000100,
12842,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL624021,BAO_0000100,
12843,1,A,1,,,,50588,Distribution in female dog adrenal medulla 24 hours after administration.,1236.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624022,BAO_0000218,
12844,1,A,1,,,,50588,Distribution in female dog adrenal medulla 72 hours after administration.,1236.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624023,BAO_0000218,
12845,1,A,1,,,,50588,Distribution in female dog bile 24 hours after administration.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624024,BAO_0000218,
12846,1,A,1,,,,50588,Distribution in female dog bile 72 hr after administration.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624025,BAO_0000218,
12847,1,A,1,,,,50588,Distribution in female dog blood 24 hours after administration.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624026,BAO_0000218,
12848,1,A,1,,,,50588,Distribution in female dog blood 72 hours after administration.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624027,BAO_0000218,
12849,1,A,1,,,,50588,Distribution in female dog heart 24 hours after administration.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624028,BAO_0000218,
12850,1,A,1,,,,50588,Distribution in female dog heart 72 hours after administration.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624029,BAO_0000218,
12851,1,A,1,,,,50588,Distribution in female dog kidney 24 hours after administration.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624030,BAO_0000218,
12852,1,A,1,,,,50588,Distribution in female dog kidney 72 hours after administration.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624031,BAO_0000218,
12853,1,A,1,,,,50588,Distribution in female dog large intestine 24 hours after administration.,160.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624032,BAO_0000218,
12854,1,A,1,,,,50588,Distribution in female dog large intestine 72 hours after administration.,160.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL874407,BAO_0000218,
12855,1,A,1,,,,50588,Distribution in female dog liver 24 hours after administration.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624033,BAO_0000218,
12856,1,A,1,,,,50588,Distribution in female dog liver 72 hours after administration.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624034,BAO_0000218,
12857,1,A,1,,,,50588,Distribution in female dog lung 24 hours after administration.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624035,BAO_0000218,
12858,1,A,1,,,,50588,Distribution in female dog lung 72 hours after administration.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624036,BAO_0000218,
12859,1,A,1,,,,50588,Distribution in female dog muscle 24 hours after administration.,2385.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624037,BAO_0000218,
12860,1,A,1,,,,50588,Distribution in female dog muscle 72 hours after administration.,2385.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624038,BAO_0000218,
12861,1,A,1,,,,50588,Distribution in female dog pancreas 24 hours after administration.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624039,BAO_0000218,
12862,1,A,1,,,,50588,Distribution in female dog pancreas 72 hours after administration.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624040,BAO_0000218,
12863,1,A,1,,,,50588,Distribution in female dog small intestine 24 hours after administration.,160.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624041,BAO_0000218,
12864,1,A,1,,,,50588,Distribution in female dog small intestine 72 hours after administration.,160.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624042,BAO_0000218,
12865,1,A,1,,,,50588,Distribution in female dog spleen 24 hours after administration.,2106.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624043,BAO_0000218,
12866,1,A,1,,,,50588,Distribution in female dog spleen 72 hours after administration.,2106.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624044,BAO_0000218,
12867,1,A,1,,,,50588,Distribution in female dog stomach 24 hours after administration.,945.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624045,BAO_0000218,
12868,1,A,1,,,,50588,Distribution in female dog stomach 72 hours after administration.,945.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624046,BAO_0000218,
12869,1,A,1,,,,50588,Distribution in female dog thyroid 24 hours after administration.,2046.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624047,BAO_0000218,
12870,1,A,1,,,,50588,Distribution in female dog thyroid 72 hours after administration.,2046.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624048,BAO_0000218,
12871,1,A,1,,,,50588,Distribution in female dog urine 24 hours after administration.,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL874408,BAO_0000218,
12872,1,A,1,,,,50588,Distribution in female dog urine 72 hr after administration.,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624049,BAO_0000218,
12873,1,A,0,,,,22224,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,1969.0,,,,,,U,Autocuration,CHEMBL624050,BAO_0000218,
12874,1,A,0,,,,22224,Plasma concentration at 7 hr after intravenous dosing,,,,,,,U,Autocuration,CHEMBL624051,BAO_0000019,
12875,1,A,1,,,,50597,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623278,BAO_0000218,
12876,1,A,1,,,,50597,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623279,BAO_0000218,
12877,1,A,1,,,,50597,Plasma concentration of 3 mg/kg iv after 1 hr in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623280,BAO_0000218,
12878,1,A,1,,,,50597,Plasma concentration of 3 mg/kg iv after 2 hr in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623963,BAO_0000218,
12879,1,A,1,,,,50597,Plasma concentration of 3 mg/kg iv after 4 hr in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623964,BAO_0000218,
12880,1,A,1,,,,50597,Plasma concentration of 3 mg/kg iv after 6 hr in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623965,BAO_0000218,
12881,1,A,1,,,,50597,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623966,BAO_0000218,
12882,1,A,1,,,,50597,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874415,BAO_0000218,
12883,1,A,1,,,,50597,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623967,BAO_0000218,
12884,1,A,1,,,,50597,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623968,BAO_0000218,
12885,1,A,1,,,,50597,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623969,BAO_0000218,
12886,1,A,1,,,,50597,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628409,BAO_0000218,
12887,1,A,1,,,,50597,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628410,BAO_0000218,
12888,1,A,1,,,,50597,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628411,BAO_0000218,
12889,1,A,1,,,,50597,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628412,BAO_0000218,
12890,1,A,0,,,,22224,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,,,,,,,U,Autocuration,CHEMBL628413,BAO_0000019,
12891,1,A,0,,,,22224,The concentration in plasmat; Not determined,1969.0,,,,,,U,Autocuration,CHEMBL628414,BAO_0000019,
12892,1,A,1,,,,50597,Tissue level at 10 mg/kg/po in wistar rats in blood,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628415,BAO_0000218,
12893,1,A,1,,,,50597,Tissue level at 10 mg/kg/po in wistar rats in brown fat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628416,BAO_0000218,
12894,1,A,1,,,,50597,Tissue level at 10 mg/kg/po in wistar rats in heart,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628417,BAO_0000218,
12895,1,A,1,,,,50597,Tissue level at 10 mg/kg/po in wistar rats in liver,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874908,BAO_0000218,
12896,1,A,1,,,,50597,Tissue level at 10 mg/kg/po in wistar rats in plasma,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628418,BAO_0000218,
12897,1,A,1,,,,50597,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628419,BAO_0000218,
12898,1,A,1,,,,50597,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628420,BAO_0000218,
12899,1,A,0,,,,22224,Water solubility at 37 degree C.,,,,,,,U,Autocuration,CHEMBL628421,BAO_0000019,
12900,1,P,0,,,,22229,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,,,,,,,U,Autocuration,CHEMBL626726,BAO_0000100,
12901,1,P,0,,,,22229,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,,,,,,U,Autocuration,CHEMBL626727,BAO_0000100,
12902,1,A,1,,,,50597,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626728,BAO_0000218,
12903,1,A,1,,,,50597,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626729,BAO_0000218,
12904,1,A,1,,,,50597,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626730,BAO_0000218,
12905,1,A,1,,,,50597,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626731,BAO_0000218,
12906,1,A,1,,,,50597,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626732,BAO_0000218,
12907,1,A,1,,,,50597,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626733,BAO_0000218,
12908,1,A,1,,,,50597,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626734,BAO_0000218,
12909,1,A,1,,,,50597,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626735,BAO_0000218,
12910,1,A,1,,,,50597,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874909,BAO_0000218,
12911,1,A,1,,,,50597,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626736,BAO_0000218,
12912,1,A,1,,,,50597,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626737,BAO_0000218,
12913,1,A,1,,,,50597,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630999,BAO_0000218,
12914,1,A,1,,,,50597,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631000,BAO_0000218,
12915,1,A,1,,,,50597,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631001,BAO_0000218,
12916,1,A,1,,,,50597,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631002,BAO_0000218,
12917,1,A,1,,,,50597,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631003,BAO_0000218,
12918,1,A,1,,,,50597,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631004,BAO_0000218,
12919,1,A,1,,,,50597,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631005,BAO_0000218,
12920,1,A,1,,,,50597,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631006,BAO_0000218,
12921,1,A,1,,,,50597,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631007,BAO_0000218,
12922,1,A,1,,,,50597,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631008,BAO_0000218,
12923,1,A,1,,,,50597,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631009,BAO_0000218,
12924,1,A,1,,,,50597,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631010,BAO_0000218,
12925,1,A,1,,,,50597,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631011,BAO_0000218,
12926,1,A,1,,,,50597,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631012,BAO_0000218,
12927,1,A,1,,,,50597,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630271,BAO_0000218,
12928,1,A,1,,,,50597,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630272,BAO_0000218,
12929,1,A,1,,,,50597,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630273,BAO_0000218,
12930,1,A,1,,,,50597,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630274,BAO_0000218,
12931,1,A,1,,,,50597,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630275,BAO_0000218,
12932,1,A,1,,,,50597,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875782,BAO_0000218,
12933,1,A,1,,,,50597,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630276,BAO_0000218,
12934,1,A,1,,,,50597,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630277,BAO_0000218,
12935,1,A,1,,,,50597,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630278,BAO_0000218,
12936,1,A,1,,,,50597,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630279,BAO_0000218,
12937,1,A,0,,,,22224,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,,,,,,,U,Autocuration,CHEMBL630280,BAO_0000019,
12938,1,A,0,,,,22224,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,,,,,,U,Autocuration,CHEMBL630281,BAO_0000019,
12939,1,A,1,,,,50592,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL630282,BAO_0000218,
12940,1,A,1,,,,50592,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL630283,BAO_0000218,
12941,1,A,0,,,,22224,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),,,,,,,U,Autocuration,CHEMBL630284,BAO_0000019,
12942,1,A,0,,,,22224,Alkylating activity was determined,,,,,,,U,Autocuration,CHEMBL630285,BAO_0000019,
12943,1,A,0,,,,22224,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),,,,,,,U,Autocuration,CHEMBL630286,BAO_0000251,
12944,1,A,1,,,,50592,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL630069,BAO_0000218,
12945,1,A,1,,,,50592,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL630070,BAO_0000218,
12946,1,A,1,,,,50592,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL630071,BAO_0000218,
12947,1,A,1,,,,50592,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL630072,BAO_0000218,
12948,1,A,1,,,,50592,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL875110,BAO_0000218,
12949,1,A,1,,,,50597,Compound was tested for antidiuretic activity in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630073,BAO_0000218,
12950,1,A,0,,,,22224,Compound was tested for inactivation kinetic values,,,,,,,U,Autocuration,CHEMBL630074,BAO_0000019,
12951,1,A,0,,,In vivo,22224,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,,,,,,,U,Autocuration,CHEMBL630075,BAO_0000218,
12952,1,A,0,,,,22224,Dissociation rate calculated from the first-order equation using the t1/2 value,,,,,,,U,Autocuration,CHEMBL630076,BAO_0000019,
12953,1,P,0,,,,22229,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,,,,,,,U,Autocuration,CHEMBL630077,BAO_0000100,
12954,1,P,0,,,,22229,Aqueous solubility was measured,,,,,,,U,Autocuration,CHEMBL630078,BAO_0000100,
12955,1,P,0,,,,22229,Aqueous solubility was measured at a pH 4,,,,,,,U,Autocuration,CHEMBL630079,BAO_0000100,
12956,1,P,0,,,,22229,Aqueous solubility (pH 7),,,,,,,U,Autocuration,CHEMBL630080,BAO_0000100,
12957,1,P,0,,,,22229,Aqueous solubility was measured at a pH 9,,,,,,,U,Autocuration,CHEMBL630081,BAO_0000100,
12958,1,A,0,,,,22224,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",,,,,,,U,Autocuration,CHEMBL630082,BAO_0000019,
12959,1,A,0,,,,22224,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",,,,,,,U,Autocuration,CHEMBL630083,BAO_0000019,
12960,1,A,0,,,,22224,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",,,,,,,U,Autocuration,CHEMBL630084,BAO_0000019,
12961,1,P,0,,,,22229,Aqueous solubility of the compound,,,,,,,U,Autocuration,CHEMBL629198,BAO_0000100,
12962,1,P,0,,,,22229,Aqueous solubility at 37 degree Celsius at pH 7.38,,,,,,,U,Autocuration,CHEMBL629199,BAO_0000100,
12963,1,P,0,,,,22229,Aqueous solubility in pH 7.4 phosphate buffer,,,,,,,U,Autocuration,CHEMBL629200,BAO_0000100,
12964,1,A,1,,,,50588,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL629201,BAO_0000218,
12965,1,A,1,,,,50588,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL629202,BAO_0000218,
12966,1,A,1,,,,50587,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL875111,BAO_0000218,
12967,1,A,1,,,,50587,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL629203,BAO_0000218,
12968,1,A,1,,,,50587,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL629204,BAO_0000218,
12969,1,A,1,,,,50587,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL629205,BAO_0000218,
12970,1,A,1,,,,50587,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL629206,BAO_0000218,
12971,1,A,0,,,,22224,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,,,,,,,U,Autocuration,CHEMBL631185,BAO_0000019,
12972,1,A,1,,,,50597,Compound was evaluated for the average bile flow rat in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631186,BAO_0000218,
12973,1,A,1,,,,50592,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL631187,BAO_0000218,
12974,1,A,1,,,,50592,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL631188,BAO_0000218,
12975,1,A,0,,,,22224,Average half life period was determined,,,,,,,U,Autocuration,CHEMBL876419,BAO_0000019,
12976,1,A,0,,,,22224,Average half life period was determined,,,,,,,U,Autocuration,CHEMBL631189,BAO_0000019,
12977,1,A,1,,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,,Human herpesvirus 1,,,,10298.0,N,Intermediate,CHEMBL631190,BAO_0000218,
12978,1,A,1,,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,,Human herpesvirus 1,,,,10298.0,N,Intermediate,CHEMBL631191,BAO_0000218,
12979,1,A,1,,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,,Human herpesvirus 1,,,,10298.0,N,Intermediate,CHEMBL631192,BAO_0000218,
12980,1,A,1,,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,,Human herpesvirus 1,,,,10298.0,N,Intermediate,CHEMBL632400,BAO_0000218,
12981,1,A,1,,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,,Human herpesvirus 1,,,,10298.0,N,Intermediate,CHEMBL630564,BAO_0000218,
12982,1,A,1,,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,,Human herpesvirus 1,,,,10298.0,N,Intermediate,CHEMBL630565,BAO_0000218,
12983,1,A,1,,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,,Human herpesvirus 1,,,,10298.0,N,Intermediate,CHEMBL630566,BAO_0000218,
12984,1,A,1,,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,,Human herpesvirus 1,,,,10298.0,N,Intermediate,CHEMBL631229,BAO_0000218,
12985,1,A,1,,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,,Human herpesvirus 1,,,,10298.0,N,Intermediate,CHEMBL631230,BAO_0000218,
12986,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL876428,BAO_0000100,
12987,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL631231,BAO_0000100,
12988,1,P,0,,,,22229,Calculated partition coefficient (clogP) (MacLogP),,,,,,,U,Autocuration,CHEMBL631232,BAO_0000100,
12989,1,A,0,,,,22224,Hydrophilicity was determined,,,,,,,U,Autocuration,CHEMBL631233,BAO_0000019,
12990,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL631234,BAO_0000100,
12991,1,A,0,,,,22224,Increased absorption was determined,,,,,,,U,Autocuration,CHEMBL883126,BAO_0000019,
12992,1,P,0,,,,22224,Lipophilicity value was evaluated,,,,,,,U,Autocuration,CHEMBL631235,BAO_0000100,
12993,1,P,0,,,,22224,Log P value of the compound.,,,,,,,U,Autocuration,CHEMBL631236,BAO_0000100,
12994,1,A,0,,,,22224,Partition coefficient of compound was determined,,,,,,,U,Autocuration,CHEMBL631237,BAO_0000019,
12995,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL631238,BAO_0000100,
12996,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL876429,BAO_0000100,
12997,1,A,0,,,,22224,Partition coefficient was measured by medchem software; Not calculated,,,,,,,U,Autocuration,CHEMBL631414,BAO_0000019,
12998,1,P,0,,,,22224,Partition coefficient was measured by octanol-water using standard shake-flask method,,,,,,,U,Autocuration,CHEMBL631415,BAO_0000100,
12999,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL631416,BAO_0000100,
13000,1,A,0,,,,22224,Partition coefficient (logP),,,,,,,U,Autocuration,CHEMBL631417,BAO_0000019,
13001,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL631418,BAO_0000100,
13002,1,P,0,,,,22229,The Octanol/Water partition coefficient CLogP,,,,,,,U,Autocuration,CHEMBL631419,BAO_0000100,
13003,1,A,0,,,,22224,The pharmacokinetic parameter C Log p was reported,,,,,,,U,Autocuration,CHEMBL631420,BAO_0000019,
13004,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL631421,BAO_0000100,
13005,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL631422,BAO_0000100,
13006,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL631423,BAO_0000100,
13007,1,A,1,,,In vivo,50597,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876430,BAO_0000218,
13008,1,A,1,,,In vivo,50597,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631424,BAO_0000218,
13009,1,A,1,,,In vivo,50588,Compound was administered intravenously in dog to evaluate plasma clearance values,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL631425,BAO_0000218,
13010,1,A,0,,,In vivo,22224,Compound was administered intravenously in monkey to evaluate plasma clearance values,1969.0,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL631426,BAO_0000218,
13011,1,A,1,,,In vivo,50594,Compound was administered intravenously in mouse to evaluate plasma clearance values,1969.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL631427,BAO_0000218,
13012,1,A,1,,,In vivo,50588,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL631428,BAO_0000218,
13013,1,A,1,,,In vitro,50797,Intrinsic clearance in Rhesus liver microsome,2107.0,Macaca mulatta,,,,9544.0,N,Intermediate,CHEMBL631429,BAO_0000218,
13014,1,A,1,,,In vitro,50588,Intrinsic clearance in dog liver microsome,2107.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL631430,BAO_0000218,
13015,1,A,1,,,In vitro,50597,Intrinsic clearance in rat liver microsome,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631431,BAO_0000218,
13016,1,A,1,,,In vivo,50797,Low plasma clearance was calculated in rhesus monkey,1969.0,Macaca mulatta,,,,9544.0,N,Intermediate,CHEMBL631432,BAO_0000218,
13017,1,A,1,,,In vivo,50588,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL631433,BAO_0000218,
13018,1,A,0,,,In vivo,22224,Plasma clearance after intravenous dose of 0.3 mg/kg,,,,,,,U,Autocuration,CHEMBL631434,BAO_0000218,
13019,1,A,0,,,In vivo,22224,Plasma clearance after intravenous dose of 1 mg/kg,,,,,,,U,Autocuration,CHEMBL631435,BAO_0000218,
13020,1,A,0,,,In vivo,22224,Plasma clearance after intravenous dose of 3 mg/kg,,,,,,,U,Autocuration,CHEMBL631436,BAO_0000218,
13021,1,A,0,,,In vivo,22224,Plasma clearance after intravenous dose of 3.87 mg/kg,,,,,,,U,Autocuration,CHEMBL631437,BAO_0000218,
13022,1,A,1,,,In vivo,50597,Plasma clearance after peroral administration at 10 mpk in Rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631438,BAO_0000218,
13023,1,A,1,,,In vivo,50797,Plasma clearance after peroral administration at 10 mpk in Rhesus,,Macaca mulatta,,,,9544.0,N,Intermediate,CHEMBL876431,BAO_0000218,
13024,1,A,1,,,In vivo,50588,Plasma clearance after peroral administration at 10 mpk in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL631439,BAO_0000218,
13025,1,A,1,,,In vivo,50597,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631440,BAO_0000218,
13026,1,A,0,,,,22224,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),,,,,,,U,Autocuration,CHEMBL631441,BAO_0000019,
13027,1,A,0,,,,22224,Critical Micellar concentration was determined,,,,,,,U,Autocuration,CHEMBL631442,BAO_0000019,
13028,1,A,0,,,,22224,Critical Micellar concentration of the compound. was determined,,,,,,,U,Autocuration,CHEMBL626525,BAO_0000019,
13029,1,A,0,,,,22224,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,,,,,,,U,Autocuration,CHEMBL627168,BAO_0000019,
13030,1,A,0,,,,22224,Critical micellar concentration was measured in water by the dye solubilization method,,,,,,,U,Autocuration,CHEMBL875618,BAO_0000019,
13031,1,B,0,,,,22224,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,,,,,,,U,Autocuration,CHEMBL626612,BAO_0000019,
13032,1,A,0,,,,22224,CMR value (relative to BAY K 8644),,,,,,,U,Autocuration,CHEMBL626613,BAO_0000019,
13033,1,A,0,,,,22224,Carbamoylating activity was determined,,,,,,,U,Autocuration,CHEMBL626614,BAO_0000019,
13034,1,A,0,,,,22224,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL626615,BAO_0000218,
13035,1,A,0,,,,22224,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,,,,,,,U,Autocuration,CHEMBL626616,BAO_0000019,
13036,1,A,0,,,,22224,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,,,,,,,U,Autocuration,CHEMBL626617,BAO_0000019,
13037,1,A,1,,,In vivo,50588,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626618,BAO_0000218,
13038,1,A,1,,,In vivo,50597,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626619,BAO_0000218,
13039,1,A,1,,,In vivo,50588,"Clearance rate at 0.46 mg/kg, iv, in dogs",,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626620,BAO_0000218,
13040,1,A,1,,,In vivo,50597,"Clearance rate at 5.5 mg/kg, iv, in rat",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626621,BAO_0000218,
13041,1,A,1,,,In vivo,100710,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL626622,BAO_0000218,
13042,1,A,1,,,In vivo,100710,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL626623,BAO_0000218,
13043,1,A,1,,,In vivo,50588,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626624,BAO_0000218,
13044,1,A,1,,,In vivo,50597,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626625,BAO_0000218,
13045,1,A,1,,,Ex vivo,50597,Clearance rate constant using isolated perfused rat liver (IPRL) assay,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626626,BAO_0000218,
13046,1,A,0,,,In vivo,22224,Tested for the total clearance of the compound,,,,,,,U,Autocuration,CHEMBL626627,BAO_0000218,
13047,1,A,1,,,In vivo,50588,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626628,BAO_0000218,
13048,1,A,0,,,In vivo,22224,Total body clearance was determined,,,,,,,U,Autocuration,CHEMBL626629,BAO_0000218,
13049,1,A,1,,,,50597,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626630,BAO_0000218,
13050,1,A,1,,,,50597,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626631,BAO_0000218,
13051,1,P,0,,,,22229,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,,,,,,,U,Autocuration,CHEMBL626632,BAO_0000100,
13052,1,P,0,,,,22229,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,,,,,,U,Autocuration,CHEMBL626633,BAO_0000100,
13053,1,P,0,,,,22229,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,,,,,,,U,Autocuration,CHEMBL626634,BAO_0000100,
13054,1,P,0,,,,22229,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,,,,,,,U,Autocuration,CHEMBL626635,BAO_0000100,
13055,1,P,0,,,,22229,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,,,,,,U,Autocuration,CHEMBL626636,BAO_0000100,
13056,1,P,0,,,,22229,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,,,,,,,U,Autocuration,CHEMBL626637,BAO_0000100,
13057,1,A,1,,,,50339,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),,Pneumocystis carinii,,,,4754.0,N,Intermediate,CHEMBL626638,BAO_0000218,
13058,1,A,1,,,,50339,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,,Pneumocystis carinii,,,,4754.0,N,Intermediate,CHEMBL626639,BAO_0000218,
13059,1,A,1,,,,50339,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,,Pneumocystis carinii,,,,4754.0,N,Intermediate,CHEMBL626640,BAO_0000218,
13060,1,A,1,,,,50339,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,,Pneumocystis carinii,,,,4754.0,N,Intermediate,CHEMBL626641,BAO_0000218,
13061,1,A,1,,,,50339,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,,Pneumocystis carinii,,,,4754.0,N,Intermediate,CHEMBL627272,BAO_0000218,
13062,1,A,1,,,,50339,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,,Pneumocystis carinii,,,,4754.0,N,Intermediate,CHEMBL627273,BAO_0000218,
13063,1,A,1,,,,50339,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),,Pneumocystis carinii,,,,4754.0,N,Intermediate,CHEMBL627441,BAO_0000218,
13064,1,A,1,,,,50339,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),,Pneumocystis carinii,,,,4754.0,N,Intermediate,CHEMBL628355,BAO_0000218,
13065,1,A,1,,,,50339,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),,Pneumocystis carinii,,,,4754.0,N,Intermediate,CHEMBL628356,BAO_0000218,
13066,1,A,1,,,,50339,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),,Pneumocystis carinii,,,,4754.0,N,Intermediate,CHEMBL628357,BAO_0000218,
13067,1,A,1,,,,50339,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),,Pneumocystis carinii,,,,4754.0,N,Intermediate,CHEMBL628358,BAO_0000218,
13068,1,A,1,,,,50339,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),,Pneumocystis carinii,,,,4754.0,N,Intermediate,CHEMBL622307,BAO_0000218,
13069,1,A,0,,,,22224,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,,,,,,,U,Autocuration,CHEMBL622527,BAO_0000019,
13070,1,A,0,,,,22224,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,,,,,,,U,Autocuration,CHEMBL622528,BAO_0000019,
13071,1,A,0,,,,22224,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,,,,,,,U,Autocuration,CHEMBL622529,BAO_0000019,
13072,1,A,0,,,,22224,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,,,,,,,U,Autocuration,CHEMBL622992,BAO_0000019,
13073,1,A,0,,,,22224,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,,,,,,,U,Autocuration,CHEMBL622993,BAO_0000019,
13074,1,A,0,,,,22224,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,,,,,,,U,Autocuration,CHEMBL622994,BAO_0000019,
13075,1,A,1,,,,50597,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622995,BAO_0000218,
13076,1,A,1,,,,50597,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622996,BAO_0000218,
13077,1,A,1,,,,50597,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622997,BAO_0000218,
13078,1,A,1,,,,50597,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622998,BAO_0000218,
13079,1,A,0,,,,22224,Cp max following ip administration at 1 mg/kg,,,,,,,U,Autocuration,CHEMBL622999,BAO_0000218,
13080,1,A,0,,,In vivo,22224,Maximum concentration in plasma was reported at 0.5 hour,1969.0,,,,,,U,Autocuration,CHEMBL623000,BAO_0000218,
13081,1,A,0,,,In vivo,22224,Maximum concentration in plasma was reported at 2 hour,1969.0,,,,,,U,Autocuration,CHEMBL623001,BAO_0000218,
13082,1,A,1,,,,50594,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL623002,BAO_0000218,
13083,1,P,0,,,,22229,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),,,,,,,U,Autocuration,CHEMBL623003,BAO_0000100,
13084,1,A,0,,,,22224,Steady state concentration was evaluated,,,,,,,U,Autocuration,CHEMBL623004,BAO_0000019,
13085,1,A,0,,,,22224,Partition coefficient (logP),,,,,,,U,Autocuration,CHEMBL623005,BAO_0000019,
13086,1,A,0,,,,22224,Partition coefficient (logD7.4),,,,,,,U,Autocuration,CHEMBL623006,BAO_0000019,
13087,1,A,1,,,In vivo,50597,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623007,BAO_0000218,
13088,1,A,1,,,In vivo,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623008,BAO_0000218,
13089,1,A,1,,,In vivo,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,2037.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876654,BAO_0000218,
13090,1,A,1,,,In vivo,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623009,BAO_0000218,
13091,1,A,1,,,In vivo,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623010,BAO_0000218,
13092,1,A,1,,,In vivo,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623011,BAO_0000218,
13093,1,A,1,,,In vivo,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,160.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623012,BAO_0000218,
13094,1,A,0,,,,22224,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,,,,,,,U,Autocuration,CHEMBL623013,BAO_0000019,
13095,1,A,0,,,,22224,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,,,,,,U,Autocuration,CHEMBL623014,BAO_0000019,
13096,1,A,0,,,,22224,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,1088.0,,,,,,U,Autocuration,CHEMBL623015,BAO_0000019,
13097,1,A,0,,,,22224,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,1088.0,,,,,,U,Autocuration,CHEMBL623016,BAO_0000019,
13098,1,A,0,,,,22224,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,1088.0,,,,,,U,Autocuration,CHEMBL624858,BAO_0000019,
13099,1,A,1,,,,50597,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624859,BAO_0000218,
13100,1,A,1,,,,50597,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624860,BAO_0000218,
13101,1,A,1,,,,50597,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624861,BAO_0000218,
13102,1,A,1,,,,50597,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624862,BAO_0000218,
13103,1,A,1,,,,50597,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624863,BAO_0000218,
13104,1,A,1,,,,50597,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876655,BAO_0000218,
13105,1,A,1,,,,50588,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624864,BAO_0000218,
13106,1,A,1,,,,50588,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624865,BAO_0000218,
13107,1,A,1,,,,50588,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624866,BAO_0000218,
13108,1,F,1,,,,50588,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Expert,CHEMBL624867,BAO_0000218,
13109,1,A,1,,,,50588,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624868,BAO_0000218,
13110,1,A,1,,,,50588,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628450,BAO_0000218,
13111,1,A,1,,,,50588,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628451,BAO_0000218,
13112,1,A,1,,,,50588,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628452,BAO_0000218,
13113,1,A,1,,,,50588,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628453,BAO_0000218,
13114,1,A,1,,,,50588,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628454,BAO_0000218,
13115,1,A,1,,,,50588,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628455,BAO_0000218,
13116,1,A,1,,,,50588,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628456,BAO_0000218,
13117,1,A,1,,,,50588,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628457,BAO_0000218,
13118,1,A,1,,,,50588,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL877505,BAO_0000218,
13119,1,A,1,,,,50588,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628458,BAO_0000218,
13120,1,A,1,,,,50588,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628459,BAO_0000218,
13121,1,A,1,,,,50588,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628460,BAO_0000218,
13122,1,A,1,,,,50588,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628461,BAO_0000218,
13123,1,B,0,,,,22224,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",,,,,,,U,Autocuration,CHEMBL628462,BAO_0000218,
13124,1,A,1,,,,50588,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628463,BAO_0000218,
13125,1,F,1,,,,50597,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",,Rattus norvegicus,,,,10116.0,N,Expert,CHEMBL625666,BAO_0000218,
13126,1,B,0,,,,22224,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,,,,,,U,Autocuration,CHEMBL625667,BAO_0000218,
13127,1,A,1,,,,50597,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,Rattus norvegicus,,,,10116.0,N,Expert,CHEMBL625668,BAO_0000218,
13128,1,A,1,,,,50597,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625669,BAO_0000218,
13129,1,A,0,,,,22224,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,,,,,,,U,Autocuration,CHEMBL625670,BAO_0000019,
13130,1,A,1,,,,50597,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625671,BAO_0000218,
13131,1,A,1,,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,,Human herpesvirus 1,,,,10298.0,N,Intermediate,CHEMBL625672,BAO_0000218,
13132,1,A,1,,,,50602,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,,Human herpesvirus 1,,,,10298.0,N,Intermediate,CHEMBL625673,BAO_0000218,
13133,1,A,1,,,,50602,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,,Human herpesvirus 1,,,,10298.0,N,Intermediate,CHEMBL625674,BAO_0000218,
13134,1,A,1,,,,50602,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,,Human herpesvirus 1,,,,10298.0,N,Intermediate,CHEMBL625675,BAO_0000218,
13135,1,A,1,,,,50602,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,,Human herpesvirus 1,,,,10298.0,N,Intermediate,CHEMBL627637,BAO_0000218,
13136,1,A,1,,,,50602,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,,Human herpesvirus 1,,,,10298.0,N,Intermediate,CHEMBL627638,BAO_0000218,
13137,1,A,1,,,,50602,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,,Human herpesvirus 1,,,,10298.0,N,Intermediate,CHEMBL627639,BAO_0000218,
13138,1,A,1,,,,50602,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,,Human herpesvirus 1,,,,10298.0,N,Intermediate,CHEMBL627640,BAO_0000218,
13139,1,A,1,,,,50602,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,,Human herpesvirus 1,,,,10298.0,N,Intermediate,CHEMBL627641,BAO_0000218,
13140,1,A,1,,,,50602,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,,Human herpesvirus 1,,,,10298.0,N,Intermediate,CHEMBL627642,BAO_0000218,
13141,1,A,1,,,,50602,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,,Human herpesvirus 1,,,,10298.0,N,Intermediate,CHEMBL877506,BAO_0000218,
13142,1,A,1,,,,50594,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627275,BAO_0000218,
13143,1,A,1,,,,50506,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",,Mustela putorius furo,,,,9669.0,N,Intermediate,CHEMBL627643,BAO_0000218,
13144,1,A,1,,,,50506,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",,Mustela putorius furo,,,,9669.0,N,Intermediate,CHEMBL631246,BAO_0000218,
13145,1,A,1,,,,50506,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",,Mustela putorius furo,,,,9669.0,N,Intermediate,CHEMBL631247,BAO_0000218,
13146,1,A,1,,,,50506,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,,Mustela putorius furo,,,,9669.0,N,Intermediate,CHEMBL629532,BAO_0000218,
13147,1,A,1,,,,50506,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,,Mustela putorius furo,,,,9669.0,N,Intermediate,CHEMBL629533,BAO_0000218,
13148,1,A,1,,,,50506,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,,Mustela putorius furo,,,,9669.0,N,Intermediate,CHEMBL629534,BAO_0000218,
13149,1,A,1,,,,50506,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,,Mustela putorius furo,,,,9669.0,N,Intermediate,CHEMBL629535,BAO_0000218,
13150,1,A,0,,,,22224,Pharmacokinetic parameter :drug bound to plasma was reported,,,,,,,U,Autocuration,CHEMBL625932,BAO_0000019,
13151,1,A,0,,,,22224,compound was evaluated for drug bound in plasma,,,,,,,U,Autocuration,CHEMBL625933,BAO_0000019,
13152,1,A,1,,,,50597,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625934,BAO_0000218,
13153,1,A,0,,,,22224,Bioavailability,,Eutheria,,,,9347.0,U,Autocuration,CHEMBL625935,BAO_0000218,
13154,1,A,1,,,,50597,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625936,BAO_0000218,
13155,1,A,1,,,,50597,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625937,BAO_0000218,
13156,1,A,1,,,,50588,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625938,BAO_0000218,
13157,1,A,1,,,,50597,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,1970.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625939,BAO_0000218,
13158,1,A,1,,,,50597,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,1970.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625940,BAO_0000218,
13159,1,A,1,,,,50597,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,1970.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874464,BAO_0000218,
13160,1,A,1,,,,50597,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,1970.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625941,BAO_0000218,
13161,1,A,1,,,,50597,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,1970.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625942,BAO_0000218,
13162,1,A,1,,,,50597,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,1970.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625943,BAO_0000218,
13163,1,A,1,,,,50587,In vitro protein binding in human serum at 5 ug/ml,1977.0,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL625944,BAO_0000218,
13164,1,A,0,,,,22224,Serum protein binding ability was measured,,,,,,,U,Autocuration,CHEMBL625945,BAO_0000019,
13165,1,A,0,,,,22224,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,,,,,,U,Autocuration,CHEMBL625946,BAO_0000019,
13166,1,A,0,,,In vivo,22224,Oral bioavailability in dog,,Canis lupus familiaris,,,,9615.0,U,Autocuration,CHEMBL625947,BAO_0000218,
13167,1,A,1,,,In vivo,50597,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625948,BAO_0000218,
13168,1,A,0,,,In vivo,22224,Absolute oral bioavailability at an iv dose of 14 mg/kg,,,,,,,U,Autocuration,CHEMBL625949,BAO_0000218,
13169,1,A,0,,,In vivo,22224,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,,,,,,,U,Autocuration,CHEMBL625950,BAO_0000218,
13170,1,A,0,,,In vivo,22224,Oral bioavailability (dose 15 mg/kg i.v.),,Eutheria,,,,9347.0,U,Autocuration,CHEMBL625951,BAO_0000218,
13171,1,A,0,,,In vivo,22224,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,,,,,,,U,Autocuration,CHEMBL625952,BAO_0000218,
13172,1,A,0,,,In vivo,22224,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,,,,,,,U,Autocuration,CHEMBL625953,BAO_0000218,
13173,1,A,0,,,In vivo,22224,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,,,,,,,U,Autocuration,CHEMBL625954,BAO_0000218,
13174,1,A,0,,,In vivo,22224,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,,,,,,,U,Autocuration,CHEMBL882959,BAO_0000218,
13175,1,A,1,,,In vivo,50588,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625955,BAO_0000218,
13176,1,A,0,,,In vivo,22224,Bioavailability in ferret,,Mustela putorius furo,,,,9669.0,U,Autocuration,CHEMBL625956,BAO_0000218,
13177,1,A,1,,,In vivo,100710,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL625957,BAO_0000218,
13178,1,A,1,,,,50597,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625958,BAO_0000218,
13179,1,A,1,,,,50597,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625959,BAO_0000218,
13180,1,A,1,,,,50597,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626642,BAO_0000218,
13181,1,A,1,,,,50597,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631330,BAO_0000218,
13182,1,A,1,,,,50597,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631331,BAO_0000218,
13183,1,A,1,,,,50597,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631332,BAO_0000218,
13184,1,A,1,,,,50597,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631333,BAO_0000218,
13185,1,A,1,,,,50597,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632018,BAO_0000218,
13186,1,A,1,,,,50597,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632019,BAO_0000218,
13187,1,A,1,,,,50597,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632020,BAO_0000218,
13188,1,A,1,,,,50597,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632021,BAO_0000218,
13189,1,A,1,,,,50597,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632022,BAO_0000218,
13190,1,A,1,,,,50597,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632023,BAO_0000218,
13191,1,A,1,,,,50597,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632024,BAO_0000218,
13192,1,A,1,,,,50597,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874472,BAO_0000218,
13193,1,A,1,,,,50597,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632025,BAO_0000218,
13194,1,A,1,,,,50597,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632026,BAO_0000218,
13195,1,A,1,,,,50597,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632027,BAO_0000218,
13196,1,A,1,,,,50597,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632028,BAO_0000218,
13197,1,A,1,,,,50597,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626430,BAO_0000218,
13198,1,A,1,,,,50597,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626431,BAO_0000218,
13199,1,A,1,,,,50597,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626432,BAO_0000218,
13200,1,A,1,,,,50597,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626433,BAO_0000218,
13201,1,A,1,,,,50597,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626434,BAO_0000218,
13202,1,A,1,,,,50597,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627280,BAO_0000218,
13203,1,A,1,,,,50597,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627281,BAO_0000218,
13204,1,A,1,,,,50597,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627282,BAO_0000218,
13205,1,A,0,,,,22224,Total body clearance was measured at given dose,,,,,,,U,Autocuration,CHEMBL627283,BAO_0000019,
13206,1,A,0,,,,22224,Total body clearance was measured at given dose.,,,,,,,U,Autocuration,CHEMBL627284,BAO_0000218,
13207,1,A,1,,,,50597,Metabolic clearance from the body in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627285,BAO_0000218,
13208,1,A,0,,,In vivo,22224,Renal clearance from the body,,,,,,,U,Autocuration,CHEMBL627286,BAO_0000218,
13209,1,A,1,,,In vivo,50597,Renal clearance from the body in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875477,BAO_0000218,
13210,1,A,1,,,In vivo,50597,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627287,BAO_0000218,
13211,1,A,1,,,In vivo,50588,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627288,BAO_0000218,
13212,1,A,1,,,,50597,Total clearance from the body in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627289,BAO_0000218,
13213,1,A,1,,,In vivo,50597,Clearance into cortex from rat plasma or PBS,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627290,BAO_0000218,
13214,1,A,0,,,In vivo,22224,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,,,,,,,U,Autocuration,CHEMBL627291,BAO_0000218,
13215,1,A,0,,,In vivo,22224,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,,,,,,,U,Autocuration,CHEMBL627292,BAO_0000218,
13216,1,A,0,,,In vivo,22224,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,,,,,,,U,Autocuration,CHEMBL627293,BAO_0000218,
13217,1,A,0,,,In vivo,22224,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,,,,,,,U,Autocuration,CHEMBL627294,BAO_0000218,
13218,1,A,0,,,In vivo,22224,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,,,,,,,U,Autocuration,CHEMBL875478,BAO_0000218,
13219,1,A,0,,,In vivo,22224,Clearance was determined,,,,,,,U,Autocuration,CHEMBL627295,BAO_0000218,
13220,1,A,1,,,In vivo,50594,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627296,BAO_0000218,
13221,1,A,1,,,In vivo,50592,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL626119,BAO_0000218,
13222,1,A,1,,,In vivo,50597,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626120,BAO_0000218,
13223,1,A,1,,,In vivo,50597,Clearance in rat after iv dose (100 ug/kg),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626121,BAO_0000218,
13224,1,A,0,,,In vivo,22224,Clearance in guinea pig,,Cavia porcellus,,,,10141.0,U,Autocuration,CHEMBL626122,BAO_0000218,
13225,1,A,1,,,In vivo,50597,Compound was evaluated for clearance in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626123,BAO_0000218,
13226,1,A,1,,,In vivo,50588,Compound was evaluated for the clearance in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623456,BAO_0000218,
13227,1,A,1,,,In vivo,50597,Compound was evaluated for the clearance in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623457,BAO_0000218,
13228,1,A,1,,,In vivo,50597,Compound was tested in vivo for clearance after iv administration in the rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623458,BAO_0000218,
13229,1,A,0,,,In vivo,22224,IV clearance determined at an iv dose of 14 mg/kg,,,,,,,U,Autocuration,CHEMBL623459,BAO_0000218,
13230,1,A,0,,,In vivo,22224,IV clearance determined at an iv dose of 15.2 mg/kg,,,,,,,U,Autocuration,CHEMBL875484,BAO_0000218,
13231,1,A,0,,,In vivo,22224,IV clearance determined at an iv dose of 15 mg/kg,,,,,,,U,Autocuration,CHEMBL623460,BAO_0000218,
13232,1,A,0,,,In vivo,22224,IV clearance determined at an peroral dose of 30 mg/kg.,,,,,,,U,Autocuration,CHEMBL623461,BAO_0000218,
13233,1,A,0,,,In vivo,22224,IV clearance determined at an peroral dose of 30.2 mg/kg.,,,,,,,U,Autocuration,CHEMBL623462,BAO_0000218,
13234,1,A,0,,,In vivo,22224,IV clearance determined at an peroral dose of 30.3 mg/kg.,,,,,,,U,Autocuration,CHEMBL627386,BAO_0000218,
13235,1,A,1,,,In vivo,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627387,BAO_0000218,
13236,1,A,1,,,In vivo,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627388,BAO_0000218,
13237,1,A,1,,,In vivo,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627389,BAO_0000218,
13238,1,A,1,,,In vivo,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627390,BAO_0000218,
13239,1,A,1,,,In vivo,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627391,BAO_0000218,
13240,1,A,1,,,In vivo,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627392,BAO_0000218,
13241,1,A,1,,,In vivo,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627393,BAO_0000218,
13242,1,A,1,,,In vivo,50597,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,3126.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627394,BAO_0000218,
13243,1,A,1,,,In vivo,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627395,BAO_0000218,
13244,1,A,1,,,In vivo,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,2037.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875485,BAO_0000218,
13245,1,A,1,,,In vivo,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627396,BAO_0000218,
13246,1,A,1,,,In vivo,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627397,BAO_0000218,
13247,1,A,1,,,In vivo,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627398,BAO_0000218,
13248,1,A,1,,,In vivo,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627399,BAO_0000218,
13249,1,A,1,,,In vivo,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627400,BAO_0000218,
13250,1,A,1,,,In vivo,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627401,BAO_0000218,
13251,1,A,1,,,In vivo,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627402,BAO_0000218,
13252,1,A,1,,,In vivo,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627403,BAO_0000218,
13253,1,A,1,,,In vivo,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627404,BAO_0000218,
13254,1,A,1,,,In vivo,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623101,BAO_0000218,
13255,1,A,1,,,In vivo,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL877480,BAO_0000218,
13256,1,A,1,,,In vivo,50597,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,3126.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623102,BAO_0000218,
13257,1,A,1,,,In vivo,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623103,BAO_0000218,
13258,1,A,1,,,In vivo,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,2037.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623104,BAO_0000218,
13259,1,A,1,,,In vivo,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623105,BAO_0000218,
13260,1,A,1,,,In vivo,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623106,BAO_0000218,
13261,1,A,1,,,In vivo,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623107,BAO_0000218,
13262,1,A,1,,,In vivo,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,160.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623108,BAO_0000218,
13263,1,A,1,,,In vivo,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623109,BAO_0000218,
13264,1,A,1,,,In vivo,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623110,BAO_0000218,
13265,1,A,1,,,In vivo,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623111,BAO_0000218,
13266,1,A,1,,,In vivo,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625060,BAO_0000218,
13267,1,A,1,,,In vivo,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625061,BAO_0000218,
13268,1,A,1,,,In vivo,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625062,BAO_0000218,
13269,1,A,1,,,In vivo,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625063,BAO_0000218,
13270,1,A,1,,,In vivo,50597,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,3126.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625064,BAO_0000218,
13271,1,A,1,,,In vivo,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,10000001.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625065,BAO_0000218,
13272,1,A,1,,,In vivo,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,2037.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625066,BAO_0000218,
13273,1,A,1,,,In vivo,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625067,BAO_0000218,
13274,1,A,1,,,In vivo,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625068,BAO_0000218,
13275,1,A,1,,,In vivo,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622159,BAO_0000218,
13276,1,A,1,,,In vivo,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,160.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622160,BAO_0000218,
13277,1,A,1,,,In vivo,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622161,BAO_0000218,
13278,1,A,1,,,In vivo,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622162,BAO_0000218,
13279,1,A,1,,,In vivo,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622163,BAO_0000218,
13280,1,A,1,,,In vivo,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622313,BAO_0000218,
13281,1,A,1,,,In vivo,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622314,BAO_0000218,
13282,1,A,1,,,In vivo,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622315,BAO_0000218,
13283,1,A,1,,,In vivo,50597,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,3126.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622316,BAO_0000218,
13284,1,A,1,,,,50212,Normal diffusion coefficient in water for Escherichia coli,,Escherichia coli,,,,562.0,N,Intermediate,CHEMBL877486,BAO_0000218,
13285,1,A,0,,,,22224,Average max percent decrease in RVR (renal vascular resistance) was determined,,,,,,,U,Autocuration,CHEMBL622317,BAO_0000019,
13286,1,A,0,,,,22224,Average max percent decrease in RVR (renal vascular resistance) was determined.,,,,,,,U,Autocuration,CHEMBL622318,BAO_0000019,
13287,1,A,0,,,,22224,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,,,,,,,U,Autocuration,CHEMBL622319,BAO_0000019,
13288,1,A,0,,,,22224,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,,,,,,,U,Autocuration,CHEMBL622320,BAO_0000019,
13289,1,A,0,,,,22224,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,,,,,,,U,Autocuration,CHEMBL622321,BAO_0000019,
13290,1,A,0,,,,22224,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,,,,,,,U,Autocuration,CHEMBL622322,BAO_0000019,
13291,1,A,0,,,,22224,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,,,,,,,U,Autocuration,CHEMBL622323,BAO_0000019,
13292,1,A,1,,,,50597,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622324,BAO_0000218,
13293,1,A,1,,,,50588,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622325,BAO_0000218,
13294,1,A,1,,,,50588,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622326,BAO_0000218,
13295,1,A,1,,,,50588,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL877487,BAO_0000218,
13296,1,A,1,,,,50588,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622327,BAO_0000218,
13297,1,A,1,,,,50588,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622328,BAO_0000218,
13298,1,A,1,,,,50588,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622329,BAO_0000218,
13299,1,A,1,,,,50588,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622330,BAO_0000218,
13300,1,A,1,,,,50588,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622331,BAO_0000218,
13301,1,A,1,,,,50588,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622332,BAO_0000218,
13302,1,A,1,,,,50588,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622333,BAO_0000218,
13303,1,A,0,,,,22224,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",1088.0,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL627658,BAO_0000218,
13304,1,A,0,,,,22224,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",1088.0,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL630428,BAO_0000218,
13305,1,A,0,,,,22224,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",1088.0,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL630429,BAO_0000218,
13306,1,A,0,,,,22224,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",1088.0,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL630430,BAO_0000218,
13307,1,A,0,,,,22224,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",1088.0,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL630431,BAO_0000218,
13308,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630432,BAO_0000218,
13309,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630433,BAO_0000218,
13310,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630434,BAO_0000218,
13311,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629372,BAO_0000218,
13312,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629553,BAO_0000218,
13313,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629554,BAO_0000218,
13314,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874447,BAO_0000218,
13315,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629555,BAO_0000218,
13316,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629556,BAO_0000218,
13317,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629557,BAO_0000218,
13318,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629558,BAO_0000218,
13319,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629559,BAO_0000218,
13320,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629560,BAO_0000218,
13321,1,A,1,,,,50588,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL629561,BAO_0000218,
13322,1,A,1,,,,50588,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL629562,BAO_0000218,
13323,1,A,1,,,,50588,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL629563,BAO_0000218,
13324,1,A,1,,,,50588,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL629564,BAO_0000218,
13325,1,A,1,,,,50588,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL629565,BAO_0000218,
13326,1,A,1,,,,50588,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL629566,BAO_0000218,
13327,1,A,1,,,,50588,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL629567,BAO_0000218,
13328,1,A,1,,,,50588,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL629568,BAO_0000218,
13329,1,A,1,,,,50588,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL629569,BAO_0000218,
13330,1,A,1,,,,50588,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL629570,BAO_0000218,
13331,1,A,0,,,,22224,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",1088.0,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL629571,BAO_0000218,
13332,1,A,0,,,In vivo,22224,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL629572,BAO_0000218,
13333,1,A,0,,,In vivo,22224,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL629573,BAO_0000218,
13334,1,A,0,,,In vivo,22224,Bioavailability (dose 20 mg/kg),,Eutheria,,,,9347.0,U,Autocuration,CHEMBL629574,BAO_0000218,
13335,1,A,0,,,In vivo,22224,Bioavailability in dog,,Canis lupus familiaris,,,,9615.0,U,Autocuration,CHEMBL629575,BAO_0000218,
13336,1,A,0,,,In vivo,22224,Bioavailability in rat (Sprague-Dawley) (male),,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL874448,BAO_0000218,
13337,1,A,0,,,In vivo,22224,Bioavailability in monkey (dose 10 mg/kg i.d.),,Primates,,,,9443.0,U,Autocuration,CHEMBL629576,BAO_0000218,
13338,1,A,0,,,In vivo,22224,Bioavailability in rat,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL629577,BAO_0000218,
13339,1,A,0,,,In vivo,22224,Bioavailability in rat,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL629578,BAO_0000218,
13340,1,A,0,,,In vivo,22224,Bioavailability in dog (dose 3.0 mg/kg p.o.),,Canis lupus familiaris,,,,9615.0,U,Autocuration,CHEMBL629579,BAO_0000218,
13341,1,A,0,,,In vivo,22224,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,,Canis lupus familiaris,,,,9615.0,U,Autocuration,CHEMBL882958,BAO_0000218,
13342,1,A,1,,,In vivo,50505,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,,Pan troglodytes,,,,9598.0,N,Intermediate,CHEMBL629580,BAO_0000218,
13343,1,A,0,,,In vivo,22224,Bioavailability,,Eutheria,,,,9347.0,U,Autocuration,CHEMBL629581,BAO_0000218,
13344,1,A,0,,,In vivo,22224,Bioavailability in squirrel monkey,,Saimiri,,,,9520.0,U,Autocuration,CHEMBL629582,BAO_0000218,
13345,1,A,1,,,In vivo,50588,Bioavailability was evaluated in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628522,BAO_0000218,
13346,1,A,1,,,In vivo,100712,Bioavailability was evaluated in hamster,,Cricetinae,,,,10026.0,N,Intermediate,CHEMBL625432,BAO_0000218,
13347,1,A,0,,,In vivo,22224,Bioavailability in rat,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL625433,BAO_0000218,
13348,1,A,1,,,In vivo,50597,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625434,BAO_0000218,
13349,1,A,1,,,In vivo,50597,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625435,BAO_0000218,
13350,1,A,0,,,In vivo,22224,Bioavailability in rat (dose 10 mg/kg p.o.),,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL625436,BAO_0000218,
13351,1,A,1,,,In vivo,100710,Bioavailability was measured in cynomolgus monkeys.,,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL874588,BAO_0000218,
13352,1,A,1,,,In vivo,50594,Bioavailability was measured in nude mice.,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625437,BAO_0000218,
13353,1,A,0,,,In vivo,22224,Bioavailability in ferret (dose 10 mg/kg i.d.),,Mustela putorius furo,,,,9669.0,U,Autocuration,CHEMBL625438,BAO_0000218,
13354,1,A,0,,,In vivo,22224,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL625439,BAO_0000218,
13355,1,A,0,,,In vivo,22224,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL625440,BAO_0000218,
13356,1,A,0,,,In vivo,22224,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL625441,BAO_0000218,
13357,1,A,0,,,In vivo,22224,Bioavailability in rat (dose 10 mg/kg i.d.),,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL625442,BAO_0000218,
13358,1,A,1,,,In vivo,50597,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625443,BAO_0000218,
13359,1,A,0,,,In vivo,22224,Bioavailability was determined; extremely poor,,,,,,,U,Autocuration,CHEMBL625444,BAO_0000218,
13360,1,A,1,,,In vivo,50594,% bioavailability in mice after oral administration of prodrug,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625445,BAO_0000218,
13361,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625446,BAO_0000218,
13362,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL882960,BAO_0000218,
13363,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625447,BAO_0000218,
13364,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625448,BAO_0000218,
13365,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625449,BAO_0000218,
13366,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL874589,BAO_0000218,
13367,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625450,BAO_0000218,
13368,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625451,BAO_0000218,
13369,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626584,BAO_0000218,
13370,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626585,BAO_0000218,
13371,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626586,BAO_0000218,
13372,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626587,BAO_0000218,
13373,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626588,BAO_0000218,
13374,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626589,BAO_0000218,
13375,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626590,BAO_0000218,
13376,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626591,BAO_0000218,
13377,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627181,BAO_0000218,
13378,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628083,BAO_0000218,
13379,1,A,0,,,In vivo,22224,IV clearance determined at an peroral dose of 15 mg/kg.,,,,,,,U,Autocuration,CHEMBL628084,BAO_0000218,
13380,1,F,1,,,In vivo,50064,Mouse oral clearance was measured against Hymenolepiasis nana.,,Hymenolepis nana,,,,102285.0,N,Expert,CHEMBL628085,BAO_0000218,
13381,1,F,1,,,In vivo,50545,Mouse oral clearance was measured against Nematospiroides dubius,,Heligmosomoides polygyrus,,,,6339.0,N,Expert,CHEMBL628086,BAO_0000218,
13382,1,F,0,,,In vivo,22224,Mouse oral clearance was measured against N. dubius; NT is Not Tested,,,,,,,U,Autocuration,CHEMBL628087,BAO_0000218,
13383,1,A,1,,,In vivo,50594,Mouse oral clearance was measured against N. nana; NT is Not Tested,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL628088,BAO_0000218,
13384,1,B,0,,,In vivo,22224,Mouse oral clearance was measured against N. nana; NT is Not Tested,,,,,,,U,Autocuration,CHEMBL628089,BAO_0000218,
13385,1,A,0,,,In vivo,22224,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,,,,,,,U,Autocuration,CHEMBL628090,BAO_0000218,
13386,1,A,0,,,In vivo,22224,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,,,,,,,U,Autocuration,CHEMBL628091,BAO_0000218,
13387,1,A,0,,,In vivo,22224,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,,,,,,,U,Autocuration,CHEMBL628092,BAO_0000218,
13388,1,A,0,,,In vivo,22224,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,,,,,,,U,Autocuration,CHEMBL628093,BAO_0000218,
13389,1,A,0,,,In vivo,22224,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,,,,,,,U,Autocuration,CHEMBL875607,BAO_0000218,
13390,1,A,0,,,In vivo,22224,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,,,,,,,U,Autocuration,CHEMBL625710,BAO_0000218,
13391,1,A,0,,,In vivo,22224,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,,,,,,,U,Autocuration,CHEMBL625711,BAO_0000218,
13392,1,A,0,,,In vivo,22224,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,,,,,,,U,Autocuration,CHEMBL625712,BAO_0000218,
13393,1,A,0,,,In vivo,22224,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,,,,,,,U,Autocuration,CHEMBL625713,BAO_0000218,
13394,1,A,1,,,In vivo,50588,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625714,BAO_0000218,
13395,1,A,1,,,In vivo,50797,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,,Macaca mulatta,,,,9544.0,N,Intermediate,CHEMBL625715,BAO_0000218,
13396,1,A,1,,,In vivo,50597,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625716,BAO_0000218,
13397,1,A,1,,,In vivo,50597,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625717,BAO_0000218,
13398,1,A,1,,,In vivo,50597,Plasma clearance was determined for the compound in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625718,BAO_0000218,
13399,1,A,1,,,In vivo,50597,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625719,BAO_0000218,
13400,1,A,1,,,In vivo,50597,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625720,BAO_0000218,
13401,1,A,1,,,In vivo,50597,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625721,BAO_0000218,
13402,1,A,1,,,In vivo,50597,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625722,BAO_0000218,
13403,1,A,1,,,In vivo,50597,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625723,BAO_0000218,
13404,1,A,1,,,In vivo,50545,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,,Heligmosomoides polygyrus,,,,6339.0,N,Intermediate,CHEMBL625724,BAO_0000218,
13405,1,A,1,,,In vivo,50545,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,,Heligmosomoides polygyrus,,,,6339.0,N,Intermediate,CHEMBL625725,BAO_0000218,
13406,1,A,1,,,In vivo,50545,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,,Heligmosomoides polygyrus,,,,6339.0,N,Intermediate,CHEMBL625726,BAO_0000218,
13407,1,A,1,,,In vivo,50545,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,,Heligmosomoides polygyrus,,,,6339.0,N,Intermediate,CHEMBL875608,BAO_0000218,
13408,1,A,1,,,In vivo,50545,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,,Heligmosomoides polygyrus,,,,6339.0,N,Intermediate,CHEMBL625727,BAO_0000218,
13409,1,A,0,,,In vivo,22224,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,1088.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL625728,BAO_0000218,
13410,1,A,0,,,In vivo,22224,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL625729,BAO_0000218,
13411,1,A,0,,,In vivo,22224,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL625730,BAO_0000218,
13412,1,A,0,,,In vivo,22224,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,1088.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL625731,BAO_0000218,
13413,1,A,0,,,In vivo,22224,Urinary clearance was determined in rat at 25 mg/kg os dosage,1088.0,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL626417,BAO_0000218,
13414,1,A,1,,,In vivo,50587,Urinary clearance was determined at 100 mg/kg oral dosage in human,1088.0,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL626418,BAO_0000218,
13415,1,A,1,,,In vivo,50588,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626419,BAO_0000218,
13416,1,A,1,,,In vivo,50588,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626592,BAO_0000218,
13417,1,A,1,,,In vivo,50597,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626593,BAO_0000218,
13418,1,A,1,,,In vivo,50597,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626594,BAO_0000218,
13419,1,A,1,,,In vivo,50588,Clearance rate in dogs,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625035,BAO_0000218,
13420,1,A,0,,,In vitro,22224,Compound was measured for intrinsic clearance,,,,,,,U,Autocuration,CHEMBL625036,BAO_0000019,
13421,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL625037,BAO_0000100,
13422,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL625038,BAO_0000100,
13423,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL625039,BAO_0000100,
13424,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL625040,BAO_0000100,
13425,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL625041,BAO_0000100,
13426,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL625042,BAO_0000100,
13427,1,A,0,,,,22224,Partition coefficient of the compound,,,,,,,U,Autocuration,CHEMBL874411,BAO_0000019,
13428,1,A,0,,,,22224,Permeability,,,,,,,U,Autocuration,CHEMBL625043,BAO_0000019,
13429,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL625044,BAO_0000100,
13430,1,A,0,,,,22224,Partition coefficient (logD),,,,,,,U,Autocuration,CHEMBL625045,BAO_0000019,
13431,1,P,0,,,,22229,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,,,,,,U,Autocuration,CHEMBL625046,BAO_0000100,
13432,1,P,0,,,,22229,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,,,,,,U,Autocuration,CHEMBL625047,BAO_0000100,
13433,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL625048,BAO_0000100,
13434,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL625049,BAO_0000100,
13435,1,P,0,,,,22229,Calculated logarithm of partition coefficient (P) was determined,,,,,,,U,Autocuration,CHEMBL625050,BAO_0000100,
13436,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL625051,BAO_0000100,
13437,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL874412,BAO_0000100,
13438,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL625052,BAO_0000100,
13439,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL625053,BAO_0000100,
13440,1,A,0,,,,22224,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,,,,,,,U,Autocuration,CHEMBL623250,BAO_0000019,
13441,1,A,0,,,,22224,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,,,,,,,U,Autocuration,CHEMBL623251,BAO_0000019,
13442,1,A,0,,,,22224,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,,,,,,,U,Autocuration,CHEMBL623252,BAO_0000019,
13443,1,A,0,,,,22224,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,,,,,,,U,Autocuration,CHEMBL623253,BAO_0000019,
13444,1,A,0,,,,22224,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,,,,,,,U,Autocuration,CHEMBL623254,BAO_0000019,
13445,1,A,0,,,,22224,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,,,,,,,U,Autocuration,CHEMBL623255,BAO_0000019,
13446,1,A,0,,,,22224,Percent degradation of compound at a pH of 1 over a 18 hr period,,,,,,,U,Autocuration,CHEMBL626831,BAO_0000019,
13447,1,A,0,,,,22224,Percent degradation of compound at pH of 1 over an 18 hr period,,,,,,,U,Autocuration,CHEMBL877494,BAO_0000019,
13448,1,A,0,,,,22224,Delta Logarithm of Partition Coefficient value was determined.,,,,,,,U,Autocuration,CHEMBL626832,BAO_0000019,
13449,1,A,0,,,,22224,Delta logPoct-cyc,,,,,,,U,Autocuration,CHEMBL626833,BAO_0000019,
13450,1,P,0,,,,22224,Lipophilicity estimated on reversed phase TLC,,,,,,,U,Autocuration,CHEMBL626834,BAO_0000100,
13451,1,A,0,,,,22224,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,,,,,,,U,Autocuration,CHEMBL626835,BAO_0000019,
13452,1,A,0,,,,22224,Delta logPoct-cyc,,,,,,,U,Autocuration,CHEMBL626836,BAO_0000019,
13453,1,P,0,,,,22229,Change in logarithm of partition coefficient of the compound,,,,,,,U,Autocuration,CHEMBL626837,BAO_0000100,
13454,1,A,0,,,,22224,Delta logD (pH 6.5),,,,,,,U,Autocuration,CHEMBL626838,BAO_0000019,
13455,1,P,0,,,,22224,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",,,,,,,U,Autocuration,CHEMBL626839,BAO_0000100,
13456,1,A,0,,,,22224,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,,,,,,,U,Autocuration,CHEMBL626840,BAO_0000019,
13457,1,A,0,,,,22224,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),,,,,,,U,Autocuration,CHEMBL626841,BAO_0000019,
13458,1,A,0,,,,22224,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,,,,,,,U,Autocuration,CHEMBL626842,BAO_0000219,
13459,1,A,0,,,,22224,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,,,,,,,U,Autocuration,CHEMBL626843,BAO_0000219,
13460,1,A,1,,,,50597,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626844,BAO_0000218,
13461,1,A,1,,,,50597,Amount of deuterium retained was reported after normal workup in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL877495,BAO_0000218,
13462,1,A,1,,,,50597,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626845,BAO_0000218,
13463,1,A,1,,,,50597,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626846,BAO_0000218,
13464,1,A,1,,,,50597,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626847,BAO_0000218,
13465,1,A,1,,,,50597,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628677,BAO_0000218,
13466,1,A,1,,,,50597,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628678,BAO_0000218,
13467,1,A,0,,,,22224,Compound was subjected to electrochemical oxidation,,,,,,,U,Autocuration,CHEMBL628679,BAO_0000019,
13468,1,A,0,,,,22224,Compound was subjected to photochemical oxidation,,,,,,,U,Autocuration,CHEMBL628680,BAO_0000019,
13469,1,A,0,,,,22224,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,,,,,,,U,Autocuration,CHEMBL628681,BAO_0000019,
13470,1,A,0,,,,22224,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,,,,,,,U,Autocuration,CHEMBL628682,BAO_0000019,
13471,1,A,0,,,,22224,Oxidation of compound by methemoglobin in presence of hydroperoxide,,,,,,,U,Autocuration,CHEMBL628683,BAO_0000019,
13472,1,A,1,,,,50597,Percent diffusion through fuzzy rat skin after 48 h of incubation,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628684,BAO_0000218,
13473,1,P,0,,,,22229,Dissociation constant (pKa),,,,,,,U,Autocuration,CHEMBL877501,BAO_0000100,
13474,1,P,0,,,,22224,Dissociation constant value of the compound; ND means not determined.,,,,,,,U,Autocuration,CHEMBL628685,BAO_0000100,
13475,1,A,1,,,,50597,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628686,BAO_0000218,
13476,1,A,1,,,,50597,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628687,BAO_0000218,
13477,1,A,1,,,,50597,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628688,BAO_0000218,
13478,1,A,1,,,,50597,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628689,BAO_0000218,
13479,1,A,1,,,,50597,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628690,BAO_0000218,
13480,1,A,1,,,,50597,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629363,BAO_0000218,
13481,1,A,1,,,,50597,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629364,BAO_0000218,
13482,1,A,1,,,,50597,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629365,BAO_0000218,
13483,1,A,1,,,,50597,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629366,BAO_0000218,
13484,1,A,1,,,,50597,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629367,BAO_0000218,
13485,1,A,1,,,,50597,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,1988.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629368,BAO_0000218,
13486,1,A,1,,,,50597,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL877502,BAO_0000218,
13487,1,A,1,,,,50594,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,2037.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL629369,BAO_0000218,
13488,1,A,1,,,,50594,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL629370,BAO_0000218,
13489,1,A,0,,,,22224,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",1088.0,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL629371,BAO_0000218,
13490,1,A,0,,,,22224,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",1088.0,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL626276,BAO_0000218,
13491,1,A,0,,,,22224,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",1088.0,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL626277,BAO_0000218,
13492,1,A,0,,,,22224,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",1088.0,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL631250,BAO_0000218,
13493,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631251,BAO_0000218,
13494,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631252,BAO_0000218,
13495,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631253,BAO_0000218,
13496,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631254,BAO_0000218,
13497,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631255,BAO_0000218,
13498,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631256,BAO_0000218,
13499,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631257,BAO_0000218,
13500,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628009,BAO_0000218,
13501,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628010,BAO_0000218,
13502,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628011,BAO_0000218,
13503,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628012,BAO_0000218,
13504,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628013,BAO_0000218,
13505,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628014,BAO_0000218,
13506,1,A,1,,,,50588,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628015,BAO_0000218,
13507,1,A,1,,,,50588,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628016,BAO_0000218,
13508,1,A,1,,,,50588,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL874461,BAO_0000218,
13509,1,A,1,,,,50588,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628017,BAO_0000218,
13510,1,A,1,,,,50588,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628018,BAO_0000218,
13511,1,A,1,,,,50588,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628019,BAO_0000218,
13512,1,A,1,,,,50588,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628020,BAO_0000218,
13513,1,A,1,,,,50588,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628021,BAO_0000218,
13514,1,A,1,,,,50588,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628022,BAO_0000218,
13515,1,A,1,,,,50588,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628023,BAO_0000218,
13516,1,A,0,,,,22224,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",1088.0,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL628024,BAO_0000218,
13517,1,A,0,,,,22224,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",1088.0,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL628025,BAO_0000218,
13518,1,A,0,,,,22224,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",1088.0,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL628026,BAO_0000218,
13519,1,A,0,,,,22224,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",1088.0,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL628027,BAO_0000218,
13520,1,A,0,,,,22224,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",1088.0,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL628028,BAO_0000218,
13521,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628029,BAO_0000218,
13522,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628030,BAO_0000218,
13523,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628031,BAO_0000218,
13524,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628032,BAO_0000218,
13525,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628033,BAO_0000218,
13526,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628034,BAO_0000218,
13527,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628035,BAO_0000218,
13528,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628036,BAO_0000218,
13529,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874462,BAO_0000218,
13530,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628037,BAO_0000218,
13531,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628123,BAO_0000218,
13532,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628124,BAO_0000218,
13533,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628125,BAO_0000218,
13534,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628126,BAO_0000218,
13535,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628127,BAO_0000218,
13536,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628128,BAO_0000218,
13537,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628129,BAO_0000218,
13538,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628130,BAO_0000218,
13539,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628131,BAO_0000218,
13540,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628132,BAO_0000218,
13541,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628133,BAO_0000218,
13542,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628134,BAO_0000218,
13543,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628135,BAO_0000218,
13544,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628136,BAO_0000218,
13545,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628137,BAO_0000218,
13546,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628138,BAO_0000218,
13547,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628139,BAO_0000218,
13548,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628140,BAO_0000218,
13549,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628141,BAO_0000218,
13550,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628142,BAO_0000218,
13551,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628143,BAO_0000218,
13552,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628144,BAO_0000218,
13553,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628145,BAO_0000218,
13554,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL628146,BAO_0000218,
13555,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625355,BAO_0000218,
13556,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625356,BAO_0000218,
13557,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625357,BAO_0000218,
13558,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625527,BAO_0000218,
13559,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL875473,BAO_0000218,
13560,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625528,BAO_0000218,
13561,1,A,1,,,In vivo,50597,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626304,BAO_0000218,
13562,1,A,1,,,In vivo,50588,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,1637.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624138,BAO_0000218,
13563,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL624139,BAO_0000100,
13564,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL624140,BAO_0000100,
13565,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL624141,BAO_0000100,
13566,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL624142,BAO_0000100,
13567,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL624143,BAO_0000100,
13568,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL624144,BAO_0000100,
13569,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL624145,BAO_0000100,
13570,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL624146,BAO_0000100,
13571,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL624147,BAO_0000100,
13572,1,P,0,,,,22229,Calculated partition coefficient (clogP) (MacLogP),,,,,,,U,Autocuration,CHEMBL883123,BAO_0000100,
13573,1,A,0,,,,22224,Partition coefficient (logP),,,,,,,U,Autocuration,CHEMBL624148,BAO_0000019,
13574,1,A,0,,,,22224,Kinetic parameter was determined,,,,,,,U,Autocuration,CHEMBL874416,BAO_0000019,
13575,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL624149,BAO_0000100,
13576,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL624150,BAO_0000100,
13577,1,P,0,,,,22224,Lipophilicity was determined,,,,,,,U,Autocuration,CHEMBL624151,BAO_0000100,
13578,1,P,0,,,,22224,Lipophilicity was determined,,,,,,,U,Autocuration,CHEMBL624152,BAO_0000100,
13579,1,P,0,,,,22224,Lipophilicity was determined,,,,,,,U,Autocuration,CHEMBL622139,BAO_0000100,
13580,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL622140,BAO_0000100,
13581,1,P,0,,,,22224,Lipophilicity was determined,,,,,,,U,Autocuration,CHEMBL622141,BAO_0000100,
13582,1,P,0,,,,22224,Lipophilicity in octanol-water,,,,,,,U,Autocuration,CHEMBL622142,BAO_0000100,
13583,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL622143,BAO_0000100,
13584,1,P,0,,,,22229,Octanol-water partition coefficient was determined,,,,,,,U,Autocuration,CHEMBL622144,BAO_0000100,
13585,1,A,0,,,,22224,Partition coefficient (logP),,,,,,,U,Autocuration,CHEMBL877473,BAO_0000019,
13586,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL622145,BAO_0000100,
13587,1,A,0,,,,22224,Partition coefficient was determined; ND means not determined,,,,,,,U,Autocuration,CHEMBL622146,BAO_0000019,
13588,1,P,0,,,,22229,Calculated partition coefficient (clogP),,,,,,,U,Autocuration,CHEMBL622147,BAO_0000100,
13589,1,A,0,,,,22224,Partition coefficient of the compound,,,,,,,U,Autocuration,CHEMBL622148,BAO_0000019,
13590,1,A,0,,,,22224,Permeability was determined,,,,,,,U,Autocuration,CHEMBL883124,BAO_0000019,
13591,1,P,0,,,,22229,The compound was evaluated for the partition coefficient,,,,,,,U,Autocuration,CHEMBL622149,BAO_0000100,
13592,1,A,0,,,,22224,Partition coefficient (logP),,,,,,,U,Autocuration,CHEMBL622150,BAO_0000019,
13593,1,P,0,,,,22224,The lipophilicity was reported,,,,,,,U,Autocuration,CHEMBL622151,BAO_0000100,
13594,1,P,0,,,,22229,logarithm of the octanol-water partition coefficient for the compound,,,,,,,U,Autocuration,CHEMBL622152,BAO_0000100,
13595,1,A,0,,,,22224,Clogp value was determined,,,,,,,U,Autocuration,CHEMBL622153,BAO_0000019,
13596,1,A,0,,,In vivo,22224,Clp at a dose of 1.5 mg/kg,,,,,,,U,Autocuration,CHEMBL877474,BAO_0000218,
13597,1,A,0,,,In vivo,22224,Clp at a dose of 2.0 mg/kg,,,,,,,U,Autocuration,CHEMBL622154,BAO_0000218,
13598,1,A,0,,,In vivo,22224,"Clp, plasma clearance at a dose of 10 mg/kg",1969.0,,,,,,U,Autocuration,CHEMBL622155,BAO_0000218,
13599,1,A,0,,,In vivo,22224,"Clp, plasma clearance at a dose of 50 mg/kg",1969.0,,,,,,U,Autocuration,CHEMBL622156,BAO_0000218,
13600,1,A,1,,,In vivo,50597,Compound was tested for plasma clearance in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622157,BAO_0000218,
13601,1,A,1,,,In vivo,50597,Compound was tested for plasma clearance in rat; Not determined,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622158,BAO_0000218,
13602,1,A,1,,,In vivo,50597,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622807,BAO_0000218,
13603,1,A,1,,,In vivo,50797,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,,Macaca mulatta,,,,9544.0,N,Intermediate,CHEMBL622808,BAO_0000218,
13604,1,A,0,,,In vivo,22224,Plasma clearance by iv administration at a dose 0.003 ug/mL,,,,,,,U,Autocuration,CHEMBL622809,BAO_0000218,
13605,1,A,0,,,In vivo,22224,Plasma clearance determined,,,,,,,U,Autocuration,CHEMBL622810,BAO_0000218,
13606,1,A,1,,,In vivo,100712,Plasma clearance after iv administration at 3 mg/kg in hamster,,Cricetinae,,,,10026.0,N,Intermediate,CHEMBL876653,BAO_0000218,
13607,1,A,1,,,In vivo,100712,Plasma clearance after iv administration at 4 mg/kg in hamster,,Cricetinae,,,,10026.0,N,Intermediate,CHEMBL622811,BAO_0000218,
13608,1,A,1,,,In vivo,50597,Rate of clearance in rat was determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622986,BAO_0000218,
13609,1,A,1,,,In vivo,50597,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622987,BAO_0000218,
13610,1,A,1,,,In vivo,50597,Total plasma clearance after iv dose of 5.10 mg/kg in rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622988,BAO_0000218,
13611,1,A,1,,,In vivo,50597,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622989,BAO_0000218,
13612,1,A,1,,,In vivo,50597,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622990,BAO_0000218,
13613,1,A,0,,,In vivo,22224,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,1969.0,Simiiformes,,,,314293.0,U,Autocuration,CHEMBL622991,BAO_0000218,
13614,1,A,1,,,In vivo,50597,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622227,BAO_0000218,
13615,1,A,1,,,In vivo,50588,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622228,BAO_0000218,
13616,1,A,1,,,In vivo,50597,Clpl value in rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622229,BAO_0000218,
13617,1,A,1,,,In vivo,50512,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,,Cavia porcellus,,,,10141.0,N,Intermediate,CHEMBL622230,BAO_0000218,
13618,1,A,1,,,In vivo,50597,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622231,BAO_0000218,
13619,1,A,1,,,In vivo,100710,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,,Macaca fascicularis,,,,9541.0,N,Intermediate,CHEMBL622232,BAO_0000218,
13620,1,A,0,,,In vivo,22224,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,,,,,,,U,Autocuration,CHEMBL622233,BAO_0000218,
13621,1,A,0,,,In vivo,22224,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,,,,,,,U,Autocuration,CHEMBL622234,BAO_0000218,
13622,1,A,0,,,In vivo,22224,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,,,,,,,U,Autocuration,CHEMBL622235,BAO_0000218,
13623,1,A,0,,,In vivo,22224,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,,,,,,,U,Autocuration,CHEMBL622236,BAO_0000218,
13624,1,A,0,,,In vivo,22224,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,,,,,,,U,Autocuration,CHEMBL622237,BAO_0000218,
13625,1,A,0,,,In vivo,22224,Cmax in minutes at a po dose of 10.0(pmol/g/h).,,,,,,,U,Autocuration,CHEMBL877482,BAO_0000218,
13626,1,A,0,,,In vivo,22224,Cmax in minutes at a po dose of 20.0(pmol/g/h).,,,,,,,U,Autocuration,CHEMBL622238,BAO_0000218,
13627,1,A,0,,,In vivo,22224,Cmax in minutes at a po dose of 40.0(pmol/g/h).,,,,,,,U,Autocuration,CHEMBL622239,BAO_0000218,
13628,1,A,0,,,In vivo,22224,Cmax was calculated as maximum concentration reached in the blood,178.0,,,,,,U,Autocuration,CHEMBL622240,BAO_0000218,
13629,1,A,0,,,In vivo,22224,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,178.0,,,,,,U,Autocuration,CHEMBL622241,BAO_0000218,
13630,1,A,1,,,In vivo,50597,Cmax was determine after peroral administration at 10 mpk in Rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631013,BAO_0000218,
13631,1,A,1,,,In vivo,50797,Cmax was determine after peroral administration at 10 mpk in Rhesus,,Macaca mulatta,,,,9544.0,N,Intermediate,CHEMBL631014,BAO_0000218,
13632,1,A,1,,,In vivo,50588,Cmax was determine after peroral administration at 10 mpk in dog,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL631015,BAO_0000218,
13633,1,A,1,,,In vivo,50597,Cmax was determine after peroral administration at 160 mpk in Rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631016,BAO_0000218,
13634,1,A,1,,,In vivo,50597,Cmax was determine after peroral administration at 20 mpk in Rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631017,BAO_0000218,
13635,1,A,1,,,In vivo,50597,Cmax was determine after peroral administration at 50 mpk in Rat,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631018,BAO_0000218,
13636,1,A,0,,,In vivo,22224,Cmax was determined,,,,,,,U,Autocuration,CHEMBL631019,BAO_0000218,
13637,1,A,1,,,,50594,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL875761,BAO_0000218,
13638,1,A,1,,,,50594,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL631020,BAO_0000218,
13639,1,A,1,,,,50594,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL631669,BAO_0000218,
13640,1,A,1,,,,50594,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL631670,BAO_0000218,
13641,1,A,1,,,,50594,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,2435.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL631671,BAO_0000218,
13642,1,A,1,,,,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631672,BAO_0000218,
13643,1,A,1,,,,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631673,BAO_0000218,
13644,1,A,1,,,,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631856,BAO_0000218,
13645,1,A,1,,,,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631857,BAO_0000218,
13646,1,A,1,,,,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631858,BAO_0000218,
13647,1,A,1,,,,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631859,BAO_0000218,
13648,1,A,1,,,,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631860,BAO_0000218,
13649,1,A,1,,,,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631861,BAO_0000218,
13650,1,A,1,,,,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631862,BAO_0000218,
13651,1,A,1,,,,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631863,BAO_0000218,
13652,1,A,1,,,,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631864,BAO_0000218,
13653,1,A,1,,,,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631865,BAO_0000218,
13654,1,A,1,,,,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631866,BAO_0000218,
13655,1,A,1,,,,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629360,BAO_0000218,
13656,1,A,1,,,,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629361,BAO_0000218,
13657,1,A,1,,,,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629362,BAO_0000218,
13658,1,A,1,,,,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630740,BAO_0000218,
13659,1,A,1,,,,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630741,BAO_0000218,
13660,1,A,1,,,,50597,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630742,BAO_0000218,
13661,1,A,1,,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630743,BAO_0000218,
13662,1,A,1,,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630744,BAO_0000218,
13663,1,A,1,,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630745,BAO_0000218,
13664,1,A,1,,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630746,BAO_0000218,
13665,1,A,1,,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630747,BAO_0000218,
13666,1,A,1,,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630748,BAO_0000218,
13667,1,A,1,,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632056,BAO_0000218,
13668,1,A,1,,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632057,BAO_0000218,
13669,1,A,1,,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632058,BAO_0000218,
13670,1,A,1,,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632059,BAO_0000218,
13671,1,A,1,,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632060,BAO_0000218,
13672,1,A,1,,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632061,BAO_0000218,
13673,1,A,1,,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629207,BAO_0000218,
13674,1,A,1,,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629208,BAO_0000218,
13675,1,A,1,,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629209,BAO_0000218,
13676,1,A,1,,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629210,BAO_0000218,
13677,1,A,1,,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629211,BAO_0000218,
13678,1,A,1,,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629212,BAO_0000218,
13679,1,A,1,,,,50597,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629213,BAO_0000218,
13680,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629214,BAO_0000218,
13681,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629215,BAO_0000218,
13682,1,A,1,,,,50597,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL635154,BAO_0000218,
13683,1,A,1,,,,50597,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629216,BAO_0000218,
13684,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629217,BAO_0000218,
13685,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629218,BAO_0000218,
13686,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629219,BAO_0000218,
13687,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629220,BAO_0000218,
13688,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629221,BAO_0000218,
13689,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631127,BAO_0000218,
13690,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631128,BAO_0000218,
13691,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631129,BAO_0000218,
13692,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631130,BAO_0000218,
13693,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631131,BAO_0000218,
13694,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631132,BAO_0000218,
13695,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631133,BAO_0000218,
13696,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631134,BAO_0000218,
13697,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875120,BAO_0000218,
13698,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631135,BAO_0000218,
13699,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631136,BAO_0000218,
13700,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631137,BAO_0000218,
13701,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631138,BAO_0000218,
13702,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631139,BAO_0000218,
13703,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631140,BAO_0000218,
13704,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631141,BAO_0000218,
13705,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631142,BAO_0000218,
13706,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631143,BAO_0000218,
13707,1,A,1,,,,50597,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631144,BAO_0000218,
13708,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL631145,BAO_0000218,
13709,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL631146,BAO_0000218,
13710,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL631147,BAO_0000218,
13711,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL631148,BAO_0000218,
13712,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL631149,BAO_0000218,
13713,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL631150,BAO_0000218,
13714,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL631151,BAO_0000218,
13715,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL631152,BAO_0000218,
13716,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL631443,BAO_0000218,
13717,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL631444,BAO_0000218,
13718,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL631445,BAO_0000218,
13719,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL631446,BAO_0000218,
13720,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL631447,BAO_0000218,
13721,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL631448,BAO_0000218,
13722,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL631449,BAO_0000218,
13723,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL631450,BAO_0000218,
13724,1,A,1,,,,50588,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL629724,BAO_0000218,
13725,1,A,1,,,In vivo,50594,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",14.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL629725,BAO_0000218,
13726,1,A,1,,,In vivo,50594,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",14.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL629726,BAO_0000218,
13727,1,A,1,,,In vivo,50594,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL629727,BAO_0000218,
13728,1,A,1,,,In vivo,50594,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630404,BAO_0000218,
13729,1,A,1,,,In vivo,50594,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630405,BAO_0000218,
13730,1,A,1,,,In vivo,50594,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630406,BAO_0000218,
13731,1,A,1,,,In vivo,50594,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",945.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630407,BAO_0000218,
13732,1,A,1,,,In vivo,50594,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",945.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630573,BAO_0000218,
13733,1,A,1,,,In vivo,50594,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",945.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630574,BAO_0000218,
13734,1,A,1,,,In vivo,50594,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",945.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630575,BAO_0000218,
13735,1,A,1,,,In vivo,50594,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630576,BAO_0000218,
13736,1,A,1,,,In vivo,50594,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630577,BAO_0000218,
13737,1,A,1,,,In vivo,50594,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630578,BAO_0000218,
13738,1,A,1,,,In vivo,50594,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630579,BAO_0000218,
13739,1,A,1,,,,50594,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630580,BAO_0000218,
13740,1,A,1,,,,50594,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630581,BAO_0000218,
13741,1,A,1,,,,50594,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630582,BAO_0000218,
13742,1,A,1,,,,50594,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630583,BAO_0000218,
13743,1,A,1,,,,50594,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630584,BAO_0000218,
13744,1,A,1,,,,50594,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630585,BAO_0000218,
13745,1,A,1,,,,50594,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630586,BAO_0000218,
13746,1,A,1,,,,50594,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630587,BAO_0000218,
13747,1,A,1,,,,50594,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630588,BAO_0000218,
13748,1,A,1,,,,50594,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630589,BAO_0000218,
13749,1,A,1,,,,50594,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630590,BAO_0000218,
13750,1,A,0,,,,22224,Removal of 238-Plutonium(IV) in feces at 24 h,1988.0,,,,,,U,Autocuration,CHEMBL630591,BAO_0000019,
13751,1,A,0,,,,22224,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),1988.0,,,,,,U,Autocuration,CHEMBL630592,BAO_0000019,
13752,1,A,0,,,,22224,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,,,,,,,U,Autocuration,CHEMBL630593,BAO_0000019,
13753,1,A,0,,,,22224,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),,,,,,,U,Autocuration,CHEMBL630594,BAO_0000019,
13754,1,A,0,,,,22224,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),1088.0,,,,,,U,Autocuration,CHEMBL630595,BAO_0000019,
13755,1,A,0,,,,22224,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),1088.0,,,,,,U,Autocuration,CHEMBL630596,BAO_0000019,
13756,1,A,0,,,,22224,Removal of 238-Plutonium(IV) in urine after 0-24 h,1088.0,,,,,,U,Autocuration,CHEMBL630597,BAO_0000019,
13757,1,A,0,,,,22224,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),1088.0,,,,,,U,Autocuration,CHEMBL630598,BAO_0000019,
13758,1,A,0,,,,22224,Removal of 238-Plutonium(IV) in urine after 0-4 h,1088.0,,,,,,U,Autocuration,CHEMBL630599,BAO_0000019,
13759,1,A,0,,,,22224,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),1088.0,,,,,,U,Autocuration,CHEMBL630600,BAO_0000019,
13760,1,A,0,,,,22224,Removal of 238-Plutonium(IV) in urine after 4-24 h,1088.0,,,,,,U,Autocuration,CHEMBL630601,BAO_0000019,
13761,1,A,0,,,,22224,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),1088.0,,,,,,U,Autocuration,CHEMBL630602,BAO_0000019,
13762,1,A,0,,,,22224,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),1088.0,,,,,,U,Autocuration,CHEMBL630603,BAO_0000019,
13763,1,A,0,,,,22224,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),1088.0,,,,,,U,Autocuration,CHEMBL630604,BAO_0000019,
13764,1,A,1,,,In vivo,50597,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624869,BAO_0000218,
13765,1,A,1,,,In vivo,50597,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624870,BAO_0000218,
13766,1,A,1,,,In vivo,50597,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623189,BAO_0000218,
13767,1,A,1,,,In vivo,50597,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623190,BAO_0000218,
13768,1,A,1,,,In vivo,50597,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623191,BAO_0000218,
13769,1,A,1,,,In vivo,50597,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623192,BAO_0000218,
13770,1,A,1,,,In vivo,50597,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623193,BAO_0000218,
13771,1,A,1,,,In vivo,50597,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623194,BAO_0000218,
13772,1,A,1,,,In vivo,50597,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623195,BAO_0000218,
13773,1,A,1,,,In vivo,50597,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623196,BAO_0000218,
13774,1,A,1,,,,50597,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623197,BAO_0000218,
13775,1,A,1,,,,50597,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623198,BAO_0000218,
13776,1,A,1,,,,50597,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623199,BAO_0000218,
13777,1,A,1,,,,50597,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623200,BAO_0000218,
13778,1,A,1,,,,50597,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623201,BAO_0000218,
13779,1,A,1,,,,50597,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623202,BAO_0000218,
13780,1,A,1,,,,50597,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623203,BAO_0000218,
13781,1,A,1,,,,50597,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623204,BAO_0000218,
13782,1,A,1,,,,50597,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623205,BAO_0000218,
13783,1,A,1,,,,50597,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623206,BAO_0000218,
13784,1,A,1,,,,50597,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623207,BAO_0000218,
13785,1,A,1,,,,50597,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623208,BAO_0000218,
13786,1,A,1,,,,50597,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623209,BAO_0000218,
13787,1,A,1,,,,50597,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623210,BAO_0000218,
13788,1,A,1,,,,50597,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623211,BAO_0000218,
13789,1,A,1,,,,50597,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,995.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623212,BAO_0000218,
13790,1,A,0,,,,22224,Tested in vitro for intrinsic activity relative to quinpirole,,,,,,,U,Autocuration,CHEMBL623213,BAO_0000019,
13791,1,A,0,,,,22224,"Relative ion enhancement, determined in pulsed ultrafiltration",,,,,,,U,Autocuration,CHEMBL623214,BAO_0000019,
13792,1,A,0,,,,22224,% ionization at the pH 7.4 at 37 degree Centigrade,,,,,,,U,Autocuration,CHEMBL623215,BAO_0000019,
13793,1,A,0,,,,22224,Percentage ionization was measured,,,,,,,U,Autocuration,CHEMBL623216,BAO_0000019,
13794,1,A,1,,,,50591,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,,Bos taurus,,,,9913.0,N,Intermediate,CHEMBL623217,BAO_0000218,
13795,1,A,0,,,,22224,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,,,,,,,U,Autocuration,CHEMBL623218,BAO_0000019,
13796,1,A,0,,,,22224,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,,,,,,,U,Autocuration,CHEMBL623913,BAO_0000019,
13797,1,A,0,,,,22224,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,,,,,,,U,Autocuration,CHEMBL623914,BAO_0000019,
13798,1,P,0,,,,22229,Compound was evaluated for the partition coefficient in octanol/water,,,,,,,U,Autocuration,CHEMBL623915,BAO_0000100,
13799,1,P,0,,,,22229,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),,,,,,,U,Autocuration,CHEMBL624080,BAO_0000100,
13800,1,A,0,,,,22224,Equilibrium constant measured by the pulse radiolysis at pH 7,,,,,,,U,Autocuration,CHEMBL624081,BAO_0000019,
13801,1,A,1,,,,50587,In vitro hydrolytic rate constant determined in human blood,,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL624082,BAO_0000218,
13802,1,A,1,,,,50587,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL625054,BAO_0000218,
13803,1,A,0,,,,22224,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,,,,,,,U,Autocuration,CHEMBL877485,BAO_0000019,
13804,1,A,1,,,,50594,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625055,BAO_0000218,
13805,1,A,1,,,,50594,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625056,BAO_0000218,
13806,1,A,1,,,,50587,In vitro oxidation of compound in presence of human plasma,,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL625057,BAO_0000218,
13807,1,A,0,,,,22224,In vitro oxidation of compound in presence of hydrogen peroxide,,,,,,,U,Autocuration,CHEMBL625058,BAO_0000019,
13808,1,A,1,,,,50594,In vitro oxidation of compound in presence of mouse brain homogenate,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625059,BAO_0000218,
13809,1,A,1,,,,50594,In vitro oxidation of compound in presence of mouse liver homogenate,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL629536,BAO_0000218,
13810,1,A,1,,,,50597,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629537,BAO_0000218,
13811,1,A,1,,,,50597,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629538,BAO_0000218,
13812,1,A,1,,,,50597,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629539,BAO_0000218,
13813,1,A,1,,,,50597,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874445,BAO_0000218,
13814,1,A,1,,,,50597,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629540,BAO_0000218,
13815,1,A,1,,,,50597,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629541,BAO_0000218,
13816,1,A,1,,,,50597,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629542,BAO_0000218,
13817,1,A,1,,,,50597,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630243,BAO_0000218,
13818,1,A,1,,,,50597,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630244,BAO_0000218,
13819,1,A,1,,,,50597,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630245,BAO_0000218,
13820,1,A,1,,,,50597,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630246,BAO_0000218,
13821,1,A,1,,,,50597,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630247,BAO_0000218,
13822,1,A,1,,,,50597,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630248,BAO_0000218,
13823,1,A,1,,,In vivo,50597,Biodistribution in rat blood at 240 minutes after dose administration.,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630249,BAO_0000218,
13824,1,A,1,,,In vivo,50597,Biodistribution in rat blood at 30 minutes after dose administration.,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630250,BAO_0000218,
13825,1,A,1,,,In vivo,50597,Biodistribution in rat blood at 360 minutes after dose administration.,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630251,BAO_0000218,
13826,1,A,1,,,In vivo,50597,Biodistribution in rat blood at 3 hr after dose administration.,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630252,BAO_0000218,
13827,1,A,1,,,In vivo,50597,Biodistribution in rat blood at 60 minutes after dose administration.,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630408,BAO_0000218,
13828,1,A,1,,,In vivo,50597,Biodistribution in rat cerebellum at 120 minutes after dose administration.,2037.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630409,BAO_0000218,
13829,1,A,1,,,In vivo,50597,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,2037.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874446,BAO_0000218,
13830,1,A,1,,,In vivo,50597,Biodistribution in rat cerebellum at 15 minutes after dose administration.,2037.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630410,BAO_0000218,
13831,1,A,1,,,In vivo,50597,Biodistribution in rat cerebellum at 240 minutes after dose administration.,2037.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630411,BAO_0000218,
13832,1,A,1,,,In vivo,50597,Biodistribution in rat cerebellum at 30 minutes after dose administration.,2037.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630412,BAO_0000218,
13833,1,A,1,,,In vivo,50597,Biodistribution in rat cerebellum at 360 minutes after dose administration.,2037.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630413,BAO_0000218,
13834,1,A,1,,,In vivo,50597,Biodistribution in rat cerebellum at 3 hr after dose administration.,2037.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630414,BAO_0000218,
13835,1,A,1,,,In vivo,50597,Biodistribution in rat cerebellum at 60 minutes after dose administration.,2037.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630415,BAO_0000218,
13836,1,A,1,,,In vivo,50597,Biodistribution in rat cortex at 120 minutes after dose administration.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630416,BAO_0000218,
13837,1,A,1,,,In vivo,50597,Biodistribution in rat cortex at 1440 minutes after dose administration.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630417,BAO_0000218,
13838,1,A,1,,,In vivo,50597,Biodistribution in rat cortex at 15 minutes after dose administration.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630418,BAO_0000218,
13839,1,A,1,,,In vivo,50597,Biodistribution in rat cortex at 240 minutes after dose administration.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630419,BAO_0000218,
13840,1,A,1,,,In vivo,50597,Biodistribution in rat cortex at 30 minutes after dose administration.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630420,BAO_0000218,
13841,1,A,1,,,In vivo,50597,Biodistribution in rat cortex at 360 minutes after dose administration.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630421,BAO_0000218,
13842,1,A,1,,,In vivo,50597,Biodistribution in rat cortex at 3 hr after dose administration.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630422,BAO_0000218,
13843,1,A,1,,,In vivo,50597,Biodistribution in rat cortex at 60 minutes after dose administration.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630423,BAO_0000218,
13844,1,A,1,,,In vivo,50597,Biodistribution in rat heart at 120 minutes after dose administration.,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630424,BAO_0000218,
13845,1,A,1,,,In vivo,50597,Biodistribution in rat heart at 15 minutes after dose administration.,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630425,BAO_0000218,
13846,1,A,1,,,In vivo,50597,Biodistribution in rat heart at 240 minutes after dose administration.,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629462,BAO_0000218,
13847,1,A,1,,,In vivo,50597,Biodistribution in rat heart at 30 minutes after dose administration.,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630426,BAO_0000218,
13848,1,A,1,,,In vivo,50597,Biodistribution in rat heart at 360 minutes after dose administration.,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630427,BAO_0000218,
13849,1,A,1,,,In vivo,50597,Biodistribution in rat heart at 3 hr after dose administration.,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625877,BAO_0000218,
13850,1,A,1,,,In vivo,50597,Biodistribution in rat heart at 60 minutes after dose administration.,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625878,BAO_0000218,
13851,1,A,1,,,In vivo,50597,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,10000000.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625879,BAO_0000218,
13852,1,A,1,,,In vivo,50597,Biodistribution in rat hippocampus at 240 minutes after dose administration.,10000000.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625880,BAO_0000218,
13853,1,A,1,,,In vivo,50597,Biodistribution in rat hippocampus at 30 minutes after dose administration.,10000000.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625881,BAO_0000218,
13854,1,A,1,,,In vivo,50597,Biodistribution in rat hippocampus at 360 minutes after dose administration.,10000000.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625882,BAO_0000218,
13855,1,A,1,,,In vivo,50597,Biodistribution in rat hippocampus at 15 minutes after dose administration.,10000000.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625883,BAO_0000218,
13856,1,A,1,,,In vivo,50597,Biodistribution in rat kidney at 120 minutes after dose administration.,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625884,BAO_0000218,
13857,1,A,1,,,In vivo,50597,Biodistribution in rat kidney at 1440 minutes after dose administration.,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625885,BAO_0000218,
13858,1,A,1,,,In vivo,50597,Biodistribution in rat kidney at 15 minutes after dose administration.,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628649,BAO_0000218,
13859,1,A,1,,,In vivo,50597,Biodistribution in rat kidney at 240 minutes after dose administration.,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628650,BAO_0000218,
13860,1,A,1,,,In vivo,50597,Biodistribution in rat kidney at 30 minutes after dose administration.,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628651,BAO_0000218,
13861,1,A,1,,,In vivo,50597,Biodistribution in rat kidney at 360 minutes after dose administration.,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628652,BAO_0000218,
13862,1,A,1,,,In vivo,50597,Biodistribution in rat kidney at 60 minutes after dose administration.,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628653,BAO_0000218,
13863,1,A,1,,,In vivo,50597,Biodistribution in rat liver at 120 minutes after dose administration.,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628654,BAO_0000218,
13864,1,A,1,,,In vivo,50597,Biodistribution in rat liver at 1440 minutes after dose administration.,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628655,BAO_0000218,
13865,1,A,1,,,In vivo,50597,Biodistribution in rat liver at 15 minutes after dose administration.,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625238,BAO_0000218,
13866,1,A,1,,,In vivo,50597,Biodistribution in rat liver at 240 minutes after dose administration.,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625239,BAO_0000218,
13867,1,A,1,,,In vivo,50597,Biodistribution in rat liver at 30 minutes after dose administration.,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625240,BAO_0000218,
13868,1,A,1,,,In vivo,50597,Biodistribution in rat liver at 360 minutes after dose administration.,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625241,BAO_0000218,
13869,1,A,1,,,In vivo,50597,Biodistribution in rat liver at 60 minutes after dose administration.,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625242,BAO_0000218,
13870,1,A,1,,,In vivo,50597,Biodistribution in rat lung at 120 minutes after dose administration.,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874587,BAO_0000218,
13871,1,A,1,,,In vivo,50597,Biodistribution in rat lung at 1440 minutes after dose administration.,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625405,BAO_0000218,
13872,1,A,1,,,In vivo,50597,Biodistribution in rat lung at 15 minutes after dose administration.,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625406,BAO_0000218,
13873,1,A,1,,,In vivo,50597,Biodistribution in rat lung at 240 minutes after dose administration.,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625407,BAO_0000218,
13874,1,A,1,,,In vivo,50597,Biodistribution in rat lung at 30 minutes after dose administration.,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625408,BAO_0000218,
13875,1,A,1,,,In vivo,50597,Biodistribution in rat lung at 360 minutes after dose administration.,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625409,BAO_0000218,
13876,1,A,1,,,,50597,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,1515.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625410,BAO_0000218,
13877,1,A,1,,,,50597,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,1515.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625411,BAO_0000218,
13878,1,A,1,,,,50597,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,1515.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625412,BAO_0000218,
13879,1,A,1,,,,50597,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,1515.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625413,BAO_0000218,
13880,1,A,1,,,,50597,Percent of maximal contractile response to compound in rat thoracic aorta strips v,1515.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625414,BAO_0000218,
13881,1,A,1,,,,50597,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,1515.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625415,BAO_0000218,
13882,1,A,1,,,,50597,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,1515.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625416,BAO_0000218,
13883,1,A,1,,,,50597,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625417,BAO_0000218,
13884,1,A,1,,,,50597,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,1988.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625418,BAO_0000218,
13885,1,A,1,,,,50597,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625419,BAO_0000218,
13886,1,A,1,,,,50597,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625420,BAO_0000218,
13887,1,A,1,,,,50597,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626996,BAO_0000218,
13888,1,A,1,,,,50597,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",1988.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626997,BAO_0000218,
13889,1,A,1,,,,50597,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626998,BAO_0000218,
13890,1,A,1,,,,50597,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626999,BAO_0000218,
13891,1,A,1,,,,50594,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627000,BAO_0000218,
13892,1,A,1,,,,50594,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627001,BAO_0000218,
13893,1,A,1,,,,50594,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627002,BAO_0000218,
13894,1,A,1,,,,50594,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627003,BAO_0000218,
13895,1,A,1,,,,50594,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,1088.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627004,BAO_0000218,
13896,1,A,1,,,,50594,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,1088.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627005,BAO_0000218,
13897,1,A,1,,,,50594,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,1088.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL874594,BAO_0000218,
13898,1,A,1,,,,50594,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,1088.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627006,BAO_0000218,
13899,1,A,1,,,,50594,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,1088.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627007,BAO_0000218,
13900,1,A,1,,,,50594,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,1088.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627884,BAO_0000218,
13901,1,A,1,,,,50594,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,1088.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627885,BAO_0000218,
13902,1,A,1,,,,50594,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,1088.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627886,BAO_0000218,
13903,1,A,1,,,,50594,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,1088.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627887,BAO_0000218,
13904,1,A,1,,,,50594,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,1088.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627888,BAO_0000218,
13905,1,A,1,,,,50594,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,1088.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL628057,BAO_0000218,
13906,1,A,1,,,,50594,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,1088.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627405,BAO_0000218,
13907,1,A,1,,,,50588,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627406,BAO_0000218,
13908,1,A,1,,,,50588,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627407,BAO_0000218,
13909,1,A,1,,,,50588,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627408,BAO_0000218,
13910,1,A,1,,,,50588,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627409,BAO_0000218,
13911,1,A,1,,,,50588,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL875486,BAO_0000218,
13912,1,A,1,,,,50588,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627410,BAO_0000218,
13913,1,A,1,,,,50588,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627411,BAO_0000218,
13914,1,A,1,,,,50588,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627412,BAO_0000218,
13915,1,A,1,,,,50588,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627413,BAO_0000218,
13916,1,A,1,,,,50588,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627414,BAO_0000218,
13917,1,A,1,,,,50588,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627415,BAO_0000218,
13918,1,A,1,,,,50588,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627416,BAO_0000218,
13919,1,A,1,,,,50588,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627417,BAO_0000218,
13920,1,A,1,,,,50588,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627418,BAO_0000218,
13921,1,A,1,,,,50588,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627419,BAO_0000218,
13922,1,A,1,,,,50588,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627320,BAO_0000218,
13923,1,A,1,,,,50588,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627321,BAO_0000218,
13924,1,A,1,,,In vivo,50597,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627322,BAO_0000218,
13925,1,A,1,,,In vivo,50597,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627323,BAO_0000218,
13926,1,A,1,,,In vivo,50597,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627491,BAO_0000218,
13927,1,A,1,,,In vivo,50597,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627492,BAO_0000218,
13928,1,A,1,,,In vivo,50597,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627493,BAO_0000218,
13929,1,A,1,,,In vivo,50597,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627494,BAO_0000218,
13930,1,A,1,,,In vivo,50597,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627495,BAO_0000218,
13931,1,A,1,,,In vivo,50597,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627496,BAO_0000218,
13932,1,A,1,,,In vivo,50597,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627497,BAO_0000218,
13933,1,A,1,,,In vivo,50597,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627498,BAO_0000218,
13934,1,A,1,,,In vivo,50597,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627499,BAO_0000218,
13935,1,A,1,,,In vivo,50597,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627500,BAO_0000218,
13936,1,A,1,,,In vivo,50597,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627501,BAO_0000218,
13937,1,A,1,,,In vivo,50597,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625616,BAO_0000218,
13938,1,A,1,,,In vivo,50597,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625617,BAO_0000218,
13939,1,A,1,,,In vivo,50597,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625618,BAO_0000218,
13940,1,A,1,,,In vivo,50597,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625619,BAO_0000218,
13941,1,A,1,,,In vivo,50597,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625620,BAO_0000218,
13942,1,A,1,,,In vivo,50597,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625621,BAO_0000218,
13943,1,A,1,,,In vivo,50597,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625622,BAO_0000218,
13944,1,A,1,,,In vivo,50597,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625788,BAO_0000218,
13945,1,A,1,,,In vivo,50597,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625789,BAO_0000218,
13946,1,A,1,,,In vivo,50597,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625790,BAO_0000218,
13947,1,A,1,,,In vivo,50597,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625791,BAO_0000218,
13948,1,A,1,,,In vivo,50597,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622334,BAO_0000218,
13949,1,A,1,,,In vivo,50597,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622335,BAO_0000218,
13950,1,A,1,,,In vivo,50597,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622336,BAO_0000218,
13951,1,A,1,,,In vivo,50597,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622337,BAO_0000218,
13952,1,A,1,,,In vivo,50597,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622338,BAO_0000218,
13953,1,A,1,,,In vivo,50597,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622339,BAO_0000218,
13954,1,A,1,,,In vivo,50597,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624153,BAO_0000218,
13955,1,A,1,,,In vivo,50597,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628430,BAO_0000218,
13956,1,A,1,,,In vivo,50597,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628431,BAO_0000218,
13957,1,A,1,,,In vivo,50597,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628432,BAO_0000218,
13958,1,A,1,,,In vivo,50597,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628433,BAO_0000218,
13959,1,A,1,,,In vivo,50597,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628434,BAO_0000218,
13960,1,A,1,,,In vivo,50597,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626789,BAO_0000218,
13961,1,A,1,,,In vivo,50597,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626790,BAO_0000218,
13962,1,A,1,,,In vivo,50597,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626791,BAO_0000218,
13963,1,A,1,,,In vivo,50597,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626792,BAO_0000218,
13964,1,A,1,,,In vivo,50597,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626793,BAO_0000218,
13965,1,A,1,,,,50597,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627436,BAO_0000218,
13966,1,A,1,,,,50597,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627437,BAO_0000218,
13967,1,A,1,,,,50597,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627438,BAO_0000218,
13968,1,A,1,,,,50597,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627439,BAO_0000218,
13969,1,A,1,,,,50597,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627440,BAO_0000218,
13970,1,A,1,,,,50597,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627602,BAO_0000218,
13971,1,A,1,,,,50597,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627603,BAO_0000218,
13972,1,A,1,,,,50597,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627604,BAO_0000218,
13973,1,A,1,,,,50597,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627605,BAO_0000218,
13974,1,A,1,,,,50597,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627606,BAO_0000218,
13975,1,A,1,,,,50597,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627607,BAO_0000218,
13976,1,A,1,,,,50597,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627608,BAO_0000218,
13977,1,A,1,,,,50597,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627609,BAO_0000218,
13978,1,A,1,,,,50597,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627610,BAO_0000218,
13979,1,A,1,,,,50597,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627611,BAO_0000218,
13980,1,A,1,,,,50597,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627612,BAO_0000218,
13981,1,P,0,,,,22229,Octanol:water partition coefficient is evaluated,,,,,,,U,Autocuration,CHEMBL627613,BAO_0000100,
13982,1,P,0,,,,22224,Partition coefficient in 1-octanol/water system,,,,,,,U,Autocuration,CHEMBL627614,BAO_0000100,
13983,1,P,0,,,,22224,Partition coefficient in 1-octanol/water system measured using radio active compounds,,,,,,,U,Autocuration,CHEMBL627615,BAO_0000100,
13984,1,P,0,,,,22224,Partition coefficient in octanol/water system was determined,,,,,,,U,Autocuration,CHEMBL627616,BAO_0000100,
13985,1,P,0,,,,22224,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,,,,,,,U,Autocuration,CHEMBL627617,BAO_0000100,
13986,1,A,0,,,,22224,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,,,,,,,U,Autocuration,CHEMBL627618,BAO_0000019,
13987,1,A,0,,,,22224,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",,,,,,,U,Autocuration,CHEMBL627619,BAO_0000019,
13988,1,A,0,,,,22224,Pseudo-first-order rate constant of the compound,,,,,,,U,Autocuration,CHEMBL627620,BAO_0000019,
13989,1,A,0,,,,22224,Pseudo-first-order rate constant with 1-min time point,,,,,,,U,Autocuration,CHEMBL627621,BAO_0000019,
13990,1,A,0,,,,22224,Pseudo-first-order rate constant without 1-min time point,,,,,,,U,Autocuration,CHEMBL627622,BAO_0000019,
13991,1,A,0,,,,22224,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,,,,,,,U,Autocuration,CHEMBL627623,BAO_0000019,
13992,1,A,0,,,,22224,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,,,,,,,U,Autocuration,CHEMBL627624,BAO_0000019,
13993,1,A,0,,,,22224,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,,,,,,,U,Autocuration,CHEMBL627625,BAO_0000019,
13994,1,A,0,,,,22224,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,,,,,,,U,Autocuration,CHEMBL628523,BAO_0000019,
13995,1,A,0,,,,22224,The alkaline hydrolysis second order rate constant(K OH) of the compound,,,,,,,U,Autocuration,CHEMBL628524,BAO_0000019,
13996,1,A,0,,,,22224,The efflux rate constant of the compound,,,,,,,U,Autocuration,CHEMBL628525,BAO_0000019,
13997,1,A,0,,,,22224,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,,,,,,U,Autocuration,CHEMBL625732,BAO_0000019,
13998,1,A,0,,,,22224,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,,,,,,U,Autocuration,CHEMBL625733,BAO_0000019,
13999,1,F,0,,,,22224,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,,,,,,U,Autocuration,CHEMBL625734,BAO_0000019,
14000,1,A,0,,,,22224,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,,,,,,,U,Autocuration,CHEMBL625913,BAO_0000019,
14001,1,A,0,,,,22224,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,,,,,,,U,Autocuration,CHEMBL625914,BAO_0000019,
14002,1,A,0,,,,22224,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,,,,,,,U,Autocuration,CHEMBL625915,BAO_0000019,
14003,1,A,0,,,,22224,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,,,,,,,U,Autocuration,CHEMBL625916,BAO_0000019,
14004,1,A,0,,,,22224,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),,,,,,,U,Autocuration,CHEMBL625917,BAO_0000019,
14005,1,A,0,,,,22224,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,U,Autocuration,CHEMBL625918,BAO_0000019,
14006,1,A,0,,,,22224,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,U,Autocuration,CHEMBL625919,BAO_0000019,
14007,1,A,0,,,,22224,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,U,Autocuration,CHEMBL625920,BAO_0000019,
14008,1,A,0,,,,22224,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,U,Autocuration,CHEMBL874453,BAO_0000019,
14009,1,A,0,,,,22224,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",,,,,,,U,Autocuration,CHEMBL625921,BAO_0000019,
14010,1,A,0,,,,22224,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,,,,,,,U,Autocuration,CHEMBL625922,BAO_0000019,
14011,1,A,0,,,,22224,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,U,Autocuration,CHEMBL625923,BAO_0000019,
14012,1,A,0,,,,22224,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,U,Autocuration,CHEMBL625924,BAO_0000019,
14013,1,A,0,,,,22224,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,U,Autocuration,CHEMBL625925,BAO_0000019,
14014,1,A,0,,,,22224,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,U,Autocuration,CHEMBL625926,BAO_0000019,
14015,1,A,1,,,In vivo,50597,Biodistribution in rat lung at 60 minutes after dose administration.,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627704,BAO_0000218,
14016,1,A,1,,,In vivo,50597,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627705,BAO_0000218,
14017,1,A,1,,,In vivo,50597,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627706,BAO_0000218,
14018,1,A,1,,,In vivo,50597,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627707,BAO_0000218,
14019,1,A,1,,,In vivo,50597,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627708,BAO_0000218,
14020,1,A,1,,,In vivo,50597,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628361,BAO_0000218,
14021,1,A,1,,,In vivo,50597,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628362,BAO_0000218,
14022,1,A,1,,,In vivo,50597,Biodistribution in rat striatum at 120 minutes after dose administration.,2435.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628363,BAO_0000218,
14023,1,A,1,,,In vivo,50597,Biodistribution in rat striatum at 1440 minutes after dose administration.,2435.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628364,BAO_0000218,
14024,1,A,1,,,In vivo,50597,Biodistribution in rat striatum at 15 minutes after dose administration.,2435.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628365,BAO_0000218,
14025,1,A,1,,,In vivo,50597,Biodistribution in rat striatum at 240 minutes after dose administration.,2435.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874454,BAO_0000218,
14026,1,A,1,,,In vivo,50597,Biodistribution in rat striatum at 30 minutes after dose administration.,2435.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628531,BAO_0000218,
14027,1,A,1,,,In vivo,50597,Biodistribution in rat striatum at 360 minutes after dose administration.,2435.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628532,BAO_0000218,
14028,1,A,1,,,In vivo,50597,Biodistribution in rat striatum at 3 hr after dose administration.,2435.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628533,BAO_0000218,
14029,1,A,1,,,In vivo,50597,Biodistribution in rat striatum at 60 minutes after dose administration.,2435.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628534,BAO_0000218,
14030,1,A,1,,,In vivo,50597,Biodistribution in rat thyroid at 120 minutes after dose administration.,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628535,BAO_0000218,
14031,1,A,1,,,In vivo,50597,Biodistribution in rat thyroid at 1440 minutes after dose administration.,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628536,BAO_0000218,
14032,1,A,1,,,In vivo,50597,Biodistribution in rat thyroid at 15 minutes after dose administration.,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628537,BAO_0000218,
14033,1,A,1,,,In vivo,50597,Biodistribution in rat thyroid at 240 minutes after dose administration.,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628538,BAO_0000218,
14034,1,A,1,,,In vivo,50597,Biodistribution in rat thyroid at 30 minutes after dose administration.,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628539,BAO_0000218,
14035,1,A,1,,,In vivo,50597,Biodistribution in rat thyroid at 360 minutes after dose administration.,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630297,BAO_0000218,
14036,1,A,1,,,In vivo,50597,Biodistribution in rat thyroid at 60 minutes after dose administration.,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630298,BAO_0000218,
14037,1,A,1,,,In vivo,50597,Biodistribution in rest of brain of rat 120 minutes after dose administration.,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630299,BAO_0000218,
14038,1,A,1,,,In vivo,50597,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628094,BAO_0000218,
14039,1,A,1,,,In vivo,50597,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628095,BAO_0000218,
14040,1,A,1,,,In vivo,50597,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874648,BAO_0000218,
14041,1,A,1,,,In vivo,50597,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628096,BAO_0000218,
14042,1,A,1,,,In vivo,50597,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628097,BAO_0000218,
14043,1,A,1,,,In vivo,50597,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628098,BAO_0000218,
14044,1,A,0,,,,22224,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",,,,,,,U,Autocuration,CHEMBL628099,BAO_0000019,
14045,1,A,0,,,,22224,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",,,,,,,U,Autocuration,CHEMBL628100,BAO_0000019,
14046,1,A,0,,,,22224,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),,,,,,,U,Autocuration,CHEMBL628101,BAO_0000019,
14047,1,A,0,,,,22224,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",,,,,,,U,Autocuration,CHEMBL628102,BAO_0000019,
14048,1,A,0,,,,22224,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",,,,,,,U,Autocuration,CHEMBL628103,BAO_0000019,
14049,1,A,0,,,,22224,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",,,,,,,U,Autocuration,CHEMBL628104,BAO_0000019,
14050,1,A,0,,,,22224,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",,,,,,,U,Autocuration,CHEMBL628105,BAO_0000019,
14051,1,A,0,,,,22224,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",,,,,,,U,Autocuration,CHEMBL628106,BAO_0000019,
14052,1,A,1,,,,50597,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628107,BAO_0000218,
14053,1,F,0,,,,22224,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,1088.0,,,,,,U,Autocuration,CHEMBL628108,BAO_0000218,
14054,1,A,1,,,,50597,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628109,BAO_0000218,
14055,1,F,0,,,,22224,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,1088.0,,,,,,U,Autocuration,CHEMBL625299,BAO_0000218,
14056,1,A,1,,,,50597,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625300,BAO_0000218,
14057,1,A,1,,,,50597,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625301,BAO_0000218,
14058,1,A,1,,,,50597,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625302,BAO_0000218,
14059,1,A,1,,,,50597,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874649,BAO_0000218,
14060,1,A,1,,,,50597,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625303,BAO_0000218,
14061,1,A,1,,,,50597,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625463,BAO_0000218,
14062,1,A,1,,,,50587,In vitro metabolism in human liver microsomes,2107.0,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL625464,BAO_0000218,
14063,1,A,1,,,,50587,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL625465,BAO_0000218,
14064,1,A,1,,,,50588,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625466,BAO_0000218,
14065,1,A,1,,,,50588,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625467,BAO_0000218,
14066,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625468,BAO_0000218,
14067,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625469,BAO_0000218,
14068,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625470,BAO_0000218,
14069,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632418,BAO_0000218,
14070,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627250,BAO_0000218,
14071,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627251,BAO_0000218,
14072,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627252,BAO_0000218,
14073,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627253,BAO_0000218,
14074,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627254,BAO_0000218,
14075,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875471,BAO_0000218,
14076,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627255,BAO_0000218,
14077,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627256,BAO_0000218,
14078,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627257,BAO_0000218,
14079,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627258,BAO_0000218,
14080,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627259,BAO_0000218,
14081,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627260,BAO_0000218,
14082,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623256,BAO_0000218,
14083,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874413,BAO_0000218,
14084,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623257,BAO_0000218,
14085,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623258,BAO_0000218,
14086,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623259,BAO_0000218,
14087,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623260,BAO_0000218,
14088,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623261,BAO_0000218,
14089,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623262,BAO_0000218,
14090,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623263,BAO_0000218,
14091,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623264,BAO_0000218,
14092,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623265,BAO_0000218,
14093,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623266,BAO_0000218,
14094,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623267,BAO_0000218,
14095,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623268,BAO_0000218,
14096,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623269,BAO_0000218,
14097,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623270,BAO_0000218,
14098,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623271,BAO_0000218,
14099,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623272,BAO_0000218,
14100,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623273,BAO_0000218,
14101,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623274,BAO_0000218,
14102,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874414,BAO_0000218,
14103,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623275,BAO_0000218,
14104,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629150,BAO_0000218,
14105,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623276,BAO_0000218,
14106,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623277,BAO_0000218,
14107,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623112,BAO_0000218,
14108,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623113,BAO_0000218,
14109,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623800,BAO_0000218,
14110,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623801,BAO_0000218,
14111,1,A,1,,,In vivo,50597,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623802,BAO_0000218,
14112,1,A,1,,,In vivo,50597,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,995.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623803,BAO_0000218,
14113,1,A,1,,,In vivo,50597,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,995.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623970,BAO_0000218,
14114,1,A,1,,,In vivo,50597,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,995.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623971,BAO_0000218,
14115,1,A,1,,,In vivo,50597,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623972,BAO_0000218,
14116,1,A,1,,,In vivo,50597,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623973,BAO_0000218,
14117,1,A,1,,,In vivo,50597,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623974,BAO_0000218,
14118,1,A,1,,,In vivo,50597,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623975,BAO_0000218,
14119,1,A,1,,,In vivo,50597,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623976,BAO_0000218,
14120,1,A,1,,,In vivo,50597,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623977,BAO_0000218,
14121,1,A,1,,,In vivo,50597,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623978,BAO_0000218,
14122,1,A,1,,,In vivo,50597,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623979,BAO_0000218,
14123,1,A,1,,,In vivo,50597,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623980,BAO_0000218,
14124,1,A,1,,,In vivo,50597,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623981,BAO_0000218,
14125,1,A,1,,,In vivo,50597,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626278,BAO_0000218,
14126,1,A,1,,,In vivo,50597,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626279,BAO_0000218,
14127,1,A,1,,,In vivo,50594,Biodistribution in mice bladder plus excreted urine was determined,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626280,BAO_0000218,
14128,1,A,1,,,,50594,"Percentage biodistribution in mouse blood, 10 minutes post injection",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626281,BAO_0000218,
14129,1,A,1,,,,50594,"Percentage biodistribution in mouse blood, 30 minutes post injection",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626282,BAO_0000218,
14130,1,A,1,,,,50594,"Percentage biodistribution in mouse blood, 5 minutes post injection",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626283,BAO_0000218,
14131,1,A,1,,,,50594,"Percentage biodistribution in mouse blood, 60 minutes post injection",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626284,BAO_0000218,
14132,1,A,1,,,,50594,"Percentage biodistribution in mouse brain, 10 minutes post injection",955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626285,BAO_0000218,
14133,1,A,1,,,,50594,"Percentage biodistribution in mouse brain, 30 minutes post injection",955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626286,BAO_0000218,
14134,1,A,1,,,,50594,"Percentage biodistribution in mouse brain, 5 minutes post injection",955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626287,BAO_0000218,
14135,1,A,1,,,,50594,"Percentage biodistribution in mouse brain, 60 minutes post injection",955.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626288,BAO_0000218,
14136,1,A,1,,,,50594,"Percentage biodistribution in mouse heart, 10 minutes post injection",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626289,BAO_0000218,
14137,1,A,1,,,,50594,"Percentage biodistribution in mouse heart, 30 minutes post injection",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626290,BAO_0000218,
14138,1,A,1,,,,50594,"Percentage biodistribution in mouse heart, 5 minutes post injection",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626291,BAO_0000218,
14139,1,A,1,,,,50594,"Percentage biodistribution in mouse heart, 60 minutes post injection",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL839888,BAO_0000218,
14140,1,A,1,,,,50594,"Percentage biodistribution in mouse intestine, 10 minutes post injection",160.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626292,BAO_0000218,
14141,1,A,1,,,,50594,"Percentage biodistribution in mouse intestine, 30 minutes post injection",160.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626293,BAO_0000218,
14142,1,A,1,,,,50594,"Percentage biodistribution in mouse intestine, 5 minutes post injection",160.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626294,BAO_0000218,
14143,1,A,1,,,,50594,"Percentage biodistribution in mouse intestine, 60 minutes post injection",160.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL626295,BAO_0000218,
14144,1,A,1,,,,50594,"Percentage biodistribution in mouse liver, 10 minutes post injection",2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627659,BAO_0000218,
14145,1,A,1,,,,50594,"Percentage biodistribution in mouse liver, 30 minutes of post injection",2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627660,BAO_0000218,
14146,1,A,1,,,,50594,"Percentage biodistribution in mouse liver, 5 minutes post injection",2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627661,BAO_0000218,
14147,1,A,1,,,In vivo,50594,Biodistribution in mice liver at 60 minutes of post injection,2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627662,BAO_0000218,
14148,1,A,1,,,In vivo,50594,Biodistribution in mice lungs at 10 min of post injection,2048.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627663,BAO_0000218,
14149,1,A,1,,,,50594,"Percentage biodistribution in mouse lung, 30 minutes post injection",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627664,BAO_0000218,
14150,1,A,1,,,,50594,"Percentage biodistribution in mousee lung, 5 minutes post injection",,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627665,BAO_0000218,
14151,1,A,1,,,In vivo,50594,Biodistribution in mice lungs at 60 min of post injection,2048.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627666,BAO_0000218,
14152,1,A,1,,,,50594,Percentage biodistribution in mouse spleen,2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627667,BAO_0000218,
14153,1,A,1,,,,50594,Percentage biodistribution in mouse stomach,945.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627668,BAO_0000218,
14154,1,A,1,,,,50594,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,1088.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL627669,BAO_0000218,
14155,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,1255.0,,,,,,U,Autocuration,CHEMBL627670,BAO_0000218,
14156,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,178.0,,,,,,U,Autocuration,CHEMBL627671,BAO_0000218,
14157,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,1474.0,,,,,,U,Autocuration,CHEMBL627672,BAO_0000218,
14158,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,,,,,,,U,Autocuration,CHEMBL627673,BAO_0000218,
14159,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,2113.0,,,,,,U,Autocuration,CHEMBL627674,BAO_0000218,
14160,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,2107.0,,,,,,U,Autocuration,CHEMBL627675,BAO_0000218,
14161,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,2048.0,,,,,,U,Autocuration,CHEMBL627676,BAO_0000218,
14162,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,2385.0,,,,,,U,Autocuration,CHEMBL627677,BAO_0000218,
14163,1,A,0,,,,22224,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",,,,,,,U,Autocuration,CHEMBL627678,BAO_0000019,
14164,1,A,1,,,,50597,Affinity for protein binding expressed as association constant in fresh rat serum,1977.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627679,BAO_0000218,
14165,1,A,0,,,,22224,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,,,,,,,U,Autocuration,CHEMBL627680,BAO_0000019,
14166,1,A,0,,,,22224,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,,,,,,,U,Autocuration,CHEMBL627681,BAO_0000019,
14167,1,A,0,,,,22224,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,,,,,,,U,Autocuration,CHEMBL627682,BAO_0000019,
14168,1,A,0,,,,22224,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,,,,,,,U,Autocuration,CHEMBL627683,BAO_0000019,
14169,1,A,0,,,,22224,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,,,,,,,U,Autocuration,CHEMBL627684,BAO_0000019,
14170,1,A,0,,,,22224,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",,,,,,,U,Autocuration,CHEMBL874441,BAO_0000019,
14171,1,A,0,,,,22224,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,,,,,,,U,Autocuration,CHEMBL627685,BAO_0000019,
14172,1,A,0,,,,22224,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",,,,,,,U,Autocuration,CHEMBL627686,BAO_0000019,
14173,1,A,0,,,,22224,Apparent rate constant Koff for inactivation of dTMP synthase.,,,,,,,U,Autocuration,CHEMBL627687,BAO_0000019,
14174,1,A,0,,,,22224,The irreversible inhibitor activity by second order rate equation.,,,,,,,U,Autocuration,CHEMBL627688,BAO_0000019,
14175,1,A,1,,,,50597,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628038,BAO_0000218,
14176,1,A,1,,,,50597,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628039,BAO_0000218,
14177,1,A,1,,,,50597,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628040,BAO_0000218,
14178,1,A,0,,,,22224,Dissociation rate calculated from the first-order equation using t1/2 value,,,,,,,U,Autocuration,CHEMBL628041,BAO_0000019,
14179,1,A,0,,,,22224,The compound was tested for Binding constant against DNA,,,,,,,U,Autocuration,CHEMBL630226,BAO_0000019,
14180,1,A,0,,,,22224,First order rate constant for cyclization of the compound,,,,,,,U,Autocuration,CHEMBL628042,BAO_0000019,
14181,1,A,0,,,,22224,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,,,,,,,U,Autocuration,CHEMBL625232,BAO_0000019,
14182,1,A,0,,,,22224,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,,,,,,,U,Autocuration,CHEMBL625233,BAO_0000019,
14183,1,A,0,,,,22224,Hydrolysis rate constant was determined,,,,,,,U,Autocuration,CHEMBL625979,BAO_0000019,
14184,1,A,0,,,,22224,Observed first order rate constant,,,,,,,U,Autocuration,CHEMBL625980,BAO_0000019,
14185,1,A,0,,,,22224,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,,,,,,U,Autocuration,CHEMBL625981,BAO_0000019,
14186,1,A,0,,,,22224,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,,,,,,U,Autocuration,CHEMBL625982,BAO_0000019,
14187,1,A,0,,,,22224,Second-order rate constant for attack on PNPA at 25 degree Centigrade,,,,,,,U,Autocuration,CHEMBL625983,BAO_0000019,
14188,1,A,0,,,,22224,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,U,Autocuration,CHEMBL625984,BAO_0000019,
14189,1,A,0,,,,22224,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,U,Autocuration,CHEMBL625985,BAO_0000019,
14190,1,A,0,,,,22224,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,U,Autocuration,CHEMBL625986,BAO_0000019,
14191,1,A,0,,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,U,Autocuration,CHEMBL625987,BAO_0000019,
14192,1,A,0,,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,U,Autocuration,CHEMBL625988,BAO_0000019,
14193,1,A,0,,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,U,Autocuration,CHEMBL625989,BAO_0000019,
14194,1,A,0,,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,U,Autocuration,CHEMBL625990,BAO_0000019,
14195,1,A,0,,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,U,Autocuration,CHEMBL625991,BAO_0000019,
14196,1,A,0,,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,U,Autocuration,CHEMBL625992,BAO_0000019,
14197,1,A,0,,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,U,Autocuration,CHEMBL625993,BAO_0000019,
14198,1,A,0,,,,22224,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,U,Autocuration,CHEMBL631973,BAO_0000019,
14199,1,A,0,,,,22224,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,U,Autocuration,CHEMBL632143,BAO_0000019,
14200,1,A,0,,,,22224,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,U,Autocuration,CHEMBL632144,BAO_0000019,
14201,1,A,0,,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,U,Autocuration,CHEMBL632145,BAO_0000019,
14202,1,A,0,,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,U,Autocuration,CHEMBL632146,BAO_0000019,
14203,1,A,0,,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,U,Autocuration,CHEMBL632147,BAO_0000019,
14204,1,A,0,,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,U,Autocuration,CHEMBL632148,BAO_0000019,
14205,1,A,0,,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,U,Autocuration,CHEMBL632149,BAO_0000019,
14206,1,A,0,,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,U,Autocuration,CHEMBL632150,BAO_0000019,
14207,1,A,0,,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,U,Autocuration,CHEMBL632151,BAO_0000019,
14208,1,A,1,,,,50587,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL632152,BAO_0000218,
14209,1,A,1,,,,50587,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL632153,BAO_0000218,
14210,1,A,1,,,,50587,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL632154,BAO_0000218,
14211,1,A,1,,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,,Human herpesvirus 1,,,,10298.0,N,Intermediate,CHEMBL632155,BAO_0000218,
14212,1,A,1,,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,,Human herpesvirus 1,,,,10298.0,N,Intermediate,CHEMBL632156,BAO_0000218,
14213,1,A,1,,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,,Human herpesvirus 1,,,,10298.0,N,Intermediate,CHEMBL632157,BAO_0000218,
14214,1,A,1,,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,,Human herpesvirus 1,,,,10298.0,N,Intermediate,CHEMBL632158,BAO_0000218,
14215,1,A,1,,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,,Human herpesvirus 1,,,,10298.0,N,Intermediate,CHEMBL632159,BAO_0000218,
14216,1,A,1,,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,,Human herpesvirus 1,,,,10298.0,N,Intermediate,CHEMBL626305,BAO_0000218,
14217,1,A,1,,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,,Human herpesvirus 1,,,,10298.0,N,Intermediate,CHEMBL626306,BAO_0000218,
14218,1,A,1,,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,,Human herpesvirus 1,,,,10298.0,N,Intermediate,CHEMBL626307,BAO_0000218,
14219,1,A,1,,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,,Human herpesvirus 1,,,,10298.0,N,Intermediate,CHEMBL626308,BAO_0000218,
14220,1,A,1,,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,,Human herpesvirus 1,,,,10298.0,N,Intermediate,CHEMBL626479,BAO_0000218,
14221,1,A,1,,,,50602,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,,Human herpesvirus 1,,,,10298.0,N,Intermediate,CHEMBL626480,BAO_0000218,
14222,1,P,0,,,,22229,Calculated partition coefficient (clogP) (MlogP),,,,,,,U,Autocuration,CHEMBL626481,BAO_0000100,
14223,1,A,0,,,,22224,Equipotent potent ratio relative to carbachol (nicotinic activity),,,,,,,U,Autocuration,CHEMBL626482,BAO_0000019,
14224,1,A,1,,,,50588,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626483,BAO_0000218,
14225,1,A,1,,,,50588,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626484,BAO_0000218,
14226,1,P,0,,,,22229,Solubility at pH 7.4 in micro g/mL;NA denotes available,,,,,,,U,Autocuration,CHEMBL626485,BAO_0000100,
14227,1,P,0,,,,22229,Solubility at pH 7.4 in micro g/mL;NA denotes not available,,,,,,,U,Autocuration,CHEMBL626486,BAO_0000100,
14228,1,P,0,,,,22229,Solubility at pH 7.4 in ug/mL;NA denotes not available,,,,,,,U,Autocuration,CHEMBL626487,BAO_0000100,
14229,1,A,1,,,In vivo,50588,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,1969.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL626488,BAO_0000218,
14230,1,A,1,,,,50597,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,1977.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626489,BAO_0000218,
14231,1,A,0,,,,22224,Area under the MAP curve measured over 5 min; ND means Not determined,,,,,,,U,Autocuration,CHEMBL626490,BAO_0000019,
14232,1,P,0,,,,22224,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,,,,,,,U,Autocuration,CHEMBL626491,BAO_0000100,
14233,1,P,0,,,,22229,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,,,,,,,U,Autocuration,CHEMBL626492,BAO_0000100,
14234,1,A,0,,,,22224,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,,,,,,,U,Autocuration,CHEMBL626493,BAO_0000019,
14235,1,A,1,,,In vivo,50597,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626494,BAO_0000218,
14236,1,A,0,,,In vivo,22224,Half life after oral tested,,,,,,,U,Autocuration,CHEMBL626495,BAO_0000218,
14237,1,A,1,,,,50597,Half life was determined in plasma of rat; NT indicates not tested,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626496,BAO_0000218,
14238,1,A,1,,,In vivo,50597,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626497,BAO_0000218,
14239,1,A,0,,,In vivo,22224,Oral bioavailability after oral tested,,,,,,,U,Autocuration,CHEMBL626498,BAO_0000218,
14240,1,A,1,,,,50597,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626499,BAO_0000218,
14241,1,A,1,,,,50597,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626500,BAO_0000218,
14242,1,A,1,,,,50597,half life was determined in plasma of rat; NT indicates not tested,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626501,BAO_0000218,
14243,1,A,1,,,,50597,half life was determined in plasma of rat; NT means not tested,1969.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626502,BAO_0000218,
14244,1,A,1,,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626503,BAO_0000218,
14245,1,A,1,,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); inactive,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626504,BAO_0000218,
14246,1,A,1,,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626505,BAO_0000218,
14247,1,A,1,,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626506,BAO_0000218,
14248,1,A,1,,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626507,BAO_0000218,
14249,1,A,1,,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626508,BAO_0000218,
14250,1,A,1,,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626509,BAO_0000218,
14251,1,A,1,,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875480,BAO_0000218,
14252,1,A,1,,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626510,BAO_0000218,
14253,1,A,1,,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626511,BAO_0000218,
14254,1,A,1,,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626512,BAO_0000218,
14255,1,A,1,,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628208,BAO_0000218,
14256,1,A,1,,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628209,BAO_0000218,
14257,1,A,1,,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628210,BAO_0000218,
14258,1,A,1,,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628211,BAO_0000218,
14259,1,A,1,,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628212,BAO_0000218,
14260,1,A,1,,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628213,BAO_0000218,
14261,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628214,BAO_0000218,
14262,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628215,BAO_0000218,
14263,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628216,BAO_0000218,
14264,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626595,BAO_0000218,
14265,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626596,BAO_0000218,
14266,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626597,BAO_0000218,
14267,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626598,BAO_0000218,
14268,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622242,BAO_0000218,
14269,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622243,BAO_0000218,
14270,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622244,BAO_0000218,
14271,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622245,BAO_0000218,
14272,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622246,BAO_0000218,
14273,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622247,BAO_0000218,
14274,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622248,BAO_0000218,
14275,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL877483,BAO_0000218,
14276,1,A,1,,,,50597,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL622249,BAO_0000218,
14277,1,A,1,,,,50588,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622250,BAO_0000218,
14278,1,A,1,,,,50588,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622251,BAO_0000218,
14279,1,A,1,,,,50588,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622252,BAO_0000218,
14280,1,A,1,,,,50588,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622253,BAO_0000218,
14281,1,A,1,,,,50588,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622254,BAO_0000218,
14282,1,A,1,,,,50588,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622255,BAO_0000218,
14283,1,A,1,,,,50588,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622256,BAO_0000218,
14284,1,A,1,,,,50588,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622257,BAO_0000218,
14285,1,A,1,,,,50588,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622258,BAO_0000218,
14286,1,A,1,,,,50588,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622259,BAO_0000218,
14287,1,A,1,,,,50588,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622927,BAO_0000218,
14288,1,A,1,,,,50588,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622928,BAO_0000218,
14289,1,A,1,,,,50588,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL622929,BAO_0000218,
14290,1,A,1,,,,50588,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623182,BAO_0000218,
14291,1,A,1,,,,50588,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL623183,BAO_0000218,
14292,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623184,BAO_0000218,
14293,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623185,BAO_0000218,
14294,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL877484,BAO_0000218,
14295,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627274,BAO_0000218,
14296,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623186,BAO_0000218,
14297,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623187,BAO_0000218,
14298,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL623188,BAO_0000218,
14299,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628055,BAO_0000218,
14300,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628056,BAO_0000218,
14301,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628200,BAO_0000218,
14302,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628201,BAO_0000218,
14303,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628202,BAO_0000218,
14304,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628203,BAO_0000218,
14305,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628204,BAO_0000218,
14306,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628205,BAO_0000218,
14307,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628206,BAO_0000218,
14308,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),2367.0,,,,,,U,Autocuration,CHEMBL628207,BAO_0000218,
14309,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,2367.0,,,,,,U,Autocuration,CHEMBL627220,BAO_0000218,
14310,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,2385.0,,,,,,U,Autocuration,CHEMBL627221,BAO_0000218,
14311,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),2367.0,,,,,,U,Autocuration,CHEMBL627222,BAO_0000218,
14312,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,,,,,,,U,Autocuration,CHEMBL627223,BAO_0000218,
14313,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,2385.0,,,,,,U,Autocuration,CHEMBL632062,BAO_0000218,
14314,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,2106.0,,,,,,U,Autocuration,CHEMBL632063,BAO_0000218,
14315,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,1255.0,,,,,,U,Autocuration,CHEMBL632064,BAO_0000218,
14316,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,178.0,,,,,,U,Autocuration,CHEMBL632065,BAO_0000218,
14317,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,1474.0,,,,,,U,Autocuration,CHEMBL632066,BAO_0000218,
14318,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,,,,,,,U,Autocuration,CHEMBL632067,BAO_0000218,
14319,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,2113.0,,,,,,U,Autocuration,CHEMBL629188,BAO_0000218,
14320,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,2107.0,,,,,,U,Autocuration,CHEMBL629189,BAO_0000218,
14321,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,2048.0,,,,,,U,Autocuration,CHEMBL629190,BAO_0000218,
14322,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,2385.0,,,,,,U,Autocuration,CHEMBL629191,BAO_0000218,
14323,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),2367.0,,,,,,U,Autocuration,CHEMBL629192,BAO_0000218,
14324,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,2385.0,,,,,,U,Autocuration,CHEMBL629193,BAO_0000218,
14325,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),2367.0,,,,,,U,Autocuration,CHEMBL629194,BAO_0000218,
14326,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,,,,,,,U,Autocuration,CHEMBL629195,BAO_0000218,
14327,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,2385.0,,,,,,U,Autocuration,CHEMBL629373,BAO_0000218,
14328,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,2106.0,,,,,,U,Autocuration,CHEMBL629374,BAO_0000218,
14329,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,2367.0,,,,,,U,Autocuration,CHEMBL629375,BAO_0000218,
14330,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,1255.0,,,,,,U,Autocuration,CHEMBL629376,BAO_0000218,
14331,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,178.0,,,,,,U,Autocuration,CHEMBL629377,BAO_0000218,
14332,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,1474.0,,,,,,U,Autocuration,CHEMBL629378,BAO_0000218,
14333,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,,,,,,,U,Autocuration,CHEMBL629379,BAO_0000218,
14334,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,2113.0,,,,,,U,Autocuration,CHEMBL629151,BAO_0000218,
14335,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,2107.0,,,,,,U,Autocuration,CHEMBL629152,BAO_0000218,
14336,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,2048.0,,,,,,U,Autocuration,CHEMBL629153,BAO_0000218,
14337,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,2385.0,,,,,,U,Autocuration,CHEMBL629154,BAO_0000218,
14338,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),2367.0,,,,,,U,Autocuration,CHEMBL629155,BAO_0000218,
14339,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,2367.0,,,,,,U,Autocuration,CHEMBL629156,BAO_0000218,
14340,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,2385.0,,,,,,U,Autocuration,CHEMBL629157,BAO_0000218,
14341,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),2367.0,,,,,,U,Autocuration,CHEMBL629158,BAO_0000218,
14342,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,,,,,,,U,Autocuration,CHEMBL629159,BAO_0000218,
14343,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,2385.0,,,,,,U,Autocuration,CHEMBL629160,BAO_0000218,
14344,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,2106.0,,,,,,U,Autocuration,CHEMBL629161,BAO_0000218,
14345,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,1255.0,,,,,,U,Autocuration,CHEMBL629162,BAO_0000218,
14346,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,178.0,,,,,,U,Autocuration,CHEMBL629163,BAO_0000218,
14347,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,1474.0,,,,,,U,Autocuration,CHEMBL629164,BAO_0000218,
14348,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,,,,,,,U,Autocuration,CHEMBL629165,BAO_0000218,
14349,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,2107.0,,,,,,U,Autocuration,CHEMBL629166,BAO_0000218,
14350,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,2048.0,,,,,,U,Autocuration,CHEMBL629167,BAO_0000218,
14351,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,2385.0,,,,,,U,Autocuration,CHEMBL629168,BAO_0000218,
14352,1,A,0,,,,22224,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,,,,,,,U,Autocuration,CHEMBL629169,BAO_0000019,
14353,1,A,0,,,,22224,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,,,,,,,U,Autocuration,CHEMBL629170,BAO_0000019,
14354,1,A,0,,,,22224,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,,,,,,,U,Autocuration,CHEMBL631153,BAO_0000019,
14355,1,A,0,,,,22224,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,,,,,,,U,Autocuration,CHEMBL875121,BAO_0000019,
14356,1,A,0,,,,22224,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,,,,,,,U,Autocuration,CHEMBL631154,BAO_0000019,
14357,1,A,0,,,,22224,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,,,,,,,U,Autocuration,CHEMBL631155,BAO_0000019,
14358,1,A,0,,,,22224,Hydrolysis rate constant was determined,,,,,,,U,Autocuration,CHEMBL631156,BAO_0000019,
14359,1,A,0,,,,22224,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",,,,,,,U,Autocuration,CHEMBL631157,BAO_0000019,
14360,1,A,0,,,,22224,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",,,,,,,U,Autocuration,CHEMBL631158,BAO_0000019,
14361,1,A,0,,,,22224,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",,,,,,,U,Autocuration,CHEMBL631159,BAO_0000019,
14362,1,A,0,,,,22224,Observed second order rate constant,,,,,,,U,Autocuration,CHEMBL631160,BAO_0000019,
14363,1,A,0,,,,22224,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,,,,,,U,Autocuration,CHEMBL631161,BAO_0000019,
14364,1,A,0,,,,22224,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,,,,,,,U,Autocuration,CHEMBL631162,BAO_0000019,
14365,1,A,0,,,,22224,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,,,,,,,U,Autocuration,CHEMBL630313,BAO_0000019,
14366,1,A,0,,,,22224,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",,,,,,,U,Autocuration,CHEMBL630314,BAO_0000019,
14367,1,A,0,,,,22224,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",,,,,,,U,Autocuration,CHEMBL630315,BAO_0000019,
14368,1,A,0,,,,22224,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,U,Autocuration,CHEMBL630316,BAO_0000019,
14369,1,A,0,,,,22224,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,U,Autocuration,CHEMBL630986,BAO_0000019,
14370,1,A,0,,,,22224,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,U,Autocuration,CHEMBL630987,BAO_0000019,
14371,1,A,0,,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,U,Autocuration,CHEMBL630988,BAO_0000019,
14372,1,A,0,,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,U,Autocuration,CHEMBL630989,BAO_0000019,
14373,1,A,0,,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,U,Autocuration,CHEMBL630990,BAO_0000019,
14374,1,A,0,,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,U,Autocuration,CHEMBL630991,BAO_0000019,
14375,1,A,0,,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,U,Autocuration,CHEMBL630992,BAO_0000019,
14376,1,A,0,,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,U,Autocuration,CHEMBL630993,BAO_0000019,
14377,1,A,0,,,,22224,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,U,Autocuration,CHEMBL630994,BAO_0000019,
14378,1,A,1,,,,50597,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630995,BAO_0000218,
14379,1,A,0,,,,22224,Association constant for compound at 31 degree C was determined,,,,,,,U,Autocuration,CHEMBL629252,BAO_0000019,
14380,1,A,0,,,,22224,Calculated antagonist equilibrium dissociation constant of the compound,,,,,,,U,Autocuration,CHEMBL629253,BAO_0000019,
14381,1,A,0,,,,22224,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,,,,,,,U,Autocuration,CHEMBL629944,BAO_0000019,
14382,1,A,1,,,,50512,Dissociation constants vs LTE4 on guinea pig trachea,3126.0,Cavia porcellus,,,,10141.0,N,Intermediate,CHEMBL629945,BAO_0000218,
14383,1,A,0,,,,22224,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",,,,,,,U,Autocuration,CHEMBL629946,BAO_0000019,
14384,1,A,0,,,,22224,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",,,,,,,U,Autocuration,CHEMBL629947,BAO_0000019,
14385,1,A,0,,,,22224,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",,,,,,,U,Autocuration,CHEMBL629948,BAO_0000019,
14386,1,A,0,,,,22224,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",,,,,,,U,Autocuration,CHEMBL856024,BAO_0000019,
14387,1,A,0,,,,22224,Affinity constant KD value was derived from TMP,,,,,,,U,Autocuration,CHEMBL629949,BAO_0000019,
14388,1,A,0,,,,22224,Apparent dissociation (binding) rate constant was evaluated,,,,,,,U,Autocuration,CHEMBL629950,BAO_0000019,
14389,1,P,0,,,,22224,Dissociation constant (KD) of the compound,,,,,,,U,Autocuration,CHEMBL630127,BAO_0000100,
14390,1,P,0,,,,22224,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,,,,,,,U,Autocuration,CHEMBL630128,BAO_0000100,
14391,1,P,0,,,,22224,Dissociation constant from ESR titration experiments,,,,,,,U,Autocuration,CHEMBL630129,BAO_0000100,
14392,1,,0,,,,22224,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),,,,,,,U,Autocuration,CHEMBL630130,BAO_0000019,
14393,1,P,0,,,,22224,Dissociation constant was evaluated.,,,,,,,U,Autocuration,CHEMBL875234,BAO_0000100,
14394,1,P,0,,,,22224,Dissociation constant was reported,,,,,,,U,Autocuration,CHEMBL630131,BAO_0000100,
14395,1,A,1,,,,50597,Dissociation constant was determined in rat pituitary cells.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630132,BAO_0000218,
14396,1,A,0,,,,22224,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,,,,,,,U,Autocuration,CHEMBL630133,BAO_0000019,
14397,1,A,0,,,,22224,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,,,,,,,U,Autocuration,CHEMBL630134,BAO_0000019,
14398,1,A,0,,,,22224,Equilibrium dissociation constant of the compound,,,,,,,U,Autocuration,CHEMBL630135,BAO_0000019,
14399,1,A,0,,,,22224,Equilibrium dissociation constant was determined,,,,,,,U,Autocuration,CHEMBL630136,BAO_0000019,
14400,1,A,0,,,,22224,Kinetic constant KD was evaluated,,,,,,,U,Autocuration,CHEMBL630137,BAO_0000019,
14401,1,A,0,,,,22224,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,,,,,,,U,Autocuration,CHEMBL630138,BAO_0000019,
14402,1,A,0,,,,22224,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,,,,,,,U,Autocuration,CHEMBL630139,BAO_0000019,
14403,1,A,0,,,,22224,Rate constant for hydrolysis in aqueous acetone.,,,,,,,U,Autocuration,CHEMBL630140,BAO_0000019,
14404,1,A,0,,,,22224,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,,,,,,,U,Autocuration,CHEMBL875235,BAO_0000019,
14405,1,A,1,,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876439,BAO_0000218,
14406,1,A,1,,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630605,BAO_0000218,
14407,1,A,1,,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630606,BAO_0000218,
14408,1,A,1,,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630607,BAO_0000218,
14409,1,A,1,,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630608,BAO_0000218,
14410,1,A,1,,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630609,BAO_0000218,
14411,1,A,1,,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630610,BAO_0000218,
14412,1,A,1,,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630611,BAO_0000218,
14413,1,A,1,,,,50597,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629552,BAO_0000218,
14414,1,A,1,,,,50597,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629733,BAO_0000218,
14415,1,A,1,,,,50597,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629734,BAO_0000218,
14416,1,A,1,,,,50597,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629735,BAO_0000218,
14417,1,A,1,,,,50597,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629736,BAO_0000218,
14418,1,A,1,,,,50597,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629737,BAO_0000218,
14419,1,A,1,,,,50597,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629738,BAO_0000218,
14420,1,A,1,,,,50597,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629739,BAO_0000218,
14421,1,A,1,,,,50597,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629740,BAO_0000218,
14422,1,A,1,,,,50597,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629741,BAO_0000218,
14423,1,A,1,,,,50597,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629742,BAO_0000218,
14424,1,A,1,,,,50597,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629743,BAO_0000218,
14425,1,A,1,,,,50597,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629744,BAO_0000218,
14426,1,A,1,,,,50597,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629745,BAO_0000218,
14427,1,A,1,,,,50597,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629746,BAO_0000218,
14428,1,A,1,,,,50597,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629747,BAO_0000218,
14429,1,A,1,,,,50597,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629748,BAO_0000218,
14430,1,A,1,,,,50597,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629749,BAO_0000218,
14431,1,A,1,,,,50597,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629750,BAO_0000218,
14432,1,A,1,,,,50597,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629751,BAO_0000218,
14433,1,A,1,,,,50597,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629752,BAO_0000218,
14434,1,A,1,,,,50597,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629753,BAO_0000218,
14435,1,A,1,,,,50597,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629754,BAO_0000218,
14436,1,A,1,,,,50597,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629755,BAO_0000218,
14437,1,A,1,,,,50597,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629756,BAO_0000218,
14438,1,A,1,,,,50597,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629757,BAO_0000218,
14439,1,A,1,,,,50597,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629758,BAO_0000218,
14440,1,A,1,,,,50597,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629759,BAO_0000218,
14441,1,A,1,,,,50597,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629760,BAO_0000218,
14442,1,A,1,,,,50597,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876443,BAO_0000218,
14443,1,A,1,,,,50588,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL629761,BAO_0000218,
14444,1,A,1,,,,50588,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL629762,BAO_0000218,
14445,1,A,1,,,,50594,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL629763,BAO_0000218,
14446,1,A,1,,,,50594,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL629764,BAO_0000218,
14447,1,A,1,,,,50594,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL629765,BAO_0000218,
14448,1,A,1,,,,50594,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL629766,BAO_0000218,
14449,1,A,1,,,,50594,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL629767,BAO_0000218,
14450,1,A,1,,,,50588,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL629768,BAO_0000218,
14451,1,A,1,,,,50594,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL629769,BAO_0000218,
14452,1,A,1,,,,50588,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL629770,BAO_0000218,
14453,1,A,1,,,,50588,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL629771,BAO_0000218,
14454,1,A,1,,,,50594,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL629772,BAO_0000218,
14455,1,A,1,,,,50594,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL629773,BAO_0000218,
14456,1,A,1,,,,50594,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625455,BAO_0000218,
14457,1,A,1,,,,50594,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625456,BAO_0000218,
14458,1,A,1,,,,50594,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL625457,BAO_0000218,
14459,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625458,BAO_0000218,
14460,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625459,BAO_0000218,
14461,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875483,BAO_0000218,
14462,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL634779,BAO_0000218,
14463,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625460,BAO_0000218,
14464,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626117,BAO_0000218,
14465,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626118,BAO_0000218,
14466,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628342,BAO_0000218,
14467,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628343,BAO_0000218,
14468,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628344,BAO_0000218,
14469,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628345,BAO_0000218,
14470,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628346,BAO_0000218,
14471,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628347,BAO_0000218,
14472,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628348,BAO_0000218,
14473,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628349,BAO_0000218,
14474,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875611,BAO_0000218,
14475,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628350,BAO_0000218,
14476,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628351,BAO_0000218,
14477,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628352,BAO_0000218,
14478,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628353,BAO_0000218,
14479,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628354,BAO_0000218,
14480,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626667,BAO_0000218,
14481,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626668,BAO_0000218,
14482,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626669,BAO_0000218,
14483,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626670,BAO_0000218,
14484,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626671,BAO_0000218,
14485,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626672,BAO_0000218,
14486,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626673,BAO_0000218,
14487,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626674,BAO_0000218,
14488,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626675,BAO_0000218,
14489,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626676,BAO_0000218,
14490,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626677,BAO_0000218,
14491,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626678,BAO_0000218,
14492,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626679,BAO_0000218,
14493,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875612,BAO_0000218,
14494,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626680,BAO_0000218,
14495,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626681,BAO_0000218,
14496,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626682,BAO_0000218,
14497,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626683,BAO_0000218,
14498,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626684,BAO_0000218,
14499,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626685,BAO_0000218,
14500,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626686,BAO_0000218,
14501,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626687,BAO_0000218,
14502,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624978,BAO_0000218,
14503,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624979,BAO_0000218,
14504,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624980,BAO_0000218,
14505,1,A,1,,,,50597,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL624981,BAO_0000218,
14506,1,A,1,,,,50588,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL624982,BAO_0000218,
14507,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),2367.0,,,,,,U,Autocuration,CHEMBL627564,BAO_0000218,
14508,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),2367.0,,,,,,U,Autocuration,CHEMBL627565,BAO_0000218,
14509,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,,,,,,,U,Autocuration,CHEMBL627566,BAO_0000218,
14510,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,2385.0,,,,,,U,Autocuration,CHEMBL627567,BAO_0000218,
14511,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,2106.0,,,,,,U,Autocuration,CHEMBL627568,BAO_0000218,
14512,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,2113.0,,,,,,U,Autocuration,CHEMBL627569,BAO_0000218,
14513,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,1255.0,,,,,,U,Autocuration,CHEMBL627570,BAO_0000218,
14514,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,178.0,,,,,,U,Autocuration,CHEMBL627571,BAO_0000218,
14515,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,1474.0,,,,,,U,Autocuration,CHEMBL627572,BAO_0000218,
14516,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,,,,,,,U,Autocuration,CHEMBL627573,BAO_0000218,
14517,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,2113.0,,,,,,U,Autocuration,CHEMBL627574,BAO_0000218,
14518,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,2107.0,,,,,,U,Autocuration,CHEMBL627575,BAO_0000218,
14519,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,2048.0,,,,,,U,Autocuration,CHEMBL627576,BAO_0000218,
14520,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,2385.0,,,,,,U,Autocuration,CHEMBL627577,BAO_0000218,
14521,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),2367.0,,,,,,U,Autocuration,CHEMBL627578,BAO_0000218,
14522,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,2367.0,,,,,,U,Autocuration,CHEMBL627579,BAO_0000218,
14523,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,2385.0,,,,,,U,Autocuration,CHEMBL627580,BAO_0000218,
14524,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),2367.0,,,,,,U,Autocuration,CHEMBL627581,BAO_0000218,
14525,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,,,,,,,U,Autocuration,CHEMBL627582,BAO_0000218,
14526,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,2385.0,,,,,,U,Autocuration,CHEMBL627583,BAO_0000218,
14527,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,2106.0,,,,,,U,Autocuration,CHEMBL627584,BAO_0000218,
14528,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,2367.0,,,,,,U,Autocuration,CHEMBL627585,BAO_0000218,
14529,1,A,0,,,In vivo,22224,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,2385.0,,,,,,U,Autocuration,CHEMBL627586,BAO_0000218,
14530,1,A,1,,,In vivo,50597,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627587,BAO_0000218,
14531,1,A,1,,,In vivo,50597,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627588,BAO_0000218,
14532,1,A,1,,,In vivo,50597,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628250,BAO_0000218,
14533,1,A,1,,,In vivo,50597,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628251,BAO_0000218,
14534,1,A,1,,,In vivo,50597,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,10000000.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628252,BAO_0000218,
14535,1,A,1,,,In vivo,50597,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,10000000.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628253,BAO_0000218,
14536,1,A,1,,,In vivo,50597,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,1898.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628254,BAO_0000218,
14537,1,A,1,,,In vivo,50597,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,1898.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL877493,BAO_0000218,
14538,1,A,1,,,In vivo,50597,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628255,BAO_0000218,
14539,1,A,1,,,In vivo,50597,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628256,BAO_0000218,
14540,1,A,1,,,In vivo,50597,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,10000000.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628257,BAO_0000218,
14541,1,A,1,,,In vivo,50597,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,1898.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628258,BAO_0000218,
14542,1,A,1,,,In vivo,50597,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628259,BAO_0000218,
14543,1,A,1,,,In vivo,50597,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628429,BAO_0000218,
14544,1,A,1,,,In vivo,50597,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,10000000.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626862,BAO_0000218,
14545,1,A,1,,,In vivo,50597,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,1898.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626863,BAO_0000218,
14546,1,A,1,,,In vivo,50597,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,2037.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625886,BAO_0000218,
14547,1,A,1,,,In vivo,50597,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,2037.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625887,BAO_0000218,
14548,1,A,1,,,In vivo,50597,Biodistribution of the [11C]-radiolabeled compound in rat cortex,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625888,BAO_0000218,
14549,1,A,1,,,In vivo,50597,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625889,BAO_0000218,
14550,1,A,1,,,In vivo,50597,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,10000000.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625890,BAO_0000218,
14551,1,A,1,,,In vivo,50597,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,10000000.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625891,BAO_0000218,
14552,1,A,1,,,In vivo,50597,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,1898.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625892,BAO_0000218,
14553,1,A,1,,,In vivo,50597,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,1898.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625893,BAO_0000218,
14554,1,A,1,,,In vivo,50597,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,2037.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625894,BAO_0000218,
14555,1,A,1,,,In vivo,50597,Biodistribution of the [18F]-radiolabeled compound in rat cortex,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625895,BAO_0000218,
14556,1,A,0,,,,22224,Reaction rate parameter value for phosphate with transfer with respect to ATP,,,,,,,U,Autocuration,CHEMBL625896,BAO_0000019,
14557,1,A,0,,,,22224,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",,,,,,,U,Autocuration,CHEMBL625897,BAO_0000019,
14558,1,A,0,,,,22224,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",,,,,,,U,Autocuration,CHEMBL625898,BAO_0000019,
14559,1,A,0,,,,22224,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",,,,,,,U,Autocuration,CHEMBL625899,BAO_0000019,
14560,1,A,0,,,,22224,Reaction rate parameter value for phosphate with transfer with respect to ATP,,,,,,,U,Autocuration,CHEMBL626124,BAO_0000019,
14561,1,A,1,,,,50212,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,,Escherichia coli,,,,562.0,N,Intermediate,CHEMBL628500,BAO_0000218,
14562,1,A,1,,,,50597,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL857856,BAO_0000218,
14563,1,A,1,,,,50597,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628501,BAO_0000218,
14564,1,A,0,,,,22224,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",,,,,,,U,Autocuration,CHEMBL628502,BAO_0000019,
14565,1,A,0,,,,22224,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,,,,,,,U,Autocuration,CHEMBL628503,BAO_0000019,
14566,1,A,0,,,,22224,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,,,,,,,U,Autocuration,CHEMBL628504,BAO_0000019,
14567,1,A,0,,,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",,,,,,,U,Autocuration,CHEMBL628505,BAO_0000019,
14568,1,A,0,,,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",,,,,,,U,Autocuration,CHEMBL874452,BAO_0000019,
14569,1,A,0,,,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",,,,,,,U,Autocuration,CHEMBL628506,BAO_0000019,
14570,1,A,0,,,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",,,,,,,U,Autocuration,CHEMBL628507,BAO_0000019,
14571,1,A,0,,,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",,,,,,,U,Autocuration,CHEMBL628508,BAO_0000019,
14572,1,A,0,,,,22224,Michaelis constant (KM) was evaluated,,,,,,,U,Autocuration,CHEMBL628509,BAO_0000019,
14573,1,A,0,,,,22224,Reaction rate parameter value for phosphate with transfer with respect to ATP,,,,,,,U,Autocuration,CHEMBL628510,BAO_0000019,
14574,1,B,0,,,,22224,Substrate concentration for half maximal velocity was reported for rat hexokinase I,,,,,,,U,Autocuration,CHEMBL628511,BAO_0000019,
14575,1,B,0,,,,22224,Substrate concentration for half maximal velocity was reported for rat hexokinase II,,,,,,,U,Autocuration,CHEMBL628512,BAO_0000019,
14576,1,B,0,,,,22224,Substrate concentration for half maximal velocity was reported for rat hexokinase III,,,,,,,U,Autocuration,CHEMBL628513,BAO_0000019,
14577,1,B,0,,,,22224,Substrate concentration for half maximal velocity was reported for yeast hexokinase,,,,,,,U,Autocuration,CHEMBL628514,BAO_0000019,
14578,1,A,0,,,,22224,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,,,,,,,U,Autocuration,CHEMBL628515,BAO_0000019,
14579,1,A,0,,,,22224,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,,,,,,,U,Autocuration,CHEMBL628516,BAO_0000019,
14580,1,A,0,,,,22224,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),,,,,,,U,Autocuration,CHEMBL628517,BAO_0000019,
14581,1,A,0,,,,22224,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),,,,,,,U,Autocuration,CHEMBL628518,BAO_0000019,
14582,1,A,0,,,,22224,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,,,,,,,U,Autocuration,CHEMBL628519,BAO_0000019,
14583,1,A,0,,,,22224,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,,,,,,,U,Autocuration,CHEMBL628520,BAO_0000019,
14584,1,A,0,,,,22224,Binding constant was determined,,,,,,,U,Autocuration,CHEMBL628521,BAO_0000019,
14585,1,A,0,,,,22224,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,,,,,,,U,Autocuration,CHEMBL630443,BAO_0000019,
14586,1,A,0,,,,22224,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,,,,,,,U,Autocuration,CHEMBL630444,BAO_0000019,
14587,1,A,0,,,,22224,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,,,,,,,U,Autocuration,CHEMBL857732,BAO_0000019,
14588,1,P,0,,,,22224,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,,,,,,,U,Autocuration,CHEMBL630445,BAO_0000100,
14589,1,A,0,,,,22224,Catalytic rate constant of the compound,,,,,,,U,Autocuration,CHEMBL630446,BAO_0000019,
14590,1,B,0,,,,22224,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,,,,,,,U,Autocuration,CHEMBL630447,BAO_0000019,
14591,1,A,0,,,,22224,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),,,,,,,U,Autocuration,CHEMBL630448,BAO_0000019,
14592,1,A,0,,,,22224,Catalytic rate constant against phospholipase A2 was determined,,,,,,,U,Autocuration,CHEMBL630449,BAO_0000019,
14593,1,A,0,,,,22224,"Compound was evaluated for catalytic constant, Kcat",,,,,,,U,Autocuration,CHEMBL630450,BAO_0000019,
14594,1,A,0,,,,22224,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,,,,,,,U,Autocuration,CHEMBL630451,BAO_0000019,
14595,1,A,0,,,,22224,Kcat calculated from 0.693/T1/2,,,,,,,U,Autocuration,CHEMBL630452,BAO_0000019,
14596,1,A,0,,,,22224,Kcat was determined,,,,,,,U,Autocuration,CHEMBL630453,BAO_0000019,
14597,1,A,0,,,,22224,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,,,,,,,U,Autocuration,CHEMBL630454,BAO_0000019,
14598,1,A,0,,,,22224,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,,,,,,,U,Autocuration,CHEMBL630455,BAO_0000019,
14599,1,A,0,,,,22224,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,,,,,,,U,Autocuration,CHEMBL631487,BAO_0000019,
14600,1,A,0,,,,22224,Kcat value was determined,,,,,,,U,Autocuration,CHEMBL631488,BAO_0000019,
14601,1,A,0,,,,22224,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,,,,,,,U,Autocuration,CHEMBL876440,BAO_0000019,
14602,1,A,0,,,,22224,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,,,,,,,U,Autocuration,CHEMBL631489,BAO_0000019,
14603,1,A,0,,,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",,,,,,,U,Autocuration,CHEMBL857742,BAO_0000019,
14604,1,A,0,,,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",,,,,,,U,Autocuration,CHEMBL631490,BAO_0000019,
14605,1,A,0,,,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",,,,,,,U,Autocuration,CHEMBL631491,BAO_0000019,
14606,1,A,0,,,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",,,,,,,U,Autocuration,CHEMBL631492,BAO_0000019,
14607,1,A,0,,,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",,,,,,,U,Autocuration,CHEMBL631493,BAO_0000019,
14608,1,A,0,,,,22224,Kinetic parameter for rate of conversion to PABA was determined,,,,,,,U,Autocuration,CHEMBL631494,BAO_0000019,
14609,1,A,0,,,,22224,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,,,,,,,U,Autocuration,CHEMBL631495,BAO_0000019,
14610,1,A,1,,,,50597,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",1988.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631496,BAO_0000218,
14611,1,A,1,,,,50597,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631497,BAO_0000218,
14612,1,A,1,,,,50597,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631498,BAO_0000218,
14613,1,A,1,,,,50597,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629776,BAO_0000218,
14614,1,A,1,,,,50597,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629777,BAO_0000218,
14615,1,A,1,,,,50597,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629778,BAO_0000218,
14616,1,A,1,,,,50597,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630456,BAO_0000218,
14617,1,A,1,,,,50597,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630457,BAO_0000218,
14618,1,A,1,,,,50597,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630458,BAO_0000218,
14619,1,A,1,,,,50597,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630459,BAO_0000218,
14620,1,A,1,,,,50597,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630460,BAO_0000218,
14621,1,A,1,,,,50597,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876550,BAO_0000218,
14622,1,A,1,,,,50597,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630461,BAO_0000218,
14623,1,A,1,,,,50597,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630462,BAO_0000218,
14624,1,A,1,,,,50597,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630463,BAO_0000218,
14625,1,A,1,,,,50597,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630464,BAO_0000218,
14626,1,A,1,,,,50597,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630465,BAO_0000218,
14627,1,A,1,,,,50597,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630466,BAO_0000218,
14628,1,A,1,,,,50597,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630467,BAO_0000218,
14629,1,A,1,,,,50597,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630633,BAO_0000218,
14630,1,A,1,,,,50597,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630634,BAO_0000218,
14631,1,A,1,,,,50597,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630635,BAO_0000218,
14632,1,A,1,,,,50597,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630636,BAO_0000218,
14633,1,A,1,,,,50597,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630637,BAO_0000218,
14634,1,A,1,,,,50592,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",1988.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL630638,BAO_0000218,
14635,1,A,1,,,,50592,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",1988.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL630639,BAO_0000218,
14636,1,A,1,,,,50592,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",1988.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL630640,BAO_0000218,
14637,1,A,1,,,,50592,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",1988.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL876551,BAO_0000218,
14638,1,A,1,,,,50592,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",1088.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL630641,BAO_0000218,
14639,1,A,1,,,,50592,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",1088.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL630642,BAO_0000218,
14640,1,A,1,,,,50592,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",1088.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL630643,BAO_0000218,
14641,1,A,1,,,,50592,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",1088.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL630644,BAO_0000218,
14642,1,A,1,,,,50592,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",1088.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL630645,BAO_0000218,
14643,1,A,1,,,,50592,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",1988.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL625599,BAO_0000218,
14644,1,A,1,,,,50592,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",1988.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL625600,BAO_0000218,
14645,1,A,1,,,,50592,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",1988.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL625601,BAO_0000218,
14646,1,A,1,,,,50592,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",1988.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL625602,BAO_0000218,
14647,1,A,1,,,,50592,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",1088.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL627470,BAO_0000218,
14648,1,A,1,,,,50592,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",1088.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL627471,BAO_0000218,
14649,1,A,1,,,,50592,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",1088.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL627472,BAO_0000218,
14650,1,A,1,,,,50592,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",1088.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL627473,BAO_0000218,
14651,1,A,1,,,,50592,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",1088.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL627474,BAO_0000218,
14652,1,A,1,,,In vivo,50597,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627475,BAO_0000218,
14653,1,A,1,,,In vivo,50597,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL627476,BAO_0000218,
14654,1,A,1,,,,50588,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627477,BAO_0000218,
14655,1,A,1,,,,50588,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627478,BAO_0000218,
14656,1,A,1,,,,50588,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627479,BAO_0000218,
14657,1,A,1,,,,50588,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627480,BAO_0000218,
14658,1,A,1,,,,50588,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627481,BAO_0000218,
14659,1,A,1,,,,50588,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627482,BAO_0000218,
14660,1,A,1,,,,50588,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL627483,BAO_0000218,
14661,1,A,1,,,,50588,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL875636,BAO_0000218,
14662,1,A,1,,,,50588,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625764,BAO_0000218,
14663,1,A,1,,,,50588,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625765,BAO_0000218,
14664,1,A,1,,,,50588,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625766,BAO_0000218,
14665,1,A,1,,,,50588,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625767,BAO_0000218,
14666,1,A,1,,,,50588,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625768,BAO_0000218,
14667,1,A,1,,,,50588,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625769,BAO_0000218,
14668,1,A,1,,,,50588,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625770,BAO_0000218,
14669,1,A,1,,,,50588,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625771,BAO_0000218,
14670,1,A,1,,,,50588,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625772,BAO_0000218,
14671,1,A,1,,,,50588,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,1088.0,Canis lupus familiaris,,,,9615.0,N,Intermediate,CHEMBL625773,BAO_0000218,
14672,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625774,BAO_0000218,
14673,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625775,BAO_0000218,
14674,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625776,BAO_0000218,
14675,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625777,BAO_0000218,
14676,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625778,BAO_0000218,
14677,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625779,BAO_0000218,
14678,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625780,BAO_0000218,
14679,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625781,BAO_0000218,
14680,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875637,BAO_0000218,
14681,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626473,BAO_0000218,
14682,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626474,BAO_0000218,
14683,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626475,BAO_0000218,
14684,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626476,BAO_0000218,
14685,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL634397,BAO_0000218,
14686,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL626477,BAO_0000218,
14687,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631069,BAO_0000218,
14688,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631070,BAO_0000218,
14689,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631071,BAO_0000218,
14690,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631072,BAO_0000218,
14691,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631073,BAO_0000218,
14692,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631074,BAO_0000218,
14693,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631075,BAO_0000218,
14694,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631725,BAO_0000218,
14695,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631726,BAO_0000218,
14696,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631727,BAO_0000218,
14697,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631728,BAO_0000218,
14698,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631729,BAO_0000218,
14699,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631730,BAO_0000218,
14700,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631731,BAO_0000218,
14701,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631910,BAO_0000218,
14702,1,A,1,,,In vivo,50597,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,10000000.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631911,BAO_0000218,
14703,1,A,1,,,In vivo,50597,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,1898.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631912,BAO_0000218,
14704,1,A,1,,,In vivo,50597,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,1898.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631913,BAO_0000218,
14705,1,A,1,,,In vivo,50597,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631914,BAO_0000218,
14706,1,A,1,,,In vivo,50597,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631915,BAO_0000218,
14707,1,A,1,,,In vivo,50597,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875778,BAO_0000218,
14708,1,A,1,,,In vivo,50597,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631916,BAO_0000218,
14709,1,A,1,,,In vivo,50597,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631917,BAO_0000218,
14710,1,A,1,,,In vivo,50597,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631918,BAO_0000218,
14711,1,A,1,,,In vivo,50597,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631919,BAO_0000218,
14712,1,A,1,,,In vivo,50597,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631920,BAO_0000218,
14713,1,A,1,,,In vivo,50597,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631921,BAO_0000218,
14714,1,A,1,,,In vivo,50597,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631922,BAO_0000218,
14715,1,A,1,,,In vivo,50597,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631923,BAO_0000218,
14716,1,A,1,,,In vivo,50597,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631924,BAO_0000218,
14717,1,A,1,,,In vivo,50597,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630234,BAO_0000218,
14718,1,A,1,,,In vivo,50597,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630235,BAO_0000218,
14719,1,A,1,,,In vivo,50597,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630236,BAO_0000218,
14720,1,A,1,,,In vivo,50597,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630237,BAO_0000218,
14721,1,A,1,,,In vivo,50597,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630238,BAO_0000218,
14722,1,A,1,,,In vivo,50597,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630239,BAO_0000218,
14723,1,A,1,,,In vivo,50597,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630303,BAO_0000218,
14724,1,A,1,,,In vivo,50597,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630304,BAO_0000218,
14725,1,A,1,,,In vivo,50597,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630305,BAO_0000218,
14726,1,A,1,,,In vivo,50597,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630306,BAO_0000218,
14727,1,A,1,,,In vivo,50597,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630307,BAO_0000218,
14728,1,A,1,,,In vivo,50597,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630308,BAO_0000218,
14729,1,A,1,,,In vivo,50597,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630309,BAO_0000218,
14730,1,A,1,,,In vivo,50597,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629309,BAO_0000218,
14731,1,A,1,,,In vivo,50597,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629993,BAO_0000218,
14732,1,A,1,,,In vivo,50597,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629994,BAO_0000218,
14733,1,A,1,,,In vivo,50597,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629995,BAO_0000218,
14734,1,A,1,,,In vivo,50597,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631993,BAO_0000218,
14735,1,A,1,,,In vivo,50597,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631994,BAO_0000218,
14736,1,A,1,,,In vivo,50597,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631995,BAO_0000218,
14737,1,A,1,,,In vivo,50597,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631996,BAO_0000218,
14738,1,A,1,,,In vivo,50597,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631997,BAO_0000218,
14739,1,A,1,,,In vivo,50597,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631998,BAO_0000218,
14740,1,A,1,,,In vivo,50597,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631999,BAO_0000218,
14741,1,A,1,,,In vivo,50597,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632000,BAO_0000218,
14742,1,A,1,,,In vivo,50597,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632001,BAO_0000218,
14743,1,A,1,,,In vivo,50597,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL874424,BAO_0000218,
14744,1,A,1,,,In vivo,50597,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632002,BAO_0000218,
14745,1,A,1,,,In vivo,50597,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632003,BAO_0000218,
14746,1,A,0,,,,22224,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,,,,,,,U,Autocuration,CHEMBL632004,BAO_0000019,
14747,1,A,0,,,,22224,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,,,,,,,U,Autocuration,CHEMBL632005,BAO_0000019,
14748,1,A,0,,,,22224,Compound was tested for amidase rate in the presence of N62C screen enzyme,,,,,,,U,Autocuration,CHEMBL632006,BAO_0000019,
14749,1,A,0,,,,22224,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,,,,,,,U,Autocuration,CHEMBL632007,BAO_0000019,
14750,1,A,0,,,,22224,Compound was tested for amidase rate in the presence of S166C screen enzyme,,,,,,,U,Autocuration,CHEMBL632008,BAO_0000019,
14751,1,A,0,,,,22224,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,,,,,,,U,Autocuration,CHEMBL632009,BAO_0000019,
14752,1,A,0,,,,22224,Compound was tested for esterase rate in the presence of N62C screen enzyme,,,,,,,U,Autocuration,CHEMBL632010,BAO_0000019,
14753,1,A,0,,,,22224,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,,,,,,,U,Autocuration,CHEMBL857750,BAO_0000019,
14754,1,A,0,,,,22224,Compound was tested for esterase rate in the presence of S166C screen enzyme,,,,,,,U,Autocuration,CHEMBL632011,BAO_0000019,
14755,1,A,0,,,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,,,,,,U,Autocuration,CHEMBL632012,BAO_0000019,
14756,1,A,0,,,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,,,,,,U,Autocuration,CHEMBL632013,BAO_0000019,
14757,1,A,0,,,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",,,,,,,U,Autocuration,CHEMBL632014,BAO_0000019,
14758,1,A,0,,,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,,,,,,U,Autocuration,CHEMBL629622,BAO_0000019,
14759,1,A,0,,,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,,,,,,U,Autocuration,CHEMBL629623,BAO_0000019,
14760,1,A,0,,,,22224,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",,,,,,,U,Autocuration,CHEMBL629624,BAO_0000019,
14761,1,A,0,,,,22224,Ratio of Kcat to that of Km was determined,,,,,,,U,Autocuration,CHEMBL629625,BAO_0000019,
14762,1,A,0,,,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",,,,,,,U,Autocuration,CHEMBL629626,BAO_0000019,
14763,1,A,0,,,,22224,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",,,,,,,U,Autocuration,CHEMBL629627,BAO_0000019,
14764,1,A,0,,,,22224,"Compound was evaluated for constant, Kd",,,,,,,U,Autocuration,CHEMBL629628,BAO_0000019,
14765,1,A,0,,,,22224,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,,,,,,,U,Autocuration,CHEMBL629629,BAO_0000019,
14766,1,A,0,,,,22224,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,,,,,,,U,Autocuration,CHEMBL629630,BAO_0000019,
14767,1,A,0,,,,22224,Dissociation Constant of compound determined,,,,,,,U,Autocuration,CHEMBL856030,BAO_0000019,
14768,1,B,0,,,,22224,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,,,,,,,U,Autocuration,CHEMBL629631,BAO_0000019,
14769,1,B,0,,,,22224,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,,,,,,,U,Autocuration,CHEMBL629632,BAO_0000019,
14770,1,P,0,,,,22224,Dissociation constant of compound with Fructose was determined,,,,,,,U,Autocuration,CHEMBL629633,BAO_0000100,
14771,1,P,0,,,,22224,Dissociation constant of compound with Fructose was determined; Not determined,,,,,,,U,Autocuration,CHEMBL629634,BAO_0000100,
14772,1,P,0,,,,22224,Dissociation constant of compound with Lactulose was determined,,,,,,,U,Autocuration,CHEMBL629635,BAO_0000100,
14773,1,P,0,,,,22224,Dissociation constant of compound with Lactulose was determined; Not determined,,,,,,,U,Autocuration,CHEMBL629636,BAO_0000100,
14774,1,P,0,,,,22224,Dissociation constant of the Compound,,,,,,,U,Autocuration,CHEMBL629637,BAO_0000100,
14775,1,P,0,,,,22224,Dissociation constant by non-linear regression analysis,,,,,,,U,Autocuration,CHEMBL629638,BAO_0000100,
14776,1,P,0,,,,22224,Dissociation constant was determined,,,,,,,U,Autocuration,CHEMBL629639,BAO_0000100,
14777,1,P,0,,,,22224,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,,,,,,,U,Autocuration,CHEMBL629640,BAO_0000100,
14778,1,P,0,,,,22224,Dissociation constant was determined,,,,,,,U,Autocuration,CHEMBL629641,BAO_0000100,
14779,1,P,0,,,,22224,Dissociation constant was determined,,,,,,,U,Autocuration,CHEMBL631344,BAO_0000100,
14780,1,A,1,,,,50597,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631345,BAO_0000218,
14781,1,A,0,,,,22224,The dissociation constant determined by fluorescence displacement assay,,,,,,,U,Autocuration,CHEMBL631346,BAO_0000019,
14782,1,A,0,,,,22224,kd value surface plasmon resonance (SPR) method,,,,,,,U,Autocuration,CHEMBL631524,BAO_0000019,
14783,1,A,1,,,,50597,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631525,BAO_0000218,
14784,1,F,0,,,,22224,First dissociation constant of the binding of compound to V30M TTR,,,,,,,U,Autocuration,CHEMBL631526,BAO_0000019,
14785,1,F,0,,,,22224,Second dissociation constant of the binding of compound to V30M TTR,,,,,,,U,Autocuration,CHEMBL631527,BAO_0000019,
14786,1,A,0,,,,22224,"Compound was evaluated for equilibrium constant, Ke",,,,,,,U,Autocuration,CHEMBL631528,BAO_0000019,
14787,1,A,0,,,,22224,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,1898.0,,,,,,U,Autocuration,CHEMBL631529,BAO_0000019,
14788,1,A,0,,,,22224,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,1898.0,,,,,,U,Autocuration,CHEMBL631530,BAO_0000019,
14789,1,A,0,,,,22224,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,,,,,,,U,Autocuration,CHEMBL631531,BAO_0000019,
14790,1,A,0,,,,22224,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,,,,,,U,Autocuration,CHEMBL631532,BAO_0000019,
14791,1,A,0,,,,22224,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,,,,,,,U,Autocuration,CHEMBL631533,BAO_0000019,
14792,1,A,1,,,,50594,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL876552,BAO_0000218,
14793,1,A,1,,,,50594,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL631534,BAO_0000218,
14794,1,A,1,,,,50594,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL631535,BAO_0000218,
14795,1,A,1,,,,50594,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL631536,BAO_0000218,
14796,1,A,1,,,,50594,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL631537,BAO_0000218,
14797,1,A,1,,,,50594,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL631538,BAO_0000218,
14798,1,A,1,,,,50594,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL631539,BAO_0000218,
14799,1,A,1,,,,50594,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL631540,BAO_0000218,
14800,1,A,1,,,,50597,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625637,BAO_0000218,
14801,1,A,1,,,,50597,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625638,BAO_0000218,
14802,1,A,1,,,,50597,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625639,BAO_0000218,
14803,1,A,1,,,In vivo,50597,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625640,BAO_0000218,
14804,1,A,1,,,In vivo,50597,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625641,BAO_0000218,
14805,1,A,1,,,In vivo,50597,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625642,BAO_0000218,
14806,1,A,1,,,In vivo,50597,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625643,BAO_0000218,
14807,1,A,1,,,In vivo,50597,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625644,BAO_0000218,
14808,1,A,1,,,In vivo,50597,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,2113.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625645,BAO_0000218,
14809,1,A,1,,,In vivo,50597,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625646,BAO_0000218,
14810,1,A,1,,,In vivo,50597,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625647,BAO_0000218,
14811,1,A,1,,,In vivo,50597,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625648,BAO_0000218,
14812,1,A,1,,,In vivo,50597,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625649,BAO_0000218,
14813,1,A,1,,,In vivo,50597,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625650,BAO_0000218,
14814,1,A,1,,,In vivo,50597,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625651,BAO_0000218,
14815,1,A,1,,,In vivo,50597,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,14.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625652,BAO_0000218,
14816,1,A,1,,,In vivo,50597,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,14.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625653,BAO_0000218,
14817,1,A,1,,,In vivo,50597,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625654,BAO_0000218,
14818,1,A,1,,,In vivo,50597,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625655,BAO_0000218,
14819,1,A,1,,,In vivo,50597,Biodistribution of Compound in rat blood after 15 minutes of administration,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625656,BAO_0000218,
14820,1,A,1,,,In vivo,50597,Biodistribution of Compound in rat blood after 2 minutes of administration,178.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625657,BAO_0000218,
14821,1,A,1,,,In vivo,50597,Biodistribution of Compound in rat brain after 15 minutes of administration,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625658,BAO_0000218,
14822,1,A,1,,,In vivo,50597,Biodistribution of Compound in rat brain after 2 minutes of administration,955.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625659,BAO_0000218,
14823,1,A,1,,,In vivo,50597,Biodistribution of Compound in rat heart after 15 minutes of administration,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625660,BAO_0000218,
14824,1,A,1,,,In vivo,50597,Biodistribution of Compound in rat heart after 2 minutes of administration,948.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625661,BAO_0000218,
14825,1,A,1,,,In vivo,50597,Biodistribution of Compound in rat liver after 15 minutes of administration,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625662,BAO_0000218,
14826,1,A,1,,,In vivo,50597,Biodistribution of Compound in rat liver after 2 minutes of administration,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL625663,BAO_0000218,
14827,1,A,1,,,In vivo,50597,Biodistribution of Compound in rat lung after 15 minutes of administration,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875621,BAO_0000218,
14828,1,A,1,,,In vivo,50597,Biodistribution of Compound in rat lung after 2 minutes of administration,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628382,BAO_0000218,
14829,1,A,1,,,In vivo,50597,Biodistribution of Compound in rat muscle after 15 minutes of administration,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628383,BAO_0000218,
14830,1,A,1,,,In vivo,50597,Biodistribution of Compound in rat muscle after 2 minutes of administration,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628384,BAO_0000218,
14831,1,A,1,,,,50597,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628385,BAO_0000218,
14832,1,A,1,,,,50597,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875753,BAO_0000218,
14833,1,A,1,,,,50597,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628386,BAO_0000218,
14834,1,A,1,,,,50597,Organ distribution in rat blood 2 minutes after intravenous injection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628387,BAO_0000218,
14835,1,A,1,,,,50597,Organ distribution in rat blood 2 hr after intravenous injection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628388,BAO_0000218,
14836,1,A,1,,,,50597,Organ distribution in rat blood 30 minutes after intravenous injection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628389,BAO_0000218,
14837,1,A,1,,,,50597,Organ distribution in rat blood 30 min after intravenous injection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632756,BAO_0000218,
14838,1,A,1,,,,50597,Organ distribution in rat brain 2 minutes after intravenous injection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628390,BAO_0000218,
14839,1,A,1,,,,50597,Organ distribution in rat brain 2 hr after intravenous injection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631811,BAO_0000218,
14840,1,A,1,,,,50597,Organ distribution in rat brain 30 minutes after intravenous injection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631812,BAO_0000218,
14841,1,A,1,,,,50597,Organ distribution in rat heart 2 minutes after intravenous injection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631813,BAO_0000218,
14842,1,A,1,,,,50597,Organ distribution in rat heart 2 hr after intravenous injection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631814,BAO_0000218,
14843,1,A,1,,,,50597,Organ distribution in rat heart 30 minutes after intravenous injection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631815,BAO_0000218,
14844,1,A,1,,,,50597,Organ distribution in rat kidney 2 minutes after intravenous injection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631816,BAO_0000218,
14845,1,A,1,,,,50597,Organ distribution in rat kidney 2 hr after intravenous injection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875758,BAO_0000218,
14846,1,A,1,,,,50597,Organ distribution in rat kidney 30 minutes after intravenous injection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631817,BAO_0000218,
14847,1,A,1,,,,50597,Organ distribution in rat liver 2 minutes after intravenous injection,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631818,BAO_0000218,
14848,1,A,1,,,,50597,Organ distribution in rat liver 2 hr after intravenous injection,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631819,BAO_0000218,
14849,1,A,1,,,,50597,Organ distribution in rat liver 30 minutes after intravenous injection,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631820,BAO_0000218,
14850,1,A,1,,,,50597,Organ distribution in rat lung 2 minutes after intravenous injection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631821,BAO_0000218,
14851,1,A,1,,,,50597,Organ distribution in rat lung 2 hr after intravenous injection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631822,BAO_0000218,
14852,1,A,1,,,,50597,Organ distribution in rat lung 30 minutes after intravenous injection,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631823,BAO_0000218,
14853,1,A,1,,,,50597,Organ distribution in rat muscle 2 minutes after intravenous injection,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631824,BAO_0000218,
14854,1,A,1,,,,50597,Organ distribution in rat muscle 2 hr after intravenous injection,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631825,BAO_0000218,
14855,1,A,1,,,,50597,Organ distribution in rat muscle 30 minutes after intravenous injection,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631826,BAO_0000218,
14856,1,A,1,,,In vivo,50594,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL631827,BAO_0000218,
14857,1,A,1,,,In vivo,50594,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL631828,BAO_0000218,
14858,1,A,1,,,In vivo,50594,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL631829,BAO_0000218,
14859,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875759,BAO_0000218,
14860,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631830,BAO_0000218,
14861,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631831,BAO_0000218,
14862,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631832,BAO_0000218,
14863,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631833,BAO_0000218,
14864,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631834,BAO_0000218,
14865,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631835,BAO_0000218,
14866,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631836,BAO_0000218,
14867,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631837,BAO_0000218,
14868,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631838,BAO_0000218,
14869,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631839,BAO_0000218,
14870,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631840,BAO_0000218,
14871,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631841,BAO_0000218,
14872,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631842,BAO_0000218,
14873,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631843,BAO_0000218,
14874,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631844,BAO_0000218,
14875,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631845,BAO_0000218,
14876,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631846,BAO_0000218,
14877,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL875760,BAO_0000218,
14878,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL632199,BAO_0000218,
14879,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631847,BAO_0000218,
14880,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631848,BAO_0000218,
14881,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628707,BAO_0000218,
14882,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628708,BAO_0000218,
14883,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628709,BAO_0000218,
14884,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628710,BAO_0000218,
14885,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628711,BAO_0000218,
14886,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628712,BAO_0000218,
14887,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628713,BAO_0000218,
14888,1,A,1,,,,50597,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,1088.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628714,BAO_0000218,
14889,1,A,1,,,,50597,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL628715,BAO_0000218,
14890,1,A,0,,,,22224,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,,,,,,,U,Autocuration,CHEMBL629179,BAO_0000019,
14891,1,A,0,,,,22224,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,,,,,,,U,Autocuration,CHEMBL629180,BAO_0000019,
14892,1,A,0,,,,22224,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,,,,,,,U,Autocuration,CHEMBL875108,BAO_0000019,
14893,1,A,0,,,,22224,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,1235.0,,,,,,U,Autocuration,CHEMBL629181,BAO_0000019,
14894,1,A,0,,,,22224,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,1235.0,,,,,,U,Autocuration,CHEMBL629182,BAO_0000019,
14895,1,A,0,,,,22224,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,,,,,,,U,Autocuration,CHEMBL629183,BAO_0000019,
14896,1,A,0,,,,22224,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,,,,,,,U,Autocuration,CHEMBL629184,BAO_0000019,
14897,1,A,0,,,,22224,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,1235.0,,,,,,U,Autocuration,CHEMBL629185,BAO_0000019,
14898,1,A,0,,,,22224,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,1235.0,,,,,,U,Autocuration,CHEMBL629186,BAO_0000019,
14899,1,A,0,,,,22224,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,,,,,,,U,Autocuration,CHEMBL629187,BAO_0000019,
14900,1,A,0,,,,22224,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,,,,,,,U,Autocuration,CHEMBL629887,BAO_0000019,
14901,1,A,0,,,,22224,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,,,,,,,U,Autocuration,CHEMBL629888,BAO_0000019,
14902,1,A,0,,,,22224,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,,,,,,,U,Autocuration,CHEMBL629889,BAO_0000019,
14903,1,A,0,,,,22224,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,1235.0,,,,,,U,Autocuration,CHEMBL629890,BAO_0000019,
14904,1,A,0,,,,22224,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,,,,,,,U,Autocuration,CHEMBL629891,BAO_0000019,
14905,1,A,0,,,,22224,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,,,,,,,U,Autocuration,CHEMBL629892,BAO_0000019,
14906,1,A,0,,,,22224,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,1235.0,,,,,,U,Autocuration,CHEMBL629893,BAO_0000019,
14907,1,A,0,,,,22224,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,,,,,,,U,Autocuration,CHEMBL629894,BAO_0000019,
14908,1,A,0,,,,22224,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,,,,,,,U,Autocuration,CHEMBL629895,BAO_0000019,
14909,1,A,0,,,In vivo,22224,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",,Canis lupus familiaris,,,,9615.0,U,Autocuration,CHEMBL875109,BAO_0000218,
14910,1,A,0,,,In vivo,22224,Absolute bioavailability in male cynomolgus monkeys,,Macaca fascicularis,,,,9541.0,U,Autocuration,CHEMBL629896,BAO_0000218,
14911,1,A,0,,,In vivo,22224,Absolute bioavailability in maleSprague-Dawley rats,,Rattus norvegicus,,,,10116.0,U,Autocuration,CHEMBL629897,BAO_0000218,
14912,1,A,1,,,In vivo,50597,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL629898,BAO_0000218,
14913,1,A,1,,,In vivo,50597,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630057,BAO_0000218,
14914,1,A,1,,,In vivo,50597,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2107.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630058,BAO_0000218,
14915,1,A,1,,,In vivo,50597,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630059,BAO_0000218,
14916,1,A,1,,,In vivo,50597,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630060,BAO_0000218,
14917,1,A,1,,,In vivo,50597,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630061,BAO_0000218,
14918,1,A,1,,,In vivo,50597,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630062,BAO_0000218,
14919,1,A,1,,,In vivo,50597,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630063,BAO_0000218,
14920,1,A,1,,,In vivo,50597,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630064,BAO_0000218,
14921,1,A,1,,,In vivo,50597,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630065,BAO_0000218,
14922,1,A,1,,,In vivo,50597,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630066,BAO_0000218,
14923,1,A,1,,,In vivo,50597,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630067,BAO_0000218,
14924,1,A,1,,,In vivo,50597,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2048.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630068,BAO_0000218,
14925,1,A,1,,,In vivo,50597,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631113,BAO_0000218,
14926,1,A,1,,,In vivo,50597,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631114,BAO_0000218,
14927,1,A,1,,,In vivo,50597,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631115,BAO_0000218,
14928,1,A,1,,,In vivo,50597,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL631116,BAO_0000218,
14929,1,A,1,,,In vivo,50597,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630528,BAO_0000218,
14930,1,A,1,,,In vivo,50597,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630529,BAO_0000218,
14931,1,A,1,,,In vivo,50597,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630530,BAO_0000218,
14932,1,A,1,,,In vivo,50597,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630531,BAO_0000218,
14933,1,A,1,,,In vivo,50597,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630532,BAO_0000218,
14934,1,A,1,,,In vivo,50597,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2385.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630533,BAO_0000218,
14935,1,A,1,,,In vivo,50594,Biodistribution in normal mice blood after 120 hr,178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630534,BAO_0000218,
14936,1,A,1,,,In vivo,50594,Biodistribution in normal mice blood after 24 hr,178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630535,BAO_0000218,
14937,1,A,1,,,In vivo,50594,Biodistribution in normal mice blood after 4 hr,178.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630536,BAO_0000218,
14938,1,A,1,,,In vivo,50594,Biodistribution in normal mice bone after 120 hr,10000001.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630537,BAO_0000218,
14939,1,A,1,,,In vivo,50594,Biodistribution in normal mice bone after 24 hr,10000001.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630538,BAO_0000218,
14940,1,A,1,,,In vivo,50594,Biodistribution in normal mice bone after 4 hr,10000001.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630539,BAO_0000218,
14941,1,A,1,,,In vivo,50594,Biodistribution in normal mice heart after 120 hr,948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630540,BAO_0000218,
14942,1,A,1,,,In vivo,50594,Biodistribution in normal mice heart after 24 hr,948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630541,BAO_0000218,
14943,1,A,1,,,In vivo,50594,Biodistribution in normal mice heart after 4 hr,948.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630542,BAO_0000218,
14944,1,A,1,,,In vivo,50594,Biodistribution in normal mice kidney after 120 hr,2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630543,BAO_0000218,
14945,1,A,1,,,In vivo,50594,Biodistribution in normal mice kidney after 24 hr,2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630544,BAO_0000218,
14946,1,A,1,,,In vivo,50594,Biodistribution in normal mice kidney after 4 hr,2113.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630545,BAO_0000218,
14947,1,A,1,,,In vivo,50594,Biodistribution in normal mice liver after 120 hr,2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630546,BAO_0000218,
14948,1,A,1,,,In vivo,50594,Biodistribution in normal mice liver after 24 hr,2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630547,BAO_0000218,
14949,1,A,1,,,In vivo,50594,Biodistribution in normal mice liver after 4 hr,2107.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630548,BAO_0000218,
14950,1,A,1,,,In vivo,50594,Biodistribution in normal mice spleen after 120 hr,2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630549,BAO_0000218,
14951,1,A,1,,,In vivo,50594,Biodistribution in normal mice spleen after 24 hr,2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL630550,BAO_0000218,
14952,1,A,1,,,In vivo,50594,Biodistribution in normal mice spleen after 4 hr,2106.0,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL876426,BAO_0000218,
14953,1,A,1,,,In vivo,50597,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630551,BAO_0000218,
14954,1,A,1,,,In vivo,50597,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630552,BAO_0000218,
14955,1,A,1,,,In vivo,50597,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630553,BAO_0000218,
14956,1,A,1,,,In vivo,50597,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630554,BAO_0000218,
14957,1,A,1,,,In vivo,50597,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630555,BAO_0000218,
14958,1,A,1,,,In vivo,50597,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630556,BAO_0000218,
14959,1,A,1,,,In vivo,50597,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630557,BAO_0000218,
14960,1,A,1,,,In vivo,50597,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630558,BAO_0000218,
14961,1,A,1,,,In vivo,50597,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630559,BAO_0000218,
14962,1,A,1,,,In vivo,50597,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2106.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630560,BAO_0000218,
14963,1,A,1,,,In vivo,50597,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,2046.0,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL876427,BAO_0000218,
14964,1,A,1,,,,50597,The Kel values in female wistar rats.,,Rattus norvegicus,,,,10116.0,N,Intermediate,CHEMBL630561,BAO_0000218,
14965,1,A,0,,,,22224,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,,,,,,,U,Autocuration,CHEMBL630562,BAO_0000019,
14966,1,A,0,,,,22224,Hydrolysis rate constant of the compound,,,,,,,U,Autocuration,CHEMBL630563,BAO_0000019,
14967,1,P,0,,,,22229,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,,,,,,,U,Autocuration,CHEMBL629673,BAO_0000100,
14968,1,A,0,,,,22224,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",,,,,,,U,Autocuration,CHEMBL629674,BAO_0000019,
14969,1,A,0,,,,22224,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",,,,,,,U,Autocuration,CHEMBL629675,BAO_0000019,
14970,1,A,0,,,,22224,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",,,,,,,U,Autocuration,CHEMBL629676,BAO_0000019,
14971,1,A,0,,,,22224,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",,,,,,,U,Autocuration,CHEMBL629677,BAO_0000019,
14972,1,A,0,,,,22224,Apparent inactivation rate constant was evaluated,,,,,,,U,Autocuration,CHEMBL629678,BAO_0000019,
14973,1,A,0,,,,22224,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,,,,,,,U,Autocuration,CHEMBL629679,BAO_0000019,
14974,1,A,0,,,,22224,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,,,,,,,U,Autocuration,CHEMBL629680,BAO_0000019,
14975,1,A,0,,,,22224,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,,,,,,,U,Autocuration,CHEMBL629681,BAO_0000019,
14976,1,A,0,,,,22224,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,,,,,,,U,Autocuration,CHEMBL629682,BAO_0000019,
14977,1,A,0,,,,22224,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,,,,,,,U,Autocuration,CHEMBL629683,BAO_0000019,
14978,1,F,0,,,,22224,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,,,,,,,U,Autocuration,CHEMBL629684,BAO_0000019,
14979,1,P,0,,,,22224,Dissociation constant was determined,,,,,,,U,Autocuration,CHEMBL629685,BAO_0000100,
14980,1,P,0,,,,22224,Dissociation constant was determined,,,,,,,U,Autocuration,CHEMBL629686,BAO_0000100,
14981,1,P,0,,,,22224,Dissociation constant at pH 7.4,,,,,,,U,Autocuration,CHEMBL872932,BAO_0000100,
14982,1,P,0,,,,22224,Dissociation constant in presence of 1 mM dithiothreitol,,,,,,,U,Autocuration,CHEMBL629687,BAO_0000100,
14983,1,A,0,,,,22224,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,,,,,,,U,Autocuration,CHEMBL872931,BAO_0000019,
14984,1,A,0,,,,22224,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,,,,,,,U,Autocuration,CHEMBL628151,BAO_0000019,
14985,1,A,0,,,,22224,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,,,,,,,U,Autocuration,CHEMBL628152,BAO_0000019,
14986,1,A,0,,,,22224,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,,,,,,,U,Autocuration,CHEMBL628153,BAO_0000019,
14987,1,A,0,,,,22224,Kinetic constant for aromatization of androstenedione,,,,,,,U,Autocuration,CHEMBL628154,BAO_0000019,
14988,1,A,0,,,,22224,Kinetic constant for aromatization of testosterone,,,,,,,U,Autocuration,CHEMBL628155,BAO_0000019,
14989,1,A,0,,,,22224,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,,,,,,,U,Autocuration,CHEMBL628156,BAO_0000019,
14990,1,A,0,,,,22224,Local inhibition constant was determined,,,,,,,U,Autocuration,CHEMBL628157,BAO_0000019,
14991,1,A,1,,,,50347,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,,Saccharomyces cerevisiae,,,,4932.0,N,Intermediate,CHEMBL857533,BAO_0000218,
14992,1,P,0,,,,22224,Dissociation constant value of the compound,,,,,,,U,Autocuration,CHEMBL628158,BAO_0000100,
14993,1,A,0,,,,22224,In vitro permeability through cornea without epithelium,964.0,,,,,,U,Autocuration,CHEMBL628159,BAO_0000019,
14994,1,A,0,,,,22224,In vitro permeability through intact cornea,964.0,,,,,,U,Autocuration,CHEMBL875616,BAO_0000019,
14995,1,A,1,,,,50592,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,964.0,Oryctolagus cuniculus,,,,9986.0,N,Intermediate,CHEMBL628160,BAO_0000218,
14996,1,A,0,,,,22224,Rate of enzyme inactivation for the compound was determined,,,,,,,U,Autocuration,CHEMBL628161,BAO_0000019,
14997,1,A,0,,,,22224,In vitro permeability through cornea without epithelium,964.0,,,,,,U,Autocuration,CHEMBL628162,BAO_0000019,
14998,1,A,0,,,,22224,In vitro permeability through intact cornea,964.0,,,,,,U,Autocuration,CHEMBL628163,BAO_0000019,
14999,1,A,0,,,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,U,Autocuration,CHEMBL628164,BAO_0000019,
15000,1,A,0,,,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,U,Autocuration,CHEMBL628165,BAO_0000019,
15001,1,A,0,,,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,U,Autocuration,CHEMBL628166,BAO_0000019,
15002,1,A,0,,,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,U,Autocuration,CHEMBL628167,BAO_0000019,
15003,1,A,0,,,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,U,Autocuration,CHEMBL628168,BAO_0000019,
15004,1,A,0,,,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,U,Autocuration,CHEMBL628169,BAO_0000019,
15005,1,A,0,,,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,U,Autocuration,CHEMBL628170,BAO_0000019,
15006,1,A,0,,,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,U,Autocuration,CHEMBL628171,BAO_0000019,
15007,1,A,0,,,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,U,Autocuration,CHEMBL627434,BAO_0000019,
15008,1,A,0,,,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,U,Autocuration,CHEMBL627435,BAO_0000019,
15009,1,A,0,,,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,U,Autocuration,CHEMBL628110,BAO_0000019,
15010,1,A,0,,,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,U,Autocuration,CHEMBL628111,BAO_0000019,
15011,1,A,0,,,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,U,Autocuration,CHEMBL628112,BAO_0000019,
15012,1,A,0,,,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,U,Autocuration,CHEMBL628260,BAO_0000019,
15013,1,A,0,,,,22224,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,U,Autocuration,CHEMBL628261,BAO_0000019,
15014,1,A,1,,,In vivo,50594,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL628262,BAO_0000218,
15015,1,A,1,,,In vivo,50587,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,,Homo sapiens,,,,9606.0,N,Intermediate,CHEMBL628263,BAO_0000218,
15016,1,A,1,,,In vivo,50594,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL628264,BAO_0000218,
15017,1,A,1,,,In vivo,50594,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL628265,BAO_0000218,
15018,1,A,1,,,In vivo,50594,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL628266,BAO_0000218,
15019,1,A,1,,,In vivo,50594,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL628267,BAO_0000218,
15020,1,A,1,,,In vivo,50594,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL628268,BAO_0000218,
15021,1,A,1,,,In vivo,50594,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL628269,BAO_0000218,
15022,1,A,1,,,In vivo,50594,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL628270,BAO_0000218,
15023,1,A,1,,,In vivo,50594,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL628271,BAO_0000218,
15024,1,A,1,,,In vivo,50594,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),,Mus musculus,,,,10090.0,N,Intermediate,CHEMBL628272,BAO_0000218,
